สิทธิบัตรเรื่ องเต็มจากฐาน EPO Worldwide (http://gb.espacenet.com) ปี 2001-2005
เกี่ยวกับ “Health
Food”
1. AU2002368480 - 08.07.2004
FOOD FOR GASTROINTESTINAL HEALTH
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=AU2002368480
Inventor(s):
BUTTERWICK RICHARD (GB); ROLFE VIVIEN (GB)
Applicant(s):
MARS UK LTD (GB); BUTTERWICK RICHARD (GB); ROLFE VIVIEN (GB)
IP Class 4 Digits: A23L; A23K
IP Class:
A23K1/18; A23L1/0522; A23L1/0534
E Class: A23K1/14C; A23K1/16L; A23K1/18N; A23K1/18N4; A23K1/18N6; A23L1/0522; A23L1/0534;
A23L1/308A; A23L1/308B
Application Number:
WO2002GB05913 (20021223)
Priority Number: WO2002GB05913 (20021223)
Family: AU2002368480
Cited Document(s):
WO9844932; WO0053030
Abstract:
THE PRESENT INVENTION RELATES TO A FOODSTUFF COMPRISING A SOURCE OF RICE
STARCH, A NON-FERMENTABLE FIBRE AND A BULK FORMING FERMENTABLE FIBRE AND, IN
PARTICULAR, ITS USE IN IMPROVING OR MAINTAINING THE GASTROINTESTINAL HEALTH OF A
DOG.Description:
1/757
Food For Gastrointestinal Health
The present invention relates to a foodstuff comprising a source of rice starch, a non-fermentable
fibre and a bulk forming fermentable fibre and its use in improving or maintaining the gastrointestinal
health of a dog. The invention further relates to a method of improving the gastrointestinal health of a
dog.
It has been observed that a proportion of the dog population exhibit non-specific dietary sensitivity
on a range of foodstuffs. This dietary sensitivity can manifest as a variety of clinical symptoms such
as vomiting, diarrhoea, skin disease, respiratory disorders and disorders of the central nervous
system. The causes or dietary drivers of this dietary sensitivity remain elusive. However, common
reported allergens in dogs include cow's milk, beef, mutton, pork, chicken, rabbit, horse, some fish,
eggs, oatmeal, corn, wheat, soy, rice, potatoes and kidney beans.
Non-specific diet sensitivity is observed with all diets, however it is particularly associated with dogs
fed on wet (moisture of 70 to 90%) or semi-wet (moisture of 15 to 70%) foodstuffs. The conventional
solution to such non-specific diet sensitivity is to provide the dog with a"sensitive"product usually in
the form of a dry diet. However, such a solution is not appropriate or desirable for all dogs.
In addition, while a wet diet may exacerbate non-specific dietary sensitivity, sensitivity can also be
associated with dry diets. Non-specific dietary sensitivity involves factors such as stress, activity
levels and dietary components.
The present invention provides a foodstuff, in particular a wet or semi-wet foodstuff, which can be
used to improve and/or treat the symptoms of canine non-specific dietary sensitivity. This foodstuff
will allow dogs suffering from non-specific dietary sensitivity to be fed on a wet or semi-wet diet. This
will avoid the problems associated with changing a dogs diet from a wet to a dry diet. In addition, the
provision of a wet or semi-wet foodstuff provides more choice and flexibility to the owner.
2/757
A first aspect of the present invention provides a foodstuff comprising a source of rice starch, a
source of non-fermentable fibre and a source of bulk forming fermentable fibre. For the purposes of
this invention, the foodstuff may have a moisture content of from 15 to 90% and is preferably wet
(moisture content of 70 to 90%) or semi wet (moisture content of from 15 to 70%).
The foodstuff of the first aspect contains a source of rice starch. The source of the rice starch is not
limiting. It can be provided, for example, as rice (either whole or broken grains), ground rice or rice
flour. The foodstuff further provides a source of non-fermentable fibre. The source of non-fermentable
fibre is not limiting. It may be one or more of cellulose, wheat bran, oat bran or barley bran. The
foodstuff further contains a source of a bulk forming fermentable fibre. For the purpose of this
invention, bulk forming fibres improve faecal bulk thereby improving transit and laxation. The source
of the bulk forming fibre is not limiting. Preferably, the bulk forming fermentable fibre is one or more
of sugar beet pulp, coconut endosperm fibre, chicory pulp, citrus pulp, carob bean or gum talha.
In a preferred feature of the invention, a foodstuff is provided comprising rice starch, sugar beet
pulp (as a source of bulk forming fermentable fibre) and cellulose (as a source of non-fermentable
fibre). The sugar beet pulp is provided at a level of approximately 5% to approximately 0. 1%
weight/dry weight, preferably, approximately 3% to approximately 0. 5%, more preferably at a level of
approximately 1.6% or above. Cellulose is provided at a level of 5% to 0. 1% weight/dry weight,
preferably, approximately 2% to approximately 0. 5%, more preferably at a level of approximately 0.
8% or above. Rice starch is provided at a level of approximately 5% to approximately 0. 1%
weight/dry weight, preferably approximately 3% to approximately 0. 5%, more preferably at a level of
approximately 1.6% or above.
The levels of fibre in a foodstuff can be analysed using the Englyst method (as defined in Englyst H.
N. , and Cumming J. H. (1984), Simplified method for the measurement of total non-starch
polysaccharides by gas-liquid chromatography of constituent sugars as alditol acetates. Analyst. 109,
937-942, and incorporated herein by reference). A description of the Englyst method is described in
Appendix 1. In principle, starch is removed enzymatically after solubilisation and NSP is measured
as the sum of the constituent sugars released by acid hydrolysis. The starch component of the fibre
source is gelatinised by boiling in hot water and is then removed with alph-amylase and pullulanase.
3/757
Starch and modified, or resistant starch are dispersed in DMSO. Three samples are then subjected
to complementary procedures measuring (I) total NSP (ii) water- soluble NSP and (iii) cellulose.
Components are hydrolysed in each case with sulphuric acid. The constituent sugars are converted
to alditols and are measured as their alditol acetates using gas-liquid chromatography (GLC).
Values for total dietary fibre as well as insoluble and soluble fractions can be
obtained. Cellulose can be measured separately and the non-cellulose polysaccharides are
characterised by measurement of the individual monosaccharides.
The level of fibre in any particular fibre source can be determined by identifying the amount of fibre
therein and comparing the level of fibre provided with that provided by the cellulose or sugar beet
pulp as discussed above. The amount of a particular fibre source to add to a foodstuff can then be
determined.
When the foodstuff of the first aspect of the invention is provided as a snack or treat, the levels of
bulk forming fermentable fibre, non-fermentable fibre and rice starch can be decreased. For example,
a snack food may be provided with approximately 0. 8% rice starch or above, approximately 0.4 %
cellulose or above and approximately 0. 8% sugar beet pulp or above.
In a preferred feature of the first aspect, the combined levels of non-fermentable fibre and bulk
forming fermentable fibre does not exceed approximately 8% w/w, preferably the combined level
does not exceed approximately 5% w/w.
The foodstuff according to the present invention encompasses any product that a pet consumes in
its diet. Thus, the invention covers standard food products as well as pet food snacks (for example,
snack bars, biscuits and sweet products- Preferably, these snackfoods are wet or semi-wet products
such as co-extruded pet treats described in EP0647410 or W099/47000. The foodstuff is preferably a
cooked product. It may incorporate meat or animal derived material (such as beef, chicken, turkey,
lamb, fish, blood plasma, marrow bone etc or one or more
4/757
thereof). The product alternatively may be meat free (preferably including a meat substitute such as
soya, maize gluten or a soya product) in order to provide a protein source. The product may contain
additional protein sources such as soya protein concentrate, milk proteins, gluten etc. The product
may also contain an additional starch source (in addition to the source of rice starch) such as one or
more grains (e. g. corn, rice, oats, barley etc).
The foodstuff of the present invention may preferable be provided as a liquid supplement. The
supplement may be provided as an accompaniment with food or may be added to a conventional
foodstuff. Alternatively, the supplement may be provided before or after the conventional foodstuff.
The supplement may further be added to a drink such as milk or water.
The foodstuff is preferably packaged. In this way, the consumer is able to identify, from the
packaging, the ingredients in the foodstuff or food supplement and confirm that it is suitable for the
particular pet in question. The packaging may be metal (usually in the form of a tin or flexifoil), plastic,
paper or card. The amount of moisture in any product may influence the type of packaging, which
can be used or is required.
According to the present invention, dogs are any canine animal, in particular the domestic or pet dog,
Canis domesticus.
The second aspect of the invention relates to a process for the manufacture of a foodstuff of the first
aspect of the invention. The process comprises admixing a source of rice starch, a non-fermentable
fibre and a bulk forming fermentable fibre. The foodstuff can be made according to any method
known the art such
as in Waltham Book of Dog and Cat Nutrition, Ed. ATB Edney, Chapter by A.
Rainbird, entitled"A Balanced Diet"in pages 57 to 74 Pergamon Press Oxford.
All preferred features of the first aspect also apply to the second.
The third aspect of the invention relates to a foodstuff of the first aspect for use in improving and/or
maintaining the gastrointestinal health of a dog. Improving and/or maintaining the gastrointestinal
5/757
health of an animal is a long held aim in the art, particularly in dogs suffering from non-specific
dietary sensitivity. The ability to maintain and/or improve gastrointestinal tract health can be
beneficial to pet owners because it has an impact on their pet's overall health.
A dog with non-specific dietary sensitivity has sub-optimal intestinal health.
This increases the risk of the dog developing viral or bacterial infections and compromises its longterm health. The foodstuff of the invention is preferably provided for improving and/or maintaining the
gastrointestinal health of a dog with a canine non-specific dietary sensitivity.
The inventors have previously showed that dogs with a non-specific dietary sensitivity exhibit
impaired water and electrolyte absorption. Furthermore, a dog with non-specific dietary sensitivity
also exhibits a rapid whole gut transit time. These colonic abnormalities result in poor faeces. In
addition, dogs with non-specific dietary sensitivity have diarrhoea and sub-optimal intestinal health.
Without being bound by scientific theory, the foodstuff of the first aspect is believed to drive
absorption and regulate whole gut transit time in dogs with non-specific dietary sensitivity. This leads
to an improvement in the gastrointestinal health of these dogs.
By improving the gastrointestinal health of the animal, the invention seeks to promote and maintain
good quality faeces in pet animals. Good faeces quality is of two-fold importance. Firstly, it is a good
indicator of a healthy pet. It is known that good faeces quality usually reflects healthy colonic
structure and function. Secondly, it is a much-favoured practicality for pet-owners. The invention
therefore provides a foodstuff of the first aspect for improving and/or maintaining faeces quality in a
dog.
Improving and/or maintaining gut health includes: improving and/or maintaining the gut motility of a
dog. The foodstuff of the first aspect improves whole gut transit time in a dog with non-specific
dietary sensitivity; improving and/or maintaining the absorption of electrolytes and colonic water in
the gastrointestinal tract of a dog. This improves faeces quality and prevents and/or reduces
diarrhoea in a dog with non-specific dietary sensitivity.
6/757
By improving the gastrointestinal health of a dog, the gastrointestinal tract is able to operate more
efficiently, leading to further improvements in the overall health of the dog.
It has been found that the foodstuff of the first aspect of the invention comprising a source of rice
starch, a source of non-fermentable fibre and a source of bulk forming fermentable fibre is more
efficient and effective than a foodstuff containing one or a combination of two of the components. It is
therefore submitted that the components, a source of rice starch, a source of non-fermentable fibre
and a source of bulk forming fermentable fibre interact to provide a synergistic result. The foodstuff
therefore provides improved benefits to a dog with non-specific dietary sensitivity.
The foodstuff of the third aspect can be administered to a dog in place of its conventional food. The
foodstuff can be administered alone or in combination with a dry food or snack. Preferably, the
foodstuff of the invention is administered to the dog daily, more preferably twice daily. Where the
foodstuff is administered as a snack or treat, the foodstuff is administered to the dog one or more
times a day, for example up to five times daily.
The fourth aspect of the invention relates to the use of a foodstuff of the first aspect to improve and/or
maintain the gastrointestinal health of a dog. The dog is preferably in need of improvement in
gastrointestinal health and may suffer from non-specific dietary sensitivity.
All preferred features of the first, second and third aspects of the invention also relate to the fourth
aspect.
The fifth aspect of the invention relates to a method of improving the gastrointestinal health of a dog.
The method comprises administering to the dog, the foodstuff of the first aspect. The dog may be
suffering from non- specific dietary sensitivity. Administration is preferably by feeding.
All preferred features of the first, second, third and fourth aspects also apply to the fifth aspect.
7/757
The sixth aspect of the invention relates to the use of a source of rice starch, a non-fermentable fibre,
and a bulk forming fibre in the manufacture of a
foodstuff wherein the foodstuff is for improving and/or maintaining gastrointestinal health in a dog.
All preferred features of the first, second, third, fourth and fifth aspects of the invention also apply to
the sixth aspect.
The invention will now be illustrated with reference to the following non- limiting examples.
EXAMPLES Methods A panel of ten control and ten sensitive dogs were fed either a standard
foodstuff or a foodstuff comprising rice starch, cellulose and sugar beet pulp (supplemented food).
The dogs were fed in accordance with individual energy requirements.
Both foodstuffs were wet foods with moisture levels of 78-79%. The major protein sources for each
diet were poultry, beef, wheat and maize. The supplemented food was supplemented at the levels
set out below (percentages relate to weight per dry weight):
Rice starch 1.6%
Cellulose 0. 8%
Sugar beet pulp 1.6%
The diets were fed in a cross-over design that included a washout phase.
Experimental Design Summary
Timings Control Control Sensitive Sensitive
8/757
(n-5) (n=5) (n=5) (n=5)
Phase 1 Std Std Std Std
3 weeks
1 week Std Supplemented Std Supplemented
food food
Phase 2 Std Washout Std Washout
Phase 3 Std Std Std Std
3 weeks
1 week Supplemented Std Supplemented Std
9/757
food food
Measurements Faeces quality was assessed daily using the WCPN 17-point linear scale. All
defecations were scored with a score of grade 1 representing dry crumbly faeces and grade 5
diarrhoea. Major intermediate points are at grade 2-ideal, well formed, does not leave a mark, easy to
pick up; grade 3-good quality slightly moist, less well formed, leaves a marked when removed from a
dry surface, tacky to the touch, soft centred; and grade 4-poor quality, moist, badly formed faeces
with consistency of putty or porridge. Statistical comparisons were made on the 7-day period during
which supplemented food was fed.
At the end of phase 1 and 3 standard and functional measurements were made: Colonic
transportfunction was measured using dialysis bags.
Mille gut transit time was measured by calculating the mean rate of transit of
barium impregnated polyethylene spheres (BIPS) through the intestinal tract.
Briefly, 20 pellets were administered with the early morning feed and all faeces voided collected for 4
days. Faeces were x-rayed and the numbers of BIPS evacuated counted.
The mean whole gut transit time (WGTT) was calculated using the following equation:
WGTT (hours) no. pellets (1) x time interval (i) (n) no. pellets (I)(i = 1 - n) Statistics All data is
expressed as the mean the standard error of the mean. Statistical significance of all parameters was
measured using Multifactoral Anova with significance assumed at p < 0.05.
RESULTS Faeces Quality Results
10/757
Mean Score % Faecal output
(SEM) Unacceptable (per dog per
day)
Control
Std 2. 3 (0.05) a 2. 4 1. 7 a
Supplemented 2.1 (0.03) a 0.5 1.9 a
Food
Sensitive
Std 2. 7 (0.05) c 11.1 2.5 a
Supplemented 2. 4 (0. 04) b 3.9 2.3 a
Food
The feeding of diet supplemented with rice starch, cellulose and sugar beet dramatically improved
the faeces quality of the sensitive dogs.
Colonic Electrolyte Transport Electrolyte transport (mM. hour) (-ve value = absorption)
Na+
Control
11/757
Std-53.3 (10) b
Supplemented food-65.8 (8.8) b
Sensitive
Std-64. 1 (9.4) b
Supplemented food-94.9 (9.3) a
Sensitive dogs showed significantly improved sodium absorption (indicating by a more negative
value) from the colon when fed the supplemented foodstuff.
Whole Gut Transit Time Administration of the supplemented food to sensitive dogs significantly
improved the whole gut transit time, as indicated by an increase in the time of transit, improving
times present to those observed in controlled dogs.
12/757
Mean Whole Gut Transit Time (Hours) [Standard Deviation]
Control dogs
Standard food 31. 1 [10.6] b
Supplemented food 26.0 [5.2] ab
Sensitive dogs
Standard food 21. 6 [5. 2] a
Supplemented food 28.4 [8.5] b
Effectiveness of foods comprising rice starch, cellulose or sugar beet pulp on faeces quality.
13/757
Standard 0. 8% 1. 6% Sugar 1. 6% Rice
food Cellulose beet pulp starch
Control dogs 2. 28'0. 4 b 2. 13+0. 23 a 2. 23+0. 37 b 2. 23+0. 40 b
Sensitive 2. 28+0. 39 b 2. 15+0. 24 a 2. 21+0. 28 ab 2. 23+0. 34 ab
dogs
Thus, the effects of feeding each of the components separately provides less benefit than providing
a combination of the components.
Appendix 1
The Englyst method, from Englyst and Cummings (Supra).
Experimental
Apparatus
14/757
The fractionation procedure was carried out in 50-60ml screw-topped glass centrifuge tubes as
previously described. Gas-liquid chromatography was performed with a Pye Unicam Series 204
chromatograph, fitted with a flame- ionisation detector. A 2. 1m x 2mm i. d. glass column packed
with Supelcoport (100-200 mesh) coated with 3% SP 2330 was used. The column temperature was
215 C (isothermal) and the injector and detector temperatures were 250 C.
The carrier gas (nitrogen) flow-rate was 20ml min-l.
Reagents High purity certified reagents were used for all analyses. Enzyme preparations were as
follows: hog pancreatic a-amylase, E. C. 3.2. 1.1. (Sigma, Cat. No.
A4268); pullulanase, E. C. 3.2. 1.41. (Boehringer, Cat. No. 108944).
Method The sequence of steps in the procedure is summarised below.
Pre-treatment of sample As far as possible, foods should be analysed without any pre-treatment. If
there are problems in taking a representative sample, foods with a low water content
can be ball milled for 2-3 minutes, and those with a higher water content homogenised, or freezedried and ball milled.
Sample Mass Accurately weigh between 50 and 1, 000mg of sample, containing not more than
150mg of starch and 50mg of NSP, into a 50-60ml screw-top centrifuge tube and add a stirrer.
Fat Extraction and Drying Samples with dry matter between 90 and 100% and with less than 203% of
fat can be analysed directly. Otherwise, add 40ml of acetone, mix for 30 minutes by using a
magnetic stirrer, centrifuge and remove by aspiration as much of the supernatant as possible without
disturbing the residue. Place the tubes in a water bath at 65 C on a magnetic stirrer hot plate and mix
the residue for a few minutes until it appears to be dry. The beaker can be covered and the acetone
vapour removed by water pump.
15/757
Dispersion of the Starch Add 2ml of DMSO, cap the tube and heat it in a boiling water bath for 1 hour,
timed from when re-boiling commences, stirring continuously. Then, without cooling, add 8ml of 0.
1M sodium acetate buffer pH5.2, at 50 C and vortex mix immediately.
50-200mg Sample I Add 2ml of DMSO
1-1 Heat for 1 hour at 100 C I
Add 8ml of buffer, pH 5. 2 and 0. 1 mol of enzyme solution
Incubate for 16 hours at 45 C
Add 40ml of EtOH I
Leave for 1 hour, centrifuge I
Wash twice with 85% EtOH, dry residue I
Add lml of 12mH2S04
Leave 1 hour at 35 C I
Add 1 lml of H2O
Leave 2 hours at 100 C I
Add 2ml of internal standard -----------13ml to uronic acids I ¦ lml I
Add 0. 2ml of 12 M NH3, 5AI of octan-2-ol and 0. 1 mol of NaBH4 solution Leave for 1 hour at 40 C I
Add 0. 1 mol of acetic acid I
To 0. 2ml add 0. 3ml of Nmetlm and 2ml of acetic anhydride
Leave for 10 min at 20 C I
Add 5ml of H20, lml of CH2CL2 and vortex t
Use 1-2y1 of the lower phase for GLC Procedure for the analysis of non-starch polysaccharides (NSP)
Enzyme Hydrolysis of the Starch
16/757
Cool the tube to 45 C and immediately add O. lml of an enzyme solution containing 5,000 units of aamylase and 5 units of pullulanase per ml of acetate buffer at pH 5.2. Incubate the samples at 45 C
for 16-18 hours, preferably mixing continuously as described previously.
Following the enzyme treatment, add 40ml of absolute ethanol, mix well and leave to stand for 1 hour
at room temperature. Centrifuge for 10 minutes or until a clear supernatant liquid is obtained.
Removed by aspiration as much of the supernatant liquid as possible, without disturbing the residue,
and discard it.
Wash the residue twice with 50ml of 85% ethanol by mixing to form a suspension, centrifuging until
clear and removing the supernatant liquid as before. Add 40ml of acetone to the washed residue, stir
for 5 minutes and then centrifuge. Remove the supernatant liquid by aspiration and dry the residue
as described under Fat extraction and drying.
Acid hydrolysis of the residuefrom enzymic digestion Disperse the dried residue in lml of 12M
sulphuric acid, using a vortex mixer.
Leave at 35 C for 1 hour to solubilise the cellulose, then rapidly add llml of water and mix.
Heat the solution in a boiling water bath for 2 hours from re-boiling, stirring continuously. Cool it to
room temperature by placing the tube in water, add 2ml of internal standard (2 mg of allose per ml of
saturated benzoic acid solution) and mix the contents of the tube. Use 1ml of the hydrolysate for the
preparation of alditol acetates and keep the remainder for the determination of uronic acids.
Uronic acids
The method used is a modification of the method of Scott. Mix 0. 3ml of hydrolysate (diluted, if
necessary, so that it contains between 25 and 100, ut of uronic acids per ml) with 0. 3ml of a mixtures
of sodium chloride-boric acid solution (prepared by adding 2g of sodium chloride and 3g of boric
acid to 100ml of water) Add 5ml of concentrated sulphuric acid and vortex mix, then place the tube
in a heating block at 70 C. Leave the tube and contents for 40 minutes and then cool them to room
temperature by placing in water. When cool, add 0. 2ml of 3.5-dimethylphenol solution (0. lg of (CH3)
2-C6H30H in 100ml of glacial acetic acid) and mix immediately. Between 10 and 15 minutes later
17/757
read the absorbance at 400 and 450nm in a spectrophotometer against a water reference. Subtract
the reading at 400nm from that at 450nm for each sample and plot the difference obtained for
glucuronic acid standards (over the range 25-125yf ml-l). Read the sample concentrations from the
graph.
Preparation of alditol acetates To 1ml of hydrolysate add 0. 2ml of 12M ammonia solution and 51AI of
octan-2- ol. Test that the solution is alkaline, and then add 0. lml of a freshly prepared solution of
100mg of sodium tetrahydroborate (III) (sodium borohydride) per ml of 3M ammonia solution. Mix,
leave the mixture for 1 hour at 40 C and add 0. 1ml of glacial acetic acid. Next, to 0. 2ml of the
acidified solution add 0. 3ml of N-methylimidazole and 2ml of acetic anhydride, and mix. Leave it for
10 minutes at 20 C (room temperature), add 5ml of water, mix, and when cooled add 1ml of
dichloromethane, agitate the contents vigorously on a vortex mixer
and centrifuge for a few minutes to separate the mixture into two phases.
Remove the bulk of the upper phase by aspiration and discard it, then transfer the lower phase to a
small vial, seal and store it at-20 C. Use 1-2AI for injection on to the chromatograph.
Alternative preparative of alditol acetates When dichloromethane is used as a solvent for the alditol
acetates it has been observed in a number of laboratories without automatic GLC injection facilities
that the injection technique is critical to the obtaining of reproducible results. A more robust method
can be obtained if dichloromethane is replaced with ethyl acetate as a solvent for alditol acetates.
The procedure is as follows: To lml of hydrolysate add 0. 2ml of 12M ammonia solution and 5, 1t1 of
octan-2- ol. Test that the solution is alkaline, then add O. lml of a freshly prepared solution of 100mg
of sodium tetrahydroborate (III) per ml of 3M ammonia solution. Mix, leave the mixture for 1 hour at 40
C and add O. lml of glacial acetic acid. To 0. 5ml of the acidified solution add 0. 5ml of Nmethylimidazole, 5ml of acetic anhydride and mix. Leave for 10 minutes at 20 C (room temperature),
then add 0. 6ml of ethanol and mix. After 5 minutes add 5ml of water, place in a water bath at room
temperature, add 5ml of 7.5M KOH and a few minutes later a further 5ml of 7. 5M KOH. Mix by
inverting and leave to separate into two phases. Transfer the top phase to a small vial and store at +5
C. Use 1-2, u1 for injection on the chromatograph.Claims:
18/757
CLAIMS 1. A foodstuff comprising a source of a rice starch, a non-fermentable fibre and a bulk
forming fermentable fibre.
2. A foodstuff as claimed in claim 1 which is a wet or semi-wet foodstuff.
3. A foodstuff as claimed in claim 1 or claim 2 wherein the source of rice starch is rice, ground rice or
rice flour.
4. A foodstuff as claimed in any one of claims 1 to 3 wherein the non- fermentable fibre is cellulose.
5. A foodstuff as claimed in any one of claims 1 to 4 wherein the bulk forming fermentable fibre is
sugar beet pulp.
6. A foodstuff as claimed in any one of claims 1 to 5 for use in improving the gastrointestinal health of
a dog.
7. A foodstuff as claimed in claim 6 wherein the dog has non-specific dietary sensitivity.
8. A foodstuff as claimed in claim 6 for use in improving intestinal function in a dog.
9. A foodstuff as claimed in claim 6 for use in improving gut motility in a dog.
10. A use of a foodstuff as claimed in any one of claims 1 to 5 to improve the gastrointestinal health
of a dog.
11. A method of improving the gastrointestinal health of a dog comprising administering a foodstuff
as claimed in claim 11.
12. A method for preventing diarrhoea in a dog comprising administering a foodstuff as claimed in
any one of claims 1 to 5.
19/757
13. The use of rice starch, a non-fermentable fibre and a bulk forming fermentable fibre in the
manufacture of a foodstuff for improving the gastrointestinal health of a dog.
14. A process for the manufacture of a foodstuff as claimed in any one of claims 1 to 9 comprising
admixing a source of rice starch, a non- fermentable fibre and a bulk forming fermentable fibre.
15. A foodstuff as claimed in claims 1 to 9 comprising of rice starch at a level of approximately 5% to
approximately 0. 1% w/w.
16. A foodstuff as claimed in claims 1 to 9 comprising sugar beet pulp at a level of approximately 5%
to approximately 0.1% w/w.
17. A foodstuff as claimed in any one of claims 1 to 9 comprising cellulose at a level of approximately
5% to approximately 0. 1 % w/w.
20/757
2. AU2003243011 - 08.01.2004
AGENT FOR CURING ANAPHLACTIC DISEASE AND HEALTH FOOD, AND MANUFACTURING
PROCESS THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=AU2003243011
Inventor(s):
FUKUDA KOJI (JP); FUKUDA HARUI (JP); OKUMURA KO (JP); MIYAJIMA
HIROAKI (JP); OHYA YOSHIKAZU (JP)
Applicant(s): FUKUDA KOJI (JP); FUKUDA HARUI (JP); OKUMURA KO (JP); MIYAJIMA
HIROAKI (JP); OHYA YOSHIKAZU (JP)
IP Class 4 Digits: A61K; A61P
IP Class:
A61K35/78; A61P37/08
E Class: A61K35/78
Application Number:
WO2003JP08223 (20030627)
Priority Number: JP20020190091 (20020628); JP20030049555 (20030226)
Family: AU2003243011
Equivalent:
JP2004083555
Cited Document(s):
WO0195922; CN1296783; JP61289865
Abstract:
THE INVENTION PROVIDES FOR AN AGENT FOR CURING ANAPHYLACTIC DISEASE, WHICH IS
OBTAINABLE BY MIXING SHOOTS OF PLANT BELONGING TO THE FAMILY PINACEAE WITH
WATER AND SACCHARIDE AND THEN FERMENTING THEM. FURTHER, THE AGENT CAN BE
PRODUCED BY USING A FERMENTATION PRODUCT OBTAINED BY YEAST ISOLATED FROM THE
AGENT.Description:
21/757
DESCRIPTION
AGENT FOR CURING ANAPHLACTIC DISEASE AND HEALTH FOOD, AND
MANUFACTURING PROCESS THEREOF Technical Field
The present invention relates to an agent for curing anaphylactic disease such as an anaphylactic
shock and food dependent exercise induced anaphylactic, and a manufacturing process of the
agent. Further, the present invention relates to a health food for improving a symptom of anaphylactic
disease, and a manufacturing process of the health food.
Background Art
A human body has an immune system that is a defense mechanism. And, when extraneous
substances such as bacteria and viruses invade body, the system antagonizes them and protects
body. Allergies are caused due to excess action of this immune system. Recently, increasing number
of people are suffering from allergies possibly because of, though the details are not clear, air
pollution, change of dietary life, physical or mental stress increase, environmental changes such as
room pollution and the like due to change in resident circumstances, or change in human body
constitution.
The allergic diseases include asthma, atopic dermatitis, allergic conjunctivitis, allergic rhinitis such
as pollenosis, food allergy, anaphylactic shock caused by drugs and food dependent exercise
induced anaphylactic.
The first remedy for these allergic diseases is to avoid the allergens, though the remedy is rather
passive. When dusts or mites in a house are the allergens, the house must be cleaned to remove the
allergens, and when a pollen is the allergen, in the season of the pollen floatation, going out should
be held or a mask should be worn to prevent
suction of the allergen, and in the case of a food allergy, the food causing the allergy should not be
eaten. However, such a passive remedy is troublesome to the patient and significantly restricts the
activities of the patient.
22/757
For remedy of asthma, the attack of asthma is stopped or is prevented by symptomatic treatments,
and for these purposes, medicines such as sympathetic nervous drugs such as adrenalin, adrenal
cortical steroid hormones, theophyllin drugs and the like are used. Though asthma is a disease
sometimes leading the patient to death, there is still no remedy for complete recovery.
In infant period, atopic dermatitis causes distresses not only to the patient but also to the parents of
the patient. Though the most of the patients are cured before maturity, there is a case where the
dermatitis lasts to the adulthood. In such a case, adolescent men and women are distressed by
thickening of the skin of face, breast, inside of elbow and knee and by severe itching. As the remedy
for this, topical treatments are the major methods to treat the patient, and depending on the symptom,
adrenal cortical hormones, antihistamine drugs and other anti-inflammatory agents are used. When
itching is strong, systemic application of an antihistamine agent would be necessary.
Effective drugs for medical treatment often cause anaphylactic shock. Therefore, it often happens
that the treatment for a patient having drug allergy is restricted. There are some cases where drugs
such as antibiotics, insulin and contrast mediums are restricted for a patient. If the patient does not
have enough information about those drugs, he may develop a serious anaphylactic shock by mistaking those drugs, and it may be fatal to the patient.
In recent years, increasing interest in food-dependent exercise induced anaphylactic shock has
been emerged. A patient with a food dependent exercise induced anaphylactic shock develops
anaphylactic shock by exercising after taking specific foods.
Many patients are diagnosed as teenage boys during puberty. Clinical symptoms are a fever, itch,
red spot, a nettle rash, edema, stomachache, diarrhea and vomiting. As a
serious case, the patient may die of breathing difficulties caused by edema of larynx, blood
pressure dropped or losing consciousness.
Conventionally, a treatment for anaphylactic disease is to avoid drugs and foods that cause
anaphylactic shock and to administer drugs such as adrenalin or steroid when anaphylactic shock
occurs.
23/757
However, such treatments just suppress the symptoms, they cannot cure allergic diseases including
anaphylactic disease completely, and the drugs may produce side effects.
When an allergen can be specified, there is a treatment called a sensitivity-reducing remedy in
which the extract of the allergen is, first, injected to the patient hypodermically in very small amount,
then, the amount is gradually increased to give a resistance against the allergen to the patient.
However, in this remedy, the injection of the extract must be repeated on the patient periodically
such as once to twice a week and the remedy requires a long period of time, additionally, an effect
may not be sufficient enough in some patients, further, anaphylactic shock sometimes leading the
patient to death may be caused in some incidents.
For remedy of asthma and atopic dermatitis, there are a lot of folk medicines, however, such
medicines may worsen the symptom in some cases.
Disclosure of Invention
The present invention relates to an agent for curing anaphylactic disease without side effects by
taking the agent for a short period, and a health food and manufacturing process thereof.
One aspect of the invention relates to an agent for curing anaphylactic disease which is obtainable
by mixing shoots of plants belonging to the family Pinaceae with water and saccharides, and then
fermenting the mixture. Another aspect of the invention relates to an agent that is effective in curing
anaphylactic disease such as an
anaphylactic disease caused by drugs and food dependent exercise induced anaphylactic disease.
As the plants belonging to the family Pinaceae, plants belonging to the genus Pinus is preferable,
and as the saccharides, sugar is preferable.
Further, another aspect of the invention relates to an agent for curing anaphylactic disease which is
obtainable by mixing shoots of pine leaves with water and sugar, and then fermenting the mixture.
Further one aspect of the invention relates to an agent that is effective in curing anaphylactic disease
such as an anaphylactic disease caused by drugs or food dependent exercise induced anaphylactic
disease.
24/757
Further, another aspect of the invention relates to a manufacturing process of a drug for curing
anaphylactic disease, which comprises the steps of: (1) dissolving saccharides in sterilized water to
obtain a saccharide solution and (2) adding shoots of plants belonging to the family Pinaceae to the
solution and fermenting them. As the plants belonging to the family Pinaceae, plants belonging to the
genus Pinus is preferable, and as the saccharides, sugar is preferable.
Further, one aspect of the invention relates to a manufacturing process of a drug, for curing
anaphylactic disease, which comprises the steps of: (1) dissolving sugar in sterilized water to obtain
a sugar solution and (2) adding shoots of pine leaves to the solution and fermenting them.
The fermentation can be conducted under anaerobic conditions, preferably at 10-70 C, more
preferably at 20-70 C, preferably for 3-9 months, more preferably for 4-8 months.
Further, one aspect of the invention relates to a manufacturing process, which comprises the steps
of: (1) dissolving sugar in hot water and cooling them to a room temperature to prepare a sugar
solution, and (2) adding washed shoots of pine leaves to the solution, sealing a container including
them, and then fermenting them. The fermentation is preferably conducted in direct sunlight until the
beginning of winter.
Further, one aspect of the invention relates to a health food (including a health
beverage) for improving anaphylactic disease, which is obtainable by mixing shoots of plants
belonging to the family Pinaceae with water and sugar, and then fermenting them.
Further, one aspect of the invention relates to a use of a fermentation product manufactured by
above process, that is, yeast isolated from the agent, for a drug, health food. One aspect of the
invention provides an agent for curing anaphylactic disease without side effects by taking the agent
for a short term, and a health dependent exercise induced by anaphylactic disease.
One aspect of the invention cures allergy type I disease represented by anaphylactic disease such
as an anaphylactic shock and a food dependent exercise induced anaphylactic disease.
Accordingly, one aspect of the invention provides an agent, health food and health beverage that are
significantly effective in curing or improving anaphylactic disease.
25/757
The yeast was disclosed in international patent application (WO/01/95922) of the present applicant,
and has been deposited as HARUISAN A-3 with Independent Administrative Agency, National
Institute of Advanced Industrial Science and Technology (AIST), International Patent Organism
Depositary, Chuo No. 6, Higashi 1-1-1, Tsukuba City, Ibaraki Prefecture (old name: National Institute
of Bioscience and Human-Technology National institute of Advanced Industrial Science and
Technology, Higashi 1-1-3, Tsukuba City, Ibaraki Prefecture, name has been changed on April 1,
2001) on March 12,2001, and specified by deposit No. FERM BP-7499. A series of yeasts having the
microbiological properties equivalent to the deposited yeast are also included in the present
invention. Further, in the present invention, a fermentation product obtained by the fermentation using
the above-mentioned yeast is included, and as the fermentation product, pharmaceutical
preparations such as allergic curative medicines, health foods, health drinks, and raw materials of
cosmetics, and the like are exemplified. Here, the health food and health drink indicate foods and
drinks such as supplements and the like used for the purpose of improving body constitution and
maintaining health.
The present disclosure relates to subject matter contained in Japanese Patent Application No. 2002190091, filed on, June 28, 2002 and No. 2003-49555, filed on February 26,2003, the disclosure of
which are expressly incorporated herein by reference in its entirety.
Brief Description of Drawings
Fig. 1 is a microscopic photograph (differential interference, X 2400) showing an example of the
ascospore of isolated yeast isolated from the agent for curing anaphylactic disease (fermentation
product) of the present invention. As the medium, malt extract agar medium was used.
Fig. 2 shows the results of the mutagenicity screening tests made on an agent for curing
anaphylactic disease of the present invention, where base pair-substituted type strains are used
(TA100: D. TA1535: 0, WP2uvrA: A). In the figure,"A" represents a result in the case of utilizing no
metabolism activation (-S9), and"B" represents a result in the case of utilizing metabolism activation
(+S9), respectively.
26/757
Fig. 3 is a graph showing the results of the mutagenicity screening test of on an agent for curing
anaphylactic disease of the present invention, and shows the results obtained by using a frame shift
type strain (TA98: D, TA1537: 0). In the figure, "A"represents a result in the case of utilizing no
metabolism activation (-S9), and"B" represents a result in the case of utilizing metabolism activation
(+S9), respectively.
Fig. 4 is a photograph that shows an example of the PCA reaction in a rat that was administered an
agent for curing anaphylactic disease of the invention. In the Figure, rats in group C are the control
group and were orally administered distilled water which is injection graded distilled water, and rats
in group D were orally administered an agent for curing anaphylactic disease. "Anti-DNP-IgE SPE-7
titer"refers to the final dilution ratio of antigen specific IgE antibody.
Best Mode for Carrying Out the Invention
The agent for curing anaphylactic disease of the present invention is obtainable by mixing shoots of
plant belonging to the family Pinaceae with water and saccharides and them fermenting them.
As the plant belonging to the family Pinaceae that can be used in the present invention, exemplified
are Abies firma Sieb. & Zucc., Abies homolepis Sieb. & Zucc., Abies mariesii M. T. Mast. , Abies
sachalinensis (Friedr, Schmidt) M. T. Mast. var marie, Abies sachalinensis (Friedr, Schmidt) M. T.
Mast. , Abies veitchii Lindl. , Cedrus deodara (Roxb. ex D. Don) G Don, Larix gmelini (Rupr. )
Kuzeneva, Larix Kaempferi (Lamb.) Carriere, Picea abies (L) Karst. , Picea glehnii (Friedr. Schmidt)
M. T. Masters, Picea jezoensis (Sieb. & Zucc. ) Carriere var. hondoensis, Picea jezoensis (Sieb. &
Zucc.) Carriere, Picea koyamae Shirasawa, Picea polita (Sieb. & Zucc.) Carriere, Pinus x densithunbergii Uyeki, Pinus densiflora Sieb. & Zucc. , Pinus densiflora Sieb. & Zucc. cv. Umbraculifera,
Pinus koraiensis Sieb. & Zucc. , Pinus palustris Mill. , Pinus parviflora Sieb. & Zucc. var. parviflora,
Pinus parviflora Sieb. & Zucc. var. pentaphylla (Mayr) Henry, Pinus pumila (Pall. ) Regel, Pinus rigida
Mill. , Pinus strobus L. , Pinus sylvestris L. , Pinus teada L, Pinus thunbergii Parl. , Pseudotsuga
japonica (Shiras.) Beissn. , Tsuga diversifolia (Maxim. ) M. T. Mast. , Tsuga Sieboldii Carriere and the
like.
27/757
Of them, Pinus x densi-thunbergii Uyeki, Pinus densiflora Sieb. & Zucc. , Pinus densiflora Sieb. &
Zucc. cv. Umbraculifera, Pinus koraiensis Sieb. & Zucc. , Pinus palustris Mill. , Pinus parviflora Sieb.
& Zucc. var. parviflora, Pinus parviflora Sieb. & Zucc. var. pentaphylla (Mayr) Henry, Pinus pumila
(Pall.) Regel, Pinus rigida Mill., Pinus strobus L, Pinus sylvestris L. , Pinus teada L. and Pinus
thunbergii Parl. which are plants belonging to the genus Pinus are preferable, and particularly, Pinus
densiflora Sieb. & Zucc. , Pinus densiflora Sieb. & Zucc. cv. Umbraculifera, Pinus koraiensis Sieb.
& Zucc. , Pinus palustris Mill. , Pinus pumila (Pall. ) Regel, Pinus thunbergii Parl. and the
like are generally grown pine trees, and also preferable from the standpoint of easy availability.
As the saccharides can be used in the present invention, sucrose, invert sugar, maltose and the like
are exemplified. Among them, sucrose is preferable from the standpoint of easy availability, and as
the sucrose used, any sugar such as white sugar, black sugar, yellow soft sugar, beet sugar, millet
sugar and the like can be used, and white sugar is preferable.
As the water can be used, previously sterilized water is preferably used to prevent proliferation of
saprophytic bacteria, and as the sterilization method, any known methods generally employed to
sterilize water can be used, for example, water can be sterilized by boiling and the like.
The agent for curing anaphylactic disease of the present invention can be obtained by dissolving
saccharides in the above-mentioned sterilized water to prepare a saccharides solution, adding to the
saccharides solution a shoots of plant belonging to the family Pinaceae, and fermenting the mixture.
The shoots of plant belonging to the family Pinaceae to be added to said aqueous solution may be a
shoots collected from any kind of plants belonging to the family Pinaceae, and particularly, a shoots
collected from a plant belonging to the genus Pinus is preferable. The preferable season for
collecting the shoots is the season after completion of blooming of the plant, and the shoots
collected in this season has the highest effectiveness as an agent for curing anaphylactic disease
and therefore is preferable. In the case of pine tree, though it depends on climate of the land,
reddish female flower blooms at the peak of a branch and yellow male flower blooms around the new
branch generally around early April to late June, therefore, the shoots at the peak of the branch are
preferably collected and used when blooming of these flowers is completed.
28/757
For preparing the starting solution used in the fermentation, about 0.5 kg of saccharide is dissolved
in 1 liter of water. Then, to the resulting solution, about 25
shoots of plant belonging to the family Pinaceae are added. In this case, the saccharide is not
required to be completely dissolved and there is no problem if the saccharide presents remaining
undissolved in the solution. The starting solution to be fermented may advantageously contain shoots
of plants belonging to the family Pinaceae such as shoots of pine leaves in the ratio set forth in the
above, and there is no problem if it contains leaves and flowers other than the shoots.
The fermentation can be conducted under anaerobic conditions and the fermentation is effected by
allowing the starting solution to stand still at 10 to 70 C, preferably 20 to 60 C for 3 to 9 months,
preferably 4 to 8 months. As the anaerobic condition, for example, the starting solution is filled into a
light-shielded vessel and the like and the vessel is sealed air tightly. The fermentation is realized by
placing this sealed vessel at a place receiving direct sunlight until around early winter. After the
period of spontaneous fermentation is completed, the vessel is opened, and the solid materials such
as shoots of plant belonging to the family Pinaceae are removed to obtain an agent for curing
anaphylactic disease of the present invention. The above-mentioned early winter is determined in
consideration of the shoots collecting period, namely, charging period, and if the blooming period is
from early April to early May and if the shoots collection period after completion of blooming is from
middle May to early June in the producing area, the period of fermentation completion shall be early
winter (middle November), however, this is only one example, and this period can optionally be
changed.
The agent for curing anaphylactic disease of the present invention is effective in widely suppressing
the allergic reaction related to anaphylactic disease and allergic disease that is caused by a
chemical mediator when the mediator is released from a cell including a mast cell and basophilic
leukocyte, as shown below. Therefore, the agent is effective in curing anaphylactic disease but also
allergic disease. In view of the mechanism of action, the agent is believed to be effective in curing
type I allergic
29/757
disease such as asthma, atopic dermatitis, allergic rhinitis, acute urticaria, pollenosis, food allergy in
addition to the above-mentioned diseases
The agent for curing anaphylactic disease of the present invention uses a fermentation product per
se obtained by the spontaneous fermentation, however, a sweetener and flavoring agent may be
added to the product to improve the acceptance of the product in drinking, or various additives such
as a preservative and the like may be added for storing the product for a long period of time or for
other purposes.
For the application of the agent for allergies of the present invention, in the case of adult, in general,
about 30 to 50 ml of the agent is administered twice or three times a day. In the case of child, half
dosage of that in the adult administration may be used.
Since the agent for allergies of the present invention has no toxicity and no mutagenicity and
therefore is safe, there is no problem if an amount over the above-mentioned dosage is used.
The fermentation product of the present invention obtained by the fermentation can be used not only
as an agent for allergies but also as health food or health beverage.
The health food or health beverage are not used mainly for treatment, but used to improve body
constitution and maintain healthy condition. Accordingly, a health food and a health beverage for
improving anaphylactic disease of the present invention improve anaphylactic disease, that is, they
can be used for alleviating or preventing from the disease. In this case, it is preferable, in view of
inclination of consumers, to add the above-mentioned sweetener, flavoring agents or the like to make
the product acceptable to drink or eat and to make the product compatible with the inclination.
Further, the present invention provides an agent for curing anaphylactic disease, a health food for
improving anaphylactic disease and a manufacturing process of them, which contain a product
using yeast that is isolated from the fermentation product or an extract of the product.
Isolation of the yeast is also described in WO 01/95922. Specifically, a
fermentation product that is the agent for curing anaphylactic disease of the present invention was
used as the specimen. GPLP agar plate culture method was used to culture the microorganisms on
30/757
the plate, and the colonies dominantly grown on the culture plate was picked up to obtain the
isolated yeast. On the isolated yeast, the morphological and physiological observations were
performed, and the yeast was identified by consulting literatures (Kurtzm an, C. P. et at.,"The yeasts,
A Taxonomic
Study"4-th edition (1998), Elsevier Science B. V ; Barnett, J. A. et al.,"Yeasts :
Characteristics and identification", 3-rd edition (2000), Cambridge University Press, these literatures
are incorporated as parts of the specification of the instant application by reference). The total
number of yeast in the fermentation product was 1. 4x105/g.
The results form the morphological and physiological observations on the isolated yeast are shown
in Table 1 and an example of ascospore of the isolated yeast is shown in Fig.
1.
Table 1: Properties of the Isolated Yeast Item Observed Result
Form of nursing cell Oval to ellipse
Proliferation form Multiple budding
Liquid culture Sedimentation observed, no film formation observed (25 C, 3 days)
Pseudohypha Formed (25 C, 3 days)
Ascospore Mating observed between individual nursing cells, 1 to 4 ascospores in the form of ellipse
formed, ascus not divided (see
Fig. 1)
Utility of nitrogen source:
Nitrate
Ethylamine + Growth in vitamin-deficient medium Growth in the presence of NaCl : 10% +
12. 5% + 15% Weak
16%- Growth in the presence of cycloheximide :
0. 1%
0. 01% Growth in the presence of 1% acetic acid + Growth at 37 C Degradation of urea Coloration of
DBB Fermentation property:
Glucose +
31/757
Galactose
Sucrose
Maltose
Lactose
Raffinose Trehalose Utilization of carbon source:
Glucose +
Galactose
Sucrose
Maltose
Cellobiose Trehalose
Lactose Melibiose
Raffinose Melezitose
Starch
D-xylose L-arabinose
D-ribose
L-rhamnose
D-glucosamine
N-acetyl-D-glucosamine
Ethanol +
Glycerol + Erythritol
Ribitol +
D-mannitol +
Citrate
Inositol
According to the above results, the isolated yeast is identified as Zygosaccharomyces bisporus from
the morphological and physiological properties.
The Zygosaccharomyces bisporus belongs to ascomycetous yeast, mates between the individual
cells and forms 1 to 4 ascospores of sphere to ellipse form. Further, Zygosaccharomyces bisporus is
osmosis resistant yeast and isolated from fermentation foods, soft drinks and the like.
32/757
Moreover, a DNA homology test was conducted between the isolated yeast and the type strain to
give the following results. Namely, Zygosaccharomyces bisporus IFO
1131 and Zygosaccharomyces bailii IFO 1098 were used as the type strains according to
Takayuki Ezaki et al. , Japanese Journal of Bacteriology, vol. 45, p. 851 (1990) and
Masaaki Takahashi et al. , Tokyo University of Agriculture Isotope Center Study Report,
No. 7, p. 69 (1993), both of which literatures are incorporated herein by reference. The
DNA homology test between them and the isolated yeast was carried out by a photo biotin labeling
method using a microplate, in a DNA-DNA hybridization test. The preparation of DNA was conducted
according to Jahnke, K.-D. et al. , Trans. Br. Mycol.
Soc. , Vol. 87, pp. 175-191 (1986) (this literature is incorporated as parts of the specification of the
instant application by reference). The results are shown in Table 2.
Table 2: Results of DNA-DNA Hybridization Homology Test between Isolated Yeast and Type Strain
Type strain Homology (%)
Zygosaccharomyces bisporus IFO 1131 72
Zygosaccharomyces bailii IFO 1098 98
According to the results of the homology test with the above-mentioned type strains, though the
yeast of the present invention is identified as Zygosaccharomyces bisporus from the morphological
and physiological properties, DNA sequence itself is close to Zygosaccharomyces bailii rather than
Zygosaccharomyces bisporus.
Accordingly, it is recognized that the yeast of the present invention is a novel strain differing from
both type strains.
The applicant named this novel yeast as"HARUISAN A-3"which is deduced to belong to
Zygosaccharomyces genus. Presently, it is not clear whether this novel yeast "HARUISAN A-3"is just
a novel strain or is a novel species or genus. However, the
33/757
applicant deposited the novel yeast isolated and named"HARUISAN A-3"with Independent
Administrative Agency, National Institute of Advanced Industrial Science and Technology (AIST),
International Patent Organism Depositary, Chuo No. 6, Higashi 1-1-1, Tsukuba City, Ibaraki
Prefecture, Japan (old name: National Institute of Bioscience and Human-Technology National
institute of Advanced Industrial Science and Technology, Higashi 1-1-3, Tsukuba City, Ibaraki
Prefecture, Japan, in accordance with the Budapest Treaty on the International Recognition of the
Deposit of Microorganisms for the Purposes of Patent Procedure, on March 12,2001, under a deposit
number of FERM BP-7499. The above-mentioned Depositary was turned into an independent
administration corporation on April 1,2001, and altered as Independent Administrative Agency,
National Institute of Advanced Industrial Science and Technology (AIST). Thus, the name was
changed on April 1,2001.
The isolated novel yeast of the present invention is believed to significantly contribute to
effectiveness of the agent for curing anaphylactic disease together with shoots of plants belonging to
the family Pinaceae, and therefore is extremely useful yeast.
Next, the agent for curing anaphylactic disease of the present invention is described in detail by
examples, but the scope of the invention is not limited to the following examples.
(Example 1: Production Example of Agent for Curing Anaphylactic Disease)
The agent for curing anaphylactic disease of the present invention can be produced, for example, by
the following method.
Shoots of pine leaves of Pinus thunbergii Parl. , Pinus densiflora Sieb. & Zucc. and Larix kaempferi
(Lamb. ) Carriere were collected when pine blooming was completed (in Fukushima prefecture in
Japan, around middle May to early June), and the collected shoots of pine leaves were washed
thoroughly with water. White sugar was added and
dissolved into hot water, and cooled to around room temperature, and the resulting sugar water and
water-washed shoots of pine leaves were placed in a vessel, for example, a plastic vessel, the vessel
is sealed, and the vessel is placed at a place receiving direct sunlight until early winter (around
middle November, in Fukushima pref. ) to cause spontaneous fermentation for the production. The
34/757
vessel was opened around early winter, and the pine leaves were removed to obtain the agent for
curing anaphylactic disease of the present invention.
For the sugar water used, about 1 kg of white sugar was used per about 2 liters of water, and 50
pine leaves were used per about 2 liters of water.
As described above, the production was conducted using 1 kg of white sugar and about 50 pine
leaf shoots were used per about 2 liter of water, which resulted in about 1. 2 liter (about 60% of the
charged sugar water) of an agent for curing anaphylactic disease in the form of liquid having white
turbidity. The components of the agent and the content were analyzed, and the results are shown in
Table 3.
Table 3: Analyzed Values of Components of Agent for Anaphylactic Disease Component Content
Analysis method used Moisture 98.0% Guidelines for food hygiene inspection "Shyokuhin Eisei
Kensa Shishin", normal pressure heating method Protein 0.0% Guidelines for food hygiene inspection
"Shyokuhin Eisei Kensa Shishin", Nitrogen quantification conversion method Lipid 0.4% Guidelines for
food hygiene inspection "Shyokuhin Eisei Kensa Shishin", ether extraction method (Soxhlet method)
Ash 0.1% Guidelines for food hygiene inspection "Shyokuhin Eisei Kensa Shishin", direct ashing
method Saccharides 1. 5% Guidelines for food hygiene inspection "Shyokuhin Eisei Kensa Shishin",
Calculated.
Crude fiber 0.0% Guidelines for food hygiene inspection "Shyokuhin Eisei Kensa Shishin", modified
Henneberg Stoman method Dietary fiber 2. 4% Guidelines for food hygiene inspection "Shyokuhin
Eisei Kensa Shishin", Prosky method Na 5.1 mg/100 g Guidelines for food hygiene inspection
"Shyokuhin Eisei Kensa Shishin" P Less than 0.50 Guidelines for food hygiene inspection mg/100
g*1"Shyokuhin Eisei Kensa Shishin" Fe 0.11 mg/100 g Guidelines for food hygiene inspection
"Shyokuhin Eisei Kensa Shishin" Ca 1.66 mg/100 g Guidelines for food hygiene inspection "Shyokuhin
Eisei Kensa Shishin" K 18.3 mg/100 g Guidelines for food hygiene inspection "Shyokuhin Eisei Kensa
Shishin" General bacteria 2700 c. f. u./g Guidelines for food hygiene inspection "Shyokuhin Eisei
Kensa Shishin" Escherichia coli Negative Guidelines for food hygiene inspection "Shyokuhin Eisei
Kensa Shishin" Thiamine Less than 0.01 HPLC method
35/757
mg/100 g*1 Riboflavin Less than 0.01 HPLC method mg/100 g*1
Ergosterol 0.07 mg/100 g HPLC method
Niacin 0.04 mg/100 g Bioassay using microorganism*2 P-glucan 0. 03 mg/100 g Enzyme method *1
less than detection limit *2 Strain used : Lactobacillus plantarum ACTT 8014
This analysis was conducted only on the above-mentioned inspection items mainly regarding general
food, and there is a possibility that the agent for curing anaphylactic disease of the present invention
contains other components than the above components.
Therefore, it could not be specified which component was particularly important as an agent for
curing anaphylactic disease, however, the agent for curing anaphylactic disease was effective in
treating allergies.
Next, with respect to a plurality of remedies for allergies of the present invention produced as
described above, number of fungi, number of yeast and number of general bacteria (viable bacteria)
contained in the agent for curing anaphylactic disease were counted. The number of fungi and the
number of yeast were measured by using GPLP agar plate culture method, and the number of
general bacteria (viable bacteria) was measured by using the anti-fungus agent-added SCDLP agar
plate culture method in two ways, namely, pH of the medium was controlled to 3.5 using tartaric acid;
pH of the medium was not controlled. The results are shown in Table 4.
Table 4: Number of Microorganisms Contained in the Agent for Anaphylactic Disease Microorganism
Fermentation Fermentation Fermentation Fermentation product 1 product 2 product 3 product 4
Number of Number/0. 1 Negative Negative Negative Negative fungi g Number of Number ; g 1. 3x10
3. 3x105 1. 6x105 3. 3x104 yeast Number of Number/g 100 or less 100 or less general bacteria
Number of Number/g 100 or less 100 or less 100 or less 100 or less general bacteria, pH controlled
According to the above results, the growth of fungus was not recognized in the agent for
anaphylactic disease of the present invention, and the number of general bacteria (viable bacteria
number) was also extremely small. Further, it can be understood that yeast was present in the order
of 102 to 105/g in the fermentation product, though the yeast concentration was slightly irregular
36/757
depending on the lot of the fermentation product. The yeast existed in the above fermentation
products corresponded to the deposited novel yeast.
(Test Example 1: Oral Toxicity of Agent for Curing Anaphylactic Disease)
Next, the oral toxicity of the agent for anaphylactic disease of the present invention was examined.
The stock solution of the agent for curing anaphylactic disease of the present invention and that
obtained by adding honey (10 wt%) to the stock solution were
used as the specimens. Two test groups each consisting of 5 male and 5 female SD [Crj : CD (SD)
IGS] rats were administered the stock solution or the honey added stock solution at a rate of 2000
mg/kg and the control group was administered the injection water (dose: 0 mg/kg) alone. The
specimens and the injection water were forcibly administered to the rats orally by using a disposable
syringe (volume: lmL) equipped with a per os stomach conductor. The toxic symptom and
approximate lethal dose were investigated over the period of 15 days after the administration
(including administration day).
Throughout the test period, no death incident was observed in either of male and female rats in the
group orally administered the agent for curing anaphylactic disease of the present invention and in
the group administered the specimen prepared by adding honey to the agent at the rate of 2000
mg/kg, including the control group. Moreover, no change ascribed to administration of the
specimens was recognized in general condition, body weight and autopsy of the rats. From the
above results, it was concluded that the approximate lethal dose of the agent for curing anaphylactic
disease of the present invention under the conditions of this test was 2000 mg/kg or more for both
male and female.
(Test Example 2: Mutagenicity of Agent for Curing Anaphylactic Disease)
Next, the mutagenicity of the agent for curing anaphylactic disease of the present invention was
investigated. Regarding the mutagenicity of the agent for curing anaphylactic disease of the present
invention, the agent was applied to the histidine-dependent Salmonella typhimurium, TA98, TA100,
TA1535 and TA1537 strains, and tryptophan-dependent Escherichia coli, WP2uvrA strain according
to the revised plate method of Ames et al. (Maron, D. M. et al.,"Revised methods for the Salmonella
mutagenicity test", Mutation Res., Vol. 113, pp. 173 to 215 (1983), this literature is incorporated as
parts of the specification of the instant application by
37/757
reference), and the mutagenicity was investigated under the presence of the metabolism activation
or the absence of the metabolism activation.
Those tests were conducted at a dose of 312.5, 625,1250, 2500 and 5000 Fg/plate of the agent of
the present invention. As the results, the number of the reverse mutation colonies of each test strain
in the specimen group showed no increase in the dose-dependent manner and no increase over 2fold or more was observed as compared to the negative control, irrespective of presence or absence
of metabolism activation system. Further, no growth inhibition and no precipitation of the specimen
were recognized. The results are shown in Figs. 2 and 3. Fig. 2 shows the result in the base pairsubstituted type strain (TA100 : D. TA1535 : 0, WP2uvrA: A). In the figure,"A"represents the result in
the absence of the metabolism activation, and"B" represents the result in the presence of the
metabolism activation to which S9 mix was added. Fig. 3 shows the results in the frame shift type
strain (TA98 : D, TA1537: 0).
In the figure,"A"represents the result in the absence of the metabolism activation, and "B"represents
the result in the presence of the metabolism activation to which S9 mix was added. As the negative
control substance, distilled injection water that was used as the solvent to prepare the specimen was
administered. As the positive control substance, compounds: 2- (2-Furyl)-3- (5-nitro-2-furyl)
acrylamide (AF-2), 2-Aminoanthracene (2-AA), Sodium azide (SA) and 9-Aminoacridine (9-AA), were
used. AF-2, 9AA and 2-AA were dissolved in DMSO and SA was dissolved in distilled injection water,
respectively, and used depending on the strain and on the presence or absence of the metabolism
activation.
From the above results, it was judged that the mutagenicity of the agent for curing anaphylactic
disease of the present invention under the conditions of this test was negative.
(Test Example 3: Medicinal Action of Agent for Curing Anaphylactic Disease)
38/757
The rats were given an epidermal of anti-DNP-IgE under the skin for intracutaneous sensitization, the
agent for curing anaphylactic disease of the invention was administered orally, and then an antigen
(DNP-BSA) and Evans blue were administered intravenously to a coccygeal vein, to confirm the
medical action of the agent by the PCA reaction.
That is, six Wister male rats of 12 weeks old obtained from Nippon Charles
River Co. , Ltd. were given an epidermal of 100 g l of monoclonal anti dinitrophenyl-IgE antibody
(anti-DNP-IgE antibody) clone: SPE-7 (produced by Sigma
Co. , Ltd.; Catalog No. D-8406, Lot No. lOOK-4850) diluted solution into the back for intracutaneous
sensitization. After the sensitization, the agent for curing anaphylactic disease of the invention of
Example 1 was administered orally for four days at the rate of 1 ml/day.
Only sterilized water of injection grade was administered orally to the control group (See Table 5).
Table 5 Test Groups
Number of Number of Days
Test Group Tested Substance Tested Animals of Administration
C (Controls) Distilled Water for Injection 3 4
D (Subjects) Curing Agent By Example 1 3 4
After administering the test substances, dinitrophenyl-binding bovine albumin (DNP-BSA) and Evans
blue, which are the PCA reaction inducing substances, were administered intravenously to a
coccygeal vein.
The results were obtained by using the end point method, that is, the method based on the results of
the PCA reaction at the final degree of dilution of anti-DNP-IgE.
The symbol (+) denotes that the reaction was seen clearly inside the skin, () denotes
that the reaction was seen unclearly, and (-) denotes that the reaction was not seen. The results are
shown in Table 6. Fig. 4 shows examples of the reaction inside the skin.
Table 6 Results of PCA Reactions
Final Dilution Ratio of anti-DNP-IgE Group X2000 x4000 x8000 x16000 x32000 x64000 C-1 + +
39/757
C-2 + +
C-3 + +
D-1 +
D-2 +----D-3 ~ - - - - Further, after the sensitization of anti-DNP-IgE under the skin, the leaked pigment (Evans blue) was
extracted from spots under the skin. According to the amount of the pigment the degree of local
reaction was determined. Table 7 shows the results.
Table 7 Amount of Pigment Indicating Degree of PCA Reaction
Final Dilution Ratio of anti-DNP-IgE Group x2000 x4000 C-1 1.67 0.65 C-2 2.93 0.79 D-1 0.69 0.33 D2 0.54 0.21
The final dilution ratio in the PCA reaction was x4000 in the control group C,
and x2000 in group D which was orally administered the agent for curing anaphylactic disease of
the invention, the PCA reaction was seen to be suppressed significantly.
Also, the dilution ratio of the monoclonal anti dinitrophenyl-IgE antibody is x2000, x4000, x8000,
x16000, x32000 and x64000 corresponding to 500 ng/100, u 1, 250 ng/100 tt 1, 125 ng/100 A 1, 63
ng/100 u 1, 31 nu/100 tel and 16 ng/100 u 1.
At least the results show that the agent for curing anaphylactic disease of the invention suppresses
the reaction related to anaphylactic or allergic reaction after a chemical mediator is released from a
cell such as a mast cell and basophilic leukocyte.
(Test Example 4: Confirmatory Study of Amount of Agent for Curing Anaphylactic Disease)
To examine an effective amount of the agent, the PCA reaction was performed in the same manner
as in Test Example 3.
That is, each rats was given an epidermal of 100gel of monoclonal anti DNP-Ig antibody (SPE-7)
diluted solution into six points on the back for intracutaneous sensitizatiion, and the agent for curing
anaphylactic disease of the invention was administered orally for four days at the rate of 0. 1ml/day,
0.5 ml/day and 1.0 ml/day, respectively.
40/757
Sterilized water of injection grade was administered orally for four days at the rate of 1.0 ml/day to
the control group.
The next day of the final administration, dinitrophenyl-binding bovine albumin (DNP-BSA) and Evans
blue as the PCA reaction-inducing substances were administered intravenously to a coccygeal vein,
and the leakage of pigment"Evans blue"around the IgE sensitized area was determined by using the
end point method 30 minutes after the administration.
Table 8 Test Groups
Number of Number of Test Group Tested Substance
Tested Animals Administrations
Distilled Water for E (Controls) 2 3
Injection (1.0 ml)
Curing Agent F (Subjects) 3 4
By Example 1 (0.1 ml)
Curing Agent G (Subjects) 3 4
By Example 1 (0.5 ml)
Curing Agent H (Subjects) 3 4
By Example 1 (1.0 ml) Table 9 Results of PCA Reactions
Final Dilution Ratio of anti-DNP-IgE
Group X2000 X4000 X8000 X16000 X32000 X64000 E-1 + + +
E-2 + + + +-- F-1 + + +
F-2 + +---F-3 - - G-1 + + - - - G-2 + - - - - G-3 - - - - - H-1 - - - - - H-2 + - - - - H-3 + + - - - -
41/757
According to Table 9, the control group (group E) shows the PCA reaction up
to x8000-16000 of dilution (63-125ng). In contrast, the PCA reaction was seen up to x4000-8000 of
dilution (125-250ng) in group F at the rate of 0. 1 ml/day, the PCA reaction of IgE was shown up to
x2000-4000 of dilution (250-500ng) in group G at the rate of 0. 5ml/day and in group H at the rate of l.
Oml/day. Also, concerning to the comparison between the control group E and group F, the
suppression of the PCA reaction in group F was calmer, but the effect of the suppression was seen
stronger.
Further, groups G and H have similar results, however, according to the observation of the leakage of
the pigment, the amount of the pigment leaked was less in group H than in group G.
The weight of rats used in the test was about 250g, and considering this, the dosage for a human
(having a weight of 60kg) is calculated to be 24 ml/day, 120 ml/day and 240 ml/day. However, it is
preferable to administer more than 120 ml/day to ensure the effect of the treatment.
(Test Example 5: Fermentation Period and Medical Action of Agent for Curing Anaphylactic Disease)
Next, the effects that the fermentation period exerts medical action were examined.
That is, by using the drugs fermented for 1,3 and 5 months, medical effects were determined by the
PCA reaction similarly to Example 3 as follows. Rats were given an epidermal of 100gel of a diluted
solution of mouse monoclonal anti DNP-IgE antibody (SPE-7) into six points on the back for
intracutaneous sensitization
Then, the agents for curing anaphylactic disease of varying fermentation terms were administered
orally at the rate of l. Oml/day for four days.
Sterilized water for injection was administered orally at the rate of 1.0 ml/day for four days to the
control group.
On the next day of the final administration, dinitrophenyl-binding bovine albumin
42/757
(DNP-BSA) and Evans blue as the PCA reaction inducing substances were administered
intravenously to a coccygeal vein, and the leakage of pigment Evans blue around the IgE sensitized
area was determined by using the end point method 30 minutes after the administration. Details of
tested groups and results are shown in Tables 10 and 11.
Table 10 Test Groups
Number of Number of
Test Group Tested Substance
Tested Animals Administrations
Distilled Water
I (Controls) 3 4 for Injection (1.0 ml)
Curing Agent Fermented
J (Subjects) 3 4 for 1 Month (1.0 ml)
Curing Agent Fermented
K (Subjects) 3 4 for 3 Months (1.0 ml)
Curing Agent Fermented
L (Subjects) 3 4 for 6 Months (1.0 ml) Table 11 Results of PCA Reactions
Final Dilution Ratio of anti-DNP-IgE
Group x2000 x4000 x8000 x16000 x32000 x64000 1-1 + + + 1-2 + + - - - - 1-2 + + + J-1 + + +
J-2 + + J-3 + + K-1 + + - - - -
K-2 + +
K-3 + +
L-1
L-2 + +
L-3 + - - - - According to Table 11, the control (group 1) showed the PCA reaction up to x8000 (125ng). In
contrast, group J, fermented for one month, suppresses up to x8000 of IgE which is almost the same
as the control group. Therefore, the suppression effect of the PCA reaction is rarely perceived in
group J. However, groups fermented for three or six months are perceived to show a suppression
effect on the PCA reaction, it is understood that the fermentation period is preferably three months,
more preferably six months.Claims:
43/757
CLAIMS 1. An agent for curing anaphylactic disease, which is obtainable by mixing shoots of plant
belonging to the family Pinaceae with water and saccharide and then fermenting them.
2. The agent for curing anaphylactic disease according to Claim 1 wherein the plant belonging to the
family Pinaceae is a plant belonging to genus Pinus.
3. The agent for curing anaphylactic disease according to Claim 1 wherein the saccharide is sugar.
4. An agent for curing anaphylactic disease, which is obtainable by mixing shoots of pine leaves with
water and sugar and them fermenting them.
5. A manufacturing process of a drug for curing anaphylactic disease, which comprises (1)
dissolving saccharides in sterilized water to obtain a saccharide solution and (2) adding shoots of
plants belonging to the family Pinaceae to the solution and fermenting them.
6. The manufacturing process according to Claim 5, wherein the plant belonging to the family
Pinaceae is a plant belonging to genus Pinus.
7. The manufacturing process according to Claim 5, wherein the saccharide is sugar.
8. The manufacturing process according to Claim 5 wherein the fermentation is conducted under
anaerobic conditions at 10 to 70 C for 3 to 9 months.
9. A manufacturing process of a drug for curing anaphylactic disease which comprises the steps of:
(1) dissolving sugar in sterilized water to obtain a sugar containing solution and (2) adding shoots of
pine leaves and fermenting them.
10. The manufacturing process according to Claim 9 wherein the fermentation is conducted under
anaerobic conditions at 10 to 70 C for 3 to 9 months.
44/757
11. A manufacturing process of a drug for curing anaphylactic disease, which comprise the steps of:
(1) dissolving sugar in hot water and cooling them to a room temperature to prepare a sugar
containing solution, and (2) adding washed shoots of pine leaves to the solution, sealing a container
including them, and then fermenting them.
12. The manufacturing process according to Claim 11 wherein the fermentation is conducted under
anaerobic conditions at 10 to 70 C for 3 to 9 months.
13. The manufacturing process according to Claim 9 wherein the fermentation is conducted in direct
sunlight.
14. A health food for improving anaphylactic disease, which is obtainable by mixing shoots of plant
belonging to the family Pinaceae with water and saccharide and then fermenting them.
15. A health food for improving anaphylactic disease, which is obtainable by mixing shoots of pine
leaves with water and sugar and them fermenting them.
16. A manufacturing process of an agent for curing anaphylactic disease, which uses yeast
deposited under deposit number FERM BP-7499, or yeast having the equivalent
microbiological property to that of the yeast deposited under deposit number FERM BP-7499.
17. A manufacturing process of a health food for improving anaphylactic disease, which uses yeast
deposited under deposit number FERM BP-7499, or yeast having the equivalent microbiological
property to that of the yeast deposited under deposit number FERM BP-7499.
18. A manufacturing process of a health beverage for improving anaphylactic disease, which uses
yeast deposited under deposit number FERM BP-7499, or yeast having the equivalent
microbiological property to that of the yeast deposited under deposit number FERM BP-7499.
45/757
3. AU2003294731 - 08.07.2004
FOOD COMPOSITIONS FOR GUT HEALTH COMPRISING BLACK TEA
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=AU2003294731
Inventor(s):
VAN KLINKEN BERNARDUS JAN-WILL (NL); RISSELADA CHRISTIAN JACOB (NL);
SMORENBURG HERMANUS EBERTUS (GH); TOSCHKA HOLGER YORK (TH)
Applicant(s): UNILEVER NV (NL); UNILEVER PLC (GB); LEVER HINDUSTAN LTD (IN); VAN
KLINKEN BERNARDUS JAN-WILL (NL); RISSELADA CHRISTIAN JACOB (NL); SMORENBURG
HERMANUS EBERTUS (GH); TOSCHKA HOLGER YORK (TH)
IP Class 4 Digits: A23L; A61K; A23F
IP Class:
A61K35/78; A23L1/30; A23F3/00
E Class: A61K35/78; A21D2/26B4; A21D2/36; A23L1/168; A23L1/30B
Application Number:
WO2003EP13303 (20031126)
Priority Number: EP20020080659 (20021220); EP20030076736 (20030604)
Family: AU2003294731
Cited Document(s):
US6068862; JP6056689
Abstract:
THE PRESENT INVENTION PROVIDES THE USE OF A COOKED FOOD PRODUCT COMPRISING
BLACK TEA LEAVES, AN EXTRACT OF BLACK TEA OR A MIXTURE THEREOF, TO MAINTAIN OR
IMPROVE MICROFLORA BALANCE AND/OR TO TREAT OR PREVENT DIARRHOEA IN A SUBJECT
CONSUMING THE COMPOSITION AND WHEREIN THE BLACK TEA LEAVES OR THE EXTRACT OF
BLACK TEA IS/ARE PRESENT IN AN UNBOUND STATE. ALSO PROVIDED IS A COOKED FOOD
PRODUCT WHICH IS A COOKIE, CAKE, BUN, PASTRY, OR PORRIDGE COMPRISING SAID BLACK
46/757
TEA LEAVES, EXTRACT OR MIXTURE AND A MILK OR MILK BASED INGREDIENT IN AN AMOUNT
OF UP TO 10 %WT.Description:
FOOD COMPOSITIONS FOR GUT HEALTH COMPRISING BLACK TEA FIELD OF THE INVENTION
The present invention relates to the use of cooked food products comprising tea leaves, or a tea
extract to promote intestinal micro-flora balance, to provide resistance against diarrhoea or to aid in
the treatment of diarrhoea.
BACKROUND OF THE INVENTION Travelers'diarrhoea is a common problem for those travelling
overseas. Current estimates are that 60 million travelers from the West visit high risk areas annually,
and of these about 30- 50% suffer bouts of diarrhoea. Furthermore, diarrhoeal diseases pose a heavy
burden on developing countries, accounting for 1.5 billion bouts of illness a year, and are the second
largest infectious killer among children under five years of age immediately after acute respiratory
infections. Today, diarrhoeal diseases claim nearly two million lives a year among children under five
years of age (WHO, 1999). There are two types of diarrhoea, infectious and non-infectious.
Some of the pathogens most strongly associated with diarrhoea are rotavirus, Shigella spp. and
enterotoxigenic Escherichia coli (ETEC). Although problems occur mostly in children, travelers to
areas of the world with poor hygiene are also at risk. Even those travelling within northern Europe,
North America, or Australia are at increased risk (4-8% chance). The most important pathogens
causing travelers'diarrhoea are ETEC and other E. coli types and Shigella. Tea can modulate the
microflora inhibiting the growth of pathogens and may limit pathogen-induced fluid losses involved in
diarrhoea.
Several suggestions have been made to use green tea to improve intestinal microflora balance in
animals. N. Ishihara et al in Livestock Production Science, 68 (2001) pages 217-219 disclose that
green tea extracts were added to the feed of calves and showed moderate and wide-spectrum
inhibitory effects on the growth of pathogenic bacteria which overall lead to an improvement in the
microflora balance in the calves guts'and a decrease in the frequency of diarrhoea.
47/757
Bruneton in"Pharacognosy, 2nd ed, chapter 5", 1999, Intercept LTD, Paris, discloses that the tea leaf
can be used, orally, traditionally for the symptomatic treatment of mild diarrhoea.
It is also known to treat tea leaves for inclusion in food products. EP-A-0 951 839 discloses treating
fresh green tea leaves with a solution of water and a crystalline trehalose to obtain a treated tealeaf.
The treated tea leaf may be incorporated into foods and avoids the need for frying food and thus
increasing the fat content thereof. US 6,207, 214 discloses a process of making traditional Korean
snacks comprising 80-95 % wt glutinous rice. The snacks may comprise 5 to 20 % wt of powdered
green tea and they are steamed to produce the snack food. Neither of these two documents are
concerned with health effects in the consumers of the food product.
JP 63169951 and JP 02265446 disclose jellies which may comprise tea.
JP 03168046 discloses the use of a tea extract with cycolodextrin and/or a peptide in foods such as
biscuits, cookies and jellies.
US 4 389 187 discloses the use of a black tea extract in a food susceptible to lipid oxidation.
It is also known in south east Asian cooking to include tea leaves in raw foods such as salads.
JP 06/056,689-A discloses food compositions for the prevention and treatment of infectious diarrhoea.
The compositions comprise a chitin which contains a tea extract either adsorbed or chemically
bonded therewith. When the tea is not bound with chitin, the compositions are said to have an
unacceptable, bitter, taste.
However, a problem with these food compositions is that the level of unbound green tea which is
taught to be possible to incorporate into the food product is very limited because the sensory
properties, especially taste, of the food composition may be adversely affected by the tea.
48/757
The binding of the tea with a carrier, such as chitin, however brings further problems or
disadvantages. Firstly, the bound tea leaves or tea extract are more expensive than their unbound
equivalents and the material to which it is bound may not always be readily available. Also, the
bound tea requires further processing and is not readily available at an affordable price in all
countries. Furthermore, the bound tea then takes up some of the formulation space in the food
product for a non-functional ingredient, thus, reducing the formulation space available for more
functional ingredients. Moreover, chitin bound tea may be derived from animal sources which is not
suitable for vegetarians and many of the inhabitants of countries in the developing world are
vegetarians.
There is therefore still a need in the art for food compositions which can be used by all people to
maintain or improve intestinal microflora balance and/or to treat or prevent diarrhoea.
Furthermore, there is also a need for such compositions which are effective and economical and
relatively simple to produce.
There is also a need for such compositions that fulfil one or more of the following criteria: - they can
be stored without refrigeration and have good keeping characteristics.
- they can be consumed as a part of the typical daily diet for all people, - they can be consumed by
all people, - they do not require any further special preparation, - they can be added to other food
products, - they can be made from readily available and economical ingredients, - the ingredients
they are prepared from do not need to be pre-prepared with other materials.
The present invention seeks to address one or more of the above-mentioned problems.
SUMMARY OF THE INVENTION We have surprisingly found that by the consumption of a food
product which comprises unbound black tea, beneficial effects upon the maintenance or
improvement of intestinal microflora
49/757
balance are obtained. This is especially true when the compositions are taken as a part of the daily
diet.
Furthermore, the food products are also beneficial in the treatment or prevention of infectious or noninfectious diarrhoea.
The present invention therefore provides, according to a first aspect, the use of a cooked food
product comprising black tea leaves, an extract of black tea or a mixture thereof, to maintain or
improve microflora balance and/or to treat or prevent diarrhoea in a subject consuming the
composition and wherein the black tea leaves or the extract of black tea is/are present in an unbound
state.
According to a second aspect the invention provides a cooked food product comprising black tea
leaves, an extract of black tea or a mixture thereof, wherein the black tea leaves or the extract of
black tea is/are present in an unbound state and further wherein the food product is a cookie, cake,
bun, pastry, or porridge which comprises a milk or milk based ingredient in an amount of up to 10 %
wt.
The term"use of tea"and"tea"as used herein refers to the tea leaves, or of pieces of tea leaves, as the
context requires.
The amount of tea extract refers to the dry weight of the tea extract.
The food product is used to maintain or improve microflora balance and/or to treat or prevent
diarrhoea (either infectious or non-infectious) in a subject consuming the composition.
Preferably the food product is consumed as a part of the subject's daily diet.
Preferably the black tea leaves, an extract of black tea or the mixture thereof is/are cooked in the
food product when it is cooked.
50/757
The products of the first aspect have several advantages. They can be used effectively by all people
to maintain or improve intestinal microflora balance and/or to treat or prevent diarrhoea. Also they are
economical and can be made by conventional production methods using conventional apparatus.
They can be stored without refrigeration and have good keeping characteristics, which is particularly
important in developing countries where refrigerated storage facilities are often not available and/or
the climate is warm.
The food products can take many forms and are suitable for inclusion as a part of the daily diet to
simply replace the non-tea containing equivalent. This means that they are readily accepted into a
daily diet by adults and children alike.
Furthermore, the food products can be prepared from readily available and economical ingredients
(as long as a supply of tea or tea extract is available). Also, the tea can be used in its conventional
state of either the leaf or as an extract and does not require pre-processing with other ingredients
before it can be added to the other ingredients of the food product.
Also, as the product is cooked, it can readily be added to other food products.
Without wishing to be bound by theory, it is believed that the polyphenols in the black tea leaves and
tea extracts are able to inhibit the growth of both Gram-negative and Gram-positive pathogenic
bacteria and viruses, which are major causative agents of intestinal infection leading to diarrhoea.
This is achieved without adversely affecting beneficial gut bacteria, such as lactobacilli and bifidio
bacteria, even at very high concentrations of the bacteria. Furthermore, it is believed that black tea
leaves and tea extracts are able to limit pathogen-and enterotoxin-induced intestinal fluid losses in
diarrhoea. Indeed the levels of beneficial bacteria in the gut may be increased to promote healthy
microflora balance in the gut.
Thus the invention provides a beneficial effect upon the intestinal microflora balance and helps to
improve or maintain this balance. This leads to health benefits for the individual consuming the food
51/757
product and also helps to treat bouts of diarrhoea (infectious or non-infectious) or to prevent its
occurrence. The invention is particularly effective for improving or maintaining intestinal microflora
balance and the treatment or prevention of infectious diarrhoea.
Without wising to be bound by theory, it is believed that the black tea may provide the effects
referred to above by one or more of the following possible modes of action: complexation of iron,
which is an essential micronutrient required for bacterial growth.
. disturbance of the membrane potential which leads to cessation of metabolic functions of the
bacteria . interaction with membrane proteins and block energy (glucose) transport into cells of the
bacteria . causing membrane damage and subsequent leakage of cell constituents into the
environment inhibition of enterotoxin secretion from pathogens neutralisation of enterotoxin . inhibition
of pathogen-or enterotoxin induced chloride and water transport to the gut wall.
According to the present invention, black tea (and extracts thereof) is advantageous in improving or
maintaining intestinal microflora balance for the individual consuming the food product and in
treating bouts of diarrhoea (infectious or noninfectious) or preventing its occurrence. This may be
because black tea is less likely to be absorbed in the gut then green tea because of its different
chemical composition arising from the fermentation process which it undergoes as compared to
green tea. The beneficial effects may be due to the longer residence time of black tea in the gut
compared to green tea.
Tea extracts have inhibitory (in vitro and in vivo) effect against Vibrio cholerae, Salmonella typhi,
Campylobacter jejuni, Campylobacter Coli, Heliobacter pylori, Shigella, Salmonella, Clostridium,
Pseudomonas, Candida, Mycoplasma and Cryptococcus, rotavirus and influenza A virus growth,
pathogen enterotoxin secretion and enterotoxin-induced intestinal fluid secretion.
This inhibitory may occur through one or more of the following active compounds in black tea and
black tea extracts :
52/757
Catechins (present in low concentrations in black tea), Theaflavins, Thearubigins, or condensed
Tannins.
Except in the operating and comparative examples, or where otherwise explicitly indicated, all
numbers in this description indicating amounts of material or conditions of reaction, physical
properties of materials and/or use are to be understood as modified by the word"about."All amounts
in the food product are by weight, based on the weight of the food product unless otherwise
specified.
"The term"comprising"is meant not to be limiting to any subsequently stated elements but rather to
encompass non- specified elements of major or minor functional importance. In other words the
listed steps, elements or options need not be exhaustive. Whenever the
words"including"or"having"are used, these terms are meant to be equivalent to"comprising"as defined
above." DETAILED DESCRIPTION OF THE INVENTION The invention will now be discussed in
greater detail.
Cooked food products The food product can be any type of food product which is subjected to a
cooking process before being eaten so that the food is eaten in a cooked and not in a raw state. The
food product may have been cooked by any cooking method including; baking, frying, roasting,
grilling, steaming, boiling or micro- waving.
The tea or tea extract The tea is used in the food product in an unbound state. As used
herein"unbound state"means that the tea is used (either as the leaf or as an extract of the tea, or as
the mixture thereof) in a state in which it is not adsorbed or chemically bound to another material.
The tea leaf may be in a dried or non-dried form. It may be as the whole leaf, as pieces of the leaf, or
as particles produced from the leaf. The tea extracts are typically added to the food products as a
liquid before the food products are cooked.
53/757
The tea extract may be produced by any conventional method such as making an extract of the tea
with hot or boiling water. The tea extract may be of any strength.
The tea is a black tea. Any black tea may be used according to the invention. The term black tea as
used herein also includes semi-fermented tea such as oolong. Green teas, which are not fermented
do not form a part of the present invention.
The food products, if they comprise the black tea leaf, preferably comprise an amount of from 0.01 to
25 % wt thereof, more preferably of from 0.1 to 15 % wt, most preferably of from 0.3 to 10 % wt. The
food products, if they comprise the black tea extract, preferably comprise an amount of from 0.01 to
15 % wt thereof, more preferably 0.05 to 10 % wt, most preferably, 0.1 to 5 % wt. A mixture of both
black tea leaf and black tea extract may be used. In this case, the products preferably comprise
each of these ingredients in the above stated amounts.
If a mixture is used, it is especially preferred to use 0.5 to 10 % wt of the black tea leaf and 0.1 to 5 %
wt of the black tea leaf extract.
For some food products it may be preferred to use the black tea extract, for example where the
visual appearance of tea leaves is not desired in the food, or, where preparation of the food product
is easier with the black tea extract.
Preferably the black tea leaves, an extract of black tea or the mixture thereof is/are cooked in the
food product when it is cooked. However, it is also possible to add the tea leaves to the cooked food
product after it has been cooked.
Dosage The cooked food products are consumed in an amount sufficient to maintain or improve
microflora balance and/or to treat or prevent diarrhoea (either infectious or non-infectious) in a
subject consuming the composition and are preferably consumed as a part of the daily diet of an
individual. The dosage required will depend upon the individual but may be, for example, in the
range of from 1 to 50 mg/kg of body weight.
54/757
Types of food product The cooked food product may be any type of cooked food product.
It is especially preferred that the food product is either a cookie (biscuit); a bread product which can
be either leavened (raised) or unleavened (unraised), such as leavened bread, tortilla, roti, chapati,
nan bread, rye-bread; pastries; cake; bun; or a snack product such as a samosa, pastie, pie, pakora,
crisps etc and cereal based products such as pasta and rice- based products.
The food product may be one which is mixed with a liquid such as milk or water during cooking.
Examples of this type of edible composition include porridges and other such cooked
cereal products. Porridges are an especially preferred type of cooked food product according to the
invention.
The present invention provides, in particular, a cooked food product comprising black tea leaves, an
extract of black tea or a mixture thereof, wherein the black tea leaves or the extract of black tea is/are
present in an unbound state and further wherein the food product is a cookie, cake, bun, pastry, or
porridge which comprises a milk or milk based ingredient in an amount of up to 10 % wt.
It is especially preferred that the food product is one that has good keeping qualities and which does
not need refrigeration, such as a dry cereal based product such as a cookie. It is also preferred that
the cooked food product does not contain substantial amounts of water in order to extend its keeping
qualities. However, for food products such as pasta and rice based products which are typically
stored in the substantially dried state and only cooked just prior to consumption, it is not so important
to have a low water content in the cooked food product.
A food product according to the present invention does not include drinks.
Water content Preferably the cooked food product comprises 20 % wt water or less, more preferably
15 % wt water or less. The exact amount of water used will depend upon the type of the product and
the levels of the other ingredients used.
55/757
Food product ingredients Any suitable ingredients may be used to produce the food product.
(i) Flour The product will usually comprise a flour of some sort. The amount and type of flour will
depend upon the food product.
The flour may be made, for example, from cassava, wheat, beans, rice, maize, millet or oats. If
desired the food product may further comprise baking powder or any other raising agent.
(ii) Fat The product will usually comprise a fat of some sort. The amount and type of fat will depend
upon the food product. The fat may be, for example, dairy-based such as butter, cream or cheese, a
vegetable oil, animal oil, nut oil etc.
(iii) Milk or milk based ingredient The product may comprise milk or milk based ingredient (not butter
as this is considered as a fat as referred to above).
Suitable examples include, milk and milk powder, especially skimmed milk powder. The amount and
type of the milk or milk based ingredient will depend upon the food product. For sweeter tasting food
products, such as cookies, cakes, buns or pastries the inclusion of a milk or milk based ingredient,
especially skimmed milk powder, provides an especially pleasing taste to the food product in
combination with the tea.
According to the second aspect of the invention, the milk or milk based ingredient is present in an
amount of up to 5 or 10 % wt, more preferably of from 0.1 to 3 % wt, most preferably of from 0.5 to
2.5 % wt. in the food product.
(iv) Egg The food products may also comprise egg in any suitable amount.
The egg may be in the form of whole egg, egg whites, egg yolk or egg-derived products.
56/757
(v) Sugar The food products may also optionally comprise one or more natural sweeteners (sugars).
Suitable natural sweeteners include sucrose, fructose, glucose, maltose and mixtures thereof.
Sucrose is especially preferred either alone or combination with another sugar. The amount of the
sugar added is a matter of taste but will usually be in the range of from 1 to 25 % wt, preferably of
from 2 to 20 % wt, most preferably 5 to 15%. In some cases sugar and/or fat free products may be
used.
Other optional ingredients The food products may contain any of the usual minor food ingredients in
conventional amounts, for example: flavourings including herbs and spices, salt, pepper colourings,
preservatives, flavour improvers, emulsifiers, stabilisers, artificial sweeteners, aromas etc. Typically
these ingredients are used in an amount of 5 % wt or less per ingredient, with the product comprising
less than 25 % wt in total of these ingredients.
Fruits and fruit pieces, vegetables and vegetable pieces, honey, cereals such as oats and rice, nuts
etc may also be added to the food product to give flavour and/or texture.
Depending upon the type of food product, it may comprise a fruit juice. Any desired fruit juice can be
added. Typically amounts of up to 30 % wt in total of these ingredients may be added.
Production of the food product The cooked food product may be produced by any suitable method
for producing that type of food product. Suitable types of cooking methods are detailed above.
The present invention will be further explained with reference to the following non-limiting examples.
Further examples within the scope of the present invention will be apparent to the person skilled in
the art.
EXAMPLES Example 1 A cookie according to the present invention was made with the formulation as
given in table 1. The conventional method for making cookies was followed.
Table 1
57/757
grams
Caster Sugar 170
Butter 170
Salt 5
Spices and flavouring 10
Baking powder 5
Skimmed milk powder 10
Tea Leaves 33
Plain Flour 450
Water 130
The cookies were found to have an acceptable taste and could be stored in an air-tight container for
a prolonged period.
58/757
Regular consumption of the cookies has a beneficial effect upon intestinal microflora balance and
can also be used to ameliorate diarrhoea infections in subjects consuming the biscuits, including for
infectious diarrhoea.
Example 2 In in-vitro experiments, black tea extract (1,5 mg/mL-4, 5 mg/mL) inhibited the growth of
Salmonella cholerasuis, Staphylococcus aureus, Staphylococcus sonnei and Escherichia coli K88.
Example 3 Anti-microbial properties have been attributed to tea.
Moreover, chewing tea was associated with improved resistance to enteric infections. To test the
effect of black tea on acute infectious diarrhoea, black tea was infused to cannulated small intestinal
segments of piglets infected with either enterotoxigenic Escherichia coli (ETEC) or Escherichia coli
heat-labile toxin (LT).
Spray-dried water extract of black tea-leaves was dissolved in osmotic solution. Black tea solutions
with similar osmolality and pH were perfused (8 mL/h) into ETEC or LT- infected small intestinal
segments of ETEC receptor-positive piglets. After 8-h perfusion, changes in net fluid and electrolyte
absorption were determined per cm2. In addition, the capacity of black tea to inhibit LT-induced
cytotoxicity was tested in a Vero cell-line. All data were expressed as mean least significant
difference (LSD). Significance levels were set at P < 0.05.
ETEC significantly impaired the intestinal net fluid absorption (171112 (-55%) versus 494112 uL/cm2)
as well as the net sodium and chloride absorption. Black tea dose dependently partially reversed (P
< 0.05) significantly the ETEC-induced reduction in net fluid (352112 (-20%) versus 171112 uL/cm2 (55%) ), as well as net sodium and net chloride absorption. Black tea also significantly restored the
LT-induced reduction in net fluid absorption (322112 (-27%) versus 494112 uL/cm2), and net sodium
59/757
and chloride absorption. In addition, black tea also dose dependently inhibited the LT-induced
cytotoxicity towards Vero cells.
Consuming black tea may be beneficial in treating secretory diarrhoea. Black tea probably not only
acts against pathogen growth or adhesion, but also against enterotoxins or enterotoxin-induced
electrolyte transport changes and ensuing fluid secretion.Claims:
Claims 1. The use of a cooked food product comprising black tea leaves, an extract of black tea or a
mixture thereof, to maintain or improve microflora balance and/or to treat or prevent diarrhoea in a
subject consuming the composition and wherein the black tea leaves or the extract of black tea
is/are present in an unbound state.
2. The use according to claim 1, wherein the black tea leaves, an extract of black tea or the mixture
thereof is/are cooked in the food product when it is cooked.
3. The use according to either one of claims 1 or 2, wherein the product comprises 0.1 to 19 % wt of
the black tea leaf.
4. The use according to any one of the preceding claims, wherein the product comprises 0.1 to 5 %
wt of the black tea extract.
5. The use according to any one of the preceding claims, wherein the food product is either a cookie;
a bread product: a pastry; cake; bun; a snack product or cereal based products.
6. The use according to any one of the preceding claims, which is a cookie, cake, bun or pastry, and
which further comprises a milk or milk based ingredient in an amount of up to 10 % wt.
7. The use according to any one of the preceding claims, wherein the product comprises a mixture of
black tea leaf and black tea extract.
60/757
8. The use according to claim 7, wherein the food product is consumed as a part of the subject's
daily diet.
9. A cooked food product comprising black tea leaves, an extract of black tea or a mixture thereof,
wherein the black tea leaves or the extract of black tea is/are present in an unbound state and further
wherein the food product is a cookie, cake, bun, pastry, or porridge which comprises a milk or milk
based ingredient in an amount of up to 10 % wt.
61/757
4. CA2422973 - 23.09.2004
HEALTH FOOD FOR GOOD SLEEP
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CA2422973
Inventor(s):
(JP)
MATSUSHIGE KATSUMICHI (JP); MORIYA RYUICHI (JP); MURAMATSU NOBUKI
IP Class 4 Digits: A61K
IP Class:
A61K35/78; A61K35/84; A61K33/06
E Class: A23L1/30B; A61K33/06+M; A61K35/78+M; A61K35/84+M
Application Number:
US20030390650 (20030319)
Priority Number: CA20032422973 (20030320); US20030390650 (20030319)
Family: CA2422973
Abstract:
AN INNOVATIVE HEALTH FOOD FOR GOOD SLEEPY IS PROVIDED FOR IMPROVING THE
FACTORS THAT INTERFERE WITH SLEEP AS MUCH AS POSSIBLE AND IS SUITABLE FOR
ATTAINING GOOD SLEEP AND DEEP SLEEP MAINLY COMPRISING HERBAL MEDICINES IN
COMBINATION. THE HEALTH FOOD FOR GOOD SLEEP CONTAINS A PANAX GINSENG EXTRACT,
A GINKGO BILOBA LEAF EXTRACT, A GANODERMA LUCIDUM EXTRACT, AND CALCIUM, WHICH
ARE MIXED TOGETHER IN PREDETERMINED PROPORTIONS. FOR EXAMPLE, THE MIXTURE
CONTAINS 0.5 TO 1.0 PARTS BY WEIGHT OF THE GINKGO BILOBA LEAF EXTRACT, 0.1 TO 0.5
PARTS BY WEIGHT OF THE GANODERMA LUCIDUM EXTRACT, AND 0.1 TO 1.0 PARTS BY
WEIGHT OF CALCIUM WITH RESPECT TO 1 PART BY WEIGHT OF THE PANAX GINSENG
EXTRACT.Description:
BACKGROUND OF THE INVENTION
[0001] 1. Field of the Invention
62/757
[0002] The present invention relates to a health food for good sleep, and in particular, the socalled health food that allows a person to have a good sleep at rest in the night by eating or drinking
the health food which is not a medicine for recovering from insomnia.
[0003] 2. Description of the Related Art
[0004] In recent years, for removing physical and mental fatigue, medicines, foods, health
appliances, bedclothes, bath preparations, and so on have been on the market.
[0005] Medicines are originally used for disease-fighting, so that daily dietary life should be basic
to maintenance of good health and prevention of a disease.
[0006] Heretofore, means for directly removing physical fatigue or the like is to take a medicine
such as one known as a revitalizer or a fatigue-recovering agent.
[0007] In addition, under the present situation, symptoms related to physical fatigue, such as
sleeplessness, stiff shoulder, feebleness, weakened four limbs, and so on are mainly dealt with
medicines.
[0008] Furthermore, these medicines should be taken essentially under direction by the physician
or the pharmacist.
[0009] In particular, with respect to sleeplessness, any sleeping drug is administered as
prescribed by the physician and is only used for sick sleeplessness. On the other hand, the
administration of sleeping drug for non-disease phenomena such as bad-falling sleep and restless
sleep is not preferable because of being at risk of finding constitutive adverse reactions.
[0010] Most of sleeping drugs as medicines directly effect on the sleep center in the brain.
Therefore, factors that interfere with sleep come to the functions of the entire body, such as pain,
swelling, sick blood, excessive sensitivity to cold, decrease in the level of blood sugar, stress,
nutritional balance (in particular, calcium deficiency), blood pressure abnormal, cardiac failure,
anemia, gastrointestinal disturbance, urination abnormal, decrease in physical strength, and
autonomic imbalance.
[0011] Many persons suffered from insomnia have two or more factors in general, so that these
factors cannot be improved by taking any medicine that only effects on the sleep center in the brain.
[0012] For simultaneously improving two or more factors, two or more medicines corresponding to
the respective factors should be taken. In this case, the risk of side effects may be increased.
[0013] Therefore, there is no appropriate medicine or food what is called for maintaining bodily
functions to improve the body as a whole for good sleep or deep sleep.
SUMMARY OF THE INVENTION
[0014] In consideration of the above facts, for improving the factors that interfere with sleep as
much as possible, it is an object of the present invention to provide an innovative health food suitable
63/757
for attaining good sleep and deep sleep mainly comprising herbal medicines (i.e., plant extracts) in
combination with each other.
[0015] The foregoing object is accomplished in one embodiment by providing a health food for
good sleep comprising a mixture of a Panax ginseng extract, a Ginkgo biloba leaf extract, a
Ganoderma lucidum extract, and calcium at a predetermined ratio.
BRIEF DESCRIPTION OF THE DRAWINGS
[0016] FIG. 1 is a block diagram for illustrating the process of preparing a health food for good
sleep in accordance with the present invention.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
[0017] Hereinafter, we will describe preferred embodiments of the present invention in detail.
[0018] A health food, which is one of the preferred embodiments of the invention, is formulated to
remove the following factors, which prevent a person from having a good sleep, as much as possible.
The factors include (1) body pain, (2) excessive sensitivity to cold, (3) feeling of hunger, (4) metal
fatigue (accumulation of stress), (5) deficiencies of calcium and vitamins B1, B6, and B12, (6)
autonomic nervous system abnormality, (7) pressure abnormality (high or low blood pressure), (8)
palpitation or irregular heartbeat, (9) anemia, (10) gastrointestinal troubles such as indigestion and
disordered digestion, (11) urination troubles such as residual urine and increased urinary frequency,
(12) constipation, (13) loss of bodily strength and worthlessness feeling in the entire body, and so on.
[0019] Therefore, the health food for good sleeping of the present embodiment comprises a
mixture of herbal materials having positive effects of removing the above factors as much as possible
and a Ginkgo biloba leaf extract. In other words, the health food of the present embodiment
comprises a mixture of a Panax ginseng extract, a Ginkgo biloba leaf extract, a Ganoderma lucidum
extract, and calcium at a predetermined ratio. Hereinafter, the details of each component will be
described.
(A) The Panax ginseng extract
[0020] Panax ginseng has properties of activation, mental stability, anti-aging, and so on. Panax
ginseng exerts effects on various symptoms and also exerts effects on a wide range of clinical
applications, so that it has been used in many Chinese medicine formulations including "ginseng
soup" and "Bojun Ikki Tan". It has been confirmed that this ginseng extract has an excellent effect on
sleeplessness, so that the research results of such an effect of the ginseng extract have been
reported in many documents. For instance, when the ginseng extract is given to a rat, the period of
non-rapid eye movement (REM) sleep increases significantly to effect on the improvement of sleep
64/757
disorder. Furthermore, it has been also confirmed that the ginseng extract has central nerve system
depressing action, mental stabilizing action, cholinergic action, histamine like action, blood pressure
stabilizing action, sedative action, availabilities to prevention and treatment of psychosomatic
disease in autonomic imbalance, and so on.
(B) Ginkgo Biloba Leaf Extract
[0021] The Ginkgo biloba leaf extract is already used as a medicine in other countries, particularly
in Germany and France. It is always the fifth-best seller in the field of medicines, so that it is
increasingly popular as a raw material for pharmaceutical production. In Japan, on the other hand,
the Ginkgo biloba leaf extract is an unauthorized medicine because of being regulated under the
Pharmaceutical Affairs Law, so that it is used as a health food in the present circumstances. The
main component of such a Ginkgo biloba leaf extract is flavonoid. It is noted that it contains double
flavone which is peculiar to the Ginkgo biloba leaf extract.
[0022] The positive effects of the Ginkgo biloba leaf extract is to normalize (protect) the capillary
blood vessel in addition to control platelet agglutination, and to facilitate the flow of blood while
preventing the formation of blood clot that clogs the blood vessel and leads to infarction. Therefore,
the Ginkgo biloba leaf extract has a wide range of applications including arteriosclerosis,
hypertension, stress syndrome, cardiac disease, cerebral apoplexy, dementia and so on.
[0023] Furthermore, in many medical documents, it has been confirmed that the Ginkgo biloba leaf
extract also significantly improves sleeplessness. Therefore, the invention pays attention to this fact
and thus the health food of the invention contains the Ginkgo biloba leaf extract as one of main
components. Furthermore, it has been reported in medical documents that Ginkgo biloba leaf extract
does not show any side effect and any contraindication when it is mixed with other food raw materials.
(C) Ganoderma Lucidum (Reishi) Extract
[0024] The Ganoderma lucidum extract is an herbal medicine extracted from a fruiting body of
Ganoderma lucidum grouped in Polyporaceae. According to the traditional Chinese medical, the
Ganoderma lucidum extract has a mental stabilizing action in addition to other actions such as tonic,
blood-supplying, and hydragogue actions. In addition, it shows an effect of sleep modification and
mental stabilization. That is, when the Ganoderma lucidum extract is given to a rat, it is confirmed the
total amount of non-REM sleep significantly increases in a dark period while not increasing in a bright
period. In addition, the total amount of REM-sleep significantly increases not only in the dark period
but also in the bright period. In this manner, it is confirmed that the Ganoderma lucidum extract
contains a component that has a sleep-promoting effect. Therefore, in the invention, the Ganoderma
lucidum extract is contained as one of main components in the health food.
65/757
(D) Calcium
[0025] Calcium is a very important element as a main component of skeleton and tooth. It has
been also medically known that the decrease in calcium content in the blood leads to an increase in
abnormality of nerve excitability. The increase in nerve excitability interrupts sleep.
[0026] Therefore, in the invention, calcium is contained as one of main components in the health
food for preventing the nerve from excessive excitation. The calcium may be one of various kinds of
calcium materials such as pearl calcium, eggshell calcium, crushed bone calcium, oyster shell
calcium, and calcium phosphate. In the invention, calcium is not limited to a specific one. Any kind of
calcium may be used. However, calcium is hardly absorbed in general, compared with other
elements. In this embodiment, therefore, pearl calcium is preferably used because of its excellent
absorbing efficiency.
[0027] In the present embodiment, the health food is prepared by mixing 0.5 to 1.0 parts by weight
of a Ginkgo biloba leaf extract, 0.1 to 0.5 parts by weight of a Ganoderma lucidum extract, and 0.1 to
1.0 parts by weight of calcium with respect to 1 part by weight of a Panax ginseng extract.
Depending on consumer demands, alternatively, the mixture may be provided as dry powders,
condensate with syrup or honey, granules and a tablet prepared by adding filler in the powders and
coagulating the mixture in a mold, and so on. Furthermore, it may be provided as a capsulated
extract, powder, or granule.
(E) Rehmanniae Radix Stem
[0028] The Rehmanniae radix stem is provided as an extract having an effect of lowering the blood
glucose level. In addition, it is also known that it shows blood-supplying, tonic, and haemostatic
actions, so that it effects on diabetes, climacteric disturbance, arteriosclerosis, and so on.
Furthermore, it acts for recovering from fatigue. Therefore, it becomes possible to recover from
fatigue and gives a good sleep, allowing a person to fall into a deep sleep.
[0029] Next, an example of a preferable intake of each component in the health food of the
present embodiment per day is as follows. On the standard scale, the Panax ginseng extract is 200
mg, the Ginkgo biloba leaf extract is 150 mg, the Ganoderma lucidum extract is 50 mg, and calcium
is 100 mg. However, the present embodiment is not limited to these contents.
(F) Tochu (Eucommia Ulmoides) Leaf
[0030] It is well known in the art that Tochu leaf is one of popular products in recent years because
of being provided as a drinkable extract prepared by cutting the leaves into pieces and boiling. It
has been confirmed that the Tochu leaf contains gutta-percha and has tonic, hypertensive, diuretic,
66/757
muscularity-strengthening, liver-strengthening, and insomniac actions in addition to the action of
lowering the sensitivity to external stimulation. From this point, the Tochu leaf may be contained as
one of components in the health food of the invention.
[0031] In the invention, as shown FIG. 1, each of Panax ginseng, Ginkgo biloba leaf, and
Ganoderma lucidum, which are main components of the health food, is subjected to the step of
extraction to prepare an extract fraction thereof. In the step of mixing, subsequently, the extracts of
theses components are mixed with calcium. Alternatively, each component may be dried and
provided as powders, followed by mixing together with other dried powdery components. The
mixture is then mixed with calcium to obtain the same product. The step of extraction may be any
extraction procedure well known in the art. The resulting mixture is further processed into the form of
the final product.
(G) Jujube (Ziziphus Jujuba)
[0032] The jujube contains sucrose, mucus, malic acid, tartaric acid, and other ingredients. The
extract of Jujube has the actions of recovering from fatigue, preventing excitation of nerve to allow
mental stabilization, and relieving drug effects. Thus, it is suitable for sleeplessness. From this point,
the jujube extract maybe one of the components of the health food of the invention.
[0033] That is, in the case of directly providing the health food for good sleep of the invention in
extract form, the mixture of extracts may be bottled. Alternatively, the mixture may be provided as a
condensate by further mixing with syrup or honey, followed by being bottled. In the case of providing
the mixture in powdery form, for instance, it may be provided as dried powders in a bag. In the case
of providing the mixture in granulated form or tablet form, the mixture may be pulverized, followed by
adding filler such as lactose in the pulverized mixture and then coagulating the mixture in a mold.
Furthermore, the mixed extract, dry powders, or granules may be capsulated in a hard capsule such
as a gelatin capsule or a soft capsule such as one prepared by adding glycerin as a plasticizer,
water, and so on in a gelatin as a base. Therefore, the health food can be provided as a capsule type
food which can be easily swallowed.
(H) Licorice
[0034] The licorice contains glycyrrhizin. The extract of licorice has the actions of detoxication,
expectorant, antitussive, pain relief, refreshing, releasing interrupted pulse, recovering from fatigue,
and so on. Thus, it has the action of clearing the cause of sleeplessness.
[0035] As described above, the health food for good sleep in accordance with the present
invention comprises the Panax ginseng extract, the Ginkgo biloba leaf extract, the Ganoderma
lucidum (Reishi) extract, and calcium. Therefore, effects of the respective components can be acted
67/757
as a synergic effect to facilitate the flow of blood while relieving each symptom which is one of the
causes of sleeplessness. Therefore, it becomes possible to effectively obtain a good sleep by
preventing an increase in excitability of cerebral nerve, stabilizing mental, and getting into better
physical condition. Consequently, the invention provides a health food which is innovative in that
herbal medicines are provided as main raw materials in combination for improving factors that
prevent the consumer from having a good and deep sleep. In addition, such a health food does not
exert any effect like a hypnotic. In other words, such a health food successively provides a person
with a good and deep sleep at a rest time in the night when it is successively eaten or drunk to
regulate the physical condition, while it does not exert any effect like a hypnotic as a conventional
medicine. Therefore, the consumer would not become sleepy even immediately after eating or
drinking the health food. In this case, also, the behavior of the consumer would not be relaxed.
(I) Aurantii Nobilis Pericarpium
[0036] The Aurantii nobilis pericarpium is used as an aromatic stomachic. In addition, the extract
thereof is also used for facilitating water absorption, increasing food appetite, releasing the sense of
fullness, and so on. Furthermore, an offensive odor of Chinese herbal medicine can be cancelled by
mixing with the Aurantii nobilis pericarpium. Therefore, it is recognized that it allows the medicine to
be easily swallowed.
(J) Chrysanthemum
[0037] The chrysanthemum is also known as a Chinese herbal medicine from a long time ago and
the extract thereof has the actions of relieving headache and lightheadedness, increasing food
appetite, and so on. As the chrysanthemum flower relieves headache and lightheadedness which
interrupt a quiet sleep, it may be provided as one of components of the health food of the invention.
(K) Coix Lacryma-joli (Adlay)
[0038] The adlay is used as a food or a Chinese medicine in the art from a long time ago. The
extract thereof has the actions of removing swelling, pain relief, anti-inflammatory, detoxication, and
so on.
[0039] In the invention, as shown in FIG. 1, each extract of Panax ginseng, Ginkgo biloba leaf,
Ganoderma lucidum, Rehmanniae radix stem, Tochu leaf, Jujube, Licorice, Aurantii nobilis
pericarpium, Chrysanthemum, and adlay in the step of extraction. The step of extraction may be any
extraction procedure well known in the art. Each of the extracts was mixed with calcium in the step of
mixing, followed by further processing into the form of the final product. Alternatively, each of the
68/757
resulting components may be mixed as dry powders, followed by extracting and mixing with calcium
to obtain the same product.
[0040] That is, in the case of directly providing the health food for good sleep of the invention in
extract form, the mixture of extracts may be bottled. Alternatively, the mixture may be provided as a
condensate by further mixing with syrup or honey, followed by being bottled. In the case of providing
the mixture in powdery form, for instance, it may be provided as dried powders in a bag. In the case
of providing the mixture in granulated form or tablet form, the mixture maybe pulverized, followed by
adding filler such as lactose in the pulverized mixture and then coagulating the mixture in a mold.
Furthermore, the mixed extract, condensate, dry powders, or granules may be capsulated in a hard
capsule such as a gelatin capsule or a soft capsule such as one prepared by adding glycerin as a
plasticizer, water, and so on in a gelatin as a base. Therefore, the health food can be provided as a
capsule type food which can be easily swallowed.
[0041] In the present embodiment, the health food is prepared as an extract mixture by mixing 0.1
to 1.0 part by weight of a Ginkgo biloba leaf extract, 0.1 to 0.5 parts by weight of a Ganoderma
lucidum extract, 0.1 to 1.0 part by weight of calcium, 0.5 to 3.0 parts by weight of a Rehmanniae
radix stem extract, 0.25 to 0.75 parts by weight of a Tochu leaf extract, 1.5 to 3.5 parts by weight of a
Jujube extract, 0.25 to 1.0 parts by weight of a Licorice extract, 0.1 to 0.5 parts by weight of an
Aurantii nobilis pericarpium extract, 0.1 to 0.5 parts by weight of a Chrysanthemum extract, and 0.3
to 2.5 parts by weight of an adlay extract with respect to 1 part by weight of a Panax ginseng extract.
Alternatively, the extract mixture may be provided as a condensate by the addition of syrup or honey.
Alternatively, the extract mixture may be provided as granules or a tablet by pulverizing the mixed
extract and adding a predetermined amount of lactose and the like as a filler in the powders and
coagulating the mixture in a mold. Alternatively, it is also possible to capsulate the extract, liquid,
powders, or granules to provide the health food in capsulate form. In the invention, furthermore, the
containing ratio of each component is not limited to its upper limit described above. It may be
appropriately changed if required.
[0042] Next, an example of a preferable intake of each component in the health food of the
present embodiment per day is as follows. When health food for good sleep being formulated on the
basis of the above mixing ratio is eaten or drunk by the consumer, it is suitable for the consumer
since the intake of each of the components becomes as follows. That is, the Panax ginseng extract is
200 mg, the Ginkgo biloba leaf extract is 150 mg, the Ganoderma lucidum extract is 50 mg, the
Rehmanniae radix stem extract is 400 mg, the Tochu extract was 100 mg, the Jujube extract is 550
mg, the Licorice extract was 150 mg, the Aurantii nobilis pericarpium extract is 50 mg, the
Chrysanthemum extract is 50 mg, the adlay extract is 300 mg, and calcium is 100 mg. These values
are standard values. Therefore, needless to say, the invention is not limited to these values.
69/757
[0043] As described above, the health food for good sleep in accordance with the invention
comprises the Panax ginseng extract, the Ginkgo biloba leaf extract, the Ganoderma lucidum (Reishi)
extract, calcium, the Rehmanniae radix stem extract, the Tochu (Eucommia ulmoides) leaf extract,
the Jujube (Ziziphus jujuba) extract, the Licorice extract, the Aurantii nobilis pericarpium extract, the
Chrysanthemum extract, and the Coix lacryma-joli (adlay) extract. Therefore, effects of the respective
components can be acted as a synergic effect to facilitate the flow of blood while relieving each
symptom which is one of the causes of sleeplessness. Therefore, it becomes possible to effectively
obtain a good sleep or a deep sleep by preventing an increase in excitability of cerebral nerve,
stabilizing mental, and getting into better physical condition.
[0044] Consequently, the invention provides a health food which is innovative in that herbal
medicines are provided as main raw materials in combination for improving factors that prevent the
consumer from having a good and deep sleep. In addition, such a health food does not exert any
effect like a hypnotic. In other words, such a health food successively provides a person with a good
and deep sleep at a rest time in the night when it is successively eaten or drunk to regulate the
physical condition, while it does not exert any effect like a hypnotic as a conventional medicine.
Therefore, the consumer would not become sleepy even immediately after eating or drinking the
health food. In this case, also, the behavior of the consumer would not be relaxed.Claims:
1. A health food for good sleep, comprising a Panax ginseng extract, a Ginkgo biloba leaf extract, a
Ganoderma lucidum extract, and calcium, which are mixed together in the proportions of:
0.5 to 1.0 part by weight of the Ginkgo biloba leaf extract;
0.1 to 0.5 parts by weight of the Ganoderma lucidum extract; and
0.1 to 1.0 part by weight of calcium,
with respect to 1 part by weight of the Panax ginseng extract.
2. A health food for good sleep as claimed in claim 1, further comprising a Rehmanniae radix stem
extract, a Tochu leaf extract, a Jujube extract, a Licorice extract, an Aurantii nobilis pericarpium
extract, a Chrysanthemum extract, and an adlay extract, which are mixed together in the proportions
of:
0.5 to 3.0 parts by weight of the Rehmanniae radix stem extract;
0.25 to 0.75 parts by weight of the Tochu leaf extract;
1.5 to 3.5 parts by weight of the Jujube extract;
0.25 to 1.0 parts by weight of the Licorice extract;
0.1 to 0.5 parts by weight of the Aurantii nobilis pericarpium extract;
0.1 to 0.5 parts by weight of the Chrysanthemum extract; and
0.3 to 2.5 parts by weight of the adlay extract.
70/757
5. CN1302564 - 11.07.2001
HEALTH-CARE FOOD FOR IMPROVING FUNCTIONS OF STOMACH AND INTESTINE AND
BEAUTIFYING FACE AND ITS PREPARING PROCESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1302564
Inventor(s):
ZHOU YONG (CN); DU LIN (CN)
Applicant(s):
ZHOU YONG (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L1/48; A23L30/05
Application Number:
CN20010102129 (20010122)
Priority Number: CN20010102129 (20010122)
Family: CN1302564
Equivalent:
CN1180723C
Abstract:
A HEALTH-CARE FOOD FOR IMPROVING THE FUNCTION OF THE STOMACH AND INTESTINE AS
WELL AS FOR BEAUTIFYING THE LOOKS IS TO USE THE CHINESE ANGELICA, THE ROOT OF
RED PEONY, PORIS COCOS, SAFFLOWER, ALOE, VITAMINE E AND B2 AS THE RAW MATERIALS
WHICH ARE TO BE PROCESSED IN SMASHING, SIEVING, HOMOGENEOUS MIXING LOADING IN
THE CAPSULES, INSPECTING, PACKAGING AND STERILIZING.
71/757
6. CN1304694 - 25.07.2001
TONIC HEALTH-CARE FOOD AND ITS PREPARING PROCESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1304694
Inventor(s):
MAO XIANGKUN (CN); QI WEIZHENG (CN); ZHANG YUNXIANG (CN)
Applicant(s):
SUZHOU DESIGN INST OF LIGHT IN (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L1/326
Application Number:
CN20010108071 (20010122)
Priority Number: CN20010108071 (20010122)
Family: CN1304694
Equivalent:
CN1180714C
Abstract:
A TONIC HEALTH-CARE FOOD IN THE FORM OF CAPSULE, TABLET, OR PILL IS PREPARED
FROM CHINESE ANGELICA ROOT, ASTRAGALUS ROOT AND EEL THROUGH PULVERIZING AND
MIXING IN RATIO OF 3:1:1. IT CAN BUILD UP BODY, PROMOTE SECRETION OF MILK FOR
PUERPERA AND IMPROVE QUALITY OF MOTHER'S MILK.
72/757
7. CN1307827 - 15.08.2001
HEALTH FERMENTED SOYBEAN FOOD, HEALTH PURIFIED FERMENTED SOYBEAN KINASE
CAPSULE AND THEIR PRODUCTION PROCESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1307827
Inventor(s):
ZHONG SHIBIN (CN); SUN NAIJUN (CN); TAO MANG (CN)
Applicant(s):
SHANGHAI FENGKANG S and T DEV CO (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/20; A23L33/571
Application Number:
CN20010105113 (20010109)
Priority Number: CN20010105113 (20010109)
Family: CN1307827
Abstract:
THE PRESENT INVENTION RELATES TO A KIND OF HEALTH-CARE FERMENTED SOYBEAN FOOD,
HEALTH-CARE PURIFIED FERMENTED SOYBEAN KINASE CAPSULE AND PRODUCTION
PROCESS THEREOF. THE SOYBEANS IS USED AS RAW MATERIAL, AFTER SELECTING MATERIAL,
REMOVING IMPURITY, WASHING AND SOAKING, COOKING, INOCULATING, FERMENTATION,
BLENDING AND PACKAGING, THE FINISHED PRODUCT WITH RICH NUTRIENTS AND PALATABLE
TASTE IS OBTAINED. BY ENRICHING AND PURIFYING ITS BIO-ACTIVE COMPONENTS AND
ADDING OTHER AUXILIARY INGREDIENTS IT CAN MAKE THE INVENTED FERMENTED SOYBEAN
KINASE CAPSULE MORE POSSESS OBVIOUS FUNCTION OF PREVENTING THROMBOSIS. SAID
PRODUCT HAS NO ANTIGENICITY AND HAS NO SIDE EFFECT, SO IT IS A SAFETY HEALTH-CARE
FOOD.
73/757
8. CN1310227 - 29.08.2001
HEALTH FOOD AND ITS PRODUCTION PROCESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1310227
Inventor(s):
ZHANG XUEBIN (CN)
Applicant(s):
ZHANG XUEBIN (CN)
IP Class 4 Digits: A61K; C12G
IP Class:
A61K35/78; A61K35/56; C12G3/00
Application Number:
CN20010111539 (20010308)
Priority Number: CN20010111539 (20010308)
Family: CN1310227
Abstract:
THE HEALTH FOOD IS PRODUCED WITH ASS-HIDE GELATIN, YELLOW WINE, WALNUT KERNEL,
DATE, CRYSTAL SUGAR AND LYCIUM CHINENSE. ITS PRODUCTION PROCESS INCLUDES
SHELLING WALNUT, PITTING DATE AND LYCIUM CHINENSE, POWDERING, MIXING YELLOW
WINE WITH POWDER, STEAMING FOR 4-5 HR INITO PASTE WHILE STIRRING EVERY TEN
MINUTES. IT HAS THE HEALTH FUNCTIONS OF NOURISHING YIN AND BLOOD, INVIGORATING
LIFE ESSENCE, MOISTENING LUNG, INVIGORATING SPLEEN AND STOMACH, PROTECTING
LIVER AND RAISING IMMUNITY AND IT HAS CERTAIN CURATIVE EFFECT ON HEPATOCIRRHOSIS,
EARLY-STAGE LIVER CANCER AND OTHER HEPATOSIS.
74/757
9. CN1313040 - 19.09.2001
HEALTH-CARE HYPOLIPEMIC AND ANTIHYPERTENSIVE FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1313040
Inventor(s):
FAN JIN (CN)
Applicant(s):
FAN JIN (CN)
IP Class 4 Digits: A23D
IP Class:
A23D9/00
Application Number:
CN20010107273 (20010323)
Priority Number: CN20010107273 (20010323)
Family: CN1313040
Equivalent:
CN1157120C
Abstract:
A HEALTH-CARE HYPOLIPEMIC AND ANTIHYPERTENSIVE FOOD IN THE FORM OF SOFT
CAPSULE OR TABLET CONTAINS FLIXWEED OIL (6-8 WT. PORTIONS) EXTRACTED FROM
FLIXWEED SEED USING HEXANE, CORN OIL (2-4) AND OPTIONAL ADDITIVE. IT CAN REDUCE
TRIGLYCERIDE IN BLOOD TO PREVENT THROMBUS.
75/757
10. CN1316196 - 10.10.2001
NUTRITIVE HEALTH-CARE FOOD FOR CONDITIONING MALE SEXUAL FUNCTION
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1316196
Inventor(s):
LI HULIN (CN)
Applicant(s):
LI HULIN (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L1/10; A61K35/60
Application Number:
CN20010116721 (20010420)
Priority Number: CN20010116721 (20010420)
Family: CN1316196
Abstract:
A NUTRITIVE HEALTH-CARE FOOD FOR REGULATING SEXUAL FUNCTION OF MAN IS PREPARED
THROUGH EXTRACTING ACTIVE COMPONENTS FROM CHINESE-MEDICINAL MATERIALS, AND
MIXING THEM WITH FOOD CARRIER. ITS ADVANTAGESINCLUDE INTEGRATION OF MEDICINAL,
HEALTH-CARE AND NUTRITIVE FUNCTIONS HIGH EFFECT AND NO BY-EFFECT.
76/757
11. CN1317340 - 17.10.2001
HEALTH FOOD FOR DIABETICS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1317340
Inventor(s):
WANG DECAI (CN); SUN GUIYING (CN)
Applicant(s):
JINGONG SCIENCE AND TECHNOLOPG (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A23L1/29; A61P3/10; A61K35/80
Application Number:
CN20010106269 (20010228)
Priority Number: CN20010106269 (20010228)
Family: CN1317340
Abstract:
A HEALTH-CARE FOOD FOR DIABETICS IS PREPARED FROM SPIRULINA AND 6 CHINESEMEDICINAL MATERIALS INCLUDING YAM, PUERARIA ROOT, POLLEN, LIQUORICE ROOT, ETC.
THROUGH HYDROLYZING THE SPIRULINA TO OBTAIN PEPTIDE POWDER AND DECOCTING THE
CHINESE-MEDICINAL MATERIALS TO OBTAIN DRIED POWDER. ITS ADVANTAGES ARE RICH
PROTEIN AND NUTRIENTS ENOUGH FOR HUMAN BODY, NO ANY TOXIC BY-EFFECT, AND
PREVENTING THE CHRONIC COMPLICATIONS.
77/757
12. CN1318316 - 24.10.2001
IMMUNITY-REGULATING AND FATIGUE-RESISTING HEALTH FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1318316
Inventor(s):
GAO MINGHUA (CN)
Applicant(s):
HUAYUAN LANKE HEALTH PRODUCT C (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A61K9/48; A23L1/056
Application Number:
CN20010112974 (20010524)
Priority Number: CN20010112974 (20010524)
Family: CN1318316
Abstract:
THE HEALTH FOOD OF THE PRESENT INVENTION IS PRODUCED BY UTILIZING CHITOSAN IN
DIFFERENT MOLECULAR WEIGHT AS MAIN MATERIAL AND COMPOUNDING WITH GLOSSY
GANODERMA FINE POWDER, WALL-BREAKING GLOSSY GANODERMA SPORE POWDER,
LYCIUM CHINESE, COIX SEED, TACKAHOE, GYNOSTEMMA PENTAPHYLLA EXTRACTION, AMINO
GLUCOSE HYDROCHLORIDE AND OTHER COMPONENTS TO PRODUCE POWDER AND
CAPSULE. ANIMAL EXPERIMENT PROVIDES THE PRESNET INVENTION, HAS DETERMINED
FUNCTIONS OF REGULATING IMMUNITY, RESISTING FATIGUE AND ASSISTING INHIBITING
TUMOR.
78/757
13. CN1318317 - 24.10.2001
WEIGHT-REDUCING AND BLOOD LIPOID REDUCING HEALTH FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1318317
Inventor(s):
GAO MINGHUA (CN)
Applicant(s):
HUAYUAN LANKE HEALTH PRODUCT C (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K9/48; A23L1/056; A61K31/194
Application Number:
CN20010112976 (20010524)
Priority Number: CN20010112976 (20010524)
Family: CN1318317
Abstract:
HEALTH FOOD OF THE PRESENT INVENTION CONTAINS CHITOSAN OF DIFFERENT MOLECULAR
WEIGHT AS WELL AS LEVOROTARY CARNITINE TARTRATE AND EDIBLE SUPPLEMENTARY
MATERIAL AND IS PRODUCED TO POWDER AND CAPSULE. ANIMAL EXPERIMENT OF SAFETY
AND TOXICITY SHOW THAT THE PRESENT INVENTION HAS NO TOXIC MATTER, QUALIFIED
STABILITY, NO EXCITANT AND THE FUNCTIONS OF REDUCING WEIGHT AND WEIGHT AND
REDUCING BLOOD LIPOID. BODY'S TRIAL SHOWS ITS OBVIOUS PHYSICAL FUNCTIONS OF
REDUCING WEIGHT AND REDUCING FAT INSIDE BODY AS WELL AS INHIBITING SERUM
CHOLESTEROL AND TRIGLYCERIDE.
79/757
14. CN1319343 - 31.10.2001
HEALTH CARE FOOD HAVING FUNCTIONS OF REDUCING WEIGHT AND PREVENTING
CARDIOVASCULAR DISEASE
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1319343
Inventor(s):
YANG WEIPING (CN)
Applicant(s):
GUANGHAN YUSONG CO LTD SICHUAN (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K9/48; A23L1/052
Application Number:
CN20010107306 (20010330)
Priority Number: CN20010107306 (20010330)
Family: CN1319343
Equivalent:
CN1102351C
Abstract:
THE FUNCTIONAL HEALTH-CARE FOOD CAPABLE OF REDUCING WEIGHT AND PREVENTING
AGNIOCARDIOPATHY CONTAINS THE COMPONENTS OF GLUCOMANNAN, NATURAL ACTIVE
POLYSACCHARIDE, LACTOSE, MAGNESIUM STEARATE, VITAMIN AND TRACE MINERAL
ELEMENTS, AND ITS PRODUCTION PROCESS INCLUDES THE STEPS OF EXTRACTING
GLUCOMANNAN FROM KONJAK, EXTRACTING NATURAL ACTIVE POLYSACCHARIDE FROM
ANIMAL TISSUE, BLENDING MATERIALS, UNIFORMLY MIXING THEM, STERILIZING AND
CAPSULIZING SO AS TO OBTAIN THE INVENTED PRODUCT WITH THE GOOD EFFECT OF
REDUCING WEIGHT, LOOSING THE BOWEL TO RELIEVE CONSTIPATION, REDUCING BLOOD
SUGAR, REDUCING BLOOD-LIPID AND REDUCING BLOOD PRESSURE.
80/757
15. CN1319344 - 31.10.2001
SPORTS HEALTH CARE FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1319344
Inventor(s):
HE JINTIAN (CN); WANG HUIQIANG (CN); GUO LIZHONG (CN)
Applicant(s):
PHARMACEUTICAL TECHNOLOGY DEV (CN)
IP Class 4 Digits: A23L
IP Class:
A23L2/52; A23L1/052
Application Number:
CN20010112508 (20010330)
Priority Number: CN20010112508 (20010330)
Family: CN1319344
Abstract:
THE PRESENT INVENTION PROVIDES A SPORTS HEALTH-CARE FOOD, AND IS CHARACTERIZED
BY THAT THE CHINESE MEDICINAL MATERIAL GINSENG OR TOTAL SAPONIN OF GINSENG AND
D-RIBOSE ARE USED AS RAW MATERIAL, PROPERAUXILIARY MATERIAL IS ADDED, AND
UNIFORMLY MIXED SO AS TO OBTAIN THE INVENTED PRODUCT WITH THE FUNCTIONS OF
PREVENTING MUSCULAR ACHING PAIN RESULTED FROM SPORTS, MYOSPASM MUSCULAR
SPASM, RAISING SPORTS RESULT, SHORTEN PHYSICAL POWER RECOVERY TIMIE AFTER
SPORTS, PREVENTING MYOCARDIAL ISCHEMIA AND PROMOTING BODY RECOVERY OF
PATIENT AFTER OPERATION OR WITH CHRONIC DISEASES.
81/757
16. CN1322488 - 21.11.2001
HEALTH FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1322488
Inventor(s):
CHENG ZIFANG (CN)
Applicant(s):
CHENG GUOYI (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/202
Application Number:
CN20010115860 (20010511)
Priority Number: CN20010115860 (20010511)
Family: CN1322488
Abstract:
SHANZHEN HEALTH FOOD AS ONE SEASONING IS PRODUCED WITH CHESTNUT, PINE NUT,
HAZELNUT, WALNUT FROM MOUNTAINS, TANGSONGCAO AND ROSE AS WELL AS SOYBEAN,
SALT, YELLOW WINE, WHITE SPIRIT, SUGAR, AND RED RICE OINTMENT. IT IS DELICIOUS AND
HAS HEALTH FUNCTION OF NOURISHING STOMACH AND AIDING DIGESTION.
82/757
17. CN1323619 - 28.11.2001
EYESIGHT-STRENGTHENING AND INFLAMMATION-RESISTING HEALTH FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1323619
Inventor(s):
CUI HAO (CN)
Applicant(s):
CUI HAO (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A23L1/29; A61P27/02
Application Number:
CN20010114015 (20010529)
Priority Number: CN20010114015 (20010529)
Family: CN1323619
Equivalent:
CN1147312C
Abstract:
A HEALTH CARE FOOD WITH EFFECT ON IMPROVING EYESIGHT AND DIMINISHING
INFLAMMATION IS MADE FROM FOLLOWING RAW MATERIALS (ACCORDING TO THEIR WEIGHT
RATIO): TUCKAHOE 30-50, LIQUORICE 20-40, CHINESE WOLFBERRY FRUIT 20-40. THE
INVENTED HEALTH CARE FOOD PROVIDES EFFECTS ON RESISTING EFFECTIVELY
INFLAMMATION ON EYE, ADJUSTING HUMAN ESPECIALLY OPHTHALMIC IMMUNITY FUNCTION.
IT IS HELPFUL TO AVOID SUFFERING FROM FATIGUE ON EYES AND ENHANCE NURTURING EYE
CELLS. THIS FOOD IS PROVIDED WITHOUT POISON AND SIDE EFFECT, WITH ADVANTAGES OF
FEWER COMPONENTS, SIMPLE PROCESSING TO PRODUCE IT AND LOW COST.
83/757
18. CN1324580 - 05.12.2001
HEALTH FOOD CONTAINING ACTIVE NUTRITIOUS PROTEIN AND ITS PRODUCTION PROCESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1324580
Inventor(s):
CAI RUNSHENG (CN); CAI KELIN (CN)
Applicant(s):
CAI RUNSHENG (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A23L1/29; A61K38/02; A61P3/02
Application Number:
CN20010112930 (20010518)
Priority Number: CN20010112930 (20010518)
Family: CN1324580
Abstract:
THE PRESENT INVENTION DISCLOSES A HEALTH-ARE FOOD CONTAINING ACTIVE NUTRIENT
PROTEIN. SAID HEALTH-CARE FOOD COMPRISES REFINED PROTEIN RAW MATERIAL, VITAMINS,
MINERAL MATTER AND ADDITIVE. AFTER THE HEALTH-CARE FOOD IS TAKEN BY HUMAN BODY,
IT CAN PROMOTE PLASMA ESSENTIAL AMINO-ACID BALANCE, PROMOTE PRODUCTION OF
SOD, RAISE INTERNAL FREE RADICAL REMOVING CAPABILITY AND CAN ATTAIN THE GOAL OF
PROMOTING GROWTH AND RESISTING SENILITY.
84/757
19. CN1324653 - 05.12.2001
HEALTH FOOD CAPABLE OF REGULATING BLOOD LIPOID AND DELAYING SENILITY
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1324653
Inventor(s):
GAO MINGHUA (CN)
Applicant(s):
HUAYUAN LANKE HEALTH PRODUCT C (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A23L1/29; A61P3/06; A61P43/00
Application Number:
CN20010112975 (20010524)
Priority Number: CN20010112975 (20010524)
Family: CN1324653
Abstract:
THE HEALTH-CARE FOOD CONTAINING MEDICINAL RAW MATERIAL AND EDIBLE MATERIAL IS
MADE UP BY USING CHITOSAN WITH CLEAR AND DEFINITE MOLECULAR WEIGHT RANGE AS
MAIN COMPONENT AND ADDING EXTRACTS OF NATURALMEDICINAL MATERIALS OF
CARTHAMUS FLOWER AND GINKGO LEAF AS AUXILIARY COMPONNET. SAID PRODUCT CAN
INHIBIT INCREMENT OF SECUM CHOLESTEROL AND TRIGLYCERIDE, CAN REDUCE PEROXIDE
LIPID DEGRADATION PRODUCTCOTENT IN BLOOD, AND CAN RAISE HIGH-DENSITY
LIPOPROTEIN AND SUPEROXIDE DISMUTASE IN BLOOD, SO THAT IT POSSESSES THE
FUNCTIONS OF REGULATING BLOOD-LIPID AND DELAYING SENILITY.
85/757
20. CN1325717 - 12.12.2001
HEALTH-CARE FOOD PREPARED FROM EXTRACTS OF ANIMALS BONE MARROW AND CHINESEMEDICINAL MATERIALS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1325717
Inventor(s):
XIE QIAN (CN)
Applicant(s):
XIE QIAN (CN)
IP Class 4 Digits: A61K; A61P
IP Class:
A61K35/78; A61P37/02; A61K35/28
Application Number:
CN20010114216 (20010524)
Priority Number: CN20010114216 (20010524)
Family: CN1325717
Equivalent:
CN1186032C
Abstract:
A HEALTH-CARE FOOD FOR IMPROVING IMMUNITY IS PREPARED FROM FRESH OX BONE,
FRESH SHEEP BONE, FRESH CAMEL BONE, TISSUE ATTACHED TO THEM, GINSENG, JUJUBE
AND WOLFBERRY FRUIT THROUGH EXTRACTING.
86/757
21. CN1328779 - 02.01.2002
HEALTH-CARE FOOD WITH FUNCTION OF REDUCING BLOOD SUGAR
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1328779
Inventor(s):
JIN QIUSHENG (CN)
Applicant(s):
JIN QIUSHENG (CN)
IP Class 4 Digits: A23L; A61P
IP Class:
A23L1/29; A23L1/48; A61P3/10
Application Number:
CN20010119917 (20010629)
Priority Number: CN20010119917 (20010629)
Family: CN1328779
Abstract:
THE PRESENT INVENTION PROVIDES A HEALTH-CARE FOOD WITH FUNCTION OF REDUCING
BLOOD SUGAR. IT IS MADE UP BY USING EGG. JUJUBE, LYCIUM BERRY, WALNUT KERNEL,
PEANUT KERNEL, BLACK SOYBEAN AND YELLOW SOYBEAN AS RAW MATERIALS THROUGH
THE PROCESS OF MAKING POWDER, UNIFORMLY MIXING ACCORDING TO A CERTAIN
PROPORTION, BAGGING, SEALING AND STERILIZING SO AS TO OBTAIN THE INVENTED
POWDER INSTANT FOOD WHICH CAN BE EATEN BY MIXING IT WITH BOILING WATER. THE
ABOVE-MENTIONED POWDER FOOD ALSO CAN BE MADE INTO GRUEL-LIKE FOOD OR OTHER
FORM FOOD. IT IS SIMPLE AND SCIENTIFIC IN PRODUCTION PROCESS, AND CAN BE EASILY
FORMED INTO SCALE PRODUCTION.
87/757
22. CN1328781 - 02.01.2002
PRODUCTION PROCESS OF ANIMAL TENDON AND ITS SERIES HEALTH-CARE FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1328781
Inventor(s):
ZHANG WEIYAO (CN)
Applicant(s):
ZHANG WEIYAO (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/312
Application Number:
CN20010119872 (20010703)
Priority Number: CN20010119872 (20010703)
Family: CN1328781
Abstract:
THE PRESENT INVENTION RELATES TO A PRODUCTION PROCESS OF ANIMAL TENDON AND ITS
SERIES HEALTH-CARE FOODS, AND IS CHARACTERIZED BY THAT THE SAID PRODUCTION
PROCESS INCLUDES THE FOLLOWING PROCEDURES: 1.SELECTING MATERIAL, USING FRESH
ANIMAL TENDON AS RAW MATERIAL, REMOVING IMPURITY, WASHING AND CLEANING; 2.
REMOVING FAT CONTAINED BY ANIMAL TENDON AND CUTTING INTO STANDARD SMALL
BLOCKS; 3. DRYING; 4. PUFFING; 5. PULVERIZING TO OBTAIN FINE POWDER; AND 6. MAKING IT
INTO DIFFERENT SERIES HEALTH-CARE FOODS, INCLUDING (1). ANIMAL TENDON NUTRIENT
POWDER; (2). ANIMAL TENDON PUFFED FOOD WITH DIFFERENT TASTES; AND (3). ANIMAL
TENDON SWEETS AND BISCUIT. SAID INVENTION CAN HAVE VARIOUS ADDITIVES AND
CORRECTIVE ADDED, ITS FOODS HAVE RICH NUTRIENTS AND ITS COST IS LOW.
88/757
23. CN1332981 - 30.01.2002
PAROTIN CONTAINED HEALTH FOOD ADDITIVES AND MAKING PROCESS THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1332981
Inventor(s):
TANG ZIJIN (CN); CHENG GUANGYU (CN); MAO WEIPING (CN)
Applicant(s):
JIANGSU DAZIRAN BIOLOG ENGINEE (CN)
IP Class 4 Digits: A23L; A61P
IP Class:
A23L1/30; A61P1/02; A23L13/05; A61P1/04
Application Number:
CN20010127031 (20010727)
Priority Number: CN20010127031 (20010727)
Family: CN1332981
Equivalent:
CN1175763C
Abstract:
THE PRESENT INVENTION RELATES TO A HEALTH-CARE FOOD ADDITIVE CONTAINING PAROTIN
AND ITS PRODUCTION PROCESS. SAID FOOD ADDITIVE IS MADE OF CARBOXYMETHYL
CHITOSAN AND MILK SERUM MIXTURE, PAROTIN, SYNTHETIC PHOSPHOPROTEIN AND CASEIN
PHOSPHOPEPTIDE ACCORDING TO A CERTAIN MIXING RATIO. ITS PRODUCTION PROCESS
INCLUDES THE FOLLOWING STEPS: PREPARING PAROTIN: PREPARING MIXTURE OF
CARBOXYMETHYL CHITOSAN AND MILK SERUM; WEIGHING THE ABOVE-MENTIONED ALL THE
RAW MATERIALS ACCORDING TO A CERTAIN RATIO; PLACING THEM INTO SCREW CONICAL
MIXING MACHINE TO MIX THEM UNIFORMLY SO AS TO OBTAIN THE INVENTED FOOD ADDITIVE.
89/757
24. CN1334117 - 06.02.2002
HEALTH-CARE FOOD FOR TREATING DIZZINESS AND EMESIS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1334117
Inventor(s):
SUN SUN (CN)
Applicant(s):
SUN SUN (CN)
IP Class 4 Digits: A61K; A61P
IP Class:
A61K35/78; A61P1/08
Application Number:
CN20010127652 (20010725)
Priority Number: CN20010127652 (20010725)
Family: CN1334117
Equivalent:
CN1187063C
Abstract:
A HEALTH-CARE FOOD FOR TREATING DIFFERENT DIZZINESSES AND EMESIS IS PREPARED
FROM NATURAL FOOD, BURREED TUBER, DRIED GINGER, ANISE, TANGERINE PEEL, JUJUBE
AND ADDITIVE. ITS ADVANTAGES ARE HIGH CURATIVE EFFECT, LOW COST, DELICIOUS TASTE
AND NO TOXIC BY-EFFECT.
90/757
25. CN1336120 - 20.02.2002
ACTIVE COLOSTRUM HEALTH-CARE FOOD AND ITS PRODUCTION PROCESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1336120
Inventor(s):
LI LIHUA (CN)
Applicant(s):
HUAFANG TIANYU BIOTECH CO LTD (CN)
IP Class 4 Digits: A23C
IP Class:
A23C9/16
Application Number:
CN20010123623 (20010816)
Priority Number: CN20010123623 (20010816)
Family: CN1336120
Abstract:
THE PRESENT INVENTION RELATES TO COLOSTRUM HEALTH CARE PRODUCT WHICH IS
PRODUCED AS FOLLOWS: (A). SEPARATING FAT AND CASEIN FROM OX COLOSTRUM. (B).
PARTIALLY DEWATERING (C). ADDING BIOPROTECTIVE AGENT. (D). STERILIZING (E). FREEZE
DRYING, PACKING TO OBTAIN PRODUCT. SAID METHOD CAN ENSURE THAT THE PROTEIN IN
COLOSTRUM IS NOT DENATURED IN PROCESSING AND THE ACTIVE COMPONENTS IS
MAINTAINED IN COLOSTRUM.
91/757
26. CN1342417 - 03.04.2002
HEALTH-CARE FOOD CONTAINING WOLFBERRY FRUIT EXTRACT AND ITS PREPARING
PROCESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1342417
Inventor(s):
LIN YONGDONG (CN)
Applicant(s):
LUGU GROUP CO LTD SHANGHAI (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A61K9/48; A23L1/052
Application Number:
CN20010126951 (20011008)
Priority Number: CN20010126951 (20011008)
Family: CN1342417
Equivalent:
CN1174690C
Abstract:
A HEALTH-CARE FOOD IN THE FORM OF CAPSULE IS PREPARED FROM WOLFBERRY FRUIT
THROUGH EXTRACTING IN WATER, DEPOSITING IN ALCOHOL, ULTRAFILTRATING WITH
HOLLOW FIBRES TO OBTAIN AN EXTRACT WITH LYCIUM POLYOSE AS MAIN COMPONENT. IT
HAS SURE HEALTH-CARE FUNCTIONS OF IMPROVING VISION AND IMMUNITY AND BUILDING
UP BODY. ITS ADVANTAGES INCLUDE SIMPLE PREPARING PROCESS, AND HIGH EXTRACTING
RATE UP TO 20%.
92/757
27. CN1343459 - 10.04.2002
MEDICINAL FLEECE FLOWER ROOT-TAIHE CHICKEN FOOD WITH HEALTH-CARE FUNCTION
AND ITS PREPARING PROCESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1343459
Inventor(s):
ZHONG SHUN E (CN)
Applicant(s):
ZHONG SHUN E (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A23L1/315; A61K35/78
Application Number:
CN20010141972 (20010926)
Priority Number: CN20010141972 (20010926)
Family: CN1343459
Equivalent:
CN1182794C
Abstract:
A MEDICINE POT FOOD MADE WITH THE TUBER OF MULTIFLOWER KNOTWEED AND BLACK
HENS IS PREPARED BY BOILING BLACK HEN OR FAMILY FED HEN WITH TWELVE KINDS OF
CHINESE MEDICINES IN THE POT AND THEN ADDING THEFLAVORINGS PREPARED IN RICE
WINE WITH 16 CHINESE MEDICINES. TO KEEP EATING THE INVENTED MEDICINE FOOD HELPS
THE PEOPLE IN GOOD HEALTH, ESPECIALLY GOOD FOR THOSE WHO ARE AFTER RADIA
THERAPY AND CHEMOTHERAPY AS WELL AS DELIVERY WOMAN AND THEIR POSTPARTUM.
93/757
28. CN1349758 - 22.05.2002
TOURIST'S HEALTH FOOD CONTAINING CORDYCEPS AND ITS PRODUCTION PROCESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1349758
Inventor(s):
ZHU NIANLIN (CN); ZHU YING (CN)
Applicant(s):
ZHU NIANLIN (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L1/056
Application Number:
CN20010129092 (20011120)
Priority Number: CN20010129092 (20011120)
Family: CN1349758
Equivalent:
CN1146329C
Abstract:
THE BASIC COMPOSITION OF HEALTH-CARE TOURIST FOOD CONTAINING CORDYCEPS
CONTAINS ONE CORDYCEPS, TRANSPARENT OR SEMITRANSPARENT FRUIT JELLY OR MEAT
JELLY 10-20G, FLAVOURING MATERIAL 1-2G, TONER 0.1-0.3G AND AUXILIARY FOOD 1-5 G. THE
DESCRIBED FLAVOURING MATERIAL CAN BE HONEY, SUGAR OR SALT, THE DESCRIBED
TONER CAN BE NATURAL EDIBLE COLOURING MATTER OR COLOUR FRUIT JUICE, AND THE
DESCRIBED AUXILIARYFOOD CAN BE LYCIUM BERRY OR FRUIT OR FRUIT PRESERVES.
94/757
29. CN1356062 - 03.07.2002
HEALTH-CARE FOOD FOR BEAUTIFYING FACE, FUNCTIONAL BEVERAGE AND SNACKS
PREPARED FROM PORK SKIN
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1356062
Inventor(s):
LIU RENJIAN (CN)
Applicant(s):
LIU RENJIAN (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/312; A23L2/38
Application Number:
CN20010128302 (20010801)
Priority Number: CN20010128302 (20010801)
Family: CN1356062
Abstract:
A FACE-BEAUTIFYING HEALTH-CARE PRODUCT, A FUNCTIONAL BEVERAGE AND A SNACK ARE
DISCLOSED, WHICH ARE PREPARED FROM FORK SKIN. THEIR PREPARING PROCESSES ARE
ALSO DISCLOSED.
95/757
30. CN1356121 - 03.07.2002
COMPOSITE HEALTH-CARE FOOD AND BEVERAGE FOR IMPROVING INTELLIGENCE, TAKING
CARE OF BRAIN HEALTH AND DELAYING SANILITY AND ITS PREPARING PROCESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1356121
Inventor(s):
LIU RENJIAN (CN)
Applicant(s):
LIU RENJIAN (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A23L2/38; A61P3/02
Application Number:
CN20010114327 (20010702)
Priority Number: CN20010114327 (20010702)
Family: CN1356121
Abstract:
A HEALTH-CARE COMPOSITE ORAL LIQUID AND BEVERAGE FOR IMPROVING INTELLIGENCE,
INVIGORATING FUNCTION OF BRAIN AND DELAYING SANILITY IS PREPARED FROM EDIBLE
FUNGUS "JINZHEN MUSHROOM" AND FRUIT SUCH AS GRAPE.
96/757
31. CN1363236 - 14.08.2002
HEALTH-CARE ZAOZHISHEN FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1363236
Inventor(s):
WU JIANHUI (CN)
Applicant(s):
WU JIANHUI (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L1/28
Application Number:
CN20010107034 (20010110)
Priority Number: CN20010107034 (20010110)
Family: CN1363236
Equivalent:
CN1184901C
Abstract:
A HEALTH-CARE FOOD IS MADE UP OF SPIRULINA (70-90 WT.%), AMERICAN GINSENG (9-25)
AND GANODERMA (1-5). ITS ADVANTAGES INCLUDE NO POISON, HIGH SAFETY, QUICKLY
TAKING ITS EFFECT ON IMPROVING SOD ACTIVITY AND REDUCING MDA, AND HIGH
FUNCTIONS OF DELAYING SANILITY, REGULATING IMMUNITY AND RESISTING RADIATION.
97/757
32. CN1363242 - 14.08.2002
HEALTH-CARE FOOD SERIES AND ITS PREPARING PROCESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1363242
Inventor(s):
ZHANG GUANGJUN (CN)
Applicant(s):
ZHANG GUANGJUN (CN)
IP Class 4 Digits: A23L
IP Class:
A23L2/38; A23L2/52; A23L1/28
Application Number:
CN20010101543 (20010101)
Priority Number: CN20010101543 (20010101)
Family: CN1363242
Abstract:
A HEALTH-CARE FOOD SERIES FOR PREVENTING PUZZLE DISEASES SUCH AS CANCER AND
AIDS, IMPROVING IMMUNITY AND DELAYING SANILITY IS PREPARED FROM THE LIQUID
EXTRACTS OF GANODERMA, CORDYCEPS, YAM, REHMANNIAROOT, ETC AND ALMOST 100
USEFUL BACTERIA THROUGH FERMENTING TO OBTAIN BACTERIAL LIQUID, AND USING IT AS
ONE OF THE RAW MATERIALS FOR DIFFERENT FOOD.
98/757
33. CN1363393 - 14.08.2002
PROCESS FOR PREPARING HEALTH-CARE COMPOUND SHEEP PLACENTA EXTRACT FOOD
SERIES
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1363393
Inventor(s):
YU NEIXUN (CN)
Applicant(s):
YU NEIXUN (CN)
IP Class 4 Digits: A61K; A61P
IP Class:
A61P17/16; A61K35/84
Application Number:
CN20020101969 (20020119)
Priority Number: CN20020101969 (20020119)
Family: CN1363393
Abstract:
A HEALTH-CARE FOOD SERIES. "COMPOUND SHEEP PLACENTA EXTRACT" IN THE FORM OF
CAPSULE OR ORAL LIQUID FOR DELAYING SENILITY, BEAUTIFYING FACE, SUPPLEMENTING
CALCIUM, AND TAKING CARE OF HEALTH IS PREPARED FROM PEARL, GANODERMA, SHEEP
PLACENTA, ROYAL JELLY, OLIGOPOLYOSE, VA, VC AND VE THROUGH LOW-TEMP FREEZING,
PULVERIZING OR ENZYMOLYSIS.
99/757
34. CN1365628 - 28.08.2002
HEALTH-CARE ANTISANILITY FOOD AND ITS PREPARING PROCESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1365628
Inventor(s):
LI ZHIXUN (CN); CHEN SHIGEN (CN); ZHOU RUNQI (CN)
Applicant(s):
LI ZHIXUN (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
CN20010128574 (20010831)
Priority Number: CN20010128574 (20010831)
Family: CN1365628
Equivalent:
CN1135935C
Abstract:
A HEALTH-CARE ANTISANILITY FOOD IS PREPARED FROM FOWL'S EGG EMBRYO THROUGH
REMOVING EGG SHELL, QUICK FREEZING WITHIN 30-60 MIN, CRUSHING, ADDING SOLUTION
OF SODIUM CITRATE, RAISING TEMP. TO -1- +4 DEG.C, FILTERING TO OBTAIN EMBRYOTIC
TISSUE LIQUID, ADDING YAM STARCH WITH WT. SAME AS EMBRYOTIC TISSUE LIQUID,
STIRRING, ADDING NUTRITIVE ADDITIVE, SPRAY-DRYING AND LOADING IN CAPSULES OR
TABLETTING. IT HAS HIGH EFFECT ON DELAYING SANILITY AND IMPROVING IMMUNITY.
100/757
35. CN1367012 - 04.09.2002
PEACH AND APRICOT HEALTH-CARE FOOD FOR CURING COUGH AND ASTHMA
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1367012
Inventor(s):
YU JIANG (CN); YU HAI (CN)
Applicant(s):
YU JIANG (CN)
IP Class 4 Digits: A61K; A61P
IP Class:
A61K35/78; A61P11/06
Application Number:
CN20020115463 (20020124)
Priority Number: CN20020115463 (20020124)
Family: CN1367012
Equivalent:
CN1169560C
Abstract:
THE HEALTH-CARE FOOD FOR CURING THE DISEASES OF UPPER RESPIRATORY TRACT
INFECTION, ACUTE AND CHRONIC BRONCHITIS, ASTHMA AND PULMONARY TUBERCULOSIS,
ETC. WITH A CERTAIN THERAPEUTIC EFFECT IS MADE UP BY UISNG SWEET APRICOT KERNEL,
PEACH KERNEL AND WALNUT KERNEL ACCORDING TO THE MIXING RATIO OF 1:1:2-3, AND
ADDING THE AUXILIARY MATERIALS OF CANE SUGAR, FINE FLOUR, VEGETABLE OIL AND
GINSENG POWDER AND ADOPTING PRODUCTION PROCESSES OF CHINESE GUANGDONG
MOON CAKE, CHINESE XIAOGAN SESAME SWEETS AND AMBER SUGAR COATED
WALNUTMEAT. IT CAN BE RESPECTIVELY MADE INTO THE FORMS OF CAKE AND SWEETS.
101/757
36. CN1369222 - 18.09.2002
HEALTH-CARE FOOD CONTAINING SHEEP PLACENTA EXTRACT AND ITS PREPARING PROCESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1369222
Inventor(s):
YOU XUAN (CN); SHI BEIKANG (CN)
Applicant(s):
FANGYUAN SCIENCE AND TECHNOLOG (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/30
Application Number:
CN20020110827 (20020208)
Priority Number: CN20020110827 (20020208)
Family: CN1369222
Equivalent:
CN1162095C
Abstract:
A HEALTH-CARE FOOD CONTAINING SHEEP PLACENTA EXTRACT IN THE FORM OF CAPSULE
OR TABLET IS PREPARED BY ULTRALOW-TEMP FREEZING PROCESS, THAT IS, PULVERIZING
THE SHEEP PLACENTA TISSUE IN LIQUID NITROGEN FREEZING STATE AND VACUUM DRYING
TO OBTAIN HIGH-QUALITY FREEZE DRIED POWDER. ITS ADVANTAGES ARE RETAINING ALL THE
ACTIVE COMPONENTS OF SHEEP PLACENTA, RICH NUTRIENTS, HIGH HEALTH-CARE
FUNCTION AND NO TOXIC BY-EFFECT.
102/757
37. CN1369510 - 18.09.2002
PROCESS FOR DECOLOURING POLYOSE AND ITS HEALTH-CARE FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1369510
Inventor(s):
DUAN JINYOU (CN); FANG JINIAN (CN)
Applicant(s):
SHANGHAI INST OF MEDICAL MATER (CN)
IP Class 4 Digits: A61K; C08B
IP Class:
A61K31/715; C08B37/00
Application Number:
CN20010105320 (20010213)
Priority Number: CN20010105320 (20010213)
Family: CN1369510
Equivalent:
CN1129612C
Abstract:
A PROCESS FOR DECOLOURING POLYOSE AND ITS HEALTH-CARE PRODUCTS INCLUDES
SUCH STEPS AS PROPORTIONALLY MIXING THE SOLUTION OF ANTI-COAGULATION MICELLAE
WITH THE PRE-TREATING LIQUID OF RAW POLYOSE AND ITS HEALTH-CARE PRODUCTS,
STRONG STIRRING, LAYING ASIDE FOR LAYERING, AND TAKING THE LOWER LAYER AS THE
DECOLOURED PRODUCTS.
103/757
38. CN1370457 - 25.09.2002
HEALTH FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1370457
Inventor(s):
LIANG CHEN (CN)
Applicant(s):
LIANG CHEN (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L2/38
Application Number:
CN20010104097 (20010223)
Priority Number: CN20010104097 (20010223)
Family: CN1370457
Abstract:
THE HEALTH FOOD OF THE PRESENT INVENTION IS PRODUCED WITH GINSENG, CORDYCEPS,
PILOSE ANTLER, SALINE CISTANCHE, EPIMEDIUM, DOGWOOD, BITTER CARDAMON,
SAFFLOWER, ETC. AS RAW MATERIAL AND IT CAN BE HEALTH WINE, GRANULE, BEVERAGE,
CAPSULE, CHEWING GUM OR TABLET. IT HAS THE FUNCTIONS OF STRENGTHENING BODY'S
IMMUNITY, ANTIFATIGUE, DELAYING SENILITY, STRENGTHENING SEXUAL FUNCTION AND CAN
BE TAKEN FOR LONG PERIOD, AND HAS NO SIDE EFFECT.
104/757
39. CN1370472 - 25.09.2002
HEALTH FOOD WITH BLOOD PRESSURE AND BLOOD LIPOID REGULATING FUNCTION AND ITS
PRODUCTION PROCESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1370472
Inventor(s):
ZHANG HONGBIN (CN); DAI XIAOCHANG (CN); LI LIANG (CN)
Applicant(s):
YUNNAN PROV NATURAL MEDICAMENT (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L2/39
Application Number:
CN20020113281 (20020125)
Priority Number: CN20020113281 (20020125)
Family: CN1370472
Equivalent:
CN1150839C
Abstract:
DISCLOSED ARE HEALTH FOOD WITH BLOOD PRESSURE AND BLOOD LIPOID REGULATING
FUNCTION AND ITS PREPARATION PROCESS IN THE PRESENT INVENTION. DURING ITS
PREPARATION, FRESH CELERY JUICE AND ETHANOL EXTRACTIVE OF CELERY DREG ARE
CONCENTRATED AND FREEZE-DRIED TO OBTAIN CELERY EXTRACTIVE; NOTOGINSENG
EXTRACTIVE IS WATER AND ETHANOL WASHED, CONCENTRATED AND FREEZE-DRIED TO
OBTAIN TO OBTAIN NOTOGINSENG GENERAL SAPONIN, ETHANOL EXTRACTIVE OF GINSENG
IS VACUUM FREEZE-DRIED TO OBTAIN GINSENG GENERAL SAPONIN POWDER; AND CELERY
EXTRACTIVE IN 20-80 PORTIONS AND NOTOGINSENG GENERAL SAPONIN AND/OR GINSENG
GENERAL SAPONIN POWDER IN 20-80 PORTIONS ARE PRODUCED INTO GRANULE, TABLE,
CAPSULE AND ORAL HEALTH FOOD.
105/757
40. CN1374037 - 16.10.2002
WIDE-SPECTRUM HEALTH FOOD 'NUCLEIC ACID SOURCE' AND ITS PRODUCTION PROCESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1374037
Inventor(s):
WANG YINGHUAI (CN)
Applicant(s):
WANG YINGHUAI (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/20; A23L1/326; A23L13/11
Application Number:
CN20010109604 (20010312)
Priority Number: CN20010109604 (20010312)
Family: CN1374037
Abstract:
THE WIDE-SPECTRUM HEALTH FOOD "NUCLEIC ACID SOURCE" IS DEVELOPED BASED ON
MODERN MOLECULAR BIOLOGY, NUCLEIC ACID NUTRIOLOGY AND NUCLEIC ACID METALOLIC
THERAPY AND IS USED FOR REPLENISHING ALLOGENETICNUCLEIC ACID. IT CAN SUPPORT
AUTONOMOUS GENE REPAIR, MAINTAIN NORMAL METABOLISM OF BODY'S CELL,
STRENGTHEN PHYSIQUE AND PREVENT DISEASES THROUGH REGULATING IMMUNITY,
STRENGTHENING AUTONOMOUS GENE REPAIR CAPACITY, PROMOTING BLOOD CIRCULATING,
IMPROVING MICROCIRCULATION, ACTIVATING BRAIN CELL, ETC.
106/757
41. CN1376417 - 30.10.2002
HEALTH-CARE 9-IN-1 FOOD FOR BUILDING UP BODY AND BEAUTIFYING FACE
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1376417
Inventor(s):
LI GUOQIANG (CN)
Applicant(s):
QUJING SCIENCE AND TECHNOLOGY (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
CN20020113569 (20020403)
Priority Number: CN20020113569 (20020403)
Family: CN1376417
Abstract:
A HEALTH-CARE FOOD FOR BUILDING UP BODY IS PREPARED FROM 9 RAW MATERIALS
INCLUDING NOTOGINSENG, RED SAGE ROOT, FLEECE FLOWER ROOT, MELISSA POWDER,
LIQUORICE ROOT, BLACK SESAME, BLACK ANT, TARTARIAN BUCKWHEAT AND HONEY. ITS
ADVANTAGES ARE HIGH EFFECT ON BEAUTIFYING FACE, IMPROVING IMMUNITY AND BODY
FUNCTIONS AND DELAY SENILITY, AND RICH NUTRIENTS.
107/757
42. CN1381195 - 27.11.2002
NUTRITIVE HEALTH-CARE FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1381195
Inventor(s):
ZHANG SHISHUN (CN)
Applicant(s):
ZHANG SHISHUN (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A61K9/48; A23L1/28
Application Number:
CN20010115318 (20010419)
Priority Number: CN20010115318 (20010419)
Family: CN1381195
Equivalent:
CN1173640C
Abstract:
A NUTRITIVE HEALTH-CARE FOOD WITH IMMUNOREGULATION AND FATIGUE RELIEVING
FUNCTIONS CONTAINS AMERICAN GINSENG (3-7 WT PORTIONS), GANODERMA SPORE
POWDER (4-8) AND GINGKO LEAF EXTRACT (0.3-1). ITS ADVANTAGES ARE HIGH HEALTH-CARE
EFFECT AND LOW COST.
108/757
43. CN1381209 - 27.11.2002
HEALTH-CARE ALLIAN FOOD WITHOUT ODOUR
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1381209
Inventor(s):
ZHOU GUANGBIN (CN)
Applicant(s):
ZHOU GUANGBIN (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L2/39; A23L12/12
Application Number:
CN20010112673 (20010419)
Priority Number: CN20010112673 (20010419)
Family: CN1381209
Abstract:
A HEALTH-CARE DEODOURED ALLICIN FOOD FOR REDUCING BLOOD PRESSION AND BLOOD
FAT CONTAINS DEODOURED ALLICIN, CHINESE MEDICINAL HERBS' DECOCTION, FRUIT OR
MELON JUICE, POLLEN, HERBACEOUS PLANT LIQUID AND ADDITIVE. ITS ADVANTAGES ARE
NO ODOUR, POISON AND HARM, HIGH EFFECT, RICH NUTRIENTS AND LOW COST.
109/757
44. CN1382390 - 04.12.2002
PROCESS FOR PREPARING HEALTH-CARE FRESH REHMANNIA ROOT FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1382390
Inventor(s):
ZHENG HUIYANG (CN)
Applicant(s):
ZHENG HUIYANG (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/212; A23L3/40; A23L33/58
Application Number:
CN20020117814 (20020522)
Priority Number: CN20020117814 (20020522)
Family: CN1382390
Abstract:
A HEALTH-CARE FRESH REHMANNIA ROOT FOOD IS PREPARED FROM THE FRESH REHMANNIA
ROOT THROUGH WASHING, LONGITUDINAL CUTTING, IMMERSING IN YELLOW WINE,
STEAMING AT 300-500 DEG.C FOR 4-8 HRS, IMMERSING IN 0.1-1.5% SOLUTION CONTAINING
DICARBONATE, BOILING IN SUGAR SOLUTION, IMMERSING AND BAKING. ITS ADVANTAGES
ARE NO BITTER TASTE AND RETAINING ALL NUTRIENTS.
110/757
45. CN1382392 - 04.12.2002
HEALTH-CARE GINGER-SCALLION-GARLIC FOOD CONTAINING RICH ELEMENT IRON
NUTRIENTS AND ITS PREPARING PROCESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1382392
Inventor(s):
LI XIAOYAN (CN); LI XIAOHONG (CN); LI YANHONG (CN)
Applicant(s):
LI XIAOYAN (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/304; A23L12/21
Application Number:
CN20020118781 (20020508)
Priority Number: CN20020118781 (20020508)
Family: CN1382392
Abstract:
A HEALTH-CARE FOOD FOR PREVENTING HYPOIMMUNITY, SEXUAL DISORDER, EARLY
SANILITY, OSTEOPOROSIS, CARDIOVASCULAR AND CEREBROVASCULAR DISEASES, DIABETES,
CANCER, ETC IS PREPARED FROM MINERAL ELEMENTS IONNUTRIENTS, GINGER, SCALLION,
GARLIC, WINE, VINEGAR, SOY AND ADDITIVE.
111/757
46. CN1383742 - 11.12.2002
HEALTH FOOD OF BLOOD FAT-REGULATING AND INTELLIGENCE GROWTH-PROMOTING
PEPTIDE
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1383742
Inventor(s):
LU XIAOMIN (CN); XU MINGGAO (CN); YU SHUXIAO (CN)
Applicant(s):
LU XIAOMIN (CN)
IP Class 4 Digits: A23L; A61P
IP Class:
A23L1/29; A23L1/48; A61P3/06; A61P43/00
Application Number:
CN20010115244 (20010427)
Priority Number: CN20010115244 (20010427)
Family: CN1383742
Abstract:
THE HEALTH FOOD USING COMPOSITE CASEIN POLYPEPTIDE AS BASIC MATERIAL AND
ADDED MATTER CONTAINING LINOLENIC ACID HAS THE HEALTH FUNCTIONS OF PREVENTING
CARDIAC AND CEREBRAL VASCULAR DISEASES, REGULATING BLOOD PRESSURE,
REGULATING BLOOD FAT AND CHOLESTERIN, INHIBITING CEREBRAL THROMBOSIS,
RESISTING TUMOR, INHIBITING ALLERGIC REACTION, RAISING IMMUNITY AND RAISING
INTELLIGENCE AND EYESIGHT.
112/757
47. CN1383751 - 11.12.2002
HEALTH FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1383751
Inventor(s):
SUN LIJUAN (CN)
Applicant(s):
SUN LIJUAN (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/33; A23L1/28; A23L13/37
Application Number:
CN20010113917 (20010427)
Priority Number: CN20010113917 (20010427)
Family: CN1383751
Abstract:
THE HEALTH FOOD IS PRODUCED WITH PEELED SHRIMP, EDIBLE FUNGUS, KELP, EGGPLANT,
EGG, VERMICELLI AND FLOUR. IT HAS CERTAIN AUXILIARY TREATING EFFECT ON
HYPERTENSION, ASTHMA AND YIN-DEFICIENCY INSOMNIA WITHOUT TOXIC SIDE EFFECT. IN
ADDITION, IT CAN BE USED TO REDUCE GASTRIC ACID AND REMIT THE SYMPTOM OF
RHEUMATIC ARTHRITIS.
113/757
48. CN1383870 - 11.12.2002
FATIGUE-RESISTING HEALTH FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1383870
Inventor(s):
KE ZUNHONG (CN)
Applicant(s):
KONGHONG PHARMACEUTICAL CO LTD (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A23L1/29; A61P43/00
Application Number:
CN20020113791 (20020528)
Priority Number: CN20020113791 (20020528)
Family: CN1383870
Equivalent:
CN1176694C
Abstract:
THE FATIGUE-RESISTING HEALTH FOOD IS PRODUCED WITH PILOSE ANTLER, RED SAGE,
PLANTAIN SEED, CHRYSANTHEMUM AND GREEN TEA. IT HAS OBVIOUS FATIGUE-RESISTING
EFFECT. ALL THE MATERIALS ARE INNOCUOUS MEDICATED FOOD MATERIALS AND THIS MAKE
THE HEALTH FOOD HAVE THE FUNCTIONS OF BOTH FOOD AND MEDICINE.
114/757
49. CN1383891 - 11.12.2002
LIFE-PROLONING PEPTIDE HEALTH FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1383891
Inventor(s):
LU XIAOMIN (CN); XU MINGGAO (CN); YU SHUXIAO (CN)
Applicant(s):
LU XIAOMIN (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61P1/14; A23L1/29; A61K38/17
Application Number:
CN20010115237 (20010427)
Priority Number: CN20010115237 (20010427)
Family: CN1383891
Abstract:
THE LIFE-PROLONGING PEPTIDE HEALTH FOOD HAS COMPOSITE CASEIN POLYPEPTIDE AS
MATRIX AND HAS EDIBLE FUNGUS, SAFFLOWER, WOLFBERRY FRUIT AND/OR WOLFBERRY
LEAF AND STEM, TUCKAHOE AND SNAKE AS ADDITIVES. IT HAS THE FUNCTIONS OF DELAYING
SENILITY, RAISING BODY'S IMMUNITY, REDUCING BLOOD FAT, REDUCING SERUM PEROXIDE
FAT, RESISTING BLOOD COAGULATION, REDUCING CHOLESTERINE DENSITY AND RESISTING
CANCER.
115/757
50. CN1386440 - 25.12.2002
HEALTH-CARE FOOD FOR REGULATING BLOOD SUGAR AND BLOOD FAT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1386440
Inventor(s):
CAO ZHIGUO (CN)
Applicant(s):
CAO ZHIGUO (CN)
IP Class 4 Digits: A23L; A61P
IP Class:
A23L1/48; A61P3/06; A61P3/10
Application Number:
CN20010118192 (20010521)
Priority Number: CN20010118192 (20010521)
Family: CN1386440
Abstract:
A HEALTH-CARE FOOD FOR REGULATING BLOOD FAT AND BLOOD SUGAR IS PREPARED FROM
DIPHENYLVINYL PHENOL GLYCOSIDES COMPOUND (2-25 WT.%) AND AUXILIARY MATERIAL
(THE BALANCE). ITS ADVANTAGES ARE HIGH EFFECT AND NO BY-EFFECT.
116/757
51. CN1387909 - 01.01.2003
NATURAL MEDICATED HEALTH FOOD WITH THE FUNCTIONS OF ROMOVING TOXIC MATERIAL
TO PROTECT LIVER AND RELAXING THE BOWELS TO EXPEL TOXIN
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1387909
Inventor(s):
HU XIAOBO (CN)
Applicant(s):
HU XIAOBO (CN)
IP Class 4 Digits: A61K; A61P
IP Class:
A61K35/78; A61P1/10
Application Number:
CN20020133474 (20020712)
Priority Number: CN20020133474 (20020712)
Family: CN1387909
Abstract:
THE NATURAL MEDICATED HEALTH FOOD IS PRODUCED WITH KUDZUVINE ROOT EXTRACTIVE
AND ALOE EXTRACTIVE. IT HAS THE FUNCTIONS OF DETOXICATING, PROTECTING LIVER,
RELAXING THE BOWELS AND ACTIVATING LIVER CELLTO ACTIVATE LIVER AND CLEAN
INTESTINE. FUNCTIONAL EXPERIMENT SHOWS THAT IT HAS OBVIOUS EFFECT OF PREVENTING
AND TREATING INDIGESTION AND CONSTIPATION.
117/757
52. CN1387910 - 01.01.2003
NATURAL MEDICATED HEALTH FOOD FOR PREVENTING AND TREATING DIABETES AND
CARDIAC VASCULAR DISEASES
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1387910
Inventor(s):
HU XIAOBO (CN)
Applicant(s):
GUIZHOU ZHENGTIANYI HEALTH PRO (CN)
IP Class 4 Digits: A61K; A61P
IP Class:
A61K35/78; A61P3/10; A61P9/10
Application Number:
CN20020133475 (20020712)
Priority Number: CN20020133475 (20020712)
Family: CN1387910
Abstract:
THE NATURAL MEDICATED HEALTH FOOD IS PRODUCED WITH MULBERRY EXTRACTIVE,
GYNOSTEMMA PENTAPHYLLA EXTRACTIVE, GINGKO EXTRACTIVE AND EDIBLE
ORGANOCHROMIUM. IT HAS THE FUNCTIONS OF BI-DIRECTIONAL REGULATION OF BLOOD
SUGAR. ANIMAL EXPERIMENT, CLINICAL APPLICATION AND TOXICOLOGICAL EXPERIMENT
SHOW THAT IT IS SAFE AND HAS NO TOXIC SIDE EFFECT.
118/757
53. CN1389141 - 08.01.2003
AMBER HONEYED GARLIC AS ONE KIND OF HEALTH FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1389141
Inventor(s):
LU TIANCAI (CN)
Applicant(s):
LU TIANCAI (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/08; A23L1/212
Application Number:
CN20010118644 (20010606)
Priority Number: CN20010118644 (20010606)
Family: CN1389141
Abstract:
THE PRESENT INVENTION DISCLOSES A PASTE SOYBEAN CHEESE AND ITS PRODUCTION
METHOD. SAID INVENTION IS CHARACTERIZED BY THAT LARGE SOYBEAN CURD BLOCK CAN
BE ADOPTED, DIRECTLY INOCULATED TO MAKE PRE-FERMENTATION, THEN IT IS PLACED INTO
A LARGE SEALED TANK, THE PREPARED FLAVOURING LIQUOR CAN BE ADDED TO MAKE
AFTER-FERMENTATION, AFTER IT IS FERMENTED COMPLETELY, OTHER FLAVOURING
MATERIAL CAN BE ADDED AND MIXED INTO THE INVENTED PASTE SOYBEAN CHEESE. SAID
INVENTION CHANGES THE ORIGINAL BLOCK SOYBEAN CHEESE PRODUCTION PROCESS AND
IMPROVES ITS PACKAGING CONTAINER, AND RAISE THE QUALITY OF ITS PRODUCT,AND IS
EASY TO CARRY ABOUT AND CONVENIENT FOR TRANSPORTION.
119/757
54. CN1389146 - 08.01.2003
BLOOD SUGAR, BLOOD PRESSURE AND BLOOD FAT DEPRESSING HEALTH FOOD CONTAINING
QINGQIAN WILLOW EXTRACT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1389146
Inventor(s):
XIE MINGYONG (CN); WANG YUANXING (CN); WEN HUILIANG (CN)
Applicant(s):
NANCHANG UNIV (CN)
IP Class 4 Digits: A23L; A61P; A21D
IP Class:
A21D2/36; A23L1/30; A61P3/10
Application Number:
CN20020138749 (20020702)
Priority Number: CN20020138749 (20020702)
Family: CN1389146
Equivalent:
CN1181759C
Abstract:
THE PREPARATION METHOD OF WATERMELON MEAT PASTE INCLDUES THE FOLLOWING
STEPS: PLACING THE COOKED SOYBEAN INTO WHEAT FLOUR, MAKING WHEAT FLOUR
UNIFORMLY ADHERE TO THE SURFACE OF SOYBEAN, PLACING THEM IN MOIST-HEAT PLACE
UNTIL THE WHITE MOULD IS GROWN ON THE SURFACE OF SOYBEAN, DRYING BY AIRING AND
REMOVING MOULD, THEN FULLY MIXING THE MUSTY SOBYEAN, WATERMELON PULP, WHEAT
FLOUR, GINGER AND STAR ANISE AND SEALING-FERMENTING IN FERMENTATION TANK, AFTER
10-ODD DAYS OBTAIN WATERMELON PASTE, THEN MIXING THE WATERMELON PASTE,
SOYBEAN OIL, MEAT, HOT PEPPER AND SESAME, STIR-FRYING TO OBTAIN THE WATERMELON
MEAT PASTE, THEN ADDING PRESERVATIVE, BAGGING OR BOTTLING, STERILIZING AND
PACKAGING.
120/757
55. CN1390476 - 15.01.2003
HEALTH-CARE FOOD AND ITS PREPARING PROCESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1390476
Inventor(s):
YANG YAJUN (CN)
Applicant(s):
YANG YAJUN (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L1/212
Application Number:
CN20020138044 (20020730)
Priority Number: CN20020138044 (20020730)
Family: CN1390476
Abstract:
A HEALTH-CARE FOOD CONTAINS MAKA (15-85%), CHINESE-MEDICINAL MATERIALS (5-70%),
TAURINE (0-20%) AND AUXILIARY (10-30%). IT IS PREPARED THROUGH PULVERIZING MAKA
AND CHINESE-MEDICINAL MATERIALS, SIEVING BY 60 MESHES, PROPORTIONING, ADDING
AUXILIARY, AND LOADING IN CAPSULES. IT FEATURES ITS HEALTH-CARE FUNCTION OF
RELIEVING FATIGUE AND IMPROVING IMMUNITY AND SEXUAL FUNCTION.
121/757
56. CN1390552 - 15.01.2003
HEALTH-CARE MINERAL FOOD AND ITS PREPARING PROCESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1390552
Inventor(s):
LI ZHENGXIONG (CN)
Applicant(s):
LI ZHENGXIONG (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61P1/10; A61P3/04; A61K35/02; A61P3/02; A23L13/04
Application Number:
CN20020132453 (20020614)
Priority Number: CN20020132453 (20020614)
Family: CN1390552
Equivalent:
CN1176666C
Abstract:
A HEALTH-CARE MINERAL FOOD FOR TREATING NEPHROSIS, GASTROENTEROPATHY,
GYNOPATHY AND INFLAMMATIONS, LOSSING WEIGHT AND BEAUTIFYING FACE IS PREPARED
FROM CHINESE MEDICINAL STONE AND ZEOLITE THROUGH REMOVING IMPURITIES,
CRUSHING, WASHING, DRYING IN AIR, PULVERIZING, ULTRAVIOLET STERILIZING AND
PROPORTIONAL MIXING.
122/757
57. CN1390590 - 15.01.2003
HEALTH-CARE FOOD FOR IMPROVING SLEEP
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1390590
Inventor(s):
KE ZUNHONG (CN)
Applicant(s):
KANGHONG PHARMACEUTICAL CO LTD (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A23L1/29; A61P25/20
Application Number:
CN20020133315 (20020620)
Priority Number: CN20020133315 (20020620)
Family: CN1390590
Equivalent:
CN1171620C
Abstract:
A HEALTH-CARE FOOD FOR IMPROVING SLEEP IS PREPARED FROM WILD JUJUBE KERNEL,
SCHISANDRA FRUIT, WHITE PEONY ROOT, GANODERMA AND GINSENG. ITS ADVANTAGES ARE
HIGH EFFECT AND NO POISON.
123/757
58. CN1391840 - 22.01.2003
HEALTH FOOD PRODUCED FROM CHINESE WOLFBERRY FRUIT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1391840
Inventor(s):
ZHANG XIAOFENG (CN)
Applicant(s):
NORTH WEST PLATEAU BIOLOG I CH (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
CN20010128704 (20010618)
Priority Number: CN20010128704 (20010618)
Family: CN1391840
Abstract:
THE HEALTH FOOD IS PRODUCED WITH WOLFBERRY FRUIT, SUPPLEMETARY MATERIAL
AND/OR CARRIER. IT HAS THE FUNCTIONS OF PROLONGING LIFE, INVIGORATING KIDNEY,
BENEFITING LIFE ESSENCE, CLEARING LIVER HEAT AND STRENGTHENING EYESIGHT, AND IT IS
A SAFE AND RELIABLE PURE NATURAL PRODUCT.
124/757
59. CN1391953 - 22.01.2003
BIOLOGICAL FOOD THERAPEUTIC HEALTH ARTICLE CONTAINING METALLOTHIONEIN FOR
TREATING DIABETES AND COMPLICATION AND ITS PREPARATION
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1391953
Inventor(s):
ZHOU GUOJIE (CN); PIAO JIANXIN (CN)
Applicant(s):
ZHOU GUOJIE (CN)
IP Class 4 Digits: A61K; A61P
IP Class:
A61P3/10; A61K38/02
Application Number:
CN20010114118 (20010619)
Priority Number: CN20010114118 (20010619)
Family: CN1391953
Equivalent:
CN1122529C
Abstract:
THE BIOLOGICAL DIETOTHERAPEUTIC HEALTH ARTICLE HAS METALLOTHIONEIN (MT) WITH
FUNCTIONS OF PROTECTING AND REPAIRING GENE AND PANCREATIC ISLAND BETA CELL OF
DIABETICS, STRENGTHENING THE SENSITIVITY OF INSULIN TARGET CELL ACCEPTOR AND
REGULATING BLOOD SUGAR. ITS INGREDIENTS INCLUDES MT, WOLFBERRY FRUIT,
GLUTAMINE, BETA-CYCLODEXTRIN AND PROTEOGLYCAN, WHICH ARE TREATED THROUGH
MIXING, FILTERING, PACKING, STERILIZING, PACKING AND OTHER TECHNOLOGICAL STEPSTO
PRODUCE THE ORAL LIQUOR.
125/757
60. CN1392263 - 22.01.2003
METHOD FOR PREPARING EASY BODY ABSORPTION PROTEIN-CALCIUM BY ENZYME AND
HEALTH FOOD PRODUCED BY SAID PROTEIN-CALCIUM
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1392263
Inventor(s):
SOONG-GYO CHI (KR)
Applicant(s):
SOONG-GYO CHI (KR)
IP Class 4 Digits: A23L; A61K; A61P; C12P
IP Class:
A23L2/38; A61K38/02; A61P3/02; C12P21/00
Application Number:
CN20010121932 (20010620)
Priority Number: CN20010121932 (20010620)
Family: CN1392263
Abstract:
THE PRESENT INVENTION RELATES TO THE PREPARATION PROCESS OF PROTEIN CALCIUM.
THE PROCESS INCLUDES SUSPENDING PROTEIN IN WATER SOLUTION OF PH 4.5-5.0, ADDING
PINEAPPLE PROTEASE AND REACTING FOR 9 HR TO OBTAIN OLIGOPEPTIDE; ADDING
CALCIUM ION AND CHELATING AND ALKALI NEUTRALIZING TO OBTAIN CALCIUMOLIGOPEPTIDE; ADDING ALCOHOL TO DEPOSIT CALCIUM-OLIGOPEPTIDE AND SEPARATING
AMMONIUM SALT; AND DRYING AND CALCIUM-OLIGOPEPTIE PRECIPITATE TO OBTAIN
POWDER. THE PROTEIN CALCIUM EAYS TO BE ABSORBED BY BODY MAY BE ADDED INTO
BEVERAGE OR FOOD TO ELIMINATE THE PROBLEM OF CALCIUM DEFICIENCY.
126/757
61. CN1392264 - 22.01.2003
PROCESS FOR PREPARING EASY BODY ABSORPTION PROTEIN ION AND HEALTH FOOD
PRODUCED THEREFROM
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1392264
Inventor(s):
SOONG-GYO CHI (KR)
Applicant(s):
SOONG-GYO CHI (KR)
IP Class 4 Digits: A61K; A61P; C12P
IP Class:
A61K38/02; A61P3/02; C12P21/00
Application Number:
CN20010121933 (20010620)
Priority Number: CN20010121933 (20010620)
Family: CN1392264
Abstract:
THE PRESENT INVENTION RELATES TO THE PREPARATION PROCESS OF PROTEIN IRON. THE
PROCESS INCLUDES SETTING PROTEIN IN PURE WATER AND ACID REGULATION TO OBTAIN
SUSPENSION OF PH 4.5-5.0; ADDING PROTEIN DECOMPOSING ENZYME AND REACTING FOR 810 HR TO OBTAIN OLIGOPEPTIDE; ADDING IRON ION AND CHELATING AND ALKALI
NEUTRALIZING TO PH 6.8-7.2 TO OBTAIN INORGANIC IRON CHELATE COMPOUND;
CONCENTRATING TO A SOLIDCOMPONENT CONTENT OF 35%, ADDING ALCOHOL TO DEPOSIT;
AND DRYING THE IRON-OLIGOPEPTIDE PRECIPITATE TO OBTAIN POWDER. THE PROTEIN IRON
EASY TO BE ABSORBED BY BODY MAY BE USED IN PREPARING BEVERAGE, CAPSULED OR
TABLET TO ELIMINATE THE PROBLEM OF IRON DEFICIENCY.
127/757
62. CN1393144 - 29.01.2003
HEALTH-CARE FOOD AND COMPOSITE BEVERAGE MADE OF PUMPKIN AND ITS PREPARING
PROCESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1393144
Inventor(s):
LIU RENJIAN (CN)
Applicant(s):
LIU RENJIAN (CN)
IP Class 4 Digits: A23D
IP Class:
A23D7/00
Application Number:
CN20010114328 (20010702)
Priority Number: CN20010114328 (20010702)
Family: CN1393144
Abstract:
A HEALTH-CARE FOOD AND A HEALTH-CARE BEVERAGE FOR PREVENTING DISEASES,
DELAYING SENILITY AND TAKING CARE OF PROSTATE GLAND HEALTH CARE PREPARED FROM
PUMPKIN AND ITS SEEDS COMBINED WITH SEVERAL RICH-NUTRITIONS SUBSTANCES. THEIR
PREPARING PROCESS IS ALSO DISCLOSED.
128/757
63. CN1393263 - 29.01.2003
HEALTH-CARE FOOD FOR IMPROVING PROSTATOPLASIA
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1393263
Inventor(s):
LIANG XUEJIAN (CN)
Applicant(s):
LIANG XUEJIAN (CN)
IP Class 4 Digits: A61K; A61P
IP Class:
A61P13/08; A61K38/02
Application Number:
CN20010115078 (20010625)
Priority Number: CN20010115078 (20010625)
Family: CN1393263
Equivalent:
CN1173734C
Abstract:
A HEALTH-CARE FOOD FOR RELAXING PROSTATOPLASIA IS PREPARED FROM THE NATURAL
PROTEIN POWDER RICH IN ZN, SE AND MN (95-98%) AND GINGER POWDER WITH FINENESS OF
100 MESHES (2-5%) THROUGH MIXING AND LOADING IN EDIBLE CAPSULES OR TABLETTING
OR GRANULATING. THE MENTIONED NATURAL PROTEIN PWODER IS MADE UP FROM
DOMESTIC FOWLS' EGG THROUGH BEATING AND SPRAY DRYING.
129/757
64. CN1394623 - 05.02.2003
HEALTH-CARE FOOD CAPABLE OF REGULATING BLOOD SUGAR AND PREPARING METHOD
THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1394623
Inventor(s):
LIU QIANYING (CN); SU XINHAI (CN); ZHUANG LIGEN (CN)
Applicant(s):
BEIJING SHUANGHE MODERN MEDICI (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A23L1/48; A61P3/10
Application Number:
CN20010120226 (20010710)
Priority Number: CN20010120226 (20010710)
Family: CN1394623
Abstract:
THE PRESENT INVENTION DISCLOSES A FORMULA OF HEALTH-CARE FOOD CAPABLE OF
REGULATING BLOOD SUGAR AND ITS PREPARATION PROCESS. IT IS MADE UP BY USING
MULBERRY LEAF AND BITTER GOURD AS RAW MATERIAL, ANDCAN BE MADE INTO THE
DOSAGE FORM OF TEA BAG BY ADOPTING SPECIAL EXTRACTION METHOD ACCORDING TO
THE CHARACTERISTICS OF EVERY CHINESE MEDICINE AND ADOPTING SUGAR-FREE
AUXILIARY MATERIAL. THE PHARMACOLOGICAL TESTS SHOW THAT IT CAN OBVIOUSLY
REDUCE POSTPRANDIAL BLOOD SUGAR OF MOUSE WITH ALLOXAN DIABETES, AND CAN
RAISE GLUCOSE TOLERANCE OF MOUSE WITH DIABETES AND DOES NOT INCREASE INSULIN
LEVEL OF NORMAL MOUSE, AND ITS CLINICAL TRIAL SHOWS THAT IT CAN OBVIOUSLY
REDUCE INCREMENT OF POSTPRANDIAL BLOOD SUGAR OF THE PATIENT WITH II-TYPE
DIABETES, SO THAT IT IS AN ORAL HEALTH-CARE FOOD CAPABLE OF EFFECTIVELY
REGULATING BLOOD SUGAR.
130/757
65. CN1394630 - 05.02.2003
FRESH CHINESE ANGELICA ROOT HEALTH-CARE FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1394630
Inventor(s):
DUAN TAILI (CN)
Applicant(s):
DUAN TAILI (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A61P1/14; A23L1/29
Application Number:
CN20020124981 (20020627)
Priority Number: CN20020124981 (20020627)
Family: CN1394630
Abstract:
THE FRESH CHINESE ANGELICA ROOT HEALTH-CARE FOOD IS CHARACTERIZED BY THAT IS IS
MADE UP BY USING (WT%) 50-80% OF FRESH CHINESE ANGELICA ROOT, 5-20% OF FRESH
CODONOPSIS ROOT, 5-15% OF FRESH ASTRAGALUSROOT AND 10-20% OF FRESH
ADENOPHORA/GLEHNIA ROOT. SAID INVENTION CAN FULLY UTILIZE EFFECTIVE COMPONENTS
OF THE ABOVE-MENTIONED FRESH MEDICINAL MATERIALS TO ATTAIN THE EFFECT IS
SUPPLEMENTING BLOOD, SUPPLEMENTING QI, PROTECTING BODY AND NOURISHING FACE.
SAID INVENTED HEALTH-CARE FOOD IS CONVENIENT FOR USAGE, GOOD IN TASTE AND
SIMPLE IN PRODUCTION PROCESS.
131/757
66. CN1394631 - 05.02.2003
HEALTH-CARE FOOD FOR RESISTING FATIGUE
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1394631
Inventor(s):
JIA JIANMIN (CN)
Applicant(s):
JIA JIANMIN (CN)
IP Class 4 Digits: A61K; A61P
IP Class:
A61K35/78; A61P1/14; A61P43/00
Application Number:
CN20020128918 (20020821)
Priority Number: CN20020128918 (20020821)
Family: CN1394631
Equivalent:
CN1178688C
Abstract:
THE FATIGUE-RESISTING HEALTH-CARE FOOD IS A POWDER PREPARATION MADE UP BY
USING CALCIUM PYRUVATE, HIGH-QUALITY AMERICAN GINSENG, ASTRAGALUS ROOT,
TAURINE, ZINC GLUCONTATE, VITAMIN C AND EXCIPIENT STARCH. THE TESTS SHOW THAT ITS
EFFECT IS UNIQUE, AND IT HAS THE OBVIOUS FUNCTIONS OF INVIGORATING ENERGY VIGOUR
AND REMOVING FATIGUE.
132/757
67. CN1394632 - 05.02.2003
HEALTH-CARE FOOD FOR IMPROVING SLEEP
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1394632
Inventor(s):
JIA JIANMIN (CN)
Applicant(s):
JIA JIANMIN (CN)
IP Class 4 Digits: A61K; A61P
IP Class:
A61K35/78; A61P25/20
Application Number:
CN20020128919 (20020821)
Priority Number: CN20020128919 (20020821)
Family: CN1394632
Abstract:
THE HEALTH-CARE FOOD FOR IMPROVING SLEEP IS CHARACTERIZED BY THAT IT IS A
CAPSULE PREPARATION MADE UP BY USING THE MELATONIN AND VALERIAN ROOT AS MAIN
RAW MATERIAL THROUGH THE PROCESSES OF DRYING, PULVERIZING, SIEVING, ROASTING,
ADDING STARCH AND ROCK CANDY TO OBTAIN THE INVENTED PRODUCT. SAID INVENTION
CAN EFFECTIVELY RAISE SLEEPING QUALITY.
133/757
68. CN1395870 - 12.02.2003
HYPOGLYCEMIC HEALTH-CARE POLYPEPTIDE FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1395870
Inventor(s):
XU JIALI (CN)
Applicant(s):
XU JIALI (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A23L1/29; A61P3/10
Application Number:
CN20020132671 (20020725)
Priority Number: CN20020132671 (20020725)
Family: CN1395870
Abstract:
A HYPOGLYCEMIC HEALTH-CARE POLYPEPTIDE FOOD IS PREPARED FROM COMPOUNDING OF
HYDROLYTIC CASEIN, YAM POWDER, CALCIUM LACTATE, FERROUS LACTATE AND ZINC
LACTATE. ITS ADVANTAGE IS HIGH EFFECT ON REDUCING BLOOD SUGAR, SUPPLEMENTING
CA, AND PREVENTING AND TREATING HYPERGLYCEMIA AND DIABETES.
134/757
69. CN1395936 - 12.02.2003
HEALTH-CARE FOOD FOR PROTECTING GASTRIC MUCOSA AND ITS PREPARING PROCESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1395936
Inventor(s):
WANG QIANG (CN)
Applicant(s):
WANG QIANG (CN)
IP Class 4 Digits: A61K; A61P
IP Class:
A61K31/715; A61P1/04
Application Number:
CN20020134541 (20020809)
Priority Number: CN20020134541 (20020809)
Family: CN1395936
Abstract:
A HEALTH-CARE FOOD FOR PROTECTING GASTRIC MUCOSA CONTAINS CHITOSAN (15-95
WT.%) AND CARRAGHEENIN (5-85 WT.%), AND IS PREPARED FROM THE EDIBLE MARINE LIVING
THINGS THROUGH EXTRACTION AND SEPARATION OFEFFECTIVE COMPONENTS. ITS
ADVANTAGES ARE HIGH EFFECT AND NO BY-EFFECT.
135/757
70. CN1397197 - 19.02.2003
HEALTH-CARE FOOD FOR NUTRITIVE AND PURPOSES
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1397197
Inventor(s):
LIANG XUEJIAN (CN); YIN DIANQIU (CN); LIANG LIMIN (CN)
Applicant(s):
LIANG XUEJIAN (CN)
IP Class 4 Digits: A23L; A61P
IP Class:
A23L1/29; A61P3/04
Application Number:
CN20010115133 (20010716)
Priority Number: CN20010115133 (20010716)
Family: CN1397197
Equivalent:
CN1173639C
Abstract:
A NUTRITIVE HEALTH-CARE FOOD FOR LOSING WEIGHT IS PREPARED FROM NATURAL
PROTEIN POWDER (95-99%) AND TUCKAHOE POWDER (1-5%) THROUGH MIXING AND
LOADING IN CAPSULES, GRANULATING OR TABLETTING. THE SAID NATURAL PROTEIN
POWDER IS PREPARED FROM EGG CONTAINING RICH ZN AND MG THROUGH STIRRING AND
SPRAY DRYING.
136/757
71. CN1398553 - 26.02.2003
GREEN HEALTH FOOD WITH FUNCTIONS OF LOWERING BLOOD PRESSURE, LOWERING BLOOD
FAT AND SOFTENING BLOOD VESSEL
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1398553
Inventor(s):
ZHANG JINWU (CN)
Applicant(s):
ZHANG JINWU (CN)
IP Class 4 Digits: A23L
IP Class:
A23L2/02; A23L2/60
Application Number:
CN20010115158 (20010720)
Priority Number: CN20010115158 (20010720)
Family: CN1398553
Abstract:
THE PRESENT INVENTION RELATES TO PREPARATION OF HEALTH BEVERAGE AND PROVIDES
ONE KIND OF HEALTH BEVERAGE CONTAINING PERSIMMON VINEGAR GUM. THE SAID
PERSIMMON VINEGAR GUM IS COLLOIDAL LIQUOR PREPARED WITH UNMATURE GREEN AND
ASTRINGENT PERSIMMON AND THROUGH CRUSHING, SOAKING IN WATER FOR CERTAIN
PERIOD AND FILTERING. THE BEVERAGE CONTAINS ALSO CRYSTAL SUGAR WITH THE WEIGHT
RATIO BETWEEN PERSIMMON VINEGAR GUM AND CRYSTAL SUGAR BEING 5-6.5 TO 3.5-5.
137/757
72. CN1399906 - 05.03.2003
PRODUCTION METHOD OF HEALTH-CARE FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1399906
Inventor(s):
WU YIGUANG (CN)
Applicant(s):
WU YIGUANG (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/056; A23L33/58
Application Number:
CN20010124525 (20010731)
Priority Number: CN20010124525 (20010731)
Family: CN1399906
Abstract:
THE PRESENT INVENTION DISCLOSES A METHOD FOR PRODUCING HEALTH-CARE FOOD. IT
CAN PREPARE BETA-CHITOSAN AND OVERCOM THE DEFECT OF ALPHA-CHITOSAN, AND IS
CHARACTERIZED BY THAT THE RAW MATERIAL BETA-CHITIN OR SOFT BONE OF SQUID IS
UNDERGONE THE PROCESS OF ALKALI TREATMENT TO MAKE DEACETYLATION SO AS TO
OBTAIN THE PRODUCT BETA-CHITOSAN, THEN GROUND TO OBTAIN THE INVENTED FINISHED
PRODUCT. THE DEACETYLATION PROCESS INCLUDES THE FOLLOWING STEPS: PLACING THE
BETA-CHITIN OR SOFT BONE OF SQUID INTO ALKALINE SOLUTION WHOSE MASS
PERCENTAGE CONCENTRATION IS 10%-60%, STIRRING THEM AT 50 RPM-3000 RPM, RETAINED
TEMP. IS 30-150 DEG.C, STIRRING TIME IS 0.5 HR-24 HR, IN THE COURSE OF REACTION THE
NITROGEN GAS IS CHARGED TO MAKE PROTECTION, AND ITS SOLID AND LIQUID RATIO OF
1:5-1:50.
138/757
73. CN1399913 - 05.03.2003
MULTIFUNCTIONAL HEALTH-CARE FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1399913
Inventor(s):
GUI XIANCHUN (CN); LIU ZHI (CN)
Applicant(s):
SANSHENG INTERNAT ZHANGJIAKOU (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
CN20010123566 (20010802)
Priority Number: CN20010123566 (20010802)
Family: CN1399913
Abstract:
THE PRESENT INVENTION DISCLOSES A MULTIFUNCTIONAL HEALTH-CARE FOOD. IT IS AN
AMORPHOUS POWDER OBTAINED BY USING ANIMAL BONE MARROW, BONE SCRAPS AND
BLOOD HYDROLYZED BY TRYPSASE AND LIVER EXTRACTED ATLOW TEMP. AND MAKING ITS
HYDROLYZATE AND EXTRACT RESPECTIVELY UNDERGO THE VACUUM DRYING TREATMENT.
SAID INVENTION PRODUCT ALSO CONTAINS THE BEER YEAST AUTOLYTIC MATTER, AND IS
SUITABLE FOR RAISING ANAEROBIC RESISTANCE, REGULATING IMMUNOLOGICAL FUNCTION
AND IMPROVING NUTRITIONAL ANEMIA.
139/757
74. CN1399915 - 05.03.2003
NATURAL HEALTH-CARE FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1399915
Inventor(s):
FU CHONG (CN)
Applicant(s):
FU CHONG (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
CN20020136450 (20020808)
Priority Number: CN20020136450 (20020808)
Family: CN1399915
Abstract:
THE COMPOSITION OF NATURAL HEALTH-CARE FOOD WITH OBVIOUS THERAPEUTIC ACTION
FOR REDUCING BLOOD SUGAR, REDUCING BLOOD LIPID, CURING DIABETES AND
ANGIOCARDIOPATHY CONTAINS 13.5-15.5 PORTIONS OF BROWN RICE, 22-24 PORTIONS OF
BLACK SESAME OIL, 25-27 PORTIONS OF GREEN TEA, 1-1.5 PORTIONS OF CITRUS GRANDIS,
0.1-0.2 PORTIONS OF MATSU TAKE, 1-2 PORTIONS OF VEILED LADY, 1-2 PORTIONS OF JACK
BEAN, 3-4 PORTIONS OF BRAZIL MUSHROOM, 2-3 PORTIONS OF STAG'S HORN GANODERMA,
1.5-2 PORTIONS OF GINSENG, 0.5-1 PORTIONS OF TANGERINE PEEL, 0.1-0.3 PORTIONS OF
ASPERGILLUS NIGER, 1-1.5 PORTIONS OF RICE VINEGAR AND 24-26 PORTIONS OF GELATIN.
SAID HEALTH-CARE FOOD ALSO CAN RAISE SLEEPING QUALITY AND CAN ELIMINATE
INTERNAL TOXIN.
140/757
75. CN1399955 - 05.03.2003
METHOD FOR USING NANO TECHNOLOGICAL PROCESS TO PREPARE CHINESE MEDICINAL
MATERIAL AND HEALTH-CARE FOOD ULTRAMICROPARTICLES
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1399955
Inventor(s):
CHEN QI (CN)
Applicant(s):
CHEN QI (CN)
IP Class 4 Digits: A61K; A61J; A23P; B82B
IP Class:
A61K9/14; A61J3/00; A23P1/04; B82B1/00
Application Number:
CN20010124957 (20010807)
Priority Number: CN20010124957 (20010807)
Family: CN1399955
Abstract:
THE RAW MATERIAL OF CLEANED CHINESE MEDICINAL MATERIAL OR HEALTH-CARE FOOD
CAN BE PLACED INTO AN ULTRAMICRO HIGH-FREQUENCY VIBRATING MACHINE, AND THE
ETHYL ALCOHOL SOLUTION WHOSE CONCENTRATION IS 55%-85% IS ADDED, THEIR RATIO OF
1-10 ML/10-100 KG, THEN THEY ARE VIBRATED BY USING ULTRAMICRO HIGH-FREQUENCY
VIBRATING MACHINE, ITS ROTATING SPEED IS 1000 RPM-4500 RPM, AND VIBRATING TIME IS
15-60 MIN. SO AS TO OBTAIN THE INVENTED CHINESE MEDICINE MICROPARTICLES OR
HEALTH-CARE FOOD MICROPARTICLES WHOSE CENTRAL GRAIN SIZE IS 5-0.3 MICROMETER
OR FURTHER LESS THAN THAT, AND ITS CELL WALL-BREAKING RATE OR CELL MEMBRANEBREAKING RATE IS ABOVE 98%, SO THAT IT NOT ONLY REMAINS COMPLETE EFFECTIVE
COMPONENTS OF CHINESE MEDICINAL MATERIAL OR HEALTH-CARE FOOD, BUT ALSO THE
ULTRAMICROPARTICLES CAN BE EASILYABSORBED BY HUMAN BODY SO AS TO RAISE ITS
BIOLOGICAL UTILIZATION RATE.
141/757
76. CN1399968 - 05.03.2003
HEALTH-CARE FOOD AND ITS PRODUCTION METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1399968
Inventor(s):
CHEN ZHIYI (CN); CHEN LIEHUI (CN); LIAO SENTAI (CN)
Applicant(s):
INST OF SILKWORM INDUSTRY GUAN (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A23L1/29; A23L1/48; A61K35/64; A61P3/02
Application Number:
CN20010127663 (20010727)
Priority Number: CN20010127663 (20010727)
Family: CN1399968
Abstract:
THE PRODUCTION METHOD OF HEALTH-CARE FOOD RICHLY CONTAINING SEVERAL
NUTRIENTS IS CHARACTERIZED BY THAT THE DOMESTIC MATURAL SILKWORM LIVING BODY
BEFORE WHICH WILL SPIN SILK CAN BE QUICKLY UNDERGONE THE PROCESS OF
INACTIVATION TREATMENT, THEN DRIED AND STERILIZED, SO THAT THE UTILIZATION OF
BENEFICIAL COMPONENTS IN THE MATURED SILKWORM LIVING BODY CAN BE EFFECTIVELY
RAISED.
142/757
77. CN1399969 - 05.03.2003
PRODUCTION METHOD OF HEALTH-CARE FOOD WITH AUXILIARY ACTION FOR CURING
DIABETOS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1399969
Inventor(s):
CHEN ZHIYI (CN); CHEN LIEHUI (CN); LIAO SENTAI (CN)
Applicant(s):
INST OF SILKWORM INDUSTRY GUAN (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A23L1/48; A61P3/10; A61K35/64
Application Number:
CN20010127664 (20010727)
Priority Number: CN20010127664 (20010727)
Family: CN1399969
Abstract:
THE PRESENT INVENTION RELATES TO A PRODUCTION METHOD OF HEALTH-CARE FOOD WITH
AUXILIARY ACTION FOR CURING DIABETES AND IS CHARACTERIZED BY THAT THE DOMESTIC
MATURED SILKWORM BEFORE 2-3 DAYS OF THAT WHICH WILL SILK CAN BE UNDERGONE THE
PROCESS OF QUICK INACTIVATION TREATMENT, THEN DRIED AND STERILIZED. SAID FOOD
RICHLY CONTAINS 1-DEOXYNOJIRINMYCIN, SO THAT IT HAS AUXILIARY ACTION FOR CURING
DIABETES, AT THE SAME TIME IT ALSO RICHLY CONTAINS OTHER VARIOUS NUTRIENT
COMPONENTS.
143/757
78. CN1403017 - 19.03.2003
SELENIUM-RICH KONJAKU-GREEN TEA HEALTH FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1403017
Inventor(s):
TIAN XUAN (CN)
Applicant(s):
TIAN XUAN (CN)
IP Class 4 Digits: A23L
IP Class:
A23L13/08; A23L1/216
Application Number:
CN20020139201 (20021024)
Priority Number: CN20020139201 (20021024)
Family: CN1403017
Abstract:
THE HEALTH FOOD IS PRODUCED WITH GLUCOMANNON AS SELENIUM-RICE KONJAKU
EXTRACTIVE AND SELENIUM-RICH GREEN TEA POWDER. THE PRESENT INVENTION COMBINES
THE NUTRITIVE COMPONENTS OF SELENIUM-RICH TEA, INCLUDING CHLOROPHYLL, VITAMIN C,
ETC. AND THE WATER SOLUBLE FIBRE AND THUS HAS BALANCED NUTRIENTS. THE PRODUCT
HAS NO STARCH, SUGAR AND ANY ADDITIVE, CONTAINS ORGANIC SELENIUM AND OTHER
RICH NUTRITIVE COMPONENTS, AND ONE GREEN FOOD WITHOUT NO TOXIC SIDE EFFECT. IT
IS ONE IDEAL FOOD FOR THE PATIENT OF HYPERLIPEMIA, OBESITY AND DIABETES AND FOR
EXPELLING TOXICITY AND NOURISHING FACE.
144/757
79. CN1403021 - 19.03.2003
HEALTH FOOD COMPOSITION FOR LIVER
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1403021
Inventor(s):
WANSUK HAN (KR)
Applicant(s):
WANSUK HAN (KR)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L1/28
Application Number:
CN20010132662 (20010905)
Priority Number: CN20010132662 (20010905)
Family: CN1403021
Equivalent:
CN1179662C
Abstract:
ONE KIND OF LIVER-BENEFITING HEALTH FOOD COMPOSITE IS DISCLOSED. IT IS PREPARED
WITH GLOSSY GANODERMA, HAW, POLYGALA ROOT, ALOE, WOLFBERRY FRUIT AND OTHER 16
KINDS OF HERBAL MEDICINAL MATERIALS. IT HAS EXCELLENT LIVER FUNCTION PROMOTING
EFFECT AND IS SAFE TO BODY.
145/757
80. CN1403026 - 19.03.2003
NATURAL COMPOSITE SLIMMING HEALTH FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1403026
Inventor(s):
ZHANG LONG (CN)
Applicant(s):
ZHANG LONG (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/308
Application Number:
CN20020137475 (20021016)
Priority Number: CN20020137475 (20021016)
Family: CN1403026
Abstract:
THE NATURAL COMPOSITE WEIGHT-REDUCING HEALTH FOOD IS PRODUCED WITH SOYBEAN
FIBER AS MAIN MATERIAL AND HAS VARIOUS NUTRIENT COMPONENTS ESSENTIAL FOR
HUMAN BODY ADDED, SUCH AS VARIOUS VITAMINS, ENZYMES, INORGANIC SALTS, ETC. IT
MAY BE IN DIFFERENT FORMS, INCLUDING HONEYED BOLUS, TABLET, CAPSULE, POWDER,
ETC. OWING TO THE SOYBEAN FIBER, THE PRODUCT OF THE PRESENT INVENTION CAN
PROMOTE CREEPAGE OF INTESTINAL TRACT, RELAX THE BOWELS, CLEAN INTESTINAL TRACT,
ABSORB GASTRIC JUICE, LOWER APPETITE AND WHILE ENSURING NUTRIENTS NEEDED BY
HUMAN BODY. IT IS ONE KIND OF IDEAL WEIGHT-REDUCING HEALTH FOOD.
146/757
81. CN1403038 - 19.03.2003
MEDICATED FOOD NUTRIENT CAPABLE OF DETOXICATING CIGARETTE, HEALTH CIGARETTE
AND ITS MAKING PROCESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1403038
Inventor(s):
YAN HUAIWEI (CN); YI MIN (CN); YAN HUAIPU (CN)
Applicant(s):
YAN HUAIWEI (CN)
IP Class 4 Digits: A23L; A24D
IP Class:
A23L1/30; A24D1/18
Application Number:
CN20020133595 (20020809)
Priority Number: CN20020133595 (20020809)
Family: CN1403038
Equivalent:
CN1161044C
Abstract:
THE MEDICATED FOOD NUTRIENT IS DESIGNED AND PREPARED BASED ON THE
DETOXICATING PRINCIPLE AND BIOCHEMICAL PRINCIPLE IN BODY AND CAN REDUCE THE
HARM OF TOXIC MATTERS PRODUCED DURING LIGHTING CIGARETTE.THE MEDICATED FOOD
NUTRIENT CONSISTS OF COMPOSITE VITAMINS, COMPOSITE TRACE ELEMENTS AND CALCIUM
AGENT; AND MAY BE USED AS FOOD, MEDICINE, OR THEIR ADDITIVE. THE HEALTH CIGARETTE
CONSISTS OF THE MEDICATED FOOD NUTRIENT AND SHREDDED TOBACCO. THE PRESENT
INVENTION MAKES IT POSSIBLE TO REDUCE THE HARM OF CIGARETTE TO ACTIVE AND
PASSIVE SMOKERS.
147/757
82. CN1404748 - 26.03.2003
PROTEIN-PEPTIDE HEALTH-CARE FOOD AND ITS PREPARING METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1404748
Inventor(s):
JIA DONGYING (CN); YAO KAI (CN); LU YUANPING (CN)
Applicant(s):
HUAYUAN SCIENCE AND TECHNOLOGY (CN)
IP Class 4 Digits: A23L; A23J
IP Class:
A23J3/16; A23L1/0562
Application Number:
CN20020133989 (20021031)
Priority Number: CN20020133989 (20021031)
Family: CN1404748
Abstract:
THE PRESENT INVENTION USES (BY WEIGHT PORTION) 60-80 PORTIONS OF COLLAGEN
PROTEIN PEPTIDE AS MAIN RAW MATERIAL, ADDS 10-20 PORTIONS OF PROTEIN FROM
SOYBEAN, 5.0-15 PORTIONS OF DEFATTED MILK POWDER, 5.0-15 PORTIONS OF LACTALBUMIN,
5.0-10 PORTIONS OF PEANUT PROTEIN AND VITAMINS AS AUXILIARY RAW MATERIAL AND
THROUGH THE PROCESSES OF CLOSED MECHANICAL VIBRATION SORTING, PLACING ALL THE
RAW MATERIAL INTURN INTO STERILE MIXING MACHINE, CONTROLLING ROTATING SPEED AT
20-60 RPM AND REFINING. SAID FOOD POSSESSES THE FUNCTIONS OF SUPPLEMENTING
PROTEIN FOR HUMAN BODY AND NOURISHING SKIN, RAISING THE ABSORPTION OF MINERAL
ELEMENTS OF CALCIUM, PHOSPHORUS AND IRON, ETC. BY HUMAN BODY AND INHIBITING
FORMATION OF INTERNAL FREE RADICAL, ETC.
148/757
83. CN1404768 - 26.03.2003
BLOOD-SUGAR-REGULATING FUNCTIONAL HEALTH-CARE FOOD AND PREPARATION METHOD
THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1404768
Inventor(s):
ZHU YOUYAO (CN); ZHOU SHUNAN (CN); YUAN YIZHENG (CN)
Applicant(s):
ZHU YOUYAO (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/337; A23L13/04
Application Number:
CN20020145043 (20021105)
Priority Number: CN20020145043 (20021105)
Family: CN1404768
Abstract:
THE FUNCTIONAL HEALTH-CARE FOOD CAPABLE OF REGULATING BLOOD SUGAR IS A
MIXTURE MADE UP BY USING 0.02-7% OF FOOD-GRADE ORGANIC CHROMIC COMPOUND, 3%12% OF MICROCAPSULE VITAMIN E AND 2-9% OF MICROCAPSULE VITAMIN C AND MIXING
THEM INTO 79-94 % OF SPIRULINA DRIED POWDER AND UNIFORMLY STIRRING AND MIXING.
SAID HEALTH-CARE FOOD CAN RAISE IMMUNITY OF HUMAN BODY, AND CAN PREVENT
DIABETES AND THE COMPLICATING DISEASE THEREOF.
149/757
84. CN1404769 - 26.03.2003
TWO-COMBINED NUTRIENT HEALTH-CARE FOOD AND BEVERAGE AND PRODUCTION METHOD
THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1404769
Inventor(s):
LIU RENJIAN (CN)
Applicant(s):
LIU RENJIAN (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/48; A23L2/38
Application Number:
CN20010114228 (20010530)
Priority Number: CN20010114228 (20010530)
Family: CN1404769
Abstract:
THE PRESENT INVENTION UTILIZES THREE KINDS OF PLANTS OF CARROT, GRAPE AND SWEET
POTATO WHICH HAVE SPECIAL NUTRIENTS AND SPECIAL FUNCTIONS TO BE COMBINED TO
MAKE TWO KINDS OF COMBINED FOODS AND BEVERAGES. SAID IVNENTION ALSO PROVIDES
THEIR PRODUCTION PROCESS.
150/757
85. CN1406515 - 02.04.2003
HEALTH-CARE FOOD OR MEDICINE FOR REDUCING BLOOD SUGAR
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1406515
Inventor(s):
ZHANG TINGJUN (CN)
Applicant(s):
ZHONGKE TIANHE BIOLOG TECHNOLO (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A23L1/29; A61P3/10; A61K35/64
Application Number:
CN20010142085 (20010911)
Priority Number: CN20010142085 (20010911)
Family: CN1406515
Abstract:
AN EFFICIENT HYPOGLYCEMIC HEALTH-CARE FOOD (OR MEDICINE) IS PREPARED FROM
CHITOSAN (40-45 WT.%), ANT (25-30), ORGANOCHROMIUM (25-30) AND FLAVOURING (5-10). IT
HAS SURE EFFECT ON LOWERING AND REGULATING BLOOD SUGAR.
151/757
86. CN1406599 - 02.04.2003
PROCESS FOR PRODUCING MEDICINE OR HEALTH-CARE FOOD FROM ABALONE SHELLS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1406599
Inventor(s):
QIU CHENGYU (CN)
Applicant(s):
JIMEI UNIV (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A23L1/30; A61P27/02
Application Number:
CN20010127161 (20010827)
Priority Number: CN20010127161 (20010827)
Family: CN1406599
Abstract:
A PROCESS FOR PREPARING MEDICINE OR HEALTH-CARE FOOD FROM SEA-EAR SHELL
INCLUDES SUCH STEPS AS DECOCTING TO OBTAIN DECOCTION, HYDROLYZING THE
DECOCTED SEA-EAR SHELL WILE ORGANIC ACID, CONCENTRATING, CRYSTALLIZING TO
SEPARATE OUT CALCIUM SALT OF ORGANIC ACID, AND MIXING THE MOTHER LIQUID WITH
SAID DECOCTION. ITS ADVANTAGES ARE HIGH UTILIZATION RATE AND SIMPLE PROCESS.
152/757
87. CN1406622 - 02.04.2003
HIGH EFFICIENCY WEIGHT REDUCTION MEDICINE OR HEALTH-CARE FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1406622
Inventor(s):
ZHANG TINGJUN (CN)
Applicant(s):
ZHONGKE TIANHE BIOLOG TECHNOLO (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A23L1/29; A61P3/04; A23L13/07
Application Number:
CN20010142084 (20010911)
Priority Number: CN20010142084 (20010911)
Family: CN1406622
Abstract:
AN EFFICIENT WEIGHT-LOSSING MEDICINE OR HEALTH-CARE FOOD IS PREPARED FROM
CARNITINE (40-45 WT.%), CHITOSAN (30-35), KONJAK (20-25) AND FLAVOURING (5-10).
153/757
88. CN1407109 - 02.04.2003
HEALTH FOOD AND ITS PRODUCTION
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1407109
Inventor(s):
SEIHANA KINOMOTO (JP); SAYURI IMAKI (JP); SHIROO NAGAI (JP)
Applicant(s):
YAEGAKI FERMENTATION TECHNOLOG (JP)
IP Class 4 Digits: A23L; C12P
IP Class:
C12P13/04; A23L13/05
Application Number:
CN20020123240 (20020614)
Priority Number: JP20010271434 (20010907)
Family: CN1407109
154/757
89. CN1409997 - 16.04.2003
BLACK FUNGUS HEALTH CARE FOOD AND ITS MAKING METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1409997
Inventor(s):
HE WEIPING (CN)
Applicant(s):
HE WEIPING (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/28
Application Number:
CN20020134109 (20021116)
Priority Number: CN20020134109 (20021116)
Family: CN1409997
Abstract:
A HEALTH-CARE AURICULARIA AURICULA-JUDAE FOOD IS PREPARED FROM THE
AURICULARIA AURICULA-JUDAE, MOMORDICA GROSVENORI, HAW AND RED JUJUBE
THROUGH PREPARING THE SOLUBLE EXTRACT OF AURICULARIA AURICULA-JUDAE,
PREPARING THE EXTRACT OF MOMORDICA GROSVENORI AND OTHER FRUITS, AND
PROPORTIONALLY MIXING.
155/757
90. CN1411739 - 23.04.2003
KONJAK GLUCOMANNAN DEGRADATION PRODUCT AND GINKGO LEAF EXTRACT HEALTHCARE FOOD AND ITS PREPARATION METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1411739
Inventor(s):
HE JIAQING (CN); WU ZHICHAO (CN); FANG CHUANFU (CN)
Applicant(s):
ANHUI UNIV (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/0528
Application Number:
CN20010134074 (20011019)
Priority Number: CN20010134074 (20011019)
Family: CN1411739
Abstract:
THE PRODUCTION METHOD OF HEALTH-CARE FOOD COMBINED BY USING KONJAK
GLUCOMANNAN CATABOLITE AND GINKGO LEAF EXTRACT MAINLY INCLUDES THE STEPS OF
1. PREPARING KONJAK GLUCOMANNAN CATABOLITE; AND 2. PREPARING GINKGO LEAF
EXTRACT. SAID HEALTH-CARE FOOD HAS THE FUNCTIONS OF CONTROLLING BLOOD SUGAR,
PREVENTING OBESITY, REDUCING ANGIOCARDIOPATHY INCIDENCE, IMPROVING DIGESTIVE
AND EXCRETORY FUNCTION AND RAISING HEALTH LEVEL, ETC.
156/757
91. CN1411747 - 23.04.2003
PRODUCTION METHOD OF COATED AND SHAPED TABLET HEALTH-CARE FOOD WITH THE
FUNCTIONS OF INCREASING BODY HEIGHT AND REDUCING WEIGHT FOR YOUNGSTERS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1411747
Inventor(s):
ZHAO GUANGJUN (CN)
Applicant(s):
ZHAO GUANGJUN (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/212; A23L13/37; A23L3/40
Application Number:
CN20020109768 (20020529)
Priority Number: CN20020109768 (20020529)
Family: CN1411747
Abstract:
THE PRESENT INVENTION RELATES TO A HEALTH-CARE FOOD FILM-COATED SHAPED TABLET
WITH THE FUNCTIONS OF RAISING INTELLIGENCE, INCREASING BODY HEIGHT AND REDUCING
WEIGHT FOR YOUNGSTERS AND ITS PRODUCTION METHOD. ITS FORMULA INCLUDES 35-25%
OF TIBET CAPILLARIES, 35-25% OF CORN SILK, 25-15% OF ALGAE, 5-3% OF FERROUS LACTATE,
5-3% OF ZINC GLUCONATE, 15-5% OF CALCIUM LACTATE AND 3-1% OF VITAMIN B1. ITS
EFFECTIVE RATE IS 100%.
157/757
92. CN1413579 - 30.04.2003
BRAIN HEALTH-CARE FOOD AND ITS MANUFACTURING TECHNOLOGY
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1413579
Inventor(s):
LIU ZHAOHUI (CN); YANG BAOFAN (CN)
Applicant(s):
HUNAN DEHAI PHARMACEUTICAL CO (CN)
IP Class 4 Digits: A61K
IP Class:
A61K35/78; A61K9/20
Application Number:
CN20010131512 (20011026)
Priority Number: CN20010131512 (20011026)
Family: CN1413579
Abstract:
A FOOD FOR TAKING CARE OF BRAIN HEALTH IS PREPARED FROM AMERICAN GINSENG AND
GASTRODIA TUBER THROUGH DRYING, PROPORTIONING, PULVERIZING BY LESS THAN 300
MESHES, STERILIZING AT 115-126 DEG.C AND 0.7-1.4 KG/SQ.CM FOR 15-30 MIN, ADDING
AUXILIARY, GRANULATING, DRYING, ADDING FLAVOURING, AND TABLETTING.
158/757
93. CN1413666 - 30.04.2003
STRONG HEALTH-CARE FOOD AND ITS PRODUCTION METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1413666
Inventor(s):
XU JIALI (CN)
Applicant(s):
XU JIALI (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A61P1/14; A23L1/29
Application Number:
CN20020132962 (20020918)
Priority Number: CN20020132962 (20020918)
Family: CN1413666
Abstract:
A STRONG HEALTH-CARE FOOD FOR PREVENTING MYOCARDIAL ISCHEMIA, ANOXIA, AND
FATIGUE AND IMPROVING SLEEP IS PREPARED FROM 5 CHINESE-MEDICINAL MATERIALS
INCLUDING RHODIOLA ROOT, LIQUORICE ROOT, WOLFBERRYFRUIT, ETC. POTASSIUM
SORBATE, AND CASEINATE PHOSPHOPEPTIDE CALCIUM.
159/757
94. CN1413667 - 30.04.2003
HEALTH-CARE FOOD WITH FATIGUE RESISTANCE, REGULATING IMMUNOLOGIC FUNCTION
AND ITS PREPARATION METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1413667
Inventor(s):
XU ZHE (CN); XU DAOTIAN (CN)
Applicant(s):
JILIN XINKEQI HEALTH CARE FOOD (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A23L1/29; A61P37/02
Application Number:
CN20020133033 (20020923)
Priority Number: CN20020133033 (20020923)
Family: CN1413667
Equivalent:
CN1171619C
Abstract:
A HEALTH-CARE FOOD FOR RELIEVING FATIGUE AND REGULATING IMMUNITY IS PREPARED
FROM 5 CHINESE-MEDICINAL MATERIALS INCLUDING EPIMEDIUM, LUCID LIGUSTRUM FRUIT,
MALE SILK MOTH, ETC THROUGH SUPERCRITICAL CO2 EXTRACTING, THERMAL REFLUX AND
PREPARING SOFTGEL. ITS ADVANTAGES ARE HIGH EFFECT, AND NO TOXIC BY-EFFECT.
160/757
95. CN1416728 - 24.06.2004
A HEALTHY FOOD FOR INCREASING BONE DENSITY AND ANTI-AGING
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1416728
Inventor(s):
TU YUBIN (CN); WANG CHENGRONG (CN); WANG LIFEN (CN); BIAN HUASHI
(CN); DENG XIU (CN)
Applicant(s): SHANGHAI SUNDISE CHINESE MEDIC (CN); WANG CHENGRONG (CN); WANG
LIFEN (CN); BIAN HUASHI (CN); DENG XIU (CN); TU YUBIN (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A23L1/29; A61P19/10; A61P39/06
E Class: A61K35/78; A23L1/30B; A23L1/20D4
Application Number:
WO2003CN01017 (20031128)
Priority Number: CN20020151147 (20021206)
Family: CN1416728
Equivalent:
AU2003289630; CN1176602C
Cited Document(s):
CN1096204; CN1096953; CN1256921; CN1304724
Abstract:
A HEALTHY FOOD FOR INCREASING BONE DENSITY AND ANTI-AGING, WHICH IS CONSISTED
OF SOYA BEAN, EPIMEDII, RADIX ASTRAGALI, RADIX ANGELICAE SINENSIS AND FRUCTUS
MORI WHICH ARE AS ACTIVE COMPONENTS, AND CALCIUM GLUCONATE, SODIUM
CARBOXYMETHYLSTARCH AND MICROCELLULOSE WHICH ARE AS SUPPLEMENTARY
MATERIALS. IT PREPARED BY FULLY MIXING THE RADIX ANGELICAE SINENSIS OIL OBTAINED
BY SUPER-CRITICAL CO2, EXTRACTION, SOYAISOFLAVONE OBTAINED BY ETHANOL
161/757
EXTRACTION OF SOYA, WITH POWDER OBTAINED BY SPRAY DRYING WATER- EXTRACTS OF
EPIMEDII, RADIX ASTRAGALI, FRUCTUS MORI AND DE-OILED RADIX ANGELICAE SINENSIS,
THEN ADDING CALCIUM GLUCONATE, SODIUM CARBOXYMETHYLSTARCH AND
MICROCELLULOSE, THUS OBTAINING PARTICLES, SUBSEQUENTLY COMPRESSING THE
PARTICLES INTO TABLETS AND COATING. THIS FOOD HAS THE FUNCTION OF INCREASING
BONE DENSITY AND ANTIAGING WHICH DEMONSTRATED BY ZOOPERY. THE RESULTS OF
MODEM PHARMACOLOGICAL AND CLINICAL RESEARCH SHOW THAT THIS FOOD HAS
HEALTHY FUNCTION OF INCREASING BONE DENSITY AND ANTIAGING, AND IS SUITABLE FOR
ADMINISTRATION OVER LONG-TERM.
162/757
96. CN1416731 - 14.05.2003
BLOOD FAT-REDUCING ANTI-FATIGUE HEALTH FOOD COMPOSITION
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1416731
Inventor(s):
LI TIANCAI (CN); SUO YOURUI (CN); DU YUZHI (CN)
Applicant(s):
INST OF NORTHWEST CHINA PLATEA (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L1/212
Application Number:
CN20010131787 (20011101)
Priority Number: CN20010131787 (20011101)
Family: CN1416731
Abstract:
THE HEALTH FOOD COMPOSITION IS PRODUCED WITH VETCHLEAF SOPHORA LEAF, SEABUCKTHORN LEAF AND WOLFBERRY LEAF. IT HAS THE FUNCTIONS OF LOWERING BLOOD FAT,
RESISTING FATIGUE, RAISING BODY'S IMMUNITY, ETC. IT IS ESPECIALLY SUITABLE FOR
PATIENT OF HYPERLIPOPROTEINEMIA, ATHEROSCLEROSIS AND OTHER CARDIAC VASCULAR
DISEASES AND HAS NO TOXIC SIDE EFFECT.
163/757
97. CN1416734 - 14.05.2003
ANTI-FATIGUE HEALTH FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1416734
Inventor(s):
CHEN WENJUN (CN)
Applicant(s):
CHEN WENJUN (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/08; A23L1/212
Application Number:
CN20020149448 (20021121)
Priority Number: CN20020149448 (20021121)
Family: CN1416734
Abstract:
THE PRESENT INVENTION RELATES TO HEALTH FOOD, ESPECIALLY ONE KIND OF ANTIFATIGUE HEALTH FOOD. THE COMPONENTS OF THE HEALTH FOOD INCLUDE MACA ROOT
AND STEM, HONEY AND FRUIT JUICE. EATING IT REGULARLYCAN ELIMINATE FATIGUE AND
STRENGTHEN PHYSIQUE AND IT HAS NO SIDE EFFECT.
164/757
98. CN1416741 - 14.05.2003
HEALTH EDIBLE-FUNGUS FOOD AND ITS PRODUCTION PROCESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1416741
Inventor(s):
LUO XINGYE (CN); LUO JIAN (CN)
Applicant(s):
LUO XINGYE (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/28
Application Number:
CN20020127936 (20021127)
Priority Number: CN20020127936 (20021127)
Family: CN1416741
Equivalent:
CN1175762C
Abstract:
THE HEALTH EDIBLE-FUNGUS HEALTH FOOD IS CAPSULE, HONEYED PILL AND HONEYED
PASTE PRODUCED WITH GOLD FUNGUS POWDER, SCHIZOPHYLLUM POWDER. AGARICUS
BLAZEI MURRILL POWDER, AND GLOSSY GANODERMA POWDER. THE PRODUCTION PROCESS
INCLUDES MICROWAVE DISINFECTION TO KILL HARMFUL MICROBES AND INSECT EGG,
ELIMINATING WATER, CRUSHING AND MIXING. COMPARED WITH TRADITIONAL EDIBLE
FUNGUS COOKING PROCESS, THE PRESENT INVENTION HAS LESS NUTRITIVE COMPONENT
LOSS AND SIMPLE PRODUCTION PROCESS, AND THE PRODUCT HAS THE MEDICINAL
FUNCTIONS OF GOLD FUNGUS, SCHIZOPHYLLUM, AGARICUS BLAZEI MURRILL, AND GLOSSY
GANODERMA.
165/757
99. CN1416751 - 14.05.2003
PRODUCTION PROCESS OF HEALTH GLOSSY GANODERMA FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1416751
Inventor(s):
YU NEIXUN (CN); ZHONG SHIBIN (CN)
Applicant(s):
YU NEIXUN (CN)
IP Class 4 Digits: A23L
IP Class:
A23L2/39; A23L33/571
Application Number:
CN20020150011 (20021108)
Priority Number: CN20020150011 (20021108)
Family: CN1416751
Equivalent:
CN1189104C
Abstract:
THE PRESENT INVENTION RELATES TO ONE KIND OF HEALTH FOOD OF GLOSSY GANODERMA
AS AN ANCIENT SLIME FUNGUS AND IMPORTANT HEALTH FOOD RESOURCE. THE CULTURE
LIQUID CONSISTS OF TOMATO JUICE, CHINESE YAM JUICE, WOLFBERRY FRUIT JUICE, YEAST
EXTRACT POWDER, ETC. THE PRODUCTION PROCESS INCLUDES FERMENTATION, FREEZE
DRYING AND OTHER STEPS AND THE PRODUCT HAS THE EFFECTIVE ACTIVE COMPONENTS,
INCLUDING PROTEIN, POLYSACCHARIDE, NUCLEIC ACID, ETC., OF GLOSSY GANODERMA
MAINTAINED. IT HAS THE FUNCTIONS OF PREVENTING TUMOR, RESISTING MUTATION AND
PROLONGING LIFE OTHER THAN ITS FUNCTION OF PROMOTING THE SECRETION OF SALIVA
TO RELIEVE THIRST.
166/757
100. CN1416838 - 14.05.2003
HEALTH FOOD CAPSULE WITH FUNCTIONS OF SOBERING UP, DETOXICATING, NOURISHING
HEART, TRANQUILIZING AND PROTECTING LIVER AND ITS PRODUCTION PROCESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1416838
Inventor(s):
LI BANGGUI (CN); SONG HONGCHANG (CN)
Applicant(s):
LI BANGGUI (CN)
IP Class 4 Digits: A61K; A61P
IP Class:
A61K35/78; A61P1/16; A61P25/22; A61P39/02
Application Number:
CN20010131515 (20011030)
Priority Number: CN20010131515 (20011030)
Family: CN1416838
Equivalent:
CN1186035C
Abstract:
IN THE PRESENT INVENTION, A HEALTH FOOD CAPSULE IS PREPARED WITH THE MATERIAL
INCLUDING HOVENIA DULCIS FRUIT, PEARL, COMMON JUJUBE AND KUDZU VINE ROOT AND
THROUGH DISINFECTION, CRUSHING, SUPERFINE GRINDING TO 500 MESH, CAPSULIZING AND
OTHER STEP. IT HAS THE FUNCTIONS OF SOBERING UP, DETOXICATING, NOURISHING HEART,
TRANQUILIZING AND PROTECTING LIVER AND HEART. TAKING IT WHILE DRINKING CAN
REDUCE THE HARM OF FREE RADICAL PRODUCED BY ETHANOL IN SPIRIT ON HUMAN BODY
OBVIOUSLY.
167/757
101. CN1416841 - 14.05.2003
ANTI-ANOXIA HEALTH FOOD COMPOSITION
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1416841
Inventor(s):
LI TIANCAI (CN); SUO YOURUI (CN); DU YUZHI (CN)
Applicant(s):
INST OF XIBEI PLATEAU BIOLOGY (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A23L1/29; A61P39/00
Application Number:
CN20010131786 (20011101)
Priority Number: CN20010131786 (20011101)
Family: CN1416841
Abstract:
THE ANTI-ANOXIA HEALTH FOOD COMPOSITION PRODUCED WITH RHODIOLA ROOT,
SPIRULINA, SAFFLOWER AND WOLFBERRY FRUIT HAS RICH NUTRITIVE COMPONENTS,
OUTSTANDING ANTI-ANOXIA FUNCTION, AND NO TOXIC SIDE EFFECT. IT IS SUITABLE FOR
TREATING PLATEAU ANOXIA, IMMUNE DEFICIENCE AND RESISTANCE DEFICIENCY.
168/757
102. CN1421157 - 04.06.2003
HEALTH VEGETABLE-FRUIT FOOD AND ITS PRODUCTION PROCESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1421157
Inventor(s):
CAO SHUWEN (CN)
Applicant(s):
CAO SHUWEN (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L1/36; A23L12/12
Application Number:
CN20020157681 (20021217)
Priority Number: CN20020157681 (20021217)
Family: CN1421157
Abstract:
THE PRESENT INVENTION RELATES TO ONE KIND OF HEALTH FOOD AND ITS PREPARATION
PROCESS. THE HEALTH FOOD IS PREPARED WITH WALNUT KERNEL, LOTUS SEED, PEARL
POWDER, ALOE AND OTHER FOOD MATERIAL WITH THE BEAUTIFYING, SKIN CARE, FACE
NURSING AND NOURISHING FUNCTIONS ARE MAIN MATERIAL AND THROUGH EXTRUSION,
PUFFING, MICROCAPSULIZING, AND OTHER MODERN FOOD PROCESSING PROCESS TO KEEP
FRESHNESS AND STABILIZE AND ADDING THE WATER AND/OR ALCOHOL EXTRACTIVE OF
SOYBEAN, CARROT, DATE, TREMELLA, LONGAN, ETC. EXPERIMENT SHOWS THAT THE
PRODUCT OF THE PRESENT INVENTION HAS EXCELLENT HEALTH EFFECTS OF IMPROVING
GSTROINTESTINAL TRACT FUNCTION AND BEAUTIFYING.
169/757
103. CN1421163 - 04.06.2003
PREPN OF HEALTH FOOD WITH HAIR BLACKENING FUNCTION
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1421163
Inventor(s):
YU NEIXUN (CN)
Applicant(s):
YU NEIXUN (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L2/38; A61K35/56
Application Number:
CN20020159766 (20021226)
Priority Number: CN20020159766 (20021226)
Family: CN1421163
Equivalent:
CN1179666C
Abstract:
THE HEALTH FOOD IS PREPARED WITH 12 KINDS OF MEDICATED FOOD MATERIAL, INCLUDING
FLEECEFLOWER ROOT, BLACK SESAME, BLACK BEAN, BLACK MULBERRY SUPERFINE PEARL
POWDER, ETC. THE HEALTH FOOD IS DEVELOPED ON THE BASIS OF FAMILY HANDED PROVED
RECIPE. IT HAS POWERFUL HAIR BLACKENING FUNCTION AND IS ONE KIND OF TONIC FOR
INVIGORATING KIDNEY, RESISTING SENILITY, BLACKENING HAIR AND NURSING FACE. IT IS
GRANULE TO CAPSULE PREPARED THROUGH LOW TEMPERATURE FREEZING AND OTHER
TECHNOLOGICAL PROCESS.
170/757
104. CN1421164 - 04.06.2003
MULTIFUNCTIONAL HEALTH FOOD AND ITS PRODUCTION PROCESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1421164
Inventor(s):
ZHOU WENCAI (CN)
Applicant(s):
ZHOU WENCAI (CN)
IP Class 4 Digits: A23L
IP Class:
A23L2/39
Application Number:
CN20020160147 (20021231)
Priority Number: CN20020160147 (20021231)
Family: CN1421164
Abstract:
THE PRESENT INVENTION RELATES TO ONE KIND OF MULTIFUNCTIONAL HEALTH FOOD AND
ITS PRODUCTION PROCESS. IT IS PRODUCED WITH THE MATERIALS INCLUDING DATE, MILLET,
MUNG BEAN, MIRABILITE AND GINGER IN THE WEIGHT PROPORTION CHANGING FOR
DIFFERENT TAKING PEOPLE AND WITH DIFFERENT TAKEN SEASON. THE PRODUCTION
PROCESS INCLUDES THE STEPS OF: MATERIAL SELECTION, WASHING, STOVING, CRUSHING,
MIXING AND DISINFECTION. THE PRODUCT IS TAKEN AFTER BEING MIXED WITH BOILED
WATER. IT HAS THE HEALTH FUNCTIONS OF NOURISHING BLOOD, INVIGORATING VITAL
ENERGY, APPETIZING, ELIMINATING FATIGUE, RELAXING THE BOWELS, ETC.
171/757
105. CN1421232 - 04.06.2003
NUTRITIVE HEALTH FOOD WITH FUNCTIONS OF REDUCING BLOOD FAT AND DELAYING
SENILITY AND ITS PREPN PROCESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1421232
Inventor(s):
JIANG TIAN (CN); HOU YONGZUO (CN); FU ZHONGHU (CN)
Applicant(s):
BEIJING HUAYUAN LIFE SCIENCE T (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A23L1/29; A61P3/02
Application Number:
CN20020155434 (20021213)
Priority Number: CN20020155434 (20021213)
Family: CN1421232
Equivalent:
CN1167459C
Abstract:
THE NUTRITIVE HEALTH FOOD CONSISTS OF OLIVE OIL, PROPOLIS TEA POLYPHENOL, AND
VITAMINS. IT HAS THE HEALTH FUNCTIONS OF REDUCING BLOODFAT, DELAYING SENILITY
AND REGULATING IMMUNE. IT HAS CERTAIN ASSISTANT TREATING FUNCTION TO
HYPERTENSION, HYPERLIPEMIA, HYPERGLYCEMIA, HEART DISEASE, DIABETES AND OTHER
DISEASES.
172/757
106. CN1425321 - 25.06.2003
HEALTH COOKED WHEATEN FOOD PRODUCTS OF JEW'S-EAR AND BUCKWHEAT AND ITS
PRODUCING METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1425321
Inventor(s):
LIN CHAOSEN (CN)
Applicant(s):
LIN CHAOSEN (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/10; A23L1/28
Application Number:
CN20030102827 (20030115)
Priority Number: CN20030102827 (20030115)
Family: CN1425321
Abstract:
THE HEALTH EDIBLE FUNGUS-BUCKWHEAT PRODUCT INCLUDING NOODLES, BREAD, ETC IS
PRODUCED WITH EDIBLE FUNGUS IN 3-40 WT% AND BUCKWHEAT FLOUR IN 60-97 WT%, AND
INTO THE MATERIAL, CALCIUM LACTATE POWDER AND/OR ZINC LACTATE POWDER MAY BE
ADDED. THE PRESENT INVENTION HAS THE OBVIOUS FUNCTIONS OF LOWERING BLOOD
VISCOSITY, RESISTING THROMBUS, LOWERING BLOOD FAT, LOWERING BLOOD SUGAR AND
ASSISTING TREATMENT OF CARDIAC VASCULAR DISEASES CAUSED BY HYPERLIPEMIA AND
DIABETES. IT IS SUITABLE FOR VARIOUS PEOPLE OF DIFFERENT AGES.
173/757
107. CN1426695 - 02.07.2003
COMPOSITE PURE FIBER HEALTH CARE FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1426695
Inventor(s):
CHU KUN (CN)
Applicant(s):
CHU KUN (CN)
IP Class 4 Digits: A23L
IP Class:
A23L13/08; A23L1/056
Application Number:
CN20020125827 (20020827)
Priority Number: CN20020125827 (20020827)
Family: CN1426695
Abstract:
A HEALTH-CARE COMPOSITE FIBROUS FOOD FOR PREVENTING AND TREATING
CONSTIPATION, OBESITY, HYPERTENSION, HYPERLIPOMIA, DIABETES, CORONARY HEART
DISEASE, CANCER, ETC. IS PREPARED FROM GLUCOMANNAN AND CHITIN THROUGH
PROPORTIONING.
174/757
108. CN1429498 - 16.07.2003
HEALTH-CARE FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1429498
Inventor(s):
AKIO OCHIAI (JP); MASANORI KOSUGE (JP); TAKAO ONAGA (JP)
Applicant(s):
DAINAGAKIKAKU CO LTD (JP)
IP Class 4 Digits: A23L; A61P
IP Class:
A23L1/223; A61P25/24
Application Number:
CN20020157491 (20021218)
Priority Number: JP20010384860 (20011218); JP20020042639 (20020220)
Family: CN1429498
175/757
109. CN1429569 - 16.07.2003
HEALTH-CARE FOOD FOR BEAUTIFYING HAIR
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1429569
Inventor(s):
SUN CHUNHUA (CN)
Applicant(s):
SUN CHUNHUA (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A23L1/29; A61P17/00
Application Number:
CN20010130266 (20011229)
Priority Number: CN20010130266 (20011229)
Family: CN1429569
Abstract:
A HEALTH-CARE FOOD FOR BEAUTIFYING HAIR AND TREATING ALOPESIA AND POLISIS IS
PREPARED FROM 8 CHINESE MEDICINAL MATERIALS INCLUDING BLACK BEAN, FLEECE
FLOWER ROOT, CHINESE ANGELICA ROOT, WOLFBERRY FRUIT, ETC..
176/757
110. CN1429580 - 16.07.2003
HEALTH-CARE FOOD MADE OF EGG AND THREE CHINESE MEDICINE HERBS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1429580
Inventor(s):
SUN JIASHENG (CN)
Applicant(s):
SUN JIASHENG (CN)
IP Class 4 Digits: A61K; A61P
IP Class:
A61K35/78; A61P15/08
Application Number:
CN20010144096 (20011229)
Priority Number: CN20010144096 (20011229)
Family: CN1429580
Abstract:
A HEALTH CARE FOOD "THREE HERB EGG" FOR PREVENTING AND TREATING MASTITIS IS
PREPARED FROM PRUNELLA SPIKE, DANDELION HERB, MOTHERWORT, AND EGG. ITS
ADVANTAGE IS HIGH EFFECT.
177/757
111. CN1430911 - 23.07.2003
HEALTH CARE NUTRITIONS FOOD OF KING VEGETABLES AND ITS CREATION METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1430911
Inventor(s):
YONGJIAN HAOLONG (CN)
Applicant(s):
YONGJIAN HAOLONG (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/212; A23L13/37
Application Number:
CN20030114506 (20030225)
Priority Number: CN20030114506 (20030225)
Family: CN1430911
Abstract:
A NUTRITIVE HEALTH-CARE FOOD "KING VEGETABLE" IS PREPARED FROM KING VEGETABLE,
SPIRULINA POWDER AND ARCTIUM, AND FEATURES THAT IT CONTAINS BETA-CAROTIN,
EDIBLE CELLULOSE AND CA. ITS ADVANTAGE IS SUREHEALTH-CARE FUNCTION OF
IMPROVING IMMUNITY AND PROVIDES NUTRIENTS TO HUMAN BODY.
178/757
112. CN1431016 - 23.07.2003
COMPOSITIONS OF HEALTH CARE FOOD FOR REGULATING BLOOD SUGAR AND FAT AS WELL
AS ITS PREPARING METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1431016
Inventor(s):
LI YONGQUAN (CN); WU DAN (CN); YAO SHU (CN)
Applicant(s):
UNIV ZHEJIANG (CN)
IP Class 4 Digits: A61K; A61P
IP Class:
A61K35/78; A61P3/06; A61P3/10; A61K38/01
Application Number:
CN20030114899 (20030113)
Priority Number: CN20030114899 (20030113)
Family: CN1431016
Abstract:
A HEALTH-CARE FOOD FOR REGULATING BLOOD SUGAR AND BLOOD FAT IS PREPARED FROM
TEA POLYOSE, TEA POLYPHENOL, PLANT PROTEIN AND TRACE ELEMENTS. ITS ADVANTAGES
ARE HIGH EFFECT ON PREVENTING HYPERGLYCEMIC AND HYPERLIPEMIA, AND QUICKLY
TAKING ITS EFFECT.
179/757
113. CN1432297 - 30.07.2003
HEALTH FOOD FOR DIABETICS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1432297
Inventor(s):
HAN JITAI (CN); HAN WENBO (CN)
Applicant(s):
HAN JITAI (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/307
Application Number:
CN20030104975 (20030304)
Priority Number: CN20030104975 (20030304)
Family: CN1432297
Abstract:
THE HEALTH FOOD FOR DIABETICS CONTAINS RICH FOOD FIBER ESPECIALLY SUITABLE FOR
DIABETICS TO EAT. BRAN WITH CELLULOSE CONTENT AS HIGH AS 18% BUT BAD TASTE IS
SOAKED WITH VINEGAR, STEAMED, MODULATED AND CRUSHED; AND THE BRAN POWDER IS
THEN MIXED WITH WHOLE WHEAT FLOUR, WHITE CHINESE YAM POWDER, BUCKWHEAT FLOUR,
SOYBEAN POWDER, HAW POWDER, DATA POWDER, WALNUT KERNEL POWDER AND SESAME;
AND THE MIXTURE IS FURTHER PRODUCED INTO CAKE. PRACTICS SHOWS THAT THE HEALTH
FOOD AS ONE KIND OF IDEAL FOOD FOR DIABETICS IS EFFECTIVE IN SUBSIDIARY TREATMENT
OF DIABETES.
180/757
114. CN1435125 - 13.08.2003
HEALTH FOOD WITH BLOOD FAT ADJUSTING FUNCTION
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1435125
Inventor(s):
XIA HUI (CN)
Applicant(s):
SHANBA BIOLOG DEV CO LTD GUIZH (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
CN20020127931 (20021129)
Priority Number: CN20020127931 (20021129)
Family: CN1435125
Abstract:
A HEALTH-CARE FOOD ABLE TO REGULATE BLOOD FAT, THAT IS, REDUCING LOW-DENSITY
CHOLESTEROL AND TRIGLYCERIDE AND INCREASING HIGH-DENSITY CHOLESTEROL FOR
PREVENTING CEREBRAL APOPLEXY, CEREBRAL THROMBOSISAND ARTERIOSCLEROSIS IS
PREPARED FROM OOLONG TEA, FLEECE FLOWER ROOT, AURICULARIA AURICULA-JUDAE,
HAW AND MALT.
181/757
115. CN1435126 - 13.08.2003
METHOD FOR PREPARING COMPOUND SUGARED GINSENG AND GLOSSY GANODERMA
HEALTH FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1435126
Inventor(s):
YU NEIXUN (CN)
Applicant(s):
YU NEIXUN (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
CN20020143026 (20020912)
Priority Number: CN20020143026 (20020912)
Family: CN1435126
Abstract:
A HEALTH-CARE FOOD IN THE FORM OF CAPSULE OR ORAL LIQUID FOR PREVENTING CANCER
AND DELAYING SENILITY IS PREPARED FROM 10 RAW MATERIALS INCLUDING XYLITOL,
GINSENG, GANODERMA, ROYAL JELLY, ETC THROUGH LOW-TEMP FREEZING, DRYING,
PULVERIZING, FERMENTING, ETC.
182/757
116. CN1436481 - 20.08.2003
FRUIT AND VEGETABLE HEALTH FOOD AND ITS MAKING PROCESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1436481
Inventor(s):
HAN YIBO (CN)
Applicant(s):
HAN YIBO (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/08; A23L1/10; A23L1/36
Application Number:
CN20030121745 (20030312)
Priority Number: CN20030121745 (20030312)
Family: CN1436481
Abstract:
THE PRESENT INVENTION RELATES TO FRUIT AND VEGETABLE HEALTH FOOD AND ITS MAKING
PROCESS. THE FRUIT AND VEGETABLE HEALTH FOOD IS MADE WITH WOLFBERRY FRUIT,
WHITE SESAME, WALNUT KERNEL, PEANUT KERNEL, DATE, RAISIN, FIG, CONCENTRATED
VEGETABLE JUICE, HONEY AND BREAD CRUMB POWDER. THE MAKING PROCESS INCLUDES
SMASHING WOLFBERRY FRUIT, DATE, RAISIN AND FIG; FRYING WHITE SESAME AND PEANUT
KERNEL; MAKINGWALNUT KERNEL POWDER, PREPARING BREAD CRUMB POWDER;
SQUEEZING AND CONCENTRATING CARROT OR TOMATO JUICE; AND MIXING. THE PRESENT
INVENTION HAS BALANCED NUTRIENT COMPONENTS AND GOOD TASTE, AND THE
PRODUCTION PROCESS HAS NO POLLUTION.
183/757
117. CN1436490 - 20.08.2003
PRODUCTION PROCESS OF NATURAL MARINE ORGANISM HEALTH FOOD WITH DEEP SEA
CLAM WORM AS MATERIAL
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1436490
Inventor(s):
GE FENG (CN); LIU XIANGHUI (CN)
Applicant(s):
INST OF ZOOLOGY CHINESE ACADEM (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K9/48; A23L1/337
Application Number:
CN20020104215 (20020209)
Priority Number: CN20020104215 (20020209)
Family: CN1436490
Abstract:
THE PRODUCTION PROCESS OF NATURAL MARINE ORGANISM HEALTH FOOD INCLUDES THE
PROCESS OF CULTURING DEEP SEA CLAM WORM IN SALT WATER FOR 3-4 DAYS TO MAKE IT
SPIT OUT CONTENT; HOMOGENIZING AND CENTRIFUGING AFTER ADDING PHYSIOLOGICAL
SALINE OR PHOSPHATE BUFFERING LIQUID; SALTING OUT, DIALYSIS OR COLUMN
CHROMATOGRAPHY AND ULTRAFILTRATION TO ELIMINATE IMPURITIES AND PURIFY
SOLUTION; SPRAY DRYING OR FREEZING DRYING TO OBTAIN POWDER; CO-60 RAY
IRRADIATINO TO STERILIZE TO OBTAIN FOOD POWDER; AND CAPSULIZING. THE HEALTH
FOOD CONTAINS RICH AMINO ACIDS, FATTY ACIDS, TRACE ELEMENTS, VITAMINES AND
BIOACTIVE ENZYMES, ESPECIALLY GREAT AMOUNT OF PLASMIN. EXPERIMENTS SHOW THAT
THE HEALTH FOOD HAS THE HEALTH FUNCTIONS OF REGULATING BLOOD PRESSURE AND
BLOOD FAT, PREVENTING THROMBUS, RESISTING SENILITY AND STRENGTHENING IMMUNITY.
184/757
118. CN1437898 - 27.08.2003
HEALTH-CARE FOOD FOR REDUCING BLOOD PRESSURE
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1437898
Inventor(s):
HAN JIANYING (CN)
Applicant(s):
HAN JIANYING (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L2/39
Application Number:
CN20020113368 (20020211)
Priority Number: CN20020113368 (20020211)
Family: CN1437898
Abstract:
THE PRESENT INVENTION RELATES TO A HEALTH-CARE FOOD WITH THE FUNCTION OF
REDUCING BLOOD PRESSURE, WHICH IS CHARACTERIZED BY THAT IT MAKES THE EXTRACT
OBTAINED BY EXTRACTING PUMPKIN ROOT BY USING WATER EXTRACTION OR ALCOHOL
EXTRACTION PROCESS INTO HEALTH-CARE FOOD FOR REDUCING BLOOD PRESSURE WITH
VARIOUS DOSAGE FORMS. THE DESCRIBED PUMPKIN COMPRISES ITS KINDRED PLANTS,
SUCH AS CUSTARD SQUASH C. PEPO. AND CUC MIS MELO VAR, FLEXUASUS C. MELO, ETC.
SAID INVENTED EXTRACT CONTAINS SEVERAL AMINO ACIDS, CAROTENE, VITAMIN B,
ASCORBIC ACID, COFFEARIN AND MANNITOL, ETC. THE TESTS SHOW THAT SAID HEALTHCARE FOOD POSSESSES OBVIOUS ACTION OF REDUCING BLOOD PRESSURE.
185/757
119. CN1437962 - 27.08.2003
SUGAR-REDUCING HEALTH-CARE FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1437962
Inventor(s):
HAN JIANYING (CN)
Applicant(s):
HAN JIANYING (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A23L1/30; A61P3/10
Application Number:
CN20020113367 (20020211)
Priority Number: CN20020113367 (20020211)
Family: CN1437962
Abstract:
THE PRESENT INVENTION RELATES TO A HEALTH-CARE FOOD FOR REDUCING BLOOD SUGAR,
WHICH IT IS CHARACTERIZED BY THAT SAID HEALTH-CARE FOOD CAN BE MADE UP BY USING
EXTRACT OF SPINACH ROOT, AND CAN BE MADE INTO VARIOUS TYPES OF HEALTH-CARE
FOOD. AS COMPARED WITH BITTER MELON AND PUMPKIN THE SPINACH ROOT HAS
STRONGER ACTIVITY FOR REDUCING BLOOD SUGAR.
186/757
120. CN1439300 - 03.09.2003
HEALTH-CARE FLOUR FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1439300
Inventor(s):
WANG AN (CN)
Applicant(s):
WANG AN (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/304
Application Number:
CN20030107186 (20030307)
Priority Number: CN20030107186 (20030307)
Family: CN1439300
Abstract:
A HEALTH-CARE NOODLE FOOD FOR REDUCING BLOOD SUGAR AND BLOOD FAT, LOWERING
BLOOD PRESSURE, IMPROVING MEMORY POWER, PREVENTING CANCER AND DELAYING
SENILITY FEATURES THAT BESIDES ORIGINAL RAW MATERIALSIT CONTAINS MG, CR AND VF.
187/757
121. CN1440675 - 10.09.2003
PRODUCTION PROCESS OF HEALTH WOLFBERRY FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1440675
Inventor(s):
HE YU (CN); REN HUARONG (CN); ZHUANG XIANGJIU (CN)
Applicant(s):
SHANDONG LONGMAI SCI TECH DEV (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/212; A23L3/44
Application Number:
CN20020104325 (20020227)
Priority Number: CN20020104325 (20020227)
Family: CN1440675
Abstract:
THE HEALTH WOLFBERRY FOOD IS PRODUCED WITH WOLFBERRY FRUIT AND THROUGH THE
TECHNOLOGICAL PROCESS OF: DRYING WOLFBERRY FRUIT MATERIAL TO WATER CONTENT
OF 2-25%; REFRIGERATING AT LOW TEMPERATURE; CRUSHING AT CERTAIN TEMPERATURE IN
A CRUSHER TO SOME FINENESS; AND KNEADING TO CERTAIN COMPACTNESS, SHAPING AND
PACKING. AS A GREEN HEALTH FOOD, THE HEALTH WOLFBERRY FOOD HAS NOT ANY
SUPPLEMENTARY MATERIALADDED.
188/757
122. CN1440762 - 10.09.2003
SLIMMING MEDICINE AND HEALTH FOOD AND THE PREPN PROCESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1440762
Inventor(s):
YANG MENGJUN (CN)
Applicant(s):
YANG MENGJUN (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A23L1/29; A61P3/04
Application Number:
CN20020104318 (20020225)
Priority Number: CN20020104318 (20020225)
Family: CN1440762
Abstract:
THE SLIMMING MEDICINE AND HEALTH FOOD IS PRODUCED WITH KONJAKU, CHINESE YAM,
TUCKAHOE, WOLFBERRY, FRUIT, SOYBEAN ISOFLAVONE AND SPIRULINA AN RAW MATERIALS,
WHICH ARE POWDERED THROUGH DIFFERENT PROCESSES, FREEZE DRYING AND SUPERFINE
CRUSHING OR HIGH PRESSURE GAS ATOMIZING, INTO FINE POWDER, MIXED IN CERTAIN
PROPORTION AND FURTHER PROCESSED INTO CASPULE OR OTHER FORM. THE UNIQUE
MATERIAL COMPOSITION AND PRODUCTION PROCESS RESULTS IN UNIQUE TREATING AND
HEALTH CARE EFFECT.
189/757
123. CN1440786 - 10.09.2003
NOURISHING HEALTH FOOD FOR TREATING CONSTIPATION
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1440786
Inventor(s):
LI ZHONGHENG (CN)
Applicant(s):
LI ZHONGHENG (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A61P1/10; A23L1/29
Application Number:
CN20030111927 (20030305)
Priority Number: CN20030111927 (20030305)
Family: CN1440786
Abstract:
THE NOURISHING HEALTH FOOD FOR TREATING CONSTIPATION CONSISTS OF HONEY IN 15-40
WT% AND GARLIC IN 60-85 WT%. THE PREPARATION PROCESS INCLUDES SEPARATING
GARLIC INTO GARLIC CLOVES WITH SKIN, ROASTING WITH CHARCOAL TO EVAPORATE ITS
WATER, ELIMIANTING THE SKIN AND SOAKING GARLIC IN HONEY. THE NOURISHING HEALTH
FOOD HAS THE FUNCTIONS OF PROMOTING DIGESTION, INVIGORATING SPLEEN AND
STOMACH, ACTIVATINGVITAL ENERGY, TREATING CONSTIPATION, ETC. IN ADDITION, THE
GARLIC THUS PROCESSED IS DELICIOUS AND EASY TO PRESERVE.
190/757
124. CN1443480 - 24.09.2003
GINKGO GANODERMA HEALTH-CARE FOOD AND ITS PRODUCTION METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1443480
Inventor(s):
XIAO FANGDAO (CN)
Applicant(s):
XIAO FANGDAO (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/29; A23L1/48; A23L1/28
Application Number:
CN20020111056 (20020312)
Priority Number: CN20020111056 (20020312)
Family: CN1443480
Abstract:
THE PRESENT INVENTION RELATES TO A GINKGO GANODERMA HEALTH-CARE FOOD AND ITS
PRODUCTION METHOD. ITS FORMULA COMPOSITION INCLUDES (BY WEIGHT PORTION) 90-96
PORTIONS OF GINKGO LEAF DRIED POWDER, 4-10 PORTIONS OF GANODERMA SPOROPHORE
POWDER AND 0.5-2 PORTIONS OF LICORICE. ITS PRODUCTION METHOD INCLUDES THE
FOLLOWING STEPS: PREPARING RAW MATERIALS, DRYING, MAKING CHOICE AND BREAKING,
SIEVING, PROPORTIONING AND MIXING UNIFORMLY, REFINING AND STERILIZING AND
PACKAGING. SAID GINKGO GANODERMA HEALTH-CARE FOOD CONTAINS 100-ODD ACTIVE
MATTER COMPONENTS BENEFICIAL FOR HEALTH OF HUMAN BODY.
191/757
125. CN1444874 - 01.10.2003
HEALTH-CARE FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1444874
Inventor(s):
GAO SI (CN)
Applicant(s):
GAO SI (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L1/08; A23L2/00
Application Number:
CN20030113933 (20030318)
Priority Number: CN20030113933 (20030318)
Family: CN1444874
Abstract:
A HEALTH-CARE FOOD FOR TAKING CARE OF THE HEALTH OF TRACHEA, BRONCHUS AND
LUNG IS PREPARED FROM 16 EDIBLE RAW MATERIALS INCLUDING LILY BULB, TREMELLA,
ALMOND, GINKGO SEED, COIX SEED, ETC.
192/757
126. CN1444877 - 01.10.2003
HEALTH-CARE FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1444877
Inventor(s):
GAO SI (CN)
Applicant(s):
GAO SI (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L2/04
Application Number:
CN20030113932 (20030318)
Priority Number: CN20030113932 (20030318)
Family: CN1444877
Abstract:
A HEALTH-CARE BEVERAGE FOR THE EARLY COLD IS PREPARED FROM 16 RAW MATERIALS
INCLUDING CHINESE-MEDICINAL MATERIALS (TANGERINE PEEL, SCHIZONEPETA, MINT, ETC)
AND TRADITIONAL FOOD (GINGER SLICES, SCALLION ROOT, CABBAGE ROOT, ETC). ITS
ADVANTAGES IS EASY STORAGING FOR THE DECOCTA AND EASY HEATING FOR DRINKING.
193/757
127. CN1449685 - 22.10.2003
HEALTH CARE FOOD AND PREPARATION METHOD THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1449685
Inventor(s):
FAN SHENGGANG (CN); HUO LONGJIANG (CN); JU PING (CN)
Applicant(s):
YANTAI ABOLUO BIOLOG SCIENCE A (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A61P1/14; A23L1/29
Application Number:
CN20030112369 (20030430)
Priority Number: CN20030112369 (20030430)
Family: CN1449685
Abstract:
THE PRESENT INVENTION DISCLOSES A HEALTH-CARE FOOD CAPABLE OF DELAYING SENILITY
AND RAISING IMMUNITY AND ITS PREPARATION METHOD. IT IS MADE OF (BY WEIGHT PORTION)
150-500 PORTIONS OF VELVET DEERHORN EXTRACT, 40-200 PORTIONS OF AMERICAN
GINSENG EXTRACT, 10-100 PORTIONS OF GINSENG SAPONIN, 1.2-3.0 PORTIONS OF SODIUM
SELENITE, 0.8-1.5 PORTIONS OF MAGNESIUM LACTATE, 1.2-2.5 PORTIONS OF ZINC
GLUCONATEAND 0.5-2.0 PORTIONS OF CORRECTIVE. ITS PREPARATION METHOD INCLUDES
THE FOLLOWING STEPS: OZONE TREATMENT, PREPARATION OF NANO POWDER
PREPARATION, ULTRASONIC MIXING, MIXING AND PACKAGING SO AS TO OBTAIN THE
INVENTED PRODUCT.
194/757
128. CN1449689 - 22.10.2003
GINKGO HEALTH CARE FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1449689
Inventor(s):
YANG MINGZHI (CN); ZHANG LICHUN (CN)
Applicant(s):
ZHANG LICHUN (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A61K9/48; A23L2/39; A23L2/38
Application Number:
CN20020113601 (20020410)
Priority Number: CN20020113601 (20020410)
Family: CN1449689
Abstract:
THE PRESENT INVENTION RELATES TO A GINKGO HEALTH-CARE FOOD, AND IS
CHARACTERIZED BY THAT ITS COMPOSITION CONTAINS 0.25-25 WT% OF GINKGO LEAF
EXTRACT, 10-30 WT% OF CORDYCEPIC MYCELIUM EXTRACT AND 45-90 WT% OF AUXILIARY
MATERIAL. SAID HEALTH-CARE FOOD HAS SEVERAL HEALTH-CARE FUNCTIONS OF
PREVENTING AND CURING CARDIO-CEREBRAL VASCULAR DISEASES, RAISING IMMUNITY OF
HUMAN BODY, RAISING KIDNEY FUNCTION, DELAYING SENILITY AND INVIGRATING SEXUAL
FUNCTION, ETC. SAID HEALTH-CARE IS SUITABLE FOR MIDDLE AGED AND OLD PEOPLE.
195/757
129. CN1451313 - 29.10.2003
HEALTH FOOD CONTG. LECITHINUM AND PURIFIED VINEGAR
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1451313
Inventor(s):
WANG HUAN (CN)
Applicant(s):
WANG HUAN (CN)
IP Class 4 Digits: A23L; C12J
IP Class:
A23L1/29; C12J1/00
Application Number:
CN20030113238 (20030418)
Priority Number: CN20030113238 (20030418)
Family: CN1451313
Abstract:
A HEALTH-CARE FOOD FOR REGULATING BLOOD FAT AND INTERNAL SECRETION, RELIEVING
FATIGUE AND DELAYING SENILITY IS PREPARED FROM SOYBEAN LECITHIN, PURIFIED
VINEGAR AND VE THROUGH PROPORTIONAL MIXING.
196/757
130. CN1452902 - 05.11.2003
HEALTH FOOD COMPOUNDED WITH SILKWORM CHRYSALIS ENZYMOLYZING LIQUID AND
FUNCTIONAL OLIGOSE
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1452902
Inventor(s):
LI ZHAOMING (CN); YU JINKUI (CN)
Applicant(s):
LI ZHAOMING (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
CN20020118706 (20020423)
Priority Number: CN20020118706 (20020423)
Family: CN1452902
Abstract:
THE PRESENT INVENTION IS HEALTH FOOD CONTAINING PROTEIN OR MICROBE AND IS
ESPECIALLY HEALTH FOOD COMPOUNDED WITH SILKWORM CHRYSALIS ENZYMOLYZING
LIQUID AND FUNCTION OLIGOSE. THE HEALTH FOOD WITH THEEFFECTS OF RAISING BODY'S
IMMUNITY AND IMPROVING BODY'S PHYSIOLOGICAL FUNCTION CONSISTS OF POLYPEPTIDE,
AMINO ACIDS, UNSATURATED FATTY ACID, POLYSACCHARIDE, FUNCTIONAL OLIGOSE,
VITAMINS AND MINERALS. THE KEY POINT OF THE PREPARING PROCESS IS THE SUPERFINE
TREATMENT TO THE GRANULARITY BELOW 10 MICRONS OF SLURRY BEFORE THE
ENZYMOLYSIS OF SILKWORM CHRYSALIS, AND THIS CAN RAISE THE ENZYMOLYSIS GREATLY
AND MATERIAL UTILIZATION WITHOUT DAMAGING THE MOLECULAR STRUCTURE.
197/757
131. CN1452903 - 05.11.2003
COMPOUND ORGANIC SILK AS ANTIOXIDANT, ANTI-SENILITY AND HEAVY METAL POLLUTIONRESISTING HEALTH FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1452903
Inventor(s):
MU YUNZHUAN (CN); GUO DASHENG (CN)
Applicant(s):
MU YUNZHUAN (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/29; A23L1/28
Application Number:
CN20030129922 (20030522)
Priority Number: CN20030129922 (20030522)
Family: CN1452903
Abstract:
THE PRESENT INVENTION BELONGS TO HEALTH FOODS AND AIMS TO RAISE THE FUNCTION
OF HEALTH FOODS. THE COMPOUND ORGANIC SILK IS ONE KIND OF MIXTURE OF ORGANIC
SILK, FLAVONOID, VITAMIN E, SODIUM SELENITE,LAURIC ACID MODIFIED SOD AND KONJAKU
POWDER. THE ORGANIC SILK CONSISTS OF CHITIN, CHITIN AMINE, CHITOSAN, CELLULOSE
AND BETA-1.4-GLYCOSIDE POLYSACCHARIDE. THE PRODUCTION PROCESS OF THE ORGANIC
SILKINCLUDES THE STEPS OF: EXTRACTING BIOLOGICAL FUNGUS FROM CHITIN, DAMAGING
THE DNA SENSITIVE AREA WITH INDUCTIVE AGENT TO OBTAIN MUTANT STRAIN, IRRADIATION
WITH ULTRAVIOLET RAY, MULTI-STAGE CULTURE AND AMPLIFICATION, FILTERING AND
COLLECTING. THE PRODUCT OF THE PRESENT INVENTION HAS OUTSTANDING FUNCTIONS OF
RESISTING OXIDATION, SENILITY AND HEAVY METAL, AND MAY BE FURTHER PRODUCED INTO
MEDICAL FILM, HEALTH FOOD FOR PREVENTING AND TREATING CARDIAC AND CEREBRAL
VASCULAR DISEASES, SLIMMING HEALTH FOOD, ETC.
198/757
132. CN1452912 - 05.11.2003
HEALTH FOOD COMPOUNDED WITH OYSTER AND SCALLOP ENZYMOLZING LIQUID AND
SOYBEAN LECITHIN
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1452912
Inventor(s):
LI ZHAOMING (CN); ZHAO XINGKUN (CN)
Applicant(s):
LI ZHAOMING (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/33; A23L33/571; A23L3/46
Application Number:
CN20020118707 (20020423)
Priority Number: CN20020118707 (20020423)
Family: CN1452912
Abstract:
THE PRESENT INVENTION IS HEALTH FOOD CONTAINING PROTEIN MATERIAL AND ITS
DERIVATIVE, AND IS HEALTH FOOD COMPOUNDED WITH OYSTER AND SCALLOP
ENZYMOLIZING LIQUID AND SOYBEAN LECITHIN. THE HEALTH FOOD CONTAINS
OLIGOPEPTIDE, AMINO ACID, POLYSACCHARIDE, TAURINE, LECITHIN, VITAMINS AND
MINERALS. THE KEY POINTS OF THE PRESENT INVENTION INCLUDES SUPERFINE TREATMENT
OF OYSTER AND SCALLOP INTO 10 MICRONS BELOW SLURRY BEFORE ENZYMOLYSIS, THE
ADDITION OF SOYBEAN LECITHIN AND THE MICROCAPSULIZING TREATMENT IN HIGH SPEED
SHEARING AND MIXING EMULSIFYING MACHINE.
199/757
133. CN1457646 - 26.11.2003
HEALTH FOOD CONTAINING AMPELOPTIN
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1457646
Inventor(s):
REN QISHENG (CN); SONG XINRONG (CN)
Applicant(s):
REN QISHENG (CN)
IP Class 4 Digits: A23L; A21D
IP Class:
A23L1/30; A23L2/52; A21D2/14
Application Number:
CN20030138053 (20030530)
Priority Number: CN20030138053 (20030530)
Family: CN1457646
Abstract:
THE PRESENT INVENTION DISCLOSES THE USE OF AMPELOPTIN AS FOOD ADDITIVE AND
PROVIDES VARIOUS KINDS OF HEALTH FOOD AND BEVERAGE WITH AMPELOPTIN.
200/757
134. CN1459289 - 03.12.2003
HEALTH-CARE FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1459289
Inventor(s):
YAN YIYI (CN); CHEN YU-AN (CN)
Applicant(s):
CHENGYI PHARMACEUTICAL CO LTD (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61P1/14; A23L1/29; A61K31/7088
Application Number:
CN20020119463 (20020522)
Priority Number: CN20020119463 (20020522)
Family: CN1459289
Abstract:
A HEALTH-CARE FOOD FOR RELIEVING FATIGUE, IMPROVING MYOCARDIAL FUNCTION, AND
RESTORING PHYSICAL STRENGTH OF PATIENT IS PREPARED FROM THE GENERAL SAPONIN
EXTRACTED FROM NOTOGINSENG AND D-RIBOSE AS EFFECTIVE COMPONENTS, AND
COMPOUNDED WITH ASSISTANT.
201/757
135. CN1460417 - 10.12.2003
HEALTH-CARE FOOD WITH IMMUNE-REGULATING AND FACE-BEAUTIFYING FUNCTION AND ITS
PREPARATION METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1460417
Inventor(s):
XU ZHE (CN); XU DAOTIAN (CN)
Applicant(s):
XINKEQI HEALTH CARE FOOD CO LT (CN)
IP Class 4 Digits: A61K; A23D
IP Class:
A61K35/78; A23D9/00
Application Number:
CN20030133474 (20030617)
Priority Number: CN20030133474 (20030617)
Family: CN1460417
Abstract:
THE PRESENT INVENTION RELATES TO A HEALTH-CARE FOOD WITH THE FUNCTIONS OF
REGULATING IMMUNE AND BEAUTIFYING FACE AND ITS PREPARATION METHOD. IT IS MADE
UP BY USING GRAPE-SEED EXTRACT, WHEAT GERM OIL,PEARL AND SOYBEAN GLYCITIN AS
RAW MATERIAL. SAID HEALTH-CARE FOOD HAS OBVIOUS FUNCTIONS.
202/757
136. CN1460480 - 10.12.2003
HYPOGLYCEMIC HEALTH-CARE FOOD FOR DIABETES TYPE Фан"
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1460480
Inventor(s):
WANG QIANG (CN)
Applicant(s):
WANG QIANG (CN)
IP Class 4 Digits: A61K; A61P
IP Class:
A61P3/10; A61K31/7016
Application Number:
CN20030126832 (20030612)
Priority Number: CN20030126832 (20030612)
Family: CN1460480
Abstract:
THE PRESENT INVENTION USES KELP EXTRACT AS MAIN RAW MATERIAL, AND ADOPTS THE
PROCESSES OF DRYING, PULVERIZING, ADDING NUTRIENT ORGANIC CHROMIUM OR SOME
AUXILIARY MATERIALS ACCORDING TO A CERTAIN PROPORTION, USING GAMMA-RAY
RADIATION STERILIZATION TO MAKE THEM INTO THE INVENTED HEALTH-CARE FOOD WHICH
CAN BE MADE INTO POWDER PREPARATION, ORAL LIQUOR, PASTE PREPARATION, TABLE AND
CAPSULE PREPARATIONFOR CURING DIABETES TYPE II AND PREVENTING ITS COMPLICATION.
203/757
137. CN1461604 - 17.12.2003
HEALTH-CARE FOOD WITH FUNCTIONS OF ANTI-SENILITY, BEAUTIFYING FACE AND
MOISTENING SKIN AND PREPN. METHOD THEREFOR
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1461604
Inventor(s):
LIU LI (CN); LIU CHANGHAI (CN); FENG TAO (CN)
Applicant(s):
LIU LI (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A23L1/29; A61P17/16; A61P11/14
Application Number:
CN20020117964 (20020527)
Priority Number: CN20020117964 (20020527)
Family: CN1461604
Equivalent:
CN1176605C
Abstract:
A HEALTH-CARE FOOD FOR DELAYING SANILITY, BEAUTIFYING FACE AND MOISTENING SKIN
IS PREPARED FROM THE EXTRACTION OF FOREST FROG SKIN, GINSENG EXTRACTION,
GINKGO EXTRACTION, RAPE POLLEN, CHINESE ANGELICA ROOT POWDER, PEARL POWDER
AND FROG FAT.
204/757
138. CN1461606 - 17.12.2003
HEALTH-CARE FRUIT AND VEGETABLE FOOD WITH FUNCTION OF LOOSEING BOWEL TO
RELIEVE CONSTIPATION AND ITS PRODN. METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1461606
Inventor(s):
HAN WENXUAN (CN); WANG HONGLIANG (CN); ZHANG GANG (CN)
Applicant(s):
HAN WENXUAN (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
CN20020120751 (20020531)
Priority Number: CN20020120751 (20020531)
Family: CN1461606
Abstract:
A HEALTH-CARE FRUIT-VEGETABLE FOOD FOR LOOSEING BOWEL TO RELIEVE CONSTIPATION
IS PREPARED FROM FRUITS (BANANA, APPLE, ETC), VEGITABLES (CARROT, ETC.) CHINESEMEDICINAL MATERIALS (ALOE, WOLFBERRY FRUIT, ETC), OLIGOSE, HONEY, WHITE GRANULAR
SUGAR, ETC THROUGH PRE-TREATING, SOFTENING, BEATING, SIEVING, PULVERIZING,
PROPORTIONAL MIXING, CONCENTRATING, SHAPING, DRYING AND PACKAGE.
205/757
139. CN1462595 - 24.12.2003
HEALTH CARE FOOD FOR REGULATING IMMUNITY, ANTIOXIDATION AND ITS PREPARING
METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1462595
Inventor(s):
SU WEIWEI (CN); PENG WEI (CN); WU ZHONG (CN)
Applicant(s):
UNIV ZHONGSHAN (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L2/04; A23L23/85
Application Number:
CN20030126992 (20030626)
Priority Number: CN20030126992 (20030626)
Family: CN1462595
Abstract:
A HEALTH-CARE FOOD FOR REGULATING IMMUNITY AND RESISTING OXIDATION IS PREPARED
FROM PINE NEEDLES, OPHIOPOGON ROOT AND STARCH OR BETA-CYCLODEXTRIN THROUGH
EXTRACTING THE EXTRACT OF PINE NEEDLES OR SQUEEZING THE PINE NEEDLE TO OBTAIN
JUICE, EXTRACTING THE ACTIVE COMPONENTS FROM OPHIOPOGON ROOT, PROPORTIONAL
MIXING, AND ADDING STARCH OR BETA-CYCLODEXTRIN.
206/757
140. CN1463629 - 31.12.2003
SELENIUM-RICH WATER-SOLUBLE DIETARY FIBER HEALTH FOOD CONTAINING GLUGLUCOSAN
AND METHOD FOR MAKING SAME
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1463629
Inventor(s):
XIANG FAYE (CN)
Applicant(s):
CHEN GUANFENG (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
CN20020121449 (20020621)
Priority Number: CN20020121449 (20020621)
Family: CN1463629
Abstract:
THE HEALTH FOOD IS PRODUCED WITH PROCESSED KONJAKU POWDER, SELENIUM PROTEIN,
ZINC LACTATE, FERROUS LACTATE, VITAMIN E, VITAMIN C, VITAMIN A, VITAMIN B1, VITAMIN B2
AND VITAMIN D AS MATERIAL AND THROUGH MIXING, PACKING AND GAMMA RAY
DISINFECTION. THE HEALTH FOOD OF THE PRESENT INVENTION HAS OBVIOUS EFFECTS OF
LOWERING BLOOD SUGAR CONTENT, LOWERING BLOOD FAT CONTENT, ELIMINATING
INTERNAL CARCINOGENIC MATTER, AND IS ONE KIND OF IDEAL HEALTH FOOD FOR
PREVENTING DISEASES.
207/757
141. CN1463712 - 31.12.2003
HEALTH FOOD ADDITIVE AND PROCESS FOR PREPARING SAME
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1463712
Inventor(s):
WU DIWU (CN); WU GAOXIONG (CN)
Applicant(s):
WU GAOXIONG (CN)
IP Class 4 Digits: A61K; A61P
IP Class:
A61K35/78; A61P1/14
Application Number:
CN20020112001 (20020606)
Priority Number: CN20020112001 (20020606)
Family: CN1463712
Abstract:
THE PRESENT INVENTION IS ONE KIND OF DISEASE PREVENTING AND PHYSIQUE
STRENGTHENING HEALTH FOOD AND ITS COMPOUNDING PROCESS. THE HEALTH FOOD IS
COMPOUNDED WITH GINSENG AS CHIEF MATERIAL, PILOSE ANTLER AS ADJUVANT MATERIAL,
ASTRAGALUS ROOT AND SEALWORT AS ASSISTANT MATERIAL, GARLIC AS GUIDE MATERIAL
AND LICORICE AS NEUTRALIZING MATERIAL. THE COMPOUNDING PROCESS INCLUDES THE
STEPS OF MATERIAL PREPARATION, WASHING, STOVING, CRUSHING, MIXING, SEALED
SOAKING IN ALCOHOL OR WHITE SPIRIT, TAKING SUPERNATANT, PACKING AND
DISINFECTION. THE HEALTH FOOD HAS EXCELLENT EFFECTS OF STRENGTHENING YANG,
NOURISHING YIN, ELIMINATING EVILS, REGULATING INTERNAL ORGANS, IMPROVING
METABOLISM, ETC.
208/757
142. CN1463744 - 31.12.2003
A HEALTH FOOD POSSESSING IMMUNITY REGULATING FUNCTION AND METHOD FOR
PREPARING THE SAME
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1463744
Inventor(s):
DU YUGUANG (CN); LI SHUGUANG (CN); BAI XUEFANG (CN)
Applicant(s):
CHINA ACADEMY OF SCIENCES DALI (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A23L1/29; A61P37/04; A61K35/84
Application Number:
CN20020109808 (20020607)
Priority Number: CN20020109808 (20020607)
Family: CN1463744
Abstract:
THE HEALTH FOOD WITH IMMUNOLOGICAL REGULATING EFFECT CONSISTS OF MAINLY
CHITIN OLIGOSACCHARIDE AND GLOSSY GANODERMA SPORE POWDER IN THE WEIGHT
RATIO OF 1-9 TO 1-9. THE PREPARATION PROCESS INCLUDES MIXING IN SOME STIRRER,
DRYING AND STERILIZING AT 50-100 DEG.C FOR 1-5 HR, AND PACKING AS CAPSULE, POWDER
OR TABLET. THE HEALTH FOOD OF THE PRESENT INVENTION MAY BE USED FOR
HYPOIMMUNITY OF VARIOUS CAUSES TO REGULATE IMMUNITY AND RAISE SELF-HEALING
CAPACITY AFTER DISEASES.
209/757
143. CN1464046 - 31.12.2003
BACILLUS ADHAERENS AND ITS USE IN PREPARING HEALTH FOOD HAVING THROMBOLYSIS
PROPERTY
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1464046
Inventor(s):
XING JIANMIN (CN); LUAN XIAODI (CN); LIU HUIZHOU (CN)
Applicant(s):
CHINA ACADEMY OF SCIENCES INST (CN)
IP Class 4 Digits: A61K; A61P; C12N
IP Class:
A61K35/74; A61P9/00; C12N1/20
Application Number:
CN20020121352 (20020614)
Priority Number: CN20020121352 (20020614)
Family: CN1464046
Equivalent:
CN1177039C
Abstract:
BACILLIIS NATTO NLSSC WITH THE PRESERVATION NUMBER CGMCC NO. 0724 IS GRAM
STAINING POSITIVE, NON-ACID FAST, STRAIGHT OR NEAR STRAIGHT, (0.6-0.8)X(1.5-2.0)
MICRON SIZED AND AEROBIC; HAS MESIAL AND UN-SWELLED SPORE WITH THE SPORE
NUMBER INSIDE ONE SPORANGE CELL NOT MORE THAN ONE, MESO DIAMINO HEPTANE
DIACID AND GLYCIN CONTAINED IN THE CELL WALL, NO CHARACTERISTIC SACCHARUM AND
PERIPHERAL FLAGELLUM;AND CAN BE GROWN WELL IN FIVE KINDS OF NATURAL ORGANIC
CULTURE MEDIUM AND CAN FORM RELATIVELY THICK MYCODERM AND BUTTER FAT
COLORED COLONY WITH SMOOTH EDGE IN SOYBEAN CAKE POWDER CULTURE MEDIUM.
BACILLIIS NATTO CAN BE CULTURED IN CULTURE MEDIUM WITH NITROGEN SOURCE TO
OBTAIN THROMBUS DISSOLVING MATTER NATTO KINASE AND THE CULTURED MATTER MAY
210/757
BE EXTRACTED TO OBTAIN POWDERED MATTER AS THE ADDITIVEFOR THROMBOLYTIC
HEALTH FOOD.
211/757
144. CN1465281 - 07.01.2004
HEALTH CARE INSTANT FOOD OF KONJAK SWEET DEW
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1465281
Inventor(s):
CAO SHAOHUA (CN)
Applicant(s):
CAO SHAOHUA (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/214
Application Number:
CN20020133327 (20020619)
Priority Number: CN20020133327 (20020619)
Family: CN1465281
Abstract:
THE PRESENT INVENTION PROVIDES A KIND OF KONJAK SWEET DEW HEALTH-CARE INSTANT
FOOD. SAID HEALTH-CARE FOOD HAS FUNCTIONS OF REDUCING SUGAR, REDUCING BLOOD
LIPID, REDUCING BLOOD PRESSURE, REDUCING CHOLESTERIN AND PROTECTING GALLBALDDER, ETC. AND ITS RAW MATERIAL COMPOSITION INCLUDES (WT%) 3-4 OF KONJAK
FLOUR, 8-10% OF OLIGOSE, 0.5-1% OF AUXILIARY MATERIAL AND THE REST IS WATER.
212/757
145. CN1465285 - 07.01.2004
LEAD-REMOVING HEALTH CARE FOOD AND PREPARATION METHOD THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1465285
Inventor(s):
DU YUGUANG (CN); LI SHUGUANG (CN); BAI XUEFANG (CN)
Applicant(s):
DALIAN CHEMICAL PHYSICS INST (CN)
IP Class 4 Digits: A23L; A61K; A61P; C12P
IP Class:
A23L1/29; A61K31/722; A61P39/02; C12P19/04
Application Number:
CN20020132494 (20020628)
Priority Number: CN20020132494 (20020628)
Family: CN1465285
Abstract:
THE PRESENT INVENTION DISCLOSES A HEALTH-CARE FOOD WITH THE FUNCTION OF
DISCHARGING LEAD FROM HUMAN BODY AND ITS PREPARATION METHOD. IT IS MADE OF
CHITOSAN, CHITOOLIGOSE, LOCIRCE AND PORIA EXTRACT ASMAIN EFFECTIVE COMPONENT,
AND USING SODIUM ALGINATE, PECTIN, VITAMIN C, ZINC GLUCONATE AND CALCIUM
GLUCONATE AS AUXILIARY MATERIAL AND COMBINING THEM TO OBTAIN THE INVENTED
PRODUCT.
213/757
146. CN1465286 - 07.01.2004
SEED WATER MELON DREGS HEALTH CARE FOOD WITH WEIGHT-REDUCING, FAT-REDUCING
FUNCTION
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1465286
Inventor(s):
LIU CHANGYING (CN); MA YONGDONG (CN)
Applicant(s):
MA YONGDONG (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/308
Application Number:
CN20020143487 (20020930)
Priority Number: CN20020143487 (20020930)
Family: CN1465286
Abstract:
THE PRESENT INVENTION RELATES TO A SEED MELON PULP HEALTH-CARE FOOD WITH THE
FUNCTIONS OF REDUCING WEIGHT AND REDUCING FAT. IT IS CHARACTERIZED BY THAT IT
USES SEED MELON PULP AS MAIN RAW MATERIAL, AND ADDS OTHER AUXILIARY MATERIALS,
AND ADOPTS A CERTAIN PRODUCTION PROCESS TO PRODUCE VARIOUS HEALTH-CARE
FOODS, SUCH AS WEIGHT-REDUCING HUMBURGE, WEIGHT-REDUCING AND FAT-REDUCING
BISCUIT, SEED MELON PASTE AND SEED MELON CELLULOSE TABLET ETC.
214/757
147. CN1466990 - 14.01.2004
HEALTH FOOD FOR PROTECTING LIVER AND ADJUSTING BLOOD FAT AND METHOD FOR
PREPARING THE SAME
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1466990
Inventor(s):
TU YUBIN (CN); ZHOU YONGCHUAN (CN); YU XIANGSEN (CN)
Applicant(s):
SHANGHAI MODERN CHINESE TRADIT (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/84; A61P1/16; A23L1/39
Application Number:
CN20020136002 (20020712)
Priority Number: CN20020136002 (20020712)
Family: CN1466990
Abstract:
A HEALTH-CARE FOOD FOR PROTECTING LIVER AND REGULATING BLOOD FAT IS PREPARED
THROUGH EXTRACTING ACTIVE COMPONENTS FROM RED SAGE ROOT, PEACH KERNEL AND
GYNOSTEMMA PENTAPHYLLUM IN SUB-BOILING WATER, ADDING CHITOSAN, FLOCCULATING
SETTING, FILTER, MIXING WITH FERMENTED CORDYCEPS POWDER, SPRAY DRYING, ADDING
STARCH AND DEXTRIN, MIXING, GRANULATING, DRYING, TABLETTING AND COATING.
215/757
148. CN1468624 - 21.01.2004
HEALTH FOOD OF HAW EXTRACTIVE AND ITS APPLICATION
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1468624
Inventor(s):
ZHANG RONGPING (CN)
Applicant(s):
ZHANG RONGPING (CN)
IP Class 4 Digits: A61K; A61P
IP Class:
A61K35/78; A61P3/10
Application Number:
CN20030117463 (20030313)
Priority Number: CN20030117463 (20030313)
Family: CN1468624
Abstract:
THE PRESENT INVENTION FEATURES THAT HAW MATERIAL IS THRICE ETHANOL REFLUX
EXTRACTED, THE EXTRACTIVE LIQUID IS CONCENTRATED TO OBTAIN EXTRACTIVE MATERIAL,
AND THE EXTRACTIVE MATERIAL IS FURTHER PRODUCED INTO TABLET OR CAPSULE
THROUGH MIXING WITH STARCH AND ETHANOL, DRYING, ETC. OR, THE HAW MATERIAL IS
REFLUX HEATED IN WATER SOLUTION OF HYDROCHLORIC ACID TO OBTAIN EXTRACTIVE, THE
EXTRACTIVE IS PH REGULATED WITH SODIUM HYDROXIDE, CONCENTRATED, HEATING
DISSOLVED, FILTERED AND FURTHER TREATED TO PRODUCE TABLET OR CAPSULE. THE
HEALTH FOOD OF HAW EXTRACTIVE HAS DETERMINED EFFECT OF LOWERING BLOOD SUGAR
CONTENT AND NO SIDE EFFECT.
216/757
149. CN1473517 - 11.02.2004
HEALTH-CARE DRINK AND FOOD AND ITS PREPARING METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1473517
Inventor(s):
LIU CHANGLAN (CN); LU HONGZHEN (CN)
Applicant(s):
LIU CHANGLAN (CN)
IP Class 4 Digits: A23L
IP Class:
A23L2/38; A23L2/52
Application Number:
CN20030138787 (20030709)
Priority Number: CN20030138787 (20030709)
Family: CN1473517
Abstract:
THE HEALTH CARE DRINK AND FOOD IS PREPARED WITH NUTRIMENT ESSENTIAL FOR HUMAN
BODY AND CAPABLE OF RAISING HUMAN BODY'S IMMUNITY 0.001-90 WT%, EDIBLE
DISINFECTANT 0.01-5 WT%, ABSORPTION PROMOTER 0.01-5 WT%, AND WATER OR OLIGOSE
THE REST. IT IS PREPARED THROUGH QUASI-NANO TECHNOLOGY IN A HOMOGENIZING AND
MIXING APPARATUS; IS PREPARED INTO AEROSOL, COLLOID OR POWDERED CONCENTRATE;
OR MAY BE FURTHERPREPARED INTO AEROSOL TYPE HEALTH FOOD TOGETHER WITH
COMPRESSION AIR PROPELLANT. IT HAS HIGH FLOW DISPERSIVITY FOR DISPERSING IN
WHOLE BODY, AND THE AMPHOTERIC PROPERTY OF THE KETONE OR AMINO RADICAL IN THE
ABSORPTION PROMOTER IS FAVORABLE TO THE ABSORPTION OF QUASI-NANO NUTRIMENTS.
217/757
150. CN1475146 - 18.02.2004
SERIES HEALTH CARE FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1475146
Inventor(s):
WU XIANTONG (CN)
Applicant(s):
WU XIANTONG (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L1/29; A23L2/38
Application Number:
CN20030123981 (20030601)
Priority Number: CN20030123981 (20030601)
Family: CN1475146
Abstract:
A HEALTH-CARE FOOD SERIES FOR IMPROVING PHYSIOLOGICAL FUNCTIONS AND THE
RESISTANCE TO DISEASES, AND PREVENTING DISEASES IS PREPARED FROM 8 CHINESEMEDICINAL MATERIALS, AND FEATURES THAT IT CONTAINS GANODERIC POLYOSE,
TRITERPENOID, ADENOSINE, ALKALOID AND CELLULOSE. ITS ADVANTAGES ARE HIGH EFFECT
AND NO BY-EFFECT.
218/757
151. CN1475147 - 18.02.2004
CALCIUM ENRICHED AND KNUCKLE HEALTH CARE FOOD AND ITS PREPARATION METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1475147
Inventor(s):
ZHAN JINMING (CN)
Applicant(s):
ZHEJIANG AOXING BIOLOG SCIENCE (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/304; A23L1/303
Application Number:
CN20030141607 (20030710)
Priority Number: CN20030141607 (20030710)
Family: CN1475147
Abstract:
A FOOD FOR SUPPLEMENTING CALCIUM TO HUMAN BODY, TAKING CARE OF JOINT HEALTH,
AND PREVENTING AND CURING ARTHRITIS IS PREPARED FROM AMINOGLUCOSE 15%-80%,
CALCIUM PREPARATION ONE OF CALCIUM GLUCONATE, CALCIUM LACTATE, CALCIUM
PHOSPHATE AND CALCIUM CARBONATE 15%-80%, AND VD 0.1%-5%.
219/757
152. CN1475167 - 18.02.2004
HEALTH CARE FOOD FOR ANTIFATIGUE AND IMPROVING SUBHEALTHY AND ITS PREPARATION
METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1475167
Inventor(s):
WEIYI WANG (--); CN FANG XIAODONG (--)
Applicant(s):
ZHEJIANG SHOUFENGTANG BIOENGIN (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L2/385
Application Number:
CN20020136519 (20020816)
Priority Number: CN20020136519 (20020816)
Family: CN1475167
Abstract:
A HEALTH-CARE FOOD FOR RELIEVING FATIGUE AND IMPROVING SUBHEALTH STATE IS
PREPARED FROM DEOXYISOSTERONE AND 6 CHINESE-MEDICINAL MATERIALS INCLUDING
GINSENG, NOTOGINSENG, LIQUORICE ROOT, ETC THROUGH RESPECTIVELY EXTRACTING THE
ACTIVE COMPONENTS FROM SAID CHINESE-MEDICINAL MATERIALS, PROPORTIONALLY
MIXING TO OBTAIN LIQUID MIXTURE, MIXING WITH DEOXYISOSTERONE, AND SHAPING TO
OBTAIN ORAL LIQUID, POWDER, TABLET, OR CAPSULE.
220/757
153. CN1475168 - 18.02.2004
HEALTH FOOD CAPABLE OF RAISIONG ORGANISM IMMUNE POWER AND ITS PREPARATION
METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1475168
Inventor(s):
FENG ZHUN (CN); WANG YONGZE (CN)
Applicant(s):
DALIAN HONGYU PHARMACEUTICAL C (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L2/39
Application Number:
CN20030133899 (20030709)
Priority Number: CN20030133899 (20030709)
Family: CN1475168
Abstract:
A HEALTH-CARE FOR IMPROVING IMMUNITY, MEMORY AND SLEEP, RELIEVING FATIGUE, AND
LOWERING BLOOD FAT AND BLOOD PRESSURE IS PREPARED FROM THE EXTRACTS OF
GINKGO LEAF AND ACANTHOPANAX BARK, AND 5 CHINESE-MEDICINAL MATERIALS
INCLUDING ASTRAGALUS ROOT, YAM, HAW, ETC THROUGH DECOCTING 5 CHINESEMEDICINAL MATERIALS, FILTER, CONCENTRATING, MIXING WITH OTHERS AND STIRRING. ITS
ADVANTAGE IS HIGH EFFECT.
221/757
154. CN1475794 - 18.02.2004
MEASURING METHOD OF ARSENIC IN FOOD, HEALTH CARE PRODUCT AND BIOLOGICAL
SAMPLE
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1475794
Inventor(s):
LIU SUHUA (CN); ZHAI MINGXIA (CN); LIU LANZHENG (CN)
Applicant(s):
JINAN DESEASE PREVENTING AND C (CN)
IP Class 4 Digits: G01N
IP Class:
G01N21/64
Application Number:
CN20030112500 (20030716)
Priority Number: CN20030112500 (20030716)
Family: CN1475794
Abstract:
A METHOD FOR DETECTING THE AS IN FOOD, HEALTH-CARE FOOD, OR BIOLOGICAL
SPECIMEN INCLUDES DISSOLVING THE SPECIMEN IN NITRIC ACID AND HYDROGENPEROXIDE
MIXTURE UNDER ACTION OF MICROWAVE, ADDING THE MIXED SOLUTION OF 150 G/L
THIOUREA AND 100G/L VC, MIXING, TAKING 25ML SOLUTION LAYING ASIDE AT ORINARY TEMP
FOR 40-50 MIN, AND ATOMIC SPECTROFLUORIMETRY. ITS ADVANTAGES ARE HIGH SPEED,
CORRECTNESS AND SENSITIVITY.
222/757
155. CN1478409 - 03.03.2004
POLYPEPTIDE HEALTH-CARE NUTRITIVE FOOD AND ITS MAKING METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1478409
Inventor(s):
HUANG YULIN (CN)
Applicant(s):
HUANG YULIN (CN)
IP Class 4 Digits: A23J
IP Class:
A23J3/34; A23J3/20
Application Number:
CN20030147366 (20030711)
Priority Number: CN20030147366 (20030711)
Family: CN1478409
Abstract:
A NUTRITIVE HEALTH-CARE POLYPEPTIDE FOOD IS PREPARED FROM ANIMAL PROTEIN AND
PLANT PROTEIN THROUGH PULVERIZING PLANT PROTEIN, ADDING CELLULASE,
CONTROLLING PH TO 8-9, HYDROLYSIS, HOMOGENIZING ANIMAL PROTEIN, PROPORTIONAL
MIXING, HEATING, COOLING, ADDING PROTEINASE, HYDROLYSIS, REGULATING PH TO 7, AND
VACUUM HEATING FOR CONCENTRATING AND DRYING. ITS ADVANTAGES ARE DELICIOUS
TASTE, AND RICH NUTRIENTS.
223/757
156. CN1478429 - 03.03.2004
MANUFACTURING METHOD OF HEALTH-CARE FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1478429
Inventor(s):
ZHANG ZHIXIN (CN)
Applicant(s):
ZHANG ZHIXIN (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L2/38
Application Number:
CN20020139403 (20020828)
Priority Number: CN20020139403 (20020828)
Family: CN1478429
Abstract:
A HEALTH-CARE FOOD IN THE FORM OF WINE IS PREPARED FROM 14 CHINESE-MEDICINAL
MATERIALS INCLUDING MALE SILKMOTH, CISTANCHE, DISPSACUS ROOT, PILOSE ANTLER ETC.
THROUGH IMMERSING THEM IN WINE. IT HAS SURE HEALTH-CARE FUNCTIONS OF
INVIGORATING YANG, NOURISHING KIDNEY AND TREATING IMPOTENCE AND LUMBUS AND
KNEE SORE.
224/757
157. CN1478489 - 03.03.2004
APPLICATION OF SEA HORSE IN PREPARATION OF MEDICINE AND HEALTH CARE FOOD FOR
TREATING BENIGN PROSTATAUXE
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1478489
Inventor(s):
XU DONGHUI (CN); XU SHIBO (CN); LI BINGJI (CN)
Applicant(s):
UNIV ZHONGSHAN (CN)
IP Class 4 Digits: A61K; A61P
IP Class:
A61P13/08; A61K35/56
Application Number:
CN20030139695 (20030704)
Priority Number: CN20030139695 (20030704)
Family: CN1478489
Abstract:
AN APPLICATION OF SEA HORSE IN PREPARING THE MEDICINES OR HEALTH-CARE FOOD FOR
TREATING BENIGN PROSTATOPLASIA IS DISCLOSED. ITS ADVANTAGES ARE HIGH CURATIVE
EFFECT AND LOW POISON.
225/757
158. CN1480072 - 10.03.2004
HEALTH FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1480072
Inventor(s):
SHEN YAOZONG (CN)
Applicant(s):
SHEN YAOZONG (CN)
IP Class 4 Digits: A23L
IP Class:
A23L2/39; A23L1/313
Application Number:
CN20020136795 (20020904)
Priority Number: CN20020136795 (20020904)
Family: CN1480072
Abstract:
A HEALTH-CARE FOOD IS PREPARED FROM CHLOROPHYLL COPPER SODIUM SALT, ZINC
GLUCONATE, REFINED KANGAROO MEAT POWDER AND REFINED STARCH. IT CAN IMPROVE
BETAMOLISM AND IMMUNITY.
226/757
159. CN1483327 - 24.03.2004
HEALTH CARE FOOD CONTAINING DIHYDROMYRICETIN AND MYRICETIN COMPOSITION
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1483327
Inventor(s):
REN QISHENG (CN); SONG XINRONG (CN)
Applicant(s):
REN QISHENG (CN)
IP Class 4 Digits: A23L; A61K; A61P; A21D
IP Class:
A61K35/78; A61P3/06; A23L1/30; A61K31/7048; A61P3/10; A23L2/52; A21D2/14;
A61K31/353; A61P1/16
Application Number:
CN20030123889 (20030530)
Priority Number: CN20030123889 (20030530)
Family: CN1483327
Abstract:
THE PRESENT INVENTION DISCLOSES A COMPOSITE CONTAINING DIHYDROMYRICETIN AND
MYRICETIN AS FOOD ADDITIVE, IN WHICH THE DIHYDROMYRICETIN CONTENT IS 20%-98% AND
THE MYRICETIN CONTENT IS 2%-80%. SAID INVENTION ALSO PROVIDES VARIOUS HEALTHCARE FOODS AND BEVERAGES CONTAINING DIHYDROMYRICETIN AND MYRICETIN.
227/757
160. CN1483347 - 24.03.2004
NATURAL BIOLOGICAL TYPE HEALTH CARE FOOD ORAL LIQUID
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1483347
Inventor(s):
MA YOULI (CN); WU XUEHAI (CN); YUAN HONGDE (CN)
Applicant(s):
YUAN HONGDE (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
CN20030146236 (20030707)
Priority Number: CN20030146236 (20030707)
Family: CN1483347
Abstract:
THE PRESENT INVENTION PROVIDES A NATURAL BIOLOGICAL HEALTH-CARE FOOD ORAL
LIQUOR. IT IS MADE UP BY USING HAIR SEAL OIL, SODIUM ALGINATE, HONEY AND DISTILLED
WATER AS RAW MATERIAL THROUGH THE PROCESSES OF MIXING RAW MATERIAL, STIRRING,
QUICKLY-HEATING, FILLING, STERILIZING, CHECKING AND PACKAGING. SAID INVENTED
PRODUCT CONTAINS RICH ACTIVE SUBSTANCES, AND CAN RAISE IMMUNITY OF HUMAN BODY
AND CAN REGULATE THE IMMUNOLOGICAL FUNCTION OF THE HUMAN BODY, AND CAN
OBTAIN OBVIOUS HEALTH-CARE EFFECT.
228/757
161. CN1483353 - 24.03.2004
NUTRITIOUS HEALTH CARE FOOD AND PREPARATION METHOD THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1483353
Inventor(s):
LU JUN (CN)
Applicant(s):
LU JUN (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A61K9/20; A23L1/48
Application Number:
CN20030133755 (20030718)
Priority Number: CN20030133755 (20030718)
Family: CN1483353
Abstract:
THE PRESENT INVENTION RELATES TO A NUTRIENT HEALTH-CARE FOOD AND ITS
PRODUCTION METHOD. SAID FOOD COMPOSITION CONTAINS (BY WEIGHT) 1-2 PORTIONS OF
MALURONG, 0.5-1.5 PORTIONS OF GINSENG, 5-10 PORTIONSOF EPIMEDIUM, 0.5-2 PORTIONS
OF DIASCOREA ROOT, 0.5-1 PORTION OF LYCIUM BERRY, 0.5-1 PORTION OF FLOWERY
KNOTWEED ROOT AND 0.5-1.5 PORTIONS OF DEXTRINE. SAID NUTRIENT HEALTH-CARE FOOD
HAS THE FUNCTIONS OF ENRICHING YIN, STRENGTHENING YANG, INVIGORATING SEXUAL
FUNCTION AND RAISING IMMUNITY OF HUMAN BODY.
229/757
162. CN1483450 - 24.03.2004
NUTRITIOUS HEALTH CARE FOOD AND PREPARATION PRLCESS THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1483450
Inventor(s):
LU JUN (CN)
Applicant(s):
LU JUN (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A61P1/14; A23L1/29; A61P37/04
Application Number:
CN20030133756 (20030717)
Priority Number: CN20030133756 (20030717)
Family: CN1483450
Abstract:
THE PRESENT INVENTION RELATES TO A NUTRIENT HEALTH-CARE FOOD WITH THE
FUNCTIONS OF REGULATING PHYSIOLOGICAL FUNCTION OF HUMAN BODY, RAISING
IMMUNITY OF HUMAN BODY, NOURISHING YIN AND STRENGTHENING YANG AND QUICKLY
RAISING SEXUAL FUNCTION. SAID NUTRIENT HEALTH-CARE FOOD IS MADE UP BY USING
VELVET DEERHORN, GINSENG, EPIMEDIUM, DIOSCOREA ROOT, LYCIUM BERRY, FLOWERY
KNOTWEED, MORINDA ROOT AND CHINESELEAK SEED.
230/757
163. CN1487075 - 07.04.2004
HEALTH FOOD MADE OF ORANGE PEEL AND JUICE AND ITS PRODUCTION PROCESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1487075
Inventor(s):
WANG XIAOSHENG (CN)
Applicant(s):
WANG XIAOSHENG (CN)
IP Class 4 Digits: C12G
IP Class:
C12G3/06
Application Number:
CN20030135539 (20030731)
Priority Number: CN20030135539 (20030731)
Family: CN1487075
Abstract:
THE PRESENT INVENTION INCLUDES ORANGE PEEL PEARL WINE, WHICH IS MADE THROUGH
SOAKING ORANGE PEEL IN WHITE SPIRIT WITH 55-60 % ALCOHOL CONTENT AND PEARL
POWDER SOLUTION AND FILTERING; HEALTH ORANGE PEEL FOOD, WHICH IS PRODUCED
WITH THE ORANGE PEEL FILTER RESIDUE AND THROUGH HARDENING, STOVING, SOAKING IN
HONEY AND CHINESE HERBAL MEDICINE DECOCTION AND RE-STOVING; AND PEARL ORANGE
JUJCE, WHICH IS PRODUCED WITH ORANGE JUICE AND PEARL POWDER AND THROUGH
HEATING, ADDING PECTASE, RE-HEATING AND LOW TEMPERATURE CONCENTRATION. THE
ORANGE PEEL PEARL WINE IS SUITABLE FOR OLD PEOPLE AND HAS CERTAIN HEALTH
FUNCTIONS ON STOMACH, LUNG AND EYES; THE HEALTH ORANGE PEEL FOOD IS SUITABLE
FOR CHILDREN AND HAS CERTAIN HEPATITIS AND INFANTILE MALNUTRITION PREVENTING
EFFECT; AND THE PEARL ORANGE JUICE HAS THE FUNCTIONS FOR OLD PEOPLE TO PROTECT
EYES AND FOR CHILDREN TO PROMOTE INTELLIGENCE GROWTH.
231/757
164. CN1488297 - 14.04.2004
HEALTH FOOD FOR CANCER PATIENT AND PREPARING METHOD THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1488297
Inventor(s):
ZHENG WEIDA (CN)
Applicant(s):
ZHENG WEIDA (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L2/39
Application Number:
CN20030146188 (20030728)
Priority Number: CN20030146188 (20030728)
Family: CN1488297
Abstract:
THE INVENTION DISCLOSES A HEALTH PRODUCT FOR CANCER PATIENTS AND PREPARING
METHOD. IT IS MADE OF SEMEN COILIS, GANODORMA LUCIDUM, MUSHROOM, GINSENG,
RHIZOMA ATRACTYLODIS MACROCEPHALAE, PORIA COCOS, RADIX ASTRAGALI, LIQUORICE,
LILY AND HAW. IT CAN BE MADE INTO CAPSULE, INFUSION PREPARATION, ORAL LIQUID,
TABLET OR BISCUIT, AND DRINK. IT HAS FUNCTIONS OF BENEFITING QI, TONIFYING SPLEEN,
EXCRETING DAMPNESS, AND ADJUSTING IMMUNITY OF ECONOMY.
232/757
165. CN1493228 - 05.05.2004
HEALTH CARE FOOD CONTAINING FERN EXTRACT AND ITS PREPARATION METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1493228
Inventor(s):
HU CHANGLIANG (CN)
Applicant(s):
NANJING ZHONGXI PREPARATION IN (CN)
IP Class 4 Digits: A23L
IP Class:
A23L2/39
Application Number:
CN20020138522 (20021101)
Priority Number: CN20020138522 (20021101)
Family: CN1493228
Abstract:
A HEALTH-CARE FOOD CONTAINING THE EXTRACT OF POTENTILLA ANSERINE FOR
REGULATING IMMUNE AND RELIEVING FATIGUE IS PREPARED THROUGH EXTRACTING THE
ACTIVE COMPONENTS FROM POTENTILLA ANSERINE IN WATER AND/OR ALCOHOL, AND
PROPORTIONALLY MIXING WITH ADDITIVE. IT CAN HAVE VARIOUS FORMS.
233/757
166. CN1493359 - 05.05.2004
CHINESE CATERPILLAR FUNGUS GLOSSY GANODERMA HEALTH PROTECTION FOOD AND ITS
PRODUCTION METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1493359
Inventor(s):
LIANG DONG (CN)
Applicant(s):
LIANG DONG (CN)
IP Class 4 Digits: A61K; A61P
IP Class:
A61P1/14; A61K35/84
Application Number:
CN20020145035 (20021031)
Priority Number: CN20020145035 (20021031)
Family: CN1493359
Abstract:
A HEALTH-CARE CORDYCEPS-GANODERMA FOOD FOR PREVENTING AND TREATING
CORONARY HEART DISEASE, ATHEROSCLEROSIS, RHINITIS, TINNITIUS, CHRONIC BRONCHITIS,
PULMONARY TUBERCULOSIS, TUMOR, ETC IS PREPARED FROM CORDYCEPS FUNGUS
(PAECILOMUCES HEPIALI), GANODERMA, TUCKAHOE, AND YAM. ITS ADVANTAGES ARE RICH
NUTRIENTS, HIGH HEALTH-CARE EFFECT AND NO TOXIC BY-EFFECT.
234/757
167. CN1498552 - 26.05.2004
METHOD FOR PREPARING NUTRITIOUS HEALTH FOOD OF SOFT CAPSULE OF COMPOSITE
YOLK LECITHIN
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1498552
Inventor(s):
LI SHOUZHANG (CN); LI HONGJUN (CN); YANG GUANGWEI (CN)
Applicant(s):
LI SHOUZHANG (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A23L1/32; A61K35/54
Application Number:
CN20020150144 (20021109)
Priority Number: CN20020150144 (20021109)
Family: CN1498552
Abstract:
A COMPOSITE YOLK LECITHIN SOFTGEL AS NUTRITIVE HEALTH-CARE FOOD IS PREPARED
FROM FRESH EGG YOLK THROUGH DEWATERING, PULVERIZING, EXTRACTING IN ALCOHOL,
FILTERING BY SILICA GEL POWDER, PURIFYING THE FILTRATE BY SUPERCRITICAL CO2,
ADDING VA, VD, VB1, VB2, FE AND ZN, MIXING, EMULSIFYING, HOMOGENIZING, AND FORMING
SOFTGELS.
235/757
168. CN1505981 - 23.06.2004
HEALTH FOOD WITH EFFECTS OF REGULATNIG BLOOD FAT AND IMPROVING INTESTINAL
TRACT FUNCTION
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1505981
Inventor(s):
SUN WUYUE (CN); MA LIN (CN)
Applicant(s):
BAI AO BIOTECHNOLOGY CO LTD TI (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A23L1/308; A61K35/78; A61P1/00
Application Number:
CN20020153865 (20021206)
Priority Number: CN20020153865 (20021206)
Family: CN1505981
Abstract:
THE PRESENT INVENTION BELONGS TO FOOD WITH EDIBLE FIBER AND MEDICAL
PREPARATION SOURCED FROM PLANT. THE HEALTH FOOD IS PREPARED WITH HEPIALID
MOTH PSEUDOPENICILLIUM POWDER 25-55 WT%, GINGKO LEAF EXTRACTIVE 10-40 WT% AND
CORN DIET FIBER 20-50 WT%, AND THROUGH MIXING AND CAPSULIZING. IT HAS THE
COMPREHENSIVE FUNCTIONS OF HEPIALID MOTH PSEUDOPENICILLIUM POWDER, GINGKO
LEAF EXTRACTIVE AND CORN DIET FIBER AND TEST PROBES ITS HEALTH EFFECTS OF
REGULATING BLOOD FAT, STRENGTHENING IMMUNITY, PROMOTING CREEPAGE OF
INTESTINAL TRACT AND PREVENTING CANCERIZATION IN INTESTINAL TRACT.
236/757
169. CN1510037 - 07.07.2004
CORNEL EXTRACTIVE, EXTRACTING METHOD AND USE FOR PREPARING MEDICINE AND
HEALTH FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1510037
Inventor(s):
LI LIN (CN); ZHANG LAN (CN); WEI HAIFENG (CN)
Applicant(s):
XUANWU HOSPITAL CAPITAL MEDICA (CN)
IP Class 4 Digits: A61K; A61P; C07H
IP Class:
A61P25/16
A61K35/78; C07H1/08; C07H17/04; A61K31/7048; A61P25/00; A61P25/28;
Application Number:
CN200310121837 (20031219)
Priority Number: CN20020158018 (20021220); CN20020158019 (20021220); CN200310121837
(20031219)
Family: CN1510037
Abstract:
AN EXTRACT OF DOGWOOD FRUIT, ITS EXTRACTING PROCESS, ITS APPLICATION IN
PREPARING MEDICINES AND HEALTH-CARE PRODUCTS FOR PREVENTING AND TREATING THE
NERVE INJURY AND THE DISEASES IN NERVOUS SYSTEM, AND ITS MEDICAL COMPOSITION
ARE DISCLOSED.
237/757
170. CN1511475 - 14.07.2004
EDIBLE VINEGAR BEAUTY HEALTH FOOD AND ITS PRODUCING METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1511475
Inventor(s):
LIU JUN (CN)
Applicant(s):
HUQINGYUTANG PHARMACEUTICAL CO (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A23L1/29; A61P17/16
Application Number:
CN20020160368 (20021230)
Priority Number: CN20020160368 (20021230)
Family: CN1511475
Abstract:
THE BEAUTIFYING HEALTH FOOD IS PRODUCED WITH EDIBLE VINEGAR 5-10 WT%, STARCH 510 WT%, VINEGAR RESIDUE 30-90 WT%, VINEGAR WINE 0-40 WT% AND SUPPLEMENTARY
MATERIAL 0-10 WT%. THE PRODUCTION PROCESS INCLUDES LOW TEMPERATURE DRYING,
CRUSHING AND MIXING AND HAS NO DAMAGE TO THE ORIGINAL COMPONENTS. THE
BEAUTIFYING HEALTH FOOD IS INSTANT FOOD AND HAS EXCELLENT BEAUTIFYING HEALTH
FUNCTION.
238/757
171. CN1513363 - 21.07.2004
HONGBAO SAUCE HEALTH-CARE FOOD, AND ITS PREPN. METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1513363
Inventor(s):
YAOKA (CN); JIA DONGYING (CN); HE QIANG (CN)
Applicant(s):
UNIV SICHUAN (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/24; A23L1/053
Application Number:
CN20020133809 (20020926)
Priority Number: CN20020133809 (20020926)
Family: CN1513363
Abstract:
A HEALTH-CARE FOOD 'HONGBAO SASS' FOR IMPROVING IMMUNITY, LOWERING BLOOD
PRESSURE, DECREASING BLOOD FAT, PROTECTING LIVER, AND PREVENTING AND TREATING
CARDIOVASCULAR AND CEREBROVASCULAR DISEASES IS PREPARED FROM RED JUJUBE,
RHODIOLA ROOT, SAFFRON, CORDYCEPS, AND WOLFBERRY FRUIT. ITS ADVANTAGES ARE
HIGH HEALTH-CARE EFFECT, AND EASY ABSORPTION.
239/757
172. CN1513367 - 21.07.2004
COMPOSITE HEALTH-CARE FOOD CONTG. PORIA COCOS AND RHODIOLA SACRA
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1513367
Inventor(s):
GAO JINGXI (CN); DING HANGJUN (CN); GAO JINGXING (CN)
Applicant(s):
GAO JINGXI (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L1/48
Application Number:
CN20030126242 (20030707)
Priority Number: CN20030126242 (20030707)
Family: CN1513367
Abstract:
A COMPOSITE HEALTH-CARE FOOD IS PREPARED FROM THE POWDERED TUCKAHOE AS A
CHINESE-MEDICINAL MATERIAL THROUGH HIGH-SPEED MICROWAVE OR INFRARED DRYING
TO BECOME POROUS PARTICLES, ADSORBING THE EXTRACT OF RHODIOLA ROOT, DRYING,
AND GRINDING BY 60 MESHES.
240/757
173. CN1513447 - 02.12.2004
THE USES OF BAMBOO LEAF TOTAL FLAVONES FOR THE PREPARATION OF MEDICAMENTS
AND HEALTH FOODS FOR PREVENTING AND TREATING FOR PROSTATE DISEASES
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1513447
Inventor(s):
ZHANG YING (CN); WU XIAOQIN (CN); ZHANG YONGHUA (CN); CAI HUAFANG
(CN); LU BOYI (CN)
Applicant(s): ZHEJIANG UNIVERSITY HANGZHOU L (CN); ZHANG YING (CN); WU XIAOQIN
(CN); ZHANG YONGHUA (CN); CAI HUAFANG (CN); LU BOYI (CN)
IP Class 4 Digits: A61K; A61P
IP Class:
A61K35/78; A61P13/08
Application Number:
WO2004CN00531 (20040524)
Priority Number: CN20030128889 (20030525)
Family: CN1513447
Cited Document(s):
CN1228968; CN1229131
Abstract:
THE INVENTION RELATES TO A NEW USE OF BAMBOO LEAF TOTAL FLAVONES IN MEDICAL
CARE FIELD. BAMBOO LEAF TOTAL FLAVONES HAVE MANY FUNCTIONS, SUCH AS ANTIBACTERIA, ANTI-INFLAMMATORY, ANTI-PROSTATIC HYPERPLASIA, ANTIHYPERTHORMBOCYTEMIA, ANTI-TUMOUR AND STIMULATING IMMUNIZATION AND SO ON.
FURTHERMORE, THE BAMBOO LEAF TOTAL FLAVONES ARE SAFE AND NON-TOXIC, AND CAN
BE USED FOR A LONG TIME, ESPECIALLY SUITABLE FOR PREVENTING AND TREATING FOR
SENILE CHRONIC RETROGRADE DISEASES HAVING MULTI TARGETS. MORE ESPECIALLY, CAN
BE USED AS A NATURE MEDICINE AND A NATURE FUNCTIONAL FOOD ADDITIVE FOR
241/757
PREVENTING AND TREATING FOR PROSTATE DISEASES CONTAINING PROSTATITIS, PROSTATIC
HYPERPLASIA AND PROSTATIC TUMOUR.
242/757
174. CN1513470 - 21.07.2004
HEALTH-CARE FOOD WITH SOBERING FUNCTION
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1513470
Inventor(s):
WANG QIANG (CN)
Applicant(s):
WANG QIANG (CN)
IP Class 4 Digits: A61K; A61P
IP Class:
A61K31/722; A61P25/32
Application Number:
CN20030126833 (20030612)
Priority Number: CN20030126833 (20030612)
Family: CN1513470
Abstract:
A SOBERING-UP HEALTH-CARE FOOD IS PREPARED FROM THE EXTRACTS OF MARINE LIVING
THINGS THROUGH DRYING, PULVERIZING, PROPORTIONALLY MIXING, ADDING AUXILIARY
MATERIAL, GAMMA-RAY RADIATING, AND SHAPING. ITS ADVANTAGES ARE HIGH EFFECT AND
NO TOXIC BY-EFFECT.
243/757
175. CN1515179 - 28.07.2004
HEALTH-CARE FOOD FOR PREVENTING CANCER
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1515179
Inventor(s):
HUANG GUANXUN (CN)
Applicant(s):
HUANG GUANXUN (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/20; A23L1/212
Application Number:
CN20030113543 (20030108)
Priority Number: CN20030113543 (20030108)
Family: CN1515179
Abstract:
THE PRESENT INVENTION RELATES TO A CANCER-PREVENTING HEALTH-CARE FOOD. IT IS
MADE UP BY USING JACK BEAN AND HARICOT BEAN AS RAW MATERIAL AND ADDING
FLAVOURING MATERIAL. ITS RAW MATERIAL COMPOSITION IS COMPOSED OF 30-70% OF JACK
BEAN AND 30-70% OF HARICOT BEAN. SAID PRODUCT HAS THE ACTIONS OF PREVENTING
CANCER, REMOVING TOXIC MATERIAL, REMOVING DAMPNESS, SUPPLEMENTING KIDNEY AND
NOURISHING LUNG, AND CAN BE USED FOR PREVENTING AND CURING DISEASES.
244/757
176. CN1520745 - 18.08.2004
FRESH GINGER EXTRACT HEALTH FOOD AND NOVEL USE THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1520745
Inventor(s):
ZHANG RONGPING (CN); ZHANG XIAODONG (CN)
Applicant(s):
ZHANG RONGPING (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/212
Application Number:
CN20030117301 (20030212)
Priority Number: CN20030117301 (20030212)
Family: CN1520745
Abstract:
THE PRESENT INVENTION IS THE HEALTH FOOD WITH GINGER EXTRACTIVE AND ITS USE.
FRESH GINGER IS CRUSHED INTO COARSE GRAINS AND THRICE REFLUX EXTRACTED WITH
DISTILLED WATER TO OBTAIN EXTRACTIVE; THE EXTRACTIVE IS THEN ALCOHOL PRECIPITATED
AND CONCENTRATED TO OBTAIN PASTE; THE PASTE IS MIXED WITH PROPER AMOUNT OF
GINGER POWDER; THE MIXTURE IS PELLETIZED WHILE ADDING ALCOHOL AND DRIED AT 60-70
DEG.C; AND THE PILL IS COOLED AND ADDED WITH MAGNESIUM STEARATE IN 0.05-0.1 WT%
BEFORE PRESSED INTO TABLET OR CAPSULIZED INTO CAPSULE PREPARATION. THE
EXTRACTIVE HAS THE FUNCTIONS OF REGULATING AND LOWERING BLOOD FAT AND THUS
CAN PREVENT HYPERTENSION, ATHEROSCLEROSIS AND CORONARY HEART DISEASE.
245/757
177. CN1520748 - 18.08.2004
PHARYNX-CLEARING AND THROAT-MOISTENING HEALTH FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1520748
Inventor(s):
ZHOU LINGXIAN (CN); ZHANG HONGBIN (CN); DAI XIAOCHANG (CN)
Applicant(s):
UNIDA CO LTD (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A23L1/29; A61P11/04
Application Number:
CN20030103289 (20030129)
Priority Number: CN20030103289 (20030129)
Family: CN1520748
Abstract:
THE PRESENT INVENTION RELATES TO HEALTH FOOD AND IS ESPECIALLY ONE KIND OF
HEALTH FOOD MADE OF PLANT EXTRACTIVE AND POSSESSING HEALTH FUNCTIONS OF
CLEARING AWAY HEAT OF PHARYNX AND LARYNX AND MOISTENING PHARYNX AND LARYNX.
THE HEALTH FOOD CONSISTS OF EMBLIC POWDER 10-90 WT% AND ALCOHOL OR WATER
EXTRACTIVE OF ONE OR SEVERAL OF NOTOGINSENG FLOWER, BOAT-FRUITED STERCULIA
SEED, ISATIS ROOT AND TARAXACUM 10-90 WT% AS MAIN COMPONENTS AS WELL AS
SWEETENER, FRESHENER, CORRECTIVE, ETC. THE MAIN COMPONENTS OF THE PRESENT
INVENTION HAS THE FUNCTIONS OF CLEARING AWAY HEAT AND TOXIC MATTER, RESISTING
BACTERIA AND DIMINISHING INFLAMMATION, SO THAT IT HAS HIGH BACTERIOSTASIS TO
PATHOGENIC BACTERIA CAUSING INFLAMMATION OF PHARYNX AND LARYNX. EXPERIMENT
SHOWS THAT THE COOPERATION OF THE SAID MATERIALS HAS SYNERGISTIC EFFECT OF
STRENGTHENING CURATIVE EFFECT.
246/757
178. CN1522609 - 25.08.2004
BLACK HEALTH FOOD AND POT FOR PRODUCING SAME AND ITS PREPARATION METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1522609
Inventor(s):
WANG RIPING (CN)
Applicant(s):
WANG RIPING (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/315; A23L1/33; A23L1/28
Application Number:
CN20030156132 (20030901)
Priority Number: CN20030156132 (20030901)
Family: CN1522609
Abstract:
THE PRESENT INVENTION RELATES TO A BLACK HEALTH-CARE FOOD, POT FOR MAKING SAID
FOOD AND METHOD FOR MAKING SAID FOOD. SAID FOOD IS ADOPTING (BY WEIGHT PORTION)
50-100 PORTIONS BLACK-BONED CHICKEN, 20-40 PORTIONS TURTLE, 20-40 PORTIONS
LENTINUS EDODES, 20-30 PORTIONS JEW'S EAR, 20-30 PORTIONS KEPT, 20-30 PORTIONS
JEW'S EAR, 20-30 PORTIONS LENTINUS EDODES, 20-30 PORTIONS JEW'S EAR, 20-30 PORTIONS
KEPT, 20-30 PORTIONS HOLOTHURIAN, 30-50 PORTIONS BLACK RICE, 5-10 PORTIONS BLACK
SOYBEAN, 40-6 PORTIONS BLACK SESAME, 3-6 PORTIONS PITTED BLACK JUJUBE, 3-6
PORTIONS OF BLACK PINE NUT AND PROPER QUANTITY OF FLAVOURING MATERIAL AND
WATER AS RAW MATERIAL. THE POT FOR MAKING SAID FOOD INCLUDES POT BODY. INTERIOR
OF SAID POT BODY IS EQUIPPED WITH AN ISOLATING BODY WHOSE SIDE WALL IS EQUIPPED
WITH SEVERAL THROUGH HOLES.
247/757
179. CN1522731 - 25.08.2004
BLOOD FAT REGULATING DRUG OR HEALTH FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1522731
Inventor(s):
GUO LINGYUN (CN)
Applicant(s):
GUO LINGYUN (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A23L1/29; A61P3/06
Application Number:
CN20030124804 (20030906)
Priority Number: CN20030124804 (20030906)
Family: CN1522731
Abstract:
THE PRESENT INVENTION RELATES TO A MEDICINE OR HEALTH-CARE FOOD WHICH NOT ONLY
HAS THE OBVIOUS ACTION OF REGULATING BLOOD LIPID OF HUMAN BODY, BUT ALSO CAN
PROMOTE BLOOD CIRCULATION TO REMOVE STASIS, STRENGTHEN THE FUNCTION OF
STOMACH TO PROMOTE DIGESTION AND RAISE IMMUNITY OF HUMAN BODY. SAID INVENTED
PRODUCT IS PREPARED BY MAKING (WT%) 5-95% OF ONY-KAK, 0-95% OF PORIA AND 0-95%
OF CRATAEGUS GO THROUGH A CERTAIN PREPARATION PROCESS.
248/757
180. CN1524433 - 01.09.2004
MULTIFUNCTIONAL BREAST DEVELOPING HEALTH CARE FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1524433
Inventor(s):
LI FENGJIA (CN)
Applicant(s):
LI FENGJIA (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L1/00
Application Number:
CN20030118100 (20030225)
Priority Number: CN20030118100 (20030225)
Family: CN1524433
Abstract:
A MULTIFUNCTIONAL BREAST BUILDING HEALTH FOOD COMPRISING THE TWO PORTIONS OF
TRADITIONAL CHINESE MEDICINE AND FOODSTUFF, WHICH CAN OVERCOME THE DRAWBACK
OF SINGLE FUNCTION OF THE CONVENTIONAL PRODUCTS. THE FUNCTIONS OF THE
INVENTION INCLUDES ENLIVENING THE SPLEEN, REPLENISHING BLOOD, SUPPLEMENTING
HORMONE, DEROPPILATION OF MAMMARY GLAND, BREAST STRENGTHENING AND
DISPELLING COLDNESS.
249/757
181. CN1524436 - 01.09.2004
BODY-BUILDING HEALTH-CARE FOOD COMPOSITION AND ITS PREPARATION METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1524436
Inventor(s):
XIE JUNMO (CN)
Applicant(s):
XIE JUNMO (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L1/076
Application Number:
CN20030115540 (20030227)
Priority Number: CN20030115540 (20030227)
Family: CN1524436
Abstract:
THE INVENTION RELATES TO A FOOD COMPOSITION FOR KEEPING FIT AND PROCESS FOR
PREPARATION, WHEREIN THE COMPOSITION COMPRISES BEE HONEY, ROYAL JELLY, BEE
GLUE LIQUID, POLLEN, WATER-SOLUBLE PEARL POWDER, GLOSSY GANODERMA SPORE
POWDER, FINE CHINESE CATERPILLAR FUNGUS DRIED POWDER MIXED ACCORDING THE
PERCENTAGE BY WEIGHT OF 58:15:1.8:21:0.9:0.3:3. THE PREPARATION PROCESS INCLUDES
THE STEPS OF EMULSION, MIXING, VACUUM CONCENTRATION, PULPING, AND FORMING INTO
TABLET AND SOFT CAPSULE.
250/757
182. CN1524444 - 01.09.2004
WEIGHT-REDUCING HEALTH-CARE FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1524444
Inventor(s):
ZHANG KANG (CN)
Applicant(s):
ZHANG KANG (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/2165
Application Number:
CN20030158272 (20030917)
Priority Number: CN20030158272 (20030917)
Family: CN1524444
Abstract:
A FAT-REDUCING HEALTH FOOD PREPARED MAINLY FROM THE RAW MATERIALS OF KONJAK,
POTATO, CHINESE YAM, DASHEEN, AND SWEET POTATO, THE RAW MATERIALS ARE DRIED,
CRUSHED INTO POWDER AND MIXED. THE POWDERY COMPOUND OF THE INVENTION CAN
EATEN DIRECTLY, AND CAN BE MADE INTO EDIBLE FOOD BY ANY OF THE CONVENTIONAL
METHODS. THE FOOD ACCORDING TO THE INVENTION POSSESSES GOOD FAT-REDUCING
AND HEALTH CARE FUNCTIONS, ITS ADVANTAGES INCLUDES GOOD TASTE, NO
OBJECTIONABLE ODOR AND CONVENIENCE IN CARRYING.
251/757
183. CN1524448 - 01.09.2004
NUTRITIOUS HEALTH-CARE FOOD FOR PROTECTING EYES AND PRODUCING METHOD
THEREFOR
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1524448
Inventor(s):
ZHENG CHUNSHAN LI (CN)
Applicant(s):
ZHENG CHUNSHAN (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K9/20; A23L1/302; A61P27/10
Application Number:
CN20030105294 (20030227)
Priority Number: CN20030105294 (20030227)
Family: CN1524448
Abstract:
THE INVENTION RELATES TO A NOURISHING HEALTH FOOD FOR VISION PROTECTION AND
METHOD FOR MAKING SAME BELONGING TO THE FIELD OF HEALTH PRODUCTS, WHICH
COMPRISES RETINOL, LACTOFLAVIN, VITAMIN E, ZINC, CAROTENE-BETA, TAURINE, SWEET
ORANGE OIL, CITRIC ACID, MALIC ACID, ASPARTAME, GLUCOSE, LUTEIN AND NBRONCHOLYSIN. THE FOOD CAN BE APPLIED FOR THE IMPROVEMENT AND PREVENTION OF
VISION FATIGUE.
252/757
184. CN1526330 - 08.09.2004
HEALTH FOOD WITH FUNCTIONS OF DELAYING SENILITY AND REGULATING IMMUNITY AND ITS
PREPN PROCESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1526330
Inventor(s):
XU ZHE (CN); XU DAOTIAN (CN)
Applicant(s):
XINKEQI HEALTH FOOD CO LTD JIL (CN)
IP Class 4 Digits: A23L; A23D
IP Class:
A23D9/00; A23L2/39
Application Number:
CN20030111132 (20030306)
Priority Number: CN20030111132 (20030306)
Family: CN1526330
Abstract:
THE HEALTH FOOD OF THE PRESENT INVENTION IS PRODUCED WITH FLATSTEM MILKVETCH
SEED, SEALWORT, GRAPE SEED, WHEAT PLUMULE AND OTHER MATERIAL. DURING THE
PRODUCTION, FLATSTEM MILKVETCH SEED AND SEALWORT ARE WATER EXTRACTED, GRAPE
SEED IS ALCOHOL EXTRACTED, THE EXTRACTIVES ARE CONCENTRATED, DRIED AND MIXED
WITH WHEAT PLUMULE AND OTHER SUPPLEMENTARY MATERIAL TO PRODUCE THE HEALTH
FOOD. THE PRESENT INVENTION HAS THE FEATURES OF REASONABLE FORMULA, SCIENTIFIC
TECHNOLOGICAL PROCESS, HIGH BIOLOGICAL UTILIZATION, OBVIOUS FUNCTIONS, EASY
ABSORPTION BY HUMAN BODY, ETC.
253/757
185. CN1526331 - 08.09.2004
HEALTH FOOD FOR REGULATING BLOOD FAT AND ITS PREPN
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1526331
Inventor(s):
XU ZHE (CN); XU DAOTIAN (CN)
Applicant(s):
XINKEQI HEALTH FOOD CO LTD JIL (CN)
IP Class 4 Digits: A23L; A23D
IP Class:
A23D9/00; A23L2/39
Application Number:
CN20030111134 (20030306)
Priority Number: CN20030111134 (20030306)
Family: CN1526331
Abstract:
THE HEALTH FOOD OF THE PRESENT INVENTION IS PRODUCED WITH HAW, KUDZU VINE ROOT,
PAGODATREE FLOWER BUD AND WHEAT PLUMULE OIL AS MATERIAL. DURING THE
PRODUCTION, HAW, KUDZU VINE ROOT AND PAGODATREE FLOWER BUD ARE HEATED AND
REFLUX EXTRACTED WITH ALCOHOL SOLUTION, AND THE EXTRACTIVES ARE MIXED WITH
WHEAT PLUMULE OIL TO PRODUCE EFFECTIVE COMPONENTS OF THE HEALTH FOOD. THE
PRESENT INVENTION AS THE HEALTH FOOD FOR REGULATING BLOOD FAT AND
STRENGTHENING PHYSIQUE HAS THE FEATURES OF REASONABLE FORMULA, SCIENTIFIC
TECHNOLOGICAL PROCESS, HIGH BIOLOGICAL UTILIZATION, OBVIOUS FUNCTIONS, EASY
ABSORPTION BY HUMAN BODY, ETC.
254/757
186. CN1528177 - 15.09.2004
METHOD FOR PREPARING WHEAT BRAN HEALTH FOOD AND WHEAT BRAN HEALTH PORRIDGE
POWDER THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1528177
Inventor(s):
HE YU (CN); REN HUARONG (CN); YANG XIAOQIANG (CN)
Applicant(s):
BEILI POWDER TECHNOLOGY ENGINE (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/10; A23L1/36; A23L1/015
Application Number:
CN200310105411 (20031013)
Priority Number: CN200310105411 (20031013)
Family: CN1528177
Abstract:
THE PRESENT INVENTION RELATES TO A PREPARATION METHOD OF WHEAT BRAN HEALTHCARE FOOD AND ITS WHEAT BRAN HEALTH-CARE GRUEL POWDER. IT IS CHARACTERIZED BY
THAT IT ADOPTS A SCENTIFIC PROCESSING METHOD TO REMOVE MOST OF HARMFUL
SUBSTANCE PHYTIC ACID FROM WHEAT BRAN, ENSURE THE METABOLIC BALANCE OF
MINERAL ELEMENT AFTER IT IS EATEN, HAVE NO NEED OF MAKE WATER WASHING
PROCEDURE AND ZYMOHYDROLYSIS, ADOPTS ULTRAMICROPULVERIZATION TECHNIQUE TO
REMAIN ALL THE NUTRIENTS, PROTEIN AND SEVERAL VITAMINS OF WHEAT BRAN SO AS TO
OBTAIN THE INVENTED WHEAT BRAN HEALTH-CARE FOOD POWDER. SAID POWDER CAN BE
ADDED INTO OTHER FOOD ACCORDING TO A CERTAIN WEIGHT RATIO SO AS TO OBTAIN THE
COMPOSITE WHEAT BRAN HEALTH-CARE GRUEL POWDER.
255/757
187. CN1528182 - 15.09.2004
HEALTH-CARE FOOD AND PREPARING METHOD THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1528182
Inventor(s):
WANG TAO (CN)
Applicant(s):
WANG TAO (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A23L1/312; A61K35/78; A23L1/20
Application Number:
CN200310100110 (20031009)
Priority Number: CN200310100110 (20031009)
Family: CN1528182
Abstract:
THE PRESENT INVENTION RELATES TO A HEALTH-CARE FOOD AND ITS PREPARATION METHOD.
IT IS MADE UP BY USING 20 CHINESE MEDICINAL MATERIALS OF ASTRAGALUS ROOT,
LONICERA FLOWER, BUPLEURUM ROOT, SCUTELLARIA ROOT, ISATIS, HONEY, ASS HIDE GLUE
AND SOYBEAN, ETC. THROUGH A CERTAIN PREPARATION PROCESS. SAID HEALTH-CARE
FOOD HAS THE HEALTH-CARE FUNCTIONS OF RAISING IMMUNITY OF HUMAN BODY,
RESISTING TUMOR, REDUCING BLOOD PRESSURE, BLOOD LIPID AND BLOOD SUGAR,
BEAUTIFYING FACE AND PROTECTING SKIN, AND HAS NO TOXIC SIDE EFFECT.
256/757
188. CN1528204 - 15.09.2004
FUNCTIONAL HEALTH-CARE FOOD WITH ANTIRADIATION, ANTI FREE RADICAL AND DNA
PROTECTION
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1528204
Inventor(s):
LIU CHENGHAN (CN)
Applicant(s):
LIU CHENGHAN (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L1/48
Application Number:
CN20030134912 (20030930)
Priority Number: CN20030134912 (20030930)
Family: CN1528204
Abstract:
THE PRESENT INVENTION RELATES TO A FUNCTIONAL HEALTH-CARE FOOD WITH THE
FUNCTIONS OF RESISTING RADIATION, RESISTING FREE RADICAL AND PROTECTING DNA. ITS
PREPARATION METHOD INCLUDES THE FOLLOWING STEPS: MAKING GANODERMA SPORE
POWDER UNDERGO THE PROCESS OF LOW-TEMP. ANTIOXIDATIVE WALL-BREAKING
TREATMENT; WATER-EXTRACTING OR ALCOHOL-EXTRACTING GANODERMA SPOROCARP TO
OBTAIN ITS COARSE POLYSACCHARIDE; USING ANY ONE METHOD DESCRIBED IN THE
APPLICATION SPECIFICATION TO EXTRACT JINSIYI (A CHINESE MEDICINAL MATERIAL) TO
OBTAIN ITS POLYSACCHARIDE; EXTRACTING TEA TO OBTAIN TEA-POLYPHENOL; MIXING THE
ABOVE-MENTIONED MATERIALS AND MAKING THEM INTO CAPSULE OR TABLET PREPARATION
SO AS TO OBTAIN THE INVENTED PRODUCT.
257/757
189. CN1528209 - 15.09.2004
HEALTH-CARE FOOD WITH IMMUNE MODULATION AND CLTIRADIATION FUNCTION AND
PREPARING METHOD THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1528209
Inventor(s):
XU ZHE (CN); XU DAOTIAN (CN)
Applicant(s):
XINKQI HEALTH CARE FOOD CO LTD (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L2/38
Application Number:
CN20030135052 (20030929)
Priority Number: CN20030135052 (20030929)
Family: CN1528209
Abstract:
THE PRESENT INVENTION RELATES TO A HEALTH-CARE FOOD WITH FUNCTIONS OF
REGULATING IMMUNITY AND RESISTING RADIATION AND ITS PREPARATION PROCESS. IT IS
MADE UP BY USING CHINESE MEDICINAL MATERIALS OF RHODIOLA, POLYGONATUM ROOT,
ASTRAGALUS ROOT, LYCIUM BERRY, HIPPOPHAE RHMNOIDES AND GREEN TEA AS RAW
MATERIAL THROUGH THE PROCESSES OF WATER-EXTRACTION, COLD STORAGE,
CENTRIFUGALIZATION, FILTRATION AND ADDING AUXILIARY MATERIAL. SAID FOOD CAN BE
EASILY ABSORBED BY HUMAN BODY, AND ITS BIOLOGICAL UTILIZATION RATE IS HIGH.
258/757
190. CN1530033 - 22.09.2004
HEALTH FOOD ADDITIVE AND PRODUCTS FOR DRUNKARD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1530033
Inventor(s):
LIU SHIPING (CN)
Applicant(s):
LIU XIAORONG (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/30
Application Number:
CN20030117479 (20030317)
Priority Number: CN20030117479 (20030317)
Family: CN1530033
Abstract:
A HEALTH-CARE ADDITIVE FOR THE WINEBIBBERS IS PREPARED FROM THE VEGETATIVE
MATERIALS THROUGH EXTRACTING IN SOLVENT. IT CAN BE USED TO PREPARE BUCCAL
LOZENGE, CHEWING TABLET, ORAL LIQUID, PARTICLES, CAPSULE, AEROSOL, BEVERAGE, ETC
FOR SOBERING UP AND PROTECTING STOMACH AND LIVER.
259/757
191. CN1530137 - 22.09.2004
HEALTH FOOD FOR DIABETES PATIENTS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1530137
Inventor(s):
HAN YONGMIAO (CN)
Applicant(s):
HAN YONGMIAO (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A23L1/29; A61K38/17; A61P3/10
Application Number:
CN20030120375 (20030317)
Priority Number: CN20030120375 (20030317)
Family: CN1530137
Abstract:
A HEALTH-CARE FOOD IN THE FORM OF PILL OR CAPSULE FOR DIABETICS FEATURES THAT IT
CONTAINS FISH PANCREAS PROTEIN. ITS ADVANTAGE IS HIGH EFFECT TO DECREASE BLOOD
SUGAR.
260/757
192. CN1533769 - 06.10.2004
COMPOUND MELATONIN HEALTH CARE FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1533769
Inventor(s):
ZHAO BANGAI (CN)
Applicant(s):
ZHAO BANGAI (CN)
IP Class 4 Digits: A61K; A61P
IP Class:
A61K35/78; A61K31/4045; A61K31/715; A61P25/20
Application Number:
CN20030114084 (20030401)
Priority Number: CN20030114084 (20030401)
Family: CN1533769
Abstract:
A HEALTH-CARE FOOD IN THE FORM OF TABLET, PARTICLE, OR CAPSULE FOR REGULATING
SLEEP AND GASTROINTESTINAL FUNCTIONS IS PREPARED FROM MELATONIN (0.01-2.0 WT.%),
OLIGOSE (10-99.8) AND FILLER (10-90).
261/757
193. CN1535620 - 13.10.2004
PREPARATION METHOD OF SILKWORM POWDER HEALTH-CARE FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1535620
Inventor(s):
LOU RONGKUI (CN); TAN LIDONG (CN); BEI YU (CN)
Applicant(s):
SHANGHAI MEISHAN BIOLOG TECHNO (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/48; A23L3/44
Application Number:
CN20030116235 (20030408)
Priority Number: CN20030116235 (20030408)
Family: CN1535620
Abstract:
THE PRESENT INVENTION DISCLOSES A PREPARATION METHOD OF WHOLE SILKWORM
POWDER HEALTH-CARE FOOD, AND SAID PREPARATION METHOD INCLUDES THE FOLLOWING
STEPS: (A). SELECTING FRESH LIVE HEALTH MULBERRY SILKWORM, CLEANING, REMOVING
IMPURITY, DISINFECTING, STERILIZING, QUICKLY-FREEZING AND STORING AS RAW MATERIAL;
(B). VACUUM FREEZE-DRYING THE ABOVE-MENTIONED RAW MATERIAL; AND (C). PULVERIZING
SAID RAW MATERIAL SO AS TO OBTAIN THE INVENTED WHOLE SILKWORM POWDER WHICH
CONTAINS VARIOUS RICH NUTRIENT COMPONNETS, AND CAN BE USED FOR RAISING
IMMUNITY OF HUMAN BODY, AND REDUCING BLOOD SUGAR OF PATIENT WITH DIABETES B.
262/757
194. CN1537434 - 20.10.2004
WHEAT FLOUR FOOD WITH NUTRITION HEALTH-CARE FLESH OF FRUIT AND NUTRITION
VEGETABLES
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1537434
Inventor(s):
JIANG CAIGUO (CN)
Applicant(s):
JIANG CAIGUO (CN)
IP Class 4 Digits: A21D
IP Class:
A21D2/36
Application Number:
CN200310100836 (20031005)
Priority Number: CN200310100836 (20031005)
Family: CN1537434
Abstract:
A HIGH-GRADE NUTRITIVE HEALTH-CARE FLOUR FOOD IS PREPARED FROM WHEAT FLOUR,
FRUIT FLESH AND NUTRITIVE PLANT. ITS ADVANTAGES ARE HIGH NUTRITIVE VALUE, SURE
HEALTH-CARE ACTION, AND AGREEABLE TASTE.
263/757
195. CN1537437 - 20.10.2004
METHOD FOR PREPARING YOGURT HEALTH-CARE FOOD WITH SLEEPING-HELPING FUNCTION
CONTG. PINEAL HORMONE
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1537437
Inventor(s):
YU NEIXUN (CN)
Applicant(s):
YU NEIXUN (CN)
IP Class 4 Digits: A23C
IP Class:
A23C9/123; A23C9/13
Application Number:
CN200310104201 (20031022)
Priority Number: CN200310104201 (20031022)
Family: CN1537437
Abstract:
A HEALTH-CARE YOGURT CONTAINING PINEAL HORMONE FOOD TAKEN AT NIGHT FOR
IMPROVING SLEEP QUALITY AND IMMUNITY, PREVENTING CANCER, LOWERING BLOOD
PRESSURE, REGULATING INTERNAL SECRETION AND DELAYING SANILITY IS PREPARED FROM
TRADITIONAL YOGURT PINE BODY, PEARL POWDER, OLIGOPECTOSE, ETC.
264/757
196. CN1537438 - 20.10.2004
METHOD FOR PREPARING HEALTH-CARE MILK POWDER WITH FOOD SLEEPING-CARE
FUNCTION CONTG. MEILATONING
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1537438
Inventor(s):
YU NEIXUN (CN)
Applicant(s):
YU NEIXUN (CN)
IP Class 4 Digits: A23C
IP Class:
A23C9/152; A23C9/16
Application Number:
CN200310101197 (20031022)
Priority Number: CN200310101197 (20031022)
Family: CN1537438
Abstract:
A HEALTH-CARE MELATONIN-MILK POWDER FOOD TAKEN AT NIGHT FOR IMPROVING SLEEP
QUALITY AND IMMUNITY, PREVENTING TUMOR, LOWER BLOOD PRESSURE, REGULATING
INTERNAL SECRETION, AND DELAYING SANILITY IS PREPARED FROM MILK POWDER,
MELATONIN, PEARL POWDER, OLIGOPECTOSE, ETC.
265/757
197. CN1537439 - 20.10.2004
METHOD FOR PREPARING HEALTH-CARE SOYMILK WITH FOOD SLEEPING-CARE FUNCTION
CONTG. MELATONIN
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1537439
Inventor(s):
YU NEIXUN (CN)
Applicant(s):
YU NEIXUN (CN)
IP Class 4 Digits: A23C
IP Class:
A23C9/152; A23C11/10
Application Number:
CN200310101198 (20031022)
Priority Number: CN200310101198 (20031022)
Family: CN1537439
Abstract:
A HEALTH-CARE MELATONIN SOYMILK FOOD TAKEN AT NIGHT FOR IMPROVING SLEEP
QUALITY AND IMMUNITY, PREVENTING TUMOR, LOWERING BLOOD PRESSURE, REGULATING
INTERNAL SECRETION AND DELAYING SANILITY IS PREPARED FROM SOYMILK, MELATONIN,
PEARL POWDER, OLIGOPECTOSE, ETC.
266/757
198. CN1537440 - 20.10.2004
METHOD FOR PREPARING HEALTH-CARE MILK FOOD SLEEPING-CARE FUNCTION CONTG.
MELATONIN
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1537440
Inventor(s):
YU NEIXUN (CN)
Applicant(s):
YU NEIXUN (CN)
IP Class 4 Digits: A23C
IP Class:
A23C9/152
Application Number:
CN200310104202 (20031022)
Priority Number: CN200310104202 (20031022)
Family: CN1537440
Abstract:
A HEALTH-CARE MELATONIN-MILK FOOD TAKEN AT NIGHT FOR IMPROVING SLEEP QUALITY
AND IMMUNITY, LOWERING BLOOD PRESSURE, REGULATING INTERNAL SECRETION, AND
DELAYING SANILITY IS PREPARED FROM MILK, NELATONIN, PEARL POWDER, OLIGOPECTOSE,
ETC.
267/757
199. CN1537441 - 20.10.2004
METHOD FOR PREPARING SOUR SOYMILK HEALTH-CARE FOOD WITH SLEEPING-HELPING
FUNCTION CONTG. PINEAL HORMONE
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1537441
Inventor(s):
YU NEIXUN (CN)
Applicant(s):
YU NEIXUN (CN)
IP Class 4 Digits: A23L; A23C
IP Class:
A23L2/38; A23L2/52; A23C11/10
Application Number:
CN200310101199 (20031022)
Priority Number: CN200310101199 (20031022)
Family: CN1537441
Abstract:
A HEALTH-CARE PINEAL SOUR SOYMILK FOOD TAKEN AT NIGHT FOR IMPROVING SLEEP
QUALITY AND IMMUNITY, PREVENTING TUMOR, LOWERING BLOOD PRESSURE, REGULATING
INTERNAL SECRETION AND DELAYING SANILITY IS PREPARED FROM SOUR SOYMILK, PINE
BODY, PEARL POWDER, OLIGOPECTOSE, ETC.
268/757
200. CN1537450 - 20.10.2004
HIGH-GRADE AND HEALTH-CARE RICE-FLOUR NOODLES FOOD WITH COMPOSITE NUTRITIONS
CONTG. FLESH OF FRUITS AND VEGETABLES
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1537450
Inventor(s):
JIANG CAIGUO (CN)
Applicant(s):
JIANG CAIGUO (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/212; A23L1/162
Application Number:
CN200310100835 (20031005)
Priority Number: CN200310100835 (20031005)
Family: CN1537450
Abstract:
A HIGH-GRADE NUTRITIVE AND HEALTH-CARE RICE FLOUR FOOD IS PREPARED FROM RICE
FLOUR, NUTRITIVE AND HEALTH-CARE FRUIT FLESH, AND NUTRITIVE PLANT. ITS ADVANTAGES
ARE RICH NUTRIENTS, SURE HEALTH-CARE FUNCTION AND AGREEABLE TASTE.
269/757
201. CN1537601 - 20.10.2004
HEALTH-CARE FOOD FOR DIABETES MELLITUS PATIENT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1537601
Inventor(s):
LI XIANGYUN (CN)
Applicant(s):
YUTAI SCIENCE and TECH CO LTD WU (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A23L1/30; A61P3/10
Application Number:
CN20030118966 (20030417)
Priority Number: CN20030118966 (20030417)
Family: CN1537601
Abstract:
A HEALTH-CARE FOOD FOR DIABETICS IS PREPARED FROM BALSAM PEAR (30-99 WT.%) AND
GINSENG POWDER (REST). ITS ADVANTAGES ARE HIGH EFFECT TO REGULATE BLOOD SUGAR
BIDIRECTIONALLY AND HIGH SAFETY.
270/757
202. CN1537622 - 20.10.2004
HEALTH-CARE FOOD USED FOR RELAXING BOWEL, ANTI-SENILITY AND BEAUTIFYING FACE
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1537622
Inventor(s):
LU GUO-AN (CN); DU YONGGUI (CN); LU HAO (CN)
Applicant(s):
LU GUO AN (CN)
IP Class 4 Digits: A61K; A61P
IP Class:
A61K35/78; A61P1/10; A61P17/14
Application Number:
CN200310106698 (20031022)
Priority Number: CN200310106698 (20031022)
Family: CN1537622
Abstract:
A HEALTH-CARE FOOD FOR REGULATING IMMUNITY, DELAYING SANILITY AND BEAUTIFYING
FACE IS PREPARED FROM GRAPE SEED EXTRACT, PEARL POWDER, ALOE, ANT, SUFFLOWER
AND ASTRAGALUS ROOT. ITS ADVANTAGES ARE SURE FUNCTION AND NO TOXIC BY-EFFECT.
271/757
203. CN1537632 - 20.10.2004
HEALTH-CARE FOOD FOR PREVENTING AND TREATING HYPERLIPOIDEMIA
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1537632
Inventor(s):
LI ZHAOHUI (CN)
Applicant(s):
LI ZHAOHUI (CN)
IP Class 4 Digits: A61K; A61P
IP Class:
A61K35/84; A61P9/12
Application Number:
CN20030117705 (20030414)
Priority Number: CN20030117705 (20030414)
Family: CN1537632
Abstract:
A HEALTH-CARE FOOD IN THE FORM OF TABLET, CAPSULE OR INSTANT POWDER FOR
PREVENTING AND TREATING HYPERLIPEMIA IS PREPARED FROM RED KOJI, CASSIA SEED,
GANODERMA AND FILLER. ITS ADVANTAGES ARE HIGH EFFECT TO REGULATE BLOOD FAT,
AND NO TOXIC BY-EFFECT.
272/757
204. CN1539335 - 27.10.2004
HEALTH FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1539335
Inventor(s):
WANG CHANGTAI (CN)
Applicant(s):
WANG CHANGTAI (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L1/36
Application Number:
CN20030116582 (20030421)
Priority Number: CN20030116582 (20030421)
Family: CN1539335
Abstract:
A HEALTH-CARE FOOD WITH THE FUNCTIONS OF PHARMACOTHERAPY AND DIETOTHERAPY IS
PREPARED FROM WOLFBERRY FRUIT, PREPARED REHMANNIA ROOT, GANODERMA, WALNUT,
SESAME, MUNG BEAM, RICE AND PEANUT.
273/757
205. CN1541566 - 03.11.2004
HEALTH FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1541566
Inventor(s):
WANG AN (CN)
Applicant(s):
WANG AN (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/304
Application Number:
CN200310114049 (20031109)
Priority Number: CN200310114049 (20031109)
Family: CN1541566
Abstract:
THE HEALTH FOOD PRODUCTS, INCLUDING MEAT, NON-STAPLE FOOD, SEASONING, CANDY,
ETC. FEATURES THAT THEY CONTAIN TRACE ELEMENTS MG AND CR AND VITAMIN F IN
CERTAIN PROPORTION AND ARE MADE INTO CERTAIN SIZES AND CONTAINED IN CERTAIN
CONTAINER. THE HEALTH FOOD PRODUCTS HAVE THE HEALTH FUNCTIONS OF LOWERING
BLOOD PRESSURE, REDUCING BLOOD SUGAR AND BLOOD FAT, MAINTAINING HEALTHY
HEART AND BRAIN, STRENGTHENING MEMORY, RESISTING CANCER, RESISTING SENILITY, ETC.
THEY ARE SUITABLE FOR VARIOUS PEOPLE, AND MAY RESULT IN THE EFFECT OF PREVENTING
AND TREATING CARDIAC AND CEREBRAL VASCULAR DISEASES, HYPERTENSION, DIABETES
AND OBESITY.
274/757
206. CN1543856 - 10.11.2004
NUTRITIOUS HEALTH FOOD FOR ASSISTANT THERAPY OF DIABETES MELLITUS AND CARDIOCEREBRAL-VASCULAR DISEASE
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1543856
Inventor(s):
SONG GE (CN); ZHAO QINGZHONG (CN)
Applicant(s):
SONG GE (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
CN200310105499 (20031110)
Priority Number: CN200310105499 (20031110)
Family: CN1543856
Abstract:
THE INVENTION DISCLOSES A NOURISHING HEALTH FOOD FOR AUXILIARY TREATMENT OF
DIABETES AND CEREBROVASCULAR DISEASES WHICH IS PREPARED FROM HULLESS
BUCKWHEAT, MUNG BEAN, SOYA BEAN, GLUTINOUS RICE, OAT AND MUSHROOM. THE FOOD
CAN BE MADE INTO THE FORMS OF NOODLE, INSTANT NOODLE, STEAMED BUN, CAKES,
BISCUIT AND DILATED FOOD, INSTANT PARTICLES.
275/757
207. CN1543857 - 10.11.2004
HEALTH FOOD HAVING FUNCTIONS OF POSTPONING SENESCENCE AND INCREASING BONE
MINERAL DENSITY
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1543857
Inventor(s):
YOU JUN (CN)
Applicant(s):
SHANGHAI OWN MEDIC HIGH TECH M (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A23L1/29; A23L1/20; A61P19/10
Application Number:
CN200310108566 (20031113)
Priority Number: CN200310108566 (20031113)
Family: CN1543857
Abstract:
THE INVENTION DISCLOSES A HEALTH FOOD HAVING THE EFFECTS OF DELAYING SENILITY
AND INCREASING COMPACT BONE SUBSTANCE DENSITY, COMPRISING PLANT EXTRACT WITH
ESTROGENIC HORMONE ACTION, CALCIUM EXTENDER, CALCIUM ABSORPTION PROMOTING
AGENT, ACTIVE POLYSACCHARIDES, PLANT POLYPHENOL, VITAMINS HAVING OXIDATION
ACTION AND FOOD WITH SENILITY LAGGING AS THE REACTIVE CONSTITUTIONS AND EDIBLE
FINDINGS.
276/757
208. CN1545922 - 17.11.2004
GAMMA GLOBULIN HEALTH FOOD (SARS HEALTH FOOD) AND MANUFACTURING PROCESS
THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1545922
Inventor(s):
YU GUOHUA (CN)
Applicant(s):
YU GUOHUA (CN)
IP Class 4 Digits: A23L; C07K
IP Class:
A23L1/29; A23L1/305; C07K16/18
Application Number:
CN20030140000 (20030731)
Priority Number: CN20030140000 (20030731)
Family: CN1545922
Abstract:
THE INVENTION DISCLOSES A HEALTH FOOD CONTAINING GAMMA GLOBULIN AND ITS
MANUFACTURE PROCESS, WHEREIN THE FOOD IS PREPARED BY USING NATURAL GAMMA
GLOBULIN (IMMUNE GLOBULIN) EXTRACTED FROM ANIMAL BLOOD, HEN'S EGGS, DUCK'S
EGGS AND OTHER FOODSTUFF AS RAW MATERIAL, ADDING THE HIGH PURITY GAMMA
GLOBULIN INTO THE FOODSTUFF RAW MATERIAL IN PRODUCTION BY THE FORM OF FOOD
ADDITIVES.
277/757
209. CN1545927 - 17.11.2004
PREPARATION METHOD OF RAW MATERIAL FOR PRODUCING HEALTH FOOD AND
PHARMACEUTICAL
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1545927
Inventor(s):
XU SHUFEN (CN)
Applicant(s):
XU SHUFEN (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/313; A23L1/39
Application Number:
CN200310105294 (20031206)
Priority Number: CN200310105294 (20031206)
Family: CN1545927
Abstract:
THE INVENTION RELATES TO A PROCESS FOR PREPARING RAW MATERIALS OF HEALTH FOOD
OR MEDICINE BY USING ASTERINA PECTINIFERA AS RAW MATERIAL, WHEREIN THE
PREPARATION PROCESS COMPRISES, (1) CLEANING THE FRESH ASTERINA PECTINIFERA,
DRYING IN SUNSHINE OR BY HEATING, (2) SOAKING THE DRIED ASTERINA PECTINIFERA IN 570% CONCENTRATION, 2-8 TIMES WEIGHT OF DRIED ASTERINA PECTINIFERA OF ALCOHOL
FOR AT LEAST 10 DAYS AT ROOM TEMPERATURE, (3) REMOVING ALCOHOL, OBTAINING
EXTRACT, (4) CONCENTRATING THE EXTRACT TILL THE SOLID CONTENT IS 1.0-10.0%, (5)
CENTRIFUGING THE CONCENTRATED EXTRACT, DESLAGGING, (6) FILTERING THE EXTRACT
LIQUID TO CLARIFICATION, (7) SPLIT CHARGING, HIGH TEMPERATURE GERMICIDAL TREATING
AND PACKAGING.
278/757
210. CN1545937 - 17.11.2004
CHILDREN HEALTH FOOD CONTAINING PREBIOTICS AND PREPARATION METHOD THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1545937
Inventor(s):
FAN XIAOBING SONG (CN)
Applicant(s):
SHANGHAI JIAODA ONLLY CO LTD (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/48
Application Number:
CN200310109037 (20031203)
Priority Number: CN200310109037 (20031203)
Family: CN1545937
Abstract:
THE INVENTION RELATES TO A HEALTH FOOD FOR CHILDREN AND PROCESS FOR
PREPARATION, WHEREIN THE HEALTH FOOD COMPRISES THE CONSTITUENTS OF HEALTH
ESSENCE 5-80%, AMINO ACID 5-30%, MICROELEMENT 0.1-3%, FOOD ADDITIVE 2-89.9%.
279/757
211. CN1545939 - 17.11.2004
FAT-REDUCING HEALTH FOOD USING IMMATURE BITTER ORANGE EXTRACT AS MAJOR
FUNCTIONAL COMPONENT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1545939
Inventor(s):
DONG YINMOU LIU (CN)
Applicant(s):
BEIJING TECHNOLOGY AND BUSINES (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/48; A23L2/39
Application Number:
CN200310116903 (20031128)
Priority Number: CN200310116903 (20031128)
Family: CN1545939
Abstract:
THE INVENTION DISCLOSES A NATURAL FAT-REDUCING HEALTH FOOD BY USING FRUIT OF
IMMATURE CITRON EXTRACT AS THE PRINCIPAL FUNCTIONAL COMPONENT, WHICH
COMPRISES PRIMARY FUNCTIONAL FAT-REDUCING COMPONENT, FAT SYNTHESIZED
DEPRESSOR, CARBOHYDRATE ABSORPTION DEPRESSOR, ALIPHATIC ACID CARRYING AGENT,
AND L-TYROSINE. THE FUNCTIONS OF THE FOOD INCLUDE, FAT COMBUSTION ACCELERATION,
FAT SYNTHESIZING BLOCKING, AND BLOOD FAT REDUCTION.
280/757
212. CN1545941 - 17.11.2004
PREPARATION METHOD FOR HEALTH FOOD COMPOUNDED BY ASPARAGUS SPRENGRERI,
RADIX REHMANNIAE PREPARATA, GINSENG FIBROUS ROOT, OFFICINAL DENDROBIUM STEM
AND ROYAL JELLY
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1545941
Inventor(s):
YU NEIXUN YU (CN)
Applicant(s):
YU NEIXUN (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A61K9/48; A23L1/48
Application Number:
CN200310123635 (20031215)
Priority Number: CN200310123635 (20031215)
Family: CN1545941
Abstract:
THE INVENTION RELATES TO A PROCESS FOR PREPARING HEALTH FOOD ASPARAGUS ROOT,
PREPARED REHMANNIA ROOT, GINSENG FIBROUS ROOT AND ROYAL JELLY, WHICH HAS THE
FUNCTIONS OF REINFORCING BODY FLUID, NOURISHING LUNGS, IMPROVING IMMUNITY,
ANTISENESCENCE AND FATIGUE RESISTANCE.
281/757
213. CN1545947 - 17.11.2004
PREPARATION METHOD FOR HEALTH FOOD COMPOUNDED BY ASPARAGUS SPRENGRERI,
GINSENG FIBROUS ROOT, LILY BULB AND OFFICINAL DENDROBIUM STEM
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1545947
Inventor(s):
YU NEIXUN YU (CN)
Applicant(s):
YU NEIXUN (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A61K9/48; A23L2/39
Application Number:
CN200310123636 (20031215)
Priority Number: CN200310123636 (20031215)
Family: CN1545947
Abstract:
THE INVENTION RELATES TO A PROCESS FOR PREPARING HEALTH COMPOUND FOOD WHICH
COMPRISES ASPARAGUS ROOT, GINSENG FIBROUS ROOT, LILY BULB, FRAGRANT
SOLOMONSEAL RHIZOME, AND FLEECE-FLOWER ROOT, WHICH HAS THE FUNCTIONS OF
REINFORCING BODY FLUID, NOURISHING THE LUNG, PROMOTING SECRETION OF THE BODY
FLUID, AND IMPROVING HUMAN BODY IMMUNITY.
282/757
214. CN1552243 - 08.12.2004
HEALTH- CARE FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1552243
Inventor(s):
WANG QINGHUA (CN)
Applicant(s):
WANG QINGHUA (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/01; A23L1/10; A23L1/337
Application Number:
CN20030157099 (20030915)
Priority Number: CN20030157099 (20030915)
Family: CN1552243
Abstract:
A HEALTH-CARE FOOD FOR REGULATING BLOOD PRESSURE AND BLOOD FAT, PREVENTING
ARTERIOSCLEROSIS AND THROMBOSIS AND SUPPLEMENTING VITAMINES AND AMINO ACIDS
TO HUMAN BODY IS PREPARED FROM THE DIETOTHERAPEUTIC PLANT FRUITS AND SEAWEEDS.
283/757
215. CN1552248 - 08.12.2004
PROCESS FOR PRODUCING SEALWORT FOOD ADDITIVES AND HEALTH FOOD THEREWITH
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1552248
Inventor(s):
CHEN FANGBIAO (CN)
Applicant(s):
CHEN FANGBIAO (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L1/29
Application Number:
CN200310122648 (20031219)
Priority Number: CN200310122648 (20031219)
Family: CN1552248
Abstract:
A FOOD ADDITIVE IS PREPARED FROM SIBERIAN SOLOMONSEAL RHIZOME THROUGH
CHOOSING, WASHING, SCRAPING/SHEARING, WETTING, SLICING, DRYING, STEAMING AT 100120 DEG.C FOR 2-4 HR IN VACUUM CONDITION, DRYING, PULVERIZING AND SIEVING. A
HEALTH-CARE FOOD IN THE FORM OF INSTANT PARTICLES, CAPSULE, ETC FOR DECREASING
BLOOD FAT AND BLOOD SUGAR, LOWERING BLOOD PRESSURE AND PREVENTING
ARTERIOSCLEROSIS AND CORONARY HEART DISEASE IS PREPARED FROM SAID FOOD
ADDITIVE AND OTHER CHINESE-MEDICINAL MATERIALS.
284/757
216. CN1554244 - 15.12.2004
NUTRITION HEALTH FOOD AND ITS PRODUCING METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1554244
Inventor(s):
GOU BANGJUN (CN)
Applicant(s):
GOU BANGJUN (CN)
IP Class 4 Digits: A23L; A21D
IP Class:
A21D2/36; A23L1/16; A23L1/162
Application Number:
CN200310104175 (20031225)
Priority Number: CN200310104175 (20031225)
Family: CN1554244
Abstract:
THE PRESENT INVENTION DISCLOSES A KIND OF NUTRITIOUS HEALTH FOOD CONTAINING
SOYBEAN POWDER AND/OR WHEAT FLOUR AS MAIN COMPONENT, SALT, SUGAR AND OTHER
SEASONING, A MAY BE PRODUCED INTO INSTANT FOOD POWDER OR INSTANT NOODLES. THE
PRESENT INVENTION FEATURES THAT THE HEALTH FOOD CONTAINS ALSO SESAME POWDER,
CARROT AND OTHER VEGETABLE, AND CHINESE MEDICINAL MATERIALS PURSLANE,
WOLFBERRY SEEDLING AND DANDELION, SO THAT THE PRESENT INVENTION HAS RICH
NUTRIENTS, GOOD TASTE AND CERTAIN DISEASE PREVENTING AND TREATING HEALTH
FUNCTION.
285/757
217. CN1555712 - 22.12.2004
PREPARATION METHOD OF MELATONIN SOYA MILK POWDER HEALTH CARE FOOD FOR
PROMOTING SLEEP
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1555712
Inventor(s):
YU NEIXUN (CN)
Applicant(s):
YU NEIXUN (CN)
IP Class 4 Digits: A23L; A23C
IP Class:
A23L1/29; A23L1/20; A23C11/10
Application Number:
CN200410000822 (20040103)
Priority Number: CN200410000822 (20040103)
Family: CN1555712
Abstract:
A HEALTH-CARE SOYBEAN MILK POWDER FOR IMPROVING SLEEP QUALITY AND IMMUNITY,
DELAYING SENILITY, REGULATING INTERNAL SECRETION, LOWERING BLOOD PRESSURE AND
PREVENTING TUMOR FEATURES THAT IT CONTAINS MELATIONIN AND SEVERAL TENS
NUTRIENTS INCLUDING PROTEIN, VITAMINES, MINERALS, ACTIVE ENZYMES, ETC.
286/757
218. CN1555732 - 22.12.2004
MANUFACTURING METHOD OF GREEN ALGAE HEALTH CARE FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1555732
Inventor(s):
ZHANG GUOXIN (CN)
Applicant(s):
ZHANG GUOXIN (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/337
Application Number:
CN200410003016 (20040110)
Priority Number: CN200410003016 (20040110)
Family: CN1555732
Abstract:
A HEALTH-CARE GREEN ALGAFOOD (BREAD, SOYBEAN MILK, NOODLES, OATMEAL, ETC)
FEATURES THAT IT CONTAINS THE COMPOSITION OF WALL-BROKEN GREEN ALGA. ITS
ADVANTAGES ARE RICH NUTRIENTS, IMPROVED TASTE, AND SURE HEALTH-CARE FUNCTION.
287/757
219. CN1555875 - 22.12.2004
NOTOGINSENG GINKGO HEALTH CARE FOOD AND ITS PREPARATION METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1555875
Inventor(s):
HUANG QIAOLING (CN); QIU YANG (CN)
Applicant(s):
HUANG QIAOLING (CN)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A23L1/29; A61P37/04; A61P9/10
Application Number:
CN200410021677 (20040112)
Priority Number: CN200410021677 (20040112)
Family: CN1555875
Abstract:
A HEALTH-CARE FOOD FOR IMPROVING IMMUNITY AND MICROCIRCULATION, AND TAKING
CARE OF CARDIOVASCULAR AND CEREBROVASCULAR HEALTH IS PREPARED FROM THE
EXTRACT OF NOTOGINSENG AND CHRYSANTHEMUM FLOWER, THE EXTRACT OF GINKGO
LEAF, DEXTRIN AND SUGAR.
288/757
220. CN1557194 - 29.12.2004
NOURISHING ,HEALTH ,FAST FOOD AND ITS MAKING METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1557194
Inventor(s):
YANG ZHONG (CN)
Applicant(s):
YANG ZHONG (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
CN200410005159 (20040212)
Priority Number: CN200410005159 (20040212)
Family: CN1557194
Abstract:
THE PRESENT INVENTION BELONGS TO THE FIELD OF FOOD PRODUCING TECHNOLOGY, AND
IS ESPECIALLY ONE KIND OF NUTRITIVE INSTANT HEALTH FOOD AND ITS MAKING PROCESS.
THE INSTANT HEALTH FOOD IS PRODUCED WITH NATURAL MATERIAL, MILK, BEANS, GRAINS
AND POTATO IN REASONABLE PROPORTION, AND HAS COMPREHENSIVE NUTRITIVE
COMPONENTS, GOOD TASTE, VARIOUS FLAVORS AND SEVERAL HEALTH FUNCTIONS. IT MAY
BE PRODUCED INTO LIQUID, SEMI-SOLID OR SOLID FORM.
289/757
221. CN1557197 - 29.12.2004
RESVERATROL-NOURISHING AND HEALTH FOOD ADDITIVE
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1557197
Inventor(s):
HOU MIN (CN)
Applicant(s):
HOU MIN (CN)
IP Class 4 Digits: A23L; A21D; A23C
IP Class:
A23L1/30; A21D2/14; A23C9/152
Application Number:
CN200410004973 (20040210)
Priority Number: CN200410004973 (20040210)
Family: CN1557197
Abstract:
THE PRESENT INVENTION PROVIDES RESVERATROL AS ONE KIND OF NUTRITIVE HEALTH
FOOD ADDITIVE AND WITH THE HEALTH FUNCTIONS OF RESISTING FREE RADICAL, RESISTING
OXIDATION, RESISTING SENILITY, LOWERING BLOOD FAT, REDUCING CARDIAC AND
CEREBRAL VASCULAR SCLEROSIS AND PREVENTING CANCER. RESVERATROL IS ONE KIND OF
ADDITIVE SUITABLE FOR VARIOUS STAPLE FOODS AND NON-STAPLE FOODSTUFFS,
INCLUDING FRESH MILK, YOGHOURT, BREAD, CAKE, ETC.
290/757
222. CN1559288 - 05.01.2005
HEALTH-CARE FOOD POWDER SPECIALLY FOR DIABETES MELLITUS PATIENTS, AND ITS PREPN.
METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1559288
Inventor(s):
FU YINLIN (CN); YANG JIANSHEN (CN)
Applicant(s):
FU YINLIN (CN)
IP Class 4 Digits: A23L; A23C
IP Class:
A23L1/29; A23L1/20; A23L1/10; A23C9/00
Application Number:
CN200410012200 (20040310)
Priority Number: CN200410012200 (20040310)
Family: CN1559288
Abstract:
A HEALTH-CARE EDIBLE POWDER FOR DIABETICS IS PREPARED FROM BLACK BEAN, SOYBEAN,
MILLET, RED BEAN, BUCKWHEAT, OATS AND MILK OR NON-SUGAR MILK POWDER THROUGH
PROPORTIONING, PULVERIZING AND PROPORTIONAL MIXING. IT HAS RICH NUTRIENTS.
291/757
223. CN1559290 - 05.01.2005
HEALTH-CARE FOOD SOFT CAPSULE, AND ITS PREPN. METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1559290
Inventor(s):
WEI YAHUI (CN); LUAN LONG (CN); LI XIAOPING (CN)
Applicant(s):
NABEI BIOLOG TECH CO LTD SHANG (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A61K9/48; A23L1/29
Application Number:
CN200410016413 (20040218)
Priority Number: CN200410016413 (20040218)
Family: CN1559290
Abstract:
A HEALTH-CARE FOOD IN THE FORM OF SOFT CAPSULE FOR REGULATING BLOOD FAT AND
DELAYING SANILITY CONTAINS THE VERATRALBINE EXTRACTED FROM THE SEED AND PEEL
OF GRAPE AND THE THEOPOLYPHENOL. ITS PREPARING PROCESS IS ALSO DISCLOSED.
292/757
224. CN1559291 - 05.01.2005
NUTRIENT HEALTH-CARE FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1559291
Inventor(s):
SHAN JINFEN (CN)
Applicant(s):
SHAN JINFEN (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L1/29; A23L1/08; A23L1/20
Application Number:
CN200410018680 (20040223)
Priority Number: CN200410018680 (20040223)
Family: CN1559291
Abstract:
A HEALTH-CARE NUTRITIVE FOOD FOR PROMOTING BLOOD CIRCULATION, NOURISHING
BLOOD, KIDNEY AND QI, AND DETOXICATING CONTAINS JUJUBE, WALNUT KERNEL, HONEY,
BEANS, AND FOOD FLAVOURINGS.
293/757
225. CN1559537 - 05.01.2005
HEALTH-CARE FOOD CAPSULE CAPABLE OF DETOXIFICATION AND FAT LOWERING AND ITS
PREPARATION METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1559537
Inventor(s):
SUN GUOJIAN (CN); YU FENG (CN)
Applicant(s):
YU FENG (CN)
IP Class 4 Digits: A61K; A61P
IP Class:
A61K35/78; A61K9/48; A61P3/06
Application Number:
CN200410016331 (20040216)
Priority Number: CN200410016331 (20040216)
Family: CN1559537
Abstract:
A HEALTH-CARE FOOD IN THE FORM OF CAPSULE FOR DETOXICATING HUMAN BODY,
REMOIVNG EXCESSIVEFAT AND BEAUTIFYING SKIN IS PREPARED FROM 15 CHINESEMEDICINAL MATERIALS INCLUDING HAW, LOTUS LEAF, ALOE, GINSENG, ETC THROUGH
PULVERIZING, PROPORTIONAL MIXING AND LOADING IN CAPSULES.
294/757
226. CN1561823 - 12.01.2005
RECIPE FOR HEALTH ROASTED INSTANT FOOD AND ITS PREPARING METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1561823
Inventor(s):
YANG DINGDING (CN); YANG CHENGLIN (CN)
Applicant(s):
YANG DINGDING (CN)
IP Class 4 Digits: A23L; A23D; A23G
IP Class:
A23L1/29; A23L1/20; A23L1/01; A23L1/10; A23L1/32; A23D9/00; A23G3/00
Application Number:
CN200410008709 (20040315)
Priority Number: CN200410008709 (20040315)
Family: CN1561823
Abstract:
A NUTRITIVE HEALTH-CARE ROASTED INSTANT FOOD SUITABLE FOR THE PATIENTS OF
INDIGESTION, ANOREXIA, OBESITY, MALNUTRITION, HYPERLIPEMIA, DIABESITES, ETC IS
PREPARED FROM THE GRAINS OTHER THAN RICE AND WHEAT BY CONTROLLING THE RATIO
OF AMINO ACIDS AND PROTEIN IN FOOD.
295/757
227. CN1562287 - 12.01.2005
HEALTH FOOD OF CHINESE TRADITIONAL MEDICINE FOR PROMOTING HEMATOPOIESIS AND
PREPARATION METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1562287
Inventor(s):
WU KEFENG (CN); LI YANPING (CN)
Applicant(s):
GUANGDONG MEDICAL COLLEGE (CN)
IP Class 4 Digits: A61K; A61P
IP Class:
A61K35/78; A61P7/06
Application Number:
CN200410026971 (20040421)
Priority Number: CN200410026971 (20040421)
Family: CN1562287
Abstract:
A CHINESE-MEDICINAL HEALTH-CARE FOOD FOR PROMOTING GROWTH OF BLOOD CELLS IS
PREPARED FROM HALIMASCH POLYOSE AND CHINESE-MEDICINAL MATERIALS.
296/757
228. CN1565234 - 19.01.2005
EDIBLE FLOWER HEALTH FOOD AND ITS PREPARATION METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1565234
Inventor(s):
LIU HANG (CN)
Applicant(s):
LIU HANG (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/10; A23L1/212
Application Number:
CN20030134381 (20030620)
Priority Number: CN20030134381 (20030620)
Family: CN1565234
Abstract:
AN EDIBLE FLOWER HEALTH FOOD IS PREPARED FROM THE RAW MATERIALS (BY WEIGHT
PORTION) OF MAIN INGREDIENTS 60-80, EDIBLE FLOWER MATERIAL 20-40, AND FLAVORING
AGENT 5-10, AND THE MAKING PROCESS COMPRISES THE STEPS OF MIXING, HIGH
TEMPERATURE CURING, FAST DRYING, DISINTEGRATING, MIXING HOMOGENEOUSLY AND
QUANTITATIVE PACKAGING.
297/757
229. CN1565439 - 19.01.2005
OSTEOPOROSIS RELIEVING HEALTH FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1565439
Inventor(s):
YU ZUXUN (CN); YANG ZHENG (CN); ZHANG HONG (CN)
Applicant(s):
YU ZUXUN (CN)
IP Class 4 Digits: A61K; A61P
IP Class:
A61K31/737; A61K31/352; A61K31/722; A61P19/10
Application Number:
CN20030145582 (20030707)
Priority Number: CN20030145582 (20030707)
Family: CN1565439
Abstract:
THE INVENTION RELATES TO AN OSTEOPOROSIS RELIEVING HEALTH FOOD WHICH
COMPRISES AT LEAST CALCIUM PYRORACEMIC ACID AND SOYBEAN ISOFLAVONE, OR OTHER
COMPATIBLE ADDITIVES, SUCH AS CHONDROITIN SULFATE CALCIUM SALT OR CHITOSAN
OLIGOSACCHARIDE OR VITAMINS.
298/757
230. CN1568794 - 26.01.2005
HEALTH FOOD, PREPARATION METHOD AND BAKING DEVICE THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1568794
Inventor(s):
WANG JIANCHENG (CN); WANG FENGQING (CN)
Applicant(s):
WANG JIANCHENG (CN)
IP Class 4 Digits: A23L; A21D
IP Class:
A23L1/29; A23L1/20; A23L1/10; A21D8/04; A21D2/36; A21D13/00
Application Number:
CN200410012270 (20040429)
Priority Number: CN200410012270 (20040429)
Family: CN1568794
Abstract:
IN A PROCESS FOR THE PRODUCTION OF PORTION PACKS OF VISCOUS TO PASTY FILLING
MATERIAL SUCH AS SAUSAGE MEAT, GREASE, PUTTY OR CEMENT AND THE LIKE IN A
TUBULAR FILM (12) WHICH IS FORMED PRIOR TO INTRODUCTION OF THE FILLING MATERIAL
(10) BY WELDING OR SEALING OF THE LONGITUDINAL EDGES OF A FILM STRIP (1) DRAWN OFF
A SUPPLY AND BENT INTO A TUBULAR FORM, AND INTO WHICH FILLING MATERIAL PORTIONS
ARE DISCONTINUOUSLY INTRODUCED UNDER PRESSURE, WHEREUPON THE TUBULAR FILM
(12) IS CLOSED WITH BRAID FORMATION, THE TUBULAR FILM (12) IS DRAWN OUT OF THE
WELDING OR SEALING STATION TOWARDS THE FILLING STATION DIRECTLY BY THE FILLING
PRESSURE AND FILM STRIP (1) IS SUBSEQUENTLY DRAWN ALONG FROM THE SUPPLY INTO
THE WELDING OR SEALING STATION.
299/757
231. CN1568795 - 26.01.2005
BEAUTY AND HEALTH FOOD WITH QUICK-SPEED FAT-REDUCING FUNCTION
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1568795
Inventor(s):
WANG KUI (CN)
Applicant(s):
WANG KUI (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L1/29; A23L1/48
Application Number:
CN200410013132 (20040502)
Priority Number: CN200410013132 (20040502)
Family: CN1568795
Abstract:
CLAMPS, SYSTEMS, AND METHODS FOR EVACUATING AND HERMETICALLY SEALING BAGS
HAVING AN INTERIOR REGION AND AN OPEN END. IN ONE EMBODIMENT, A CLAMP INCLUDES
A FIRST CLAMP PORTION HAVING A FIRST CHAMBER PORTION AND A SECOND CLAMP
PORTION HAVING A SECOND CHAMBER PORTION. THE SECOND CLAMP PORTION IS MOVABLE
BETWEEN A RELEASED POSITION AND A CLAMPED POSITION. WHEN THE SECOND CLAMP
PORTION IS IN THE CLAMPED POSITION, THE FIRST AND SECOND CHAMBER PORTIONS
DEFINE A VACUUM CHAMBER FOR REMOVING GAS FROM THE BAG. THE CLAMP FURTHER
INCLUDES A VALVE CARRIED BY THE FIRST OR SECOND CLAMP PORTION TO CONTROL THE
FLOW OF THE GAS OUT OF THE VACUUM CHAMBER.
300/757
232. CN1568806 - 26.01.2005
GOOSE BONE MUD HEALTH FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1568806
Inventor(s):
PENG MEI (CN); LI QIZHI (CN); ZHANG CHUANSHENG (CN)
Applicant(s):
PENG MEI (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/315; A23L1/312
Application Number:
CN20030132516 (20030723)
Priority Number: CN20030132516 (20030723)
Family: CN1568806
Abstract:
AN ELEVATOR INSTALLATION INCLUDES AN ELEVATOR CAR, AT LEAST ONE GUIDE RAIL FOR
VERTICAL GUIDANCE OF THE ELEVATOR CAR, AND TWO SUPPORT DEVICES, SUCH AS ROPES
OR BELTS, THAT SUPPORT A COUNTERWEIGHT AT ONE SIDE OF THE ELEVATOR CAR AND
UNDERLOOP THE ELEVATOR CAR. EACH OF THE TWO SUPPORT DEVICES HAS ONE END AT A
FIXING POINT AT ONE SIDE OF THE ELEVATOR CAR. A ROCKER DEVICE HAS TWO ARMS AND IS
FASTENED TO THE GUIDE RAIL TO PROVIDE A ROCKING MOVEMENT. EACH OF THE SUPPORT
DEVICES HAS AN OPPOSITE END AT A FIXING POINT ON AN ASSOCIATED ONE OF THE AND
THE ROCKING MOVEMENT PROVIDES A LENGTH COMPENSATION IN THE CASE OF UNEQUAL
LENGTHENING OF THE TWO SUPPORT DEVICES.
301/757
233. CN1568819 - 26.01.2005
HEALTH CARE FOOD AND MAKING METHOD THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1568819
Inventor(s):
SU BAO (CN); LIU YUN (CN)
Applicant(s):
YUNNAN XIN YUN SANQI IND CO LT (CN)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A61K9/48; A23L1/48
Application Number:
CN20030135453 (20030719)
Priority Number: CN20030135453 (20030719)
Family: CN1568819
Abstract:
A CATHODE-RAY-TUBE PANEL ACCORDING TO THE PRESENT INVENTION IS MADE OF A GLASS
CONTAINING 300 TO 1000 PPM OF H2O ON A MASS PERCENTAGE BASIS.
302/757
234. CN1569171 - 26.01.2005
HEALTH FOOD FOR PREVENTING AND TREATING INFLUENZA
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1569171
Inventor(s):
PEI MEILIN (CN)
Applicant(s):
PEI MEILIN (CN)
IP Class 4 Digits: A61K; A61P
IP Class:
A61K35/78; A61K9/48; A61P31/16
Application Number:
CN200410024053 (20040428)
Priority Number: CN200410024053 (20040428)
Family: CN1569171
Abstract:
A MOBILE COMMUNICATION TERMINAL COMPRISING WIRELESS COMMUNICATION DEVICE
FOR MAKING WIRELESS COMMUNICATIONS, IMAGE DISPLAYING DEVICE FOR DISPLAYING AN
IMAGE AND SOUND OUTPUTTING DEVICE FOR OUTPUTTING A SOUND, THE MOBILE
COMMUNICATION TERMINAL GENERATES AN EXECUTION VARIABLE IN ORDER TO CHANGE A
PROGRESS OF GAME BY USE OF INCOMING HISTORY DATA INDICATING A HISTORY OF
INCOMINGS WHICH HAVE BEEN PERFORMED BY THE WIRELESS COMMUNICATION DEVICE,
AND EXECUTES A GAME BY USE OF THE GENERATED EXECUTION VARIABLE.
303/757
235. CN1579233 - 16.02.2005
CALCIUM-CUPPLEMEUTING HEALTH FOOD CONTAINING STACHYOSE
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1579233
Inventor(s):
GAO PENG (CN)
Applicant(s):
DAPENG BIOLOG SCIENCE TECHNOLO (CN)
IP Class 4 Digits: A23L
IP Class:
A23L1/308; A23L1/304
Application Number:
CN20030152719 (20030810)
Priority Number: CN20030152719 (20030810)
Family: CN1579233
304/757
236. CN1579449 - 16.02.2005
HEALTH-CARE SKIN-CARE FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1579449
Inventor(s):
CHAI XUEQIONG (CN)
Applicant(s):
CHAI XUEQIONG (CN)
IP Class 4 Digits: A61K; A61P
IP Class:
A61K35/78; A61P1/10; A61P17/16
Application Number:
CN20030143997 (20030808)
Priority Number: CN20030143997 (20030808)
Family: CN1579449
305/757
237. CN1579501 - 16.02.2005
FUNCTIONAL HEALTH-CARE FOOD FOR DIGESTION PROMOTING, INTESTINE-STOMACH
EXPANDING AND CONSTIPATION PREVENTING AND ITS PREPARATION METHOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN1579501
Inventor(s):
LIN QINLU (CN)
Applicant(s):
LIN QINLU (CN)
IP Class 4 Digits: A61K; A61P
IP Class:
A61K35/78; A61K9/14; A61K9/20; A61K9/48; A61P1/14; A61P1/10
Application Number:
CN200410023203 (20040517)
Priority Number: CN200410023203 (20040517)
Family: CN1579501
306/757
238. CN2554180Y - 04.06.2003
BIO-CHIP FOR DETECTING HEALTH EXAMINATION INDEX OF FOOD WORKER
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=CN2554180Y
Inventor(s):
WANG TAIHU (CN); MA QINRONG (CN); TAN WUHONG (CN)
Applicant(s):
XI AN LIANER BIO TECHNOLOGICAL (CN)
IP Class 4 Digits: G01N; C12Q
IP Class:
C12Q1/68; G01N33/68
Application Number:
CN20020261902U (20020701)
Priority Number: CN20020261902U (20020701)
Family: CN2554180Y
307/757
239. EP1287828 - 05.03.2003
COMPOSITION OF HEALTH FOOD FOR PROPHYLAXIS AND TREATMENT OF CONSTIPATION
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=EP1287828
Inventor(s):
WAN-SEOK HAN (KR)
Applicant(s):
HAN WAN SEOK (KR)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L1/30
E Class: A23L1/30B; A61K35/78+M
Application Number:
EP20010119755 (20010828)
Priority Number: EP20010119755 (20010828)
Family: EP1287828
Cited Document(s):
JP2001086953
CN1172673; JP6327434; CN1232696; CN1262116; JP1197440;
Abstract:
DISCLOSED IS A COMPOSITION FOR USE IN HEALTH FOODS FOR THE PROPHYLAXIS AND
TREATMENT OF CONSTIPATION, PREPARED FROM MEDICINAL HERBS, INCLUDING ANGELICA
GIGAS NAKAI, ASTRAGALUS MEMBRANACEUS (FISCH.) BUNGE, PAEONIA ALIFLORA PALLAS
VAR. TRICHOCARPA BUNGE, ATRACTYLODES JAPONICA (KOIDZ.) KITAG, CRATAEGUS
PINNATIFIDA BUNGE, ZANTHOXYLUM PIPERITUM (L.) DC., LYCIUM CHINENSE MILLER,
MACROCARPIUM OFFICINALE SIEB. ET ZUCC., AND GLYCYRRHIZA GLABRA L. IN ADDITION TO
BEING SAFE TO THE BODY, THE COMPOSITION EXHIBITS EXCELLENT PHARMACEUTICAL
EFFECTS AND PROVIDE CONTENTMENT FOR THE USER WITHOUT SIDE EFFECTS.Description:
308/757
1. Field of the invention
[0001] The present invention relates, in general, to a composition of health foods for the
prophylaxis and treatment of constipation and, more particularly, to a composition made of medicinal
herbs, including Angelica gigas Nakai, Astragalus membranaceus (Fisch.) Bunge, Paeonia aliflora
Pallas var. trichocarpa Bunge, Atractylodes japonica (Koidz.) Kitag, Crataegus pinnatifida Bunge,
Zanthoxylum piperitum (L.) DC., Lycium chinense Miller, Macrocarpium officinale Sieb. et Zucc., and
Glycyrrhiza glabra L., suitable for use in health foods for the prophylaxis and treatment of
constipation.
2. Description of the Prior Art
[0002] These days, high-calorie diets such as high-fat diets and fast foods are popularized in
developed countries. Generally, those who eat such high-calorie diets, but do not ingest fibrous
materials nor take exercise are liable to suffer from obesity and constipation. In fact, the number of
patients suffering form obesity and constipation is on upward tend. Now, obesity and constipation
are recognized as serious disorders threatening the health management of modem people.
[0003] Constipation may be defined as infrequent or hard stools or difficulty passing stools.
Constipation is a relative term. There is wide variability is what is considered normal patterns of
bowel evaculation. While some healthy people may have consistently soft or near runny stools others
may have consistently hard firm stools, but no difficulty in passing them. When the stool is hard,
infrequent, and requires significant effort to pass, the person has constipation. Quantitatively, the
person who has 30 g or less of rigid excrements daily or evacuates the bowels twice or less times a
week is diagnosed to have constipation. Constipation may cause discomfort with passage of stools,
and passage of large stools may tear the mucosal membrane of the anus, especially in children,
causing bleeding and the possibility of an anal fissure. Once afflicted with constipation, persons may
suffer from complications such as headache or skin rash, in serious cases, piles, and in the worst
case, rectal cancer. Constipation can be caused by changes in diet, decrease in physical activity,
309/757
lack of toilet facilities, behavior and psychological problems, dehydration, diseases of the bowel,
neurological diseases, congenital diseases, medications, and many other causes.
[0004] Constipation means the residing of excrements in the colon for a longer time period than
usual. As a rule, foods are excreted as dung 12 to 72 hours after their ingestion. Kinds of ingested
foods have considerable influence on the excretion time. For instance, fiber-rich foods increase in
volume by absorbing water in the intestines so as to promote the passing of stools. However, lowfiber diets do not promote evacuation.
[0005] In order to prevent constipation, regular diets are necessary. Occasional fasting may disturb
habitual bowel movements. Chronic constipation may result from physiological difficulty in passing
stools or from physical troubles associated with diseases. Alternatively, chronic constipation may be
caused by senile dysfunction. In general, there are basically three types of constipation; and this
classification relates back to the causes of the ailment.
[0006] Flaccid or atonic constipation is the most common and is the result of a lack of sufficient
fluids in the diet. This ailment results from insufficient muscle contraction or low activity. In other
words, the activity of the intestines to perform excretion is insufficient, due to weak peristalsis, so that
the intestinal contents move slowly. This type of constipation often occurs in the elderly whose
metabolic activity is lowered. Also, this aliment is found in those who suffer from obesity or fever,
undergo surgical operation, or are pregnant. It occurs due mainly to a lack of roughage in diet,
irregular meal hours, fasting, insufficient time period to pass stools, and not taking sufficient water or
adequate fruits and vegetables (and hence lack of bulk-forming cellulose).
[0007] The second type is convulsive or spastic constipation, a kind of an excitatory colopathy,
having causes opposite from those of the flaccid constipation. Convulsive or spastic constipation is
caused by the excessive contraction of the nerve endings in the intestines. In this case, the sigmoid
colon is of excessive activity or its action is not harmonious with that of other sections of the colon. In
addition, the strength of the rectal contraction tends to decrease. Persons who are afflicted with this
type of constipation often suffer from abdominal pain and feel nausea. Also, they have loose bowels
alternating with constipation with concomitant excretion of mucus. Causes relevant to convulsive or
spastic constipation are diverse, including very coarse diets, drinking too much tea and coffee and
alcohol, the frequent use of purgatives, heavy smoking, intestinal infection, tension, emotional turmoil,
and environmental factors (insufficient sleep, rest, and water ingestion). The patients feel unpleasant
and suffer intestinal expansion and abdominal pains and may be seriously convulsed with the
310/757
abdomen bulging. They are of underweight and of nervous temperament. Also, they are afraid of
eating owing to the memory of previous pain and seized with fear of future pain.
[0008] The third type - obstructive constipation - is usually due to the malignancy of the colon, what
is known as the 'impacted colon' and may require surgery. Symptoms of severely constipated people
include heaviness of head, insomnia, a furred, coated tongue, foul breath, headache or dizziness,
and a loss of appetite.
[0009] For the treatment of constipation, its causes, if they are identified, such as metabolism or
endocrine disturbance, nervous tissue dysfunction, anal diseases, etc., must be treated in advance.
However, patients with functional constipation, whose causes are not identifiable, are primarily
required to change their lifestyles and undergo bowel training. Particularly, it is recommended for the
patient to cultivate the habit of passing stools after breakfast. Additionally, a dietary treatment is
necessary, together with the bowel training. Ingestion of fibrous materials and water not only
improves the transportation of foods along digestive tracts, but also absorbs sloughed intestinal cells
and mucous to increase the amount of stools, thereby making excretion easy. For these reasons,
functional foods for treating constipation have been under extensive study.
SUMMARY OF THE INVENTION
[0010] Leading to the present invention, the intensive and thorough research to develop health
foods for promoting the circulation of blood, conducted by the present inventor aiming to overcome
the problems encountered in prior arts, resulted in the finding that certain wild herbs promote the
functions of the organs relevant to excretion and are medicinally effective for the prophylaxis and
treatment of constipation.
[0011] Therefore, it is an object of the present invention to provide a composition of health foods for
the prophylaxis and treatment of constipation, which is safe to the body and can allow the user to
have regular and easy bowel movements.
[0012] In accordance with the present invention, the above object could be accomplished by a
provision of a composition of health foods for the prophylaxis and treatment of constipation,
comprising: 8-15 % by weight of Angelica gigas Nakai, 8-15 % by weight of Astragalus
311/757
membranaceus (Fisch.) Bunge, 8-15 % by weight of Paeonia aliflora Pallas var. trichocarpa Bunge,
8-15 % by weight of Atractylodes japonica (Koidz.) Kitag, 8-15 % by weight of Crataegus pinnatifida
Bunge, 8-15 % by weight of Zanthoxylum piperitum (L.) DC., 8-15 % by weight of Lycium chinense
Miller, 8-15 % by weight of Macrocarpium officinale Sieb. et Zucc., and 2-20 % by weight of
Glycyrrhiza glabra L.
DETAILED DESCRIPTION OF THE INVENTION
[0013] Angelica gigas Nakai is a perennial herb which grows to a height of 1-2 m. It grows at damp
sites in mountain valleys that rise 200-1,500 m above the sea level. Roots of female Angelica gigas
Nakai, which does not sprout flower stalks in Fall can be used as a medicine. In this regard, the roots
of the female herb are cleaned with water and dried under sunshine. On the other hand, the roots of
male Angelica gigas Nakai are not used as a medicine. Coumarin is obtained at a yield of 1.38 %
from the leaves and at a yield of 2-3 % from the roots. The roots also contain pyrano-coumarin such
as decursin C19H20O5, decrusinol C14H14O4, nodakenetin C14H14O4, umbelliferon, and
nodakenin. In addition, other coumain derivatives such as xanthotoxin, yasopimpineline, ostol, and
umbellifrenin are isolated from the roots. Further, roots have essential oils (0.3-0.6 %) and resinous
materials. Decursinol is found in fruits of the herb. Like the roots, the leaves contain essential oils and
coumain in an amount of 1 %. The essential oils and coumain derivatives of the roots are found to
have a variety of medicinal functions, including sedation, contraparetion, blood pressure depression,
and pain relief and anti-inflammation for arthritis. In Oriental medicine, the roots are used as a
hematic, an anodyne, a sedative, and a cordial for the treatment of anemia and
obstetric/gynecological diseases. In combination with other medicinal herbs, the roots are
particularly prescribed for women who suffer from irregular menstruation, menstrual colic, and uterine
hypoplasia, and who are staying for the benefit of their health at home or hospitals after parturition.
[0014] Astragalus membranaceus (Fisch.) Bunge is a perennial herb with a height of 1-1.5 m. From
the roots, 2',4'-dihydroxy-5',6'-dimethoxyisoflavan, 5,4'-dioxy-3,7-dimethoxyflavon, a flavonoid
(C16H12O5), and coumatagenin are isolated. The roots also contain beta -sitosterol, fructose,
glucose, starch, mucous materials, alkaloids, saponin-reactive materials, choline, betain, linolic acid,
linoleic acid, and amino acids such as leucine (16 mg%), glycine (24 mg%), serine (28 mg%),
alanine (55 mg%), glutamic acid (77 mg%), arginine (83 mg%), and gamma -aminobutyric acid (2466 mg%). With medicinal functions, including sedation, blood pressure depression, and vasodilation,
312/757
Astragalus membranaceus (Fisch.) Bunge is used for the treatment of hypertension, cardiovascular
dysfunction, and acute and chronic heart diseases. In Oriental medicine, this herb is used as a
cordial, a restorative, and a diuretic, so that it is applied for promoting the function of the kidneys and
invigorating the body.
[0015] Roots of Paeonia aliflora Pallas var. trichocarpa Bunge are used as a medicinal material
after being peeled and dried under sunshine. Glycosides such as paeonolide and paeoniflorin
C22H28O11 are obtained in the amount of 1.5-6 %, along with paeonin, tannin materials, resinous
materials, sugars, starch, salicylic acid (0.37 %), methylsalicylate, and essential oils. Water or alcohol
extracts from the roots show sedation and analgesic functions and increase the acidity of the gastric
juice. They are also found to stimulate intestinal peristalsis and have inhibitory activity against some
pathogenic bacteria. The alkaloid paeonin shows medicinal effects beneficial to the womb in addition
to having functions similar to those of the alkaloid aconitine. Paeoniflorin shows useful medicinal
functions, including sedation, weak antiphlogistic function, and ulcer-preventive function, without
affecting respiration. In addition, the herb is found to have effects of antihypertension, sedation, pain
alleviation, anti-inflammation, stress ulcer-preventive function, relaxation of smooth muscle, and
vasodilation. In Oriental medicine, the herb is used as an anodyne and a sedative for the treatment of
longissimus dorsi convulsion, neuralgia, menstrual colic, and abdominal ache.
[0016] Atractylodes japonica (Koidz.) Kitag is a perennial herb about 80 cm high. In Oriental
medicine, its root is useful. For use in a medicinal material, roots of Atractylodes japonica (Koidz)
Kitag are collected in Spring or Fall and deprived of rootlets, followed by drying under sunshine.
Dried, thick and massive roots which are stripped of their skin are known to show more potent
medicinal effects. The roots contain essential oils in the amount of about 1.5 % by weight as well as
carotin, inulin, and alkaloid. The essential oils extracted from the root are found to have the functions
of sedation, central nerve paralysis, hypotension, and promotion of urination, in addition to being
used as an aromatic stomachic for the treatment of dyspepsia. In Oriental medicine, the root of
Atractylodes japonica (Koidz.) Kitag is described to promote excretion of water from the body.
Accordingly, it is used as a diuretic for the treatment of renal failure, and as a hidrotic. It is also
prescribed for the patients who suffer from diarrhea, nausea, diabetes mellitus, pulmonary
tuberculosis, coughing, rheumatoid arthritis, gout, fever, cold, hepatic diseases, splenopathy, and
malignant tumors.
[0017] Fruits of Crataegus pinnatifida Bunge contain amygdalin, organic acids such as ursolic acid
(C30H43O3), chlorogenic acid, lemon acid, and wine acid, flavonoids, and vitamin C. In addition,
313/757
many other components remain unidentified. Alcohol extracts from the fruits are found to reduce the
excitation of the cerebral nerves, as well as exerting continuous sedation effects. With a cordial effect,
the fruit extract considerably improves the activity of the heart and shows antagonistic activity
against the dysrhythmia caused by aconitine. In Oriental medicine, the fruit is used as a digestive, an
antidiuretic, and a sedative, and is prescribed for patients afflicted with dyspepsia or stomach upset.
Also, its medications are applied for leukemia, pain, and disorders of the biliary tract.
[0018] Fruits or fruit rinds of Zanthoxylum piperitum (L.) DC. contain essential oils in the amount of
2 to 4 % by weight, which consist mainly of dipentene (C10H16, 54 %), citronellal (C10H18, 8 %), 1beta - phellandrene (C10H16), geraniol, and citronellol. Additionally, the characteristic spicy taste of
the fruits is attributed to zanthol I and II that they contain in the amounts of 5 to 8 %, respectively. The
components are known to exhibit local anesthetic effects. The fruit shows more potent anesthetic
effects as it becomes more mature. In addition, the fruit is found to have inhibitory activity against
various pathogenic bacteria. In Oriental medicine, the fruit is used as an aromatic stomachic to treat
gastroenteritis, gastric dilation, and gastroptosis. Also, it is applied as a diuretic, a local stimulant,
and a vermicide.
[0019] Fruits of Lycium chinense Miller contain vitamins and zeaxanthine. Recently, scopletin, a
biologically active material, has been isolated from the fruits. Also, there were isolated carotinoid and
sterin, which are identified as physalien and beta -sitosterin, respectively. In Oriental medicine, the
fruits of Lycium chinense Miller are utilized as a hypotensive agent. Found to have the function of
lowering blood cholesterol, the fruits are used for the prophylaxis and treatment of arteriosclerosis. In
some historical medical books, the fruits are described to be useful for the treatment of lumbago,
asthenia, vertigo, headache, and diabetes mellitus. It is also described that humans who have been
administered with the fruit for a long period of time may enjoy medicinal effects including increased
bone density, vigor, keen eyesight, resistance to cold and heat, and longevity.
[0020] Fruits of Macrocarpium officinale Sieb. et Zucc. contain crystalline organic acids, gallic acid,
malic acid, tartaric acid, etc. In the skin of the fruits are found morroniside, loganin and sworoside. In
Oriental medicine, the fruits are used to aid renal function and applied to persons who often sweat or
urinate in small amounts, or suffer from lumbago or irregular menstruation.
[0021] Glycyrrhiza glabra L. is a perennial herb which grows to a height of 30-80 cm. Its roots and
root stems from which glycyrrhizin is isolated in the amount of 5-23 %, along with glycyrrhetinic acid
(C30H46O5) are medicinally useful. Glycyrrhizin, known as a medicinally useful compound, is 40-50
314/757
fold sweeter than sugar and promotes the function of the respiratory tract. Glycyrrhetinic acid,
generated by the hydrolysis of glycyrrhizin, lacks the sweet taste and has hemolyzation. Some
research has revealed that the root of Glycyrrhiza glabra L. has expectorant, anti-inflammation,
sedation, and anti-histamine activity. In Oriental medicine, the root is used to sweeten tastes of
decoctions of almost all herbal medicines and neutralize the toxins that the medicinal herbs contain.
Recently, it has been applied for the treatment of gastric and duodenal ulcer, Adison's disease,
bronchial asthma, jaundice, hepatitis, and eczema.
[0022] As described above, the materials used in the present invention are obtained from herbs
which grow naturally and are safe to the body. For use in the composition of health foods for the
prophylaxis and treatment of constipation, the medicinal herbs, Angelica gigas Nakai, Astragalus
membranaceus (Fisch.) Bunge, roots of Paeonia aliflora Pallas var. trichocarpa Bunge, Atractylodes
japonica (Koidz.) Kitag, fruits of Crataegus pinnatifida Bunge, fruits or fruit rinds of Zanthoxylum
piperitum (L.) DC., fruits of Lycium chinense Miller, fruits of Macrocarpium officinale Sieb. et Zucc.,
and Glycyrrhiza glabra L., are dried and powdered. The powder mixture may be formulated in forms
of tablets, granules or capsules, or used as materials of drinks or soups. Alternatively, the herbs may
be extracted with hot water or organic solvents.
[0023] A better understanding of the present invention may be obtained in light of the following
examples which are set forth to illustrate, but are not to be construed to limit the present invention.
EXAMPLE 1
Composition of Health Food for the Prophylaxis and Treatment of Constipation
[0024] A composition of a health food for the prophylaxis and treatment of constipation was
prepared from the following components:
Columns=2
Angelica gigas Nakai12wt%
Astragalus membranaceus (Fisch.) Bunge12wt%
Root of Paeonia aliflora Pallas var. trichocarpa Bunge12wt%
315/757
Atractylodes japonica (Koidz.) Kitag12wt%
Fruits of Crataegus pinnatifida Bunge12wt%
Fruits of Zanthoxylum piperitum (L.) DC.12wt%
Fruits of Lycium chinense Miller12wt%
Fruits of Macrocarpium officinale Sieb. et Zucc.12wt%
Glycyrrhiza glabra L.4wt%
[0025] In the following animal tests, the composition was assayed for anti-constipation effect.
EXPERIMENTAL EXAMPLE 1
Effect of the Composition of Health Food on Constipation (Animal Test)
[0026] For assaying the composition of the present invention for anti-constipation activity, rats were
quantitatively monitored for their stools and water contents thereof.
[0027] Before testing, 20 Sprague-Dawley female rats which were three weeks old were adapted to
a new environment while being fed with pellet diets. They were divided into two groups of 10, which
were raised in metabolic cages, separately. The composition was suspended in saline and injected
abdominally at a dose of 0.14 mg per 250 g of body weight once a day for four weeks to the test
group, while the other control group was administered with saline. During the time period of the
injections, the rats were quantitatively monitored for stools and water content thereof at the same time
(8:30 AM) every day. The results are given in Tables 1 and 2, below.
[0028] As seen in Tables 1 and 2, the test group to which the composition of health foods for the
prophylaxis and treatment of constipation was injected had increased amounts of stools compared to
the saline-administered control, and the composition is found to be useful for the treatment of
constipation as demonstrated by the increase in the water content of stools.
Id=TABLE 1 Columns=8
Title: Amount of Stools According to Administration Time Period
316/757
Head Col 1: Group
Head Col 2: Day 16
Head Col 3: Day 18
Head Col 4: Day 20
Head Col 5: Day 22
Head Col 6: Day 24
Head Col 7: Day 26
Head Col 8: Day 28
Control10086.489.198.690.585.480.6
Test100138.1150.5164.7153.4142.1138.3
Id=TABLE 2 Columns=6
Title: Water Content of Stools According to Administration Time Period
Head Col 1: Group
Head Col 2: Day 16
Head Col 3: Day 18
Head Col 4: Day 20
Head Col 5: Day 23
Head Col 6: Day 28
Control10093.295.490.789.1
Test100108.4122.1112.699.3
EXPERIMENTAL EXAMPLE 2
Effect of the Composition of Health Food on Constipation (Human Test)
[0029] 15 men and 15 women, all in their twenties or thirties, who had been afflicted with
constipation, were let to drink a beverage made of the composition of the present invention and
317/757
interviewed for the change in their passage of stools. The interview results are given in Table 4,
which were evaluated according to the criteria suggested in Table 3. As seen in Table 4, the subjects
replied easy passage of stools with no feelings of residual stools. Also, they had had bowel
movements once every other or three days before the testing, but were measured to have bowel
movements once every day or every other day after the drinking of the composition. Therefore, the
composition of the present invention is effective for the treatment of constipation as demonstrated by
the human test.
Id=TABLE 3 Columns=3
Title: Criteria
Head Col 1: Item
Head Col 2: Criteria
Head Col 3: Decision of Improvement
Defecating Feeling1. Very strong urge, but difficult to defecate.Subject tending toward criterion 3
2. Small defecation with feelings of residual stools
3. No difficulty in passing stools
Frequency of Bowel Movements1. Once a daySubject tending toward criterion 1
2. Once every two days
3. Once every three days
4. Irregular
Effect Grade 0 to 5Answer for improvement from no effect (0) to excellent effect (5) of subject
Id=TABLE 4 Columns=14
Title: Result of Questionaire the Effect of the Composition on Anti-Constipation
Head Col 1:
Head Col 2 to 4: Defecating Feeling
Head Col 5 to 8: Freq. of bowel movements
Head Col 9 to 14: Effect Grade
SubHead Col 1:
SubHead Col 2: 1
SubHead Col 3: 2
SubHead Col 4: 3
SubHead Col 5: 1
318/757
SubHead Col 6: 2
SubHead Col 7: 3
SubHead Col 8: 4
SubHead Col 9: 0
SubHead Col 10: 1
SubHead Col 11: 2
SubHead Col 12: 3
SubHead Col 13: 4
SubHead Col 14: 5
Before Drinking1416008913
After Drinking811111116551135416
[0030] As described hereinbefore, a composition of health food is provided for preventing and
treating constipation in accordance with the present invention. Made of medicinal herbs, the
composition is safe to the liver and exhibits excellent pharmaceutical effects and provide comfort for
the user without side effects.
[0031] The present invention has been described in an illustrative manner, and it is to be
understood that the terminology used is intended to be in the nature of description rather than of
limitation. Many modifications and variations of the present invention are possible in light of the
above teachings. Therefore, it is to be understood that within the scope of the appended claims, the
invention may be practiced otherwise than as specifically described.Claims:
1. A composition of health foods for the prophylaxis and treatment of constipation, comprising:
8-15 % by weight of Angelica gigas Nakai,
8-15 % by weight of Astragalus membranaceus (Fisch.) Bunge,
8-15 % by weight of Paeonia aliflora Pallas var. trichocarpa Bunge,
8-15 % by weight of Atractylodes japonica (Koidz.) Kitag,
8-15 % by weight of Crataegus pinnatifida Bunge,
8-15 % by weight of Zanthoxylum piperitum (L.) DC.,
8-15 % by weight of Lycium chinense Miller,
319/757
8-15 % by weight of Macrocarpium officinale Sieb. et Zucc., and
2-20 % by weight of Glycyrrhiza glabra L.
320/757
240. EP1413208 - 28.04.2004
HEALTH FOOD AND ANTITUMOR AGENT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=EP1413208
Inventor(s):
HAYASHI HIROMICHI (JP)
Applicant(s):
ADAPTGEN PHARMACEUTICAL CO LTD (JP)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L1/30
E Class: A61K35/78; A23L1/30B
Application Number:
EP20030009107 (20030419)
Priority Number: JP20020309975 (20021024); US20030393704 (20030321)
Family: EP1413208
Equivalent:
US2004185124
Cited Document(s):
JP2002017248; JP2001095521; JP2000104063; CN1057196;
JP2002035770; JP7300424
321/757
Description:
BACKGROUND OF THE INVENTION
1. Field of the Invention
322/757
[0001] The present invention relates to a health food for the purpose of maintaining the health of
individuals and to an antitumor agent having an antitumor effect.
2. Description of the Related Art
[0002] In Japan, it has been customary since ancient times to eat bamboo shoots which grow from
bamboo rootstock. Furthermore, powdering fully grown bamboo for use as livestock feed is known.
SUMMARY OF THE INVENTION
[0003] The applicant has discovered that an alcohol extract of bamboo, which may include
bamboo sprouts, has an excellent antitumor effect. The present invention is based on this discovery,
and an object thereof is to provide a health food that contributes to the promotion and maintenance
of health in individuals. A further object of the present invention is to provide an antitumor agent
having an antitumor effect.
[0004] In order to achieve the aforementioned object, the present invention provides a health food
comprising a bamboo extract, which is extracted in an alcohol solution. Alcohol extracts of bamboo
have an excellent antitumor effect; accordingly, if a health food comprising such an alcohol extract of
bamboo is orally consumed on a regular basis, the progression of malignant tumors (cancers) can
be prevented or limited. The antitumor effect of such an alcohol extract is more pronounced with an
aqueous alcohol solution, which contains water, than with a 100% alcohol solution. The alcohol
concentration of such an aqueous alcohol solution is preferably 50% to 70%, and it is most
preferable that the alcohol concentration of this aqueous alcohol solution be 60%. In terms of the
bamboo, the flesh of moso bamboo (Phyllostachys pubescens) sprouts and the outer part of the
stem of this same type of bamboo are particularly preferred.
[0005] Furthermore, antitumor agents having the aforementioned extract as an active component
thereof are highly effective in the treatment of malignant tumors.
323/757
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a graph showing the results (right leg) for trial 1;
FIG. 2 is a graph showing the results (left leg) for trial 1;
FIG. 3 is a graph showing the results for trial 2;
FIG. 4 is a graph showing the results for trial 2;
FIG. 5 is a graph showing the results for trial 2;
FIG. 6 is a graph showing the results for trial 3;
FIG. 7 is a graph showing the results for trial 3;
FIG. 8 is a graph showing the results for trial 3; and
FIG. 9 is a graph showing the results for trial 4.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0007] In the following, modes of embodiment of the present invention are described. Firstly, the
bamboo which serves as the primary material may be hachiku bamboo (Phyllostachys nigra var.
henonis), Japanese timber bamboo (Phyllostachys bambusoides), moso bamboo, Indonesian Tali
bamboo (Gigantochloa apus), or the like, but the invention places no particular restrictions on the
type of bamboo. Furthermore, bulk bamboo, wherein different kinds of bamboo are combined, may
also be used. Both fully grown bamboo and bamboo shoots may be used. The parts of the bamboo
plant which may be used include the stem, the roots, and the leaves. It is preferable that the bamboo
be fresh and that parts of the plant other than the shoot be used within one year of harvest. If
bamboo shoots are used, it is preferable that these be processed soon after harvest. In either case,
however, if the bamboo is frozen while still fresh, it can be stored for usage at a later date.
[0008] Next, the bamboo is washed to remove any impurities, and then ground in a mill to a particle
size which passes through a 10 mm screen. For mills that are not fitted with screens, the bamboo
may be milled to a particle length of 3 mm to 5 mm. Next, 1 kg of ground bamboo is immersed in 10
kg of an alcohol solution or an aqueous alcohol solution until it is thoroughly bleached. The period of
324/757
time required for this is normally approximately 6 months. However, if this is heated to approximately
60 DEG C, approximately 2 hours is sufficient.
[0009] Next, the solid component is separated in a centrifuge, and the liquid alcohol extract of
bamboo is recovered. This liquid extract is concentrated to 20% of the original weight thereof by
heating it to 60 DEG C. If an equivalent solid amount of starch is added to this concentrated bamboo
extract, this can be freeze-dried to form a powder, which serves as the final health food or antitumor
agent. It is a matter of course that vitamins and the like can be added to this powder. The health-food
product or antitumor agent may take the form of a solid, a powder, a liquid, granules, or the like.
[0010] In the process described above, the dross that remains after centrifuging may be recovered,
6 parts by weight of an alcohol solution or an aqueous alcohol solution may be added to each 1 part
by weight of dross, and the liquid produced by heating this to 60 DEG C for 2 hours may be mixed
into the liquid produced in the process described above. In this manner, the bamboo can be fully
exploited, without waste.
[0011] If the antitumor agent described above is to be used as an injectable agent, a resin
purification process is further performed, before concentration to 20% of the original volume
described in the process above, and the concentrated extract is further deproteinized with ethanol or
the like. This is then subject to microfiltration so as to purify it and remove bacteria, whereafter it is
autoclaved, for example, at 120 DEG C for 30 minutes. In the case of ethanol deproteinization, the
product is concentrated by heating at 80 DEG C to completely remove the alcohol.
[0012] As is made clear from the foregoing description, the present invention includes the technical
idea of "a method of preparing a health-food product or an antitumor agent comprising a step
wherein bamboo is immersed in an alcohol solution or an aqueous alcohol solution, and a step
wherein a liquid alcohol extract of this bamboo is recovered and concentrated."
[0013] Samples of a product according to the present invention prepared by means of the method
described above were tested for antitumor effect in the following trials 1 to 4.
Trial 1
325/757
[0014] Malignant sarcoma cells (Meth-A fibrosarcoma) were transferred to both subcutaneous
inguinal regions of BALB/c mice, a solid tumor was grown, and changes in the surface area of the
tumor over time were measured for 25 days. For 3 days, beginning on the third day following the
transfer, 0.1 ml of a sample A (a liquid wherein a powder extracted from moso bamboo, using an
aqueous alcohol solution having an alcohol concentration of 60%, is dissolved in a physiological
saline solution) was administered to the interior of the tumor on the right leg of each mouse. A
physiological saline solution was administered under the same conditions to a control group. The
content of powder in 0.1 ml of sample A was 1 mg. The results are shown in the graphs in FIG. 1 and
FIG. 2.
[0015] As is made clear by the trial results shown in FIG. 1 and FIG. 2, tumor growth was
suppressed by the administration of sample A in both legs. Changes in the surface area of the
tumors in the right leg represent the direct effect of the product according to the present invention,
while changes in the surface area of the tumors in the left leg are thought to be the result of
sensitization and activation of immune functions within the organism as a result of the product
according to the present invention.
Trial 2
[0016] Ascites tumor cells (sarcoma-180) in the amount of 1 x 10 were transferred and grown in the
right subcutaneous inguinal region of ICR mice to form solid tumors. A sample B, wherein a powder
extracted from moso bamboo with an aqueous ethanol solution having an ethanol concentration of
60% is dissolved in a physiological saline solution, and a sample C, wherein a powder extracted from
moso bamboo with a 100% ethanol solution is dissolved in a physiological saline solution, were
administered orally at 1000 mg/kg/day beginning 24 hours after transplant. Administration was
performed every other day, and the mice were raised for 28 days. Under the same conditions, a
physiological saline solution was administered to a control group, and a hot water extract of bamboo
was used as a comparative example. Meanwhile, the surface area of the tumors and the changes in
body mass of the ICR mice were measured and, on the 28th day, the tumors were excised and
weighed. Changes in the surface areas of the tumors are shown in the graph in FIG. 3, changes in
the weight of the tumors are shown in the graph in FIG. 4, and changes in body mass are shown in
the graph in FIG. 5.
326/757
[0017] As is made clear from the results shown in FIG. 3, the values for both sample B and sample
C are significantly lower than for the control group from day 12 to day 28. As compared to this, the
values for the hot water extract of bamboo were only significantly lower than those of the control
group on day 26, but a significant difference was not found on day 28. Furthermore, as shown in the
graph in FIG. 4, the values for the weights of the excised tumors were significantly lower for samples
B and C than for the control group, but a significant difference was not found between the control
group and the hot water extract of bamboo. These trial results made it clear that samples of B and C
inhibited tumor growth without impairing body growth, demonstrating an excellent antitumor effect.
As is made clear from the graph in FIG. 5, there were no significant differences in body weight
between any of the groups during the trial period, and neither sample affected the growth of the mice.
Trial 3
[0018] Ascites tumor cells (sarcoma-180) in the amount of 1.2 x 10 were transferred to the right
subcutaneous inguinal region of ICR mice and grown to form solid tumors. Beginning 24 hours after
the transplant, a sample D, wherein a powder extracted from bamboo shoots using a 60% aqueous
ethanol solution was dissolved in a physiological saline solution, and a sample E, which was
produced in like manner from bulk bamboo (a mixture of approximately equal amounts of Japanese
timber bamboo, moso bamboo, black bamboo (Phyllostachys nigra var. nigera), arrow bamboo
(Pseudosasa japonica) hachiku bamboo, medake bamboo (Pleioblastus simonii), all of which are
grown in Japan, and Indonesian Tali bamboo), and a sample F, produced in like manner from
Indonesian Tali bamboo, were administered orally at 1000 mg/kg/day. Administration was performed
every other day, and for each group, nine mice were raised for 28 days. A physiological saline
solution was administered under the same conditions to a control group. During this time, the surface
areas of the tumors were measured over time. The tumors were excised and weighed on the 28th
day. The results are shown in Table 1 and in the graphs in FIG. 6 to FIG. 8. In Table 1, the tumor
inhibition rate (%) is found by the formula [1-(weight of tumors in the group to which the product
according to the present invention was administered/weight of the tumors in the control group)] x100,
based on the weight of the tumors on the last day.
Id=Table 1 Columns=4
Trial of Antitumor Effect on Ascites Tumor Cells
Head Col 1:
327/757
Head Col 2: Average Tumor Weight (g/SE)
Head Col 3: Tumor Inhibition Rate (%)
Head Col 4: Number of Cases Cured
Sample D (shoots)1.79 +/-0.78
*
78.23/9
Sample E (bulk)1.76 +/-0.87
*
78.54/9
Sample F (Tali)5.24 +/-1.7136.12/9
Control (saline)8.20 +/-1.82--0/9
* p < 0.01 compared to control group
[0019] From this trial 3 it was understood that while the strength differed according to the type of
bamboo, all of samples D to F had excellent antitumor effects as compared with the control groups.
Trial 4
[0020] Moso bamboo (sample G), the outer part of the fully grown stem of moso bamboo (sample
H), the inner part of the fully grown stem of moso bamboo (sample I) (note: the outer part of the stem
is a thin portion representing approximately one-half of the stem, and the inner part is a thick portion
representing approximately one-half of the stem), the flesh of the bamboo shoot, which is the inner
part of the shoot with the skin removed and is the part commonly used for cooking (sample J), and
bamboo shoot skin (sample K) were immersed in aqueous ethanol solutions with 60% ethanol
concentrations, which were heated to 60 DEG C for two hours, whereupon the liquid extract was
filtered, vacuum concentrated (60 DEG C), and dried (60 DEG C). Note that for each 1 part of
sample H, 10 parts of ethanol solution were used, and for each 1 part of the other samples, 5 parts of
ethanol solution was used.
[0021] Sarcoma-180 cells in the amount of 1 x 10 cells/ml were transplanted into the right lower
abdomen of ICR mice (males, five weeks old), and on day 0 after the transplant, normal feed (Nosan
328/757
Corporation, Labo MR Breeder TM ) was given to the control group, while the test group was allowed
to feed freely from feed to which the samples G to K had been admixed at a ratio of 20%. Each
group contained 10 animals. On the 28th day after transplant, the tumors were excised and weighed.
The mean weights of the tumors are shown in FIG. 9.
[0022] From this trial 4 it was understood that the flesh of bamboo shoots (sample J) was much
more effective than the skin of bamboo shoots (sample K). Furthermore, for the same type of bamboo,
the outer part of the fully grown stem (sample H) was more effective than the inner part of the fully
grown stem (sample I). Moso bamboo was found to be highly effective.
[0023] Modes of embodiment of the present invention have been described above, but it is a
matter of course that the present invention is not limited to these modes of embodiment. For example,
in these modes of embodiment, ethanol was used for the alcohol solution, but methanol and other
alcohol solutions may be used. Furthermore, in this mode of embodiment, an aqueous alcohol
solution having an alcohol concentration of 60% was used, but for mass production, an aqueous
alcohol solution having an alcohol concentration of 50% to 70% may be used.Claims:
1. A health food comprising an extract extracted from bamboo with an alcohol solution.
2. A health food comprising an extract extracted from bamboo with an aqueous alcohol solution.
3. A health food comprising an extract extracted from bamboo with an aqueous alcohol solution
having an alcohol concentration of 50% to 70%.
4. A health food comprising an extract extracted from bamboo with an aqueous alcohol solution
having an alcohol concentration of 60%.
5. The health food of any one of claims 1 to 4 wherein said bamboo is moso bamboo (Phyllostachys
pubescens).
6. The health food of any one of claims 1 to 4 wherein said bamboo is bamboo shoot flesh.
329/757
7. The health food of any one of claims 1 to 4 wherein said bamboo is the outer part of a fully grown
bamboo stem.
8. An antitumor agent comprising as an active ingredient the extract according to any one of claims 1
to 7.
330/757
241. EP1455600 - 15.09.2004
FOOD OR PET FOOD COMPOSITION CONTAINING PLANT EXTRACT FOR BONE HEALTH
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=EP1455600
Inventor(s):
OFFORD-CAVIN ELIZABETH (CH); FEDERICI ERMANNO (GB); LEMAURE
BERNARD (FR); COURTOIS DIDIER (FR)
Applicant(s):
NESTLE SA (CH)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A23L1/30; A61P19/00
Application Number:
EP20020792794 (20021210)
Priority Number: WO2002EP13174 (20021210); EP20010204839 (20011211); EP20020792794
(20021210)
Family: EP1455600
331/757
242. GB2378134 - 19.05.2005
HEALTH FEED
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=GB2378134
Inventor(s):
(GB)
BUTTERWICK RICHARD F (GB); ROLFE VIVIEN E (GB); VALLANCE CHARLENE E
IP Class 4 Digits: A61K
IP Class:
A61K31/198; A61K38/06; A61K38/05; A61K38/04
E Class: A23K1/18N; A23K1/16G1; A23K1/18; A61K31/198
Application Number:
US20040480373 (20041214)
Priority Number: GB20010014419 (20010613); WO2002GB02752 (20020613)
Family: GB2378134
Equivalent:
AU2918202; EP1395127WO02100189; WO02100189; ZA200301169
Abstract:
THE PRESENT INVENTION RELATES TO A METHOD OF PROMOTING IMMUNOGLOBULIN A
SECRETION IN THE MUCOSAL MEMBRANES OF NON-HUMAN ANIMALS. THE METHOD
COMPRISES ADMINISTERING A FOODSTUFF COMPRISING GLUTAMINE TO THE NON-HUMAN
ANIMAL.Description:
CROSS-REFERENCE TO RELATED APPLICATIONS This application is the National Stage
Application of International Application No. PCT/GB02/0752 filed Jun. 13, 2002, which claims priority
to Great Britain Application No. 0114419.5 filed Jun. 13, 2001, which are incorporated herein in their
entirety.
332/757
TECHNICAL FIELD The present invention relates to a method of promoting immunoglobulin A
secretion in the mucosal membranes of non-human animals. The method comprises administering a
foodstuff comprising glutamine to the non-human animal.
BACKGROUND OF THE INVENTION Glutamine is a neutral amino acid, which is readily transported
across plasma membranes. As an important intermediate in a number of metabolic pathways,
cellular utilization of glutamine can far exceed that of other amino acids especially within intestinal
and immune cells. Glutamine is important in the transport of amino nitrogen and ammonia, as a
substrate in gluconeogenesis and ammoniagenesis, as a fuel source for rapidly dividing cells and
may also be involved in the regulation of protein synthesis. The high rate of glutamine utilization by
the intestine (identified to occur in man) may be due in part to the large lymphocyte and macrophage
populations in intestinal walls and Peyer's patches. These cells exhibit high glutaminase activity and
utilize glutamine as their preferential fuel source, even in the quiescent state. However, as with many
other cells that require glutamine, both enterocytes and lymphocytes lack the synthetic apparatus to
produce glutamine relying solely on circulatory or dietary sources. It is suggested that a fall in the
plasma concentration could compromise lymphocyte function accounting for the increase in
susceptibility to viral infection. Gut-associated lymphoid tissue in the gastrointestinal tract appears to
provide immunologic protection for the gastrointestinal tract and for extra intestinal mucosal sites
such as the nasopharynx, mammary glands, salivary glands and lungs. Lymphocytes, which provide
or control the production of immunoglobulin A are released by the gut-associated lymphoid tissue
and distributed to the gastrointestinal tract and extra intestinal sites via the mesenteric lymphatic
channels and thoracic duct. Feeding of an individual by total parenteral nutrition results in the
atrophy of gut-associated lymphoid tissue and a decrease in immunoglobulin A levels. Addition of
glutamine to a total parenteral nutrition solution was shown by Li et al to normalize gut-associated
lymphoid tissue population. Work by Gismondo et al (Gismondo, M. R., Drago, L., Fassina, M. C.,
Vaghi, I., Abbiati, R. and Grossi, E. (1998). Immunostimulating effect of oral glutamine. Dig. Dis. Sci,
43, 1752-1754) has indicated that the oral administration of glutamine to congenitally
immunosuppressed mice provides a positive effect on serum levels of interleukin 2 and the intestinal
population of T cells. In addition, studies in man by Fujita and Sakura (Fujita, T. and Sakurai, K.
(1995) Efficacy of glutamine-enriched enteral nutrition in an experimental model of mucosal
ulcerative colitis. Br. J. Surg, 82, 749-751) have indicated that the administration of glutamine is
therapeutically beneficial to patients with inflammatory bowel disease. It is a desire in the area of pet
food products and companion animal health as well as farm animal health to provide diets suitable to
support the health of non-human animals. In particular it is desire to provide diets suitable to promote
or maintain the health of already healthy non-human animals.
333/757
BRIEF SUMMARY OF THE INVENTION The first aspect of this invention relates to a method of
promoting immunoglobulin secretions in the mucosal membranes of a non-human animal comprising
administering a foodstuff comprising glutamine to a non-human animal. Mucosal membranes are the
moist membranes lining many tubular structures and cavities. These membranes provide a
protective layer between the external environment and the internal organs of an animal. Mucosal
cells/tissues include mucosal coverings of the gut, the mouth, the nasal passage, the esophagus, the
stomach, the lung, the small intestine, the large intestine, epithelial tissue, urogenital tract, the eyes,
and mammary glands. The method of the first aspect seeks to improve and maintain the health of a
non-human animal. In particular, the animals of the first aspect of the invention are pet or companion
animals such as cats or dogs or farm animals such as swine (porcine), sheep (ovine) or cattle
(bovine) or poultry. The animals may be at any life-stage, such as young, adult or senior. Accordingly,
kittens, puppies, piglets, lambs, calves and chicks are covered by the present invention. The
maintenance and improvement of the health of a pet or companion animal and of other animals, such
as farm animals is a constantly ongoing aim in the art. It is possible to monitor the improved health of
an animal as achieved by the invention in a number of ways. Two of these are feces quality and
gastrointestinal (GI) tract health. By improving the health of the animal, the invention seeks to
promote and maintain good quality feces in animals (such as pet animals). Good feces quality is of
two-fold importance. Firstly, it is a good indicator of a healthy animal (such as a pet). It is known that
good feces quality usually reflects healthy colonic structure and function. Secondly, it is a muchfavored practicality for pet-owners. The invention also aims to improve the GI tract health of animals
(such as pet animals). The ability to maintain and improve GI tract health can be beneficial to animal
owners (such as pet owners) because it has an impact on their animal's overall health. Without being
bound by scientific theory, it is believed that by increasing the level of secretary immunoglobulin A in
the mucosal membranes, glutamine maintains and promotes health of a non-human animal. It is
postulated that elevated levels of immunoglobulin A improve the defense mechanisms of the
mucosal membranes by eliminating viruses from epithelial cells and by forming a barrier which
prevents the adherence of pathogenic bacteria. For example, elevated levels of immunoglobulin A in
the lungs and/or the nasopharynx may protect an animal from micro-organisms that cause influenza
or pneumonia. Within the gastrointestinal tract, immunoglobulin A is believed to decrease intestinal
permeability and to enhance intestinal absorption. Therefore, a preferred feature of the first aspect of
the invention relates to a method for increasing levels of secretory immunoglobulin A in the
gastrointestinal tract comprising administering a foodstuff comprising glutamine to the non-human
animal. A further preferred feature of the first aspect of the invention relates to a method for
increasing the levels of secretory immunoglobulin A in the urogenital tract comprising administering a
334/757
foodstuff comprising glutamine to a non-human animal. It is a preferred feature of the invention that
the foodstuff of the first aspect is administered to a non-human animal, which is healthy. It is
postulated that administering a foodstuff comprising glutamine to a healthy non-human animal will
allow the healthy status of that animal to be maintained, as the animal will be less susceptible to viral
or bacterial infection. For the purposes of this invention, 'health' is defined as an absence of clinical
disease. Thus a healthy animal is an animal which does not exhibit the symptoms of a clinical
disease, for example, by its immune status or histology. In a preferred aspect of this invention, the
term healthy encompasses animals at optimal health. In another preferred aspect of this invention,
the term healthy encompasses animals at optimal or sub optimal health, for example animals with
one or more subclinical diseases. An assessment of the health of a particular animal can be carried
out by the owner (i.e. by assessing the quality of the feces of the animal and/or monitoring the
appetite of the animal) or by an individual qualified to do so (e.g. a veterinary surgeon, dietician) by
assessing the histology and/or immune status of the animal. The method of the first aspect
comprises administering a foodstuff comprising glutamine. The foodstuff may comprise one or more
components which provide a source of glutamine such as one or more of gliadin, oat bran, soya
bean meal, linseed, cereals, forages, sunflower, lupin, beans, lentils, milk powder, caesin, whey or
soy. For the purposes of this invention, cereals include barley, oats, wheat, bran and rye and forages
include grass, hay, rye grass etc. Alternatively, the foodstuff may be supplemented by a source of
glutamine. The glutamine source may be the free amino acid (preferably L-glutamine), a peptide rich
in L-glutamine or an extract containing L-glutamine. Suitable peptides rich in L-glutamine include
dipeptides, tripeptides, tetrapeptides, pentapeptides, hexapeptides, longer chain peptides or
peptide mixtures. Such peptide mixtures include proteins rich in L-glutamine, hydrolates or fractions
thereof (e.g. peptide mixture(s) obtained from one or more of gliadin, oat bran, soya bean meal,
linseed, cereals, forages, sunflower, lupin, beans, lentils, milk powder, caesin, whey or soy).
Glutamine can be further provided by an extract containing L-glutamine either as a free amino acid
or as a peptide containing L-glutamine (e.g. extracts of gliadin, oat bran, soya bean meal, linseed,
cereals, forages, sunflower, lupin, beans, lentils, milk powder, caesin, whey or soy). Other Lglutamine derivatives include L-glutamine salts, N-acyl derivatives of L-glutamine including Nalkanoyl L-glutamine compounds such as N-acetyl L-glutamine. The N-acylation of L-glutamine
stabilises the peptide, in comparison with free amino acid L-glutamine. Such peptides may be pH
and fluid stable. The dipeptide can be but is not limited to L-alanyl-L-glutamine or L-glycyl-Lglutamine. The dipeptide containing L-glutamine should be stable in solution. Preferably, the
glutamine is provided as the free amino acid L-glutamine or a dipeptide containing L-glutamine.
Alternatively, the glutamine is provided either as an extract or peptide mixture from or by wheat
gluten or a casein hydrosylate such as sodium caseinate. Glutamine is preferably provided to the
335/757
foodstuff at a level of from 0.01% to 10% w/w on a dry matter basis. Preferably the glutamine is
provided as free glutamine or a source thereof having an equivalent amount of bioavailable
glutamine. Preferably, the glutamine is provided at a level of 0.01% to 5% w/w on a dry matter basis,
most preferably, approximately 1% w/w on a dry matter basis or above. The glutamine of the
invention would be provided by the foodstuff at levels of approximately 0.01 g to approximately 1 g
per kg body weight per day, more preferably, approximately 0.1 g per kg body weight or above per
day. The foodstuff is preferably administered daily, more preferably twice daily. Where the foodstuff
is a treat or snack, the foodstuff can be administered one or more times a day, preferably five or
more times a day. The amount of glutamine in a foodstuff may therefore vary depending on the
number of times a day the foodstuff is to be administered. The foodstuff of the invention may be a
dry product (with approximately 3, 4 or 5 to approximately 15% moisture), a semi-moist product (with
approximately 15 to approximately 70% moisture) or a wet product (with approximately 70 to
approximately 90% moisture). The foodstuff according to the present invention encompasses any
product that an animal, (such as a pet) consumes in its diet. Thus, the invention covers standard
food products as well as food snacks, such as pet food snacks (for example, snack bars, treats,
biscuits and sweet products). The foodstuffs preferably a cooked product. It may incorporate meat or
animal derived material (such as beef, chicken, turkey, lamb, fish, blood plasma, marrow bone etc or
one or more thereof). The product alternatively may be meat free (preferably including a meat
substitute such as soya, maize gluten or a soya product) in order to provide a protein source. The
product may contain additional protein sources such as soya protein concentrate, milk proteins,
gluten etc. The product may also contain a starch source such as one or more grains (e.g. wheat,
corn, rice, oats, barley etc), or may be starch free. The foodstuff of the invention is preferably
produced as a dry product containing from approximately 3%, 4% or 5% to approximately 15%
moisture. The preferred dry food is more preferably presented as small biscuit-like kibbles. The
foodstuff is preferably packaged. In this way, the consumer is able to identify, from the packaging,
the ingredients in the foodstuff and confirm that it is suitable for the particular animal (such as a pet)
in question. The packaging may be metal (usually in the form of a tin or flexifoil), plastic (usually in
the form of a pouch), paper or card. The amount of moisture in any product may influence the type of
packaging, which can be used or is required. The foodstuff of the first aspect can be provided as a
food supplement. The food supplement can be a powder, sauce, topping, biscuit, kibble, pocket or
tablet that can be administered with or without an additional foodstuff. Where the food supplement is
administered with an additional foodstuff, the food supplement can be administered sequentially
simultaneously or separately. The food supplement may mixed with the foodstuff, sprinkled over the
foodstuff or served separately. Alternatively, the food supplement can be added to a liquid provided
for drinking such as water or milk. The foodstuff can be made according to any method known in the
336/757
art. Foodstuffs for pet animals can be any, including such as in Waltham Book of Dog and Cat
Nutrition, Ed. ATB Edney, Chapter by A. Rainbird, entitled "A Balanced Diet" in pages 57 to 74
Pergamon Press Oxford. The glutamine may be mixed with the other components of the foodstuff or
can be added to the completed foodstuff. In a preferred feature of the invention, the glutamine is
coated or sprayed on to the surface of the foodstuff. Alternatively, one or more components
comprising glutamine are admixed, with one or more other components of the foodstuff. The second
aspect of the invention relates to the use of glutamine in the manufacture of a foodstuff for preventing
or treating infection in the gastrointestinal tract. It is proposed that the administration of the foodstuff
will result in an increase in the level of secretary immunoglobulin A in the gastrointestinal tract. It is
postulated that such elevated levels of immunoglobulin A will prevent viral or bacterial infection by
eliminating viruses from epithelial cells and forming a barrier which prevents adherence of
pathogenic bacteria. In addition, elevated immunoglobulin A levels are believed to decrease
intestinal permeability and enhance intestinal absorption. Thus the second aspect of the invention
further relates to the use of glutamine in the manufacture of a foodstuff for preventing or treating
bacterial or viral infections such as calicivirus in the gastrointestinal tract. All preferred features of
the first aspect of the invention also relate to the second aspect. The third aspect of the invention
relates to the use of glutamine in the manufacture of a foodstuff for the promotion or maintenance of
the urogenital health of a non-human animal. In particular, the third aspect relates to the use of
glutamine in the manufacture of a foodstuff for preventing or treating infection in the urogenital tract
of a non-human animal. For the purposes of the third aspect, the infections are preferably bacterial or
viral infections of the urogenital tract, such as calicivirus. All preferred features of the first and
second aspects of the invention also relate to the third aspect.
DETAILED DESCRIPTION OF THE INVENTION The invention will now be illustrated with reference to
the following non-limiting examples.
EXAMPLES Composition of a Foodstuff Comprising Glutamine. The foodstuff is a dry product
containing less than 10% water. The foodstuff comprises the following ingredients (is approximately).
Rice20%
Poultry23%
Maize17%
Maize meal 9%
Beef Tallow10%
Glutamine 1% All ingredients except glutamine are mixed, cooked and formed into a dry kibble.
Glutamine (provided as L-glutamine) is then sprayed onto the external surface of the foodstuff.
337/757
Experimental Data
Example 1 The study was carried out using eight members of the cat colonic health panel, which
were known to be in good (intestinal) health. Cats were wormed and vaccinated 6 months prior to the
start of the trial. The cats underwent the following trial regime;
14 daysControl diet
28 daysGlutamine enriched diet
14 daysControl diet Both the control diet and the glutamine enriched diet provided 405 kCal/100 g.
The control diet was a dry diet containing approximately 4% water. The control diet comprised the
following ingredients (is approximately):
Poultry37%
Beef Tallow10%
Rice20%
Maize meal and gluten26%
Sunflower oil 3%
Brewers yeast and vitamins 3% The glutamine-supplemented diet comprised 1% dry weight by
weight glutamine provided as L-glutamine. The glutamine was sprayed onto the external surface of
the dry control product. Measurement of Immunoglobulin Production Levels of immunoglobulin A
production by mid colon biopsy samples were measured by enzyme linked immunosorbent assay
(ELISA). IgA ELISA test was obtained from Bethyl and performed as described in provided protocol
sheets. In short, 96 well microplates were taken and coated with 100 [mu]l anti-canine IgA overnight
at 4[deg.] C. After each step the plates were washed with ELISA wash (50 Mm) Tris, pH 8.0, 0.1M
NaCl, 0.05% Tween 20). Unreacted sites were blocked with tris-buffered saline (TBS) containing 1%
bovine serum albumin (BSA) for 30 minutes. Standards and samples were diluted as required, 100
[mu]l added to the plate and incubated for 1 hour at room temperature. After washing, horseradish
peroxidase-conjugated anti-canine IgA immunoglobulins were diluted as described in the protocol
and incubated on the plate for 1 hour at room temperature. 200 [mu]l of 3,3',5,5'-tetramethyl
benzidine (TMB) was added to the plate as an enzyme substrate and the reaction was stopped with
100 [mu]l of 0.5M H2SO4 after 30 minutes. Finally, the absorbence was read spectrophotometrically
at 450 nm using an ELISA plate reader. Results A significant increase in IgA production by the
colon was found in the samples taken from below the transwell when cats were fed diets containing
1% glutamine (P=0.048, GLM) compared to the other three diets. Results are summarized below in
the below table.
TABLE
338/757
IgA production by biopsy samples
IgA production (ng/mg protein)
DietIntestinal Sample
Standard 569.8 +- 206.7 (a)
Glutamine1003.1 +- 762.9 (b)
Same letter denotes no significant different (p > 0.05).Claims:
1. A method of promoting immunoglobulin A secretion in a mucosal membrane of a non-human
animal comprising administering a foodstuff comprising glutamine to the non-human animal.
2. The method of claim 1, wherein the mucosal membrane is the gastrointestinal tract of the nonhuman animal.
3. The method of claim 1, wherein in the mucosal membrane is the urogenital tract of the non-human
animal.
4. A method as claimed in claim 1 for the use of maintaining or improving the health of a non-human
animal.
5. The method of claim 4, wherein the non-human animal is healthy.
6. The method of claim 1, wherein the non-human animal is a companion animal selected from the
group consisting of a cat and a dog, or wherein the animal is a porcine, ovine, bovine or poultry
animal.
7. The method of claim 1, wherein glutamine is one or more of L-glutamine, a peptide comprising
glutamine or an extract comprising glutamine.
8. The method of claim 7, wherein the peptide is one or more of a dipeptide, tripeptide, tetrapeptide,
pentapeptide, hexapeptide, a longer chain peptide or a peptide mixture.
9. The method of claim 8, wherein the peptide mixture is derived from one or more of gliadin, oat
bran, soya bean meal, linseed, cereals, forages, sunflower, lupin, beans, lentils, milk powder, caesin,
whey, soy casein hydrosylate or wheat gluten.
339/757
10. The method of claim 1, wherein glutamine is provided to the foodstuff at a level of approximately
1% w/w on a dry matter basis or above.
11. The method of claim 1, wherein the foodstuff contains from approximately 3% to approximately
15% moisture.
12. The method as of claim 1, wherein glutamine is provided to the non-human animal at a level of
approximately 0.1 g per kilogram body weight or above per day.
13. The method as of claim 1, wherein the foodstuff is provided one or more times per day.
14. A method of producing a composition for preventing or treating infection in the gastrointestinal
tract of a non-human animal comprising the step of providing glutamine to a foodstuff.
15. A method of producing a composition for promoting urogenital health in a non-human animal
comprising the step of providing glutamine to a foodstuff.
16. The method of claim 15, wherein the composition prevents or treats infection in the urogenital
tract of a non-human animal.
17. The method claim 14, wherein the infection is caused by a virus or a bacteria.
18. The method of claim 14, wherein the non-human animal is healthy.
19. The method of claim 14, wherein the non-human animal is a companion animal selected from the
group consisting of a cat and a dog or wherein the animal is a porcine, ovine, bovine or poultry
animal.
20. The method of claim 19, wherein glutamine is one or more of L-glutamine, a peptide comprising
glutamine or an extract comprising glutamine.
21. The method of claim 20, wherein the peptide is one or more of a dipeptide, tripeptide,
tetrapeptide, pentapeptide, hexapeptide, a longer chain peptide or a peptide mixture.
340/757
22. The method of claim 21, wherein the peptide mixture is derived from one or more of gliadin, oat
bran, soya bean meal, linseed, cereals, forages, sunflower, lupin, beans, lentils, milk powder, caesin,
whey, soy, casein hydrosylate or wheat gluten.
23. The method of claim 14, wherein the glutamine is provided to the composition at a level of
approximately 1% w/w on a dry matter basis or above.
24. The method of claim 14, wherein the composition contains from approximately 3%, 4% or 5% to
approximately 15% moisture.
25. The method of claim 14, wherein the glutamine is provided to the non-human animal at a level of
approximately 0.1 g per kilogram body weight or above per day.
26. The method of claim 14, wherein the composition is provided one or more times per day.
27. (canceled)
341/757
243. HK1039866 - 02.07.2003
HEALTH CARE FOOD CAPABLE OF PROMOTING FEMALE BREAST WELL DEVELOPED
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=HK1039866
Inventor(s):
SHAOQIU YOU (HK)
Applicant(s):
SHAOQIU YOU (HK)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A23L1/30; A61P15/08
Application Number:
CN20010144764 (20011221)
Priority Number: CN20010144764 (20011221)
Family: CN1426805
Abstract:
A HEALTH-CARE FOOD FOR ROUNDING THE FEMALE BREAST CONTAINS 7 COMPONENTS
INCLUDING THAI TARO, CHINESE ANGELICA ROOT, MOTHERWORT, WILD YARM, ETC.. THE
FEMALE BREAST CAN BE ROUNDED AFTER IT IS EATEN FOR3-6 MONTHS.
342/757
244. HK1039867 - 02.07.2003
HEALTH CARE FOOD CAPABLE OF ASSISTING COMBUSTION AND DECOMPOSING EXCESS FAT
TO REDUCE BODY WEIGHT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=HK1039867
Inventor(s):
SHAOQIU YOU (HK)
Applicant(s):
SHAOQIU YOU (HK)
IP Class 4 Digits: A61K; A61P
IP Class:
A61K35/78; A61P3/04
Application Number:
CN20010144766 (20011221)
Priority Number: CN20010144766 (20011221)
Family: CN1426807
Abstract:
A HEALTH-CARE FOOD FOR DECOMPOSING THE EXCESSIVE FAT OF HUMAN BODY TO LOSE
WEIGHT CONTAINS 9 COMPONENTS INCLUDING CACTUS, ALFALFA, HOT PEPPER, GREEN TEA
EXTRACT, ETC.. AFTER THE SAID FOOD IS EATEN FOR ABOAT 3 MONTHS, THE METABOLISM OF
HUMAN BODY CAN BE QUICKENED TO DECOMPOSE THE FAT, RESULTING IN LOSING WEIGHT.
343/757
245. HK1041769 - 02.07.2003
HEALTH CARE FOOD FOR MAINTAINING INTESTINAL HEALTH AND ASSISTING TO REDUCE
ABDOMEN FAT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=HK1041769
Inventor(s):
SHAOQIU YOU (HK)
Applicant(s):
SHAOQIU YOU (HK)
IP Class 4 Digits: A23L; A61P
IP Class:
A61P3/04; A23L1/307
Application Number:
CN20010144762 (20011221)
Priority Number: CN20010144762 (20011221)
Family: CN1426702
Abstract:
A HEALTH-CARE FOOD FOR TAKING CARE OF INTESTINAL TRACT HEALTH AND REDUCING THE
FAST OF ABDOMEN CONTAINS 13 RAW MATERIALS INCLUDING FLAX SEED, APPLE PECTIN,
OATS FIBRE, MINT, GARLIC CLOVE, ALOE, RHUBARB, ETC..
344/757
246. HK1041770 - 02.07.2003
HEALTH CARE FOOD CAPABLE OF ELIMINATING HONEYCOMB FAT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=HK1041770
Inventor(s):
SHAOQIU YOU (HK)
Applicant(s):
SHAOQIU YOU (HK)
IP Class 4 Digits: A61K; A61P
IP Class:
A61K35/78; A61P3/04
Application Number:
CN20010144765 (20011221)
Priority Number: CN20010144765 (20011221)
Family: CN1426806
Abstract:
A HEALTH-CARE FOOD FOR PREVENTING AND ELIMINATING HONEYCOMB FAT OR ORANGE
PEEL WRINKLES CONTAINS 12 RAW MATERIALS INCLUDING STIFFLEAF JUNIPER CONE,
GINKGO LEAF, GRAPE KERNEL ESSENCE, ETC.. AFTER IT IS TAKEN FOR 3 MONTHS WITH ONE
TABLET PER DAY, THE HONEYCOMB FAT OR ORANGE PEEL WRINKLES CAN BE ELIMINATED.
345/757
247. HK1041771 - 02.07.2003
HEALTH CARE FOOD FOR REDUCING BODY WEIGHT DUE TO EXCESS FAT IN MEAL
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=HK1041771
Inventor(s):
SHAOQIU YOU (HK)
Applicant(s):
SHAOQIU YOU (HK)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A61P3/04; A23L13/08
Application Number:
CN20010144763 (20011221)
Priority Number: CN20010144763 (20011221)
Family: CN1426804
Abstract:
A HEALTH-CARE FOOD FOR LOSING WEIGHT BY ABSORBING ITS EXCESSIVE FAT IS PREPARED
FROM 6 RAW MATERIALS INCLUDING GAMBOGE FRUIT, SHEABUTTER TREE ESSENCE,
ORANGE ESSENCE, ETC.. IT FEATURES THAT AFTER THEFOOD IS TAKEN, ITS EXCESSIVE FAT IS
ABSORBED BY HUMAN BODY, THE HUNGRY FEELING IS ELIMINATED, SO LOSING WEIGHT
AFTER IT IS EATEN FOR 3-5 WEEKS.
346/757
248. JP2002209979 - 12.11.2003
MEDICINE AND HOLDER FOR HEALTH SUPPLEMENT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=JP2002209979
Inventor(s):
ISO KATUO (JP)
Applicant(s):
ISO KATUO (JP)
IP Class 4 Digits: B65D; A61J
IP Class:
B65D77/22; B65D73/00; A61J1/14
E Class: A61J1/03; A61J7/04; B42D5/04C1
Application Number:
EP20020715718 (20020110)
Priority Number: WO2002JP00068 (20020110); JP20010005828 (20010115)
Family: JP2002209979
Equivalent:
JP3438039B2; US2004050747; WO02055404
347/757
Abstract:
A CALENDAR MOUNT 11 HAS NUMERALS INDICATED THEREON IN AN ORDER, THE NUMERALS
REPRESENTING DATES, AND PACKAGE BAGS 21 ARE RESPECTIVELY ATTACHED TO EACH OF
NUMERAL REPRESENTATION PARTS 12 OF THE MOUNT SO AS TO COVER THE NUMERAL, EACH
OF THE PACKAGE BAGS 21 CONTAINING MEDICINE OR DIETARY SUPPLEMENTS 31 THEREIN IN
A SEALED CONDITION. ON A SURFACE 23 OF EACH OF THE PACKAGE BAGS 21, A NUMERAL IS
REPRESENTED, WHICH IS IDENTICAL WITH THE NUMERAL (DATE) TO BE COVERED. FURTHER,
EACH OF CALENDAR CARDS 11A HAS A NUMERAL OF A DATE INDICATED THEREON, AND
PACKAGE BAGS 21 ARE ATTACHED TO NUMERAL REPRESENTATION PARTS 11A OF THE
RESPECTIVE CARDS 12A SO AS TO COVER THE NUMERALS. ON A SURFACE OF THE PACKAGE
BAG 21, A NUMERAL IS REPRESENTED, WHICH IS IDENTICAL WITH THE NUMERAL (DATE) TO
BE COVERED. FURTHERMORE, A PLURALITY OF PACKAGE BAGS 21 HAS NUMERALS OF DATES
REPRESENTED THEREON AND MEDICINE OR DIETARY SUPPLEMENTS ARE CONTAINED
THEREIN IN A SEALED CONDITION. A SUPPORT MEMBER 51 SUPPORTS THE PACKAGE BAGS 21
IN ORDER OF THE REPRESENTED DATES. THIS INVENTION IS HELPFUL IN PREVENTING
FAILURES OT INTAKE OR EXCESSIVE INTAKE OF MEDICINE OR DIETARY
SUPPLEMENTS.Description:
348/757
Technical Field
[0001] The present invention relates to a holder for medicine (drugs or quasi-drugs) or dietary
supplements (nutritive supplements).
Technical Background
[0002] In general, people take medicine (drugs or quasi-drugs) for recovery of health. Similarly,
medicine is given to sick pets such as sick cats or dogs.
[0003] In recent years, various dietary supplements or nutritive supplements are put on the market
since health has become a matter of people's concern. Dietary supplements (nutritive supplements)
tend to be taken by many people who desire health.
[0004] The medicine or dietary supplements are available in a variety of forms, such as tablets,
granules, powder, capsules or liquid, and an amount of those to be taken in many days arc
packaged in one packaging bag, box or bottle.
[0005] As the medicine is not to be taken all together at the same time, it is necessary to take the
medicine in accordance with dose and usage instructions indicated on the packaging bag, box or
bottle, periodically, e.g., every day. Further, the supplements tend to exhibit their effects slowly in
comparison with the medicine, it is necessary to continuously take the supplements in a long term of
time.
(The problem to be solved by the present invention)
[0006] In general, people tend to steadily take the medicine in accordance with the dose and
usage instructions at the beginning. However, as physical conditions become well, they often fail to
take the medicine or excessively take the medicine in a day in spite of having already taken the
predetermined amount of medicine
349/757
[0007] Especially, in cases of supplements, people are apt to fail appropriate intake of the
supplements from the beginning, because relatively many sorts and large amount of supplements
are usually taken and failure of taking the supplements does not significantly affect physical
conditions.
[0008] Further, old people, in general, often take medicine or the like, but they are relatively
forgetful, so that failure of intake or excessive intake of medicine and so forth often occurs.
[0009] It is an of the present invention to provide a holder for medicine or dietary supplements,
which can be used to prevent failure of intake or excessive intake of medicine or dietary supplements.
Disclosure of the Invention
[0010] According to the present invention, a calendar mount and packaging materials are provided.
The mount has numerals indicated thereon in an order, and the numerals represent dates in a
predetermined term of time. The packaging materials are respectively attached to each of numeral
representation parts of the mount so as to cover the numerals, each of the packaging materials
containing medicine or dietary supplements therein in a sealed condition. A numeral is indicated on
a surface of each of the packaging materials, and the numeral on the packaging material is identical
with the numeral of the mount covered by the packaging material.
[0011] It is important to know the date in a daily life. The date can be confirmed by the numerals on
the packaging materials, and after removal of the packaging materials, by the numerals on the
calendar mount.
[0012] Since the numeral identical with the numeral of the mount behind the packaging material is
indicated on the surface of each of the attached packaging materials, the user of the contents (or the
user giving the contents to a pet) has to feel a psychological resistance to ending the day if the
packaging material of the day is left on the mount. Therefore, the user has an incentive motivation for
intake of the contents, and it is possible to avoid forgetting daily intake or ingestion.
350/757
[0013] Further, removal of the packaging material from the mount makes it apparent that the intake
or ingestion of the day has been Finished, and therefore, an excessive or duplicate intake or
ingestion can be also prevented from occurring. Whenever the user watches the holder to confirm
the date, the user can also confirm properly administered intake or ingestion, in view of the removal
condition of the packaging materials, whereby the user is impressed with the attainment level and
encouraged to continue the administered intake of the medicine or the like.
[0014] In addition, since each of the packaging materials contains all of various kinds of medicine
or supplements to be taken in the day, it is unnecessary for the user to adjust the daily dose of
various kinds of medicine or the like every time and therefore, the user can continue the administered
intake or ingestion thereof for a long term without much effort.
[0015] Thus, this invention is helpful in prevention of missing or exceeding intake or ingestion of the
medicine or supplements.
[0016] From another aspect of the invention, a calendar mount has numerals thereon in an order,
the numerals representing dates in a predetermined term of time, and packaging materials are
respectively held by means of each of transparent pockets so as to cover the respective numerals on
numeral representation parts of the mount, each of the packaging materials containing medicine or
dietary supplements therein in a sealed state. A numeral is indicated on a surface of each of the
packaging materials, the numeral on the packaging material being identical with the numeral on the
mount covered by the packaging material.
[0017] As the pockets are transparent, the packaging materials contained in the pockets are
clearly visible from the outside, and after the packaging materials are removed from the pockets, the
numeral representation parts of the mount are clearly visible from the outside.
[0018] Since the numeral identical with the numeral of the mount behind the packaging material is
indicated on the surface of each of the packaging materials contained in the transparent pockets; the
user of the contents (or the user giving the contents to a pet) has to feel a psychological resistance to
ending the day while the packaging material of the day is left on the mount. Therefore, the user has
an incentive motivation for intake of the contents, and failure of daily intake or ingestion is avoidable.
[0019] Further, each of the packaging materials contains all of various kinds of medicine or
supplements to be taken in the day, and therefore, it is unnecessary for the user to adjust the daily
351/757
dose of various kinds of medicine or the like every time. Thus, the user can continue the administered
intake or ingestion thereof for a long term without much effort.
[0020] Furthermore, removal of the packaging material from the pocket makes it apparent that the
intake or ingestion of the day has been finished, and therefore, excessive intake or ingestion can be
also prevented from occurring. Therefore, this invention is helpful to prevention of failure or excess of
intake or ingestion of the medicine or supplements. In addition, as the holder is adapted to keep the
packaging materials in the transparent pockets, packaging materials can be used which are even
difficult to be attached to the mount because of heavy weights or specific configurations.
[0021] In accordance with the present invention, information relating to usage or intake of the
medicine or dietary supplements can be represented on the mount adjacently to the numeral of the
date.
[0022] According to such an arrangement, upon removal of the packaging material from the mount,
the information (encouraging words, indication of the remaining days before the end of intake ur
ingestion of the medicine or the like, physical checkup items, marks or characters, and so forth) in
relation to intake of the medicine and so forth can be seen, in addition to the revealed numeral of the
date behind the packaging material. This provides much pleasure in removal of the packaging
material from the mount and encouragement of periodical intake or ingestion. Therefore, in addition
to the effects or advantages to be obtained from the invention defined in claim 1 or 2, it is possible to
prevent failure of intake or ingestion of the medicine or supplements more surely.
[0023] In accordance with the present invention, the mount is adapted to be folded into two or
three, so that the packaging materials can be positioned inside of the folded mount.
[0024] When the mount is folded into two or three, the size of the holder become a half size or
trisected size, and therefore, the holder can be displayed in a shop or the like without occupying a
large space. Transportation and storage thereof also become easier. In addition, the packaging
materials are positioned inside of the mount folded into two or three, so that the mount acts as a
shock absorbing material. Therefore, the wrapping materials arc prevented from being damaged by
an external shock and the like.
[0025] According to the present invention, the mount can be formed so that a size of surface of the
folded mount is a convention standard size.
352/757
[0026] In a case where the mount folded into two or three has its surface size corresponding to a
conventional standard size, e.g., "A4" size of the Japanese Industrial Standard (JIS), the mount can
be placed for safekeeping together with the other articles, such as notes or books, having the same
size ("A4" size), without impression of irregularity.
[0027] From another aspect of the present invention, a plurality of calendar cards and a packaging
material attached to a numeral representation part of each of the cards are provided. Each of the
cards has a numeral of a date represented thereon, and the packaging material covers the numeral.
Each of the packaging materials contains medicine or dietary supplements therein in a sealed
condition. A numeral is indicated un a surface of each of the packaging materials, and the numeral
on the packaging material is identical with the numeral on the card covered by the packaging
material.
[0028] As the numeral identical with the numeral of the card behind the packaging material is
indicated on the surface of each of the packaging materials attached to the card, the user of the
contents (or the user giving the contents to a pet) feels a psychological resistance to finishing the
day if the packaging material of the day is left on the card. Therefore, the user has an incentive
motivation for intake or ingestion of the contents, and failure of daily intake or ingestion is avoidable.
[0029] Further, each of the packaging materials contains all of various kinds of medicine or
supplements to be taken in the day, and therefore, it is unnecessary for the user to prepare the daily
dose of various kinds of medicine or the like every time. Thus, the user can continue the administered
intake or ingestion thereof for a long term of time without much effort.
[0030] Furthermore, if the packaging material has been removed from the card, it is apparent that
the intake or ingestion of the day has been finished, and therefore, an excessive intake or ingestion
can be also prevented from occurring. Therefore, this invention is helpful to prevention of failure or
excess of intake or ingestion of the medicine or supplements.
[0031] In accordance with the present invention, information relating to usage or intake of the
medicine or dietary supplements can be represented on the card adjacently to the numeral of the
date.
353/757
[0032] According to such an arrangement, when removing the packaging material from the card,
the information (encouraging words, indication of the remaining days before the end of intake or
ingestion, physical checkup items, marks or characters, and so forth) in relation to intake or ingestion
of the medicine or the like can be seen, in addition to the numeral of the date revealed behind the
packaging material. This provides much pleasure in removal of the packaging material from the card
and encouragement of periodical intake or ingestion. Therefore, this is helpful in surely preventing
failure of intake or ingestion of the medicine or supplements.
[0033] From another aspect of the present invention, a plurality of packaging materials and a
support member are provided. Each of the packaging materials has a numeral of a date represented
thereon and contains medicine or dietary supplements therein in a sealed condition. The support
member carries the packaging materials in order of the represented dates.
[0034] As the numeral representing the date is indicated on the surface of each of the packaging
materials supported by the supporting member, the user of the contents (or the user giving the
contents to a pet) has to feel a psychological resistance to ending the day if the packaging material
of the day is left on the card. Therefore, the user has an incentive motivation for intake of the contents,
and failure of daily intake or ingestion is avoidable.
[0035] Further, each of the packaging materials contains all of various kinds of medicine or
supplements to be taken in the day, and therefore, it is unnecessary for the user to prepare the daily
dose of various kinds of medicine or the like every day. Thus, the user can continue the administered
intake or ingestion thereof for a long term without much effort.
[0036] Furthermore, removal of the packaging material from the supporting member makes it
apparent that the intake or ingestion of the day has been finished, and therefore, an excessive intake
or ingestion can be also prevented from occurring. Therefore, this invention is helpful to prevention of
failure or excess of intake or ingestion of the medicine or supplements. In addition, since the
packaging materials also have the function of the aforementioned calendar cards, the holder can be
manufactured simply and economically.
Brief Description of the Drawings
354/757
FIG 1 is an illustration showing a first embodiment of the present invention;
FIG 2 is a vertical cross-sectional view showing a package bag in the present invention;
FIG 3 is an illustration showing numeral representation part of a calendar mount in the present
invention;
FIG 4 is an illustration showing a condition in that marks are added to the numeral representation
parts of the mount in the present invention;
FIG 5 is an illustration showing a condition in that remaining days are indicated on the numeral
representation parts of the mount in the present invention;
FIG 6 is an illustration showing an alternative of the packaging material in the present invention;
FIG 7 is an illustration showing an indication which represents days of week in the present invention;
FIG. 8 is an illustration showing a transparent pocket in the present invention;
FIG. 9 is an illustration showing a second embodiment of the present invention;
FIG 10 is an illustration showing a condition before assembly in the present invention;
FIG. 11 is an illustration showing a relation among a calendar card, a package bag and a base
plate in the present invention;
FIG 12 is an illustration showing a condition in that a numeral is represented on a surface of the
package bag in which the numeral is identical with a date (numeral) of the calendar card behind the
bag in the present invention;
FiG 13 is an illustration showing the package bag substituted for the calendar card in the present
invention;
FIG. 14 is an illustration showing a condition in that three package bags are attached in the present
invention;
FIG. 15 is an illustration showing the calendar mount which is adapted to be folded into two in the
present invention;
FIG. 16 is an illustration showing a condition in that the two calendar mounts, each folded into two,
are wrapped by a wrapping paper in the present invention;
FIG 17 is an illustration showing a condition in that the calendar mounts, each folded into two, are
regularly arranged without a space being formed between the mounts in the present invention; and
FIG 18 is an illustration showing the calendar mount which is adapted to be folded into three.
Best Mode for Carrying out the Invention
355/757
[0038] The present invention is described in detail with reference to the attached drawings
hereinafter.
(First Embodiment)
[0039] The holder for medicine or dietary supplements according to the present invention is
constituted as a full presentation style. As shown in FIGS. 1A and 1B, the holder comprises a
calendar mount 11 on which numerals representing dates within a predetermined term are indicated
in order, and packaging materials 21 respectively attached to each of numeral representation parts
12 of the mount 11 so as to cover the numerals respectively, each of the packaging materials 21
containing therein dietary supplements (nutritive supplements) 31 in a sealed condition, wherein
each of the packaging materials 21 is provided with a numeral on its surface, which is identical with
the numeral of the mount 11 representing the date behind the packaging material 21.
[0040] In this embodiment, the mount 11 is made of a thick cardboard of paper, and the numerals,
which represent dates in one month, e.g., 1 SIMILAR 31, are indicated on a surface 13 of the
cardboard in order. For instance, numeral "3" represents the third day in the month, or the third of the
month. In FIG 1, the numerals representing the dates start from "1" , but they may start from an
intermediate date, e.g., "15" representing the fifteenth day of the month.
[0041] Each of the packaging materials encloses the dietary supplements (nutritive supplements)
31 in a sealed condition and the packaging material is attached so as to cover the numeral
representation part 12 of the mount 11. In this embodiment, a bag (package bag 21) for containing
various kinds of dietary supplements 31 in a sealed condition is used as the packaging material, as
illustrated in FIG. 2. For instance, the package bag 21 having numeral "3" indicated thereon is
detachably adhered to a portion of the mount 11 having numeral "3" indicated thereon, with use of an
adhesive.
[0042] The adhesive is used, which loses its adhesive strength once having heen peeled off,
whereby the package bag 21 once detached from the mount 11 cannot be put back to the previous
position on the mount 11. This also gives a strong incentive to ingest the supplements 31.
356/757
[0043] Alternatively, the package bag 21 may be attached to the mount 11 with use of an adhesive
double-coated tape, a plastic magnet or the like. In this embodiment, the dietary supplements 31
may be various kinds of diet foods.
[0044] As shown in FIGS. 7A and 7B, days of week may be represented on the mount 11. The
holder shown in FIGS. 7A and 7B is adapted to change of the day-of-week indication. A day-of-week
indicator 41 is provided in a form of an endless loop structure which can circle, extending through
slits 15, 16 formed at an upper part of the mount 11. The respective days of a week, i.e., Mon
(Monday) through Sun (Sunday), are represented on an outer surface of the indicator 41, spaced
predetermined intervals. Therefore, circulation of the indicator 41 allows its seven days indication to
easily change.
[0045] As set forth above, the holder for medicine or dietary supplements has the package bags
21 attached to the mount 11, and the numeral represented on a surface 23 of each of the bags 21 is
identical with the numeral representing the date on the mount 11 behind the bag 21. Therefore, if a
user of the contents (or a user giving the contents to a pet) leaves the bag 21 of the day on the
mount 11, the user has to feel a psychological resistance to ending the day. This gives the user a
strong motivation for intake of the contents in the bag 21 by removing the bag 21 from the mount 11,
and the user can avoid forgetting the daily intake of dietary supplements.
[0046] Since the bag 21 contains all of the dietary supplements to be ingested in the day, it is
unnecessary for the user to prepare the daily dose every day and therefore, the user can continue to
ingest the various kinds of supplements 31 for a long period without much effort.
[0047] Further, removal of the bag 21 from the mount 11 shows the result of an intake of the
supplements for the day, and therefore, an excessive intake of the supplements is avoidable. Thus,
this invention is helpful to prevent the intake of the supplements 31 from being failed or exceeded.
[0048] In the first embodiment as set forth above, the package bag 21 is attached to the mount 11.
However, the bag 21 may be held on each of the respective numeral representation parts 12 of the
mount 11 by means of a transparent pocket 81 as shown in FIGS. 8A and 8B. The pocket 81 has an
upper opening 82 through which the bag 21 is inserted to be held therein. The pocket 81 is required
to be transparent, regardless of whether it is uncolored or colored.
357/757
[0049] The holder as shown in FIGS. 8A and 8B comprises the package bags 21 respectively held
by each of the transparent pockets 81 in such a manner that the numerals of the respective numeral
representation parts 12 of the mount 11 are covered with the respective bags 21, and the bag 21 has
supplements 31 contained therein in a sealed condition, wherein the numeral represented on the
surface 23 of each of the bags 21 is identical with the numeral of the date on the mount 11 covered
by the bag 21.
[0050] According to this arrangement of the holder, since the pocket 81 is transparent, the bag 21
in the pocket 81 can be clearly viewed from the outside and the numeral representation part 12 of the
mount 11 can be clearly seen from the outside when the bag 21 is removed from the pocket 81.
[0051] The numeral represented on the surface 23 of the bags 21 in the pocket 81 is identical with
the date (numeral) represented on the mount 11, e.g., "7". A user of the contents has to feel a
psychological resistance to finishing the day, i.e., 7 day of the month, if the user leaves the bag 21 of
the day on the mount 11. A strong motivation for intake of the contents in the bag 21 by removing the
bag 21 from the pocket 81 is given to the user, and it is possible to prevent the user from missing
daily intake of dietary supplements 31.
[0052] Further, since the bag 21 contains all of the dietary supplements to be ingested in the day, it
is unnecessary for the user to adjust the daily dose every day and therefore, the user can continue to
ingest the various kinds of supplements 31 for a long period without much effort.
[0053] Furthermore, if the bag 21 is removed from the mount 11, result of intake of the day is
apparent. Therefore, an excessive intake of the supplements is avoidable. Thus, this invention is
helpful in prevention from missing or exceeding a suitable intake of the supplements 31. In addition,
owing to the arrangement that the package bags 21 are contained in the transparent pockets 81
respectively, it is possible to use package bags which arc difficult to be adhered to the mount 11 for
the reasons of their weights, configurations and so forth.
[0054] Adjacently to the numeral of the date on the mount 11, any information may be indicated in
relation to ingestion of the supplements 31. As the information, representation of advice or
encouraging words as shown in FIG. 3, marks as illustrated in FIGS. 4 and 8A (smile marks or the
like), presentations indicating the remaining days before the expiration of the intake term as shown in
FIG. 5, or physical checkup items (not shown) are exemplified.
358/757
[0055] According to such an arrangement, the user can see, upon removal of the package bag 21
from the mount 11, the information (encouraging words or the like) relating to ingestion of the
supplements 31 in addition to the numeral of the date on the mount 11. This results in much pleasure
in removing the bag 21 from mount 11 and encouragement of periodical ingestion. Therefore, this
arrangement is helpful to surely prevent the user from missing or exceeding necessary intake of the
supplements 31.
[0056] The mount 11 can be constituted to be folded into two in such a manner that the package
bags 21 is positioned inside of the folded mount, as shown in FIGS. 15A, 15B and 15C. The mount
11 is provided with two straight folding lines 101, 101 made thereon, which are positioned in a center
zone as seen in longitudinal direction of the mount 11 (as seen in a vertical direction of FIGS. 15A
and 15B) and which are spaced apart a predetermined distance L2. The distance L2 is set to be
20mm in this embodiment. The mount 11 is folded into two by inwardly bending the folding lines 101,
101 at a right angle (90 DEG ).
[0057] Especially, the mount 11 folded into two in this embodiment is adapted, in its surface size,
for a conventional standard size, e.g., "A4" size of the Japanese Industrial Standard (JIS). More
specifically, the length L0 of the mount 11 in FIGS 15A is set to be 2xL1+L2=2x210 mm+
20mm=440mm, and the width L5 is set to be 297mm.
[0058] Spacers 105 as illustrated in FIGS. 15A, 15B and 15C function to ensure the space between
the opposite faces of the folded mount 11, so as to reliably prevent the package bags 21 on the
opposing faces of the folded mount 11 from being damaged.
[0059] As shown in FIG. 15C by solid lines, the overall size of the mount 11 is reduced to a half by
folding the mount 11, and therefore, the space occupied by the mount 11 is reduced in its
dimensions. As illustrated in FIGS. 17, a plurality of mounts 11 can be placed side by side without
spaces therebetween, whereby the mounts 11 can be displayed in a shop without occupying a large
space.
[0060] Form another aspect, such a structure of the mount 11 allows transportation and storage
thereof to be easier. Especially, a plurality of mounts 11 can be surely enveloped by a wrapping
paper 107 since each of the mounts 11 has a regulated size, and the wrapping paper 107 is
prevented from being damaged owing to deformation of the mounts 11 during transportation.
359/757
[0061] Further, the package bags 21 are positioned in the inner area of the folded mount 11 during
transportation and storage, and the mount 11 act as a shock absorbing material for the bags 21.
Therefore, it is possible to surely protect the bags 21 against damage resulting from an external
shock and the like.
[0062] The mount 11 may be formed to be folded into three layers so as to enclose the package
bags 21 inside thereof, as illustrated in FIGS. 18A and 18B. With this arrangement, it is possible to
obtain substantially the same advantages or effects as those in the aforementioned folio arrangement.
[0063] In addition, the mount 11, which is folded into two so as to have the size of its surface
corresponding to a conventional standard size ("A4" size in this case), can be placed for safekeeping
together with the other articles having the same size (''A4" size), such as notes or books, without
impression of irregularity.
[0064] Further, this invention is not limited to presentation of numerals corresponding to the days of
one month. For example, numerals corresponding to the days of two weeks or numerals
corresponding to every two days may be represented on the mount 11.
[0065] Furthermore, the package bag may be formed by a portion-type container 21A as shown in
FIG 6. In FIG. 6, a bottom of the portion-type container 21A is adhered to each of the numeral
representation part 12 of the mount 11 by an adhesive or the like, and an upper surface 23A has the
numeral represented, which is identical with the numeral (date) covered by the portion-type container
21A.
[0066] In the present embodiment, the mount 11 is made of a thick cardboard or paperboard, but it
may be made of a waste pulp material (a recycled paper), a waste plastic, or the like.
[0067] Further, the mount 11 may be provided with a hole 72 for a drawing pin at an upper center
part of the mount 11, or magnets 71 attachable to a door of refrigerator or the like at upper side
edges of the back of the mount 11, as shown by tow-dot chain lines.
[0068] Furthermore, the surface size of the folded mount 11 is not limited to A4 size as in this
embodiment, but may he the letter size (216mm x 280mm), B4 size (257mm x 364mm) and so forth.
360/757
(Second Embodiment)
[0069] The second embodiment is shown in FIGS. 9 through 13, wherein FIG. 9 shows a front
elevation in an assembled condition, FIG. 10 shows a condition before assembly, FIG. 11 is an
explanatory view showing relation among a calendar card, a package bag and a base plate, FIG. 12
is an illustration showing a condition of a numeral (date) of the card and the package bag which
covers the numeral and which has the same numeral thereon, and FIG. 13 is an explanatory view of
the package bag substitutable for the calendar card.
[0070] The holder for medicine or dictary supplements in the second embodiment is constituted as
being a daily flip-page style. As shown in FIGS. 9 and 12, a plurality of calendar cards 11A with
numerals indicating dates, and package bags 21, each attached to the card 11A to cover the
numeral on a numeral representation part 12A of the card 11A. The numeral on a surface of each of
the bags 21 corresponds to the numeral on the card 11A behind the bag 21.
[0071] More specifically, the cards 11A are made of thick cards of paper, which can be turned
over one after another by support members.
[0072] In this embodiment, the support members comprises a pair of supporting rods 51 arranged
in parallel, as shown in FIGS. 9 and 11, which arc fixed to base plates 55, 56 at the ends 52, 53 of
the rods, respectively. The rod 51 can be bent at its center part to be in a form of character "U", and
the cards 11A with the bags 21 are engaged with the rod 51 to be movable along the rod 51. The
base plates 55, 56 are formed with a projection 57 and a recess 58 engageable with each other at
their joint faces.
[0073] Therefore, the cards are turned over one after another as shown by two-dot chain lines in
FIG. 9, wherein the rods 51 as shown in FIG. 10 have been bent at their center parts in a form of
character "U" and wherein the projection 57 and the recess 58 of the base plates 55, 56 have been
engaged with each other.
[0074] The cards 11A are provided with the numerals corresponding to the dates of one month,
e.g., 1 through 31. For instance, the seventh card 11A has numeral "7" represented, which means 7th
day of the month, as shown in FIG 12. In this embodiment, columns of check items of the day are
additionally provided on the card adjacently to numeral "7", as illustrated in FIG. 12. Holes 51h
361/757
depicted in FIG 12 are formed as the card 11A so that the card 11A can be movably carried on the
rods 51.
[0075] In relation to ingestion of the supplements 31, any information may be indicated, such as
physical check items as shown in FIG 12, words or advice for encouraging the user or the like, marks
(smile marks) or the like, and presentations indicating the remaining days before the expiration of the
ingestion term.
[0076] According to such an arrangement, the user can see, upon removal of the package bag 21
from the card 11A, the information (encouraging word and so forth) in relation to ingestion of the
supplements 31, in addition to the numeral of the date on the card 11A behind the bag 21. This leads
to much pleasure in removal of the bag 21 from the card 11A and encouragement of periodical
ingestion. Therefore, this arrangement is helpful to surely prevent the user from missing or exceeding
an administered intake of the supplements 31.
[0077] Each of the packaging materials sealingly containing the supplements 31 is attached to the
numeral representation part 12A of the card 11A so as to cover the numeral. For instance, the
package bag 21 with numeral "7" on its surface is removably attached to the card 11A with numeral
"7", by means of an adhesive. In this embodiment, the supplements 32 are various lands of diet foods.
[0078] In the holder for medicine or dietary supplements as set forth above, since the numeral of
the day is represented on the surface 23 of each of the bags 21 attached to each of the cards 11A,
the user of the contents has to feel a psychological resistance to finishing the day if the user leaves
the bag 21 of the day on the card 11. Therefore, owing to an incentive motivation for intake of the
supplements 31, failure of daily ingestion of the supplements 31 can be prevented.
[0079] Further, since the bag 21 contains all of the dietary supplements 31 to be ingested in the
day, it is unnecessary for the user to adjust the daily dose every day and therefore, the user can
continue to ingest the various kinds of supplements 31 for a long period without much effort.
[0080] Furthermore, if the bag 21 is removed from the card 11A, result of intake of the day is
apparent. Therefore, an excessive intake of the supplements is avoidable and this is helpful to
prevention of failure of ingestion or excessive ingestion of the supplements 31.
362/757
[0081] In the second embodiment as set forth above, the bags 21 are attached to the numeral
representation part 12A of the card 11A, but the holder may be constituted by the bags 21 and the
supporting members (a pair of supporting rods 51) without use of the cards 11A, as shown in FIG. 13.
[0082] That is, the holder for medicine or dietary supplements as shown in FIG. 13 comprises a
plurality of packaging materials (at least thirty package bags 21), each having a numeral of date
(e.g., "7") represented on the surface 23 and containing medicine or dietary supplements therein in a
sealed condition, and the supporting member (a pair of supporting rods 51) for carrying the
packaging materials 21 in an order of days. In FIG. 13, the holes 51h are opened so as to make the
bags 21 carried movably.
[0083] Since the numeral of the day is represented on the surface 23 of each of the bags 21
supported by the rods 51, the user of the contents has to feel a psychological resistance to finishing
the day if the user leaves the bag 21 of the day on the rods 51, and therefore, owing to an incentive
motivation for ingesting medicine or supplements by removing the bag 21 from the rods 51, failure of
daily ingesting the supplements 31 is prevented.
[0084] If the bag 21 is removed from the rods 51, result of intake of the day is apparent, and
therefore, an excessive intake of the medicine or supplements is avoidable. Thus, the
aforementioned arrangement is helpful to prevention of failure of ingestion and excessive ingestion of
the medicine or supplements.
[0085] In the first and second embodiments as set forth above, dietary supplements are contained
in the package bag 21 (portion-type container 21A), but medicine (drugs or quasi-drug) may be
contained therein. Further, it is possible to contain in the bag 21 (portion-type container 21A),
periodically used cosmetics.
[0086] Further, a plurality of package bags 21 may be attached to the numeral representation part
of the mount 11 (or the card 11A). For example, if the user is to ingest the contents three times in a
day, three bags 21 are attached to the same position on the mount 11 (card 11A) as illustrated in FIG.
14. In this case, marks indicating the first (morning), second (noon) and third (night) may be added
to the respective surfaces 23 of the bag 21.
(The effects or advantages to be obtained from the invention)
363/757
[0087] According to the present invention defined in claim 1, there are provided a calendar mount
having numerals thereon in an order, the numerals representing dates in a predetermined term of
time, and packaging materials respectively attached to each of numeral representation parts of the
mount so as to cover the respective numerals, each of the packaging materials containing medicine
or dietary supplements therein in a sealed condition, wherein a numeral is indicated on a surface of
each of the packaging materials, the numeral on the packaging material being identical with said
numeral on said mount covered by the packaging matcrial. The user of the contents (or the user
giving the contents to a pet) has an incentive motivation to peel the packaging material off from the
mount for intake of the contents, and failure of daily intake or ingestion of the medicine or
supplements is avoidable. Since each of the packaging materials contains all of various kinds of
medicine or supplements to be taken in the day, it is unnecessary for the user to prepare the daily
dose of various kinds of medicine or the like every day and therefore, the user can continue the
administered intake ur ingestion thereof for a long term without much effort. Further, removal of the
packaging material from the mount makes it apparent that the intake or ingestion of the day has been
finished, and therefore, an excessive intake or ingestion can be also prevented from occurring.
[0088] According to the present invention defined in claim 2, a calendar mount has numerals
thereon in an order, the numerals representing dates in a predetermined term of time, and packaging
materials are respectively held by means of each of transparent pockets so as to cover the
respective numerals, each of the packaging materials containing medicine or dietary supplements
therein in a sealed condition, wherein a numeral is indicated on a surface of each of the packaging
materials, the numeral on the packaging material being identical with the numeral on the mount
covered by the packaging material. The user of the contents (or the user giving the contents to a pet)
has an incentive motivation to peel the packaging material off from the mount for intake of the
contents, and failure of daily intake or ingestion of the medicine or supplements is avoidable. Since
each of the packaging materials contains all of various kinds of medicine or supplements to be taken
in the day, it is unnecessary for the user to prepare the daily dose of various kinds of medicine or the
like every day and therefore, the user can continue the administered intake or ingestion thereof for a
long term without much effort. Further, removal of the packaging material from the mount makes it
apparent that the intake or ingestion of the day has been finished, and therefore, an excessive intake
or ingestion can be also prevented from occurring. In addition, since the holder is adapted to keep
the packaging materials in the transparent pockets, packaging materials can be used which are
even difficult to be attached to the mount because of their heavy weights or specific configurations.
364/757
[0089] According to the present invention defined in claim 3, information relating to intake or
ingestion of the medicine or dietary supplements is represented on the mount adjacently to the
numeral representing the date. This provides much pleasure in removal of the packaging material
from the mount and encouragement of periodical intake or ingestion. Therefore, in addition to the
effects or advantages to be obtained from the invention defined in claim 1 or 2, failure of intake or
ingestion of the medicine or supplements is advantageously avoidable more surely.
[0090] According to the present invention defined in claim 4, the mount is adapted to be folded into
two or three, whereby the holder can be advantageously displayed in a shop or the like without
occupying a large space, in addition to the effects or advantages to be obtained from the invention
defined in claim 1, 2 or 3. Further, the holders can be easily transported and stored, and can be
prevented from being damaged by an external shock and the like.
[0091] According to the present invention defined in claim 5, the mount is formed so that a size of
surface of the folded mount is a conventional standard size. In addition to the effects or advantages
to be obtained from the invention defined in claim 1, 2, 3 or 4, the mount, which is folded into two or
three to be a conventional standard size in its surface dimensions, e.g., "A4" size (210mm x 297mm)
of the Japanese Industrial Standard (JIS), can be advantageously placed for safekeeping together
with the other articles, such as notes or books, having the same size ("A4" size), without impression of
irregularity.
[0092] According to the present invention defined in claim 6, each of calendar cards has a numeral
of a date represented thereon, and a packaging material is attached to a numeral representation part
of each of the cards so as to cover the numeral, each of the packaging materials containing
medicine or dietary supplements therein in a sealed condition, wherein a surface of each of the
packaging materials has a numeral indicated thereon which is identical with the numeral of the date
on the card behind the packaging material. The user has an incentive motivation for intake or
ingestion of the contents by peeling the packaging material from the card, and therefore, failure of
daily intake or ingestion is avoidable. Further. each of the packaging materials contains all of various
kinds of medicine or supplements to be taken in the day, and therefore, it is unnecessary for the user
to prepare the daily dose of various kinds of medicine or the like every day. Thus, the user can
continue the administered intake or ingestion thereof for a long term without much effort. Furthermore,
removal of the packaging material from the card makes it apparent that intake or ingestion of the day
has been finished, and therefore, an excessive intake or ingestion can be also prevented from
occurring.
365/757
[0093] According to the present invention defined in claim 7, information relating to usage or intake
of the medicine or dietary supplements is represented on the card adjacently to the numeral
representing the date. This provides much pleasure in removal of the packaging material from the
card and encouragement of periodical intake or ingestion. Therefore, it is helpful in surely preventing
failure or excess of intake or ingestion of the medicine or supplements.
[0094] According to the present invention defined in claim 8, a plurality of packaging materials and
a support member are provided. Each of the packaging materials has a numeral of a date
represented thereon and contains medicine or dietary supplements therein in a sealed condition. The
support member supports the packaging materials in order of the represented dates. The user of the
contents (or the user giving the contents to a pet) has an incentive motivation for intake of the
contents, and failure of daily intake or ingestion is avoidable. Each of the packaging materials
contains all of various kinds of medicine or supplements to be taken in the day, and therefore, it is
unnecessary for the user to prepare the daily dose of various kinds of medicine or the like every day.
Thus, the user can continue the administered intake or ingestion thereof for a long term without much
effort. Further, removal of the packaging material from the supporting member makes it apparent that
the intake or ingestion of the day has been finished, and therefore, an excessive intake or ingestion
can be also prevented from occurring. In addition, since the packaging materials substitute for the
aforementioned calendar cards, the holder can be manufactured simply and economically.
Industrial Applicability
[0095] As described above, the present invention can provide a useful holder for medicine (drug or
quasi-drug) or dietary supplements.Claims:
1. A holder for medicine or dietary supplements comprising a calendar mount having numerals
thereon in an order, the numerals representing dates in a predetermined term of time, and packaging
materials respectively attached to each of numeral representation parts of the mount so as to cover
the respective numerals, each of the packaging materials containing medicine or dietary
supplements therein in a sealed condition,
366/757
wherein a numeral is indicated on a surface of each of the packaging materials, the numeral on
the packaging material being identical with said numeral of said mount to be covered by the
packaging material.
2. A holder for medicine or dietary supplements comprising a calendar mount having numerals
thereon in an order, the numerals representing dates in a predetermined term of time, and packaging
materials respectively held by means of respective transparent pockets so as to cover the respective
numerals, each of the packaging materials containing medicine or dietary supplements therein in a
sealed condition,
wherein a numeral is indicated on a surface of each of the packaging materials, the numeral on
the packaging material being identical with said numeral of said mount to be covered by the
packaging material.
3. A holder as defined in claim 1 or 2, wherein information relating to intake or ingestion of the
medicine or dietary supplements is represented on said mount adjacently to said numeral
representing the date.
4. A holder as defined in one of claims 1 to 3, wherein said mount is adapted to be folded into two or
three, so that the packaging materials are positioned inside of the folded mount.
5. A holder as defined in claim 4, wherein said mount is formed so that a size of surface of the folded
mount corresponds to a conventional standard size.
6. A holder for medicine or dietary supplements comprising a plurality of calendar cards, each
having a numeral of a date represented thereon, and packaging materials respectively attached to a
numeral representation part of each of the cards so as to cover the numeral, each of the packaging
materials containing medicine, or dietary supplements therein in a sealed condition,
wherein a numeral is indicated on a surface of each of the packaging materials, the numeral on
the packaging material being identical with said numeral on said card to be covered by the
packaging material.
7. A holder as defined in claim 6, wherein information relating to intake or ingestion of the medicine or
dietary supplements is represented on said card adjacently to said numeral representing the date.
367/757
8. A holder for medicine or dietary supplements comprising a plurality of packaging materials, each
having a numeral representing a date indicated thereon and containing medicine or dietary
supplements therein in a sealed condition, and a support member supporting said packaging
materials in order of the represented dates.
368/757
249. JP2003245054 - 05.02.2003
HEALTH FOOD PRODUCTS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=JP2003245054
Inventor(s):
OCHIAI AKIO (JP); KOSUGE MASAKI (JP); DAICHO TAKAO (JP)
Applicant(s):
DAICHO KIKAKU INC COMPANY (JP)
IP Class 4 Digits: A23L
IP Class:
A23L1/30
E Class: A23L1/30B; A23L1/302; A23L1/29F; A23L1/305A; A23L2/52
Application Number:
EP20020254887 (20020711)
Priority Number: JP20010230909 (20010731); JP20010384860 (20011218); JP20020042639
(20020220)
Family: JP2003245054
Equivalent:
CA2396049; CN1406516; US2003157199
Cited Document(s):
EP1198994; US6264995; US5904924; WO0059523; US5567424;
WO02062367; GB976096; JP5058898; JP5009119; CN1094592; KR9504648; KR2001100043
Abstract:
AN OBJECT OF THE PRESENT INVENTION IS TO PROVIDE A VERY EFFECTIVE HEALTH FOOD
FOR SUPPLYING A PUNGENT SUBSTANCE, A BITTER SUBSTANCE OR A SOUR SUBSTANCE, IN
PARTICULAR A PUNGENT SUBSTANCE, THEREBY REFRESHING A BODY OR FEELING,
PREVENTING FORGETTING, AND INTENSIFYING WEAKENED MUSCLES WHEREBY THE HEALTH
FOOD IS USEFUL IN TREATING RHEUMATISM, ETC. THE PRESENT INVENTION RELATES TO A
HEALTH FOOD PRODUCT COMPRISING A PUNGENT, BITTER AND/OR SOUR SUBSTANCE,
369/757
ESPECIALLY TO A HEALTH FOOD PRODUCT COMPRISING AT LEAST AN EFFECTIVE AMOUNT OF
PUNGENT SUBSTANCES.Description:
TECHNICAL FIELD
[0001] The present invention relates to novel health food products. The present invention relates to
novel nutritional food products useful for providing effective elements to a health conscious
population.
BACKGROUND OF THE INVENTION
[0002] Serotonin and noradrenaline referred to as brain hormones control satisfaction of the will,
and in turn, spiritual satisfaction. In response to satisfaction of the will, voluntary muscles are
activated by adrenaline, an adrenal medullary hormone, secreted from adrenal medulla and
chromaffin cells on nerve muscles.
[0003] Serotonin, noradrenaline and adrenaline are also referred to as biogenic monoamines, and
are oxidatively decomposed by an enzyme called monoamine oxidase within as long as 3 hours or
reabsorbed into nerve tissues and so forth, resulting in the extinction of most effects of secreted
monoamines.
[0004] This is an ingenious body mechanism that prevents fatigue produced by the long time
action of monoamines.
[0005] The onset of depressive syndrome (depression) is caused by retention of a depressive
condition when deprived of satisfaction of will and spirit due to a decrease in the secretory capability
of biogenic monoamines, whereby the spirit is, on occasion, extremely lowered leading to strong
suicidal tendencies.
370/757
[0006] Until now, for treatment of depression, passive nosotropic therapy has been carried out in
which either healthy foods which inhibit an action of monoamine oxidase or healthy foods which
prevent reabsorption of such monoamines are administered so that the concentration of, as a result
of decrease in the secretory capability, reduced monoamines would be maintained and an extreme
decrease in spirit would be prevented.
[0007] However, this therapy is not a fundamental therapy the aim of which is to eliminate the
cause of depression, that is, to cure the decreased secretory ability of biogenic monoamines. Thus, it
is a therapy in expectation of only naturally recovering the secretion capacity of monoamines over a
long period of therapy.
[0008] Natural recovery is still a therapy with drawbacks, i.e., not only the secretory ability of
monoamines is further decreased due to the continued presence of monoamines, but also physical
strength is readily lowered due to fatigue caused by adrenaline-mediated excess burning of sugars
and lipids.
[0009] Furthermore, "KI" (in Japanese; vital energy) refers to all the functions of the human body.
Such body's functions are generically classified into 2 types.
One function is controlled by autonomic nerves, which are found in various organs, hormone
secretions and blood vessels. The other one works for voluntary muscles which act according to
commands released from brain thought functions and thought patterns.
[0010] It has previously been pointed out that "KI", as represented by "HOKI" (in Japanese;
complementing energy) and "RIKI" (in Japanese; circulating energy) in Chinese medicine, indicates
only the former functions controlled by autonomic nerves. The commands for "which functions will be
activated" and "how they will be exerted" are released from the medulla oblongata located at the
lower part of the brain. Considering that "HOKI-YAKU" (in Japanese; drug for complementing "KI")
activates all functions controlled by autonomic nerves, instead of only activating certain organs and
tissues, it is likely that the target point on which the "HOKI-YAKU" acts may be medulla oblongata (a
source of commands) rather than each organ or tissue. That is, it is concluded that the actions of
"HOKI-YAKU" are for enhancing and facilitating the emission and transmission of commands from the
medulla oblongata.
[0011] I have found that the "HOKI-YAKU" localizes body blood to various organs. This might be
aimed at achieving such a blood localization via, as a result of the blood vessel-dilating and
371/757
constricting action (one of the important actions of medulla oblongata), not only dilating blood
vessels directed to the autonomic nervous control system but also constricting blood vessels
directed to the brain and brain-controlled organs whereby more nutrient elements will be delivered to
required parts as a secondary action of the "HOKI-YAKU".
[0012] In former times, depression was a rare disease. However, the onset rate of depression has
recently increased worldwide, and it is said that one in 150 individuals is a depressive patient in the
Tokyo Metropolitan Area.
[0013] Recently, an interesting opinion has been published concerning the causes for increases in
the occurrence of depressive symptoms. Such a theory is as follows:
That is, there has been no war crisis worldwide except in some troubled regions. In addition, social
order has been well maintained resulting in reducing opportunities for encountering contingent
accidents.
Thus, there has been almost no need for the human body to gird itself and enhance the spirit for
such dangers.
Therefore, the need for secretion of biogenic amines has also remarkably decreased, whereby the
secretory capability has degenerated with the result that persons would be apt to develop
depression.
[0014] If this theory is correct, when secretion of biogenic monoamines is artificially stimulated, for
example using a secretomotory means once a day, the onset of depression may be prevented, the
capability of secreting biogenic monoamines may be recovered even in patients whose secretion
capability of biogenic monoamines is lowered, and the patient may recover from depression.
[0015] Proctoptosia, and pains in legs, lumbar regions and arms have occurred with aging. These
have been considered to be due only to hematogenous disorders at the respective local sites or
resultant inflammation. However, regular dosing of drug products alone which are assumed to be
sufficiently capable of eliminating hematogenous disorders has been insufficient in ameliorating such
conditions.
372/757
[0016] These disorders are attributed to insufficient communication of the brain commands to the
local sites. Hematogenous disorders and the occurrence of inflammation are problems caused by
abnormal motions of muscles due to the incomplete communication of brain commands.
SUMMARY OF THE INVENTION
[0017] Although all muscle disorders are not ascribed to insufficient brain communication, it seems
that the majority of such disorders are elicited by insufficient communication of brain commands. In
particular, it has been found that muscle disorders such as backaches and pains in limbs
attributable to aging are easily eliminated by curcumin and others which ameliorate the
communication of brain commands.
[0018] The present inventor has succeeded in developing pharmaceutical drugs based upon such
a new theory. Thus, the present invention is to provide very effective pharmaceutical drugs each
exhibiting a muscle-intensifying activity and/or an anti-inflammatory activity.
[0019] The present inventor has succeeded in developing health foods based upon such a new
theory. Thus, the present invention is to provide health foods which are very effective for persons who
are not feeling well because of depression.
[0020] The present invention relates to health food products each comprising at least one or more
members selected from the group consisting of pungent substances, bitter substances and sour
substances (or acid substances), in particular to health food products each comprising at least one
or more members selected from the group consisting of pungent, bitter and/or sour principles in
foods.
DETAILED DESCRIPTION OF THE INVENTION
[0021] A most preferable health food product comprises at least a pungent substance therein.
[0022] The pungent substance as used herein includes preferably curcumin
373/757
(isolated from Curcumae Rhisoma (root of Curcuma longa L.)),
capsaicine
(isolated from fruit of Capsicum annuum L.),
piperine
(isolated from black peper (fruit of Piper nigrum L.)),
zingerone
(isolated from ginger root (Zinglber officinale Roscce)),
(6)-shogaol
(isolated from ginger root),
(6)-gingerol
(isolated from ginger root),
etc. Among them, curcumin is most preferable.
[0023] The bitter substance as used herein includes preferably swertiamarin, gentiopicrin, loganin,
etc.
[0024] The sour substance as used herein includes preferably citric acid, lactic acid, etc.
[0025] The daily dose of the pungent substance is preferably 1 to 1000 mg, more preferably 10 to
300 mg, and most preferably 20 to 70 mg. When it is administered alone, its daily dose is preferably
100 to 800 mg, and most preferably 300 to 500 mg. When it is administered in combination with
"KAMPO" pharmaceutical preparations or drugs ("KAMPO", Japan's traditional herbal medicine)
having the efficacy of "
" ("FU-SEI" as pronounced in Japanese: aid for keeping the body normal), such as JUZEN-TAIHO-TO
(as pronounced in Japanese), its daily dose is preferably 100 to 200 mg.
[0026] In accordance with the present invention, it is allowable that the health food product
contains a pungent substance, a bitter substance, and/or a sour substance. It is preferable that the
374/757
health food product is in admixture with one or more members selected from the group consisting of
isoflavones, acyl isoflavones and isoflavone glycosides. The particularly preferable isoflavone
includes soybean isoflavones comprised in soybean. The particularly preferable acyl isoflavone
includes soybean acyl isoflavones comprised in soybean. The particularly preferable isoflavone
glycoside includes soybean isoflavone glycosides comprised in soybean. For the acyl isoflavone, the
preferable acyl group includes acid residues derived from saturated or unsaturated fatty acids each
having 2 to 18 carbon atoms. The more preferable acyl group includes acid residues derived from
acetic acid, palmitic acid, stearic acid, etc. Hydroxy groups of the isoflavone may be completely or
partially acylated. Since acylation allows acylated products to have increased oil solubility, a large
amount of acylated isoflavones can be dissolved in oil-based preparations.
[0027] The daily dose of isoflavone, acyl isoflavone and isoflavone glycoside is preferably 1 to 500
mg, more preferably 5 to 200 mg, and most preferably 10 to 100 mg. The daily dose of cholic acid is
preferably 1 to 1000 mg, more preferably 2 to 300 mg, and most preferably 10 to 100 mg.
[0028] In accordance with the present invention, although it is allowable that the health food
product contains a pungent substance, a bitter substance, and/or a sour substance, it is preferable
that the health food product is in admixture with one or more members selected from the group
consisting of cholic acid, scymnol and scymnol esters. Particularly, it is preferable that the health
food product is in admixture with one or more members selected from the group consisting of cholic
acid, scymnol and scymnol esters, in combination with one or more members selected from the
group consisting of isoflavones, acyl isoflavones and isoflavone glycosides. When isoflavone, acyl
isoflavone or isoflavone glycoside is administered, it is desirable that cholic acid is admixed therein.
[0029] The daily dose of cholic acid is preferably 1 to 1000 mg, more preferably 2 to 300 mg, and
most preferably 10 to 100 mg. The daily dose of scymnol and scymnol esters is preferably 0.1 to 100
mg, more preferably 0.1 to 50 mg, and most preferably 0.3 to 10 mg. It is also allowable that the
health food product is in admixture with other ingredients including not only generic health foods but
also vitamins, heme Fe, prune extracts (Prunus Domestica fruit extracts), crude drugs or herbal and
animal drugs (galenicals; "SHOU-YAKU" as pronounced in Japanese), and the like. The "SHOUYAKU" includes preferably those having the efficacy of "FU-SEI", for example those capable of
activating or stimulating the functions of organs, glands and blood vessels, all controlled by
autonomic nerves, those capable of aiding digestion, and others.
375/757
[0030] The crude drugs of 10 or more kinds have been known as those capable of activating or
stimulating the functions of organs, glands and blood vessels, all controlled by autonomic nerves.
Examples of such crude drugs are ginseng (Ginseng Radix, Panax Ginseng), etc. Some of active
elements have been revealed for not only ginseng but also such crude drugs.
[0031] Accordingly, such active elements can be preferably admixed therewith. The admixture of
such active elements will lead to achievement of activating body-functions.
[0032] The particularly preferable crude drugs include Ginseng (Panax Ginseng or Ginseng Radix),
Codonopsltis Radix, Psuodostellariae Radix, American Ginseng, Astragali Radix, Atractylodis
Rhizoma, Dioscoreae Rhizoma, Glycyrrhia (Glycyrrhizae Radix), Jujube Fruit (Zizyphi Fructus,
Zizyphus vulgaris), Dulcium (malt sugar derived from Oryza seed), Polygonati Rhizoma, Codonopsis
lanceolata Benth. et Hock. fil. ("SHI-YO-U-JIN" in Japanese; Oryza sativa L.), etc.
[0033] Crude drugs capable of aiding digestion can be preferably admixed therewith. The
particularly preferable crude drugs capable of aiding digestion include Crataegi Fructus, Massa
Medicata Fermentat, Raphani Semen, Fructus Hordei Germinatus, Fructus Oryzae Germinatus
("KOKU-GA" in Japanese; Oryza sativa L.), Galli Stomachichum Corium, Asa Foetida, etc.
[0034] Scymnol and/or scymnol esters are comprised in biles of shark. Scymnol has the following
formula:
[0035] Sodium scymnol sulfate has the following formula:
[0036] Other materials as used herein include isoflavones, acyl isoflavones and isoflavone
glycosides.
[0037] For the health food products, the active elements contained in soybean are several species
of isoflavone glycosides including daidzin, glycitin, genistin, etc. and aglycons thereof, i.e., several
species of isoflavones including daidzein, glycitein, genistein, etc.
376/757
[0038] The soybean is a starting material for producing soybean oil. There is a great demand for
soybean oil. Therefore, large amounts of soybean oil are manufactured together with large amounts
of by-products, soybean cakes. Although part of such soybean cakes are employed as sources for
preparing soybean proteins, etc. which are starting materials for food products, the soybean cake is
mainly used for a fertilizer or feed for livestock and its price is therefore extremely low. The soybean
cakes which are almost industrial wastes can be used as starting materials to produce inexpensively
soybean isoflavones, soybean acyl isoflavones and soybean isoflavone glycosides with high purity.
[0039] The health food products of the present invention can be eaten as conventional forms
including powdery, solid, and liquid forms. Materials for admixture include lactose, starch, vegetable
oil, etc.
EXAMPLES
[0040] Described below are examples of the present invention which are provided for illustrative
purposes.
[0041] Soybean isoflavones, soybean acyl isoflavones and soybean isoflavone glycosides as used
in examples are set to be 40% in purity. Cholic acid as used in examples is set to be 90% in purity
except for pure cholic acid.
Columns=2
Title: EXAMPLE 1 (Powders)
Curcumin45 mg
Scymnol1 mg
Soybean isoflavone125 mg
Lactose800 mg
Cornstarchqs
Magnesium stearate10 mg
Total2000 mg
(1 g per container (powder paper), twice a day)
377/757
[0042] A formula except that soybean isoflavone was replaced with soybean isoflavone glycoside
was blended to afford powders in the same fashion as above.
Columns=2
Title: EXAMPLE 2 (Granules)
Curcumin45 mg
Sodium scymnol sulfate1 mg
Soybean isoflavone125 mg
Lactose1500 mg
Cornstarchqs
Magnesium stearate10 mg
Total2000 mg
(1 g per container (powder paper), twice a day)
[0043] A formula except that soybean isoflavone was replaced with soybean isoflavone glycoside
was granulated to afford granules in the same fashion as above.
Columns=2
Title: EXAMPLE 3 (Tablets)
Curcumin45 mg
Sodium scymnol sulfate1 mg
Soybean isoflavone125 mg
Crystalline celluloseqs
Lactose140 mg
Magnesium stearate6 mg
Talc3 mg
Total1120 mg
(280 mg per tablet, 2 tablets per dose, twice a day)
[0044] A formula except that soybean isoflavone was replaced with soybean isoflavone glycoside
was compressed to afford tablets in the same fashion as above.
Columns=2
Title: EXAMPLE 4 (Tablets)
Curcumin45 mg
Scymnol1 mg
378/757
Soybean isoflavone250 mg
Ginseng powder2000 mg
Lactose886 mg
Crystalline celluloseqs
Carboxymethylcellulose calcium320 mg
Hydroxypropylcellulose558 mg
CARPLEX30 mg
Magnesium stearate55 mg
Total5600 mg
(280 mg per tablet, 5 tablets per dose, twice a day)
[0045] A formula except that soybean isoflavone was replaced with soybean isoflavone glycoside
was compressed to afford tablets in the same fashion as above.
Columns=2
Title: EXAMPLE 5 (Hard capsules)
Curcumin45 mg
Scymnol1 mg
Soybean isoflavone125 mg
Lactose218 mg
Cornstarchqs
Magnesium stearate6 mg
Total1150 mg
(for 4 #1 capsules, 2 capsules per dose, twice a day)
[0046] A formula except that soybean isoflavone was replaced with soybean isoflavone glycoside
was blended and packed to afford hard capsules in the same fashion as above.
Columns=2
Title: EXAMPLE 6 (Soft capsules)
Curcumin45 mg
Sodium scymnol sulfate1 mg
Soybean isoflavone125 mg
Cod liver oil80 mg
Tocopherol acetate5 mg
379/757
Ginseng extract200 mg
Yellow beeswax55 mg
Edible oilqs
Total1200 mg
(4 capsules a day)
[0047] A formula except that soybean isoflavone was replaced with acetylated soybean isoflavone
or soybean isoflavone glycoside was blended and packed to afford soft capsules in the same
fashion as above.
Columns=2
Title: EXAMPLE 7 (Drink)
Curcumin45 mg
Sodium scymnol sulfate1 mg
Soybean isoflavone125 mg
Korean ginseng extract10 mg
Rehmanniae Radix extract10 mg
(Rehmannia glutinosa Liboschitz var. purpurea Makino)
Royal jelly100 mg
Thiamin nitrate10 mg
Riboflavin sodium phosphate5 mg
Pyridoxine hydrochloride10 mg
Anhydrous caffeine50 mg
Ethanol1.2 mL
Ethyl parahydroxybenzoate4 mg
Purified waterqs
Total50 mL/bottle
[0048] A formula except that soybean isoflavone was replaced with soybean isoflavone glycoside
was mixed to afford drinks in the same fashion as above.
Columns=2
Title: EXAMPLE 8 (Preparations admixed with vitamin, hard capsules)
Curcumin45 mg
Sodium scymnol sulfate1 mg
380/757
Soybean isoflavone125 mg
Thiamin hydrochloride25 mg
Pyridoxine hydrochloride10 mg
Riboflavin10 mg
Cyanocobalamin12 mu g
Nicotinamide20 mg
Calcium pantothenate20 mg
Ascorbic acid60 mg
L-cysteine10 mg
Lactose263 mg
Magnesium stearate6 mg
Cornstarchqs
Total1150 mg
(2 capsules per dose, twice a day)
[0049] A formula except that soybean isoflavone was replaced with soybean isoflavone glycoside
was blended and packed to afford hard capsules in the same fashion as above.
Columns=2
Title: EXAMPLE 9 (Powders)
Curcumin45 mg
Cholic acid60 mg
Soybean isoflavone glycoside125 mg
Lactose2700 mg
Cornstarchqs
Light anhydrous silicic acid5 mg
Magnesium stearate10 mg
Total4000 mg
(2 g per container (powder paper), twice a day)
[0050] A formula except that soybean isoflavone glycoside was replaced with soybean isoflavone
was blended to afford powders in the same fashion as above.
Columns=2
Title: EXAMPLE 10 (Granules)
381/757
Curcumin45 mg
Cholic acid60 mg
Soybean isoflavone glycoside125 mg
Lactose2700 mg
Cornstarch800 mg
Crystalline cellulose300 mg
Light anhydrous silicic acid5 mg
Magnesium stearate10 mg
Total4000 mg
[0051] A formula except that soybean isoflavone glycoside was replaced with soybean isoflavone
was granulated to afford granules in the same fashion as above.
Columns=2
Title: EXAMPLE 11 (Spherical granules)
Curcumin45 mg
Cholic acid60 mg
Soybean isoflavone glycoside125 mg
Lactose515 mg
Cornstarchqs
"KAN-BAI-KO" (in Japanese)500 mg
(Prunus mume fruit powder)
Crystalline cellulose400 mg
Total2000 mg
[0052] A formula except that soybean isoflavone glycoside was replaced with soybean isoflavone
was granulated to afford spherical granules in the same fashion as above.
Columns=2
Title: EXAMPLE 12 (Tablets)
Curcumin45 mg
Cholic acid140 mg
Soybean isoflavone glycoside280 mg
Lactose4000 mg
Carboxymethylcellulose calcium320 mg
382/757
Hydroxypropylcellulose74 mg
Crystalline celluloseqs
CARPLEX30 mg
Magnesium stearate10 mg
Total5484 mg
(280 mg per tablet, 5 tablets per dose, twice a day)
[0053] A formula except that soybean isoflavone glycoside was replaced with soybean isoflavone
was compressed to afford tablets in the same fashion as above.
Columns=2
Title: EXAMPLE 13 (Hard capsules)
Curcumin45 mg
Cholic acid60 mg
Soybean isoflavone glycoside125 mg
Cornstarchqs
Magnesium stearate9 mg
Total1153 mg
(#1 capsule, 4 capsules a day)
[0054] A formula except that soybean isoflavone glycoside was replaced with soybean isoflavone
was blended and packed to afford hard capsules in the same fashion as above.
Columns=2
Title: EXAMPLE 14 (Soft capsules)
Curcumin45 mg
Cholic acid60 mg
Soybean isoflavone glycoside125 mg
Yellow beeswax55 mg
Edible oilqs
Total1200 mg
(4 capsules for a daily dose)
383/757
[0055] A formula except that soybean isoflavone glycoside was replaced with acetylated soybean
isoflavone or soybean isoflavone was blended and packed to afford soft capsules in the same
fashion as above.
Columns=2
Title: EXAMPLE 15 (Drink)
Curcumin45 mg
Cholic acid60 mg
Soybean isoflavone glycoside125 mg
Korean ginseng extract1500 mg
Euphoria longan extract100 mg
Schizandrae Fructus fluidextract300 mg
(fruit of Schizandra chinensis Baill.)
Royal jelly150 mg
Riboflavin sodium phosphate10 mg
Ethanol1.2 ml
Parahydroxybenzoic acid4 mg
Purified waterqs
Total50 ml
[0056] A formula except that soybean isoflavone glycoside was replaced with soybean isoflavone
was mixed to afford drinks in the same fashion as above.
Columns=2
Title: EXAMPLE 16 (Granules)
Curcumin45 mg
Cholic acid60 mg
Soybean isoflavone glycoside125 mg
Thiamin hydrochloride10 mg
Pyridoxine hydrochloride100 mg
Hydroxocobalamin hydrochloride1.027 mg
Tocopherol acetate100 mg
Lactose2700 mg
Crystalline cellulose300 mg
Light anhydrous silicic acid5 mg
Magnesium stearate10 mg
384/757
Cornstarchqs
Total4000 mg
(2 g per container (powder paper), twice a day)
[0057] A formula except that soybean isoflavone glycoside was replaced with soybean isoflavone
was granulated to afford granules in the same fashion as above.
Columns=2
Title: EXAMPLE 17 (Capsules)
Curcumin45 mg
Cholic acid60 mg
Soybean isoflavone glycoside125 mg
Vitamin A oil4 mg
Cholecalciferol0.005 mg
Tocopherol acetate10 mg
Vitamin C600 mg
Crystalline cellulose250 mg
Magnesium stearate6 mg
Cornstarchqs
Total1150 mg
(#1 capsule, 4 capsules a day).
[0058] A formula except that soybean isoflavone glycoside was replaced with soybean isoflavone
was blended and packed to afford capsules in the same fashion as above.
Columns=2
Title: EXAMPLE 18 (Powders)
Curcumin30 mg
Scymnol1 mg
Soybean isoflavone125 mg
Lactose800 mg
Cornstarchqs
Magnesium stearate10 mg
Total2000 mg
385/757
[0059] A formula except that soybean isoflavone was replaced with soybean isoflavone glycoside
was blended to afford powders in the same fashion as above.
Columns=2
Title: EXAMPLE 19 (Granules)
Curcumin30 mg
Sodium scymnol sulfate1 mg
Soybean isoflavone125 mg
Lactose1500 mg
Cornstarchqs
Magnesium stearate10 mg
Total2000 mg
[0060] A formula except that soybean isoflavone was replaced with soybean isoflavone glycoside
was granulated to afford granules in the same fashion as above.
Columns=2
Title: EXAMPLE 20 (Tablets)
Curcumin25 mg
Scymnol1 mg
Soybean isoflavone250 mg
Ginseng powder2000 mg
Lactose886 mg
Crystalline celluloseqs
Carboxymethylcellulose calcium320 mg
Hydroxypropylcellulose558 mg
CARPLEX30 mg
Magnesium stearate55 mg
Total5600 mg
[0061] A formula except that soybean isoflavone was replaced with soybean isoflavone glycoside
was compressed to afford tablets in the same fashion as above.
Columns=2
Title: EXAMPLE 21 (Soft capsules)
386/757
Curcumin25 mg
Sodium scymnol sulfate1 mg
Soybean isoflavone125 mg
Cod liver oil80 mg
Tocopherol acetate5 mg
Ginseng extract200 mg
Yellow beeswax55 mg
Edible oilqs
Total1200 mg
[0062] A formula except that soybean isoflavone was replaced with acetylated soybean isoflavone
or soybean isoflavone glycoside was blended and packed to afford soft capsules in the same
fashion as above.
Columns=2
Title: EXAMPLE 22 (Drink)
Curcumin30 mg
Sodium scymnol sulfate1 mg
Soybean isoflavone125 mg
Korean ginseng extract10 mg
Rehmanniae Radix extract10 mg
Royal jelly100 mg
Thiamin nitrate10 mg
Riboflavin sodium phosphate5 mg
Pyridoxine hydrochloride10 mg
Anhydrous caffeine50 mg
Ethanol1.2 L
Ethyl parahydroxybenzoate4 mg
Purified waterqs
Total50 mL/bottle
[0063] A formula except that soybean isoflavone was replaced with soybean isoflavone glycoside
was mixed to afford drinks in the same fashion as above.
Columns=2
387/757
Title: EXAMPLE 23 (Powders)
Curcumin30 mg
Cholic acid60 mg
Soybean isoflavone glycoside125 mg
Lactose2700 mg
Cornstarchqs
Light anhydrous silicic acid5 mg
Magnesium stearate10 mg
Total4000 mg
(2 g per powder paper, twice a day)
[0064] A formula except that soybean isoflavone glycoside was replaced with soybean isoflavone
was blended to afford powders in the same fashion as above.
Columns=2
Title: EXAMPLE 24 (Granules)
Curcumin25 mg
Cholic acid60 mg
Soybean isoflavone glycoside125 mg
Lactose2700 mg
Cornstarchqs
Crystalline cellulose300 mg
Light anhydrous silicic acid5 mg
Magnesium stearate10 mg
Total4000 mg
[0065] A formula except that soybean isoflavone glycoside was replaced with soybean isoflavone
was granulated to afford granules in the same fashion as above.
Columns=2
Title: EXAMPLE 25 (Tablets)
Curcumin30 mg
Cholic acid140 mg
Soybean isoflavone glycoside280 mg
Lactose4000 mg
388/757
Carboxymethylcellulose calcium320 mg
Hydroxypropylcellulose74 mg
Crystalline celluloseqs
CARPLEX30 mg
Magnesium stearate10 mg
Total5484 mg
(280 mg per tablet, 5 tablets per dose, twice a day)
[0066] A formula except that soybean isoflavone glycoside was replaced with soybean isoflavone
was compressed to afford tablets in the same fashion as above.
Columns=2
Title: EXAMPLE 26 (Hard capsules)
Curcumin25 mg
Cholic acid60 mg
Soybean isoflavone glycoside125 mg
Cornstarchqs
Magnesium stearate9 mg
Total1153 mg
(4 #1 capsules a day)
[0067] A formula except that soybean isoflavone glycoside was replaced with soybean isoflavone
was blended and packed to afford hard capsules in the same fashion as above.
Columns=2
Title: EXAMPLE 27 (Drink)
Curcumin30 mg
Cholic acid60 mg
Soybean isoflavone glycoside125 mg
Korean ginseng extract1500 mg
Euphoria longan extract100 mg
Schizandrae Fructus fluidextract300 mg
Royal jelly150 mg
Riboflavin sodium phosphate10 mg
Ethanol1.2 ml
389/757
Parahydroxybenzoic acid4 mg
Purified waterqs
Total50 ml
[0068] A formula except that soybean isoflavone glycoside was replaced with soybean isoflavone
was mixed to afford drinks in the same fashion as above.
[0069] No studies have been conducted on the efficacy of curcumin, zingerone, or shogaol on the
stimulation of adrenaline secretion. However, the secretomotory actions on adrenaline have been
clarified through animal experiments using mice in which blood glucose levels were remarkably
elevated.
[0070] Tablets (250 mg each) containing curcumin (15 mg), cholic acid (20 mg) and soybean
isoflavone glycoside (40 mg) in admixture with lactose were administered at a dose of 3 tablets a day
(at a dose of 45 mg of curcumin once a day) to 10 patients who had regularly received drugs having
the efficacy of "FU-SEI" (in Japanese). The results are shown in the following Table:
[0071] As shown in the above Table, the drug is effective in 90% of the cases and the significantly
effective case equals 60%.
[0072] These good results indicate the possibility of recovery from depression which had been said
to be a non-curable disease. The examples as disclosed in the Table show results obtained from
dosage trials over two months after the initiation of administration; however, long term observation is
required for recurrence of depression.
Thus, it has been proven that many curcumin-dosed patients are able to return to daily life routines
nearly identical to those of ordinary people (non-sufferers of depression), demonstrating that these
healthy foods are extremely effective and invigorating.
[0073] When tablets (250 mg each) containing, in admixture with lactose, sodium scymnol sulfate
(1 mg) in place of cholic acid were administered, similar results were obtained.
390/757
[0074] Granules of Examples 2 and 10 were administered to 12 and 14 females with menopausal
disorders including broodiness, depression and dizziness, etc., respectively, at 45 mg of curcumin
per day. Five days after the dosing, the broodiness, depression and dizziness were mitigated in five
and six individuals, respectively. Three weeks later, improvements were seen in 11 and 12
individuals, respectively.
[0075] When granules of Example 2 were administered to 10 elderly patients in the preliminary
stages of senile dementia, memory loss was ameliorated in 7 individuals. When granules of Example
10 were administered, similar results were obtained. Such products are also effective for Alzheimer's
disease.
[0076] It has been clarified that the products according to the present invention are significantly
useful as prophylactic or therapeutic drugs for climacteric disorders, senile dementia and
Alzheimer's disease. Thus, methods are provided according to the present invention, for preventing
or treating a member selected from the group consisting of climacteric disorders, senile dementia
and Alzheimer's disease.
[0077] Curcumin is readily available. For instance, highly pure curcumin is on the market.
[0078] Capsules wherein powders produced by admixture of capsaicine (50 mg) with lactose were
packed in combination with isoflavone glycoside and cholic acid were administered to patients with
depression once daily. Several days later, effects were dramatic. The patient were nearly completely
recovered from depression after a week. Capsaicine is a powerful irritant with burning aftertaste.
[0079] Tablets of Example 20 were administered once a day.
[0080] For an eighty-three year old male afflicted with walking difficulties and severe anal prolapse,
occurred as he was aging, the dosing led to easy mobility and recovery from proctoptosia, with a
clear feeling that the anal sphincter functioned. One-month dosing led to clear amelioration of his
conditions.
[0081] For a male (age 63) afflicted with difficulty in walking up and down stairs, the dosing led to
easy movement on staircases. One-month dose trials led to clear amelioration. The tablet of example
25 has a similar efficacy.
391/757
[0082] If these results were simply attributable to pharmacological action to improve local muscle
activity, such information would be contained in European and American data and in results found in
Okinawa, wherein curcumin is applied. No such data exists therein. This indicates that these results
might be attributed to improvements in brain communication of commands (released as a result of
brain thought) to local sites.
[0083] In Western medicine, it has been understood that proctoptosia and leg, lumbus and arm
aches are attributable only to hematogenous disorders and resultant inflammation at local sites.
However, these pathological conditions were not significantly ameliorated by a single regular dose of
drugs admixed with one of scymnol, isoflavone, and cholic acid which are significantly capable of
removing hematogenous disorders. Thus, it can be understood that these disorders are attributed to
insufficient communication of brain commands to local sites and therefore the hematogenous
disorders and onset of inflammation are problems caused by abnormal motions of muscles due to
incomplete communication of brain commands.
[0084] When male and female patients (5 each, age 60 to 75) complained of backaches, limb
pains and muscle disorders such as proctoptosia (which occurred as they were aging) took doses,
such clinical conditions were alleviated or cured.
[0085] Although all muscle disorders are not ascribable to insufficient brain communication, it
seems that the majority of such disorders are elicited by insufficient communication of brain
commands.
[0086] Coadministration of isoflavone, cholic acid, scymnol, curcumin and so on enables the
removal of muscle disorders as such components have the stimulating actions on brain activity. This
is good news to the elders for both physical and mental rejuvenation. These formulations are
extremely effective for arthritis such as rheumatism and in particular, greatly influence the prevention.
[0087] Curcumin is readily available. For instance, highly pure curcumin is on the market.
[0088] Capsaicine (30 mg) instead of curcumin preparations of Example 18 was administered to
elderly patients between the ages of 76 and 83 once daily. Several days later, its effects were
dramatic. It has been proved that the drug is effective for muscular degeneration, arthritis and
rheumatism after one week.
392/757
ADVANTAGES OF THE PRESENT INVENTION
[0089] The present invention is to provide very effective health foods for supplying a pungent
substance, a bitter substance or a sour substance, thereby refreshing a body or feeling, preventing
forgetting, and intensifying weakened muscles. Thus the health food products are advantageous in
view of prevention or treatment of rheumatism, etc.Claims:
1. A health food product comprising at least one or more members selected from the group
consisting of pungent substances, bitter substances and sour substances.
2. The health food product according to claim 1 wherein the pungent substance, the bitter substance
or the sour substance is selected from foods.
3. The health food product according to claim 1 or 2 which comprises a pungent substance.
4. The health food product according to any of claims 1 to 3 wherein the pungent substance is
curcumin.
5. The health food product according to any of claims 1 to 4 which is in admixture with at least one or
more members selected from the group consisting of cholic acid, scymnol and scymnol esters.
6. The health food product according to any of claims 1 to 5 which is in admixture with at least one or
more members selected from the group consisting of isoflavones, acyl isoflavones and isoflavone
glycosides.
7. The health food product according to claim 6 wherein the isoflavone is a soybean isoflavone, the
acyl isoflavone is a soybean acyl isoflavone and the isoflavone glycoside is a soybean isoflavone
glycoside.
8. The health food product according to any of claims 1 to 7 which is in admixture with a vitamin.
393/757
9. The health food product according to any of claims 1 to 8 which is in admixture with at least one or
more members selected from crude drugs.
10. The health food product according to claim 9 wherein the crude drug has the property of exerting
a"
" action.
11. The health food product according to claim 10 wherein the crude drug is one or more members
selected from the group consisting of Ginseng (Panax Ginseng or Ginseng Radix), Codonopsitis
Radix, Psuodostellariae Radix, American Ginseng, Astragali Radix, Atractylodis Rhizoma, Dioscoreae
Rhizoma, Glycyrrhia (Glycyrrhizae Radix), Jujube Fruit (Zizyphi Fructus, Zizyphus vulgaris), Dulcium
(malt sugar derived from Oryza seed), Polygonati Rhizoma, and Codonopsis lanceolata Benth. et
Hock. fil. ("SHI-YO-U-JIN" in Japanese).
12. The health food product according to claim 10 or 11 wherein the crude drug is one or more
members selected from the group consisting of Crataegi Fructus, Massa Medicata Fermentat,
Raphani Semen, Fructus Hordei Germinatus, Fructus Oryzae Germinatus ("KOKU-GA" in Japanese;
Oryza sativa L.), Galli Stomachichum Corium, and Asa Foetida.
394/757
250. JP2004008215 - 10.12.2003
A HEALTH-CARE PRODUCT COMPRISING LOTUS RHIZOME AND PROCESS FOR ITS
PREPARATION
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=JP2004008215
Inventor(s):
PAN LING (CN); LI DELIANG (CN); ZHANG LIQUN (CN); TANG WENXU (CN);
YANG CHENGJIN (CN); GAO CHONGKUN (CN); FENG YOU (CN); CHEN MIAN (CN)
Applicant(s):
YUNNAN BAIYAO GROUP CO LTD (CH)
IP Class 4 Digits: A61K; A61P
IP Class:
A61K35/78; A61P3/10
E Class: A61K35/78
Application Number:
EP20030253287 (20030524)
Priority Number: CN20020113847 (20020607)
Family: JP2004008215
Equivalent:
CN1385196; US2003232099
Cited Document(s):
JP61025461
Abstract:
THE PRESENT INVENTION PERTAINS TO A MULTIFUNCTION HEALTH-CARE PRODUCT AND TO A
PROCESS FOR THE PREPARATION OF THE SAME. THE HEALTH-CARE PRODUCT COMPRISES A
POWDER OF LOTUS ROOT JOINTS OR AN EXTRACT OF THE JOINTS AS MAIN ACTIVE
INGREDIENT. A PREFERRED COMPOSITION OF THE PRODUCT COMPRISES (PART BY WEIGHT):
AN EXTRACT OF THE JOINTS 4 SIMILAR 7.5, A POWDER OF LOTUS ROOT JOINTS 2 SIMILAR 15,
GREEN TEA AND/OR EXTRACT THEREOF 0.08-2, NOTOGINSENG AND/OR EXTRACT THEREOF
395/757
0.08-0.5. THE PROCESS FOR PREPARATION OF THE COMPOSITION COMPRISES: DIRECTLY
PULVERIZING THE LOTUS ROOT JOINTS, PUTTING THE PULVERIZED LOTUS ROOT JOINTS IN
PRODUCT-GRADE SOLVENT FOR EXTRACTION, THEN FILTERING IT, THE FILTRATE SOLUTION IS
THUS THE EXTRACT OF THE JOINTS. THE PRODUCT OF THE INVENTION CAN EFFECTIVELY
IMPROVE IR, THUS IMPROVING AND PREVENTING TYPE-II DIABETES MELLITUS, HYPERTENSION,
HYPERLIPOIDEMIA AND CARDIO-CEREBRAL VASCULAR DISEASES CAUSED BY BEING OBESITY.
IT ALSO HAS THE EFFECT OF LOSING WEIGHT.Description:
Technical field
[0001] The present invention pertains to a health-care product, especially to a health-care product
capable of improving insulin resistance(IR) and to a process for its p reparation as well as its uses.
Background of prior art
[0002] Along with the continuous improvement of living standard and the change of lifestyle, the
number of people suffering from obesity, type-II Diabetes Mellitus, hypertension, hyerlipoidemia and
cardio-cerebral vascular diseases have continuously increased, and these diseases often appear in
complications. Own to high lethality and disability rate, these diseases represent important ones
threatening human health at present. In recent decade, many domestic and foreign studies have
indicated that, the the said diseases have the same pathogenetic basis, i.e. Insulin Resistance
(referred to as IR). IR is the key cause of the said diseases, and obesity is the prelude of other
diseases. IR means that the normal or higher insulin (Ins) level is contained in blood of human body,
but it could just perform an insufficient biological effect, i.e., the Ins-sensitivity and -reactivity of the
targeted tissue and organs (muscle, liver and fat tissue, et al) of organic Ins have being decreased.
To overcome IR, B islet cells have to secret more Ins, thus cause compensative high
hyperinsulinemia (HI), and HI could in turn further induce or aggravate the said diseases. At present,
modern medicine has turned its affords to improve IR for a better treatment of the said diseases.
396/757
[0003] At present, the medicines for improving IR are mainly chemically synthesized substances
(referred to as western medicine), such as insulin s ensitizer, Thiazolidine d iketone derivatives (TZD)
for the treatment of type-II Diabetes Mellitus. However, the time in clinical application of this type of
medicines is not long enough, the long-term adverse effect thereof still needs to be examined, so
these medicines seem to be unsuiTable for administration for long time. Until now, there is still no
instant Chinese herbal medicine or health-care product that has definite improvement and/or
treatment effect on IR.
[0004] Since IR has complicated pathogenesis, which involves deficiency of different level and link
in Ins pre-receptor, receptor and post-receptor. So far, there is still a strong demand for a safe,
effective medicine that could comprehensively improve IR and the related diseases.
Summary of the invention
[0005] To overcome the deficiency in existing technology, the present invention is directed to
provide a multifunction health-care product, which could improve IR effectively, prevent the onset of
type-II Diabetes Mellitus, hypertension, hyperlipoidemia and cardio-cerebral vascular disease
caused by being obesity without adverse effect. As to the existing symptoms caused by the said
diseases, they could also be substantially improved; Meanwhile, it also has a good anti-obesity effect.
Detailed description of the invention
[0006] According to one aspect of the invention, there is provided a multifunction health-care
product comprising a powder of lotus root joints or an extract of lotus root joints.
[0007] In one preferred embodiment of the health-care product, it is preferably to further comprise
either green tea and/or its extract or notoginseng and/or its extract, or the mixture of the both. The
composition of the preferred product thereof comprises: extract of lotus root joints 4 tilde& 30 part
by weight, more preferably 5 tilde& 15 part by weight, most preferably 4 tilde& 7.5 part by weight,
green tea and/or its extract 0.08-2 part by weight, notoginseng and/or its extract 0.08-0.5 part by
weight. In addition, it could further comprise 4 tilde& 15 part by weight of a powder of lotus root joints.
397/757
[0008] The health-care product described above could be formulated into conventional
administration form, such as Tablet, capsule, soluble granule, solution or injection, et al.
[0009] According to another aspect of the invention, there is provided a process for preparation of
the health-care product comprising the following steps:
a) Pulverizing lotus root joints and thus obtaining a powder of the joints;
b) Putting the powder of the joints in a product-grade solvent for extraction, then filtering it, and
using the filtrate solution as the extract of the joints; and
c) Blending conventional product-grade adjuvant with the powder of the joints or the extract of the
joints, and then formulating the blend into a form of Tablet, capsule, soluble granule, solution or
injection.
[0010] The said solvent is conventional food-grade solvent, among which fresh water and ethanol
are preferred.
[0011] The steps a) and b) could be carried out by any of the following variants:
( 1 )Drying lotus root joints and pulverizing the dried joints into a powder having a granule size of
20 mesh; putting the powder into a container and adding therein 5 tilde& 10 times by weight of 30%
tilde& 90% ethanol, based on the weight of the powder; extracting it at room temperature for 24
hours, then filtering the mixture; extracting the filtrate residue for another 2 times using the same
procedure; combining the filtrate solutions, concentrating the combined filtrate solution under
vacuum and freeze-drying it into a dried powder; or
(2) Drying the lotus root joints and pulverizing the dried joints into a powder having a granule size
of 20 mesh, putting the powder into a container and adding therein 5 tilde& 10 times by weight of
30% tilde& 90% ethanol, based on the weight of the powder; heating it in water bath and refluxing
for 30 tilde& 60 minutes, then filtering it while it is hot; extracting the filtrate residue for another 2
times using the same procedure as mentioned above; combining the filtrate solutions, concentrating
it at a low temperature under reduced pressure, and freeze-drying it into a dried powder; or
(3) Drying lotus root joints and pulverizing it into granules of soybean's size; putting it into a
container and adding therein 6 tilde& 10 times by weight of fresh water, based on the weight of the
powder; heating it at its boiling point for 30 tilde& 40 minutes, then filtering it while it is hot;
398/757
extracting the filtrate residue for another 2 times using the same procedure as mentioned above;
combining the filtrate solutions, concentrating the combined solution under vacuum and drying it into
a powder.
[0012] Where a product in the form of a capsule is to be produced, it is preferred to further use 2
tilde& 15 part by weight of a powder of lotus root joints in step b) described above, as powder of
lotus root joints contains not only active substances, but could also act as an adjuvant required for
capsule. The said green tea extract contains mainly tea polyphenol, notoginseng extract contains
mainly full notoginseng saponin. In addition, a cinnamon naptha enveloped with beta -cyclodextrin
could also be blended into the composition of the capsule product, according to the invention.
[0013] According to an additional aspect of the invention, there are provided new uses of the
inventive product in preparation of medicines for improving human insulin resistance; for treating or
preventing obesity; for treating or preventing hypertension; for treating or preventing hyperlipoidemia;
for treating or preventing Diabetes Mellitus; for improving blood viscosity, preventing thrombosis and
promoting microcirculation; for treating or preventing Alzheimer's Disease and against senility.
[0014] The health-care product according to the invention is made from natural edible plant
products, mainly from natural lotus root joints, and it thus takes the advantages of an easy availability
and a cheaper price of the raw materials, a safety in administration of it in long term without adverse
effect, in addition to its capability of effectively improving IR, preventing the onset of type-II Diabetes
Mellitus, hypertension, hyperlipoidemia and cardio-cerebral vascular diseases caused by being
obesity and a good anti-obesity effect.
Brief description of Figures
Figure 1 shows a trend of Change in weight of rats in different group for trial.
Preferred embodiments of the Invention
399/757
[0016] For a better understanding in the essence of the present invention, the favorable medical
effects of the product according to the invention are shown through systemic pharmacological test
data and result as follows. However, they should not be understood as any restriction to the
protection scope of the present invention that is defined by the appended claims.
Example 1. The effect of lotus root joints on model of nutrition-type obesity rat
1.1 Material and test method
1.1.1 Preparation of experimental material and feed
( 1 ) Experimental material
[0017] Clean and dry the lotus root joints in ambient air, then put them in an oven and dry them in
forced air under 65 squ& , and pulverize them into a fine powder having a granular size of less than
20 mesh. The powder is ready for use on that very day.
( 2 ) Positive medicine
[0018] The Ninghong anti-obesity tea (a product manufactured by Jiangxi Ninghong group, Trade
No. 21101102) is pulverized into a fine powder for use on that very day.
400/757
( 3 ) Experimental feed
[0019] Concentrated high calorific feed: basal feed 40%, lard oil 35%, saccharose 15%, egg 8%,
salt 2%.
[0020] Experimental feed: Take samples of the concentrated high calorific feed in certain amount
and combine it respectively with certain amount of the basal feed, the powder of lotus root joints and
the positive medicine powder, make them into model-type high calorific feed, lotus root joints-type
high calorific feed and positive medicine-type high calorific feed using pelleter (the lotus root jointstype high calorific feed contains 68% concentrated high calorific feed, 32% the powder of lotus root
joints, the model-type high calorific feed contains 32% basal feed in replacement of positive
medicine powder, the 32% of the positive medicine powder in the positive medicine-type high
calorific feed is consisted of 21% the basal feed and 11% fine powder of the Ninghong anti-obesity
tea).
[0021] After the preparation of the feeds described above, desiccate them in ambient air, and
process a new batch every 7 tilde& 10 days.
1.1.2. Experimental animals and their group
[0022] SD male rats having weight of 444+/-17g, randomly assigned to: blank group (group squ& ),
model control group (group squ& ), lotus root joints group (group squ& ) and positive medicine
group (group squ& ). 8 animals for each group and are separately fed in single cage.
1.1.3. Model establishment and administration
[0023] Each rat is allowed to have 22g corresponding experimental feed at 5 p.m. everyday, i.e.
basal feed 22g/animal for group squ& ; model-type high colorific feed, lotus root joints-type high
colorific feed and positive medicine-type high colorific feed 22/animal are given respectively to group
squ& tilde& squ& (every 22g of each feed contains 15g concentrated high colorific feed, the rest
401/757
7g are consisted respectively of 4.6g of basal feed, powder of lotus root joints and basal feed and
2.4g positive medicine powder). Each rat is allowed to have 8g basal feed the next morning, and no
additional feed is additionally supplied, tap water is available ad libitum for rats in each group.
1.1.4. Observation indicator and method
(1) General items
[0024] Including appearance of spirit, skin and hair, eyes, activity, eating, drinking and evacuation
of the animal.
( 2) Intake amount
[0025] A form is designed and intake amounts are recorded every day using the form.
( 3 ) Weight taken once a week.
( 4 ) Glucose tolerance
[0026] Measured at the end of 4 weeks after the beginning of experiment. Rats have been on fast
for 6 hours, then take 6 of them, intraperitoneally inject 2g glucose/Kg animal, and sample blood
through vena caudalis, and blood sugar is measured in 0, 0.5, 1 and 2 hours using rapid blood sugar
calcimeter.
402/757
( 5 ) Blood sugar, serum TC, TG, HDL -c and Ins on Fast
[0027] At the end of experiment, sample blood from femoral vein, separate the serum, a part of it is
submitted to the clinical laboratory in No. 1 hospital affiliated to Kunming medical college for test (by
full automatic biochemical analyzer), and blood sugar, serum TC, TG, (color comparison in 7230
spectrophotometer) are manually measured by ourselves according to kit instruction.
( 6 ) Wet weight of celiac fat and testicle fat pad
[0028] Dissect the rat after blood sample, separate celiac fat and testicle fat pad, place them on
the filtering paper to remove tissue fluid, their weight is taken by electronic scales and recorded.
1.1.5 Statistical method
[0029] Process the experimental data obtained with PEMS (Package for Encyclopaedia of Medical
Statistics, edited by Public Health-Care College of Huaxi Medical University). Single factor analysis of
variance and q-test are adopted for multi-group mean and pair-wise comparison.
1.2 Test result
1.2.1. GENERAL ITEMS
[0030] Except for the death of No. 1 rat in group squ& and the poor uptake of positive medicinetype feed by rats in group squ& (since rats in this group had never eaten up the positive medicinetype high colorific feed given to them, which cause it impossible to reflect the true effect of medicine,
thus it was eliminated from the experiment), no abnormality was found in other rats.
403/757
1.2.2 The Change in weight of rats in each group at the end of 0 tilde& 4 week
[0031] See Table 1 tilde& Table 5 and figure 1. Table 1 shows that, there was no difference in the
weight of rat in each group before experiment, thus the weight of each group was comparable. It
could be found that, at the end of 1 week, there was no significant difference among weight of rats in
each group, while the rat weight of each group had decreased at various degrees. It was considered
to be caused mainly by the sudden change of living environment and lifestyle.
[0032] Table 3 shows that, at the end of 2 week, weight in model group and lotus root joints group
are respectively 4.6% and 3.9% higher than that in blank group, but without significant difference.
According to the amount of and percentage of weight gaining, model group had the largest gaining,
which was significant higher than that in blank group ( P<0.05 ), lotus root joints group is less higher,
but they had no significant difference from the blank group. This result indicated that the high
colorific feed could increase the weight in adult rats having a about 400gbody weight, thus
continuous feeding with this kind of feed could induce obesity in rats. Lotus root joints' preventive
effect on excessive weight gaining induced by high colorific feed had not demonstrated here.
[0033] Table 4 shows that, at the end of 3 week, weight in model group was significantly higher
than that in blank group (9.7% higher, p0.05). According to the amplitude of weight gaining, model
group had the largest one (p<0.01 compared with blank group), lotus root joints group was just
slightly higher than blank group, but without significance. This result indicated that, up-taking this
high colorific feed could cause the weight of adult rats of about 400g to be significantly heavier than
that of rats at the same age that intake a common feed, and lotus root joints has relatively significant
preventive effect on the excessive weight gaining caused by high colorific feed.
[0034] Table 5 shows that, at the end of 4 week, weight in model group further exceeded that in
blank group (12.3% higher ,p0.05), while compared with model group, their weight had been
significantly reduced (p<0.01). The amplitude of weight gaining in each group was smaller than that
before previous 2 weeks, while amplitude in model group was relatively larger. This result further
indicated that, taking-up this high colorific feed could cause the weight of adult rats of about 400g to
be significantly heavier than that of rats at the same age that intake a common feed, and lotus root
joints had significant preventive effect on the excessive weight gaining caused by high colorific feed.
404/757
[0035] Figure 1 shows the trend of Change in weight in each group during the whole process of
experiment from start to end.
[0036] It could be seen from figure 1 that, situation of lotus root joints group was relatively similar to
that of blank group, especially in the late stage of experiment; model group demonstrated
continuously higher weight than blank group. It indicated that this high colorific feed could cause
progressively excessive weight gaining in adult rats of about 400g, and the weight at final stage of
experiment was significantly heavier than rats at the same age that intake a common feed; lotus root
joints had relatively significant preventive effect on this weight gaining trend.
1.2.3 Blood glucose( Glu ), blood insulin ( Ins )and insulin sensitivity index (ISI) of rats in each
group(Table 6)
[0037] Table 6 shows that, model group had higher Glu, but without significance, when compared
with blank group; Lotus root joints group had lower Glu. Except for lotus root joints group, blood Ins
in each experimental group was significantly higher than that in blank group (p<0.01 for all groups),
and ISI thereof was significantly lower than blank group (p<0.01 for all groups); ISI in lotus root joints
group had a smaller difference from blank group (p<0.05), but it was significantly higher than the
other experimental groups (p<0.01 for all groups). This result indicated that, this obesity model had
produced hyperinsulinemia, with significant peripheral insulin resistance (IR); lotus root joints could
prevent the hyperinsulinemia caused by high colorific product, and could significantly reduce
peripheral IR.
1.2.4 The result of total cholesterol (TC), triglyceride (TG) and high density lipoprotein cholesterol
(HDL-c) of rats in each group (Table 7)
[0038] Table 7 shows that, TC in model group was significantly higher than blank group( p<0.01 ),
so it was also true in the other experimental groups( p<0.01 ), which had no significant difference
from model group. TG in model group was also higher, but without significant difference from blank
group; lotus root joints group had the lowest TG; HDL-c in lotus root joints group was significantly
405/757
higher than that in blank group. This result indicated that, this obesity model had abnormal blood fat,
which was demonstrated by significant increase of blood TC, and blood TG also had a trend to
increase; lotus root joints could effectively prevent the increasing trend of blood TG Lotus root joints
didn't have significant preventive effect on the increase of TC, but a little effect had been
demonstrated. Lotus root joints had shown the effect to increase blood HDL-c.
1.2.5 Weight of intraperitoneal fat and fat index in each group (Table 8)
[0039] Table 8 shows that, weight of intraperitoneal fat and fat index in model group had a
significant trend to increase; lotus root joints group has a opposite trend to that of model group.
1.3 Summary
1.3.1 Evaluation of obesity rat model
[0040] Usually, there are two methods for establishing obesity model: nutrition-type obesity model
and hypothalamic-type obesity model. The former one adopts SD rats that had just past the breast,
raise them with high nutritional feed (basal feed plus milk powder, egg, lard oil, vitamin AD and fresh
soybean sprout, et al) for a period of time (45 days), their weight will significantly exceed that of rats
at the same age fed with basal feed. This model adopts young rat, which are in flourishing growth
period and need a lot of nutrition. Giving high nutrition feed rich in protein, fat and various vitamins,
they will obviously grow faster, which is demonstrated by significant increase of weight, similar to the
obesity case among children of human being. There is no detailed report in articles concerning the
issue: whether the obesity is complicated with other pathophysiological changes, such as abnormal
blood fat, IR or glucose tolerance, et al. Analyzed from the growth phase (flourishing growth and
development period) and the nutrition formulation provided (rich and complete in nutrition, high
colorific), it is estimated that at least the pathological change caused by being obesity in this obesity
model would not be significant, which would be quite different from practical clinical situation
observed from most obesity and overweight patient.
406/757
[0041] This experimental model also belongs to nutrition-type obesity model, the rats adopted
weight about 444g having past their flourishing growth and development period, and equivalent to
adult, the model feed adopted is basal feed plus abundant lard oil, saccharose and eggs, which
contains high colorific but unbalanced nutrition, which was relatively similar to the dietary factor
causing clinical obesity and related diseases such as type-II Diabetes Mellitus. The result of this
experiment shows that, rat weight in basal feed group increased slowly, while rat weight in high
colorific feed group progressively increased, and became significantly higher than that of rats in
basal feed group in short time (28 days), the rats were complicated with significant higher cholestrol,
triglyceride and hyperinsulinemia, ISI was significantly reduced, so was glucose tolerance;
intraperitoneal fat and fat index also has a trend to increase. This result indicated that, this rat obesity
model could simulate most clinical adult obesity, thus it could be used as a more suitable model for
screening anti-obesity medicine.
1.3.2. Evaluation of lotus root joints' anti-obesity effect
[0042] In this experiment, lotus root joints was dried and pulverized into fine powder, blended it into
high colorific feed to feed three groups of rats for comparison; meanwhile, rats fed with pure high
colorific feed and basal feed were taken as the control. As a result, it was found that, the weight
gaining in lotus root joints group was significantly less than that of model control group, but similar to
that in blank group, and the final weight thereof is significantly lower than that of model control group,
without significant difference from blank group. This result indicated that, lotus root joints had a
preventive effect on obesity caused by high colorific product. Its effect on celiac fat tissue was
similar to what described above.
[0043] Obesity is not the sole problem of weight- or fat gaining. Clinically, obesity patients often
have metabolic disorders in sugar and fat, IR is an important pathophysiological basis for obesity,
and also an important and harmful factor for obesity patients' susceptibility to type-II Diabetes
Mellitus, hypertension, hyperlipoidemia and ischemic heart disease. Therefore, to inspect the antiobesity effect of a medicine, it should not only take weight and fat as the indicator, but should also
investigate the effect of medicine on the pathophysiological changes described above.
407/757
[0044] The result of this experiment shows that, serum Ins of rats in model control group had
significantly increased, while ISI significantly decreased, thus significant amount of IR had been
produced, with significant increase in serum TC; TG also showed a trend to increase; serum Ins in
lotus root joints group was significantly lower than that of model group, while ISI thereof was
significantly higher than that of model group, thus IR had been relieved; meanwhile, serum TG level
was not high. In retrospect of its effect on weight, the increasing trend of weight in lotus root joints
group became similar to that in blank group at late stage. The above results indicated that, lotus root
joints had a comprehensive effect on the prevention of being obesity caused by high colorific
product.
[0045] Summary: the high colorific feed of this formulation could cause obesity in adult rats with
complications of abnormal blood fat and IR; lotus root joints could prevent the excessive weight
gaining in rats caused by this high colorific feed, and had a function to reduce intraperitoneal fat;
lotus root joints could also reduce IR in this obesity rat model and had a function to prevent increase
of TG thereof. Lotus root joints containing relatively more starch had the best anti-obesity effect.
Example 2. The effect of extract of lotus root joints on nutrition-type obesity rat
2.1 Material and method
2.1.1 Medicine and preparation thereof
[0046] Water decoction extract of lotus root joints : take proper amount of dry lotus root joints,
pulverize it into granules of soybean's size, add it in 6 tilde& 10 times by weight of fresh water,
based on the weight of the granules; after it is heated to boiling point, continue to decoct it on small
fire to keep boiling for 30 tilde& 40 minutes, and then filter it while it is hot; extract the filtrate residue
once more using the same method, and combine the extracted solutions; after being concentrated
under reduced pressure and being frozen till to a powder having a water content of 6%, seal and
store it for future use.
408/757
[0047] Ethanol refluxing extract of lotus root joints: take proper amount of dry lotus root joints,
pulverize it into granules of 20 mesh, add it in 6 tilde& 10 times of 30% tilde& 90% by weight
ethanol solutions, and heat it in water bath and refluxing for 1 hour, filter it while it is hot; Extract the
filtrate residue once more using the same method, and combine the extracted solution; After
concentrating it under reduced pressure, retrieve ethanol, freeze dry it in vacuum, the water content
was 5%, seal and store it for future use.
[0048] Cold maceration extract of lotus root joints: take proper amount of dry lotus root joints,
pulverize it into granules of 20 mesh, add it in 6 tilde& 10 times of 30% tilde& 90% by weight of
ethanol solutions, and macerate it at room temperature for 24 hours; After filtration, add the ethanol
solution at the same concentration described above to the filtrate residue for another 2 extractions,
and combine the extracted solution; After concentrating it under reduced pressure, retrieve ethanol,
freeze it in vacuum till to a powder having a water content of 5%, seal and store it for future use.
2.1.2 animal group, model establishment and administration of the product
[0049] SD male rats, weighed 434+/-17g were provided by animal laboratory of Yunnan Baiyao
Group Co., Ltd. The animals were randomly assigned to: blank group, model group, water decoction
extract group (water decoction group), ethanol refluxing extract group (ethanol refluxing group),
ethanol cold maceration extract group (ethanol cold maceration group). 8 animals for each group,
and were fed in separate cages. Model establishment was the same as that in experiment 1, i.e. give
basal feed to blank group, high colorific feed to each of the other groups, dosage was the same as
described before. Tap water was available ad libitum.
[0050] In the mean time of model establishment, administrate the animals with different feeds
through gastric injection at 9 a.m. every day. The dosages of three extract powders described above
were 2.4g/kg for water decoction group , 1.92g/kg for ethanol refluxing group , and 1.32g/kg for
ethanol cold maceration group. All of them were diluted with distilled water of same volume before
gastric injection. Distilled water of same volume was adopted for gastric injection in blank group and
model group. The experimental period was 35days.
409/757
2.1.3 Observation indicator and method: identical to example 1.
2.1.4 Statistical method: identical to example 1.
2.2 Test result
2.2.1 General items
[0051] The animals' spirit, appetite, skin and hair, stool of rats in each group were all as usual
during the whole process of experiment.
2.2.2 Effect of three lotus root joints extracts on the weight, Lee's index and fat index of adult
nutrition-type obesity rats (Table 9)
[0052] Table 9 shows that, at the end of experiment, the rat's weight, Lee's index and fat index in
model group were all significantly higher than those in blank group (p<0.01). Among the three test
groups, the weights of animals in water decoction group and refluxing group were still heavier than
that in blank group (p<0.01 for both), cold maceration group had no significant difference from blank
group; compared with model group, weight in the three test groups were all significantly reduced
(p<0.01); Lee's index in both water decoction group and refluxing group were higher than that in
blank group (p<0.05), while cold maceration group had no significant difference from blank group;
compared with model group, Lee's index in cold maceration group was relatively lower (p<0.01).
None of the fat index in three test groups had significant difference from that in blank group, wherein
the model group was the most similar to blank group. This result indicated that, all the lotus root joints
water extract, lotus root joints ethanol refluxing extract and ethanol cold maceration extract had
preventive effect on the excessive weight gaining and on increase of intraperitoneal fat in rats
410/757
caused by high colorific feed, among which ethanol cold maceration extract seemed to have the
best effect; lotus root joints water extract had comparable effect to that of lotus root joints ethanol
refluxing extract.
2.2.3 The effect of three lotus root joints extracts on the blood sugar, insulin (Ins) and ISI of adult
nutrition-type obesity rats (Table 10)
[0053] Table 10 shows that, the blood sugar in model group was higher than that in blank group
(p<0.05), while the rest groups had no significant difference from blank group. Blood Ins in model
group was significantly higher than that in blank group( p<0.01); Among three test groups, only water
decoction group was slightly higher than blank group (p<0.05); compared with model group, blood
Ins in all three test groups were reduced (p<0.05, p<0.01), with the cold maceration group being the
lowest (p<0.01). ISI in model group was significantly reduced, among three test groups, ISI in both
water decoction group and refluxing group were reduced, wherein the refluxing group was even
lower (p<0.01), cold maceration group had no significant difference from blank group; Compared
with model group, ISI in all the three test groups had increased to some extent, with the cold
maceration group being increased more. This result indicated that, all the lotus root joints water
extract, lotus root joints ethanol refluxing extract and ethanol cold maceration extract had preventive
effect on increasing blood sugar and blood Ins in rats, and could improve IR, and ethanol cold
maceration extract seemed to have the best effect, while lotus root joints water extract had
comparable effect to that of lotus root joints ethanol refluxing extract.
2.2.4 The effect of three lotus root joints extracts on the serum TC, TG and HDL-c of adult nutritiontype obesity rats (Table 11)
[0054] Table 11 shows that, TC in model group had significantly increased (p<0.01), so did the
three test groups (p<0.01); there was no significant decrease compared with model group. TG in
model group had significantly increased (p0.05), and the cold maceration group was more similar to
blank group. Had a lower HDL-c than blank group (p<0.05), the other three groups were all higher
than that of model group, with cold maceration group was the highest (p 30% , Rg1>20%;
notoginseng leaf saponin : content of saponin element squ& 32%, calculated as original ginseng
411/757
diol) ; squ& green tea extract(tea polyphenol squ& 40% catechin squ& 25%, EGCG squ& 25% ,
caffeine < 5 %=
3.1.2 Animal group and model establishment administration
[0058] SD male rats, weighed 435+/-16g, were provided by animal laboratory of Yunnan Baiyao
Group Co., Ltd. Animals were randomly assigned to: blank group, model group, lotus root joints
ethanol cold maceration extract freeze dry powder group (lotus root joints simple prescription group),
lotus root joints ethanol cold maceration extract freeze dry powder plus notoginseng extract group
(lotus root joints compound prescription group 1), lotus root joints ethanol cold maceration extract
freeze dry powder plus green tea extract group (lotus root joints compound prescription group 2)
and lotus root joints ethanol cold maceration extract freeze dry powder plus notoginseng extract plus
green tea extract group (lotus root joints compound prescription group 3). 8 animals were in each
group, which were fed in separate cages. Give basal feed to blank group, high colorific feed to each
of the other groups to establish model (the method was identical to that in previous two experiments).
Tap water was available ad libitum for each rat.
[0059] In the mean time of model establishment, administrate the feed through gastric injection at 9
a.m. every day: 1.32g/Kg lotus root joints cold maceration extract freeze dry powder for lotus root
joints simple prescription group; 1.32g/Kg lotus root joints cold maceration extract freeze dry powder
+ 0.066g/Kg notoginseng saponin and 0.066g/Kg notoginseng leaf saponin for lotus root joints
compound prescription group 1; 1.32g/Kg lotus root joints cold maceration extract freeze dry powder
+ 0.132g/Kg tea polyphenol for lotus root joints compound prescription group 2; 1.32g/Kg lotus root
joints cold maceration extract freeze dry powder + 0.066g/Kg notoginseng saponin and 0.066g/Kg
notoginseng leaf saponin + 0.132g/Kg tea polyphenol . Each medicine described above was diluted
with distilled water of the same volume before gastric injection. Distilled water of the same volume
was adopted for gastric injection in blank group and model group. Administration of the feeds
continued for 28days.
3.1.3 Observation indicator and method
412/757
General Items: Animal's spirit, appetite, skin and hair, activity and stool
[0060] Body weight, length and Lee's index: weight was taken once a week; length was measured
at the end of experiment (the length from nose tip to the anal of rat, expressed in cm). Lee's index =
weight (g)/body length (cm2).
[0061] Glucose tolerance: After on fast for 6 hours, rats were intraperitoneally injected with 2g
glucose/Kg, and blood sugar was measured at 0, 30, 60 and 120 minutes.
[0062] Blood sugar after on fast, Ins and blood fat (including TC, TG, LDL-c and HDL-c),
calculation of arteriosclerosis index AI (AI=TC/HDL-c) and Ratio of Coronary Heart Disease R-CHR
(R-CHR=LDL/HDL-c).
Fat weight in body: Intraperitoneal fat, et al, converted to celiac fat g/100g weight
[0063] The size and amount of fat cell: Take a small piece of fat from the same area around
genitals, fix it in 2.5% formaldehyde-ethanol solution, slice it in paraffin, count the fat cells in a full
visual field under 400xmicroscope, and measure the size of fat cells with micrometer.
Serum SOD and LPO
Blood viscosity
3.1.4 Statistical method: identical to example 1.
413/757
3.2 Test result
3.2.1 General items: The general items of rats in each groups were good during the whole process of
experiment, no abnormality was found.
3.2.2 The effect of lotus root joints compound prescription on the weight, Lee's index of nutrition-type
obesity rats(Table 12)
[0064] Table 12 shows that, at the beginning of experiment, there was no difference in rats' weight
among all groups. At the end of experiment, the rats' weight in model group was significantly higher
than that in blank group ( p<0.01 ); Among four test groups, the simple prescription group,
compound prescription group 1, compound prescription group 2 also had weight higher than blank
group (p<0.01,P<0.05), the amplitude in compound prescription group 2 was relatively smaller
(P<0.05), compound prescription group 3 had no significant difference from blank group. Compared
with model group, weight in four test groups were all significantly reduced (p<0.01); compared with
single prescription group, only weight in compound prescription group 3 was lower (p<0.05). There
was no significant difference among body length of the animal in each group. Lee's index in model
group was significantly higher than that in blank group (p<0.01); while four test groups had no
significant difference from blank group; compared with model group, Lee's index in four test groups
were relatively lower (p<0.01), in which compound prescription group 3 had the lowest. This result
indicated that, all these four formulations had preventive effect on the excessive weight gaining and
increase of Lee's index in rats caused by high colorific feed, and the compound prescription 3 had
the best effect, then is compound prescription 2; compound prescription 1 had a comparable effect
to that of simple prescription.
3.2.3 The effect of lotus root joints composition on the body fat and fat cells of nutrition-type obesity
rats (Table 13)
414/757
[0065] Table 13 shows that, the celiac fat of rats in model group was significantly more than that in
blank group (p<0.01); Among the four test groups, only simple prescription group and compound
prescription group 1 were higher than blank group (P<0.05); compound prescription group 3 was
most similar to blank group. Fat cells of rats in model group were significantly less than that in blank
group (p<0.01); Among four test groups, only simple prescription group and compound prescription
group 1 were lower than blank group (P<0.05, p<0.01); compared with model group, all the four test
group had relatively more fat cells; compared with simple prescription group, compound prescription
group 2 and compound prescription group 3 had more fat cells (P<0.05, p<0.01), with compound
prescription group 3 having the most and being most similar to blank group. A fat cell diameter of
rats in model group was significantly larger than that in blank group ( p<0.01 ); Four test groups were
also larger than that in blank group, but the difference between compound prescription group 2 and
compound prescription group 3 was relatively smaller (p<0.05); All the four test group had relatively
smaller fat cell diameter than that in model group (p<0.01); compound prescription group 3 had a
significantly smaller diameter than simple prescription group (P<0.01). This result indicated that, all
these four formulations had preventive effect on the increase of celiac fat, on fat cell hypertrophy and
on the decrease of fat cells caused by high colorific feed, and the compound prescription 3 had the
best effect, then was compound prescription 2, while compound prescription 1 and simple
prescription had comparable effect.
3.2.4 The effect of lotus root joints compound prescription on the blood fat of nutrition-type obesity
rats(Table 14)
[0066] Table 14 shows that, the serum TC of rats in model group was significantly elevated
( p<0.01 ) ; Among the four test groups, simple prescription group was still significantly higher than
blank group (P<0.05), compound prescription group 1 and compound prescription group 2 were
slightly higher than blank group (p<0.05), compound prescription group 3 had no significant
difference from blank group; all the three compound prescription groups were lower than model
group (p<0.05, p<0.01). Serum TG in model group was also elevated (p<0.05); All the four test
groups were lower than model group (p<0.05), with no significant difference from blank group. LDL-c
in model group was significantly elevated (p<0.05), so was in simple prescription group (p<0.01),
without increase in other three test groups. HDL-c in model group was reduced (p<0.05); all the four
415/757
test groups were higher than model group (P<0.05), with no significant difference from blank group.
This result indicated that, lotus root joints simple prescription didn't have had significant preventive
effect on the increase of serum TC of rats caused by high colorific feed, while compound
prescription 1 and compound prescription 2 had some effect, and compound prescription 3 had the
best effect. All these four formulations had preventive effect on the increase of serum TG in this
model. Lotus root joints simple prescription didn't have significant preventive effect on the increase
of serum LDL-c in this model, while three compound prescriptions did. All these four formulations
could prevent the decrease of serum HDL-c in this model.
3.2.5 The effect of lotus root joints compound prescription on the arteriosclerosis index (AI) and Ratio
of coronary heart disease ( R-CHD ) in nutrition-type obesity rats(Table 15)
[0067] Table 15 shows that, AI of rats in model group was significantly elevated ( p<0.01 ); All the
four test groups had no significant difference from blank group, wherein compound prescription
group 1 and compound prescription group 3 were lower than model group and more similar to blank
group. R-CHD in model group was significantly higher than that in blank group (p<0.01), among four
test groups, simple prescription group was still significantly higher than blank group (p<0.01),
compound prescription group 2 was slightly higher than blank group (p<0.05); all the four test
groups were significantly lower than model group (P<0.05), with three test groups being significantly
lower than simple prescription group (P<0.05, P<0.01), and compound prescription group 3 was the
lowest (p<0.01). This result indicated that, All these four formulations had preventive effect on the
increase of AI and R-CHD in this model, wherein compound prescription had the best result, then
was compound prescription 1, and followed by compound prescription 2, with simple prescription
being left behind.
3.2.6 The effect of lotus root joints compound prescription on the glucose tolerance in nutrition-type
obesity rats (Table 16)
[0068] Table 16 shows that, among the fasted blood sugar of each group, model group was
relatively higher, but without significant difference. At each time point after glucose load, blood sugar
in model group had been significantly elevated; blood sugar of simple prescription group, compound
416/757
prescription group 1 and compound prescription group 2 were higher than blank group at each time
interval after glucose load, only compound prescription group 3 was similar to blank group. But
compared with model group, blood sugar of each group at each time point after glucose load was
lower (p<0.01 for all). At each time interval after glucose load, blood sugar in compound prescription
group 3 was lower than that in single prescription group (p<0.01), compound prescription group 1
and compound prescription group 2 were lower than single prescription group (p<0.05) at
120minutes after glucose load. This result indicated that, All these four formulations had certain
preventive effect on the decrease of glucose tolerance in rats caused by high colorific feed, among
which compound prescription 3 had the best effect, compound prescription 1 and compound
prescription 2 had obvious effect, while simple prescription had relatively weak effect.
3.2.7 The effect of lotus root joints compound prescription on the blood sugar, Ins and ISI in nutritiontype obesity rats (Table 17)
[0069] Table 17 shows that, there was no significant difference among the fasted blood sugar of
each group, while fasted serum Ins in model group had significantly increased (P<0.01); All the four
test groups had significantly lower serum Ins than model group (P<0.01), with no significant
difference from blank group. Ins in model group was significantly lower than that in blank group
( P<0.01 ); Among four test groups, simple prescription group, compound prescription group 1 and
compound prescription group 2 were still lower than blank group ( P<0.05 ) , compound prescription
group 3 was similar to blank group; All the four test groups were significantly higher than model
group. This result indicated that, All these four formulations could prevent the increase of serum Ins
caused by high colorific feed, thus reduce the decrease of body's sensitivity to insulin, and
compound prescription 3 had the best effect, while the other three prescriptions had similar effect.
3.2.8 The effect of lotus root joints compound prescription on the blood viscosity in nutrition-type
obesity rats(Table 18).
[0070] Table 18 shows that, serum viscosity in model group had significantly increased (P<0.01);
All the four test groups had lower serum viscosity than model group, in which three compound
prescription groups were even lower (P<0.01); simple prescription group and compound
417/757
prescription group 2 were still higher than blank group (P<0.01, P<0.05); both compound
prescription group 1 and compound prescription group 3 were significantly lower than simple
prescription group. Hct in model group was larger than that in blank group (P<0.05), while four test
groups had no significant difference from blank group, wherein compound prescription group 3 was
most similar to blank group. This result indicated that, all these four formulations had preventive
effect on the increase of serum viscosity in this model, wherein compound prescription 3 and
compound prescription 1 had the best effect, then was compound prescription 2, while simple
prescription had a relatively weak effect. The situations were similar with regard to their effect on Hct.
3.2.9 The effect of lotus root joints compound prescription on SOD and LPO in nutrition-type obesity
rats(Table 19).
[0071] Table 19 shows that, serum SOD in model group had significantly decreased (P<0.01), with
no significant decrease in four test groups, in which compound prescription group 3 and compound
prescription group 2 were more similar to blank group. LPO in model group had significantly
increased (P<0.01); All the four test groups were significantly lower than that of model group
(P<0.01) ; Except that simple prescription group was still higher than blank group (P<0.01), all the
three compound prescription groups had no significant difference from blank group, and compound
prescription group 3 was most similar to blank group, then was compound prescription group 2; all
the three compound prescription groups were lower than simple prescription group
( P<0.05,p<0.01 ) , in which compound prescription group 2 and compound prescription group 3
were even lower ( p<0.01 ) . This result indicated that, all these four formulations had preventive
effect on the increase of serum SOD and LPO in this model, wherein compound prescription 3 and
compound prescription 2 had the best effect, then was compound prescription 1, while simple
prescription had a relatively weak effect.
3.3 Summary
[0072] Example 3 adopted the adult nutrition-type obesity rat model which had been proven to
have good repeatability. Investigations had been made on the effect of pure lotus root joints product,
lotus root joints combined with extracted total notoginseng saponin and green tea extract tea
418/757
polyphenol on many items of animals in this model such as weight, celiac fat, fat cell's size and
number, glucose tolerance, IR, blood fat, blood viscosity and LPO, et al. The result showed that,
using the pure lotus root joints product had caused certain improvement on items described above
except serum TC, but its effect on celiac fat reduction, blood fat adjustment, blood viscosity
improvement, anti-arteriosclerosis, anti-oxidization was still weak. In combination with total
notoginseng saponin, it could cause more significant decrease in serum TC and blood viscosity, and
cause quite smaller AI and R-CHD; in combination with tea polyphenol, it could cause the amount of
celiac fat and the number and size of fat cells to be closerer to normal value, and could increase the
activity of SOD, reduce LPO. If it is combined with notoginseng total saponin and tea polyphenol,
then all the above items would tend to become normal.
[0073] Notoginseng and one of its main effective active ingredient, notoginseng total saponin, is a
Chinese traditional medicine and natural chemical substance under extensive study. Many studies
have shown that, notoginseng saponin and notoginseng leaf saponin have good effect on blood fat
adjustment, blood viscosity reduction and protection of vascular endothelial function. Obesity
patients often show a complication of hyperlipoidemia and increased blood viscosity, with
significantly higher incidence of arteriosclerosis than persons without obesity. This experiment
adopted lotus root joints in combination with notoginseng saponin and notoginseng leaf saponin, the
result indicated that the blood fat and blood viscosity in this obesity model tend to become normal,
thus indicated that this combination was necessary for the comprehensive treatment of obesity.
[0074] Green tea is an herbal drug/food double function product that has been used for weight and
fat reduction since thousands year ago; one of its main active ingredient, tea polyphenol, is also a
kind of natural chemical substance under extensive study. Studies have shown that, tea polyphenol
has significant inhibiting effect on accumulation of fat in the body and liver of rats which had been
raised with fat-rich feed, and it could reduce TC in blood; At the same time, tea phenol also has
excellent anti-oxidization effect, it could inhibit the oxidization of cholesterol through self-oxidization,
thus reduce the deposition of cholesterol on artery wall. This adopted lotus root joints in combination
with tea polyphenol had brought about the result: celiac fat in this model had significantly decreased,
with significant decrease in fat cell's size, at the same time, blood SOD had significantly increased,
with significant reduction of LPO, thus could lead to a conclusion that this composition had a
comprehensive and good effect on obesity and the effect was also better than the single use of lotus
root joints.
419/757
[0075] Compound prescription 3 in this experiment adopted lotus root joints extract as the principal
drug to be combined with saponin from root, stem and leaf of notoginseng and with green tea
polyphenol, the result showed that, this combination had integrated the advantages of these three
substances, this model had achieved a relatively ideal effect in every respect. It was indicated that
lotus root joints, as the principle drug, in combination with saponin from root, stem and leaf of
notoginseng and with green tea polyphenol was a relatively ideal combination for the treatment of
obesity.
[0076] Obesity is a complicated disease with various conditions, it is not only a matter of gaining in
weight and fat, but, more important, obesity patients have significant IR and glucose, fat metabolic
disorders, it is the very pathophysiological disorders that complicate obesity patients with other
serious diseases such as type-II Diabetes Mellitus, abnormal blood fat, hypertension and
arteriosclerosis, and cause the average lifetime of obesity population shorter than that of non-obesity
population. This new combination according to the invention uses lotus root joints as the principal
active ingredient, it not only has good anti-obesity effect, but more important, it has an outstanding
effect on improving IR significantly. IR is the pathophysiological basis for obesity patient to have
metabolic disorders in glucose, fat and to be susceptible for the said serious diseases, therefore,
lotus root joints products, such as its powder or its extract, used as the principal active ingredient in
the prescription, have irreplaceably important effect on the treatment and prevention of obesity. A
combination with tea polyphenol and notoginseng saponin obtained from root, stem, leaf makes the
prescription more effective, act more quickly for cleaning unwanted fat within body, for adjustment of
blood fat, improvement of blood viscosity and protection of arterial wall, et al, and makes the
prescription capable of not only hitting the key point of obesity, i. e., IR, enabling a thorough
treatment to the basic grounds causing obesity, but also taking the advantage of combination of
various positive effects on various pathophysiological disorders in obesity. Thus, the product of the
invention has better effect not only on obesity itself, but also on the treatment and prevention of
various complications thereof.
Beneficial effect:
[0077] In one word, the present invention represents a substantial breakthrough in development of
a safe and effective health-care product that could comprehensively improve IR and the related
diseases through extensive and systemic study. The present invention adopts natural lotus root joints
420/757
as the principal raw material, which was abundant in source, without adverse effect, of high quality
and inexpensive, and readily acceptable to people, thus it could benefit millions of patients. The lotus
root joints composition according to the invention in combination with tea polyphenol and
notoginseng root-, stem- and leaf saponin, makes the prescription more effective, acts more quickly
for cleaning unwanted fat within body, for adjustment of blood fat, for improvement of blood viscosity
and for protection of arterial wall, et al; the product of the invention has not only a good therapy effect
on the key link of being obesity, i.e., IR, enabling an effective and thorough treatment of it, but could
also take the advantage of combination of various positive effects of the various active ingredients,
taking account of various complicated pathophysiological disorders caused from being obesity. Thus,
this combination has surprising effect not only on obesity itself, but also on the treatment and
prevention of type-II Diabetes Mellitus, hypertension, hyperlipoidemia and cardio-cerebral vascular
diseases induced by it.
Id=Table 1. Columns=3
Weight of rats in each group at 0 week
Head Col 1 to 3 AL=R: X+/-SD
SubHead Col 1: Group
SubHead Col 2: Number of animals n
SubHead Col 3: Body weight (g)
Blank Group8444.0+/-13.1
Model control group7442.0+20.8
Lotus root joints group8443.0+/-19.0
p>0.05 for all
421/757
Id=Table 9. Columns=6
Effect of three lotus root joints extracts on the weight, Lee's index and the fat index of adult nutritiontype obesity rats
Head Col 1 to 6 AL=R: X+/-S
SubHead Col 1: Group
SubHead Col 2: Init. Weight (g)
SubHead Col 3: End weight (g)
SubHead Col 4: Body length (cm)
SubHead Col 5: Lee's index (g/cm)
SubHead Col 6: Fat rate (g/kg)
Blank group434.5+/-22.5461.4+/-25.625.7+/-1.30.68+/-0.025.78+/-1.79
Model group434.3+/-19.3574.2+/-30.7
**
26.4+/-2.10.82+/-0.08
**
9.87+/-2.24
**
Water decoction group434.8+/-21.2530.3+/-30.1
**
26.3+/-1.70.77+/-0.04
*
8.18+/-2.01
Ethanol refluxing group433.9+/-15.1528.3+/-29.4
422/757
**
26.3+/-1.20.76+/-0.06
*
7.92+/-1.89
Ethanol cold maceration group434.7+/-17.2489.7+/-30.0
26.2+/-1.70.71+/-0.05
6.77+/-1.54
Compared with normal group : * p<0.05,
** p<0.01;
compared with model group : squ& p<0.05,
squ& squ& p<0.01 DEG n=8
Id=Table 10. Columns=4
Effect of three lotus root joints extracts on the blood sugar, insulin (Ins) and ISI of adult nutrition-type
obesity rats
Head Col 1 to 4 AL=R: X+/-S
SubHead Col 1: Group
SubHead Col 2: Blood sugar (mmol/L)
SubHead Col 3: Ins(mmol/L)
SubHead Col 4: ISI
Blank group4.62+/-0.5136.78+/-5.89- 5.106+/-0.173
Model group5.83+/-0.69
*
423/757
70.14+/-12.13
**
- 6.013+/-0.324
**
Water decoction group5.33+/-0.8456.34+/-13.91
*
- 5.691+/-0.412
**
Ethanol refluxing group5.28+/-0.7651.48+/-15.74
- 5.604+/-0.293
*
Ethanol cold maceration group5.02+/-0.5445.10+/-14.09
- 5.416+/-0.231
Compared with normal group : * p<0.05,
** p<0.01;
compared with model group : squ& p<0.05,
squ& squ& p<0.01 DEG n=8
424/757
Id=Table 11. Columns=4
Effect of three lotus root joints extract on the serum TC, TG and HDL-c of adult nutrition-type obesity
rats
Head Col 1 to 4 AL=R: X+/-S
SubHead Col 1: Group
SubHead Col 2: TC ( mmol/L )
SubHead Col 3: TG(mmol/L)
SubHead Col 4: HDL-c(mmol/L)
Blank group1.66+/-0.301.04+/-0.701.01+/-0.13
Model group2.58+/-0.41
**
2.84+/-1.02
**
0.74+/-0.15
*
Water decoction group2.41+/-0.32
**
2.43+/-1.070.98+/-0.29
Ethanol refluxing group2.43+/-0.54
**
1.98+/-1.121.06+/-0.24
Ethanol cold maceration group2.31+/-0.47
**
1.68+/-1.041.22+/-0.26
Compared with normal group : * p<0.05,
425/757
** p<0.01;
compared with model group : squ& p<0.05,
squ& squ& p<0.01 DEG n=8
Id=Table 12. Columns=5
Effect of lotus root joints composition on the weight, Lee's index of adult nutrition-type obesity rats
Head Col 1 to 5 AL=R: X+/-S
SubHead Col 1: Group
SubHead Col 2: Initial weight (g)
SubHead Col 3: End weight (g)
SubHead Col 4: Body length (cm)
SubHead Col 5: Lee's index (g/cm2)
Blank group436.5+/-16.2458.3+/-21.025.5+/-1.20.69+/-0.03
Model group436.2+/-18.1569.7+/-28.3
**
26.1+/-2.00.89+/-0.05
**
Simple prescription group436.8+/-16.9513.6+/-33.4
**
26.1+/-1.80.75+/-0.07
Compound prescription 1 group436.3+/-15.3517.2+/-30.0
**
26.2+/-1.30.74+/-0.05
426/757
Compound prescription 2 group436.4+/-17.2503.2+/-31.2
*
26.1+/-1.40.73+/-0.06
Compound prescription 3 group436.5+/-16.2458.3+/-21.025.5+/-1.20.69+/-0.03
Compared with normal group : * p<0.05,
** p<0.01;
compared with model group : squ& squ& p<0.01 ;
compared with simple prescription group : # p<0.05; n=7
Id=Table 13. Columns=4
Effect of lotus root joints compound prescription on the body fat and fat cells of nutrition-type obesity
rats
Head Col 1 to 4 AL=R: X+/-S
SubHead Col 1: Group
SubHead Col 2: Celiac fat (g/kg)
SubHead Col 3: Fat cell (number/HPF)
SubHead Col 4: Fat cell size ( mu m)
Blank group5.27+/-1.83126.3+/-11.527.1+/-1.8
Model group9.52+/-2.11
**
85.4+/-9.1
**
44.3+/-2.5
**
427/757
Simple prescription group8.14+/-1.62
*
106.5+10.4
*
36.5+/-2.1
**
Compound prescription 1 group7.83+/-2.23
*
98.2+/-8.3
**
38.1+/-3.4
**
Compound prescription 2 group7.07+/-1.64112.4+/-11.5
34.2+/-3.3
*
Compound prescription 3 group6.06+/-1.58
118.5+/-13.2
428/757
31.02.4
*
Compared with normal group : * p<0.05,
** p<0.01;
compared with model group : squ& p<0.05,
squ& squ& p<0.01;
compared with simple prescription group : # p<0.05,
# # p<0.01; n=7
Id=Table 14. Columns=5
Effect of lotus root joints compound prescription on the blood fat of nutrition-type obesity rats
Head Col 1 to 5 AL=R: X+/-S
SubHead Col 1: Group
SubHead Col 2: TC (mmol/L)
SubHead Col 3: TG (mmol/L)
SubHead Col 4: LDL-c (mmol/L)
SubHead Col 5: HDL-c(mmol/L)
Blank group1.54+/-0.250.92+/-0.642.43+/-0.411.32+/-0.15
Model group2.73+/-0.41
429/757
**
2.68+/-1.02
*
5.16+/-1.33
**
1.08+/-0.18
*
Simple prescription group2.45+/-0.32
**
1.34+/-1.13
4.97+/-1.47
**
1.37+/-0.09
Compound prescription 1 group2.09+/-0.40
*
1.20+/-0.89
3.55+/-1.331.32+/-0.20
Compound prescription 2 group2.14+/-0.46
*
1.24+/-0.88
3.87+/-1.541.28+/-0.19
430/757
Compound prescription 3 group1.93+/-0.52
1.01+/-0.66
3.16+/-1.391.35+/-0.23
Compared with normal group : * p<0.05,
** p<0.01;
compared with model group : squ& p<0.05,
squ& squ& p<0.01 . n=7
Id=Table 15. Columns=3
Effect of lotus root joints compound prescription on the AI and R-CHD of nutrition-type obesity rats
Head Col 1 to 3 AL=R: X+/-S
GroupAIR-CHD
Blank group1.17+/-0.371.83+/-0.34
Model group2.53+/-0.75
**
4.76+/-0.59
**
Simple prescription group1.77+/-0.813.62+/-0.70
**
Compound prescription 1 group1.48+/-0.69
2.65+/-0.66
431/757
Compound prescription 2 group1.56+/-0.722.81+/-0.54
*
Compound prescription 3 group1.40+/-0.58
2.42+/-0.45
Compared with normal group : * p<0.05,
** p<0.01;
compared with model group : squ& p<0.05,
squ& squ& p<0.01 ;
compared with simple prescription group : # p<0.05,
## p<0.01 . n=7
Id=Table 16. Columns=5
Effect of lotus root joints compound prescription on the glucose tolerance of nutrition-type obesity
rats
432/757
Head Col 1 to 5 AL=R: X+/-S
SubHead Col 1 AL=L>Group:
SubHead Col 2 to 5: Blood sugar (mmol/L)
Blank group03060120(min)
Model group5.06+/-0.4411.21+/-0.429.62+/-0.765.64+/-0.83
Simple prescription group6.02+/-0.8615.97+/-1.06
**
16.34+/-1.03
**
11.74+/-0.94
**
Compound prescription 1 group5.33+/-0.4914.02+/-0.97
**
14.11+/-1.01
**
9.83+/-1.12
**
Compound prescription 2 group5.41+/-0.9113.98+/-1.04
**
12.76+/-1.21
**
8.01+/-0.98
433/757
**
Compound prescription 3 group5.30+/-0.5614.11+/-1.15
**
11.22+/-1.19
**
7.88+/-1.02
**
Compared with normal group : * p<0.05, ** p<0.01;
compared with model group : squ& p<0.05, squ& squ& p<0.01 ;
compared with simple prescription group : # p<0.05, ## p<0.01 . n=7
Id=Table 17. Columns=4
Effect of lotus root joints compound prescription on the blood sugar, Ins and ISI of nutrition-type
obesity rats
Head Col 1 to 4 AL=R: X+/-S
SubHead Col 1: Group
434/757
SubHead Col 2: Blood sugar (mmol/L)
SubHead Col 3: Ins (Mu/L)
SubHead Col 4: ISI
Blank group4.38+/-0.5236.54+/-5.78- 5.142+/-0.164
Model group5.44+/-0.7669.08+/-11.33
**
- 6.083+/-0.214
**
Simple prescription group5.03+/-0.4848.14+/-15.22
- 5.504+/-0.204
*
Compound prescription 1 group5.21+/-0.8346.57+/-12.36
- 5.493+/-0.291
*
Compound prescription 2 group5.13+/-0.7247.03+/-13.34- 5.481+/-0.128
*
Compound prescription 3 group4.79+/-0.5542.35+/-7.83
- 5.301+/-0.172
Compared with normal group : * p<0.05,
435/757
** p<0.01;
compared with model group : squ& p<0.05, squ& squ& p<0.01 . n=7
Id=Table 18. Columns=3
Effect of lotus root joints compound prescription on the blood viscosity of nutrition-type obesity rats
Head Col 1 to 3 AL=R: X+/-S
SubHead Col 1: Group
SubHead Col 2: Serum viscosity ( cP )
SubHead Col 3: Hct ( % )
Blank group1.32+/-0.0934.12+/-2.01
Model group2.26+/-0.17
**
37.85+/-1.98
*
Simple prescription group1.98+/-0.34
**
35.87+/-2.15
Compound prescription 1 group1.35+/-0.28
34.35+/-1.79
Compound prescription 2 group1.77+/-0.21
*
35.76+/-2.43
Compound prescription 3 group1.340+/-0.31
436/757
34.19+/-2.03
Compared with normal group : * p<0.05,
** p<0.01;
compared with model group : squ& p<0.05,
squ& squ& p<0.01;
compared with simple prescription group : ## p<0.01 . n=7
Id=Table 19. Columns=3
Effect of lotus root joints compound prescription on the SOD and LPO of nutrition-type obesity rats
Head Col 1 to 3 AL=R: X+/-S
SubHead Col 1: Group
SubHead Col 2: SOD(u/g)
SubHead Col 3: LPO(nmol/ml)
Blank group17.31+/-1.940.69+/-0.12
Model group12.35+/-2.01
**
2.74+/-0.45
**
Simple prescription group14.83+/-1.99
1.58+/-0.37
**
437/757
Compound prescription 1 group15.02+/-2.351.16+/-0.23
Compound prescription 2 group16.04+/-2.51
0.98+/-0.32
Compound prescription 3 group16.98+/-1.84
0.81+/-0.14
Compared with normal group : * p<0.05, ** p<0.01;
compared with model group : squ& p<0.05,
squ& squ& p<0.01;
compared with simple prescription group : # p<0.05,
# # p<0.01. n=7
Claims:
438/757
1. A health-care product, wherein it comprises a powder of or an extract of lotus root joints.
2. A health-care product according to claim 1, characterized in that it comprises: an extract of lotus
root joints 4 tilde& 30 part by weight, a green tea and/or extract thereof 0.08-2 part by weight, and
notoginseng and/or extract thereof 0.08-0.5 part by weight.
3. A health-care product according to claim 2, characterized in that it contains 4 tilde& 7.5 part by
weight of the extract of lotus root joints.
4. A health-care product according to claim 2, characterized in that it further contains 2 tilde& 15
part by weight of a powder of lotus root joints.
5. A health-care product according to claim 1, characterized in that the health-care product is
formulated in the form of a Tablet, capsule, soluble granule, solution or injection.
6. A process for preparation of a health-care product, comprising the following steps:
a) Pulverizing lotus root joints and thus obtaining a powder of the joints;
b) Putting the powder of the joints in a product-grade solvent for extraction, then filtering it, and
using the filtrate solution as the extract of the joints; and
c) Blending conventional product-grade adjuvant with the powder of the joints or the extract of the
joints, and then formulating the blend into a form of Tablet, capsule, soluble granule, solution or
injection.
7. A process according to claim 6, characterized in that the steps a) and b) are carried out by any of
the following variants:
( 1 )Drying lotus root joints and pulverizing the dried joints into a powder having a granule size of
20 mesh; putting the powder into a container and adding therein 5 tilde& 10 times by weight of 30%
tilde& 90% ethanol, based on the weight of the powder; extracting it at room temperature for 24
hours, then filtering the mixture; extracting the filtrate residue for another 2 times using the same
procedure; combining the filtrate solutions, concentrating the combined filtrate solution under
vacuum and freeze-drying it into a dried powder; or
439/757
(2) Drying the lotus root joints and pulverizing the dried joints into a powder having a granule size
of 20 mesh, putting the powder into a container and adding therein 5 tilde& 10 times by weight of
30% tilde& 90% ethanol, based on the weight of the powder; heating it in water bath and refluxing
for 30 tilde& 60 minutes, then filtering it while it is hot; extracting the filtrate residue for another 2
times using the same procedure as mentioned above; combining the filtrate solutions, concentrating
it at a low temperature under reduced pressure, and freeze-drying it into a dried powder; or
(3)Drying lotus root joints and pulverizing it into granules of soybean's size; putting it into a
container and adding therein 6 tilde& 10 times by weight of fresh water, based on the weight of the
powder; heating it at its boiling point for 30 tilde& 40 minutes, then filtering it while it is hot;
extracting the filtrate residue for another 2 times using the same procedure as mentioned above;
combining the filtrate solutions, concentrating the combined solution under vacuum and drying it into
a powder.
8. A process according to claim 6, characterized in that 4 tilde& 7.5 part by weight of extract of
lotus root joints is prepared according to steps a) and b); and another 0.08-2 part by weight of green
tea and/or extract thereof, 0.08-0.5 part by weight of notoginseng and/or extract thereof are added.
9. A process according to claim 8, characterized in that further 2 tilde& 15 part by weight of powder
of lotus root joints is added.
10. Use of the health-care product according to any one of claim 1 to 5 in preparation of following
medicines:
Medicine for improving human insulin resistance;
Medicine for treating or preventing obesity;
Medicine for treating or preventing hypertension;
Medicine for treating or preventing hyperlipoidemia;
Medicine for treating or preventing Diabetes Mellitus;
Medicine for improving blood viscosity, preventing thrombosis, and promoting microcirculation;
Medicine for treating or preventing Alzheimer's Disease and against senility.
440/757
251. JP2004083517 - 03.03.2004
PHARMACEUTICAL COMPOSITIONS AND HEALTH FOODS FOR PREVENTING AND TREATING
MALE STERILITY COMPRISING OYSTER EXTRACT AND GINSENG EXTRACT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=JP2004083517
Inventor(s):
MATSUI MATSUTARO (JP); KURUMIYA MOTOSHI (JP)
Applicant(s):
TOKIWA KANPO PHARMA (JP)
IP Class 4 Digits: A61K; A61P
IP Class:
A61K35/78; A61K35/56; A61P15/00
E Class: A61K35/78+M; A23L1/30; A61K35/56+M
Application Number:
EP20030255159 (20030820)
Priority Number: JP20020248810 (20020828)
Family: JP2004083517
Equivalent:
CA2436708; US2004043080
Cited Document(s):
WO02094297; JP2002173434; JP60066960; CN1075639; CN1096205
Abstract:
THE PRESENT INVENTION PROVIDES A PHARMACEUTICAL COMPOSITION AND A HEALTH
FOOD WHICH CAN BE INGESTED CONVENIENTLY, AND CAN EFFECTIVELY PREVENT OR TREAT
MALE STERILITY. THE PHARMACEUTICAL COMPOSITION AND THE HEALTH FOOD COMPRISE
AN OYSTER EXTRACT AND A GINSENG EXTRACT.Description:
441/757
FIELD OF THE INVENTION
[0001] The present invention relates to a pharmaceutical composition or a health food for
preventing or treating male sterility. More specifically, the present invention relates to a
pharmaceutical composition or a health food for preventing or treating male sterility comprising an
oyster extract and a ginseng extract, which can be ingested conveniently.
BACKGROUND OF THE INVENTION
[0002] Some obstetricians and gynecologists, and urologists report that the frequency of causing a
marital sterility derived from male causes (male sterility) is generally 30-50%. Approximately 90% of
the causes for the male sterility are associated with sperm and, inter alia, occur by diseases such as
oligospermia, asthenozoospermia, azoospermia, and the like. Thus, there is desired development of
preventive or therapeutic drugs for the male sterility, which can increase the number of sperms and
can be ingested conveniently.
OBJECTS OF THE INVENTION
[0003] An object of the present invention is to provide a pharmaceutical composition which can be
ingested conveniently, and can efficiently prevent or treat male sterility, or a health food having the
similar effects to those of the pharmaceutical composition.
SUMMARY OF THE INVENTION
[0004] In view of the above object, the present inventors intensively studied and, as a result, found
out that a mixture of oyster and ginseng derived from natural products surprisingly exerts superior
effects of preventing or treating male sterility, which resulted in completion of the present invention.
442/757
[0005] Thus, the present invention provides (1) a pharmaceutical composition for preventing or
treating male sterility comprising an oyster extract and a ginseng extract as an active ingredient.
[0006] Also, the present invention provides (2) a health food for preventing or treating male sterility
comprising an oyster extract and a ginseng extract as an active ingredient.
[0007] Further, the present invention provides (3) a pharmaceutical composition for increasing the
number of sperms comprising an oyster extract and a ginseng extract as an active ingredient.
[0008] Also, the present invention provides (4) a pharmaceutical composition for increasing motility
of sperms comprising an oyster extract and a ginseng extract as an active ingredient.
[0009] Further, the present invention provides (5) a health food for increasing the number of
sperms comprising an oyster extract and a ginseng extract as an active ingredient.
[0010] Also, the present invention provides (6) a health food for increasing motility of sperms
comprising an oyster extract and a ginseng extract as an active ingredient.
DETAILD DESCRIPTION OF THE INVENTION
[0011] The pharmaceutical composition and the health food of the present invention will be
explained below.
[0012] The pharmaceutical composition and the health food of the present invention contain a
mixture of an oyster extract and a ginseng extract as an active ingredient.
[0013] An oyster extract used as an active ingredient is obtained from Crassostreagigas. Such the
extract is obtained by enzymolysis of Crassostreagigas.
[0014] Upon enzymolysis of Crassostreagigas, the following enzymes are used alone or in
combination of two or more to treat Crassostreagigas in water normally at 40-80 DEG C for 1-10
hours: an acidic protease derived from Aspergillus niger, Aspergillus oryzae, Aspergillus sp.,
Bacillus sp., or Rhizopus niveus; a neutral protease derived from Bacillus subtilis, Bacillus sp.,
443/757
Aspergillusoryzae, Aspergillus melleus, Pineapple cannery, or Carica papaya; and an alkaline
protease derived from Bacillus subtilis, or Bacillus species. Enzymolysis is performed, for example, in
an enzymatic reaction can. By such the treatment, enzymatic hydrolysates and water-soluble
components are dissolved in water. Then, the solution is filtrated by using a rotary vaccum filter or
the like and is centrifuged at a high speed to give a water-soluble extract, which is filtrated and
concentrated with a filter press and a vacuum concentrator to obtain a concentrated extract, which is
further dried by freeze-drying and spray-drying to obtain a powder (an oyster extract powder).
[0015] The oyster extract powder thus prepared contains large amounts of total amino acid and a
free amino acid, such as taurine, proline and arginine.
[0016] The oyster extract used in the present invention as an active ingredient also means a
concentrate at any step of these concentrating steps. It can be used, for example, as the abovementioned water-soluble extract, concentrated extract or oyster extract powder for formulating into a
pharmaceutical composition or a health food.
[0017] The ginseng extract used as an active ingredient in the present invention can be obtained
via steps of extracting rhizomes or thin roots of Panax ginseng of Araliaceae with water, 10-90%
hydrous alcohol, or 90-100% ethanol and, then, filtrating, concentrating and drying them.
[0018] The ginseng extract may be used at any concentration rate of 1:1-1:100 of the galenical vs.
the extract, and it is desired to take 600-30,000 mg as a daily dose of the galenical.
[0019] As a raw material for extracting ginseng the materials harvested from any areas such as
Siberia, China, Korea, North Korea, America, Japan or Canada can be used, and the raw materials
which have been cultivated for one year or more can be used.
[0020] After the dried and powdered ginseng is dissolved in no less than 80% ethanol, the
procedure of resin adsorption or column separation can give an extract, which is filtrated and
concentrated to obtain a dried extract containing a high content of ginseng saponin as a main
component.
[0021] The content of ginseng saponin in the dried ginseng extract is in a range of 0.2-90.0%, and
it is desirable that a daily dose is 600-30,000 mg of the galenical.
444/757
[0022] The above-resulting oyster extract and ginseng extract can be admixed at a desired ratio to
obtain a mixture. It is preferred that a mixing ratio is in a range of oyster extract: ginseng extract =
4,000:5-4,000:600 by weight from a viewpoint of efficacy.
[0023] Such the mixture can be formulated into granules and tablets by the known methods, after
drying for liquid extracts or without further processing for dried extracts, to obtain a final granule or
tablet product in an individual package. Upon formulation into the granules and the tablets,
excipients such as lactose, dextrin, starch and cellulose may be employed. Alternatively, such an
extract may be filled in a suitable bottle (e.g. glass, can, moisture-proof fiber papers).
[0024] A total amount of an oyster extract and a ginseng extract which are incorporated into the
pharmaceutical composition of the present invention, is in a range of 200-4,600 mg per one dosage.
[0025] It is preferred that in the case of a tablet in which a total amount of an oyster extract and a
ginseng extract is 100-400 mg per tablet, 1-20 tablet(s) per one dosage is (are) taken three times a
day before breakfast, lunch, and dinner. It is preferred that in the case of a granule in which a total
amount of an oyster extract and a ginseng extract is 500-5,000 mg per one bag, 1-4 bag(s) per one
dosage is (are) also taken three times a day before breakfast, lunch, and dinner. In addition, it is
preferred that in the case of a solution in which a total amount of an oyster extract and a ginseng
extract is 0.4-230 mg per 1 ml of preparation, 20-500 ml per one dosage is taken three times a day
before breakfast, lunch, and dinner.
[0026] In the health food of the present invention, the mixture obtained as described above and the
excipient and/or additive as described above can be formulated into a different form of supplemental
food (e.g. an individually packaged fine granule, solid pill, and triangular pill), a divided form in which
they are redissolved in an aqueous solution to incorporate into a drink, or a divided concentrated
solution.
[0027] Further, since the oyster extract and the ginseng extract which are active ingredients in the
pharmaceutical composition and the health food of the present invention, are components derived
from foods, it is not considered that they have toxicity or side effects. Moreover, their mixtures
possess the excellent male sterility treating efficacy as shown in the following Examples.
EXAMPLES
445/757
[0028] The present invention will be explained in more detail below by way of Preparations and
Examples, but is not limited by them.
PREPARATION 1: Oyster extract
[0029] Two thousand kilograms of farm-raised Crassostrea gigas was treated at 60 DEG C for 7.5
hours in water in an enzyme reaction can by using a mixture of a neutral protease derived from
Bacillus sp. and Aspergillus oryzae (Orientase 90N.ONS; Hankyu Bioindustries Inc.) and an acidic
protease derived from Bacillus sp. and Aspergillus sp. (Orientase 20A; Hankyu Bioindustries Inc.),
and then filtrated with a vacuum rotary filtration device, centrifuged at a high speed for one hour to
obtain the water-soluble extract. The water-soluble extract was concentrated with a filter press and a
vacuum rotary filtration device to obtain the concentrated extract. Finally, the concentrated extract
was freeze-dried to obtain 120 kg of a power (an oyster extract powder).
PREPARATION 2: Ginseng extract
[0030] One hundred kilograms of ginseng which is bearded roots and out of selection of three
years growing roots produced in Kirin Province, China and had been cut into no more than 5 mm
pieces, was extracted at 75+/-5 DEG C for 2 hours in 500 kg of a 65% by weight ethanol solution
while stirring. The resulting extract solution was subjected to solid-liquid separation to recover a
solution. The solution was treated with a filter press to obtain a clear solution. The ethanol in the
solution was then evaporated in a concentrator, replaced by water, and the solution was
concentrated to no more than 10% of solid content. Since an oil special to ginseng separates out in
the upper part of the concentrated solution, the upper solution containing the oil was removed by
liquid-liquid-solid separation with a centrifuge. Ginseng saponin was adsorbed onto HP-20 resin
(manufactured by Mitsubishi Kasei Corporation) by passing the resulting lower solution through a
stainless column charged with HP-20. After adsorption, water-soluble impurities were removed by
washing the resin by passing ion-exchange water through the column. The impurities which are
poorly soluble in an alcohol were then eluted, and the column was washed by passing ion-exchange
446/757
water through the column. After washing, the ginseng saponin adsorbed onto the resin was eluted by
passing a 70% by weight ethanol solution therethrough, and then concentrated. The resulting
concentrated extract was freeze-dried to obtain 1 kg of a powder (containing a ginseng extract and
ginseng saponin at 80% by weight).
EXMAPLE 1
[0031] Two hundred milligrams of the resulting oyster extract from PREPARAION 1, 20 mg of the
resulting ginseng extract from PREPARATION 2, 20 mg of reducing maltose syrup, 10 mg of dextrin
and 10 mg of sucrose fatty acid ester were admixed, granulated, dried, and then sieved at 60 mesh.
Following conventional procedures, the pharmaceutical composition of the invention was then
obtained in a tablet form (hexagonal tablet, pill or triangular tablet).
EXAMPLE 2
[0032] Three hundred milligrams of the resulting oyster extract from PREPARAION 1, 50 mg of the
resulting ginseng extract from PREPARATION 2, 30 mg of reducing maltose syrup, 10 mg of
crystalline cellulose and 10 mg of sucrose fatty acid ester were admixed, granulated, dried, and then
sieved at 60 mesh. Following conventional procedures, the health food of the invention was then
obtained in a tablet form (hexagonal tablet, pill or triangular tablet).
EXAMPLE 3
[0033] Fifteen hundred milligrams of the resulting oyster extract from PREPARAION 1, 150 mg of
the resulting ginseng extract from PREPARATION 2, 500 mg of reducing maltose syrup, 150 mg of
dextrin and 200 mg of CMC-Ca were admixed, granulated, dried, and then sieved at 10-60 mesh.
Following conventional procedures, the mixture was then granulated to obtain the pharmaceutical
composition of the invention in a granule form.
447/757
EXAMPLE 4
[0034] Fifteen hundred milligrams of the resulting oyster extract from PREPARAION 1, 50 mg of the
resulting ginseng extract from PREPARATION 2, 300 mg of reducing maltose syrup, 50 mg of dextrin
and 100 mg of CMC-Ca were admixed, granulated, dried, and then sieved at 10-60 mesh. Following
conventional procedures, the mixture was then granulated to obtain the health food of the invention in
a granule form.
EXAMPLE 5
[0035] Twenty two thousand and five hundred milligrams of the resulting oyster extract from
PREPARAION 1, and 180 mg of the resulting ginseng extract from PREPARATION 2 were dissolved
in distilled water, to a total amount of 30 ml. The mixture was filled into a 30 ml grass dropper bottle
to obtain the pharmaceutical composition of the invention in a solution form.
EXAMPLE 6
[0036] Eighteen thousand milligrams of the resulting oyster extract from PREPARAION 1, and 900
mg of the resulting ginseng extract from PREPARATION 2 were dissolved in distilled water, to a total
amount of 30 ml. The mixture was filled into a 30 ml grass dropper bottle to obtain the health food of
the invention in a solution form.
TEST EXAMPLE
Effect on the number and motility of human sperms.
448/757
[0037] A test was carried out in human subjects for the effect of improving the number and motility
of human sperms and the safety after administration of a mixture of an oyster extract and a ginseng
extract.
1. Methods
Test drugs: (A) Tablet containing 200 mg of oyster extract in one tablet
(B) Tablet containing 200 mg of oyster extract and 20 mg of ginseng extract in one tablet
Dose: 10 Tablets/dosage
(2 times per day in the morning and evening)
Dosing period: Four weeks
Number of test subjects: A total of eighteen male subjects consisting of each 6 male subjects of the
following group:
(1) Group of administration of mixture of both oyster and ginseng extracts (including three patients
with oligospermia).
(2) Group of administration of oyster extract.
(3) Control group
(No administration of test drugs)
Measurement periods: Before administration of test drugs, 2 and 4 weeks after administration of
them
Sampling: Test subject's sperm samples were obtained by their own masturbation, provided that
test subjects did not ejaculate for three days before the sampling to mainly homogenize a density of
sperms.
Measurement: The number of sperms was counted with a microscope, and their motilities were
measured by video recording of sperms via a microscope.
Criteria: The number and motility of sperms were compared in each group at 2 and 4 weeks after
administration.
449/757
2. Test results
[0039] Changes in the number and motility of sperms with time in each test subject before and
after administration of such the test drugs, are shown in Table 1 and 2, respectively.
Id=Table 1. Columns=8
Effects on the number of human sperms
Head Col 1 AL=L: Groups
Head Col 2 AL=L: Test subject No.
Head Col 3 to 4 AL=L: Before administration
Head Col 5 to 6 AL=L: 2 weeks after administration
Head Col 7 to 8 AL=L: 4 weeks after administration
SubHead Col 1:
SubHead Col 2:
SubHead Col 3:
Number of sperms
SubHead Col 4: Increase rate (%)
SubHead Col 5: Number of sperms
SubHead Col 6: Increase rate (%)
SubHead Col 7: Number of sperms
SubHead Col 8: Increase rate (%)
Control (No administration)15810055955697
25510052955193
31291001098411488
463100651036197
56610065986497
69910085868788
Mean10093.593.3
Standard error0.007.234.41
Administration of test drug A765100609266102
8731008511685116
9851009010692108
450/757
10381004612153139
11103100119116119116
126100711712200
Mean100111.3130.2
Standard error0.0010.6936.44
Administration of test drug B1385100829695112
14791009211693118
15371004612461165
16181004323967372
178710093107109125
18251005622463252
Mean100151.0190.7
Standard error0.0063.23103.04
Number of sperms (x 10/ml)
Id=Table 2. Columns=8
Effects on motility of human sperms
Head Col 1 AL=L: Groups
Head Col 2 AL=L: Test subject No.
Head Col 3 to 4 AL=L: Before administration
Head Col 5 to 6 AL=L: 2 weeks after administration
Head Col 7 to 8 AL=L: 4 weeks after administration
SubHead Col 1:
SubHead Col 2:
SubHead Col 3: Motility of sperms (%)
SubHead Col 4: Increase rate (%)
SubHead Col 5: Motility of sperms (%)
SubHead Col 6: Increase rate (%)
SubHead Col 7: Motility of sperms (%)
SubHead Col 8: Increase rate (%)
Control (No administration)15510050915396
265100639765100
451/757
39510090958589
4551006511858105
56010055925795
685100851008195
Mean10098.896.7
Standard error0.009.955.39
Administration of test drug A7551007513677140
8551006511867122
9601006510870117
10501006513073146
11651008012382126
12151002013330200
Mean100124.7141.8
Standard error0.0010.5030.54
Administration of test drug B13791008310590114
14951009810396101
15651007010885131
1675100719579105
17901009510696107
18551007513689162
Mean100108.8120.0
Standard error0.0014.0523.13
[0040] While increase in the number of sperms was not recognized in a control group taking no test
drugs over a test period, increase in the number of sperms was recognized in a group of
administration of a drug, at 2 and 4 weeks after taking them, as compared with before administration.
In the oyster extract-administered group, the number of sperms at 2 and 4 weeks after administration
of them was increased by 111.3 and 130.2%, respectively and, further, in the mixture of both oyster
extract and ginseng extract-administered group, the number of sperms at 2 and 4 weeks after
administration of them was remarkably increased by 151.0 and 190.7%, respectively, as compared
with before administration (100%). Meanwhile, the motility of sperms was a lower rate in such the
mixture-administered group, as compared with the oyster extract-administered group, but increase
rates of 108.8 and 120.0% were shown, respectively, at 2 and 4 weeks after administration. Thus,
effects of increasing (improving) the number and motility of sperms were recognized in the group in
452/757
which a mixture of an oyster extract and a ginseng extract was taken, and increase in the number of
sperms was more prominent as compared with administration of an oyster extract alone. Abdominal
pain, diarrhea, fever, hepatopathy, and other abnormality were not observed in the test subjects
taking a test drugs.
[0041] Therefore, it was found that such the mixture of the present invention exerts preventive and
therapeutic effects useful for male sterility induced from causes such sperm production dysfunction
and sperm abnormalities.
INDUSTRIAL APPLICABILITY
[0042] According to the present invention, the pharmaceutical compositions and health foods are
provided which can be ingested conveniently, and can exert effective preventive and therapeutic
effects on male sterility.Claims:
1. A composition comprising a combination of an oyster extract and a ginseng extract as active
ingredients for preventing or treating male sterility.
2. The composition according to claim 1 which is a pharmaceutical composition.
3. The composition according to claim 1 which is a health food.
4. The composition according to any preceding claim, wherein said oyster extract is obtained from
Crassostreagigas.
5. The use of a combination of an oyster extract and a ginseng extract as active ingredients for the
manufacture of a composition for the prevention or treatment of male sterility.
6. Use according to claim 5, wherein said composition is a pharmaceutical composition.
7. Use according to claim 5, wherein said composition is a health food.
453/757
8. Use according to any of claims 5-7, wherein said composition increases the number of sperm.
9. Use according to any of claims 5-7, wherein said composition increases the motility of sperm.
454/757
252. JP2004201568 - 30.06.2004
BLOOD FLUIDITY-IMPROVING HEALTH FOODS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=JP2004201568
Inventor(s):
HAGINO HIROSHI (JP); SAITO MASANOBU (JP)
Applicant(s):
SHIRAKO CO LTD (JP)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A23L1/304; A23L1/30; A23L1/337; A61P9/10; A61P9/12; A61K35/80
E Class: A23L1/30B; A23L1/30C2; A23L1/304; A23L1/337; A61K35/80
Application Number:
EP20030029056 (20031217)
Priority Number: JP20020374170 (20021225)
Family: JP2004201568
Equivalent:
US2004131636
Cited Document(s):
US6217879; EP0528033; US4690828; JP2000226333; JP5103641;
JP57033579; JP2003304830; JP2002187849
455/757
Abstract:
THIS INVENTION PROVIDES A NOVEL HEALTH FOOD WHICH IS EFFECTIVE IN PREVENTION AND
TREATMENT OF LIFE-STYLE RELATED DISEASES IN ORGANS IN THE CIRCULATORY SYSTEM,
SUCH AS HYPERTENSION, CEREBRAL INFARCTION, MYOCARDIAL INFARCTION ETC. BY
IMPROVING BLOOD FLUIDITY. PHOSPHOLIPID COMPONENTS OR MINERAL COMPONENTS ARE
COLLECTED FROM SEAWEEDS OF THE GENUS PORPHYRA AND/OR SEAWEEDS OF THE GENUS
UNDARIA AND THEN FORMED INTO A HEALTH FOOD IMPROVING BLOOD FLUIDITY. THIS
HEALTH FOOD HAS AN IMPROVING ACTION ON BLOOD FLUIDITY, AND IS THUS EFFECTIVE IN
PREVENTION AND TREATMENT OF LIFE-STYLE RELATED DISEASES IN ORGANS IN THE
CIRCULATORY SYSTEM, SUCH AS HYPERTENSION, CEREBRAL INFARCTION, MYOCARDIAL
INFARCTION ETC.Description:
Technical Field
456/757
[0001] The present invention relates to blood fluidity-improving health foods capable of improving
the fluidity of blood.
Background Art
[0002] Blood plays an important role in maintaining life by transporting oxygen and nutriments and
simultaneously transferring waste matter, carbon dioxide etc. from organs to the lung, kidney, liver
etc. by circulation through blood vessels in the body.
[0003] In recent years, patients with life-style related diseases such as hypertension, hyperlipemia
and diabetes are rapidly increasing in Japan because of westernization of eating habits and
disturbance in way of life and habits, to cause a social problem. It was revealed that these diseases
are related closely to blood fluidity. That is, it is observed that blood fluidity is lowered due to aging,
smoking, disturbance in way of life and habits, and the life-style related diseases. A reduction in
blood fluidity in micro blood vessels is also noted in diseases in organs in the circulatory system. In
addition, it is suggested that the reduction in blood fluidity causes ischemic cerebrovascular
disorders, cerebral infarction, pulmonary thromboembolism, myocardial infarction, bleeding in the
atrium, mesenteric thrombosis, lower-extremity arteriovenous thrombosis etc.
[0004] Conventionally, chemicals such as isoxsuprine hydrochloride, cinnarizine and cinepazide
maleate have been used as chemicals for ameliorating easily occurring blood accumulation and
micro thrombosis in the minor circulatory system, and many of these chemicals improve the
circulation of peripheral blood by expanding blood vessels by their relaxing action on smooth
muscles. For improving blood circulation in micro blood vessels, it is important to improve blood
fluidity not only by expanding blood vessels with these chemicals but also by improving erythrocyte
deformability to reduce blood viscosity. Accordingly, improvements in the fluidity of blood itself are
brought into focus while attention is paid to blood rheology in recent years. Examples of
improvements in blood fluidity include reports on a mixture of rutin contained in buckwheat, ginkgo
leaves and herb medicines (see JP-A 6-172196), hydroxymethyl furfural derivatives (see Japanese
Patent No. 2979305), 5-hydroxymethyl furan derivatives (see JP-A 9-216821), gamma -linolenic acid
alone or gamma -linolenic acid and a lipid-soluble antioxidant (see JP-A 10-147523), catechin (see
JP-A 10-72460), fish bile and/or its extract with a polar solvent (see JP-A 7-138168), saffron or a
tissue culture of saffron (see JP-A 10-287576), a glucosamine salt or a glucosamine salt derivative
457/757
(see JP-A 2002-97143) and collagen peptides (see Japanese Patent No. 3197547). It is also
reported that by giving feed containing unsaturated fatty acids to rats, the deformability of
erythrocytes was improved (Johannes M. B. et al.: Thrombosis Research, 81(2), pp. 283-288), or
upon ingestion of unsaturated fatty acids by humans, the deformability of erythrocytes was also
improved (T. Terano et al.,: Atherosclerosis, 46, pp. 321-331 (1983); I. J. Cartwright et al.:
Atherosclerosis, 55, pp. 267-281 (1985); J. B. Hansen et al.: Journal of Internal Medicine, 225, Suppl.
1, pp. 133-139 (1989)).
Summary of Invention
[0005] The object of this invention is to provide a novel health food which is effective in prevention
and treatment of life-style related diseases in organs in the circulatory system, such as hypertension,
cerebral infarction, myocardial infarction etc. by improving blood fluidity.
[0006] The present inventors searched for substances having high safety, capable of being
incorporated into a wide variety of general foods and exhibiting an improving effect on blood fluidity,
and as a result, they found that seaweeds of the genera Porphyra and seaweeds of the genera
Undaria satisfy these conditions, and their active ingredients are phospholipid components and
mineral components of seaweeds of the genera Porphyra or seaweeds of the genera Undaria, and
this invention was thereby made.
[0007] That is, this invention relates to a blood fluidity-improving health food comprising
phospholipid components of seaweeds of the genera Porphyra and/or seaweeds of the genera
Undaria, and also to a blood fluidity-improving health food comprising ash components of seaweeds
of the genera Porphyra and/or seaweeds of the genera Undaria.
Brief Description of Drawing
[0008] Fig. 1 is a graph showing the results of an erythrocyte deformability test using rats.
458/757
Disclosure of Invention
[0009] The fluidity of blood is influenced by physical characteristics of blood cells, such as
erythrocyte deformability, leukocyte deformability and adherence, and platelet aggregation ability.
For example, erythrocyte is deformed so as to pass through a blood vessel having a diameter
smaller than its diameter. This ability to be deformed is called deformability. Normal erythrocyte has a
diameter of about 8 mu m, but can easily pass without disruption through a vessel as very thin as
about 3 mu m in diameter because of its deformability. Such deformability plays a very important
role in passing through a thin capillary vessel.
[0010] The present inventors found that blood fluidity was improved by administering seaweeds of
the genera Porphyra or seaweeds of the genera Undaria into rats whose blood fluidity had been
significantly reduced by administering a high-fat food. Upon administration of the seaweeds,
promotion of erythrocyte deformability and reduction in platelet aggregation were observed, and a
change in formulation of fatty acids present in erythrocyte membranes was confirmed. Specifically,
an increase in linoleic acid, a decrease in arachidonic acid and an increase in eicosapentaenoic
acid in the formulation of fatty acids in rat erythrocyte membranes were observed. In addition, it was
found by analysis of mineral components in rat blood that major mineral components such as
calcium, magnesium etc. in seaweeds of the genera Porphyra or seaweeds of the genera Undaria
were absorbed into blood.
[0011] The present inventors made extensive study, and as a result, they found that seaweeds of
the genera Porphyra or seaweeds of the genera Undaria themselves have an improving effect on
blood fluidity, and that the seaweeds can further improve the effect by extracting phospholipid
components and mineral components therefrom, and can be utilized as health food having a
significant improving effect on blood fluidity.
[0012] The seaweeds of the genera Porphyra or the seaweeds of the genera Undaria used in the
present invention, including those generally eaten by us, may be in any forms such as raw, dried or
salted forms or in the form of dry powder, or of any varieties.
[0013] To extract phospholipid components from these seaweeds, generally used extraction
methods such as solvent extraction, supercritical extraction etc. are used. In experiments conducted
by the present inventors, the phospholipid components could be efficiently extracted with a water-
459/757
soluble organic solvent such as ethanol or a water-soluble organic solvent such as water-containing
ethanol. To extract mineral components, methods such as a method of extraction with water or a
water-soluble solvent or an ashing method are used.
[0014] As described above, the mineral components or phospholipid components from the
seaweeds of the genera Porphyra or the seaweeds of the genera Undaria are added in a
predetermined amount to food materials and processed in a usual production method, to give blood
fluidity-improving nutrient drinks, nutrient assistant foods and health foods endowed with blood
fluidity-improving functions. The phospholipid components and/or mineral components may be used.
The amount thereof in foods is not particularly limited. Because the seaweeds of the genera Porphyra
or the seaweeds of the genera Undaria are originally highly safe food materials, their extracted
components can also be incorporated in a wide range.
Best Mode for Carrying Out the Invention
[0015] Hereinafter, embodiments of this invention are described. This invention is not limited to the
following examples.
Example 1. Preparation of phospholipids from dry laver
[0016] Dry laver was milled into powder of about 50-mesh size with a high-speed mill and then
extracted with 20 L of 60% ethanol under stirring at ordinary temperature for 3 hours. The material
was separated by centrifugation into dry seaweed powder and an ethanol extract. The fraction
extracted with ethanol was concentrated under reduced pressure to remove the ethanol.
[0017] This ethanol fraction was analyzed for formulation of fatty acids in the phospholipid
components. The results are shown in Table 1.
Id=Table 1 Columns=2
Head Col 1: Fatty acid
Head Col 2: (mol%)
460/757
Myristic acid1.21
Palmitic acid19.22
Stearic acid1.43
Oleic acid5.01
Linoleic acid3.69
gamma -Linolenic acid2.24
Icosenoic acid6.59
Icosadienoic acid1
Arachidonic acid5.77
Eicosapentanoic acid53.84
Example 2. Preparation of mineral components from dry laver
[0018] 5 kg of the laver powder used in Example 1 was converted into ashes under strong heating
at 550 DEG C, to give 986 g mineral components of the laver. The mineral components were
subjected to elemental analysis. The results are shown in Table 2.
Id=Table 2. Columns=2
Head Col 1: Element
Head Col 2: (mg%)
Calcium440.0
Phosphorus650.0
Iron13.0
Sodium625.0
Potassium3100.0
Manganese4.0
Zinc10.0
Copper1.5
Iodine0.1
Selenium0.1
Magnesium270.0
461/757
Example 3. Preparation of phospholipids from dry laver
[0019] Dry wakame seaweed was milled into powder of about 50-mesh size with a high-speed mill
and then extracted with 200 ml of 60% ethanol under stirring at ordinary temperature for 3 hours. The
material was separated by centrifugation into dry wakame seaweed powder and an ethanol extract.
The ethanol extract was concentrated under reduced pressure to remove the ethanol.
[0020] This fraction extracted with ethanol was analyzed for formulation of fatty acids in the
phospholipid components. The results are shown in Table 3.
Id=Table 3 Columns=2
Head Col 1: Fatty acid
Head Col 2: (mol%)
Myristic acid9.64
Palmitic acid25.17
Stearic acid1.92
Oleic acid10.54
Linoleic acid13.21
gamma -Linolenic acid3.45
Icosenoic acid10.7
Icosadienoic acid0.27
Arachidonic acid14.3
Eicosapentanoic acid10.8
Example 4. Preparation of mineral components from dry wakame seaweed
[0021] 20 g of the wakame seaweed powder used in Example 3 was converted into ashes under
strong heating at 550 DEG C, to give 1.9 g mineral components of the wakame seaweed. The
mineral components were subjected to elemental analysis. The results are shown in Table 4.
462/757
Id=Table 4 Columns=2
Head Col 1: Element
Head Col 2: (mg%)
Calcium960.0
Phosphorus400.0
Iron5.4
Sodium6100.0
Potassium5500.0
Manganese0.6
Zinc2.0
Copper0.3
Iodine7.8
Selenium0.1
Magnesium1172.0
Test Example 1. Measurement of the fluidity of whole blood
[0022] Two to three hours after breakfast, blood was collected via a median cubitus vein from a 56years-old healthy person sitting at rest, and 5% heparin (1000 U/ml) was added to the obtained fresh
blood. Then, the obtained blood was pipetted in an amount of 500 mu l/sample. The mineral
components obtained in Example 2 or 4 were diluted 20-fold with physiological saline, and 5 mu l of
the dilution was added to a supernatant of each sample. 5 mu l physiological saline was added to
the control group. The fluidity of each whole blood was measured with a cytomicrorheology
measuring instrument MC-FAN (Hitachiharamachi Denshi Kogyo Co., Ltd.). The results are shown in
Table 5. As can be seen from the results, the mineral components obtained from each of the dry
laver and dry wakame seaweed were confirmed to exhibit an excellent blood fluidity-improving action.
Id=Table 5 Columns=2
Head Col 1:
Head Col 2: Passage time of whole blood
463/757
SubHead Col 1: Control group
SubHead Col 2: 62 seconds
Addition of the 20-fold dilution of the laver mineral components41 seconds
Addition of the 200-fold dilution of the laver mineral components52 seconds
Addition of the 20-fold dilution of the wakame mineral components47 seconds
Addition of the 200-fold dilution of the wakame mineral components53 seconds
Example 5
[0023] The mineral components obtained in Example 1 were used to produce a health food in the
form of tablets. 100 g of the mineral components from the dry seaweed, 50 g reducing maltose syrup,
1 g citric acid and 0.5 g perfume were well mixed and tabletted into tablets (300 mg/tablet) as health
food.
Test Example 2
[0024] The object of clinical examination was 12 healthy men in their forties to fifties. They were
examined for the passage time of their whole blood in the same manner as in Test Example 1 and
divided into two groups such that the two groups have almost the same passage time. Six tablets
(about 1.8 g) obtained in Example 5 were ingested by one group every day for 1 week. The other
group was instructed not to take processed foods of laver and wakame seaweed. Both the groups
were instructed not to change their way of life. One week thereafter, they were examined again for
the passage time of their whole blood. The results are shown in Table 6. As can be seen from the
results, an excellent blood fluidity-improving effect by daily administration of 6 tablets obtained in
Example 5 was recognized.
Id=Table 6 Columns=3
Head Col 1:
Head Col 2: Just before the test
Head Col 3: after 1 week
464/757
Control group53.0+/-4.4753.2+/-4.71
Group given the laver minerals52.8+/-6.2446.7+/-3.56
Test Example 3. Test of improvement of erythrocyte deformability in rats
[0025] 4-Weeks-old male Wister rats were preliminarily bred for 1 week as experimental animals,
then divided into groups each consisting of 5 animals and bred for 2 weeks in this experimental. The
non-administration group was continuously given MF powdery feed. The test group was given lipidcontaining feed containing 5% olive oil, 5% margarine, 1% cholesterol and 1% cholic acid as
fundamental feed to which the fraction extracted with ethanol or the mineral components obtained in
each of Examples 1 to 4 had been added. The control was given only the fundamental feed.
[0026] The feed was exchanged every day, and the animals were allowed drinking water ad libitum.
An animal breeding chamber was maintained at room temperature (25 DEG C) in 50+/-5% humidity
in a bright (12 hours)/dark (12 hours) cycle (lighting at 8 AM and light out at 8 PM). The animals were
bred for 2 weeks and fasted for 18 hours, the abdomen was opened under ether anesthesia, and
from the heart, the blood was collected in a sodium citrate solution such that the final concentration
of sodium citrate was 3.8%. The blood was centrifuged (1200xg, 10 minutes) to remove a
supernatant, and the erythrocytes were washed with a phosphate buffer. The deformability of the
resulting erythrocytes was measured, and the formulation of fatty acids in the resulting erythrocyte
membranes was analyzed. The results are shown in Fig. 1 and Table 7.
[0027] The deformability of the erythrocytes in the control group, as compared with those of the
group not given lipid, was confirmed to be significantly lowered. On the other hand, the groups given
the phospholipid-containing fraction extracted with ethanol or the mineral fraction obtained in
Examples 1 to 4, as compared with the control group, were confirmed to significantly promote
erythrocyte deformability. Further, a change in the formulation of fatty acids in the erythrocyte
membrane was observed in the group given the phospholipid components.
Id=Table 7 Columns=5
Head Col 1:
Head Col 2: Non-administration group
465/757
Head Col 3: Control group
Head Col 4: Group given the fraction extracted from the laver with ethanol
Head Col 5: Group given the fraction extracted from the wakame with ethanol
Myristic acid3.544.773.552.87
Palmitic acid40.2337.2038.2333.95
Stearic acid8.997.337.647.55
Oleic acid7.5512.4310.0114.12
Linoleic acid5.989.018.549.22
gamma -Linolenic acid0.770.550.800.84
alpha -Linolenic acid1.011.771.941.23
Icosenoic acid0.991.231.441.34
Icosadienoic acid0.470.710.440.61
Arachidonic acid24.2519.2217.8522.05
Eicosapentaenoic acid0.991.024.111.34
Docosatetraenoic acid3.111.882.881.92
Docosahexaenoic acid1.111.661.221.43
Hexacosanoic acid1.011.221.351.53
Example 6.
[0028] The fraction extracted with ethanol obtained in Example 1 was used to prepare a dressing.
That is, 15 g of the fraction extracted from the seaweed with ethanol, 0.2 g xanthane gum, 45 g water,
30 g salad oil, 3 g flavor seasoning, 1.4 vinegar, 2.5 g sorbitol, 1.5 g common salt, 0.1 g starch, 0.5 g
sodium glutamate, 0.5 g sucrose fatty ester and 0.3 g gum arabic were mixed to prepare a dressing.
Industrial Applicability
[0029] The health food of this invention is useful for improving blood fluidity and can be used for
treatment and prevention of hypertension, ischemic cerebrovascular disorders, cerebral infarction,
pulmonary thromboembolism, myocardial infarction, bleeding in the atrium, mesenteric thrombosis,
466/757
lower-extremity arteriovenous thrombosis etc. The health food of this invention is highly safe and can
be added widely to general foods because the starting material thereof is seaweed of the genus
Porphyra or Undaria.Claims:
1. A blood fluidity-improving health food comprising phospholipid components of seaweeds of the
genus Porphyra and/or seaweeds of the genus Undaria.
2. The blood fluidity-improving health food according to claim 1, wherein the phospholipid
components of seaweeds of the genus Porphyra and/or seaweeds of the genus Undaria are
components obtained by extracting seaweeds of the genus Porphyra and/or seaweeds of the genus
Undaria with ethanol.
3. The blood fluidity-improving health food according to claim 1, which is used as a food additive.
4. A blood fluidity-improving health food comprising mineral components of seaweeds of the genus
Porphyra and/or seaweeds of the genus Undaria.
5. The blood fluidity-improving health food according to claim 4, wherein the mineral components are
obtained by extracting seaweeds of the genus Porphyra and/or seaweeds of the genus Undaria with
a water-soluble solvent or by conversion the seaweeds into ashes.
6. The blood fluidity-improving health food according to claim 4, which is used as a food additive.
467/757
253. JP2004244359 - 18.08.2004
VASODILATOR PHARMACEUTICAL PREPARATION AND HEALTH FOOD COMPOSITION
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=JP2004244359
Inventor(s):
HAGINO HIROSHI (JP)
Applicant(s):
SHIRAKO CO LTD (JP)
IP Class 4 Digits: A61K
IP Class:
A61K38/01
E Class: A61K38/01
Application Number:
EP20040003013 (20040211)
Priority Number: JP20030035063 (20030213)
Family: JP2004244359
Equivalent:
US2004162231
Cited Document(s):
WO03063778; JP62169732
468/757
Abstract:
THIS INVENTION PROVIDES A NOVEL MATERIAL HAVING A VASODILATOR ACTION THEREBY
SUPPRESSING OR AMELIORATING VARIOUS HUMAN DISEASES AND DISORDERS. A
COMPOSITION COMPRISING, AS AN ACTIVE INGREDIENT, PEPTIDES OBTAINED BY
HYDROLYZING PROTEINS SUCH AS PROTEINS DERIVED FROM A SEAWEED SELECTED FROM
LAVER, WAKAME, EDIBLE BROWN ALGAE, SEA TANGLE, CHLORELLA AND SPIRULINA,
PROTEINS DERIVED FROM A PLANT SELECTED FROM SOYBEAN AND SESAME, PROTEINS
DERIVED FROM A FISH SELECTED FROM BONITO, MACKEREL, SAURY AND HORSE MACKEREL,
PROTEINS DERIVED FROM MILK PROTEINS SELECTED FROM POWDERED SKIM MILK AND WHEY,
PROTEINS DERIVED FROM AN ANIMAL SELECTED FROM CATTLE AND SWINE, AND COLLAGENLIKE PROTEINS DERIVED FROM BOVINE COLLAGEN, PORCINE SKIN COLLAGEN AND FISH
SCALE-DERIVED COLLAGEN IS USED AS A PHARMACEUTICAL COMPOSITION AND A HEALTH
FOOD COMPOSITION THEREBY EXHIBITING A VASODILATOR EFFECT BY WHICH VARIOUS
PHENOMENA CAUSED BY A REDUCTION IN BLOOD STREAM, SUCH AS STIFF NECK, HEADACHE
AND POOR CIRCULATION, CAN BE SUPPRESSED OR AMELIORATED.Description:
469/757
Technical Field
[0001] The present invention relates to a pharmaceutical preparation and a health food
composition having a vasodilator action thereby enabling suppression and amelioration of stiff neck,
headache, poor circulation and functional depressions related thereto and in particular to the
pharmaceutical preparation and health food composition comprising, as an active ingredient,
peptides obtained by hydrolyzing various proteins.
Background Art
[0002] Improvement of blood circulation leads to amelioration of symptoms such as stiff neck, poor
circulation, headache and numbness of extremities, recovery from fatigue, and promotion of
metabolism for peripheral tissues and hair. By promoting blood circulation, oxygen and nutriment
spread sufficiently to peripheral tissues as a whole, while wastes such as carbon dioxide gas and
lactic acid are collected, and thus the body is felt to be comfortable and warm just like a state after
bathing, thus ameliorating symptoms such as fatigue, neuralgia and menopausal disorders.
[0003] There are some mechanisms promoting blood stream. One is to increase blood flow by
improving the deformability of erythrocytes, and the other is to increase the amount of flowing blood
by dilation of blood vessels. The prior art related to the former includes the prevention of deterioration
in the deformability of erythrocytes by jujubes and an extract thereof (see JP-A 05-210639 and JP-A
07-61933) and also a report on collagen peptides reducing the viscosity of blood components such
as erythrocytes, leucocytes and platelets thereby improving blood flow (see Japanese Patent No.
3197547).
[0004] There are also reports on the ameliorating effect of the following naturally occurring
materials and extracts thereof on blood stream, but the mechanism ameliorating blood stream is not
necessarily evident. Such known examples include saffron or an extract of saffron (see JP-A 10287576), extracts of dandelions and mugwort (see JP-A 60-160856), a bouillon of bovine internal
organs and bones (see JP-A 54-41354), burned materials of lotus root nodes and root hairs (see JPA 53-133646), a water-soluble extract of red sweet potato (see JP-A 2001-145471), a theanine-
470/757
containing material (see JP-A 2000-247878), rehmannia roots (see JP-A 2000-169385), and
woundwort saponin (see JP-A 07-233191).
[0005] As an example in which vasodilatation was recognized, there is also a report on dilation of
blood vessels in rabbit ears by peptides derived from sardine muscles (see Japanese Patent No.
2732056). However, these reports are those on only phenomena, and do not describe effectiveness
and uses in humans.
[0006] In recent years, there has been demand for further development of blood stream improvers
having various mechanisms improving blood stream.
Summary of Invention
[0007] The object of the present invention is to provide a novel material having a vasodilator action
thereby improving blood circulation to suppress or reduce stiff neck, poor circulation, headache,
fatigue and menopausal disorders and to promote metabolism, and to further provide a health food
and a pharmaceutical preparation having such action.
Brief Description of Drawing
Fig. 1 is a graph showing experimental results of the vasodilator action of seaweed-derived
peptides on rabbit ears.
Fig. 2 is a graph showing experimental results of the vasodilator action of seaweed-derived
peptides on rabbit ears.
Fig. 3 is a graph showing experimental results of the vasodilator action of plant-derived peptides
on rabbit ears.
Fig. 4 is a graph showing experimental results of the vasodilator action of fish-derived peptides on
rabbit ears.
Fig. 5 is a graph showing experimental results of the vasodilator action of mammal-derived
peptides on rabbit ears.
471/757
Fig. 6 is a graph showing experimental results of the vasodilator action of animal-derived peptides
on rabbit ears.
Fig. 7 is a graph showing experimental results of the vasodilator action of collagen-derived
peptides on rabbit ears.
Disclosure of Invention
[0009] The present inventors have used ear vessels in rabbits to screen components based on
peptides obtained by hydrolyzing various proteins, and as a result, they have found that these
peptides have an effect of dilating blood vessels. That is, components containing peptides obtained
by hydrolysis of various proteins by an acid or an alkali and/or an enzyme protease were orally
administered as such or after purification into rabbits, to confirm dilatation of blood vessels.
[0010] The vasodilatation recognized in these rabbit ears has led to an increase in blood stream,
and as a result, various effects such as an effect of depressing blood pressure, an ameliorating
effect on stiff neck, poor circulation and headache, an effect of recovery from fatigue, an effect of
suppressing and reducing menopausal disorders, an effect of restoring hair by promotion of
metabolism, and an effect of improving skin conditions have been confirmed.
[0011] The protein hydrolysates recognized to have such effects include hydrolysates of proteins
from plants such as soybeans and sesame seeds, hydrolysates of proteins from animals such as
cattle and swine, hydrolysates of proteins from fishes such as bonito, mackerel, saury and horse
mackerel, hydrolysates of proteins from seaweeds such as laver, wakame, edible brown algae, sea
tangle etc. and micro-algae such as chlorella and spirulina, hydrolysates of milk proteins from
powdered skim milk and whey proteins, hydrolysates of proteins derived from livestock products
such as beef and pork, and hydrolysates of collagen proteins derived from bovine collagen, porcine
collagen from porcine skin, and from fishes such as fish scales, and peptides contained in these
hydrolysates were recognized to have a vasodilator effect.
[0012] Accordingly, the present invention relates to a vasodilator pharmaceutical preparation and
health food composition comprising, as an active ingredient, peptides obtained by hydrolyzing the
various proteins described above.
472/757
[0013] In hydrolysis of proteins in the present invention, acid or alkali decomposition and/or
enzymatic decomposition with a protease is generally used. The acid or alkali may be an organic or
inorganic acid or alkali, and it is preferable that the pH in acid hydrolysis is in the range of 1 to 4, and
the pH in alkali hydrolysis is in the range of pH 8 to 13. The decomposition temperature and time are
suitably established.
[0014] As the protease, use can be made of any generally used enzymes having a protease
activity, such as pepsin, pancreatin, papain, Prolaser (Amano Pharmaceutical Co., Ltd.), Samoase
(Yamato Kasei Co., Ltd.), Sumizyme AP, Sumizyme MP, Sumizyme FP (Shin-Nippon Kagaku Kogyo
Co., Ltd.), etc. Reaction conditions such as the concentration of the enzyme used, reaction pH,
reaction temperature, etc. may be selected such that the conditions are optimum for the enzyme
used.
[0015] In acid and alkali hydrolysis, it is not necessarily easy to regulate the reaction so as to
proceed uniformly. Accordingly, strict control of the reaction is necessary. Hydrolysis treatment with
an acid or alkali can be used in combination with enzymatic hydrolysis. By acid or alkali treatment
and subsequent treatment with a proteolytic enzyme, the molecular weight of the peptides is
decreased thus increasing the ratio of low-molecular peptides. The low-molecular peptides are
readily absorbed in digestive tracts and exhibit a high vasodilator effect, and it is thus desirable to
increase the ratio of the low-molecular peptides in this manner. In the human digestive tracts,
however, high-molecular peptides are degraded into low-molecular peptides by pepsin, trypsin and
peptidases, and thus peptides other than the low-molecular peptides can be considered to exhibit
the effect. It is however estimated that the low-molecular peptides exhibit the effect rapidly and
reliably. Accordingly, the molecular weight of the peptides is preferably lower, but when the peptides
are used as food, the same vasodilator effect can be recognized even if high-molecular peptides are
contained therein.
[0016] Although the reaction products (peptide components) obtained by hydrolyzing each protein
may be used as such, the peptide components may be concentrated and purified. The concentration
and purification treatment can be carried out using desalting treatment by an electrodialysis
membrane, desalting/concentration treatment with ion-exchange resin, discoloration, deodorization
and concentration treatment with activated carbon and precipitation treatment with an organic
solvent. The respective components may be used in a solution form, but can also be powdered by
473/757
spray drying or lyophilization. The peptide components used may be further purified by
chromatography.
[0017] It is desirable that various protein materials to be subjected to hydrolysis treatment are
purified proteins. Various materials such as seaweeds, plant materials, fish, milk proteins, animal
meat, and animal collagens can be used as such, but when the content of fat in the starting materials
is high, fat remains in the resulting hydrolysate and undergoes oxidation, thus often generating nasty
smells and tastes. Accordingly, starting materials from which oil was removed are desirably utilized.
For example, soybeans or sesame used is preferably a bean cake or sesame seed cake with a lower
content of oil after oil expression. Alternatively, oil can be removed after hydrolysis. It is also
important to subject fish and livestock meat to treatment for removing oil. When seaweeds are used,
on the other hand, the seaweeds can be subjected directly to hydrolysis without degreasing, and
even after hydrolysis, a degreasing procedure is not particularly necessary because of a lower
content of lipid components.
[0018] The vasodilator effect was confirmed with rabbit ears. That is, a sample was orally
administered to rabbits, and a change in blood vessels in ears was confirmed with the naked eye,
and from a photograph of the ears, the degree of vasodilatation was numerically expressed by using
area calculation software. By this method, the vasodilator effects in the Examples shown later were
confirmed.
[0019] In the present invention, it is estimated that as a result of the vasodilatation of blood vessels
by protein hydrolysates, blood stream is increased thereby improving the transfer of nutriment to
peripheral tissues and simultaneously improving the transfer of wastes. As a result, the protein
hydrolysates can be used in humans for the purpose of suppressing and reducing stiff neck,
headache and poor circulation. Further, the protein hydrolysates can improve blood circulation
thereby improving physiological functions in which not only the circulatory organ system but also the
nerve system, internal secretion system and immune system are involved, and thus the protein
hydrolysates can be used for the purpose of suppressing and improving difficulty of sleep and
menopausal disorders. Further, wastes such as carbon dioxide gas, lactic acid etc. can be suitably
collected from peripheral tissues, while oxygen and nutriment can spread sufficiently to peripheral
tissues, thus achieving recovery from fatigue and improvements in skin conditions, cosmetic effect
and hair restoration effect. These effects are shown in test results in humans in the Examples.
474/757
[0020] The protein hydrolysates in the present invention can be used as a food additive added to
general foods or as a health food composition or a pharmaceutical composition. The protein
hydrolysates may be used in any forms such as an aqueous solution, a suspension, powder, and
molded products, and their form is not particularly limited. Accordingly, the protein hydrolysates can
be used in a wide variety of general foods, and can be provided as a health food and a
pharmaceutical preparation in the form of capsules, tablets, powder, granules and drink. In this case,
the protein hydrolysates can be used not only as a single tasting component but also in combination
with functional materials such as other tasting components, excipients, stabilizers, Chinese
medicines and herbs or their functional components, and the hydrolysates can be mixed with, and
used in combination with, nutritive components such as vitamins and minerals and materials
allowable as foods.
[0021] To exhibit these effects, the amount of the protein hydrolysates administered into humans is
preferably 0.5 to 2000 mg/kg/day, more preferably 10 to 400 mg/kg/day. However, the dose is not
limited to the above range because the type and degree of symptom are varied from individual to
individual.
Best Mode for Carrying Out the Invention
[0022] Hereinafter, embodiments of this invention are described in more detail by reference to the
Production Examples and the Examples.
Production Example 1
[0023] Laver peptides were prepared from laver proteins of seaweeds of the genus Porphyra in the
following manner.
[0024] 50 kg dry laver was suspended in 950 L hot water heated at 95 DEG C and then boiled for 1
hour, and the broth was removed. Thereafter, 950 L water at 50 DEG C was added thereto and
adjusted to pH 2.0 with sulfuric acid, and 2 kg pepsin (Amano Pharmaceutical Co., Ltd.) was added
thereto and reacted at 50 DEG C for 24 hours under stirring. The resulting decomposed solution was
475/757
adjusted to pH 5.0 with 1 N NaOH and kept at 50 DEG C for 10 minutes to inactivate the pepsin.
Then, extraction residues were removed by centrifugation (14000 r.p.m. for 20 minutes), and the
supernatant was concentrated under reduced pressure and spray-dried to give a pepsin-digested
laver product (sample 1).
[0025] 1 kg of the pepsin-digested laver product was dissolved in distilled water, applied onto a
Dowex-50 (H) column, phi 50 cmx200 cm (Bio-Rad) previously equilibrated with hydrochloric acid,
then the column was washed with 120 L distilled water, and the adsorbed peptides were eluted with
2 N ammonia water. After the ammonia was removed with an evaporator, the sample was lyophilized
to give 385 g of 90% laver peptides (sample 2).
Production Example 2
[0026] 10 L water was added to 2 kg laver powder (10- to 50-mesh size) which was then stirred
and milled with an automatic mortar at room temperature for 1 hour, and the milled material was
separated into laver extraction residues and a supernatant by centrifugation.
[0027] Ethanol was added to the resulting supernatant which was then left at -20 DEG C for 12
hours to precipitate protein components and centrifuged to give 400 g water-soluble laver proteins
as precipitates.
[0028] The laver proteins were subjected to acid hydrolysis and subsequent enzymatic
decomposition in the following manner, to give low-molecular peptides. That is, 200 g laver proteins
were dissolved in 1 L of 1 N hydrochloric acid and decomposed with the acid by heating at 100 DEG
C for 2 hours. Then, the solution was adjusted to pH 6.0 with sodium hydroxide, and after 5 g
Sumizyme FP (Shin-Nippon Kagaku Kogyo Co., Ltd.) was added thereto, the solution was
decomposed at 40 DEG C for 8 hours. The decomposed solution was heated at 100 DEG C for 20
minutes to inactivate the enzyme, and then concentrated under reduced pressure and treated in the
same manner as for sample 2 in Production Example 1, to give 160 g laver peptides (sample 3).
Production Example 3
476/757
[0029] Wakame peptides were prepared from wakame proteins in the following manner. 1 kg dry
wakame seaweed was finely divided into powder of 35-mesh size, suspended in 20 L distilled water
and milled with a wet mill. Then, the sample was centrifuged to give 5 L wakame protein-containing
solution. The solution was concentrated into 1 L under reduced pressure, and then 8 L ethanol was
added to the concentrate which was then left at -20 DEG C for 12 hours to precipitate the proteins.
The sample was then centrifuged, and the resulting precipitates were air-dried to give 100 g watersoluble wakame proteins.
[0030] 50 g of the wakame proteins were dissolved in 500 ml phosphate buffer (pH 7.7), and 2.5 g
thermolysin was added thereto and reacted at 40 DEG C for 12 hours, to hydrolyze the proteins. After
the reaction, the reaction solution was kept at 100 DEG C for 20 minutes to inactivate the enzyme,
and the reaction solution was lyophilized to give 35 g wakame peptides (sample 4).
[0031] Sea tangle peptides (sample 5) and edible brown alga peptides (sample 6) were obtained
in the same treatment as described above.
Production Example 4
[0032] Chlorella peptides and spirulina peptides were prepared respectively in the following
manner. 50 g chlorella or spirulina powder was dissolved in 1 L of 0.5 N sodium hydroxide and
decomposed with the alkali by heating at 80 DEG C for 5 hours. Then, the sample was neutralized
with hydrochloric acid and applied onto a Dowex-50 (H) column ( phi 10 cmx65 cm) previously
equilibrated with hydrochloric acid, then the column was washed with 5 L distilled water, and the
adsorbed peptides were eluted with 2 N ammonia water. After the ammonia was removed with an
evaporator, the sample was lyophilized to give 21 g chlorella peptides (sample 7) or 18 g spirulina
peptides (sample 8).
Production Example 5
477/757
[0033] As examples of the protein hydrolysates derived from plants, soybean peptides and sesame
peptides were obtained from degreased bean cakes and degreased sesame seed cakes,
respectively. That is, 1 kg degreased bean cakes or degreased sesame seed cakes were ground,
then suspended in 5 L water and adjusted to pH 2.0 with sulfuric acid, and 40 g porcine stomachderived pepsin (Amano Pharmaceutical Co., Ltd.) was added thereto and reacted at 50 DEG C for
24 hours under stirring. After the reaction, the solids were separated by filtration, and the resulting
supernatant was adsorbed onto Dowex-50 (H), then washed with water, eluted with ammonia water,
made free from ammonia, concentrated and lyophilized in the same manner as in Production
Example 1, to give 200 g soybean peptides (sample 9) and 98 g sesame peptides (sample 10).
Production Example 6
[0034] As examples of the protein hydrolysates derived from fish meats, peptides were obtained
from fish meats of bonito, mackerel, saury and horse mackerel, respectively. 500 g fresh fish meat of
bonito, mackerel, saury and horse mackerel were collected and milled, and after 1 L water was
added thereto, the meat was thermally denatured by keeping it at 100 DEG C for 10 minutes. The pH
was adjusted to pH 2.0 with sulfuric acid, and 20 g pepsin (Amano Pharmaceutical Co., Ltd.) was
added thereto and kept at 50 DEG C for 16 hours. After the reaction was finished, the sample was
adjusted to pH 5.0 with an aqueous sodium hydroxide solution and heated at 50 DEG C for 10
minutes to inactivate the enzyme. The reaction solution was centrifuged, and the resulting
supernatant was adsorbed onto Dowex-50 (H), then washed sufficiently with water and eluted with 2
N ammonia water to give a peptide fraction. The peptide solution was concentrated under reduced
pressure, made free from ammonia and lyophilized. By the above procedure, 30 g bonito-derived
peptides (sample 11), 32 g mackerel-derived peptides (sample 12), 45 g saury-derived peptides
(sample 13) or 33 g horse mackerel-derived peptides (sample 14) was obtained.
Production Example 7
[0035] As examples of the protein hydrolysates derived from livestock milk, peptides were obtained
in the following manner from powdered skim milk and whey respectively. 1 kg commercial powdered
skim milk or commercial separated whey protein was suspended in 2 L warm water and adjusted to
478/757
pH 7.5, and then 40 g Samoase (Yamato Kasei Co., Ltd.) was added thereto and reacted at 50 DEG
C for 16 hours. After the reaction, the reaction solution was heated at 100 DEG C for 10 minutes to
inactivate the enzyme, then adsorbed onto Dowex-50 (H), washed with water and eluted with
ammonia water to give a peptide fraction. The peptide solution was concentrated under reduced
pressure, made free from ammonia and lyophilized to give 270 g powdered skim milk peptides
(sample 15) or 333 g separated whey protein peptides (sample 16).
Production Example 8
[0036] As examples of the protein hydrolysates derived from livestock meat, peptides were
obtained in the following manner from beef and pork respectively.
[0037] 1 kg minced beef with less oil was added to 2 L of 1 N hydrochloric acid and heated at 100
DEG C for 2 hours. After cooling, the sample was adjusted to pH 2.0 with sodium hydroxide, and 40
g porcine stomach-derived pepsin (Amano Pharmaceutical Co., Ltd.) was added thereto and
reacted at 50 DEG C for 16 hours under stirring. After the reaction was finished, the reaction solution
was neutralized to pH 5.0 with sodium hydroxide and kept at 50 DEG C for 10 minutes to inactivate
the enzyme. The reaction solution was centrifuged (3000 r.p.m., 10 minutes) to separate a
supernatant. The oil phase in the supernatant was removed to the maximum degree, and the
supernatant was applied onto Dowex-50 (H), then sufficiently washed with water and eluted with 2 N
ammonia water to give a peptide fraction. The peptide solution was concentrated under reduced
pressure, made free of ammonia and lyophilized to give 343 g beef-derived peptides (sample 17).
318 g pork-derived peptides (sample 18) were also obtained in the same manner as described
above.
Production Example 9
[0038] As examples of the collagen hydrolysates, peptides were obtained in the following manner
from porcine skin-derived glue and fish scales respectively.
479/757
[0039] 2 kg glue derived from a commercial porcine skin was ground and suspended in 4 L water
previously made acidic (pH 3.0) with hydrochloric acid, and stirred at room temperature for 3 days.
Thereafter, the suspension was adjusted to pH 2 with hydrochloric acid, and 40 g porcine stomachderived pepsin (Amano Pharmaceutical Co., Ltd.) was added thereto and reacted at 50 DEG C for
16 hours. After the reaction was finished, the reaction solution was neutralized to pH 5.0 with sodium
hydroxide and kept at 50 DEG C for 10 minutes to inactivate the enzyme. Thereafter, the reaction
suspension was centrifuged to give a supernatant which was then applied onto a Dowex-50 (H)
column, then washed with water and eluted with 2 N ammonia water to give a peptide fraction. The
peptide eluate was concentrated under reduced pressure and lyophilized to give 720 g glue-derived
collagen peptides (sample 19).
[0040] Separately, 1 L commercial fish scale-derived 50% collagen solution (Timely Co., Ltd.) was
decomposed with pepsin, purified with the cation-exchange resin and powdered by lyophilization in
the same manner as described above, to give 265 g fish scale-derived collagen peptides (sample
20).
[0041] The vasodilator effects of the samples obtained in the Production Examples above were
confirmed and then the samples were used as shown in the following examples.
Example 1
[0042] Nine-week-old male rabbits (Slc : JW.CSK) each weighing 1.5 to 1.8 kg were preliminarily
bred for 1 week and then subjected to experiment. An animal breeding chamber was maintained at a
temperature of 22 DEG C+/-1 DEG C in 50% humidity in a bright (12 hours)/dark (12 hours) cycle,
and the animals were allowed feed Lab Diet 5L95 (Nippon SLC) and drinking water ad libitum.
Before administration of a sample, the animals were fasted for 2 hours. The sample, 1000 mg/kg
body weight, was dissolved in 3 to 10 ml physiological saline and administered forcibly through an
oral probe into the animals.
[0043] The state of blood vessels in the rabbit was examined in the following manner. The rabbit
was fixed to a blood collection box, and when the rabbit became quiet to show no change in ear
vessels, a photograph of the ear was taken with a digital camera and this point in time was regarded
as 0 minute. From 10 minutes after the sample was administered, a photograph of the ear was taken
480/757
repeatedly at intervals of 10 minutes until the vasodilatation became calm. The sectional area of a
vessel in the photograph was calculated with area calculation software LIA32 and numerically
expressed.
[0044] Samples 1 to 20 obtained in Production Examples 1 to 9 were measured as described
above. The results are shown in graphs in Figs. 1 to 7. In the graph, the sectional area of a blood
vessel measured is shown on the ordinate wherein the area at 0 minute is 1, and the change of this
area with time is illustrated. As a result, all samples were recognized to exhibit a vasodilator action in
the rabbit ears.
Example 2
[0045] 1.2 g granules consisting of 75 weight% sample 1, 15% reducing maltose syrup, 5.8%
dextrin, 0.9% citric acid, 2.3% perfume and 1.0% sweetener (stevia) were enveloped as one
package and used as a pharmaceutical preparation. Separately, tablets each weighing 300 mg,
consisting of 88 weight% sample 1, 9% reducing maltose and 3% sucrose fatty ester, were produced.
Example 3
[0046] Tablets each weighing 300 mg, consisting of 80 weight% of each of samples 2 to 20, 10
weight% reducing maltose syrup, 7 weight% dextrin and 3 weight% sucrose fatty ester, were
produced.
Example 4
[0047] Two packages of the granules in Example 2 were administered (one package in the
morning and one package in the evening) every day for 30 days into each of 20 volunteers suffering
from stiff neck. After 30 days, each volunteer was allowed to fill in a questionnaire. The result is
481/757
shown in Table 1. As a result, 70% volunteers dissolved or reduced stiff neck, to indicate an effect on
them.
Id=Table 1 Columns=2
Head Col 1: Symptoms
Head Col 2: Number of persons
Dissolved stiff neck5
Reduced stiff neck9
Not changed6
Severer stiff neck0
Example 5
[0048] Six tablets containing sample 2 in Example 3 were administered every day for 30 days into
each of 10 volunteers suffering from stiff neck. After 30 days, each volunteer was allowed to fill in a
questionnaire. The result is shown in Table 2. The result indicated that 60% volunteers dissolved or
reduced stiff neck.
Id=Table 2 Columns=2
Head Col 1: Symptoms
Head Col 2: Number of persons
Dissolved stiff neck2
Reduced stiff neck4
Not changed4
Severer stiff neck0
Example 6
482/757
[0049] Six tablets containing sample 3 in Example 3 were administered every day for 30 days into
each of 10 volunteers suffering from stiff neck. When each volunteer was allowed to fill in a
questionnaire after 30 days, 3 person dissolved stiff neck, 3 persons reduced stiff neck, and the
other 4 persons were not changed.
Example 7
[0050] Six tablets in Example 2 were administered every day for 2 weeks into each of 20- to 40year-old 20 female volunteers suffering from poor circulation, and after 2 weeks, each volunteer was
allowed to fill in a questionnaire. The result is shown in Table 3. The result indicated that 13
volunteers dissolved or reduced poor circulation.
Id=Table 3 Columns=2
Head Col 1: Symptoms
Head Col 2: Number of persons
Dissolved poor circulation3
Reduced poor circulation10
Not changed7
Severer poor circulation0
Example 8
[0051] Six tablets containing sample 10 in Example 3 were administered every day for 2 weeks into
each of 20- to 40-year-old 10 female volunteers suffering from poor circulation, and after 2 weeks,
each volunteer was allowed to fill in a questionnaire. The result is shown in Table 4. The result
indicated that 6 volunteers dissolved or reduced poor circulation.
Id=Table 4 Columns=2
Head Col 1: Symptoms
Head Col 2: Number of persons
483/757
Dissolved poor circulation2
Reduced poor circulation4
Not changed4
Severer poor circulation0
Example 9
[0052] The temperature of a fingertip after administration of tablets containing each of samples 1 to
20 described in Examples 2 and 3 was measured. In this test, 10 volunteers were selected from
those experiencing an effect of dissolving or reducing poor circulation in Example 7, and examined
for several days. Those without breakfast entered a room regulated at 20 DEG C in 50% humidity,
and after 1 hour, given 6 tablets containing each of samples 1 to 20, together with 50 ml water, and
30 minutes after this administration, a change in the temperature of their fingertip was measured with
a thermistor thermometer, to determine an increase in the temperature from 0 hour. Two volunteers
were examined for each sample, and the average was recorded.
Id=Table 5 Columns=4
Head Col 1: Sample
Head Col 2: Increased temp. ( DEG C)
Head Col 3: Sample
Head Col 4: Increased temp. ( DEG C)
10.3110.5
20.5120.2
30.4130.1
40.3140.3
50.2150.3
60.1160.4
70.5170.5
80.4180.4
90.4190.2
100.5200.2
484/757
Example 10
[0053] Two packages containing granules in Example 2 were administered every day for 30 days
into each of 15 volunteers suffering from migraine headache. After 30 days, each volunteer was
allowed to fill in a questionnaire. As shown in Table 6, the result indicated that 8 volunteers dissolved
or reduced headache.
Id=Table 6 Columns=2
Head Col 1: Symptoms
Head Col 2: Number of persons
Dissolved headache2
Reduced headache6
Not changed7
Severer headache0
Example 11
[0054] Two packages containing granules in Example 2 were administered every day for 30 days
into each of 55- to 63-year-old 5 women having menopausal high blood pressure. Together with this
preparation, estrogen was given to any persons. As a result, the blood pressure in any persons was
reduced to the normal range, and the body was left to be warmer than when they had used estrogen
only. It was also recognized that menopausal disorders was reduced.
Example 12
[0055] Five athletes were allowed to run for 1500 m with all their strength, and before the running
and 5 minutes after the running, blood was collected, and the lactic acid level in blood was
485/757
measured. On the next day, they were given two packages of granules in Example 2, and then
allowed to run for 1500 m with all their strength, and the lactic acid level in blood was measured in
the same manner as on the previous day. The result is shown in Table 7. The lactic acid level in
blood in the athletes given the granules was lower than that without administering the granules.
Id=Table 7 Columns=5
Title: Blood lactic acid level (mmol/l)
Head Col 1:
Head Col 2 to 3: Not given the granules
Head Col 4 to 5: Given the granules
SubHead Col 1:
SubHead Col 2: before running
SubHead Col 3: after running
SubHead Col 4: before running
SubHead Col 5: after running
A1.010.51.19.0
B1.110.81.08.3
C0.911.11.07.8
D1.112.10.97.6
E1.212.31.28.1
Example 13
[0056] Six tablets in Example 2 were given to each of 30- to 35-year-old 20 women, and after 1
month, a change in skin conditions was evaluated by themselves (checks in plural items were
allowable). As a result, the following skin-improving effects were recognized.
[0057] Their complexion was improved (14 persons), skin gloss was improved (12), skin moistness
was improved (9), skin roughness was eliminated (9), cosmetics could stick more easily to the skin
(8), and skin elasticity was improved (7).
486/757
Example 14
[0058] Six tablets containing sample 4 in Example 3 were administered into each of 30- to 35-yearold 10 women, and after 1 month, a change in skin conditions was evaluated by themselves (checks
in plural items were allowable). As a result, the following skin-improving effects were recognized.
[0059] Their complexion was improved (7 persons), skin gloss was improved (6), skin roughness
was eliminated (4), skin moistness was improved (4) and cosmetics could stick more easily to the
skin (3).
Example 15
[0060] Two packages of granules in Example 2 were given every day for 3 months to each of
twenty men aware of loss of a lot of hair, and thereafter, they were questioned about a change in hair
loss. The result indicated that 8 persons recognized a reduction in hair loss, and 7 persons had
thicker hair.
Industrial Applicability
[0061] According to the present invention, a composition comprising peptides obtained by
hydrolyzing various proteins such as seaweed-derived proteins, plant-derived proteins, fish-derived
proteins, milk proteins, animal-derived proteins and collagen-like proteins is used in a
pharmaceutical preparation and a health food thereby exhibiting a vasodilator effect by which stiff
neck, headache, poor circulation and functional depressions related thereto can be suppressed or
ameliorated.Claims:
487/757
1. A vasodilator pharmaceutical composition comprising, as an active ingredient, peptides obtained
by hydrolyzing proteins derived from a seaweed selected from laver, wakame, edible brown algae,
sea tangle, chlorella and/or spirulina, peptides obtained by hydrolyzing proteins derived from a plant
selected from soybean and/or sesame, peptides obtained by hydrolyzing proteins derived from a fish
selected from bonito, mackerel, saury and/or horse mackerel, peptides obtained by hydrolyzing
proteins derived from an animal selected from cattle and/or swine, or peptides obtained by
hydrolyzing collagen-like proteins derived from bovine collagen, porcine skin collagen and/or fish
scale-derived collagen.
2. A vasodilator health food composition comprising, as an active ingredient, peptides obtained by
hydrolyzing proteins derived from a seaweed selected from laver, wakame, edible brown algae, sea
tangle, chlorella and spirulina, peptides obtained by hydrolyzing proteins derived from a plant
selected from soybean and/or sesame, peptides obtained by hydrolyzing proteins derived from a fish
selected from bonito, mackerel, saury and/or horse mackerel, peptides obtained by hydrolyzing
proteins derived from milk proteins selected from powdered skin milk and/or whey, peptides
obtained by hydrolyzing proteins derived from an animal selected from cattle and/or swine, or
peptides obtained by hydrolyzing collagen-like proteins derived from bovine collagen, porcine skin
collagen and/or fish scale-derived collagen.
3. Use of peptides obtained by hydrolyzing proteins derived from a seaweed selected from laver,
wakame, edible brown algae, sea tangle, chlorella and/or spirulina, peptides obtained by hydrolyzing
proteins derived from a plant selected from soybean and/or sesame, peptides obtained by
hydrolyzing proteins derived from a fish selected from bonito, mackerel, saury and/or horse mackerel,
peptides obtained by hydrolyzing proteins derived from an animal selected from cattle and/or swine,
or peptides obtained by hydrolyzing collagen-like proteins derived from bovine collagen, porcine
skin collagen and/or fish scale-derived collagen for the preparation of a medicament useful in the
treatment of a stiff neck, poor circulation, headache, fatigue, or menopausal disorders.
4. Use of peptides obtained by hydrolyzing proteins derived from a seaweed selected from laver,
wakame, edible brown algae, sea tangle, chlorella and/or spirulina, peptides obtained by hydrolyzing
proteins derived from a plant selected from soybean and/or sesame, peptides obtained by
hydrolyzing proteins derived from a fish selected from bonito, mackerel, saury and/or horse mackerel,
peptides obtained by hydrolyzing proteins derived from an animal selected from cattle and/or swine,
or peptides obtained by hydrolyzing collagen-like proteins derived from bovine collagen, porcine
skin collagen and/or fish scale-derived collagen as a food additive.
488/757
5. Use of peptides obtained by hydrolyzing proteins derived from a seaweed selected from laver,
wakame, edible brown algae, sea tangle, chlorella and/or spirulina, peptides obtained by hydrolyzing
proteins derived from a plant selected from soybean and/or sesame, peptides obtained by
hydrolyzing proteins derived from a fish selected from bonito, mackerel, saury and/or horse mackerel,
peptides obtained by hydrolyzing proteins derived from an animal selected from cattle and/or swine,
or peptides obtained by hydrolyzing collagen-like proteins derived from bovine collagen, porcine
skin collagen and/or fish scale-derived collagen in cosmetics for the improvement of skin conditions
and for hair restoration.
489/757
254. JP2004331556 - 18.11.2004
2"-HYDROXYNICOTIANAMINE, PROCESS FOR PRODUCING THE SAME AND ANGIOTENSIN
CONVERTING ENZYME INHIBITOR, HYPOTENSIVE DRUG AND HEALTH FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=JP2004331556
Inventor(s):
AOYAGI YASUO (JP)
Applicant(s):
JAPAN SCIENCE and TECH AGENCY (JP); AOYAGI YASUO (JP)
IP Class 4 Digits: C07D
IP Class:
C07D205/04
E Class: C07D205/04
Application Number:
WO2004JP03868 (20040322)
Priority Number: JP20030128838 (20030507)
Family: JP2004331556
Cited Document(s):
JP2003231675; JP2002179647; JP5246865; JP63087990
Abstract:
IT IS INTENDED TO PROVIDE 2"-HYDROXYNICOTIANAMINE; A PROCESS FOR PRODUCING 2"HYDROXYNICOTIANAMINE WHICH COMPRISES EXTRACTING A BUCKWHEAT SAMPLE AND
THEN SUBJECTING THE EXTRACT TO ION EXCHANGE CHROMATOGRAPHY WITH THE USE OF
AN ANION EXCHANGE RESIN TO THEREBY GIVE A FRACTION HAVING AN ACTIVITY OF
INHIBITING ANGIOTENSIN CONVERTING ENZYME; NOVEL MATERIALS (AN ANGIOTENSIN
CONVERTING ENZYME (ACE) INHIBITOR, A HYPOTENSIVE DRUG AND A HEALTH FOOD) HAVING
AN ACE INHIBITORY ACTIVITY WHICH CONTAIN 2"-HYDROXYNICOTIANAMINE; A PROCESS FOR
PRODUCING SUCH A NOVEL MATERIAL; AND AN ANGIOTENSIN CONVERTING ENZYME
490/757
INHIBITOR AND A HYPOTENSIVE DRUG CONTAINING THE NOVEL MATERIAL AS THE ACTIVE
INGREDIENT AND A HEALTH FOOD CONTAINING THE NOVEL MATERIAL.
491/757
255. KR2001044542 - 05.06.2001
HEALTH AUXILIARY FOOD COMPOSITION HAVING INTESTINE FUNCTION ACTIVATING EFFECT
AND FOOD CONTAINING THE SAME
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2001044542
Inventor(s):
YOON YEONG BAE (KR)
Applicant(s):
SAILMONDIAL CO LTD (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010011275 (20010305)
Priority Number: KR20010011275 (20010305)
Family: KR2001044542
492/757
256. KR2001069433 - 25.07.2001
HEALTH FOOD COMPOSITION CONTAINING HERICIUM ERINACEUM
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2001069433
Inventor(s):
KIM SANG MIN (KR)
Applicant(s):
NC BIOTEC COM (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/28
Application Number:
KR20010015032 (20010322)
Priority Number: KR20010015032 (20010322)
Family: KR2001069433
493/757
257. KR2001079226 - 22.08.2001
PRODUCTION OF HEALTH AUXILIARY FOOD USING SOY BEANS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2001079226
Inventor(s):
KIM JAE MAN (KR)
Applicant(s):
SAM BO NATURAL CO LTD (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/202
Application Number:
KR20010036446 (20010625)
Priority Number: KR20010036446 (20010625)
Family: KR2001079226
494/757
258. KR2001079227 - 22.08.2001
PRODUCTION OF HEALTH AUXILIARY FOOD USING CHITOSAN AND VITAMIN
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2001079227
Inventor(s):
KIM JAE MAN (KR)
Applicant(s):
SAM BO NATURAL CO LTD (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010036447 (20010625)
Priority Number: KR20010036447 (20010625)
Family: KR2001079227
495/757
259. KR2001088631 - 28.09.2001
METHOD FOR PREPARING HEALTH FOOD COMPOSITION THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2001088631
Inventor(s):
YOU SO SOON (KR)
Applicant(s):
YOU SO SOON (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010049115 (20010814)
Priority Number: KR20010049115 (20010814)
Family: KR2001088631
496/757
260. KR2001099115 - 09.11.2001
PRODUCTION OF HEALTH SUPPLEMENTARY FERMENTED FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2001099115
Inventor(s):
SONG YOON KANG (KR)
Applicant(s):
SONG YOON KANG (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010053754 (20010901)
Priority Number: KR20010053754 (20010901)
Family: KR2001099115
497/757
261. KR2002003164 - 10.01.2002
HEALTH FOOD FOR IMPROVING CONSTIPATION AND MANUFACTURING METHOD THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002003164
Inventor(s):
KIM MYOUNG SIK (KR)
Applicant(s):
KIM MYOUNG SIK (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010073261 (20011123)
Priority Number: KR20010073261 (20011123)
Family: KR2002003164
498/757
262. KR2002003165 - 10.01.2002
PRODUCTION OF FERMENTED FOOD FOR HEALTH SUPPLEMENT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002003165
Inventor(s):
SONG YOON KANG (KR)
Applicant(s):
SONG YOON KANG (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010073536 (20011123)
Priority Number: KR20010073536 (20011123)
Family: KR2002003165
499/757
263. KR2002003166 - 10.01.2002
PRODUCTION OF HEALTH-SUPPLEMENTARY FOOD USING PYROLIGNEOUS ACID SOLUTION
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002003166
Inventor(s):
CHANG MYENG SOO (KR)
Applicant(s):
FINEBIO CO LTD (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010073650 (20011124)
Priority Number: KR20010073650 (20011124)
Family: KR2002003166
500/757
264. KR2002003177 - 10.01.2002
PRODUCTION OF UNCOOKED HEALTH FOOD PRODUCT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002003177
Inventor(s):
LEE DO HUN (KR)
Applicant(s):
LEE DO HUN (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010077218 (20011207)
Priority Number: KR20010061285 (20010927)
Family: KR2002003177
501/757
265. KR2002004926 - 16.01.2002
FOOD SERVICE INDUSTRY SYSTEM CAPABLE OF PROVIDING HEALTHFUL MENU ACCORDING
TO HEALTH INFORMATION MANAGEMENT SYSTEM THROUGH THE INTERNET
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002004926
Inventor(s):
KIM EUK SU (KR); KIM UI CHANG (KR); YOON YEONG HO (KR)
Applicant(s):
KIM EUK SU (KR)
IP Class 4 Digits: G06F
IP Class:
G06F17/60
Application Number:
KR20010076908 (20011206)
Priority Number: KR20010076908 (20011206)
Family: KR2002004926
502/757
266. KR2002005169 - 17.01.2002
HEALTH AUXILIARY FOOD AND PRODUCTION THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002005169
Inventor(s):
LEE CHANG GYU (KR)
Applicant(s):
SIM SAN CO LTD (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010003407 (20010120)
Priority Number: KR20010003407 (20010120)
Family: KR2002005169
503/757
267. KR2002019114 - 09.03.2002
ADJUVANT HEALTH FOOD USING ORIENT MEDICINAL MATERIAL
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002019114
Inventor(s):
GO IN SANG (KR); KIM EUN SEOB (KR)
Applicant(s):
GO IN SANG (KR); KIM EUN SEOB (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020007224 (20020207)
Priority Number: KR20020007224 (20020207)
Family: KR2002019114
504/757
268. KR2002019510 - 12.03.2002
HEALTH AUXILIARY FOOD PRODUCT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002019510
Inventor(s):
JU HAK (KR)
Applicant(s):
JU HAK (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020009321 (20020221)
Priority Number: KR20020009321 (20020221)
Family: KR2002019510
505/757
269. KR2002024020 - 29.03.2002
HEALTH FOOD CONTAINING SAFFLOWER SEED AS MAIN INGREDIENT AND PREPARATION
METHOD THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002024020
Inventor(s):
CHU YEONG JIN (KR)
Applicant(s):
CHU YEONG JIN (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020000939 (20020108)
Priority Number: KR20020000939 (20020108)
Family: KR2002024020
506/757
270. KR2002029350 - 18.04.2002
PRODUCTION OF DIET FOOD COMPOSITION CONTAINING SUBSTANCES PURPORTED TO BE OF
HEALTH BENEFIT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002029350
Inventor(s):
SON YOUNG SUK (KR)
Applicant(s):
SON YOUNG SUK (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020012622 (20020308)
Priority Number: KR20020012622 (20020308)
Family: KR2002029350
507/757
271. KR2002029353 - 18.04.2002
PRODUCTION OF PROCESSED FOOD PRODUCT FOR DIET CONTAINING SUBSTANCES
PURPORTED TO BE OF HEALTH BENEFIT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002029353
Inventor(s):
SON YOUNG SUK (KR)
Applicant(s):
SON YOUNG SUK (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/212
Application Number:
KR20020012802 (20020309)
Priority Number: KR20020012802 (20020309)
Family: KR2002029353
508/757
272. KR2002029412 - 18.04.2002
HEALTH FOOD PRODUCT HAVING EFFICACY FOR CHANGING WHITE HAIR TO BLACK AND
PRODUCTION THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002029412
Inventor(s):
KIM HAN CHAL (KR); SHIN SUNG HO (KR)
Applicant(s):
HANMIB and TCO LTD (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020017198 (20020329)
Priority Number: KR20020017198 (20020329)
Family: KR2002029412
509/757
273. KR2002034112 - 08.05.2002
PRODUCTION OF FOOD PRODUCT FOR DIET CONTAINING SUBSTANCES PURPORTED TO BE
OF HEALTH BENEFIT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002034112
Inventor(s):
SON YOUNG SUK (KR)
Applicant(s):
SON YOUNG SUK (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020014617 (20020318)
Priority Number: KR20020014617 (20020318)
Family: KR2002034112
510/757
274. KR2002034115 - 08.05.2002
PRODUCTION OF PROCESSED FOOD PRODUCT CONTAINING SUBSTANCES PURPORTED TO BE
OF HEALTH BENEFIT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002034115
Inventor(s):
SON YOUNG SUK (KR)
Applicant(s):
SON YOUNG SUK (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020016875 (20020327)
Priority Number: KR20020016875 (20020327)
Family: KR2002034115
511/757
275. KR2002035813 - 15.05.2002
HEALTH FOOD FOR REMOVING HANGOVER
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002035813
Inventor(s):
SONG JONG SANG (KR)
Applicant(s):
SONG JONG SANG (KR)
IP Class 4 Digits: A23L
IP Class:
A23L2/38
Application Number:
KR20020022136 (20020423)
Priority Number: KR20020022136 (20020423)
Family: KR2002035813
512/757
276. KR2002037018 - 17.05.2002
CAPSULE TYPE HEALTH FOOD CONTAINING MUDFISH AND SILKWORM
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002037018
Inventor(s):
PARK YOUNG CHAL (KR)
Applicant(s):
PARK YOUNG CHAL (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020024389 (20020503)
Priority Number: KR20020024389 (20020503)
Family: KR2002037018
513/757
277. KR2002038620 - 23.05.2002
HEALTH FOOD COMPOSITION CONTAINING PYROLIGNEOUS ACID POWDER, GERMANIUM
POWDER, AND SAURURUS CHINENSIS BAILL POWDER
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002038620
Inventor(s):
JANG MYEONG SU (KR)
Applicant(s):
JANG MYEONG SU (KR)
IP Class 4 Digits: A61K
IP Class:
A61K9/70
Application Number:
KR20020014349 (20020316)
Priority Number: KR20020014349 (20020316)
Family: KR2002038620
514/757
278. KR2002040691 - 30.05.2002
PRODUCTION OF FOOD CONTAINING SUBSTANCES OF HEALTH BENEFIT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002040691
Inventor(s):
SON YOUNG SUK (KR)
Applicant(s):
SON YOUNG SUK (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/00
Application Number:
KR20020008608 (20020218)
Priority Number: KR20020008608 (20020218)
Family: KR2002040691
515/757
279. KR2002042583 - 05.06.2002
HEALTH FOOD CONTAINING SALICORNIA HERBACEA AND KELP AS MAIN MATERIAL
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002042583
Inventor(s):
KIM DAI GON (KR)
Applicant(s):
KIM DAI GON (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020025692 (20020506)
Priority Number: KR20020025692 (20020506)
Family: KR2002042583
516/757
280. KR2002043206 - 08.06.2002
BIONIC VENDING MACHINE FOR HEALTH FOOD AND HERB TEA
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002043206
Inventor(s):
PARK DONG OK (KR)
Applicant(s):
PARK DONG OK (KR)
IP Class 4 Digits: G07F
IP Class:
G07F13/06
Application Number:
KR20020027821 (20020520)
Priority Number: KR20020027821 (20020520)
Family: KR2002043206
517/757
281. KR2002044046 - 14.06.2002
FUNCTIONAL HEALTH FOOD FOR ENHANCING INTESTINAL FUNCTION
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002044046
Inventor(s):
BANG HYEON A (KR); JANG YUN HYEON (KR); JU YEONG CHEOL (KR); LEE
GWANG HO (KR)
Applicant(s):
B and IT CO LTD (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29; A23L1/28
Application Number:
KR20010045942 (20010730)
Priority Number: KR20010045942 (20010730)
Family: KR2002044046
518/757
282. KR2002044122 - 14.06.2002
HEALTH FOOD CONTAINING ACANTHOPANACIS CORTEX AS MAIN MATERIAL
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002044122
Inventor(s):
LEE JONG SUN (KR)
Applicant(s):
LEE JONG SUN (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020028284 (20020517)
Priority Number: KR20020028284 (20020517)
Family: KR2002044122
519/757
283. KR2002057695 - 12.07.2002
PRODUCTION OF HEALTH FOOD BASED MULTIVITAMINS USING VEGETABLES
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002057695
Inventor(s):
YOO KYONG LOUL (KR)
Applicant(s):
YOO KYONG LOUL (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29; A23L1/212
Application Number:
KR20010000260 (20010103)
Priority Number: KR20010000260 (20010103)
Family: KR2002057695
520/757
284. KR2002059125 - 12.07.2002
MIXED HEALTH FOOD AND PRODUCTION THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002059125
Inventor(s):
CHOI HAY MIE (KR); KIM WAN SOO (KR)
Applicant(s):
CHOI HAY MIE (KR); KIM WAN SOO (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010000029 (20010102)
Priority Number: KR20010000029 (20010102)
Family: KR2002059125
521/757
285. KR2002059905 - 16.07.2002
PRODUCTION OF HEALTH FOOD USING GLYCINE MAX L. MERR. TO MAINTAIN BLACK HAIR
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002059905
Inventor(s):
SHIN MIN KYO (KR)
Applicant(s):
KYO (KR)
HWANG SUNG YEOUN (KR); KOREA MEDICAL SCIENCE INST (KR); SHIN MIN
IP Class 4 Digits: A23L
IP Class:
A23L1/20
Application Number:
KR20010001063 (20010109)
Priority Number: KR20010001063 (20010109)
Family: KR2002059905
522/757
286. KR2002059906 - 16.07.2002
HEALTH FOOD COMPOSITION FOR BLACK HAIR AND PRODUCTION THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002059906
Inventor(s):
SHIN MIN KYO (KR)
Applicant(s):
KYO (KR)
HWANG SUNG YEOUN (KR); KOREA MEDICAL SCIENCE INST (KR); SHIN MIN
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010001064 (20010109)
Priority Number: KR20010001064 (20010109)
Family: KR2002059906
523/757
287. KR2002061372 - 24.07.2002
METHOD FOR MANUFACTURING HEALTH SUPPLEMENTARY FOOD PRODUCTS FOR THE
DIABETIC
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002061372
Inventor(s):
KIM JUNG WOONG (KR)
Applicant(s):
KIM JUNG WOONG (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010002407 (20010116)
Priority Number: KR20010002407 (20010116)
Family: KR2002061372
524/757
288. KR2002061425 - 24.07.2002
METHOD FOR MANUFACTURING HEALTH FOOD PRODUCTS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002061425
Inventor(s):
LEE YONG JU (KR)
Applicant(s):
MYUNG SE DANG CO LTD (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010002560 (20010117)
Priority Number: KR20010002560 (20010117)
Family: KR2002061425
525/757
289. KR2002062873 - 31.07.2002
PROCESS FOR PREPARING HEALTH FOOD CONTAINING NATURAL FOOD COMPONENTS FOR
DIET
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002062873
Inventor(s):
KIM SUNG DO (KR)
Applicant(s):
KIM SUNG DO (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/307
Application Number:
KR20020033214 (20020614)
Priority Number: KR20020033214 (20020614)
Family: KR2002062873
526/757
290. KR2002062899 - 31.07.2002
HEALTH FOOD PRODUCT USING RED GINSENG AND PAECILOMYCES JAPONICA
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002062899
Inventor(s):
SEO BONG SEOK (KR)
Applicant(s):
SEO BONG SEOK (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020039510 (20020704)
Priority Number: KR20020039510 (20020704)
Family: KR2002062899
527/757
291. KR2002069702 - 05.09.2002
METHOD FOR EXTRACTING POLYSACCHARIDE OF ACANTHOPANAX AND HEALTH FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002069702
Inventor(s):
CHO SEON HAENG (KR)
Applicant(s):
BIOGENKOREA CO LTD (KR)
IP Class 4 Digits: C08B
IP Class:
C08B37/00
Application Number:
KR20010010030 (20010227)
Priority Number: KR20010010030 (20010227)
Family: KR2002069702
528/757
292. KR2002072619 - 18.09.2002
PHARMACEUTICAL COMPOSITION AND HEALTH AUXILIARY FOOD CONTAINING ORGANIC
SOLVENT-ABSORBABLE MICRO-SPHERICAL CRUDE DRUGS TO REDUCE HANGOVER
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002072619
Inventor(s):
CHO MIN GYEONG (KR); KANG GEON UK (KR); KIM SANG GEON (KR); PARK
YONG JIN (KR)
Applicant(s):
CRUX INC (KR); PROTHERAPEUTICS INC (KR)
IP Class 4 Digits: A61K
IP Class:
A61K35/78
Application Number:
KR20010012533 (20010312)
Priority Number: KR20010012533 (20010312)
Family: KR2002072619
529/757
293. KR2002072878 - 19.09.2002
SOLID CULTIVATION METHOD OF MYCELIA OF AND FRUIT BODIES OF HERICICUM ERINACEUS
USING MEDICINAL HERBS AND HEALTH FOOD CONTAINING THE EXTRACT OF MYCELIUM OF
AND FRUIT BODY OF HERICICUM ERINACEUS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002072878
Inventor(s):
JEONG JAE HYEON (KR)
Applicant(s):
HNM BIO CO LTD (KR); JEONG JAE HYEON (KR)
IP Class 4 Digits: C12N
IP Class:
C12N1/14
Application Number:
KR20010012904 (20010313)
Priority Number: KR20010012904 (20010313)
Family: KR2002072878
530/757
294. KR2002074285 - 30.09.2002
MEMORY ENHANCING CRUDE DRUG COMPOSITION CONTAINING REHMANNIAE RADIX
PREPARATA EXTRACT, PRODUCTION THEREOF, AND HEALTH SUPPLEMENTARY FOOD AND
FOOD ADDITIVE CONTAINING THE SAME
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002074285
Inventor(s):
BAE HYEON SU (KR); HONG MU CHANG (KR); LEE EUNG SE (KR); PARK SEUNG
WON (KR); SHIN MIN GYU (KR)
Applicant(s):
PURIMED CO LTD (KR)
IP Class 4 Digits: A61K
IP Class:
A61K35/78
Application Number:
KR20010014152 (20010319)
Priority Number: KR20010014152 (20010319)
Family: KR2002074285
531/757
295. KR2002074905 - 04.10.2002
HEALTH SUPPLEMENTARY FOOD COMPOSITION CONTAINING RADISH EXTRACT AND CRUDE
DRUG EXTRACT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002074905
Inventor(s):
CHOO YEONG GUK (KR); JUNG GYU YONG (KR); JUNG HEON YEONG (KR);
JUNG JANG HYUN (KR); KUEM GYEONG SU (KR)
Applicant(s):
JUNG JANG HYUN (KR)
IP Class 4 Digits: A23L
IP Class:
A23L2/02
Application Number:
KR20010014974 (20010322)
Priority Number: KR20010014974 (20010322)
Family: KR2002074905
532/757
296. KR2002075757 - 05.10.2002
HEALTH FOOD CONTAINING EXTRACTS OF HERB WILD GEESE AND ACANTHOPANACIS
CORTEX
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002075757
Inventor(s):
SONG DEUK YONG (KR)
Applicant(s):
SONG DEUK YONG (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020050271 (20020821)
Priority Number: KR20020050271 (20020821)
Family: KR2002075757
533/757
297. KR2002077735 - 14.10.2002
PRODUCTION OF PILLED HEALTH FOOD USING MARINE PRODUCTS AND CRUDE DRUG
MATERIAL AS MAIN MATERIAL
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002077735
Inventor(s):
LEE TAE HO (KR)
Applicant(s):
LEE TAE HO (KR)
IP Class 4 Digits: A61K
IP Class:
A61K35/78
Application Number:
KR20010017485 (20010402)
Priority Number: KR20010017485 (20010402)
Family: KR2002077735
534/757
298. KR2002077737 - 14.10.2002
PRODUCTION OF ENCAPSULATED HEALTH FOOD USING MARINE PRODUCTS AND CRUDE
DRUG MATERIAL AS MAIN MATERIAL
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002077737
Inventor(s):
LEE TAE HO (KR)
Applicant(s):
LEE TAE HO (KR)
IP Class 4 Digits: A61K
IP Class:
A61K35/78
Application Number:
KR20010017487 (20010402)
Priority Number: KR20010017487 (20010402)
Family: KR2002077737
535/757
299. KR2002078314 - 18.10.2002
PRODUCTION OF HEALTH FOOD USING ANIMAL/PLANT CRUDE DRUG
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002078314
Inventor(s):
CHO GAB HWAN (KR)
Applicant(s):
CHO GAB HWAN (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010018652 (20010409)
Priority Number: KR20010018652 (20010409)
Family: KR2002078314
536/757
300. KR2002079609 - 24.10.2002
HEALTH FOODS SUPPLEMENTARY FOR TREATMENT AND PREVENTION OF CONSTIPATION
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002079609
Inventor(s):
KIM SUNG KYU (KR); YOO SANG WOO (KR)
Applicant(s):
JOOSIN R and D CO LTD (KR); KIM SUNG KYU (KR); YOO SANG WOO (KR)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L1/29; A23L1/28
E Class: A23L1/30B; A23L1/28; A23L1/304; A23L1/308; A61K35/84
Application Number:
WO2001KR01611 (20010926)
Priority Number: KR20010019803 (20010413)
Family: KR2002079609
Cited Document(s):
JP2092251; US5039707; KR92003525; JP2000281583
Abstract:
THE PRESENT INVENTION RELATES TO A HEALTH SUPPLEMENTARY FOOD FOR IMPROVING
CONSTIPATION, MORE PARTICULARLY, HEALTH SUPPLEMENTARY FOOD CONTAINING
AURICULARIA AURIACULA, WHICH IS EFFECTIVE IN PREVENTION AND TREATMENT OF
CONSTIPATION BY LOOSENING THE BOWELS AND STIMULATING BOWEL MOVEMENTS.
CONTINUOUS INTAKE OF THE HEALTH SUPPLEMENTARY FOOD ACCORDING TO HE PRESENT
INVENTION INCREASES THE AMOUNT OF FECES AND STIMULATES THE BOWEL MOVEMENTS.
ACCORDINGLY, IT IS EFFECTIVE IN PREVENTION AND TREATMENT OF
CONSTIPATION.Description:
537/757
Health foods supplementary for treatment and prevention of constipation
TECHNICAL FIELD
The present invention relates to health supplementary food for improving constipation, more
particularly, health supplementary food containing Auricularia auricula, which is effective in
prevention and treatment of constipation by loosening the bowels and stimulating bowel movements.
BACKGROUND OF THE INVENTION
Constipation is a symptom that stool is very hard and dry compared with normal condition, and the
frequency of bowel movements and amount of feces are decreased, thereby causing discomfort and
physiological disorder. Most of constipation is habitforming constipation. It is divided to hypertonicand hypotonic constipation, depending on a symptom. In case of the hypotonic constipation, strain
of large intestines weakens and the bowel movements come to slow. Accordingly, fecal moisture
content is decreased, being dull to a reflex of the bowel movements. While, in case of the hypertonic
constipation, peristalsis in large intestines accelerates and a spasm in intestinal wall occurs, so that
stools in form of small lumps or stick that is as thick as a pencil may be excreted. Constipation may
be caused by temporary factors related to changes in environment and diet during travel, etc. In
addition, constipation may be caused by rectal cancer, rectal stricture, lesion around the rectum,
chronic colitis, or acute illness in digestive system.
5 Meanwhile, when fibers lack in dietary intake, feces may be lightened in weight, leading readily to
constipation. However, if a lot of fibers are included in diet, enough moisture may be absorbed into
intestines. Accordingly, feces increase in amount, which promotes the bowel movements. As abovementioned, fibers stimulate the intestines.
Besides, since the fibers have a lot of moisture, stools are not hard, leading to loosen the 10 bowels.
Moreover, carcinogens, cholesterol, and many other toxic substances in the intestines are absorbed
into fibers and promptly discharged from human body. Intestinal bacteria decompose fibers in diet,
to generate hydrogen-, methane-and carbon dioxide gas, etc. The gases strengthen stimulation into
the intestines, thereby activating peristalsis in the intestines. Therefore, the simplest and easiest
method for prevention and treatment 15 of constipation is to take foods with enough fibers suitably.
The other method for treatment of constipation is to make an effort to have regular bowel movements
in every morning and to eat cold water or carbonated water, or to take moderate exercise in early
morning.
538/757
In addition, laxatives such as magnesium phosphate, fenobarin, sena, Rhubarb 20 (Rhe217n
uhdulatum) and the like may be used as a drug. As occasion demands, an enema may be given.
Recently, researches have been carried out on foods to improve constipation using various kinds of
natural foods or natural medicines in order to prevent constipation.
5 Korean Patent No. 15879 disclosed a tea too improve constipation using natural medicines such
as alvae Semen, Pleuropterus multflo7us, Geranium nepalense subsp.
Thunbergii, fig tree, Polygonum aviculare, rhubarb (Rheum ztndulatun2), etc. Besides,
Korean Patent No. 32660 disclosed a drug to treat constipation using Lycium chinense
MILL. and maize (Zea mays L.) However, the drug for treating constipation that can be 10 utilized as
food, has been not yet met the requirements. For that reason, the development of food for preventing
and treating constipation has been necessary urgently.
Therefore, the present inventors have studied on studied on food that is effective in constipation
using natural foods. As a result, the present inventors completed the 15 present invention by
manufacturing health supplementary food that is effective in improving constipation with an
Auricularia auricule rich in fibers and natural gelatins, and a laxative such as a cascara sagrada.
The said health supplementary food can increase fecal excretion and stimulate bowel movement by
the two ingredients, Auricularia auricula and the laxative, respectively.
20
DISCLOSURE OF THE INVENTION
The purpose of the present invention is to provide health supplementary food that is effective in
improving constipation by increasing fecal excretion and stimulating the bowel movements.
5
To accomplish this purpose, the present invention provides health supplementary food for improving
constipation containingAuricularia auricula as an active ingredient.
In addition, the health supplementary food for improving constipation according to the present
invention further may include cascara sagrada, and a powder of mulberry 10 leaves or magnesium
hydroxide.
539/757
All amounts in this specification are % by weight (w/w) of the health supplementary food, unless
otherwise noted.
15 Hereinafter, the present invention will be described in detail.
The health supplementary food according to the present invention contains Auricularia auricula rich
in fibers as an active component.
In Auricularia auricula, natural gelatins as well as the above fibers are also plentiful. Therefore, in
the presence of exposure to water, Auricularia auricula swells 20 and its volume increases 5-6 times.
By this property of Auricularia auricula, fecal excretion may be increased, accordingly, Auricularia
auricula may have an effect on improvement of constipation.
Furthermore, the health supplementary food according to the present invention may include the
following ingredients as a bowel-stimulator together with Auricularia
5 auricula : lubricants such as mineral oil and olive oil; bulk forming agents such as psyllium and
aloe ; the small intestine-stimulants such as castor oil and calomel; and the large intestine-stimulants
such as cascara sagrada, dulcolax and bicogreen, etc. However, the lubricants can cause disorder
of nutrient-adsorption with prolonged daily use and the bulk forming agent should be taken with
water. Therefore, it is desirable to use cascara 10 saqrada as the stimulants. It was known that
cascara sagrada, a derivative of hydroxy anthracite, acts on the large intestines to stimulate the
bowel movements and on the nerve through a blood vessel to facilitate purgative effects.
Where the cascara sagrada is added intoSuricularia auricula, it is preferable that the cascara
sagrada and Auricularia auricula are present in the range of 10-40% and 6015 90% by weight,
respectively. If the amount of Azipiculaiia amictila exceeds 90% by weight, it raises discomfort such
as abdominal distention caused by the excessive intake.
While, if it is below 60% by weight, it has a little effect on an improvement of constipation caused by
the insufficient amount. Therefore, it is desirable that the amount of Auricularia auricula is in the
above-mentioned range.
20 The cascara sagrada is resolved in the intestinal tract, and then stimulates a mucous membrane
of the intestines to cause vermiculation, thereby loosening the bowels.
540/757
However, if its amount exceeds 40% by weight, it stimulates the large intestines to undue extent,
thereby causing diarrhea and stomachache. Therefore, it is preferable that the amount of the
cascara sagrada covers above-mentioned range.
5 Meanwhile, the health supplementary food containing Auricularia azзricula according to the
present invention may further include a powder of mulberry leaves as well as the cascara sagrada.
According to the reports, the powder of mulberry leaves abounds in minerals such calcium, iron, etc.
and dietary fibers. It has been investigated that the dietary fibers are present in green tea in amount
of 10.6%, whereas in the powder 10 of mulberry leaves in amount of 52.9%. Preferably, the health
supplementary food may further include the powder of mulberry leaves, particularly, in amount of 1030% by weight.
In addition, the health supplementary food containing Auricularia auricula according to the present
invention may further include saline agents such as magnesium 15 sulfate, magnesium carbonate,
magnesium hydroxide, etc., as well as the cascara sagrada.
The saline agents prevent moistures from being absorbed into the bowel wall, causing diarrhea.
Particularly, it is preferable that the amount of magnesium hydroxide is present in the range of 5-15%
by weight. If the magnesium hydroxide exceeds 15% by weight, it may cause diarrhea. Therefore, it
is preferable that the amount of the magnesium 20 hydroxide covers the above range.
The health supplementary food containingAuricularia au7 ? cula according to the present invention
may be manufactured in the form of liquid, powder or granule, more preferably, granule, to sell. A
concrete manufacturing process comprises the following steps: selection of materials; mixing of
materials ; production of granules; drying ; and packing.
First, each material of the standard quality is selected and mixed in together according to the
common method known to the present art. Ingredients generally required for formation of granule, for
example, water, alcohol and crystal cellulose, are added to the above mixture of materials, thereby
producing granules. The produced granules are dried in the airtight dryer. It is preferable that
granules are dried at 35-45 C for 1-2hrs. Paxticularly, granules are airtightly wrapped in fourfold
papers to sell. The health supplementary food produced in this manner may be taken anywhere
easily and conveniently. The health supplementary food also has an advantage of facility in keeping.
BEST MODE FOR CARRYING OUT TUTIE
541/757
Hereinafter, the present invention is more specifically illustrated by the following examples.
However, it should be understood that these examples are provided only for illustration of the
present invention, but not intended to limit the present invention in any manner.
In order to confirm the effect of Au7-icularia aui-icula on constipation, in vivo assay was performed
with 8-weeks old Sprague-Dawley male rats.
First, in order to induce constipation, 14 rats were fed with a inhibitor of bowel movements,
loperamide (1. 5mg/kg, Sigma) diluted in 0.9% saline solution at AM 9: 00 and PM 6: 00, twice daily
for 5 days, to inhibit evacuation. The constipation-induced rats were then fed with a 20mg of
Auricularia auricula extract at AM 9: 00 and PM 6: 00, twice daily for 5 days.
During the experimental period, 5 days, food intake in each rat was measured daily. At 3 day and 5
day after feeding, body weight of each rat was measured.
Results are shown in tables 1 and 2, respectively. During the experimental period, all feces excreted
from each rat were also daily collected in polystyrene tube at AM 9: 00 and lyophilized to measure a
diy weight. Feces excreted from rats at AM 9 : 00 at 2, 4 and 5 day after feeding were put in micro
tube, and then weight of moisture-contained feces and lyophilized feces were measured respectively.
Fecal moisture content was measured by calculating the difference of weights in the two forms of
feces. Results are shown in table 3.
< Example 2 >
3g ofaziriculapia auricula and 1. 5g of cascara sagrada were mixed to prepare a composition. 20
mg of the composition was fed to 14 constipation-induced rats, respectively. Except this, food intake,
change in weight, amount of feces and fecal
5 moisture content were measured as described in Example 1. Results are shown in tables
1 to 3, respectively. The prepared composition included 66.6% of Auricularia auricula and 33.4% of
cascara sagrada.
10 4.875g of Auricularia auricula, 1.5g of cascara sagrada and 1.125g of powder of mulberry
leaves were mixed to prepared a composition. 20mg of the composition was fed to 14 rats having
constipation induced by loperamide. Except this, food intake, change in weight, amount of feces
542/757
and fecal moisture content were measured as described in Example 1. Results are shown in tables 1
to 3, respectively. The prepared 15 composition included 65% of Auricularia auricula, 20% of
cascara sagrada and 15% of powder of mulberry leaves.
4.875g of Auricularia auricula, 1.5g of cascara sagrada and 1.125g of 20 magnesium hydroxide were
mixed to prepared a composition 20mg of the composition was fed to 14 rats having constipation
induced by loperamide. Except this, food intake, change in weight amount of feces and fecal
moisture content were measured as described in Example 1. Results are shown in tables 1 to 3,
respectively. The prepared composition included 65% of Auricularia auricula, 20% of cascara
sagrada and 15% of magnesium hydroxide.
< Comparative Example 1 >
8-week old Sprague-Dawley male rats were fed with only 0.9% saline solution.
Rats to the number of 14 were used in this experiment. Food intake, change in weight, amount of
feces and fecal moisture content were measured as described in Example 1.
Results are shown in tables 1 to 3, respectively.
< Comparative Example 2 >
8-week old Sprague-Dawley male rats were fed with loperamide. Rats to the number of 14 were
used in this experiment. Food intake, change in weight, fecal excretion and fecal moisture content
were measured as described in Example 1. Results are shown in tables 1 to 3, respectively.
[Table 1]
Measurement of food intake
Comparative Comparative Example Example Example Example
Example 1 Example 1 1 2 3 4
1-2 days 17 2.0 13.8 + 1.3 16.2 16. 5 ~ 16. 4 16. 1
1.3 1.3 1.3 1.3
2-3 days 15 ~ 1.9 12.9 ~ 1.5 17.0 ~ 15.4 ~ 16.7 ~ 16.4 ~
543/757
Food 1.2 1.2 1.2 1.2
intakt
3-4days 14 1. 5 12. 9 ~ 1. 9 14.1 16.6 16.3 16. 5
(g/day)
1. 2 1.2 1.2 1.2
4-5 days 13 ~ 1.8 12.0 ~ 1.2 14. 2 15. 6 15. 9 15. 5
1.3 1. 4 1.3 1.3
As shown in table 1, food intake was decreased in rats of Comparative Example 2 that had not been
given any treatment after induction of constipation, compared with in rats of Comparative Example 1,
control. Whereas, it was not almost changed in rats of
Example 1 that were fed with Auricularia auricula extract. In addition, in rats of Example 2 that were
fed with the composition of Auricularia auricula and cascara sagrada, rats of
Example 3 that were fed with the composition of Auricularia auricula, cascara sagrada and powder
of mulberry leaves, and rats of Example 4 that were fed with the composition of Auricularia auricula,
cascara sagrada and magnesium hydroxide, food intake was not changed during the experimental
period.
[Table 2
Measure of change in body weight
Comparative Comparative Example Example Example Example
Example 1 Example 1 1 2 3 4
Body At 243.9 236.0 244. 3 244. 2 243.2 245.1
weight 3"day 12. 1 ~ 8. 12 13. 1 12.5 12.6 12.3
(g/day) At 241. 4 235. 7 242. 3 243. 8 245.2 243.9
5th day ~ 12. 5 10. 8 ~ 13. 0 13. 1 13.0 12.8
As shown in Table 2, body weight was decreased in rats of Comparative Example 2 that had not
been given any treatment after induction of constipation, compared with in rats of Comparative
Example 1, control. Whereas, it was not almost changed in rats of
Example 1 that had been fed with Auricularia auricula extract. In rats of Example 2 that had been fed
with the composition of Auricularia auricula and cascara sagrada, rats of
544/757
Example 3 that had been fed with the composition of Auricularia auricula, cascara sagrada and
powder of mulberry leaves was fed, and rats of Example 4 that we had been fed with the composition
of Aziriczilaria auricula, cascara sagrada and magnesium hydroxide, body weight was not changed.
[Table 3]
Effect of each composition on constipation
Comparative Comparative Example Example Example Example
Example 1 Example 1 1 2 3 4
ist 3 0.3 2.2 0.3 3.2 0. 3 3.5 ~ 0.3 3. 6 0.3 3.6 0.3
day
2nd 2.8~ 0.2 2. 2 ~ 0.2 3.0 ~ 0. 2 3.4 ~ 0. 2 3.5 ~ 0. 3 3. 6 ~ 0. 3
day
3rd 2. 8 ~ 0.2 1.8 ~ 0.2 3.1 ~ 0. 2 3. 5 ~ 0.3 3. 6 ~ 0. 3 3. 7 ~ 0. 3
Amount of
day
feces
4th 2. 9 0. 3 2.2 ~ 0. 3 3.3 i 0. 3 3.6 0. 3 3.7 ~ 0. 3 3.7 + 0.3
(g/day)
day
2nd 65 ~ 4 58 ~ 3 70 ~ 4 72 ~ 4 73 ~ 4 74 ~ 4
Fecal day
Moisture 4th 68 ~ 3 59 ~ 4 71 ~ 3 73 ~ 3 73 ~ 4 75 ~ 4
Content day
(%) 5th 69 ~ 4 61 ~ 4 71 ~ 5 75 ~ 3 74 ~ 4 75 ~ 4
day
As shown in Table 3, an amount of feces was remarkably increased in rats of
545/757
Example 1 that had been fed with Auricularia auricula after induction of constipation with loperamide,
compared with in rats of Comparative Example 2 that had not been given any treatment after
induction of constipation. Fecal moisture content was also increased. In addition, the amount of feces
and fecal moisture content was increased in rats of Example 2 that had been fed with the
composition of Auricularia auricula and cascara sagrada, rats of Example 3 that had been fed with
the composition of Auricularia auricula, cascara sagrada and powder of mulberry leaves, and rats of
Example 4 that had been fed with the composition of Auricularia auricula, cascara sagrada and
magnesium hydroxide.
From the results of in vivo experiments, it was confirmed that Auricularia au7, 7cula extract
according to the present invention has an excellent effect on constipationimprovement. In addition, it
was confirmed that the effect of constipation-improvement was increased when cascara sagrada
and powder of mulberry leaves were further added to Auricularia auricula extract.
INDUSTRIAL APPLICABILITY
As shown obviously in above-mentioned description, the present invention manufactured health
supplementary food containing an Auricularia auricula rich in fibers and natural gelatins, as an active
ingredient. A continuous intake of the health supplementary food according to the present invention
increases the fecal excretion and stimulates the bowel movements. Accordingly, it is effective in
prevention and treatment of constipation.Claims:
WHAT IS CLAIMED IS:
1. A Health supplementary food for improving constipation, which contains an Auriczllaria auricula
as an active ingredient.
2. The health supplementary food according to claim 1, wherein the food further comprises a
cascara sagrada.
3. The health supplementary food according to claim 2, wherein the food further comprises a
magnesium hydroxide.
4. The health supplementary food according to claim 2, wherein the food further comprises a
powder of mulberry leaves.
546/757
5. The health supplementary food according to claim 2, wherein the food comprises the following
weight percentages of ingredients: (i) 60% to 90% Au7, icula7ia auricula ; and (i i) 10% to 40%
cascara sagrada.
6. The health supplementary food according to claim 3, wherein the food comprises the following
weight percentages of ingredients: (i) 60% to 85% 4uiiculaila auricula, (i i) 10% to 35% cascara
sagrada; and (iii) 5% to 15% a magnesium hydroxide.
7. The health supplementary food according to claim 4, wherein the food comprises the following
weight percentages of ingredients : (i) 60% # to 80% Auricularia auricula ; (i i) 10% to 30% cascara
sagrada ; and (iii) 10% to 30% a powder of mulberry leaves.
547/757
301. KR2002080813 - 26.10.2002
HEALTH FOOD USING BIO-GARLIC SEASONING STUFF AND MANUFACTURING METHOD
THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002080813
Inventor(s):
LEE SUNG MOON (KR)
Applicant(s):
LEE SUNG MOON (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/221
Application Number:
KR20010020605 (20010417)
Priority Number: KR20010020605 (20010417)
Family: KR2002080813
548/757
302. KR2002080814 - 26.10.2002
HEALTH FOOD USING BIO-SALTS AND MANUFACTURING METHOD THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002080814
Inventor(s):
LEE SUNG MOON (KR)
Applicant(s):
LEE SUNG MOON (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/237
Application Number:
KR20010020606 (20010417)
Priority Number: KR20010020606 (20010417)
Family: KR2002080814
549/757
303. KR2002084781 - 11.11.2002
MANUFACTURING METHOD OF MINERAL-OLIGOPEPTIDE CAPABLE OF BEING ABSORBED BY
ENZYME IN A HUMAN BODY AND HEALTH FOOD USING THE SAME
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002084781
Inventor(s):
JI SEONG GYU (KR)
Applicant(s):
JI SEONG GYU (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/304
Application Number:
KR20010024160 (20010503)
Priority Number: KR20010024160 (20010503)
Family: KR2002084781
550/757
304. KR2002084970 - 16.11.2002
HEALTH FERMENTED FOOD PRODUCT CONTAINING NATURAL DRUG PLANT AS MAIN
COMPONENT AND PRODUCTION THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002084970
Inventor(s):
SHIM SANG HEE (KR)
Applicant(s):
SHIM SANG HEE (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010024121 (20010503)
Priority Number: KR20010024121 (20010503)
Family: KR2002084970
551/757
305. KR2002085981 - 18.11.2002
CHOLESTEROL REDUCER AND HEALTH FOOD CONTAINING LOW MOLECULAR WEIGHT OF
CHITOSAN AND -POLYLYSINE AS MAIN RAW MATERIALS AND METHOD FOR PRODUCING THE
LOW MOLECULAR WEIGHT CHITOSAN
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002085981
Inventor(s):
JUNG SEONG HAK (KR); KIM YEONG HUN (KR); LEE JIN HUI (KR); LIM JAE GAK
(KR); SON JONG UK (KR)
Applicant(s):
CJ CORP (KR)
IP Class 4 Digits: A61K
IP Class:
A61K31/722
Application Number:
KR20010025555 (20010510)
Priority Number: KR20010025555 (20010510)
Family: KR2002085981
552/757
306. KR2002088147 - 21.11.2002
HEALTH FOOD AND METHOD FOR PREPARATION THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002088147
Inventor(s):
KIM HYUN-YOUNG (KR)
Applicant(s):
CYCLOGEN CO LTD (KR); KIM HYUN-YOUNG (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
E Class: A23L1/30B; A61K35/78+M; A23L1/30; A61K35/12+M
Application Number:
WO2001KR02094 (20011204)
Priority Number: KR20010027085 (20010517)
Family: KR2002088147
Cited Document(s):
CN1104907; JP63112522; BE905763; JP4054129
Abstract:
A HEALTH FOOD INCLUDING A CRUDE DRUG FOR A PREGNANT WOMAN INCLUDES A
PHARMACEUTICALLY ALLOWABLE MEDICINE AND COMPRISES A DEER ANTLER, ANGELICAE
GIGANTIS RADIX AND LIGUSTICUM CHUANXIONG IN A MIXING RATIO OF ABOUT 0.8-4 : 0.5-4 : 1
BY WEIGHT. A DEER ANTLER, ANGELICAE GIGANTIS RADIX AND LIGUSTICUM CHUANXIONG
ARE MIXED IN A MIXING RATIO OF ABOUT 0.8-4 : 0.5-4 : 1 BY WEIGHT AND THEN, THUS
OBTAINED MIXTURE IS MIXED WITH AN EXTRACTING SOLUTION. THUS OBTAINED MIXTURE IS
HEATED TO A TEMPERATURE ABOVE A BOILING POINT OF THE EXTRACTING SOLUTION. THE
MIXTURE IS CONCENTRATED BY KEEPING HEATING TO A TEMPERATURE RANGE OF A BOILING
POINT OF THE EXTRACTING SOLUTION 10&+/- DEG C. THUS OBTAINED CONCENTRATED
SOLUTION IS COOLED. THEN, A PHARMACEUTICALLY ALLOWABLE MEDICINE IS PREPARED BY
553/757
USING THUS OBTAINED COOLED SOLUTION. THE HEALTH FOOD LEADS A STABLE AND FAST
DELIVERY THROUGH FUNCTIONING A SPONTANEOUS UTERINE CONTRACTION.Description:
Health Food and Method for Preparation thereof
Technical Field
The present invention relates to a health food for a pregnant woman and a method of preparing the
same, and more particularly, to a heath food for a pregnant woman, which includes a crude drug of a
deer antler, Angelicae gigantis radix,
Ligusticum chuanxiong, etc. and can be used instead of oxytocin hormone and a method of
preparing the same.
Background Art
Recently, the economic conditions and the quality of life are improved and medical appliances are in
the van of the era. Meantime, for the delivery at obstetrics and gynecology field, side effects and
damages onto an infant and a woman delivering of a child during the delivery by means of the
conventional artificial method are scientifically verified. Therefore, much concern is concentrated on
research and development on a stable delivery such as a spontaneous delivery instead of a
Caesarean operation and delivery using a hormone pharmaceutics.
Generally, an oxytocin hormone is a typically used pharmaceutics for facilitating and accelerating a
delivery. The oxytocin hormone improves the number of the uterine contraction and the uterine
contraction power and so is widely used in a clinic field as an oxytocic during a childbirth.
However, the oxytocin hormone is apprehensive of a uterine hyperdynamic, excessive colic of a
woman delivering of a child, a uterine hyper-bleeding, etc. In addition, if an excessive amount of the
oxytocin hormone is dispensed to unhealthy woman delivering of a child, both of the woman
delivering of a child and an infant might face a dangerous situation. Further, the oxytocin hormone
functions onto the uterine contraction of both of a pregnant or non-pregnant woman. That is, the
function of the oxytocin hormone is accomplished by an external impulsive factor and this function is
interpreted as a damaging phenomenon onto a spontaneous physiologic mechanism.
Disclosure of the Invention
It is an object in the present invention considering the conventional problems, to provide a health
food for a pregnant woman including a stable Chinese medicine of a crude drug including a
554/757
predetermined mixing ratio of a deer antler, Angelicae gigantis radix and Ligusticum chuanxiong,
which improves a kidney function and a uterine function during a delivery.
Another object of the present invention is to provide an advantageous method of preparing the
above-described health food for a pregnant woman.
To accomplish the object, there is provided in the present invention a health food for a pregnant
woman including a pharmaceutically allowable medicine and comprising a deer antler, Angelicae
gigantis radix and Ligusticum chuanxiong in a mixing ratio of about 0.8-4: 0.5-4: 1 by weight.
The object of the present invention also can be accomplished by a health food for a pregnant
woman including a pharmaceutically allowable medicine and comprising a deer antler and
Ligusticum chuanxiong in a mixing ratio of about 0.8-4: 1 by weight, a health food for a pregnant
woman including a pharmaceutically allowable medicine and comprising Angelicae gigantis radix
and
Ligusticum chuanxiong in a mixing ratio of about 0.5-4: 1 by weight, and a health food for a pregnant
woman including a pharmaceutically allowable medicine and comprising a deer antler and
Angelicae gigantis radix in a mixing ratio of about 0.8-4: 0.5-4 by weight.
The object of the present invention also can be accomplished by a health food for a pregnant
woman including a pharmaceutically allowable medicine and comprising a deer antler.
The medicine can prepared as one of a powder form, a liquid form and a globule form.
Another object of the present invention is accomplished by a method of preparing a health food for a
pregnant woman comprising the following steps of : mixing a mixture of a deer antler, Angelicae
gigantis radix and Ligusticum chuanxiong in a mixing ratio of about 0.8-4: 0.5-4: 1 by weight with an
extracting solution; heating thus obtained mixture to a temperature above a boiling point of the
extracting solution; concentrating by keeping heating said mixture to a temperature range of a
boiling point of the extracting solution- 10'C ; cooling thus obtained concentrated solution; and
preparing a pharmaceutically allowable medicine by using thus obtained cooled solution.
Particularly, the preferred extracting solution is one of water and alcohol.
555/757
Water-soluble granules can be prepared by drying the cooled solution and a lyophilization of the
cooled solution can be implemented to dry the cooled solution.
A health food for a pregnant woman also can be prepared by the method comprising the following
steps of : preparing a mixture of a deer antler, Angelicae gigantis radix and Ligusticum chuanxiong
in a mixing ratio of about 0.8-4: 0.5-4: 1 by weight; and grinding the mixture to a powder.
Thus obtained powder can be taken with water or can be taken as a drink after admix the powder
with water.
At this time, the powder can be mixed with white honey or a starch syrup to prepare a globule. The
preferred amount of the white honey or starch syrup is in a range of about 15-20% by weight of the
powder.
In order to minimize side effects and damages induced by using a hormone and to keep a stable
delivery, an extract of a crude drug composition which can result an optimized delivery condition is
provided in the present invention.
Particularly, the side effects during the delivery induced by using the oxytocin hormone, such as a
hyper-bleeding, distocia, etc. can be reduced and sequel of the woman after the delivery,
gynopathic can be prevented. In addition, the function of kidney and uterine can be enhanced.
According to the present invention, various types of foods including the crude drug compositions
which can be used in treatment and prevention of various unfavorable effects instead of the oxytocin
hormone and method of preparing the same are provided. The food can include commonly used and
pharmaceutically allowable various excipients to prepare as a medicine.
Best Mode for Carrying Out the Invention
The present invention will be described in more detail, below.
In Chinese medical science, the fidelity of a kidney function of a woman delivering of a child is
considered as an important factor during a delivery. Within the same functional group of the kidney,
uterine, bladder, etc. are regarded as being in a condition of direct concern with each other.
Therefore, interaction and function between them have a close relation.
556/757
The inventor of the present invention has found that the composite of a deer antler, Angelicae
gigantis radix and Ligusticum chuanxiong is non-toxic, can accelerate delivery and is physiologically
more stable than the oxytocin hormone.
Particularly, the young antler (a Chinese medicine) keeps the kidney in a fine condition and functions
to aid a hormone. Accordingly, the young antler itself is a component which can promote the delivery.
Angelicae gigantis radix (a Chinese medicine called as dangui in Korean pronunciation) aids the
function of liver and kidney and is a hematinic, and so complements lost blood after the delivery.
Ligusticum chuanxiong (a Chinese medicine called as chungung in Korean pronunciation) aids a
smooth circulation of the blood and so a smooth delivery. One of the three components has each
characteristic and a combination of any two components of the three can strengthen the body of the
pregnant woman. For the young antler, a sufficient effect is obtained. However, a medicine using a
mixture of the three components illustrates the most effective result.
In order to prepare an edible medicine by using the crude drug, any type of pharmaceutical form is
applicable without exception. For example, a powder form, a liquid form, a globule form, etc. can be
used.
A crude drug extraction used in an experiment was prepared by the following method. The young
antler, Angelicae gigantis radix and Ligusticum chuanxiong are cut into a small size and then is
heated using a heated water at a temperature of about 90-100 C for 1.5-3 hours. After sufficiently
extracting the drug components by heating, the extracted solution was filtered and thus obtained
filtered solution was dried by lyophilization method.
Preferred embodiments of the present invention will be described in more detail through examples
and experiments.
Example 1
75g of a deer antler, 56.25g of Angelicae gigantis radix and 37.5g of
Ligusticum chuanxiong were added into 1 liter of heating water and then were extracted at 90-100 C
for 3 hours. After filtering the extracted solution, the filtered solution was gathered and dried by a
liophilization method.
Experiment 1
Pregnant SD rats of which pregnancy were confirmed by Voipio and
557/757
Nevalainen method and non-pregnant rats were separated into three groups of a control group, a
group into which the extract of the present invention was administrated and a group into which the
oxytocin hormone was administrated.
After 17-18 days, the uterus was ablated and then the organ was equilibrated for 60 minutes. Then,
the solvent used for the preparation of the extract, the extracted solution of the present invention with
various concentration and the oxytocin hormone with various concentration were applied onto the
organ. The number of the uterine contraction and the uterine contraction power were observed for
each case.
The number of the uterine contraction and the uterine contraction power onto the non-pregnant three
groups and onto the pregnant three groups were observed.
The six groups are as follows.
1. control group (pregnant, non-pregnant)
2. oxytocin hormone administrated group (pregnant, non-pregnant)
3. extract of the a deer antler, Angelicae gigantis radix and Ligusticum chuanxiong administrated
group (pregnant, non-pregnant) * the ablation of the uterus of the non-pregnant group and test on
the uterine contraction
6-Estradiol benzoate dissolved in ethanol (40, ug/O. 9 Q/body/day) was continuously administrated
through a hypodermic injection for two days before the test. After inducing estrus, the rats were killed
by the cervical vertebrae deossification. Immediately after that, the hypogastrium was abdominally
sectioned to ablate the uterus. The vessel, connective tissue, etc. around the uterus were removed
and the uterus near both crus uteri was cut into about 1. 5cm length. Cut uterus was suspended in
an organ bath and is connected to a transducer (PT300,
Grass, U. S. A.) and a polygraph (powerlab 400, Adinstruments, U. S. A.).
After equilibrating the organ for 60 minutes, 100au of the solvent used for the extraction, the extract
of the present invention with various concentration and the oxytocin hormone with various
concentration was applied into the organ bath for 10 minutes. The uterine contraction power and the
number of the uterine contraction were observed for a constant period. Lock-Ringer Solution was
used as a nutrition in the organ bath and the temperature in the organ bath was kept to about 37 C.
As for an injecting gas of the nutrition, a mixture of carbogen gas (95% 2, 5% CO2) was used and
a resting tension was set to 1 g.
558/757
* the ablation of the uterus of the pregnant group and test on the uterine contraction
After 17-18 days from the pregnancy, the rats were killed by the cervical vertebrae deossification.
Immediately after that, the hypogastrium was abdominally sectioned to extract a fetus and ablate the
uterus. The vessel, connective tissue, etc. around the uterus were removed and the uterus near both
crus uteri was cut into about 1. 5cm length. Cut uterus was suspended in a organ bath and is
connected to a transducer (PT300, Grass, U. S. A.) and a polygraph (powerlab 400, Adinstruments,
U. S. A.).
After equilibrating the organ for 60 minutes, 100ut of the solvent used for the extraction, the extract
of the present invention with various concentration and the oxytocin hormone with various
concentration was applied into the organ bath for 10 minutes. The uterine contraction power and the
number of the uterine contraction were observed for a constant period. Lock-Ringer Solution was
used as a nutrition in the organ bath and the temperature in the organ bath was kept to about 37 C.
As for an injecting gas of the nutrition, a mixture of carbogen gas (95% 02, 5% CO2) was used and
a resting tension was set to 1 g.
* preparation of a testing material and administration thereof
Extracted solution of a crud drug prepared by the present invention was freeze dried under a
reduced pressure by utilizing a lyophilizer. Thus prepared testing material in a solid form and the
oxytocin were dissolved in a Lock-Ringer
Solution by the following concentration. The testing material solution was prepared by the
concentration of 0.1,1,10 and 30mg/m#, while the oxytocin solution was prepared by the
concentration of 0.01,0.1 and 1 U/m. In order to induce the estrus of the rat in the non-pregnant
group, 6-estradiol benzonate was dissolved in ethanol (40 g/0.2m#/body/day) and thus obtained
solution was continuously and hypodermically injected for two days before the test. The composition
of the
Lock-Ringer Solution was as follows: mQ/liter ; NaCl : 154, MgCl2-6H20 : 2.1, CaCl2 : 2.6, NaHC03 :
3.4, Glucose: 2.8. The pH of the Lock-Ringer Solution was controlled to about 7.4 and then was
saturated into a mixture gas of carbogen (95% 02, 5% CO20.
Experimental group
1. control group (before the treatment of each testing material)
2. a group treated by the extract of the present invention
Table 1
559/757
testing group prepared concentration practical concentration after treatment
( g/m#) in organ bath (g/m
extract of 0.1 1
Example 1
extract of 1 10
Example 1
extract of 10 100
Example 1
extract of 30 300
Example 1
3. a group treated by the oxytocin
Table 2
testing prepared concentration practical concentration after treating in
group (, ag/mQ) organ bath (, ag/mQ)
oxytocin 0. 01 0. 1
oxytocin 0.1 1
oxytocin 1 10
* test animal and breeding condition
White rats of a female Sprague-Dawley of which weight was 200g were supplied from Cheil
Company. The condition in a breeding room was controlled to a temperature of about 231 C, a
relative humidity of about 55~15% with a luminance of about 300-500 Lux. Light and darkness was
controlled to change by a time period of 12 hours. Five rats were put into one breeding box made of
polycarbonate (240W x 39L x 175H, mm) for a week or more for a defecation. Then, normal animals
were taken after observing their symptom with naked eyes and were applied for the test. Solid feed
for test animal (Samyang Co.) and water were sufficiently supplied for a free adoption.
The number of the uterine contraction and the uterine contraction power of the non-pregnant uterus
after treating with the extract of example 1 were observed.
The testing result is illustrated in Table 3.
560/757
Table 3
testing group contraction contraction power
number (%) (%)
control 100. 0 0. 0 100. 0 0. 0
extract of Example 1 1 g/m# 89.6 3. 2 101.1 3.9
extract of Example 1 10 g/m# 82.4~3.3 101.6~3.0
extract of Example 1 10 g/m# 87.6~3.0 103.0~3.5
82. 4~3. 3 96. 8~2. 4
extract of Example 1300g/m.
158.3 ~0.6* 110.2 ~ 1.5***
oxytocin 0.1mU/m# 308.3~0.7* 119.6 A 1. 8
oxytocinlmU/m# 368.8~0.7* 122.4~2.1***
oxytocin 10 mU/mQ
Data represented by t correspond to mean value obtained by observing 3-5 rats.
*(P < 0.05), *** (P < 0.001); a large difference with the control group.
From the result illustrated in Table 3, it is confirmed that the extracted solution of example 1 induces
no effect onto a non-pregnant uterus and so has a selectivity. However, the oxytocin hormone
induces an effect onto the non-pregnant uterus and has an impulsive function, thereby resulting in
some damages onto a human body.
The number of the uterine contraction and the uterine contraction power of the pregnant uterus after
treating with the extract of example 1 were observed. The testing result is illustrated in Table 4.
Table 4
561/757
Testing group contraction contraction power
number (%) (%)
control 100. 0 0. 0 100. 0 0. 0
extract of Example 1 1, ug/mQ 111.0 4.32 115.3 3.44
extract of Example 1 10 g/m# 109.6~5.55 157.2~6.11*
112.4~5.54 172.7~6.26**
extractof Example 1 100 g/ml
111.1~ 7.17 231.7 ~ 4.71**
extract of Example 1 300 g/m#
133.9~3.21** 155.3~1.96**
oxytocin 0.1mU/m#
217.3~4.75** 205.9~2.48**
oxytocin lmU/m# 249.0~ 1.92 249.6 2.06
oxytocin10mU/mQ
Data represented by correspond to mean value obtained by observing 3-5 rats.
* (P < 0. 05), *** (P < 0. 001); a large difference with the control group.
From the result illustrated in Table 4, it is confirmed that the number of the uterine contraction after
administrating the extract of example 1 according to the present invention is not much larger than
that of the control group. Therefore, the extract of the present invention does not induce an excessive
burden and is stable to the fetus and the woman delivering of a child. Meantime, the contraction
power is strengthened and a spontaneous delivery is facilitated when applying the extract of the
present invention. The value representing the contraction power is similar to that obtained when
applying the oxytocin hormone. On the contrary, it is confirmed that the number of the uterine
contraction is too much when applying the oxytocin hormone and the probability of inducing a hyperbleeding of the woman delivering of a child and a death of the fetus is increased.
* toxicity test: the extracted solution used for the test according to the present invention was
ingested into male and female rats of Sprague-Dawley lineage. Then, the illustration of the toxicity
was observed. The amount of the administration was three types of I g/kg, 2g/kg and 5g/kg. Each
dosage was administrated into five rats at once and was observed for 14 days. General symptom,
weight change and autopsy result were considered and the observation result is as follows.
562/757
(1) During the whole time period, no rat administrated with the extracted solution of the present
invention, died and no peculiar symptom was observed when comparing with the control.
(2) With the weight change, no significant difference was observed between the group administrated
with the extracted solution of the present invention and the control.
(3) After implementing an autopsy, no abnormal factor was observed for the group administrated
with the extracted solution of the present invention according to an examination with the naked eye.
From the above-described result, it is known that no death and no peculiar symptom were observed
for the rat administrated with the extracted solution of the present invention. Also, no peculiar
symptom was observed when examining the weight change and autopsy result. That is, no toxicity
was illustrated with the dosage of 5g/kg or less of the crude drug extract according to the present
invention.
Accordingly, it is assumed that the LDIO (lethal dose) of the extracted solution of the present
invention onto the rat through the oral administration is regarded as 5g/kg or more.
Hereinafter, preferred embodiments on various medicine forms of the extracted crude drug
suggested by the present invention will be described in detail.
56.25g of Angelicae gigantis radix and 37.5g of Ligusticum chuanxiong were cut into small pieces
and mixed. Then, the mixture was extracted by using an extracting solution such as heating water,
alcohol, and the like. Thus obtained extract was cooled and then filtered. A tablet and liquid type
preparation for an oral administration was prepared by using the filtered solution.
75g of a deer antler and 37.5g of Ligusticum chuanxiong were cut into small pieces and mixed. Then,
the mixture was extracted by using an extracting solution such as heating water, alcohol, and the like.
Thus obtained extract was cooled and then filtered. A tablet and liquid type preparation for an oral
administration was prepared by using the filtered solution.
563/757
75g of a deer antler and 56.25g of Angelicae gigantis radix were cut into small pieces and mixed.
Then, the mixture was extracted by using an extracting solution such as heating water, alcohol, and
the like. Thus obtained extract was cooled and then filtered. A tablet and liquid type preparation for
an oral administration was prepared by using the filtered solution.
< Preparation Example 4 >
75g of a deer antler, 56.25g of Angelicae gigantis radix and 37.5g of
Ligusticum chuanxiong were cut into small pieces and mixed. Then, the mixture was extracted by
using an extracting solution such as heating water, alcohol, and the like. Thus obtained extract was
cooled and then filtered. A tablet and liquid type preparation for an oral administration was prepared
by using the filtered solution.
75g of a deer antler was cut into small pieces and mixed. Then, the mixture was extracted by
using an extracting solution such as heating water, alcohol, and the like. Thus obtained extract was
cooled and then filtered. A tablet and liquid type preparation for an oral administration was prepared
by using the filtered solution.
As described above, the crude drug extract prepared from the young antler,
Angelicae gigantis radix and Ligusticum chuanxiong facilitates the delivery of a pregnant woman and
can replace the conventionally used oxytocin hormone. The extract of the present invention is a
health food which leads a smooth and stable uterine contraction and a fast delivery. This health food
can remove the possibility of generating cancer, fetal death, hyper-bleeding of the woman delivering
of a child, etc.
In addition, when comparing with the oxytocin hormone which functions to both of the pregnant and
non-pregnant woman, and so induces an impulsive action and side effects, the extract of the present
invention does not function to non-pregnant woman but function to pregnant woman during delivery
and so is considered as a remarkably stable one.
While the present invention is described in detail referring to the attached embodiments, various
modifications, alternate constructions and equivalents may be employed without departing from the
true spirit and scope of the present invention.Claims:
CLAIMS
564/757
1. A health food for a pregnant woman including a pharmaceutically allowable medicine and
comprising a deer antler, Angelicae gigantis radix and
Ligusticum chuanxiong in a mixing ratio of about 0.8-4: 0.5-4: 1 by weight.
2. A health food for a pregnant woman as claimed in claim 1, wherein said medicine is obtained as
one of a powder form, a liquid form and a globule form.
3. A health food for a pregnant woman including a pharmaceutically allowable medicine and
comprising a deer antler and Ligusticum chuanxiong in a mixing ratio of about 0.8-4: 1 by weight.
4. A health food for a pregnant woman as claimed in claim 3, wherein said medicine is obtained as
one of a powder form, a liquid form and a globule form.
5. A health food for a pregnant woman including a pharmaceutically allowable medicine and
comprising Angelicae gigantis radix and Ligusticum chuanxiong in a mixing ratio of about 0.5-4: 1 by
weight.
6. A health food for a pregnant woman as claimed in claim 5, wherein said medicine is obtained as
one of a powder form, a liquid form and a globule form.
7. A health food for a pregnant woman including a pharmaceutically allowable medicine and
comprising a deer antler and Angelicae gigantis radix in a mixing ratio of about 0.8-4: 0.5-4 by
weight.
8. A health food for a pregnant woman as claimed in claim 7, wherein said medicine is obtained as a
powder form, a liquid form or a globule form.
9. A health food for a pregnant woman including a pharmaceutically allowable medicine and
comprising a deer antler.
10. A health food for a pregnant woman as claimed in claim 9, wherein said medicine is obtained as
one of a powder form, a liquid form and a globule form.
11. A method of preparing a health food for a pregnant woman comprising the following steps of :
mixing a mixture of a deer antler, Angelicae gigantis radix and Ligusticum chuanxiong in a mixing
565/757
ratio of about 0.8-4: 0.5-4: 1 by weight with an extracting solution; heating thus obtained mixture to a
temperature above a boiling point of said extracting solution; concentrating by keeping heating said
mixture to a temperature range of a boiling point of said extracting solution 10 C ; cooling thus
obtained concentrated solution; and preparing a pharmaceutically allowable medicine by using thus
obtained cooled solution.
12. A method of preparing a health food for a pregnant woman as claimed in claim 11, wherein said
extracting solution is one of water and alcohol.
13. A method of preparing a health food for a pregnant woman as claimed in claim 11, further
comprising a step of preparing water-soluble granules by drying said cooled solution.
14. A method of preparing a health food for a pregnant woman as claimed in claim 11, further
comprising a lyophilization step of said cooled solution.
15. A method of preparing a health food for a pregnant woman comprising the following steps of :
preparing a mixture of a deer antler, Angelicae gigantis radix and Ligusticum chuanxiong in a mixing
ratio of about 0.8-4: 0.5-4: 1 by weight; and grinding said mixture to a powder.
16. A method of preparing a health food for a pregnant woman as claimed in claim 15, further
comprising the step of mixing white honey or a starch syrup with said powder to prepare a globule.
17. A method of preparing a health food for a pregnant woman as claimed in claim 16, wherein an
amount of said white honey or starch syrup is in a range of about 15-20% by weight of said powder.
566/757
307. KR2002090077 - 30.11.2002
HEALTH AUXILIARY FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002090077
Inventor(s):
JEONG SEONG YIL (KR)
Applicant(s):
JEONG SEONG YIL (KR)
IP Class 4 Digits: A61K
IP Class:
A61K35/78
Application Number:
KR20010030239 (20010523)
Priority Number: KR20010030239 (20010523)
Family: KR2002090077
567/757
308. KR2002090175 - 30.11.2002
HEALTH SUPPLEMENTARY FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002090175
Inventor(s):
KIM HYEON JUN (KR)
Applicant(s):
KIM HYEON JUN (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/212
Application Number:
KR20020056275 (20020912)
Priority Number: KR20020056275 (20020912)
Family: KR2002090175
568/757
309. KR2002091404 - 06.12.2002
PRODUCTION OF LIGNUM ACRONYCHIAE EXTRACT, LIGNUM ACRONYCHIAE EXTRACT
THEREFROM AND PHARMACEUTICAL COMPOSITION AND HEALTH FOOD FOR PREVENTION
AND TREATMENT OF OSTEOPOROSIS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002091404
Inventor(s):
HA HYE GYEONG (KR); KIM JEONG SUK (KR); KIM JIN SUK (KR); LEE JE HYEON
(KR); SONG GYE YONG (KR)
Applicant(s):
KOREA INST OF ORIENTAL MEDICIN (KR)
IP Class 4 Digits: A61K
IP Class:
A61K35/78
Application Number:
KR20010030064 (20010530)
Priority Number: KR20010030064 (20010530)
Family: KR2002091404
569/757
310. KR2002091899 - 11.12.2002
SUPPLEMENTARY HEALTH FOOD FOR CONSTIPATION AND CORPULENCE AND
MANUFACTURING METHOD THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002091899
Inventor(s):
KIM JUNG WOONG (KR)
Applicant(s):
KIM JUNG WOONG (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010030703 (20010601)
Priority Number: KR20010030703 (20010601)
Family: KR2002091899
570/757
311. KR2002093672 - 16.12.2002
HEALTH FOOD CONTAINING OSTRICH MEAT AND ACANTHOPANACIS CORTEX AS MAIN
MATERIALS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002093672
Inventor(s):
SONG DEUK YONG (KR)
Applicant(s):
SONG DEUK YONG (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/315; A23L1/29
Application Number:
KR20020061108 (20021004)
Priority Number: KR20020061108 (20021004)
Family: KR2002093672
571/757
312. KR2002094179 - 18.12.2002
HEALTH SUPPLEMENTARY FOOD PRODUCT FOR DIABETES
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002094179
Inventor(s):
PYO JEOM DEOK (KR)
Applicant(s):
PYO JEOM DEOK (KR)
IP Class 4 Digits: A61K
IP Class:
A61K35/78
Application Number:
KR20010032751 (20010612)
Priority Number: KR20010032751 (20010612)
Family: KR2002094179
572/757
313. KR2002096436 - 31.12.2002
HEALTH FOOD USING A MALLOW AND A CASCARA SAGRADA AS MAIN INGREDIENTS AND
MANUFACTURING PROCESS THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2002096436
Inventor(s):
KIM JONG GYU (KR)
Applicant(s):
KOREA LIFE TECHNOLOGY CO LTD (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010034870 (20010619)
Priority Number: KR20010034870 (20010619)
Family: KR2002096436
573/757
314. KR2003000186 - 06.01.2003
METHOD AND SYSTEM FOR SELLING HEALTH FOOD BY ANALYZING CONSTITUTION BASED ON
NETWORK
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003000186
Inventor(s):
PARK HEE JUNG (KR)
Applicant(s):
PARK HEE JUNG (KR)
IP Class 4 Digits: G06F
IP Class:
G06F19/00
Application Number:
KR20010035855 (20010622)
Priority Number: KR20010035855 (20010622)
Family: KR2003000186
574/757
315. KR2003004993 - 15.01.2003
METHOD FOR MANUFACTURING A FERMENTED HEALTH FOOD PRODUCT USING NATURAL
PLANT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003004993
Inventor(s):
KIM YONG MOON (KR)
Applicant(s):
KIM YONG MOON (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020017478 (20020329)
Priority Number: KR20020017478 (20020329)
Family: KR2003004993
575/757
316. KR2003005121 - 15.01.2003
HEALTH FOOD USING A MUDFISH AND ACANTHOPANAX AS MAIN INGREDIENTS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003005121
Inventor(s):
LEE CHUN YEL (KR)
Applicant(s):
LEE CHUN YEL (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020078042 (20021206)
Priority Number: KR20020078042 (20021206)
Family: KR2003005121
576/757
317. KR2003005122 - 15.01.2003
HEALTH FOOD USING ACANTHOPANAX AS A MAIN INGREDIENT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003005122
Inventor(s):
JANG YUN SU (KR)
Applicant(s):
JANG YUN SU (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020078544 (20021206)
Priority Number: KR20020078544 (20021206)
Family: KR2003005122
577/757
318. KR2003005127 - 15.01.2003
HEALTH FOOD PRODUCTS USING HOVING DULIS THUNB AND ALNUS RUBRA AS MAIN
INGREDIENTS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003005127
Inventor(s):
HWANG JUNG KU (KR)
Applicant(s):
HWANG JUNG KU (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020079386 (20021210)
Priority Number: KR20020079386 (20021210)
Family: KR2003005127
578/757
319. KR2003005129 - 15.01.2003
HEALTH FOOD USING SALICORNIA HERBACEA AND ACANTHOPANAX AS MAIN INGREDIENTS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003005129
Inventor(s):
LEE JONG SUN (KR)
Applicant(s):
LEE JONG SUN (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020080518 (20021213)
Priority Number: KR20020080518 (20021213)
Family: KR2003005129
579/757
320. KR2003006171 - 23.01.2003
METHOD FOR MANUFACTURING HEALTH SUPPLEMENTARY FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003006171
Inventor(s):
SUH YOUNG HUN (KR)
Applicant(s):
SUH YOUNG HUN (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010041745 (20010711)
Priority Number: KR20010041745 (20010711)
Family: KR2003006171
580/757
321. KR2003006847 - 23.01.2003
METHOD FOR MANUFACTURING HEALTH FOOD PRODUCTS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003006847
Inventor(s):
OH JUNG WOOK (KR)
Applicant(s):
OH JUNG WOOK (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/33
Application Number:
KR20010042799 (20010716)
Priority Number: KR20010042799 (20010716)
Family: KR2003006847
581/757
322. KR2003007986 - 24.01.2003
METHOD FOR PRODUCING A HEALTH FOOD SUPPLEMENT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003007986
Inventor(s):
LEE MYEONG SU (KR)
Applicant(s):
NEW MEDI COM CO LTD (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010032111 (20010608)
Priority Number: KR20010032111 (20010608)
Family: KR2003007986
582/757
323. KR2003008184 - 24.01.2003
HEALTH FOOD USING SALICORNIA HERBACEA AS MAIN INGREDIENTS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003008184
Inventor(s):
KIM DAI GON (KR)
Applicant(s):
KIM DAI GON (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020083763 (20021218)
Priority Number: KR20020083763 (20021218)
Family: KR2003008184
583/757
324. KR2003009972 - 05.02.2003
PRODUCTION OF HEALTH FOOD PRODUCT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003009972
Inventor(s):
CHOE MYONG HUI (KR)
Applicant(s):
CHOE MYONG HUI (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/10
Application Number:
KR20010044667 (20010724)
Priority Number: KR20010044667 (20010724)
Family: KR2003009972
584/757
325. KR2003010352 - 05.02.2003
HEALTH FOOD COMPOSITION CONTAINING CORTEX EUCOMMIAE AND ISOFLAVONE
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003010352
Inventor(s):
BYUN SANG YO (KR); LEE DONG SEON (KR)
Applicant(s):
COLLEGE PHARMA (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010045258 (20010726)
Priority Number: KR20010045258 (20010726)
Family: KR2003010352
585/757
326. KR2003010369 - 05.02.2003
HEALTH FOOD USING CARTHAMI FLOS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003010369
Inventor(s):
LEE JONG SUN (KR)
Applicant(s):
LEE JONG SUN (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010045285 (20010724)
Priority Number: KR20010045285 (20010724)
Family: KR2003010369
586/757
327. KR2003011464 - 11.02.2003
HEALTH FOOD COMPOSITION ELIMINATING ACTIVATED OXYGEN(FREE RADICAL) USING
HERBS AND METHOD FOR EXTRACTION OF HERBS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003011464
Inventor(s):
JEON GEON TAE (KR); KIM SUNG MO (KR); SUNG DUCK MO (KR)
Applicant(s):
JEON GEON TAE (KR); KIM SUNG MO (KR); SUNG DUCK MO (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29; A23L1/212
Application Number:
KR20010046932 (20010803)
Priority Number: KR20010046932 (20010803)
Family: KR2003011464
587/757
328. KR2003011752 - 11.02.2003
PRODUCTION OF HEALTH SUPPLEMENTARY FOOD FOR PROTECTION OF BRONCHI
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003011752
Inventor(s):
KWAN SOON JIK (KR)
Applicant(s):
KWAN SOON JIK (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020085650 (20021223)
Priority Number: KR20020085650 (20021223)
Family: KR2003011752
588/757
329. KR2003012714 - 12.02.2003
PROCESS FOR PREPARING HEALTH FOOD FOR GROWTH PROMOTION IN JUVENILES
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003012714
Inventor(s):
LEE YOUNG CHUL (KR); YANG SANG CHUL (KR)
Applicant(s):
LEE YOUNG CHUL (KR); YANG SANG CHUL (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010047119 (20010804)
Priority Number: KR20010047119 (20010804)
Family: KR2003012714
589/757
330. KR2003014478 - 19.02.2003
PROCESS FOR PREPARING HEALTH FOOD USING DRIED SNAKEHEAD MULLET AND DRIED
SEAFOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003014478
Inventor(s):
LEE HEUNG SU (KR)
Applicant(s):
LEE HEUNG SU (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/325
Application Number:
KR20010048500 (20010811)
Priority Number: KR20010048500 (20010811)
Family: KR2003014478
590/757
331. KR2003017792 - 04.03.2003
HEALTH FOOD COMPOSITION CONTAINING PHYTONCIDE AND PROTEIN
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003017792
Inventor(s):
SO MU CHUL (KR); SO MU SEONG (KR); SO SEONG GEUN (KR)
Applicant(s):
SO MU CHUL (KR)
IP Class 4 Digits: A61K
IP Class:
A61K35/78
Application Number:
KR20010050813 (20010822)
Priority Number: KR20010050813 (20010822)
Family: KR2003017792
591/757
332. KR2003019496 - 06.03.2003
HEALTH FOOD USING RED GINSENG AND ACANTHOPANAX AS MAIN INGREDIENTS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003019496
Inventor(s):
LEE JONG SUN (KR)
Applicant(s):
LEE JONG SUN (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20030004978 (20030121)
Priority Number: KR20030004978 (20030121)
Family: KR2003019496
592/757
333. KR2003019739 - 07.03.2003
MANUFACTURING METHOD OF DRINK COMPOSITION AS HEALTH SUPPLEMENTARY FOOD
FROM PLANT GROUP
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003019739
Inventor(s):
LEE HOON (KR)
Applicant(s):
LEE HOON (KR)
IP Class 4 Digits: A23L
IP Class:
A23L2/38
Application Number:
KR20010053018 (20010830)
Priority Number: KR20010053018 (20010830)
Family: KR2003019739
593/757
334. KR2003022500 - 17.03.2003
HEALTH FOOD COMPOSITION FOR WHITENING SKIN
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003022500
Inventor(s):
PARK MYUNG HWAN (KR)
Applicant(s):
PARK MYUNG HWAN (KR)
IP Class 4 Digits: A61K
IP Class:
A61K35/78
Application Number:
KR20010055613 (20010910)
Priority Number: KR20010055613 (20010910)
Family: KR2003022500
594/757
335. KR2003023913 - 26.03.2003
HEALTH SUPPLEMENTARY FOOD COMPOSITION USING QUASSIA SEED AND PRODUCTION
THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003023913
Inventor(s):
(KR)
LEE HYUK GYU (KR); LEE KWANG GYU (KR); LEE SOO HWUN (KR); LEE SUK JIN
Applicant(s):
(KR)
LEE HYUK GYU (KR); LEE KWANG GYU (KR); LEE SOO HWUN (KR); LEE SUK JIN
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010056653 (20010914)
Priority Number: KR20010056653 (20010914)
Family: KR2003023913
595/757
336. KR2003024356 - 26.03.2003
HEALTH SUPPLEMENTARY FOOD CONTAINING LAMINARIA AND COLLOIDAL SILVER AS MAIN
COMPONENT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003024356
Inventor(s):
CHOI SOON OK (KR)
Applicant(s):
CHOI SOON OK (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010057468 (20010918)
Priority Number: KR20010057468 (20010918)
Family: KR2003024356
596/757
337. KR2003024422 - 26.03.2003
PRODUCTION OF HEALTH FOOD CONTAINING MISCELLANEOUS GRAIN TREATED WITH LOESS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003024422
Inventor(s):
CHA YOUNG SUP (KR)
Applicant(s):
CHA YOUNG SUP (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/10
Application Number:
KR20010057567 (20010918)
Priority Number: KR20010057567 (20010918)
Family: KR2003024422
597/757
338. KR2003024740 - 26.03.2003
PRODUCTION OF HEALTH FOOD USING HERBAL PLANTS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003024740
Inventor(s):
CHANG JOON HO (KR)
Applicant(s):
CHANG JOON HO (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20030011282 (20030224)
Priority Number: KR20030011282 (20030224)
Family: KR2003024740
598/757
339. KR2003026077 - 31.03.2003
PRODUCTION OF GRANULAR HEALTH FOOD USING KELP
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003026077
Inventor(s):
KIM SANG KWON (KR); YANG JI YEONG (KR)
Applicant(s):
KIM SANG KWON (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010059068 (20010924)
Priority Number: KR20010059068 (20010924)
Family: KR2003026077
599/757
340. KR2003026128 - 31.03.2003
PRODUCTION OF HEALTH SUPPLEMENTARY FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003026128
Inventor(s):
RYOU JAE MAN (KR)
Applicant(s):
RYOU JAE MAN (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/304
Application Number:
KR20010059179 (20010924)
Priority Number: KR20010059179 (20010924)
Family: KR2003026128
600/757
341. KR2003026178 - 31.03.2003
PRODUCTION OF HEALTH FOOD FOR MEN
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003026178
Inventor(s):
SUH YOUNG HUN (KR)
Applicant(s):
SUH YOUNG HUN (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/10
Application Number:
KR20010059474 (20010925)
Priority Number: KR20010059474 (20010925)
Family: KR2003026178
601/757
342. KR2003026384 - 03.04.2003
HEALTH AND SUPPLEMENTARY FOOD FOR DIABETIC AND MANUFACTURING METHOD
THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003026384
Inventor(s):
JUNG OK CHO (KR)
Applicant(s):
JUNG OK CHO (KR); KIM JUNG SOOK (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010056287 (20010912)
Priority Number: KR20010056287 (20010912)
Family: KR2003026384
602/757
343. KR2003026939 - 03.04.2003
TEA COMPOSITION CONTAINING AS ACTIVE INGREDIENT, GUAVA LEAVES FOR TREATING
DIABETES AND OBESITY, AND PREVENTING AGING, AND HEALTH FOOD CONTAINING THE
SAME
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003026939
Inventor(s):
CHOI MI HOI (KR); JUNG HUI CHEOL (KR); PARK GYEONG MIN (KR)
Applicant(s):
CHOI MI HOI (KR)
IP Class 4 Digits: A23L; A23F
IP Class:
A23L1/30; A23L2/38; A23F3/00
Application Number:
KR20030005387 (20030127)
Priority Number: KR20030005387 (20030127)
Family: KR2003026939
603/757
344. KR2003027133 - 07.04.2003
HEALTH AND SUPPLEMENTARY FOOD OR DRUG USING ELDERBERRY FOR PREVENTION AND
TREATMENT OF INFLUENZA VIRUS INFECTION AND MANUFACTURING METHOD THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003027133
Inventor(s):
CHOI DAL JEONG (KR)
Applicant(s):
CHOI DAL JEONG (KR)
IP Class 4 Digits: A61K
IP Class:
A61K35/78
Application Number:
KR20010056309 (20010912)
Priority Number: KR20010056309 (20010912)
Family: KR2003027133
604/757
345. KR2003028251 - 08.04.2003
PRODUCTION OF HEALTH SUPPLEMENTARY FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003028251
Inventor(s):
SUH YOUNG HUN (KR)
Applicant(s):
SUH YOUNG HUN (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/10
Application Number:
KR20010060272 (20010927)
Priority Number: KR20010060272 (20010927)
Family: KR2003028251
605/757
346. KR2003028638 - 10.04.2003
PRODUCTION OF FUNCTIONAL HEALTH FOOD OF MULBERRY LEAVES BY CULTURING
MUSHROOM MYCELIUM
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003028638
Inventor(s):
LEW IN DEOK (KR)
Applicant(s):
LEW IN DEOK (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29; A23L1/28
Application Number:
KR20010058344 (20010920)
Priority Number: KR20010058344 (20010920)
Family: KR2003028638
606/757
347. KR2003029271 - 14.04.2003
PRODUCTION OF UNCOOKED HEALTH FOOD PRODUCT CAPABLE OF BEING USED BY
PERSONS OF DIFFERENT AGES AND SEXES
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003029271
Inventor(s):
SUH YOUNG HUN (KR)
Applicant(s):
SUH YOUNG HUN (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/10
Application Number:
KR20010061547 (20011005)
Priority Number: KR20010061547 (20011005)
Family: KR2003029271
607/757
348. KR2003029557 - 14.04.2003
MANUFACTURING METHOD OF A HEALTH FOOD BY MIXING GASTRODIAE RHIZOMA AND
MEDICINE HERBS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003029557
Inventor(s):
LEE JU BAEK (KR)
Applicant(s):
HANULSAM CO LTD (KR); TAEGU HEALTH COLLEGE (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20030015440 (20030312)
Priority Number: KR20030015440 (20030312)
Family: KR2003029557
608/757
349. KR2003031058 - 18.04.2003
METHOD AND APPARATUS OF PRODUCING RICE PASTE PRODUCT FOR HEALTH FOOD USING
EMBRYO-RETAINING RICE AND CHITOSAN AS MAIN COMPONENT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003031058
Inventor(s):
KIM CHANG GYUN (KR)
Applicant(s):
KIM CHANG GYUN (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/10; A23L1/172
Application Number:
KR20030017632 (20030320)
Priority Number: KR20030017632 (20030320)
Family: KR2003031058
609/757
350. KR2003034415 - 09.05.2003
METHOD FOR CULTIVATING NONPOISONOUS RIVER PUFFER AND METHOD FOR PRODUCING
HEALTH AUXILIARY FOOD PRODUCT USING THE SAME
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003034415
Inventor(s):
YUN HWANG BYEONG (KR)
Applicant(s):
YUN HWANG BYEONG (KR)
IP Class 4 Digits: A01K
IP Class:
A01K61/00
Application Number:
KR20010065344 (20011023)
Priority Number: KR20010065344 (20011023)
Family: KR2003034415
610/757
351. KR2003037380 - 14.05.2003
HEALTH FOOD USING RED GINSENG EXTRACT, AND METHOD FOR PREPARING THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003037380
Inventor(s):
JUN BYEONG SEON (KR); KIM SEOK CHANG (KR); PARK CHAE GYU (KR); PARK
MYEONG HAN (KR); YANG JAE WON (KR)
Applicant(s):
KT and G CORP (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010068354 (20011103)
Priority Number: KR20010068354 (20011103)
Family: KR2003037380
611/757
352. KR2003040788 - 23.05.2003
HEALTH FOOD COMPOSITION FOR REGULATING WEIGHT AND IMPROVING ARTHRALGIA AFTER
GIVING BIRTH
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003040788
Inventor(s):
KIM SANG MAN (KR)
Applicant(s):
REXGENE BIOTECH CO LTD (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010071370 (20011116)
Priority Number: KR20010071370 (20011116)
Family: KR2003040788
612/757
353. KR2003040995 - 23.05.2003
STEAMING DEVICE FOR EXTRACTING HEALTH FOOD AND RESTORATIVE
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003040995
Inventor(s):
KIM CHANG YONG (KR)
Applicant(s):
MOON JIN OK (KR)
IP Class 4 Digits: A47J
IP Class:
A47J31/00
Application Number:
KR20010071700 (20011119)
Priority Number: KR20010071700 (20011119)
Family: KR2003040995
613/757
354. KR2003044967 - 09.06.2003
HEALTH FOOD USING SASA BOREALIS AND ACORUS GRAMINEUS SOLAND AS A MAIN
INGREDIENT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003044967
Inventor(s):
KIM DAI GON (KR)
Applicant(s):
KIM DAI GON (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20030030740 (20030512)
Priority Number: KR20030030740 (20030512)
Family: KR2003044967
614/757
355. KR2003046798 - 18.06.2003
HEALTH FOOD SUPPLEMENT HAVING IMPROVEMENT EFFECTS ON CONSTIPATION AND
INTESTINE ACTIVITY AND COMPOSITIONS THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003046798
Inventor(s):
PARK DONG KI (KR)
Applicant(s):
PARK DONG KI (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010077055 (20011206)
Priority Number: KR20010077055 (20011206)
Family: KR2003046798
615/757
356. KR2003047134 - 18.06.2003
METHOD FOR MANUFACTURING HEALTH FOOD USING ORGANIC GERMANIUM WATER AND
PURIFIED WATER AS MAIN INGREDIENT WITH COLD AND HOT WATER TANK
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003047134
Inventor(s):
LEE SUNG MOON (KR)
Applicant(s):
LEE SUNG MOON (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/00
Application Number:
KR20010077531 (20011207)
Priority Number: KR20010077531 (20011207)
Family: KR2003047134
616/757
357. KR2003047627 - 18.06.2003
HEALTH FOOD PRODUCT USING COMI FRUCTUS AS A MAIN INGREDIENT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003047627
Inventor(s):
SEO BONG SEOK (KR)
Applicant(s):
SEO BONG SEOK (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010079883 (20011210)
Priority Number: KR20010079883 (20011210)
Family: KR2003047627
617/757
358. KR2003051517 - 25.06.2003
HEALTH FOOD USING HOVENIA DULCIS THUNBERG AND SEMISULCOSPIRA LIBERTINA AS
MAIN INGREDIENT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003051517
Inventor(s):
SEO BONG SEOK (KR)
Applicant(s):
SEO BONG SEOK (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20030035009 (20030528)
Priority Number: KR20030035009 (20030528)
Family: KR2003051517
618/757
359. KR2003053417 - 28.06.2003
HEALTH FOOD COMPOSITION CONTAINING SAURURUS CHINENSIS BAILL. AS MAIN
INGREDIENT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003053417
Inventor(s):
HAHM JONG CHEON (KR); KO JAE PIL (KR); LEE SEUNG HO (KR)
Applicant(s):
GREENTEK21 CO LTD (KR); HAHM JONG CHEON (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20010083730 (20011222)
Priority Number: KR20010083730 (20011222)
Family: KR2003053417
619/757
360. KR2003059015 - 07.07.2003
PRODUCTION OF HEALTH FOOD USING OSTRICH EXTRACT AS MAIN MATERIAL
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003059015
Inventor(s):
KIM SE IN (KR)
Applicant(s):
KIM SE IN (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/315
Application Number:
KR20030036546 (20030602)
Priority Number: KR20030036546 (20030602)
Family: KR2003059015
620/757
361. KR2003063074 - 28.07.2003
HEALTH FOOD REMOVING ASTHMA AND MANUFACTURE METHOD THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003063074
Inventor(s):
LEE YOUNG KOOK (KR)
Applicant(s):
LEE YOUNG KOOK (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020048138 (20020814)
Priority Number: KR20020048138 (20020814)
Family: KR2003063074
621/757
362. KR2003065673 - 09.08.2003
COMPOSITION OF HEALTH FOOD PRODUCT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003065673
Inventor(s):
SHIN SU HYEON (KR)
Applicant(s):
BIO AND BIO (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020005388 (20020130)
Priority Number: KR20020005388 (20020130)
Family: KR2003065673
622/757
363. KR2003067426 - 14.08.2003
CALCIUM-SUPPLEMENTED HEALTH FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003067426
Inventor(s):
KIM JIN BAE (KR)
Applicant(s):
KIM JIN BAE (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/312
Application Number:
KR20020007624 (20020208)
Priority Number: KR20020007624 (20020208)
Family: KR2003067426
623/757
364. KR2003067795 - 19.08.2003
PRODUCTION OF HEALTH SUPPLEMENTARY FOOD USING RADISH JUICE
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003067795
Inventor(s):
KWAN SOON JIK (KR)
Applicant(s):
KWAN SOON JIK (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020007249 (20020208)
Priority Number: KR20020007249 (20020208)
Family: KR2003067795
624/757
365. KR2003072162 - 13.09.2003
HEALTH TONIC FOOD USING MEDICINAL HERBS FOR DIABETES
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003072162
Inventor(s):
LEE KON KYUNG (KR)
Applicant(s):
LEE KON KYUNG (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020012288 (20020302)
Priority Number: KR20020012288 (20020302)
Family: KR2003072162
625/757
366. KR2003072997 - 19.09.2003
HEALTH FOOD USING SEA CUCUMBER AS MAIN MATERIAL AND PRODUCTION THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003072997
Inventor(s):
YANG DAE YOON (KR)
Applicant(s):
LEE SYE GI (KR); YANG DAE YOON (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/333
Application Number:
KR20020012330 (20020308)
Priority Number: KR20020012330 (20020308)
Family: KR2003072997
626/757
367. KR2003073495 - 19.09.2003
PRODUCTION OF PICKLED TOHWA PANCAKE AS HEALTH SUPPLEMENTARY FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003073495
Inventor(s):
KIM DUCK MAN (KR)
Applicant(s):
KIM DUCK MAN (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020013091 (20020312)
Priority Number: KR20020013091 (20020312)
Family: KR2003073495
627/757
368. KR2003073720 - 19.09.2003
HEALTH FOOD USING PHELLINUS LINTEUS AS MAIN MATERIAL AND PRODUCTION THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003073720
Inventor(s):
JUNG YEON CHEOL (KR)
Applicant(s):
N and S KOREA CO LTD (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020013415 (20020313)
Priority Number: KR20020013415 (20020313)
Family: KR2003073720
628/757
369. KR2003073734 - 19.09.2003
PRODUCTION OF HEALTH FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003073734
Inventor(s):
BAEK DAE JIN (KR)
Applicant(s):
BAEK DAE JIN (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020013438 (20020313)
Priority Number: KR20020013438 (20020313)
Family: KR2003073734
629/757
370. KR2003073901 - 19.09.2003
PRODUCTION OF HEALTH FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003073901
Inventor(s):
PARK JOON HEE (KR)
Applicant(s):
PARK JOON HEE (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020013664 (20020311)
Priority Number: KR20020013664 (20020311)
Family: KR2003073901
630/757
371. KR2003075613 - 26.09.2003
HEALTH SUPPLEMENTARY FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003075613
Inventor(s):
MYUNG NO KYUNG (KR)
Applicant(s):
MYUNG NO KYUNG (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020014929 (20020320)
Priority Number: KR20020014929 (20020320)
Family: KR2003075613
631/757
372. KR2003078248 - 08.10.2003
HEALTH FOOD SUPPLEMENT FOR INCREASING SEXUAL POTENCY USING RAW GRAIN FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003078248
Inventor(s):
LEE GWANG BOK (KR); LIM JUN GYU (KR)
Applicant(s):
GOEULBIT SEANGSIK MAUL CO LTD (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020017154 (20020328)
Priority Number: KR20020017154 (20020328)
Family: KR2003078248
632/757
373. KR2003079190 - 10.10.2003
HEALTH FOOD SUPPLEMENT FOR PROVIDING PREGNANT WOMEN AND NURSING MOTHERS
WITH NUTRIENTS USING RAW GRAIN FOODS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003079190
Inventor(s):
LEE GWANG BOK (KR); LIM JUN GYU (KR)
Applicant(s):
GOEULBIT SEANGSIK MAUL CO LTD (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020018038 (20020402)
Priority Number: KR20020018038 (20020402)
Family: KR2003079190
633/757
374. KR2003079376 - 10.10.2003
CAPSULE TYPED HEALTH FOOD USING HERICIUM ERINACEUS AS MAIN INGREDIENT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003079376
Inventor(s):
KIM GO JUNG (KR); PARK MUN JA (KR); KIM YANG HEE (KR)
Applicant(s):
KIM GO JUNG (KR); PARK MUN JA (KR); KIM YANG HEE (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020018352 (20020403)
Priority Number: KR20020018352 (20020403)
Family: KR2003079376
634/757
375. KR2003080629 - 17.10.2003
PRODUCTION OF HEALTH FOOD
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003080629
Inventor(s):
JANG GAM YONG (KR); CHOI SU YEONG (KR)
Applicant(s):
CLEAN WORLD HI TECH (KR); GOOD MORNIG INDUSTIAL SYSTEM C (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020019360 (20020410)
Priority Number: KR20020019360 (20020410)
Family: KR2003080629
635/757
376. KR2003081928 - 22.10.2003
HEALTH SUPPLEMENTARY FOOD USING RED GINSENG AS MAIN COMPONENT AND
PRODUCTION METHOD THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003081928
Inventor(s):
LEE GYU HWAN (KR)
Applicant(s):
LEE GYU HWAN (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020020388 (20020415)
Priority Number: KR20020020388 (20020415)
Family: KR2003081928
636/757
377. KR2003082157 - 22.10.2003
HEALTH SUPPLEMENTARY FOOD FOR TREATMENT OF PULMONARY DISEASE CAUSED BY
OBESITY AND SMOKING
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003082157
Inventor(s):
JEONG SEONG YIL (KR)
Applicant(s):
JEONG SEONG YIL (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020020741 (20020412)
Priority Number: KR20020020741 (20020412)
Family: KR2003082157
637/757
378. KR2003082654 - 23.10.2003
PRODUCTION OF HEALTH SUPPLEMENTARY FOOD USING THEAE FOLIUM, MUME FRUCTUS
AND SCHIZANDRAE FRUCTUS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003082654
Inventor(s):
CHOI JAE POONG (KR)
Applicant(s):
CHOI JAE POONG (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020021060 (20020417)
Priority Number: KR20020021060 (20020417)
Family: KR2003082654
638/757
379. KR2003085148 - 05.11.2003
HEALTH FOOD PRODUCT "NATURAL BEAUTY ROAD GOLD"
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003085148
Inventor(s):
CHOE SUNG HYU (KR)
Applicant(s):
CHOE SUNG HYU (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020023301 (20020429)
Priority Number: KR20020023301 (20020429)
Family: KR2003085148
639/757
380. KR2003089353 - 21.11.2003
PRODUCTION METHOD OF HEALTH SUPPLEMENTARY FOOD USING RADIX ACONITI HAVING
EFFECTS OF IMPROVING STAMINA AND PREVENTING CANCER AND ENHANCING OVERALL
HEALTH
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003089353
Inventor(s):
SIK (KR)
KIM BYOUNG KI (KR); KIM SANG KUEN (KR); SHIN JIN SAN (KR); SHIN JUNG
Applicant(s):
SIK (KR)
KIM BYOUNG KI (KR); KIM SANG KUEN (KR); SHIN JIN SAN (KR); SHIN JUNG
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020027529 (20020517)
Priority Number: KR20020027529 (20020517)
Family: KR2003089353
640/757
381. KR2003089537 - 22.11.2003
HEALTH FOOD HAVING BLOOD-CLEANING FUNCTION AND COMPRISING REFINED FISH OIL,
POLLEN, CRATAEGI FRUCTUS EXTRACT, GARLIC OIL, GINKGO LEAVES POWDER OR LIKE AND
THE COMPOSITION THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003089537
Inventor(s):
BYUN GUK YEON (KR)
Applicant(s):
STK PHARMACEUTICAL CO LTD (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29
Application Number:
KR20020026899 (20020515)
Priority Number: KR20020026899 (20020515)
Family: KR2003089537
641/757
382. KR2003095547 - 24.12.2003
PRODUCTION OF HEALTH FOOD BY MIXING ACORN WITH BEAN, SILKWORM POWER,
SCHIZANDRAE FRUCTUS AND PUERARIA LOBATA
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=KR2003095547
Inventor(s):
KIM JIN U (KR)
Applicant(s):
GNF CO LTD (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/29; A23L1/36
Application Number:
KR20020032799 (20020612)
Priority Number: KR20020032799 (20020612)
Family: KR2003095547
642/757
383. PL356690 - 19.04.2004
METHOD OF MANUFACTURE OF HEALTH DIARY PRODUCTS AND HEALTH FOOD DIARY
PRODUCT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=PL356690
Inventor(s):
PAWLIK STEFAN (PL); GAWEL JULIAN (PL); DAJNOWIEC ZBIGNIEW (PL);
SLIWINSKI MARIUSZ (PL); JARON EWA (PL); OBERBEK ANNA (PL); OBERBEK MAREK (PL)
Applicant(s):
INST MLECZARSTWA (PL)
IP Class 4 Digits: A23C
IP Class:
A23C9/152
Application Number:
PL20020356690 (20021017)
Priority Number: PL20020356690 (20021017)
Family: PL356690
643/757
384. SG92789 - 19.11.2002
A BINDER COMPOSITION PREPARATION FOR USE IN READY-TO-EAT HEALTH SNACK FOOD
AND A METHOD OF PREPARATION THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=SG92789
Inventor(s):
RATHINAM VETRIMANI (--); RAGU SAI MANOHAR (--); KRISHNARAU
LEELAVATHI (--); THEKKAR RATNAKAR PRABHU (--); RAO PUNAROOR HARIDAS (--);
VISHWESHWARAIAH PRAKASH (--)
Applicant(s):
COUNCIL SCIENT IND RES (--)
IP Class 4 Digits: A23L
IP Class:
A23L1/10; A23L1/212; A23L1/164; A23L1/34
Application Number:
SG20010001973 (20010330)
Priority Number: SG20010001973 (20010330)
Family: SG92789
644/757
385. SG94797 - 18.03.2003
A READY-TO-EAT HEALTH SNACK FOOD AND A PROCESS FOR THE PREPARATION THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=SG94797
Inventor(s):
RATHINAM VETRIMANI (--); RAGU SAI MANOHAR (--); KRISHNARAU
LEELAVATHI (--); VALLIKANNAN BASKARAN (--); MUTHY KESTURE VENKATESH (--); THEKKAR
RATNAKAR PRABHU (--); RAO PUNAROOR HARIDAS (--); VISHWESHWARAIAH PRAKASH (--)
Applicant(s):
COUNCIL SCIENT IND RES (--)
IP Class 4 Digits: A23L
IP Class:
A23L1/29; A23L1/212; A23L1/30; A23L1/36; A23L1/305; A23L1/164
Application Number:
SG20010001974 (20010330)
Priority Number: SG20010001974 (20010330)
Family: SG94797
645/757
386. WO02066042 - 22.04.2004
HERBAL, EXTRACT HAVING THERAPEUTIC ACTIVITY ON INJURIES, AND PHARMACEUTICAL
COMPOSITION AND HEALTH FOOD CONTANINING THE SAME
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=WO02066042
Inventor(s):
HONG JONG-SOO (RU)
IP Class 4 Digits: A61K
IP Class:
A61K35/78
E Class: A61K35/78; A23L1/30B
Application Number:
US20030468421 (20030818)
Priority Number: KR20010008383 (20010220); WO2002KR00266 (20020220)
Family: WO02066042
Equivalent:
KR2002068126
Abstract:
646/757
THE PRESENT INVENTION RELATES TO AN EXTRACT HAVING HEALING ACTIVITY ON INJURIES,
WHICH IS OBTAINED BY EXTRACTING ASTRAGALI RADIX, GINSENG RADIX, CARTHAMI FLOS,
ANGELICAE GIGANTIS RADIX, CNIDII RHIZOMA, REHMANNIAE RADIX PREPARATA, PAEONIAE
RADIX AND CINNAMOMI CORTEX SPISSUS WITH WATER WHILE HEATING, AND A
PHARMACEUTICAL COMPOSITION FOR TREATING INJURIES, A HEALTH FOOD FOR POSTSURGICAL RECOVERY AND AN ANIMAL FEED CONTAINING SAID EXTRACT AS THE ACTIVE
INGREDIENT.Description:
TECHNICAL FIELD
[0001] The present invention relates to a herbal extract composition having healing activity for
injuries, and, more specifically, to the extract composition obtained by extracting Astragali Radix,
Ginseng Radix, Carthami Flos, Angelicae Gigantis Radix, Cnidii Rhizoma, Rehmanniae Radix
Preparata, Paeoniae Radix, and Cinnamomi Cortex Spissus with water while heating, and to a
pharmaceutical composition for healing injuries, and a health food and an animal feed for postsurgical recovery containing said extract as the active ingredient.
BACKGROUND ART
[0002] Bones, flesh, etc. are hurt by injuries, for example, punctured wound, laceration, wound or
fracture, or surgical operations. Many studies on methods to heal the injuries and to repair the bones
and flesh have been continuously made, and thus, a number of healing methods and agents are
known in the Oriental and Western Medicines at the present time.
[0003] In the Western medicine, surgical operation techniques have more advanced than in the
Oriental medicine. Healing agents administered after injuries or surgeries, however, do not have very
good effects and have the problem to cause many side effects. For this reason, despite
administering several wound- or fracture-healing agents to patients with injuries or surgeries, it is
frequently shown that injuries are not well healed up, patients are weakened or suffered from severe
pain, suture of fractured bone is delayed, and side effects like gastric disorders from healing agents,
e.g. anti-inflammatory drugs, are accompanied.
[0004] In contrast, according to the Chinese medicine, if human beings, who live by
Qi.blood.essence of life.vitality, are injured on bones or flesh, skin, subcutaneous fatty layer, flesh
and muscle are regenerated, and bones, bone marrow and brain are replenished, and stagnated
blood is replaced with fresh blood, by making Qi.blood.essence of life.vitality higher and eliminating
extravasated blood to promote vital essence and energy. Based on this theory, various kinds of
healing methods and agents are handed down in the Chinese medical literature. However, it has
been difficult to get satisfactory effects only by such traditional prescriptions.
647/757
DISCLOSURE OF THE INVENTION
[0005] The present inventors referred to many Chinese medical literature handed down from ancient
times, and conducted many studies and experiments to develop a healing agent for various injuries,
particularly wounds, fractures, etc., or health food for post-surgical recovery. As a result, the
inventors found that a suitable combination of specific herbal medicines has excellent healing effects
on injuries compared with other known agents without any toxicity and side effect, and completed the
present invention.
[0006] The present invention relates to an extract composition having healing activity for injuries,
which is obtained by extracting Astragali Radix, Ginseng Radix, Carthami Flos, Angelicae Gigantis
Radix, Cnidii Rhizoma, Rehmanniae Radix Preparata, Paeoniae Radix and Cinnamomi Cortex
Spissus with water while heating.
[0007] The extract composition of the present invention exhibits healing activity from the abovedescribed herbal medicines for injuries, but to strengthen its activity, one or more selected from the
group consisting of Atractylodis Rhizoma alba, Hoelen, Aurantii Nobilis Pericarpium, Glycyrrhizae
Radix, Eucommiae Cortex, Myrrh, Amomi Semen, Walnut, Zingiberis Rhizoma and Zizyphi Fructus
are further mixed and the whole mixture is extracted with water while heating.
[0008] As raw herbal medicines essential for the present invention, Astragali Radix has Qireplenishing, pus-evacuating by administering tonics, and pain-arresting activities; Ginseng Radix
has tonic, stamina-strengthening, calming and fatigue-relieving activities; Carthami Flos enhances
functions of bone tissue cells to promote growth of bones; Angclicae Gigantis Radix has bloodreplenishing, moistening, calming, analgesic and antibacterial activities; Cnidii Rhizoma has bloodand Qi-promoting activities; Rehmanniae Radix Preparata has blood-replenishing, tonic and
nourishing activities; Paeoniae Radix has calming, antispasmodic, antipyretic, analgesic,
antibacterial, anti-inflammatory and vasodilating activities; and Cinnamomi Cortex Spissus has
analgesic and antispasmodic activities.
[0009] As raw herbal medicines which can be further added for the present invention, Atractylodis
Rhizoma alba has spleen-tonifying and Qi-replenishing, dampness-eliminating. and diuresis-inducing,
and exterior-reinforcing and sweating-suppressing activities; Hoelen has stomachic, diuretic and
calming activities; Aurantii Nobilis Pericarpium has Qi-flow-regulating and spleen-tonifying,
stagnation of Qi-removing and phlegni-eliminating, and antiasthmatic and cough-relieving activities;
Glycyrrhizae Radix has cough-relieving, phlegm-eliminating, detoxifying, antispasmodic, antiinflammatory, analgesic, and anti-hypersensitive activities; Eucornmiae Cortex has tonic, staminastrengthening, and analgesic activities; Myrrh has blood-circulation-promoting and pain-arresting
activities, and swelling-inducing and Qi-vitalizing activities; Amomi Semen has spleen-tonifying and
Qi-promoting, and spleen-warming and antidiarrheal activities; Walnut has kidney reinforcing and
648/757
muscle-and-bone-strengthening activities; Zingiberis Rhizoma has a stomachic activity; and Zizyphi
Fructus has tonic, blood-replenishing, laxative, calming, and analgesic activities.
[0010] The composition of the present invention may be preferably obtained by extracting 4-20 parts
of Astragali Radix, 2-12 parts of Ginseng Radix, 2-12 parts of Carthami Flos, 2-12 parts of Angelicae
Gigantis Radix, 2-12 parts of Cnidii Rhizoma, 2-12 parts of Rehmanniae Radix Preparata, 2-12 parts
of Paeoniae Radix, and 2-12 parts of Cinnamomi Cortex Spissus, wherein all the above parts are
based on weights of raw herbal medicines, with water while heating. More preferably, the
composition is prepared from 8-16 parts of Astragali Radix, 4-8 parts of Ginseng Radix, 4-8 parts of
Carthami Flos, 4-8 parts of Angelicae Gigantis Radix, 4-8 parts of Cnidii Rhizoma, 4-8 parts of
Rehmanniae Radix Preparata, 4-8 parts of Paeoniae Radix, and 4-8 parts of Cinnamomi Cortex
Spissus, wherein all the above parts are based on weights of raw herbal medicines.
[0011] Also, the composition of the present invention is preferably prepared by further mixing 2-12
parts of Atractylodis Rhizoma alba, 2-12 parts of Hoelen, 2-10 parts of Aurantii Nobilis Pericarpium,
2-12 parts of Glycyrrhizae Radix, 2-18 parts of Eucommiae Cortex, 2-8 parts of Myrrh, 2-12 parts of
Amomi Semen, 4-20 parts of Walnut, 2-10 parts of Zingiberis Rhizoma, and 2-10 parts of Zizyphi
Fructus, wherein all the above parts are based on weights of raw herbal medicines, and extracting
the whole mixture with water while heating. More preferably, the composition is prepared by further
mixing 4-8 parts of Atractylodis Rhizoma alba, 4-8 parts of Hoelen, 3-8 parts of Aurantii Nobilis
Pericarpium, 4-8 parts of Glycyrrhizae Radix, 4-10 parts of Eucommiae Cortex, 2-6 parts of Myrrh, 48 parts of Amomi Semen, 6-15 parts of Walnut, 3-8 parts of Zingiberis Rhizoma, and 3-8 parts of
Zizyphi Fructus, wherein all the above parts are based on weights of raw herbal medicines.
[0012] The above composition ratios of the herbal medicines are based on the results of many times
of clinical and animal experiments, and, if lower than the lower limits, pharmacological effects of the
ingredients are remarkably decreased, and, if higher than the upper limits, pharmacological effects
of other ingredients are decreased to remarkably deteriorate synergistic and cooperative effects of
the composition.
[0013] As shown in the following Experiments 1 and 2, the herbal extract composition prepared by
the above-described method, has healing activity for injuries, particularly, wounds or fracture.
Therefore, the extract composition of the present invention can be used as a healing agent for
injuries such as wounds or fractures, or as a health food or an animal feed for post-surgical recovery
of human beings or animals.
[0014] Therefore, the present invention provides a pharmaceutical composition for healing injuries in
human beings or animals comprising the above extract composition as the active ingredient. Also,
the present invention provides a health food or an animal feed for post-surgical recovery of human
beings or animals comprising the above extract composition as the active ingredient.
649/757
[0015] The composition of the present invention may be prepared in the form of solution, suspension,
pill, tablet, capsule or granule by combining the extract composition obtained by extracting the
mixture of the above herbal medicines with water while heating, a mixture of the extract obtained by
extracting each herbal medicine with a solvent depending upon its physicochemical properties, or
powder obtained by concentrating and drying the extract, with pharmaceutically acceptable carriers,
according to conventional methods. The composition is preferably prepared in the form of oral
solution, suspension or tablet, for good pharmacological effects, but, if necessary, may be prepared
in the form of pill, capsule or granule, and, if necessary, may be changed into another dosage form
before its use.
[0016] For example, the pharmaceutical composition of the present invention is prepared by pouring
300 ml of water into the mixture of 4-20 g of Astragali Radix, 2-12 g of Ginseng Radix, 2-12 g of
Carthami Flos, 2-12 g of Angelicae Gigantis Radix, 2-12 g of Cnidii Rhizoma, 2-12 g of Rehmanniae
Radix Preparata, 2-12 g of Paeoniae Radix and 2-12 g of Cinnamomi Cortex Spissus, and optionally,
one or more selected from the groups consisting of 2-12 g of Atractylodis Rhizoma alba, 2-12 g of
Hoelen, 2-10 g of Aurantii Nobilis Pericarpium, 2-12 g of Glycyrrhizae Radix, 2-18 g of Eucommiae
Cortex, 2-8 g of Myrrh, 2-12 g of Amomi Semen, 4-20 g of Walnut, 2-10 g of Zingiberis Rhizoma, and
2-10 g of Zizyphi Fructus, extracting the whole mixture while heating for about 2 hours, filtering the
extract, and concentrating the filtrate to 120 ml or freeze-drying it.
[0017] A single dose of the present composition is usually in the range of 0.1 to 30 g as freeze-dried
powder for an adult, and it is taken once to three times a day. However, a dosage of the composition
of the present invention may be suitably changed depending upon a patient's body weight, age,
sexuality, severity of disease, and digestibility. Other formulations may also be taken at suitable
dosages.
BRIEF DESCRIPTION OF THE DRAWINGS
[0018] FIG. 1 is a photograph of a rat in which skin wounds are induced;
[0019] FIGS. 2 to 7 are photographs showing the wounded sites after orally administering 0 mg/kg
(control), 50 mg/kg (low-dosage group), and 200 mg/kg (high-dosage group) of the present
composition for 7 and 14 days, respectively;
[0020] FIG. 8 is a graph showing changes in body weights of rats in control and experimental groups;
[0021] FIGS. 9 to 14 are optical micrographs showing the HE-stained wound tissues in control and
experimental groups;
650/757
[0022] FIG. 15 is a graph showing changes in body weights after orally administering 0 mg/kg
(control), 50 mg/kg (first group), and 100 mg/kg (second group) of the present composition for 6
weeks, respectively;
[0023] FIGS. 16 to 25 are radiographs of the fractured sites in control and first group;
[0024] FIG. 26 is a graph showing the endurance time in a rota-rod test after administering the
present composition for 5 weeks;
[0025] FIGS. 27 to 29 are photographs showing the gross examination results of the extracted tibia
and fibula in control, first, and second groups; and,
[0026] FIGS. 30 to 32 are photographs showing the examination results of the fibular tissues in
control, first, and second groups.
BEST MODE FOR CARRYING OUT THE INVENTION
[0027] Hereinafter, this invention will be more specifically explained with reference to examples, but
they should not be construed to limit the present invention in any manner.
EXAMPLE 1
Preparation of Solution and Freeze-Dried Powder
[0028] Into a mixture of 80 g of Astragali Radix, 60 g of Ginseng Radix, 60 g of Carthami Flos, 50 g of
Angelicae Gigantis Radix, 50 g of Cnidii Rhizoma, 50 g of Rehmanniae Radix Preparata, 50 g of
Paeoniae Radix, 50 g of Cinnamomi Cortex Spissus, 50 g of Atractylodis Rhizoma alba, 50 g of
Hoelen, 50 g of Aurantii Nobilis Pericarpium, 60 g of Glycyrrhizae Radix, 60 g of Eucommiae Cortex,
20 g of Myrrh, 40 g of Amomi Semen, 60 g of Walnut, 40 g of Zingiberis Rhizoma, and 40 g of Zizyphi
Fructus was poured 2000 ml of water. The whole mixture was extracted while heating for about 2
hours and filtered, and then, the filtrate was concentrated to 900 ml. Then, the concentrate was
freeze-dried to obtain 110 g of the powdered extract.
EXAMPLE 2
Preparation of Other Formulations
[0029] According to conventional methods, pills, granules, sprays, tablets, and capsules were
prepared using the extract composition or its concentrated dried powder obtained from the above
Example 1.
651/757
Experiment 1: Evaluation of Wound-Healing Effect
[0030] The composition of the present invention, which was orally administered, was tested for its
healing effect on full-thickness skin wound induced in the dorsal area of rats.
[0031] Three square skin wounds, each of which had the size of 1 cm*1 cm, were induced in the
dorsal side of fifteen male rats with the age of 10 weeks.
[0032] For trial groups, the composition obtained from the above Example 1 was orally administered
to the rats at 200 mg/kg body weight (high-dosage group), 50 mg/kg body weight (low-dosage
group), and 0 mg/kg body weight (control group) once a day for 14 days, respectively, and degrees
of contraction, re-epithelialization, and healing of wound were histopathologically examined with the
naked eyes.
[0033] As a result, at 7 days after inducing wounds, degrees of contraction and healing of wound
were observed to be higher in the high-dosage group (FIG. 4) than in the control group (FIG. 2), and
degree of wound healing was high on both ends in the case of the low-dosage group (FIG. 3). At 14
days after inducing wounds, a more noticeable healing effect was observed in the high-dosage
group (FIG. 7) than in the control group (FIG. 5), and the higher healing effect was also observed in
the low-dosage group (FIG. 6) than in the control group, even though it was lower than in the highdosage group. For changes of body weights for 14 days, it was observed that body weights slightly
decreased because of stress and pain after inducing wounds, but there was no significant difference
in body weights between the groups during the whole experiments (FIG. 8).
[0034] At 14 days after inducing wounds, the wound tissues in the control and experimental groups
were made into specimens and the specimens were stained with HE and observed under an optical
microscope. In the control group (FIGS. 9 and 10), thin epithelial layer, sparse tissue texture, and low
distribution of vessels were observed. On the contrary, in the low-dosage group (FIGS. 11 and 12),
thicker epithelial layer and denser tissue texture than the control group were observed. In the highdosage group, smoother epithelial surface than in other groups, slowly curved epithelial layer, and
sweat gland and hair follicles were observed (FIGS. 13 and 14). Usually, sweat gland and hair
follicles could be observed at 28 days after injury, but hair follicles could be observed in most highdosage groups and some low-dosage groups, which means that the wound healing effect of the
composition of the present invention was very fast. Therefore, the present composition was
demonstrated to have a fast wound healing effect upon oral administration.
Experiment 2: Evaluation of Fracture-Healing Effect
[0035] 1. Healing Process of Bone Fracture
[0036] The healing process of bone fracture is a very complex one including normal wound healing
processes, which leads to restoration of original integrity and strength which can stand against the
652/757
loading of skeleton through normal physiological processes. The healing processes of bone fracture
may be divided into the following three phases:
[0037] First phase: Inflammatory phase wherein an inflammatory reaction is triggered by formation of
hematoma that is a mass of blood clot from blood leaked out of injured vessels in a fractured area,
followed by acute edema;
[0038] Second phase: Reconstructive phase wherein fibroblast proliferation and granulation tissue
formation with angiogenesis induce tissue organization, which leads to progressive endochondral
ossification through formation of cartilage and callus (immature bone tissue) around fractured sites;
and,
[0039] Third phase: Remodeling phase wherein a newly formed callus is gradually replaced by a
mature lamellar bone and an excessively formed bone is absorbed by osteoclasts.
[0040] In this experiment, in order to examine a fracture-healing effect of the composition of the
present invention, the healing index of bone fracture was evaluated with a bone fracture model in rats.
[0041] 2. Methods
[0042] After the fibular fracture was surgically induced in rats, the composition obtained from
Example 1 was administered with changing doses for six weeks.
[0043] That is, after fifteen adult male rats (318+-40 g) were intraperitoneally injected with 15 mg/100
of ketamine HCl to induce general anesthesia, the rat's hairs were shaven in the right hind leg with an
electric clipper, and the rats were laid on the left side, and disinfected at the surgical area with
povidon-iodine and alcohol. After skin incision, anterior tibia muscle and gastrocnemius muscle were
dissected bluntly and the fibula was exposed. The exposed fibula was forced with a clamp to induce
the transverse fracture. Then, the fifteen rats with fibular fracture were divided into three groups, five
rats per group, and the composition of the present invention was orally administered at 100 mg/kg
body weight (1st group), 50 mg/kg body weight (2nd group) and 0 mg/kg body weight (control group)
as the freeze-dried powder, respectively.
[0044] The healing process of bone fracture was radiologically examined at 1, 2, 3, 4 and 5 weeks
after inducing bone fracture, and, at the final week, the locomotion amount was measured and
compared between the groups by performing the rota-rod test at 8 rpm, and the rats were autopsied
for the subsequent histopathological examination.
[0045] 3. Results
[0046] As an index of fracture healing effect, gross examination, radiography, histomorphological
examination of callus, and rota-rod test for tissues of the fractured sites were performed.
[0047] (1) Changes in Body Weights
[0048] Body weights were measured once a week, and during the whole experiments, there was no
significant difference in body weights compared with the control group (FIG. 15).
653/757
[0049] (2) Radiological Examination
[0050] Radiographs were taken at 1, 2, 3, 4, and 5 weeks after inducing bone fracture to observe
healing of the right fibular fracture. The results are shown in FIGS. 16 to 25.
[0051] Radiographs taken at one week after fracture did not show any significant difference between
control and drug administered groups (FIGS. 16 and 21). On radiographs taken at 3 weeks after
fracture, however, significant differences were shown between the groups and they were in
proportion to administered doses. The healing speed in the first group was faster than that in control
group by about one week and the healing speed in the second group was about as half fast as that
in the first group. On the final radiograph taken at 5 weeks after fracture, complete calcification was
observed in the first group (FIG. 25), while only callus formation and incomplete calcification were
observed in the control group (FIG. 20).
[0052] (3) Rota-Rod Test
[0053] In order to indirectly examine the degree of fracture healing in the trial groups before autopsy
at 5 weeks, locomotion ability was evaluated. Individual animals in all the trial groups were placed on
a rota-rod and the endurance time was measured, and the results are shown in FIG. 26. It shows that
the first group had the longest endurance time.
[0054] (4) Gross Examination After Extraction of Bone
[0055] The extracted tibia and fibula from autopsies were examined with the naked eyes. Healing
process seemed to be in remodeling phase after completing the formation of callus in the lowdosage group (FIG. 28) and the final step of remodeling phase in the high-dosage group (FIG. 29),
while the callus was actively formed in the control group at five weeks (FIG. 27).
[0056] (5) Histopathological Examination
[0057] A histopathological examination was performed after decalcifying the extracted fibula and
making specimen. Ossification seemed to progress by mineral deposition in the low-dosage group
(FIG. 31) and restoration of normal bone tissues by reconstruction (remodeling) was observed in the
high-dosage group (FIG. 32), while only the callus was formed and lacunar structures were clearly
observed in the control group (FIG. 30).
[0058] 4. Conclusion
[0059] From the above results, the composition of the present invention was concluded to have a fast
healing effect on bone fracture upon oral administration.
Industrial Applicability
[0060] As can be seen from the above experiments, the extract composition of the present invention
having the healing effect for injuries, particularly, wound or bone fracture is extremely useful as a
654/757
pharmaceutical composition for healing injuries, or a health food or an animal feed for post-surgical
recovery of human beings or animals.Claims:
What is claimed is:
1. An extract composition having healing activity for injuries, prepared by extracting Astragali Radix,
Ginseng Radix, Carthami Flos, Angelicae Gigantis Radix, Cnidii Rhizoma, Rehmanniae Radix
Preparata, Paeoniae Radix and Cinnamomi Cortex Spissus with water while heating.
2. The extract composition of claim 1, prepared by further mixing one or more herbal medicines
selected from the group consisting of Atractylodis Rhizoma alba, Hoelen, Aurantii Nobilis
Pericarpium, Glycyrrhizae Radix, Eucommiae Cortex, Myrrh, Amomi Semen, Walnut, Zingiberis
Rhizoma, and Zizyphi Fructus, and extracting the whole mixture with water while heating.
3. The extract composition of claim 1, wherein the weight ratio of Astragali Radix, Ginseng Radix,
Carthami Flos, Angelicae Gigantis Radix, Cnidii Rhizoma, Rehmanniae Radix Preparata, Paeoniae
Radix, and Cinnamomi Cortex Spissus is 4-20: 2-12: 2-12: 2-12: 2-12: 2-12: 2-12: 2-12.
4. The extract composition of claim 3, wherein the weight ratio of Astragali Radix, Ginseng Radix,
Carthami Flos, Angelicae Gigantis Radix, Cnidii Rhizoma, Rehmanniae Radix Preparata, Paeoniae
Radix and Cinnamomi Cortex Spissus is 8-16: 4-8: 4-8: 4-8: 4-8: 4-8: 4-8: 4-8.
5. The extract composition of claim 3, prepared by further mixing one or more herbal medicines
selected from the group consisting of 2-12 parts of Atractylodis Rhizoma alba, 2-12 parts of Hoelen,
2-10 parts of Aurantii Nobilis Pericarpium, 2-12 parts of Glycyrrhizae Radix, 2-18 parts of Eucommiae
Cortex, 2-8 parts of Myrrh, 2-12 parts of Amomi Semen, 4-20 parts of Walnut, 2-10 parts of Zingiberis
Rhizoma, and 2-10 parts of Zizyphi Fructus, and extracting the whole mixture with water while
heating.
6. The extract composition of claim 5, prepared by further mixing one or more herbal medicines
selected from the group consisting of 4-8 parts of Atractylodis Rhizoma alba, 4-8 parts of Hoelen, 3-8
parts of Aurantii Nobilis Pericarpium, 4-8 parts of Glycyrrhizae Radix, 4-10 parts of Eucommiae
Cortex, 2-6 parts of Myrrh, 4-8 parts of Amomi Semen, 6-15 parts of Walnut, 3-8 parts of Zingiberis
Rhizoma, and 3-8 parts of Zizyphi Fructus, and extracting the whole mixture with water while heating.
655/757
7. A pharmaceutical composition for healing injuries in human beings or animals, containing the
extract composition of any one of claims 1 to 6 as the active ingredient.
8. A health food or an animal feed for post-surgical recovery, containing the extract composition of
any one of claims 1 to 6 as the active ingredient.
9. The composition, or health food or animal feed of claim 7 or 8, which is in the form of solution,
suspension, tablet, pill, capsule or granule.
656/757
387. WO03004044 - 20.08.2002
FORTIFIED RICE BRAN FOOD PRODUCT AND METHOD FOR PROMOTING CARDIOVASCULAR
HEALTH
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=WO03004044
Inventor(s):
HOFFPAUER DIANE WRIGHT (US); WRIGHT LLL SALMON L (US)
IP Class 4 Digits: A23L; A61K
IP Class:
A61K35/78; A23L1/302; A61K31/375; A61K31/51; A61K31/4415; A61K31/355;
A61K31/495; A61K31/202
E Class: A23L1/30C2; A23L1/302; A23L1/303; A61K31/202+M; A61K31/355+M; A61K31/375+M;
A61K31/4415+M; A61K31/51+M; A61K31/519+M; A61K31/714+M; A61K45/06
Application Number:
US20010895335 (20010702)
Priority Number: US20010895335 (20010702)
Family: EP1411960
Equivalent:
CA2451704; EP1411960WO03004044; JP2004537302T
Abstract:
A FORTIFIED RICE BRAN FOOD PRODUCT FOR PREVENTING AND/OR TREATING
CARDIOVASCULAR DISEASE IN ANIMALS, CONTAINS IN ADMIXTURE:(A) RICE BRAN AS A
CARRIER;(B) AT LEAST ABOUT 12.5 MILLIGRAMS OF VITAMIN B1 PER 30 GRAMS OF THE RICE
BRAN;(C) AT LEAST ABOUT 250 MILLIGRAMS OF VITAMIN C PER 30 GRAMS OF THE RICE
BRAN;(D) AT LEAST ABOUT 12.5 MILLIGRAMS OF VITAMIN B6 PER 30 GRAMS OF THE RICE
BRAN;(E) AT LEAST ABOUT 75 MICROGRAMS OF VITAMIN B12 PER 30 GRAMS OF THE RICE
BRAN;(F) AT LEAST ABOUT 100 INTERNATIONAL UNITS OF VITAMIN E PER 30 GRAMS OF THE
RICE BRAN;(G) AT LEAST ABOUT 0.25 MILLIGRAMS OF FOLIC ACID PER 30 GRAMS OF THE RICE
BRAN; AND(H) AT LEAST ABOUT 250 MILLIGRAMS OF OMEGA-3-FATTY ACIDS PER 30 GRAMS
657/757
OF THE RICE BRAN.A METHOD FOR PREVENTING AND/OR TREATING CARDIOVASCULAR
DISEASE IN AN ANIMAL INVOLVES ORALLY ADMINISTERING A THERAPEUTICALLY EFFECTIVE
AMOUNT OF THE FORTIFIED RICE BRAN FOOD PRODUCT TO THE ANIMAL FOR A
THERAPEUTICALLY EFFECTIVE PERIOD OF TIME.Description:
BACKGROUND OF THE INVENTION
[0011] This invention relates to a fortified food product which can be used as a dietary supplement or
as an added ingredient for fortifying various food components. More particularly, this invention
relates to a fortified rice bran food product that is capable of preventing and/or treating
cardiovascular disease including, e.g., hypertension. In addition, this invention relates to a method of
preventing and/or treating cardiovascular disease involving oral ingestion of the food product of this
invention.
[0012] Cardiovascular disease is a major health issue in the United States. Several compositions and
methods have been developed over the years in an attempt to prevent or treat this disease.
[0013] U.S. Pat. No. 6,126,943 (Cheruvanky et al.) discloses a method for reducing mammalian
serum total cholesterol, LDL cholesterol, apolipoprotein B and triglyceride levels, by ingesting a
stabilized rice bran derivative selected from the group consisting of an enzyme treated stabilized rice
bran, an insolubilized fraction and mixtures thereof. The patent teaches that the rice bran used
therein is rich in B-complex vitamins, vitamin E and its isomers, minerals like potassium, magnesium,
and phosphorous, and several potent antioxidants.
[0014] U.S. Pat. No. 5,962,062 (Carrie, et al.) discloses a dietetically balanced milk product
containing a lipid mixture based on a combination of milk fats and vegetable oils formulated so as to
obtain an optimum balance of active substances in order to prevent unbalanced metabolic charges,
in particular cardiovascular risks, and so that its organoleptic properties are close to those of milk.
The lipid mixture may contain fatty acid oils such as EPA and DHA. The composition may also
contain oils rich in vitamin E, oils rich in non-vitamin antioxidants (e.g., rice bran oil). The milk product
may also be enriched with vitamins, e.g., E, A, D, C, B6, B12, folate and trace elements, e.g., iron,
magnesium, and zinc.
[0015] U.S. Pat. No. 5,948,443 (Riley, et al.) discloses a total modular system of multivitamin and
mineral supplementation composed of seven distinct modules for improving public health by insuring
adequate intake of micronutrients needed for disease prevention and protection against nutritional
losses and deficiencies. Module 4 contains aspirin or the like and is directed primarily for persons
known to be at risk of coronary heart disease. The patent teaches that specific antioxidant
micronutrients such as vitamins C, E, beta-carotene, selenium, copper, manganese, magnesium,
folic acid, vitamin B6, and vitamin B12 enhance aspirin's ability to reduce risk of coronary heart
disease.
658/757
[0016] WO 91/17670 discloses a foodstuff which is said to have prophylactic and/or curative effects
and is suitable for use in the prevention and/or cure for diseases such as cardiovascular disease and
cancer. The foodstuff is composed of at least one combination of at least polyunsaturated omega-3
fatty acid and/or its esters and one or more vitamins and pro-vitamins. The omega-3 fatty acid is
preferably eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA) or their esters. The
vitamin component is preferably made up of beta-carotene, vitamin C and vitamin E.
[0017] EP 0699437 discloses pharmaceutical preparations containing polyunsaturated fatty acids
(e.g., EPA and DHA), their esters or salts, together with antioxidant vitamins or provitamins (e.g.,
vitamins E, A and C and carotenes, wherein the preparations are said to be useful in the prevention
and/or treatment of atherosclerosis and of cardiovascular, nervous system, skin and malignant
pathologies.
[0018] U.S. Pat. No. 6,210,686 (Bell et al.) discloses a dietary supplement and method for lowering
risk of heart disease, wherein the supplement includes yeast fiber, folic acid or a salt thereof, vitamin
B6, vitamin B12, and vitamin E. Optionally, the supplement may contain one or a combination of
other vitamins (e.g., niacinamide, vitamin C), minerals, antioxidants, fibers and other dietary
supplements (e.g., protein, amino acids, choline, lecithin, omega-3 fatty acids). The patent to Bell et
al. teaches that, due to the presence of folate and vitamin B6, the dietary supplement provides a
second benefit of suppressing the level of homocysteine in the blood. The supplement provides a
third benefit due to the presence of vitamin E which, according to the patent, preserves low density
lipoproteins from oxidation.
[0019] U.S. Pat. No. 5,952,393 (Sorkin, Jr.) discloses a composition for reducing serum cholesterol in
humans and animals, wherein the composition includes phytosterol and policosanol which together
produce a synergistic effect in lowering serum cholesterol levels. The patent teaches that the
policosanol used in the preferred embodiment of the invention is obtained from rice bran wax.
[0020] U.S. Pat. No. 6,180,660 (Whitney et al.) discloses a method for reducing or preventing the risk
of first occurrence of a cardiovascular event in a subject having an average to mildly elevated level
of LDL cholesterol and below average high-density lipoprotein ML) cholesterol, with no clinical
evidence of coronary heart disease, comprising administering a prophylactically effective amount of
a lipid altering agent such as a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
inhibitor alone or in combination with another lipid altering agent such as a fibrate, or niacin, to the
subject. The active ingredients used in the method can be administered in oral forms such as tablets,
capsules, pills, powders, granules, elixirs, tinctures, suspensions, syrups and emulsions.
[0021] Studies have shown that folic acid and vitamin B6, taken in excess of recommended daily
allowance, reduce the risk for developing heart disease by reducing levels of homocysteine.
Homocysteine is associated with arterial occlusive disease.
659/757
[0022] Rice bran in and of itself has been considered for several years as an ingredient for food use
because of the health benefits derived from its consumption. The bran as a by-product of rice milling
has been used in the feed industry for many years, but with advanced techniques has only been
recently considered as a food for human consumption. The nature of the bran is such that the
remaining rice oils become rapidly oxidized so as to render it unacceptable for food. New and
advanced techniques for stabilizing rice bran in the past ten years have altered its perception as an
acceptable food grade product.
[0023] Several components of rice bran are desirable for the human diet. Rice bran protein has a
high nutritional value that is highly digestible and is hypoallergenic. The proximate composition of
stabilized, parboiled, defatted rice bran as stated in Saunders, R. M., "The Properties of Rice Bran as
a Foodstuff", Cereal Foods World, 35:632 (1990), is as follows: moisture-6 to 9%, protein-23 to 27%;
fat-0.5 to 1.5%, crude fiber-16 to 20%, and ash-11 to 14%. The fatty acid composition of the rice bran
oil consists mainly of oleic, palmitic, and linoleic acids. In addition to the fatty acids, naturally
occurring vitamins and minerals are present in varying amounts depending on growing conditions
and milling methods. Vitamins and minerals present include vitamin A, thiamine, riboflavin, niacin,
pyridoxine, panothenic acid, biotin, myoinositol, choline, para-aminobenzoic acid, folic acid, vitamin
B12, vitamin E, calcium, iron, magnesium, manganese, phosphorus, potassium and zinc. The major
carbohydrates present are cellulose, hemicelluloses (pentosans), and starch. Beta-glucans are also
present, forming part of the dietary fiber complex. Total dietary fiber content ranges from about 44%
to about 51%, with the soluble fiber constituting from 2.4% to 2.9% of that total (see Marshall, W. E.
and Wadsworth, J. J (editors), Rice Science and Technology, Marcel Dekker, Inc., New York, pp.
384-389 (1994)).
[0024] Due to the overall nutritional value of rice bran due to the high dietary fiber and low fat
concentration, there has been considerable research in the last ten years on the use of rice bran in
the diet for reducing the risk of cardiovascular disease. In a study reported in Gerhardt, A. L. and
Gallo, N. B., "Effect of a Processed Medium Grain Rice Bran and Germ on Hypercholesterolemia",
American Association of Cereal Chemists Meeting, Washington, D.C. (1989) (poster presentation), it
was determined that rice bran was at least as effective in lowering cholesterol in male subjects as oat
bran.
[0025] The American Heart Association (AHA) dietary guidelines for Americans has emphasized the
importance of consuming a variety of fiber sources to obtain the different types of fibers found in
foods. The AHA also states that fiber is important for gastrointestinal health as well as for cholesterollowering benefits. The AHA recommends a total dietary fiber intake of 25 to 30 grams from foods per
day to maximize the cholesterol-lowering impact of a fat-modified diet. Current dietary fiber intakes
among adults in the United States average about 15 grams or half the AHA-recommended intake of
660/757
fiber per day (see Alaimo, K., McDowell, M., Briefel, R, Bischof, A, Caughman, C., Loria, C., and
Johnson, C., "Dietary Intake: Vitamins, Minerals and Fiber of Persons Age Two Months and Over in
the United States: Third National Health and Nutrition Examination Survey: Phase 1, 1988-91.,
Advance Data. (1994) 258:1-28.
[0026] Other dietary ingredients have also been recommended by the scientific community for the
treatment of cardiovascular disease. These ingredients include vitamin E, vitamin C, vitamin B6,
vitamin B12, vitamin B1, niacin, folic acid, and omega 3 fatty acids from fish oil.
[0027] Numerous studies have been conducted suggesting that the omega 3 fatty acids in fish oil,
including eicosapentaenoic acid (EPA) and decosahexaenoic acid DHA), are beneficial to
cardiovascular health. While not conclusive at this time, the studies have shown the lowering of LDL
cholesterol levels and triglyceride levels. The mechanism is not clear as yet, but the results of an
Italian study by GISSI-Prevenzione that included 11,000 blood clot patients who were studied for 2-3
years showed that a daily fish oil supplement containing 1 gram of omega 3 fatty acid reduced the
death rate about 15% and reduced the risk of heart attacks by 50% (see Berlingske Tidende article,
"Fish Can Save Heart Patients", week of 21/2000, Copenhagen, Denmark). Health organizations
around the world, including the Food & Drug Administration (FDA), have recognized the possible
benefit of omega-3-fatty acids from fish oil for the treatment of coronary heart disease (CHD). The
concentrations recommended vary from organization to organization, but the range is from about 150
milligrams to about 2000 milligrams per day of omega-3-fatty acids.
[0028] Other nutrients that have been recommended for the treatment of cardiovascular disease also
have ranges of recommended concentrations. In a survey of the literature, minimum levels for the
nutrients are as follows: vitamin E-100 IU/day, vitamin C-250 mg/day, vitamin B6-12.5 mg/day,
vitamin B12-75 mcg/day, vitamin B1 -12.5 mg/day, niacin-25 mg/day, and folic acid-0.25 mg/day.
Four times the concentrations listed equals the optimal concentrations per day suggested for
cardiovascular health (see Balch, J. F. and Balch, P. A., "Prescription for Nutritional Healing", Avery
Publishing Group, Garden City Park, N.Y., page 6 (1997)).
[0029] In consideration of the possible health benefits in the treatment of coronary heart disease or in
maintaining cardiovascular health with a diet high in fiber, low in fat, and adequate intakes of the
nutrients vitamins B1, B2, B6, B12, C, E, niacin, folic acid, and omega-3-fatty acids from fish oil, a
food product that contains all of those ingredients in specific concentrations would be of value to
consumers.
[0030] While there are naturally occurring nutrients in rice bran such as vitamins B1,B6, B12, and E,
niacin, and folic acid, the concentrations vary depending on growth conditions of the rice and
processing methods. Enzymes must be destroyed to prevent oxidation of the fat components of the
rice bran and vitamins may also be destroyed in the process. Due to the variable concentrations of
661/757
the natural vitamins, it would be desirable to fortify rice bran with these ingredients in controlled
concentrations for treatment of cardiovascular disease. It would be further desirable to fortify rice
bran with ingredients such as vitamin C and omega 3 fatty acids from fish oil that are not naturally
present in rice bran, but would contribute significantly to the treatment of cardiovascular disease.
[0031] Therefore, a primary object of this invention is to provide a rice bran food product which has
been fortified with controlled concentrations of cardiovascular-improving nutrients.
[0032] A further object of this invention is to provide a method for treating and/or preventing
cardiovascular disease in animals, particularly humans, using a rice bran food product which has
been fortified with controlled concentrations of cardiovascular-improving nutrients.
[0033] A still further object of this invention is to provide a food article composed of a rice bran food
product which has been fortified with controlled concentrations of cardiovascular-improving nutrients.
[0034] These and other objects are achieved in the present invention.
SUMMARY OF THE INVENTION
[0035] The present invention provides a functional food product that is designed to prevent heart
disease by providing nutrients which prevent and treat hypertension and coronary heart disease. The
food product contains vitamins such as vitamins E, C, B6, B12, B1, and niacin, folic acid (folate), and
the omega-3-fatty acid(s) from fish oil, with rice bran as the carrier or base for the product. The
properties of the rice bran also contribute to the cardiovascular health-providing benefits of the
product because of the rice bran's inherent fiber and trace minerals. The food product contains the
nutrients in quantities that promote a healthy cardiovascular system and that will prevent, and, in
some cases, reverse the effects of coronary heart disease in progress.
[0036] Thus, one aspect of the present invention is directed to a fortified rice bran food product
which is effective in preventing and/or treating cardiovascular disease and contains in admixture:
[0037] (a) rice bran as a carrier;
[0038] (b) at least about 12.5 milligrams of vitamin B1 per 30 grams of the rice bran;
[0039] (c) at least about 250 milligrams of vitamin C per 30 grams of the rice bran;
[0040] (d) at least about 12.5 milligrams of vitamin B6 per 30 grams of the rice bran;
[0041] (e) at least about 75 micrograms of vitamin B12 per 30 grams of the rice bran;
[0042] (f) at least about 100 International Units of vitamin E per 30 grams of the rice bran;
[0043] (g) at least about 0.25 milligrams of folic acid per 30 grams of the rice bran; and
[0044] (h) at least about 250 milligrams of omega-3-fatty acids per 30 grams of the rice bran.
[0045] The fortified rice bran of this invention is preferably in the form of a stabilized powder that is
easily used as a dietary supplement or that can be added as an ingredient to a variety of foods to
fortify the levels of the named nutrients in the food. Thus, a further aspect of this invention is directed
to a food article containing the fortified rice bran food product.
662/757
[0046] The present invention also provides a method of preventing and/or treating cardiovascular
disease in an animal, involving the step of orally administering a therapeutically effective amount of
the food product of this invention to the animal for a therapeutically effective period of time.
DETAILED DESCRIPTION OF THE INVENTION
[0047] As stated above, one aspect of the present invention is directed to a fortified rice bran food
product capable of preventing and/or treating cardiovascular disease. The food product of this
invention contains:
[0048] (a) rice bran as a carrier;
[0049] (b) at least about 12.5 milligrams, preferably from about 12.5 milligrams to about 50
milligrams, of vitamin B1 per 30 grams of the rice bran;
[0050] (c) at least about 250 milligrams, preferably from about 250 milligrams to about 1000
milligrams, of vitamin C per 30 grams of the rice bran;
[0051] (d) at least about 12.5 milligrams, preferably from about 12.5 milligrams to about 50
milligrams, of vitamin B6 per 30 grams of the rice bran;
[0052] (e) at least about 75 micrograms, preferably from about 75 micrograms to about 300
micrograms, of vitamin B12 per 30 grams of the rice bran;
[0053] (f) at least about 100 International Units (IU), preferably from about 100 to about 400 IU, of
vitamin E per 30 grams of the rice bran (wherein 1 IU of vitamin E is equal to about 1 milligram of
vitamin E);
[0054] (g) at least about 0.25 milligrams, preferably from about 0.25 milligrams to about 1.00
milligram, of folic acid (or folate) per 30 grams of the rice bran; and
[0055] (h) at least about 250 milligrams, preferably from about 250 milligrams to about 1000
milligrams, of one or more omega-3-fatty acids per 30 grams of the rice bran.
[0056] In a preferred embodiment, the food product of this invention contains at least about 30
grams of the rice bran.
[0057] The omega-3-fatty acid(s) used as ingredient (h) in the food product of this invention may be
EPA and/or DHA.
[0058] In addition to ingredients (a)-(h), the food product of this invention may contain one or more of
other nutrients. Non-limiting examples of such nutrients include vitamin A, riboflavin, pantothenic acid,
biotin, myoinositol, choline, para-aminobenzoic acid, calcium, iron, magnesium, manganese,
phosphorus, potassium, zinc, carbohydrates (such as cellulose, hemicellulose and starch), betaglucans, and one or more fatty acids (e.g., oleic, palmitic and/or linoleic acid).
[0059] The fortified rice bran food product of this invention is preferably prepared as follows. The first
step involves mixing the nutrients (i.e., the vitamins B1, B6, B12, C, E, niacin, folic acid and omega-3-
663/757
fatty acids (from fish oil)) in the amounts recited above with the rice bran, using appropriate mixing
equipment. The resulting mixture should be homogeneous and of even particle size. An approved
food-grade antioxidant may be added at this point to prevent degradation of the materials before
stabilization. A flow aid may also be added to make the materials easier to mix. The second step
involves coating the materials with a food-grade coating such as cellulose, gums, sugars, or starch
to seal the ingredients from oxygen and to stabilize them. The third step involves drying the mixture
to a final moisture of from about 3% to about 5% by weight and homogenizing the particles. The
fourth step should be an analytical assay to assure the minimum concentration of the required
ingredients. The analysis may be performed by standard AOAC (Association of Official Agricultural
Chemists) methods for grain or by specialized and validated solid phase extraction (SPE) and high
pressure liquid chromatography HPLC) methods. In the case of specialized testing methods,
extraction of the nutrients without destroying them is a critical step and requires methods not
currently published by AOAC. An analysis of the crude and soluble fiber may, also be helpful for
future studies on the fortified rice bran food product.
[0060] The food product of this invention may further contain one or more of flavors, coloring agents,
spices and the like. Flavorings can be in the form of flavored extracts, volatile oils, chocolate
flavorings, peanut butter flavoring, cookie crumbs, crisp rice, vanilla or any commercially available
flavoring. Examples of suitable flavoring include but are not limited to pure anise extract, imitation
banana extract, imitation cherry extract, chocolate extract, pure lemon extract, pure orange extract,
pure peppermint extract, imitation pineapple extract, Imitation rum extract, imitation strawberry
extract, or pure vanilla extract; or volatile oils, such as balm oil, bay oil, bergamot oil, cedarwood oil,
walnut oil, cherry oil, cinnamon oil, clove oil, or peppermint oil.
[0061] Emulsifiers may be added for stability of the final product. Examples of suitable emulsifiers
include, but are not limited to, lecithin (e.g., from egg or soy), and/or mono- and di-glycerides.
[0062] Preservatives may also be added to the food product to extend product shelf life. Non-limiting
examples of suitable preservatives include potassium sorbate, sodium sorbate, potassium benzoate,
sodium benzoate, or calcium disodium EDTA.
[0063] The fortified rice bran food product of this invention is preferably in the form of a stabilized
powder. As stated previously herein, the food product of this invention may be used as a dietary
supplement or as an added ingredient to fortify food systems. Thus, another aspect of the present
invention is directed to a food article comprising the fortified rice bran product of this invention. Nonlimiting examples of food articles in which the food product of this invention may be used include
beverages, snack bars, baked goods and puddings.
[0064] A further aspect of this invention is directed to a method for treating and/or preventing
cardiovascular disease using the food product of this invention. The method involves orally
664/757
administering a therapeutically effective amount of the food product to an animal, preferably a human,
for a therapeutically effective period of time.
[0065] As used herein with respect to the amount of the food product administered to the animal, the
term "therapeutically effective" means that amount of the product which will prevent and/or treat
cardiovascular disease in the animal. With respect to the period of time in which the animal is
administered the product, the term "therapeutically effective" means that period of time which is
sufficient to prevent and/or treat cardiovascular disease in the animal.
[0066] The food product is preferably orally administered on a daily basis to the animal. In such
instance, the food product is preferably administered in an amount of at least about 32 grams per
day for a period of at least about 2 weeks. If the product is not administered on a daily basis, the
amount and period of time will increase accordingly.Claims:
What is claimed is:
[0067] 1. A fortified rice bran food product for treating and/or reducing the risk of cardiovascular
disease in animals, comprising in admixture:(a) rice bran as a carrier; (b) at least about 12.5
milligrams of vitamin B1 per 30 grams of the rice bran; (c) at least about 250 milligrams of vitamin C
per 30 grams of the rice bran; (d) at least about 12.5 milligrams of vitamin B6 per 30 grams of the
rice bran; (e) at least about 75 micrograms of vitamin B12 per 30 grams of the rice bran; (f) at least
about 100 International Units of vitamin E per 30 grams of the rice bran; (g) at least about 0.25
milligrams of folic acid per 30 grams of the rice bran; and (h) at least about 250 milligrams of omega3-fatty acids per 30 grams of the rice bran.
[0068] 2. A product according to claim 1, containing from about 12.5 to about 50 milligrams of
vitamin B1 per 30 grams of the rice bran.
[0069] 3. A product according to claim 1, containing from about 250 to about 1000 milligrams of
vitamin C per 30 grams of the rice bran.
[0070] 4. A product according to claim 1, containing from about 12.5 to about 50 milligrams of
vitamin B6 per 30 grams of the rice bran.
[0071] 5. A product according to claim 1, containing from about 75 to about 300 micrograms of
vitamin B12 per 30 grams of the rice bran.
665/757
[0072] 6. A product according to claim 1, containing from about 100 to about 400 International Units
of vitamin E per 30 grams of the rice bran.
[0073] 7. A product according to claim 1, containing from about 0.25 to about 1 milligram of folic
acid per 30 grams of the rice bran.
[0074] 8. A product according to claim 1, containing from about 250 to about 1000 milligrams of
omega-3-fatty acids per 30 grams of the rice bran.
[0075] 9. A product according to claim 1, containing at least about 30 grams of the rice bran.
[0076] 10. A food article comprising the fortified rice bran food product of claim 1.
[0077] 11. A method for treating and/or reducing the risk of cardiovascular disease in an animal,
comprising(A) providing a fortified rice bran food product comprising in admixture: (a) rice bran as a
carrier; (b) at least about 12.5 milligrams of vitamin B1 per 30 grams of the rice bran; (c) at least
about 250 milligrams of vitamin C per 30 grams of the rice bran; (d) at least about 12.5 milligrams of
vitamin B6 per 30 grams of the rice bran; (e) at least about 75 micrograms of vitamin B12 per 30
grams of the rice bran; (f) at least about 100 International Units of vitamin E per 30 grams of the rice
bran; (g) at least about 0.25 milligrams of folic acid per 30 grams of the rice bran; and (h) at least
about 250 milligrams of omega-3-fatty acids per 30 grams of the rice bran; and (B) orally
administering to the mammal for a therapeutically effective period of time a therapeutically effective
amount of the fortified rice bran food product.
[0078] 12. A method according to claim 11, wherein the product provided in step (A) contains from
about 12.5 to about 50 milligrams of vitamin B1 per 30 grams of the rice bran.
[0079] 13. A method according to claim 11, wherein the product provided in step (A) contains from
about 250 to about 1000 milligrams of vitamin C per 30 grams of the rice bran.
[0080] 14. A method according to claim 11, wherein the product provided in step (A) contains from
about 12.5 to about 50 milligrams of vitamin B6 per 30 grams of the rice bran.
[0081] 15. A method according to claim 11, wherein the product provided in step (A) contains from
about 75 to about 300 micrograms of vitamin B12 per 30 grams of the rice bran.
666/757
[0082] 16. A method according to claim 11, wherein the product provided in step (A) contains from
about 100 to about 400 International Units of vitamin E per 30 grams of the rice bran.
[0083] 17. A method according to claim 11, wherein the product provided in step (A) contains from
about 0.25 to about 1 milligram of folic acid per 30 grams of the rice bran.
[0084] 18. A method according to claim 11, wherein the product provided in step (A) contains from
about 250 to about 1000 milligrams of omega-3-fatty acids per 30 grams of the rice bran.
[0085] 19. A method according to claim 11, wherein the product provided in step (A) contains at
least about 30 grams of the rice bran.
[0086] 20. A method according to claim 11, wherein the therapeutically effective amount of the
product is at least about 32 grams.
[0087] 21. A method according to claim 11, wherein the product is orally administered on a daily
basis and the therapeutically effective period of time is at least about 2 weeks.
[0088] 22. A method according to claim 11, wherein the animal is a human.
667/757
388. WO03024244 - 27.01.2005
ALKALINE HEALTH FOOD AND METHOD FOR PRODUCTION THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=WO03024244
Inventor(s):
UEDA HIDEO (JP); KIM JONGAP (KR); JO J W (KR)
IP Class 4 Digits: A23L
IP Class:
A23L1/30
E Class: A23L1/304; C01D3/08
Application Number:
US20040489218 (20040913)
Priority Number: WO2001JP08016 (20010914)
Family: WO03024244
Abstract:
THE PRESENT INVENTION RELATES TO AN ALKALINE HEALTH FOOD USEFUL FOR
MAINTAINING HEALTH OF THE BODY AND TO A METHOD FOR PRODUCTION THEREOF. THE
PRESENT INVENTION PROVIDES AN ALKALINE HEALTH FOOD HAVING A HIGH REDUCTION
CAPACITY AND CONTAINING A LARGE QUANTITY OF MINERAL COMPONENTS. SEAWATER IS
INTRODUCED INTO A SALT FIELD PROVIDED WITH A DIFFERENCE OF ALTITUDE. SEAWATER IS
GRADUALLY GUIDED FROM ZONES WITH A HIGH ALTITUDE TO ZONES WITH A LOW ALTITUDE,
PRODUCING SALTY WATER WITH A HIGH SALT CONCENTRATION. CRYSTALS OF THE SALTY
668/757
WATER ARE PRECIPITATED TO FORM COARSE SALT WHICH IS FIRED AT A TEMPERATURE OF
700-1600 DEG C. IN THE AQUEOUS SOLUTION OF THE HEALTH FOOD IN ACCORDANCE WITH
THE PRESENT INVENTION, WHICH IS OBTAINED IN THE ABOVE-DESCRIBED MANNER, THE
REDOX POTENTIAL IS FROM -10 MV TO -620 MV AND THE MINERAL CONTENT IS 4 TO 10
WT. %.Description:
TECHNICAL FIELD
[0001] This invention relates to an alkaline health food with a powerful reductive action and a high
mineral content, and to a method for producing the same.
BACKGROUND ART
[0002] Reductive water has been recognized by many people as having a beneficial effect on the
body. Cathode water and anode water are obtained when tap water is filtered to remove impurities
and then electrolyzed in an electrolytic tank, and the resulting cathode water exhibits a negative
value for redox potential. Because it has a negative redox potential and has reducing power,
cathode water is therefore called reductive water.
[0003] Reductive water has the action of eliminating active oxygen in the body. Active oxygen can
oxidize biological molecules, and this damages genes and cells, creating factors that can lead to
various kinds of disease. Reductive water imparts electrons to active oxygen and thereby inhibits the
oxidation of biological molecules by active oxygen, and thus serves to suppress the occurrence of
disease.
[0004] However, reductive water made with an electrolyzer does not exhibit enough potential on
the reduction side to achieve a satisfactory redox potential, and therefore cannot be considered to
have adequate reducing power. Another drawback is that the redox potential varies over time,
making a transition from the negative to the positive side, which means that reducing power is lost as
time passes. Furthermore, the mineral content of such reductive water is low, making it lacking in
quality for a health beverage.
[0005] The applicant has already proposed the invention of an alkaline health food produced by
baking natural salt at 500 to 2000[deg.] C., and have also proposed a method for producing an
alkaline health food wherein natural salt is packed into a container, the lid of the container is closed,
and the salt is baked at 500 to 2000[deg.] C. and then cooled and pulverized (Japanese Patent No.
2,092,094). With the invention in this Patent No. 2,092,094, a redox potential is obtained with a large
negative value (a negative numerical value indicates reductivity); for example, this invention
discloses redox potentials of -303 mV (Example 1), -204 mV (Example 3), and -163 mV (Example 4).
[0006] Today, however, there is a need for the development of an alkaline health food that has
greater reducing power and has a high mineral content.
669/757
[0007] The present invention is an improvement to Patent No. 2,092,094, and it is an object thereof
to provide an alkaline health food with greater reducing power.
[0008] Moreover, it is an object of the present invention to provide an alkaline health food that has
a high mineral content and is beneficial in terms of keeping the body functions.
[0009] It is a further object of the present invention to provide a method for producing an alkaline
health food with which the producing process is simpler than that in Patent No. 2,092,094 and the
production efficiency is increased.
DISCLOSURE OF THE INVENTION
[0010] The present invention is an alkaline health food, produced by baking natural salt at 700 to
1600[deg.] C., wherein the redox potential in an aqueous solution is from -10 mV to -620 mV. The
alkaline health food of the present invention is rich in minerals, having a mineral content of 4 to 10
wt %. The raw material of the health food of the present invention is natural salt, but it is preferable to
use sun-dried salt as this natural salt. The natural salt is baked at 700 to 1600[deg.] C. and then
cooled to obtain a block of salt, and this block is then pulverized into a powder or granules.
[0011] The coarse salt that serves as the producing raw material of the health food of the present
invention is made by a salt-field salt production method. The salt field is preferably terraced, and
seawater flows successively down from higher levels to lower levels. Some of the water in the
seawater is evaporated by solar heat to produce salt water (kansui) with a higher salt concentration
than the seawater. More of the water in this salt water (kansui) is then evaporated to raise the salt
concentration further and precipitate crystals of salt water (kansui), grow said crystals, and produce
coarse salt.
[0012] The coarse salt thus obtained is baked at 700 to 1600[deg.] C. In this case, the baking is
preferably divided up into three stages, with the first stage baking performed at 700 to 1000[deg.] C.,
the second stage baking at 1000 to 1400[deg.] C., and the third stage baking at 1400 to 1600[deg.]
C.
[0013] In order to increase the reducing power of the health food of the present invention, it is
preferable to mix the extract of a plant having reducing power into the baked salt during the baking.
[0014] Because its redox potential in an aqueous solution is from -10 to -620 mV, the alkaline
health food of the present invention has strong reducing power, and as a result, when the health food
of the present invention is ingested, it serves to maintain good health and prevent disease.
Specifically, a food with a high reducing power works to impart electrons to active oxygen in the
body, the result of which is that it suppresses the action of active oxygen (oxidizing biological
molecules and damaging genes or cells) and thereby prevents the occurrence of disease.
670/757
[0015] Also, the alkaline health food of the present invention contains a large amount of minerals,
and can be dissolved in water and used as alkaline ion water, which is beneficial in terms of keeping
the body healthy when made into a beverage or a health drink.
[0016] With the present invention, in the production of the coarse salt, seawater is introduced into
a salt field provided with a difference of altitude, and the seawater is successively guided from zones
of higher altitude to zones of lower altitude, so large quantities of the natural mineral components
contained in the salt field are dissolved into the seawater, and the coarse salt thus obtained contains
large quantities of mineral components. Thus, since coarse salt with a high mineral content is used in
the present invention, even if the number of bakings is reduced in the baking of the coarse salt, it is
still possible to production a health food with a high reducing power (a redox potential of -10 to -620
mV in an aqueous solution), and therefore the producing process is simplified and production
efficiency is enhanced.
BRIEF DESCRIPTION OF THE DRAWINGS
[0017] FIG. 1 is a vertical cross section of the main components of the terraced salt field provided
with a difference of altitude that is used in the producing method of the present invention.
BEST MODE FOR CARRYING OUT THE INVENTION
[0018] The alkaline health food of the present invention is produced by baking natural salt at 700
to 1600[deg.] C. Below 700[deg.] C., it will be difficult to obtain a redox potential that affords good
reducing power, and the mineral content will also be inadequate. It is also undesirable to exceed
1600[deg.] C., though, because some of the minerals will decompose. The preferred baking
temperature range is from 900 to 1400[deg.] C.
[0019] Sun-dried salt is preferable as the natural salt, and sun-dried salt produced using a
terraced salt field as discussed below is particularly favorable.
[0020] A property of the health food of the present invention is that it has a redox potential of -10 to
-620 mV when dissolved in water to produce an aqueous solution. This redox potential value of from 10 to -620 mV means that the product has good reducing power. Specifically, when the numerical
value indicating the redox potential is negative, it indicates that the product is reductive, and the
greater is the absolute value thereof, the better is the reducing power. Conversely, a positive
numerical value for potential means that the product is oxidative. In the present invention, the
preferred redox potential is from -150 to -620 mV.
[0021] The health food of the present invention is rich in minerals, having a mineral content of 4 to
10 wt %. Examples of the main mineral components contained include potassium, magnesium,
calcium, iron, and manganese.
671/757
[0022] When the natural salt is baked at 700 to 1600[deg.] C. and then cooled, a block of salt is
obtained, and this block is pulverized into a powder or granules.
[0023] In the production of the health food of the present invention, it is preferable to use sun-dried
salt made in a salt field as the raw material salt. Sun-dried salt is produced in a salt field, and in the
present invention a salt field provided with a difference in altitude is used, and seawater is moved
from the higher levels to the lower levels. It is preferable for this salt field provided with a difference in
altitude to be a terraced salt field provided with different levels. In addition to the terraced type
mentioned above, the salt field provided with a difference in altitude in the present invention can also
be a salt field that slopes continuously and linearly. In any case, the overall angle of slope must be
gentle enough that the seawater does not move too fast.
[0024] FIG. 1 illustrates a terraced salt field provided with a difference in altitude. This terraced salt
field comprises a plurality of salt field sections 1a, 1b, 1c, and id corresponding to the number of
levels. The levels may be continuous in only one direction, or may be continuous both vertically and
horizontally. If the levels are continuous in only one direction, then this terraced salt field is provided
as numerous parallel rows.
[0025] The bottoms of the sections 1a, 1b, 1c, and 1d may be horizontal or somewhat sloped.
Each of the salt field sections 1a, 1b, 1c, and 1d is surrounded by a border 2, and this border 2
serves as a partition demarcating the salt field sections 1a, 1b, 1c, and 1d from one another. The salt
field sections are demarcated as square salt fields by the borders 2.
[0026] The distance L between the various salt field sections 1a, 1b, 1c, and 1d (that is, the
distance of the floor in a single salt field section) is preferably 25 to 35 meters. If the distance L
between levels is too short, the seawater residence time in each salt field section will be too short
and not enough water will be evaporated, and furthermore the mineral components contained in the
soil of the salt field will not be sufficiently dissolved into the seawater.
[0027] Just as with a farming field, the soil in the salt field is plowed deeply under once a year, and
is allowed to rest about six months until microbes proliferate. Once this cultivation period has
elapsed, seawater is drawn into the salt field. First, the seawater 3 is introduced into salt field section
1a, and then after remaining in this salt field section 1a for a specific length of time, it flows into the
next lower salt field section 1b. Although not especially depicted in the drawing, communicating
passages are provided between one salt field section and the salt field section located at the next
lower level, and the seawater flows from the upper salt field section to the lower salt field section
through these communicating passages. In one salt field section, the communicating passages are
closed off when seawater is to be retained for a specific period, and the communicating passages
are opened up after this specific period has elapsed and the seawater is to be allowed out.
672/757
[0028] The means for opening and closing these communicating passages can be as follows, for
example. Blockers that block off the communicating passages are removably attached to the
communicating passages, and the communicating passages are blocked off by inserting these
blockers into the communicating passages, or the blockers are taken out of the communicating
passages to open up the passages.
[0029] While the seawater 3 is held within the salt field section 1a, water is gradually evaporated
by solar heat and wind, which raises the salt concentration. Also, any mineral components contained
in the soil of the salt field are dissolved into the seawater 3, which raises the mineral concentration in
the seawater 3 as well. The seawater 3 whose salt and mineral concentrations have thus been raised
within the salt field section 1a is then allowed to flow into the salt field section 1b at the next lower
level, whereupon water is similarly evaporated by solar heat and wind, which further raises the salt
concentration, and any mineral components contained in the soil of the salt field are also dissolved in
the seawater 3, which further raises the mineral concentration in the seawater 3. In this manner, the
seawater 3 successively flows to the lower salt field sections, and the salt and mineral concentrations
in the seawater steadily rise as the water moves downward in this fashion. Since a terraced salt field
is used in the present invention, any harmful substances contained in the seawater are decomposed
and rendered nontoxic by the solar heat.
[0030] While the seawater is slowly moving through the salt field, any pollutants in the seawater
gradually rise to the surface of the water and are removed. Some kinds of pollutants may be
absorbed into the soil of the salt field. The seawater is then guided from a salt field section to a
cooling pond, where it remains and is cooled for about a week so that any other harmful substances
will precipitate out. Once these harmful substances have been removed, the seawater is guided
back to the salt field section, and the above process of allowing the water to stand in each salt field
section and flow down to the next salt field section is continued. The salt water (kansui) obtained by
this process can be adjusted to a high quality.
[0031] The salt field is preferably one whose soil is rich in germanium. Germanium has the
property of absorbing pollutants and harmful substances in seawater, and turns black when these
substances have been absorbed and oxidized. This black coloring makes the absorption of solar
heat more efficient, raises the seawater temperature, and as a result promotes the dissolution of the
mineral components in the soil into the seawater, allowing a larger amount of minerals to be
dissolved in the seawater.
[0032] Salt water (kansui) with an extremely high salt concentration is produced at the final level of
the salt field sections. This salt water (kansui) is stored just as it is in the salt field section, where
more water is evaporated to precipitate salt crystals in the salt water (kansui). For these crystals of
salt to be precipitated, it is important for the solar heat to be absorbed efficiently. Accordingly, it is
673/757
preferable to line of the bottom of the final salt field section with a sheet of heat-resistant black rubber
felt.
[0033] With time, the crystals of salt grow larger, producing coarse salt. This coarse salt is
collected and baked. The baking is performed between 700 and 1600[deg.] C., and baking in three
separate stages is preferred. In the case of three-stage baking, the first stage baking is performed at
700 to 1000[deg.] C., the second stage baking at 1000 to 1400[deg.] C., and the third stage baking
at 1400 to 1600[deg.] C.
[0034] In performing the baking, it is preferable to mix the extract of a plant having reducing power
into the coarse salt. Mixing such a plant extract into the coarse salt allows the redox potential of the
health food that is produced to be raised to a higher numerical value for reducing power. Garlic,
onion, pine needle, kelp, sesame, licorice, and Magnolia bark, either singly or as a mixture of two or
more types, are favorable as the plant having reducing power, but the present invention is not limited
to these. These plants are boiled in water, after which the product is filtered and the supernatant is
used as a plant extract.
[0035] For example, in the case of licorice and Magnolia bark, 200 g of each is added to 10 liters
of water and heated for several hours, boiling down the solution until its volume is about 8.5 liters.
This product is then filtered and the supernatant is used as an extract of licorice and Magnolia bark.
The redox potential of an extract of licorice and Magnolia bark is approximately -60 mV.
[0036] The amount of the above-mentioned plant extract mixed into the coarse salt is preferably 1
to 5 wt % with respect to the coarse salt. The extract of a plant having reducing power may be
admixed at any stage of the process, but mixing into the baked salt during the second baking and
the third baking is preferred.
[0037] When the baking is carried out in three stages as above, the coarse salt is placed in a
furnace and first subjected to the first stage baking. The preferable temperature of the first stage
baking is 800 to 900[deg.] C., and the baking time is 4 to 6 hours. After baking, the salt is allowed to
cool naturally.
[0038] The baked salt obtained from the first stage baking is in the form of a block, so this block is
pulverized into a powder, an extract of a plant having reducing power is mixed into this powder, and
the mixture is packed into a bamboo tube and subjected to the second stage baking. The preferable
temperature of the second stage baking is 1000 to 1200[deg.] C., and the baking time is 5 to 10
hours. In this baking, preferably the bamboo tube packed with the baked salt and extract mixture is
placed in a ceramic furnace and baked. Hydrogen gas, Japanese red pine firewood, pine sap, or the
like can be used as fuel. The bamboo tube is incinerated during this baking.
[0039] After baking, the salt is allowed to cool naturally. The cooling time will be from 75 to 85
hours. This second stage baking is preferably performed twice. If performed twice, the block of
674/757
baked salt obtained from the first baking is pulverized into a powder, and then just as in the first
baking, an extract of a plant having reducing power is mixed in, this baked salt and extract mixture is
packed into a bamboo tube, and baking is performed under the same conditions as the first time.
Repeating the baking in this manner makes it possible to production a salt having higher reducing
power.
[0040] After the second stage baking, the salt is allowed to cool naturally, the resulting block of
baked salt is pulverized into a powder, and just as above, an extract of a plant having reducing
power is mixed in and the third stage baking is performed. The preferable temperature of the third
stage baking is 1400 to 1500[deg.] C., and the baking time is from 5 to 10 hours. Since the baking
temperature at this stage is quite high, it is preferable to perform the baking with the baked salt in a
ceramic crucible. This high-temperature baking decomposes and removes any pollutants and
harmful substances.
[0041] The result of baking at 1400 to 1500[deg.] C. is that the salt is in the form of a thick melt.
After baking, the salt is allowed to cool naturally. The cooling time will be from 75 to 85 hours. After
cooling, the block of baked salt thus obtained is taken out of the crucible, and the block is pulverized
to obtain a powdered finished product.
[0042] The form of the alkaline health food of the present invention is not limited to that of a powder,
and can also be that of large or small granules. The health food of the present invention can be eaten
just as it is, or it can be dissolved in water and drunk as alkaline ion water. It can also be used as a
seasoning just like regular salt. The health food of the present invention does taste like table salt, but
is not that salty.
[0043] The present invention can also be made into a finished product by admixing inorganic salts,
cinnamon, dry ginger, or other such additives as needed to the powdered baked salt obtained from
the baking steps discussed above.
[0044] Examples of the present invention will now be given.
EXAMPLES
[0045] Coarse salt was produced using a terraced salt field, and this coarse salt was collected,
put into a ceramic furnace, and baked for 5 hours at 900[deg.] C. (first stage baking). Upon
completion of the first stage baking, the salt was allowed to stand and cool, the block of baked salt
thus obtained was pulverized into a powder, and to this was added an extract of licorice and
Magnolia bark in an amount of 2 wt % with respect to the baked salt. The baked salt and extract
mixture was packed into a bamboo tube, which was then placed in the above-mentioned ceramic
furnace and baked for 10 hours at 1200[deg.] C. (second stage baking). The bamboo tube was
675/757
completely burned away during this baking. Upon completion of the second stage baking, the salt
was allowed to stand and cool for 80 hours. This baking step was performed twice.
[0046] Specifically, the block of baked salt obtained in the first baking of the second stage baking
was pulverized into a powder, and then just as the first time, an extract of licorice and Magnolia bark
was added to this in an amount of 2 wt % with respect to the baked salt, and this baked salt and
extract mixture was packed into a bamboo tube and baked for 10 hours at 1200[deg.] C.
[0047] Upon completion of the second stage baking, the salt was allowed to stand and cool, the
block of baked salt thus obtained was pulverized into a powder, and to this was added an extract of
licorice and Magnolia bark in an amount of 2 wt % with respect to the baked salt. The baked salt and
extract mixture was packed into a ceramic crucible, which was then placed in the above-mentioned
ceramic furnace and baked for 10 hours at 1400[deg.] C. (third stage baking). The baked salt was in
the form of a thick melt that was bright red in color, and it was confirmed that the salt was completely
molten.
[0048] Upon completion of the baking, the salt was allowed to stand and cool for 80 hours. After
cooling, the block of baked salt was taken out of the crucible and pulverized to obtain a powdered
finished product. Hydrogen gas, Japanese red pine firewood, and pine sap were used as fuel in the
various baking steps.
[0049] The components of the baked salt (health food of the present invention) thus obtained were
analyzed, the results of which are given in Table 1.
TABLE 1
ComponentCompositionAnalysis method
Chlorine56.6%Mohr's method
Sodium37.3%atomic absorption
spectrophotometry
Gallium7650ppmatomic absorption
spectrophotometry
Magnesium6730ppmatomic absorption
spectrophotometry
Silicon5710ppmmolybdenum blue
spectrophotometry
Sulfur4000ppmbarium sulfate weight
method
Potassium3280ppmpermanganic acid
volume method
Calcium1800ppmatomic absorption
676/757
spectrophotometry
Iron1100ppmo-phenanthroline
spectrophotometry
Phosphorus831ppmvanadomolybdic
acid spectrophotometry
Bromine232ppmiodine titration
Strontium84ppmatomic absorption
spectrophotometry
Zinc57.10ppmatomic absorption
spectrophotometry
Boron14.00ppmcurcumin
spectrophotometry
Barium12.00ppmICP emission
analysis
Molybdenum9.00ppmICP emission
analysis
Copper5.70ppmatomic absorption
spectrophotometry
Lithium1.00ppmatomic absorption
spectrophotometry
Lead0.65ppmatomic absorption
spectrophotometry
arsenic0.30ppmDDTC-Ag
spectrophotometry
[0050] Next, 6 g of the baked salt (health food) of the present invention was dissolved in 100 cc of
tap water to prepare an aqueous solution, and the redox potential of this aqueous solution was
measured. For the sake of comparison, salt aqueous solutions of the same concentration were also
prepared for natural salt, natural baked salt, refined salt (chemical salt), and refined baked salt, and
the redox potentials were measured. The same measurement was also performed for alkaline ion
water made with a household apparatus for making alkaline ion water. Further, the same
measurement was also performed for the above-mentioned salt aqueous solutions.
[0051] The redox potential was measured using a redox potential measurement device made by
Toa Denpa Kogyo Corporation. These results are given in Table 2.
TABLE 2
Redox potential
677/757
(mV)
Baked salt of present invention (upon-158
completion of first stage baking)
Baked salt of present invention (upon-575
completion of third stage baking)
Natural salt+263
Natural baked salt+121
Refined salt (chemical salt)+282
Refined baked salt+136
Alkaline ion water-112
Tap water (from Shibuya Ward in Tokyo)+610
[0052] It can be seen from Table 2 that the redox potential of the baked salt of the present
invention has a large negative value, which means that it has good reducing power.
Industrial Applicability
[0053] The health food of the present invention can be eaten just as it is, or it can be dissolved in
water and drunk as alkaline ion water, and is beneficial at keeping the body healthy when made into
a reductive health food.Claims:
1. An alkaline health food, produced by baking natural salt at 700 to 1600[deg.] C., wherein the
redox potential in an aqueous solution is from -10 mV to -620 mV.
2. The alkaline health food according to claim 1, wherein the mineral content is 4 to 10 wt %.
3. An alkaline health food, produced by baking natural salt at 700 to 1600[deg.] C., wherein the
mineral content is 4 to 10 wt %.
4. An alkaline health food, wherein the redox potential in an aqueous solution is from -10 mV to -620
mV, and the mineral content is 4 to 10 wt %.
5. A method for producing an alkaline health food, comprising the steps of:
introducing seawater into a salt field provided with a difference of altitude;
successively guiding the seawater from zones of higher altitude to zones of lower altitude;
evaporating water from the seawater with solar heat to produce salt water (kansui) with a salt content
higher than that of the seawater;
678/757
evaporating water from this salt water (kansui) to precipitate crystals of salt water (kansui) and
produce coarse salt; and
baking said coarse salt at 700 to 1600[deg.] C.
6. The method for producing an alkaline health food according to claim 5, wherein the salt field
provided with a difference of altitude is a terraced salt field.
7. The method for producing an alkaline health food according to claim 5, wherein an extract of a
plant having reducing power is mixed into the coarse salt before the baking is performed.
8. The method for producing an alkaline health food according to claim 7, wherein the plant having
reducing power is one type or a mixture of at least two types of plants selected from among garlic,
onion, pine needle, kelp, sesame, licorice, and Magnolia bark.
9. The method for producing an alkaline health food according to claim 5, wherein the baking is
performed in three separate stages, with the first stage baking performed at 700 to 1000[deg.] C.,
the second stage baking at 1000 to 1400[deg.] C., and the third stage baking at 1400 to 1600[deg.]
C.
10. The method for producing an alkaline health food according to claim 9, wherein the extract of a
plant having reducing power is mixed into the baked salt during the second stag baking and third
stage baking.
11. The method for producing an alkaline health food according to claim 9, wherein the second stage
baking is repeated twice.
679/757
389. WO03053166 - 09.07.2003
FOOD OR PET FOOD COMPOSITION CONTAINING PLANT EXTRACTS FOR MAINTENANCE OF
BONE HEALTH AND PREVENTION OR TREATMENT OF BONE DISEASES
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=WO03053166
Inventor(s):
OFFORD-CAVIN ELIZABETH (CH); LEMAURE BERNARD (FR); COURTOIS DIDIER
(FR); FEDERICI ERMANNO (CH)
Applicant(s):
NESTLE SA (CH)
IP Class 4 Digits: A23L; A61K; A61P
IP Class:
A61K35/78; A23L1/30; A61P19/00
E Class: A61K35/78; A23K1/18N; A23L1/30B; A23K1/14; A23K1/16M
Application Number:
EP20010204839 (20011211)
Priority Number: EP20010204839 (20011211)
Family: EP1325682
Equivalent:
AU2002358530; BR0214865; CA2466617; US2005106215
Cited Document(s):
RU2102460
DE19814725; CN1169863; WO0103716; US2001024664; WO9955351;
Abstract:
THE PRESENT INVENTION RELATES TO A COMPOSITION FOR MAINTENANCE OF BONE HEALTH
OR PREVENTION, ALLEVIATION AND/OR TREATMENT OF BONE DISORDERS. IT ALSO RELATES
TO THE USE OF THE COMPOSITION IN THE MANUFACTURE OF A NUTRITIONAL PRODUCT, A
SUPPLEMENT OR A MEDICAMENT; AND A METHOD OF PROMOTING BONE GROWTH OR FOR
680/757
THE MAINTENANCE OF BONE HEALTH WHICH COMPRISES ADMINISTERING AN EFFECTIVE
AMOUNT OF THE COMPOSITION.Description:
[0001] This invention relates to a human or pet composition for maintenance of bone health or
prevention, alleviation and/or treatment of bone disorders. It also relates to the use of the composition
in the manufacture of a nutritional product, a supplement or a medicament; and a method of
promoting bone growth or for the maintenance of bone health which comprises administering an
effective amount of the composition.
Background of the Invention
[0002] Healthy bones require effective bone remodeling involving an equilibrium between bone
formation and resorption. Most bone diseases are due to increased bone resorption , rendering its
inhibition a primary therapeutic objective, therefore most pharmaceutical agents, developed to date,
are anti-resorptive. For example, estrogens block production of cytokines that promote osteoclast
generation and differentiation. SERMs (selective estrogen response modulator), are being developed
which provide benefits for bone health while reducing the risk of adverse hormonal effects on breast
or endometrial tissues. It is assumed that they work by a similar mechanism to estrogen in bone.
Bisphosphonates (such as alendronate, risedronate etc) concentrate in bone and are, to date, the
most effective inhibitors of bone resorption. They inhibit a critical enzyme pathway, required for
osteoclast activity and survival. Calcitonin is a polypeptide hormone that inhibits bone resorption by
blocking osteoclast activity. New targets include blocking of the TNF receptor/ligand family members
and their signalling pathways, particularly of RANK/RANKL, inhibition of bone-specific
metalloproteinases such as cathepsin K or inhibition of specific kinases.
[0003] Development of therapeutic agents stimulating bone formation has lagged behind that of
resorption. Some chemical or pharmaceutical agents are known for promoting bone growth in human.
For example, WO 9619246 describes a method for promoting bone growth in a human patient by
(normally intermittent not continuous) administration of parathyroid hormone, PTH-related protein or
an agonist for at least one month. In WO 9619501, a pancreatic-derived factor inhibits the resorption
of bone and stimulates bone cells to proliferate and increases the formation of bone.
681/757
[0004] Although these chemicals and pharmaceutical compounds have been proved for the
treatment of bone disorders, it would be of interest to provide a safe, efficient nutritional way to
promote bone growth and prevent or alleviate the symptoms of bone/joint disorders in mammals.
Summary of the Invention
[0005] Accordingly, in a first aspect, the present invention provides a composition intended for the
prevention, alleviation and/or treatment of bone disorders or maintenance of bone health in mammals,
which comprises as an active ingredient an effective amount at least one plant or plant extract
selected from the group consisting of Taraxacum and Amelanchier.
[0006] Remarkably, it has now been found that some plants or plant extracts have a particular
positive effect on bone formation and repair, on maintenance of bone health or prevention, alleviation
and/or treatment of bone disorders.
[0007] The composition according to the invention can be used for the manufacture of a nutritional
product, a supplement, a treat or a medicament intended for humans or pets.
[0008] Administering to a mammal a composition according to the present invention, results in an
improved bone regeneration during fracture healing. It helps to inhibit bone resorption. It also helps
to increase bone formation and bone mineral density during growth and optimize peak bone mass.
Also, this composition helps to decrease bone loss, in particular bone loss associated with age in
mammals. It reduces risk of osteoporosis. Furthermore it helps to build cartilage in mammals, to
prevent osteoarthritis in pets or humans, which results in a better activity or mobility of the individual.
[0009] In another aspect, the invention relates to the use of a plant or plant extract as described
above, for the preparation of a composition intended for the prevention, alleviation and/or treatment
of bone disorders or maintenance of bone health in mammals.
[0010] It also relates to the use of a plant or plant extract as described above, for the preparation of
a composition intended for inhibiting bone resorption.
682/757
[0011] It further relates to the use of a plant or plant extract as described above, for the preparation
of a composition intended for improving activity and/or mobility of pets or humans.
[0012] In addition, the invention provides a method for the treatment, alleviation and/or prophylaxis
of bone disorder or maintenance of bone health in mammals which comprises administering an
effective amount of a composition as described above.
[0013] The invention further provides a method of increasing bone formation, bone mineral density
during growth and optimize peak bone mass, treating or preventing osteoporosis, stimulating bone
regenaration during fracture healing which comprises administering an effective amount of a
composition as described above.
[0014] It further relates to a method for the treatment, alleviation and/or prophylaxis of osteoarthritis
in pets or in humans, comprising the step of feeding an individual, a composition as described
above.
[0015] It further provides a method decreasing bone loss, in particular bone loss associated with
age in humans and pets, comprising the step of feeding an individual, a composition as described
above.
Detailed Description of the Invention
[0016] With respect to the first object of the present invention, the plant or plant extract is selected
from the group consisting of Taraxacum and Amelanchier.
[0017] In a preferred embodiment, the plant or plant extract is Taraxacum officinale (common
dandelion), Taraxacum kok-saghyz or Amelanchier ovalis, Amelanchier alnifolia, Amelanchier laevis,
Amelanchier arborea, Amelanchier asiatica, for example.
[0018] The plant according to the invention may be from any part of the plant source, e.g. leaves,
tubers, fruit or roots. In a most preferred embodiment, leaves or roots of Taraxacum species, or fruits
of Amelanchier species, or a mixture thereof are used. The plant or plant extract may be in the form
of a dried, lyophilized extract of leaves, roots and/or fruits depending on the source of plant, or fresh
683/757
plant, or enriched fraction obtained by inorganic or organic solvant extraction process known in the
art.
[0019] The plant or plant extract according to the invention may be used in the preparation of a
food composition. The said composition may be in the form of a nutritionally balanced food or pet
food, a dietary supplement, a treat or a pharmaceutical composition.
[0020] The plant or plant extract may be used alone or in association with other plants such as
chicory, tea, cocoa, or with other bioactive molecule such as antioxidants, fatty acids, prebiotic fibers,
glucosamine, chondroitin sulphate, for example.
[0021] In one embodiment, a food composition for human consumption is prepared. This
composition may be a nutritional complete formula, a dairy product, a chilled or shelf stable
beverage, soup, a dietary supplement, a meal replacement, and a nutritional bar or a confectionery.
[0022] Apart from the plant extract according to the invention, the nutritional formula may comprise
a source of protein. Dietary proteins are preferably used as a source of protein. The dietary proteins
may be any suitable dietary protein; for example animal proteins (such as milk proteins, meat
proteins and egg proteins); vegetable proteins (such as soy protein, wheat protein, rice protein, and
pea protein); mixtures of free amino acids; or combinations thereof. Milk proteins such as casein,
whey proteins and soy proteins are particularly preferred. The composition may also contain a
source of carbohydrates and a source of fat.
[0023] If the nutritional formula includes a fat source, the fat source preferably provides about 5%
to about 55% of the energy of the nutritional formula; for example about 20% to about 50% of the
energy. The lipids making up the fat source may be any suitable fat or fat mixtures. Vegetable fats
are particularly suitable; for example soy oil, palm oil, coconut oil, safflower oil, sunflower oil, corn oil,
canola oil, lecithins, and the like. Animal fats such as milk fats may also be added if desired.
[0024] A source of carbohydrate may be added to the nutritional formula. It preferably provides
about 40% to about 80% of the energy of the nutritional composition. Any suitable carbohydrates
may be used, for example sucrose, lactose, glucose, fructose, corn syrup solids, and maltodextrins,
and mixtures thereof. Dietary fibre may also be added if desired. If used, it preferably comprises up
to about 5% of the energy of the nutritional formula. The dietary fibre may be from any suitable origin,
including for example soy, pea, oat, pectin, guar gum, gum arabic, and fructooligosaccharides.
684/757
Suitable vitamins and minerals may be included in the nutritional formula in an amount to meet the
appropriate guidelines.
[0025] One or more food grade emulsifiers may be incorporated into the nutritional formula if
desired; for example diacetyl tartaric acid esters of mono- and di- glycerides, lecithin and mono- and
di-glycerides. Similarly suitable salts and stabilisers may be included. Vitamins and minerals may
also be combined with the plant extract.
[0026] The nutritional formula is preferably enterally administrable; for example in the form of a
powder, tablet, capsule, a liquid concentrate, solid product or a ready-to-drink beverage. If it is
desired to produce a powdered nutritional formula, the homogenised mixture is transferred to a
suitable drying apparatus such as a spray drier or freeze drier and converted to powder.
[0027] In another embodiment, a nutritional composition comprises a milk based cereal together
with a prebiotic formulation. Preferably the milk based cereal is an infant cereal which acts as a
carrier for the prebiotic formulation.
[0028] In another embodiment, a usual food product may be enriched with at least one plant or
plant extract according to the present invention. For example, a fermented milk, a yoghurt, a fresh
cheese, a renneted milk, article of confectionery, for example a sweet or sweetened beverage, a
confectionery bar, breakfast cereal flakes or bars, drinks, milk powders, soy-based products, nonmilk fermented products or nutritional supplements for clinical nutrition.
[0029] The amount of the plant or plant extract in the composition may vary according to the plant
source and its utilization. In a preferred embodiment, an efficient daily dose amount is of at least
about 1 mg, and more preferably from 1 mg to 200mg of the active molecule per day.
[0030] Also, the plant or plant extract according to the invention may be used in the preparation of
a pet food composition. The said composition may be administered to the pet as a supplement to its
normal diet or as a component of a nutritionally complete pet food, and more preferably in an
hypocaloric pet food. It may also be a pharmaceutical composition.
[0031] Preferably, the pet food composition contains about 0.01 to 0.5 g of dry plants per gram of
dry pet food for a 15 kg dog; and 0.001 to 0.1 g of dry plants per gram of wet pet food for a 15 kg
dog.
685/757
[0032] The nutritionally complete pet food composition according to the invention may be in
powdered, dried form, a treat or a wet, chilled or shelf stable pet food product. These pet foods may
be produced by ways known in the art. Apart from the plant or plant extract, these pet foods may
include any one or more of a starch source, a protein source and a lipid source. Suitable starch
sources are, for example, grains and legumes such as corn, rice, wheat, barley, oats, soy, and
mixtures of these. Suitable protein sources may be selected from any suitable animal or vegetable
protein source; for example meat and meal, poultry meal, fish meal, soy protein concentrates, milk
proteins, gluten, and the like. For elderly animals, it is preferred for the protein source to contain a
high quality protein. Suitable lipid sources include meats, animal fats and vegetable fats.
[0033] The choice of the starch, protein and lipid sources will be largely determined by the
nutritional needs of the animal, palatability considerations, and the type of product applied. For
elderly pets, the pet food preferably contains proportionally less fat than pet foods for younger pets.
Furthermore, the starch sources may include one or more of rice, barley, wheat and corn.
[0034] The pet food may optionally also contain a prebiotic, a probiotic micro-organism or another
active agent, for example a long chain fatty acid. The amount of prebiotic in the pet food is preferably
less than 10% by weight. For example, the prebiotic may comprise about 0.1% to about 5% by
weight of the pet food. For pet foods which use chicory as the source of the prebiotic, the chicory
may be included to comprise about 0.5% to about 10% by weight of the feed mixture; more
preferably about 1% to about 5% by weight.
[0035] If a probiotic micro-organism is used, the pet food preferably contains about 10 to about 10
cells of the probiotic micro-organism per gram of the pet food; more preferably about 10 to about 10
cells of the probiotic micro-organism per gram. The pet food may contain about 0.5% to about 20%
by weight of the mixture of the probiotic micro-organism; preferably about 1% to about 6% by weight;
for example about 3% to about 6% by weight.
[0036] Suitable long chain fatty acids include linoleic acid, alpha-linolenic acid, gamma linolenic
acid, eicosapentanoic acid, and docosahexanoic acid. Fish oils are a suitable source of
eicosapentanoic acids and docosahexanoic acid. Borage oil, blackcurrent seed oil and evening
primrose oil are suitable sources of gamma linoleic acid. Safflower oils, sunflower oils, corn oils and
soybean oils are suitable sources of linoleic acid.
686/757
[0037] If necessary, the pet food is supplemented with minerals and vitamins so that they are
nutritionally complete. Further, various other ingredients, for example, sugar, salt, spices, seasonings,
flavouring agents, and the like may also be incorporated into the pet food as desired.
[0038] For dried pet food a suitable process is extrusion cooking, although baking and other
suitable processes may be used. When extrusion cooked, the dried pet food is usually provided in
the form of a kibble. If a prebiotic is used, the prebiotic may be admixed with the other ingredients of
the dried pet food prior to processing. A suitable process is described in European patent
application No 0850569. If a probiotic micro-organism is used, the organism is preferably coated
onto or filled into the dried pet food. A suitable process is described in European patent application
No 0862863.
[0039] For wet food, the processes described in US patents 4,781,939 and 5,132,137 may be used
to produce simulated meat products. Other procedures for producing chunk type products may also
be used; for example cooking in a steam oven. Alternatively, loaf type products may be produced by
emulsifying a suitable meat material to produce a meat emulsion, adding a suitable gelling agent,
and heating the meat emulsion prior to filling into cans or other containers.
[0040] The amount of pet food to be consumed by the pet to obtain a beneficial effect will depend
on the size of the pet, the type of pet, and age of the pet. However, an amount of the pet food to
provide a daily amount of about 0.5 to 5 g of dry plants per kg of body weight, would usually be
adequate for dogs and cats.
[0041] Administering to a human or animal, the food or pet food composition as described above,
results in an improved bone regeneration during fracture healing. It helps to stimulate bone formation
and bone mineral density during growth and optimize peak bone mass. In particular it may provide
an optimal bone growth during childhood for humans or pets. This food composition helps to prevent
bone loss, in particular bone loss associated with age in mammals or bone loss associated with long
term hospitalization. It reduces risk of osteoporosis. Furthermore it helps to build cartilage in
mammals, prevent osteoarthritis in humans and pets, which results in a better activity or mobility of
the individual.
[0042] The following examples are given by way of illustration only and in no way should be
construed as limiting the subject matter of the present application. All percentages are given by
weight unless otherwise indicated. The examples are preceded by a brief description of the figure.
687/757
Figure 1 : comparision of measured inhibition values for the Calvaria Assay (A) and the Pit Assay (B)
for the extract of fruits of Amelanchier alnifolia (10 mu g/ml) : P.E. 734.
Examples
Example 1 : Effect of Amelanchier and Taraxacum species on bone formation
[0043] Extracts of the plant species Amelanchier and Taraxacum were tested for their potential to
induce bone formation or inhibit bone resorption.
Materials and methods
Preparation of extracts for screening assays:
[0044] The ground plant material is defatted with hexane then extracted with a mixture of alcohol
and water, with different percentages of water from 10 to 90%, preferably with 50%. The alcohols can
be methyl or ethyl alcohols, giving the extract 1a.
[0045] On an aliquot of the residue of this first extract, an enzymatic hydrolysis is carried out with a
and b glucosidases. Enzymes can be replaced by acidic conditions. The operation may be done
under mild conditions (room temperature) or through reflux with different acid concentrations. The
aqueous hydrolysed phase is extracted with a non-miscible solvent, preferably ethylacetate to give
the extract 2a.
688/757
[0046] The extract can be dried, freeze-dried or supplied as a liquid form.
In some cases, polyphenols can be discarded through a polyvinylpolypyrrolidone (PVPP) treatment,
avoiding artefact with the screening assays.
[0047] Following the extract preparation, each extract was weighed, redissolved in
dimethylsulphoxide (DMSO) to a final concentration of 20 mg/ml and stored in aliquots at -20 DEG C.
This was used as a stock solution and was subsequently diluted in media for each assay. A range of
doses was tested in the assay systems.
[0048] Extracts of Amelanchier ovalis (P.E. 219 (MeOH/water)), and of Taraxacum officinale (P.E.
750 (ethylacetate)) were further tested in a human periosteal /preosteoblast cell line, hPOB-tert for
their ability to induce the endogenous expression of BMP-2.
[0049] The validation of this assay was performed with statins as a positive control. At confluence,
cells were incubated with 0.05 mg/ml Lovastatin or with the plant extracts. Total RNA was extracted
with TRIzol Reagent (Gibco). 10 mu g RNA were reverse transcribed using the 1st Strand cDNA
Synthesis Kit (Boehringer). BMP-2 cDNA sequences were amplified for 35 cycles at an annealing
temperature of 55 DEG C using specific oligonucleotide primers (5':TTGCGGCTGCTCAGCATGTT;
3':CATCTTGCATCTGTTCTCGGAA). PCR products were separated by agarose gel electrophoresis
and detected by ethidium bromide staining. Quantification was performed using NIH Image Software
and normalizing results with Actin as housekeeping gene.
Results :
[0050] For Amelanchier ovalis : induction of BMP-2 by 2.5 fold.
For Taraxacum officinale induction of BMP-2 by 2.0 fold.
Example 2 : Effect of Amelanchier and Taraxacum species on bone resorption
689/757
[0051] The ability of the extracts prepared as in example 1, to inhibit IL-1 (10 M) stimulated bone
resorption was assessed in the neonatal bone resorption assay. Each extract was assessed for its
capacity to inhibit bone resorption at 10 mu g/ml
[0052] Extracts of fruits of Amelanchier alnifolia (10 mu g/ml) (P.E. 734 (ethylacetate)) were able to
inhibit IL-1 induced bone resorption in the murine calvaria assay ( R.J. Murills, "In vitro Bone
Resorption Assays" in Principles of Bone Biology (Academic Press) 1986, chap. 90). This effect was
confirmed in a second bone resorption test, namely the pit assay using rabbit bone mixed cell
cultures on bovine bone slices (Tezuka K., et al., 1992, Biochem. Biophys. Res. Commun.
186(2):911-7 and Lorget F., et al., 2000, Biochem. Biophys. Res. Commun. 268(3):899-903) .
Resorption pits are visualized by staining for TRAP (tartrate resistant acid phosphatase) positive cells
and counted.
[0053] A comparison of activity of the extracts at 10 mu g/ml in the two assay systems is shown in
Figure 1.
Example 3: Dry pet food
[0054] A feed mixture is made up of about 58% by weight of corn, about 5.5% by weight of corn
gluten, about 22% by weight of chicken meal, 2.5% dried chicory, about 10% of extract of
Taraxacum leaves, salts, vitamins and minerals making up the remainder.
[0055] The feed mixture is fed into a preconditioner and moistened. The moistened feed is then fed
into an extruder-cooker and gelatinised. The gelatinised matrix leaving the extruder is forced through
a die and extruded. The extrudate is cut into pieces suitable for feeding to dogs, dried at about 110
DEG C for about 20 minutes, and cooled to form pellets.
[0056] This dry dog food has a positive effect on bone and cartillage health and increase their
mobility.Claims:
690/757
1. A food composition intended for the prevention, alleviation and/or treatment of bone disorders or
maintenance of bone health in humans and pets, which comprises as an active ingredient an
effective amount of at least one plant or plant extract selected from the group consisting of
Taraxacum and Amelanchier.
2. A composition according to claim 1, wherein the plant or plant extract is selected from the group
consisting of Taraxacum officinale (common dandelion), Taraxacum kok-saghyz, Amelanchier ovalis,
Amelanchier alnifolia, Amelanchier laevis, Amelanchier arborea and Amelanchier asiatica
3. A composition according to claims 1 or 2, wherein the plant or plant extract is from leaves or roots
of Taraxacum species, or fruits of Amelanchier species, or a mixture thereof.
4. A composition according to one of claims 1 to 3, wherein the plant extract is used alone or in
association with other plants such as chicory, tea, cocoa, or with other bioactive molecule such as
antioxidants, fatty acids, prebiotic fibers, glucosamine or chondroitin sulphate.
5. A composition according to one of claims 1 to 4, which is in the form of a nutritionally balanced
food or pet food, a dietary supplement, a treat or a pharmaceutical composition.
6. A composition according to one of claims 1 to 5, which helps bone regenaration during fracture
healing, helps to increase bone formation and bone mineral density during growth and optimize peak
bone mass or to decrease bone loss, in particular bone loss associated with age in humans or pets.
7. A food composition according to one of claims 1 to 6, which helps to build cartilage in humans or
pets.
8. A food composition according to one of claims 1 to 7, which helps to prevent osteoarthritis in
humans or pets, which results in a better activity or mobility of the individual.
9. Use of a plant or a plant extract selected from the group consisting of Taraxacum or Amelanchier,
for the preparation of a food or pet food composition intended for the prevention, alleviation and/or
the treatment of bone disorders or maintenance of bone health in humans or pets.
10. The use of a plant extract selected from the group consisting of Taraxacum or Amelanchier, for
the preparation of a food or pet food composition intended to help bone regenaration during fracture
691/757
healing, increase bone formation and bone mineral density during growth and optimize peak bone
mass or to decrease bone loss, in particular bone loss associated with age in humans or pets.
11. The use of a plant or a plant extract selected from the group consisting of Taraxacum or
Amelanchier, for the preparation of a food or pet food composition intended for preventing or
alleviating the symptoms of osteoartritis in humans or pets, improving activity and/or mobility of the
individual.
12. The use of a plant extract selected from the group consisting of Taraxacum or Amelanchier, for
the preparation of a food or pet food composition intended help to build cartilage in humans or pets.
13. The use according to claim 9 or 12, wherein the composition is as described in one of claims 1 to
5.
14. A method of treatment, alleviation or prevention of bone disorders or maintenance of bone health
in humans or pets, which comprises administering an effective amount of a composition according to
one of claims 1 to 5.
15. A method of increasing bone formation, bone mineral density during growth and optimize peak
bone mass in humans or pets, comprising the step of feeding an individual, a composition according
to any of claims 1 to 5.
16. A method for the treatment, alleviation and/or prophylaxis of osteoarthritis in humans or pets,
comprising the step of feeding the individual, a composition according to any of claims 1 to 5.
17. A method of treating or preventing osteoporosis, comprising administering an effective amount of
a composition according to any one of claims 1 to 5.
18. A method of stimulating bone regenaration during fracture healing, comprising the step of
feeding an individual, a food composition according to any of claims 1 to 5.
19. A method of decreasing bone loss, in particular bone loss associated with age in humans or pets,
comprising the step of feeding the individual, a food composition according to any of claims 1 to 5.
692/757
390. WO2004103391 - 02.12.2004
HEPATIC LIPID METABOLISM ACCELERATING AGENT, HEPATIC LIPID METABOLISM
ACCELERATING HEALTH FOOD AND PROCESS FOR PRODUCING PEPTIDE MIXTURE AS ACTIVE
INGREDIENT THEREOF
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=WO2004103391
Inventor(s):
FUKUTA NOBUHIRO (JP); SAKONO MASANOBU (JP); IRITANI NOBUKO (JP);
NAKAMORI TOSHIHIRO (JP); FURUTA HITOSHI (JP); SUGANO MICHIHIRO (JP)
Applicant(s): FUJI OIL CO LTD (JP); FUKUTA NOBUHIRO (JP); SAKONO MASANOBU (JP);
IRITANI NOBUKO (JP); NAKAMORI TOSHIHIRO (JP); FURUTA HITOSHI (JP); SUGANO MICHIHIRO
(JP)
IP Class 4 Digits: A23L; A61K; A61P; A23J
IP Class:
A23J3/34; A61P1/16; A23L1/305; A61K38/01; A61K38/02
E Class: A23L1/305B
Application Number:
WO2004JP06525 (20040514)
Priority Number: JP20030144391 (20030522)
Family: WO2004103391
Abstract:
A HEPATIC LIPID METABOLISM ACCELERATING AGENT OR HEPATIC LIPID METABOLISM
ACCELERATING HEALTH FOOD THAT IS EFFECTIVE IN ACCELERATION OF HEPATIC LIPID
METABOLISM AND THUS AMELIORATION TO OR PREVENTION OF, FOR EXAMPLE, LIFE-STYLE
RELATED DISEASES ASSOCIATED WITH HEPATIC LIPID METABOLISM ABNORMALITY. IN
PARTICULAR, A HEPATIC LIPID METABOLISM ACCELERATING AGENT OR HEPATIC LIPID
METABOLISM ACCELERATING HEALTH FOOD, COMPRISING AS AN EFFECTIVE INGREDIENT A
MIXTURE OF HYDROPHILIC PEPTIDE WHEREIN 30 TO 70 WT.% OF THE CONSTITUENT AMINO
693/757
ACIDS CONSIST OF ACIDIC AMINO ACIDS. THERE IS FURTHER PROVIDED A PROCESS FOR
PRODUCING A PEPTIDE MIXTURE, CHARACTERIZED BY DECOMPOSING A PROTEIN WITH THE
USE OF AT LEAST ONE TYPE OF PROTEASE AND TREATING THE DECOMPOSITION PRODUCT BY
MEANS OF A HYDROPHOBIC RESIN.
694/757
391. WO2004110462 - 23.12.2004
PHARMACEUTICAL COMPOSITION OR HEALTH FOOD HAVING ANTIOXIDIZING ACTIVITY
COMPRISING POLYPHOSPHATE AS AN EFFECTIVE INGREDIENT
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=WO2004110462
Inventor(s):
KIM HONG YEOUL (KR); CHOI MOONJAE (KR); HWANG SUNGMIN (KR); SEO
INBEOM (KR); PARK SEONG KYU (KR); LEE HYOUNG CHEOL (KR); SHIN EUN KYUNG (KR); PARK
EUN MI (KR)
Applicant(s): KIM HONG YEOUL (KR); CHOI MOONJAE (KR); HWANG SUNGMIN (KR); SEO
INBEOM (KR); PARK SEONG KYU (KR); LEE HYOUNG CHEOL (KR); SHIN EUN KYUNG (KR); PARK
EUN MI (KR); HELIXPHARMS INC (KR)
IP Class 4 Digits: A61K
IP Class:
A61K31/795
Application Number:
WO2004KR01403 (20040611)
Priority Number: KR20030037891 (20030612)
Family: WO2004110462
Cited Document(s):
KR2001099037; JP62039684; JP63146829
Abstract:
THE PRESENT INVENTION RELATES TO A PHARMACEUTICAL COMPOSITION OR HEALTH FOOD
HAVING AN ANTIOXIDANT ACTIVITY CONTAINING POLYPHOSPHATE AS AN EFFECTIVE
INGREDIENT, MORE PRECISELY, A PHARMACEUTICAL COMPOSITION OR HEALTH FOOD
HAVING AN ANTIOXIDANT ACTIVITY CONTAINING POLYPHOSPHATE REPRESENTED BY
FOLLOWING AS AN EFFECTIVE INGREDIENT. POLYPHOSPHATE IS ABLE TO RELIEVE THE
OXIDATION OF DNA CAUSED BY FREE RADICAL GENERATED BY UV, SO THAT A COMPOSITION
OF THE PRESENT INVENTION CONTAINING THE SAME BECOMES AN EXCELLENT CANDIDATE
695/757
FOR A PHARMACEUTICAL COMPOSITION OR HEALTH FOOD HAVING AN ANTIOXIDANT
ACTIVITY.Description:
Description PHARMACEUTICAL COMPOSITION OR HEALTH FOOD
HAVING ANTIOXIDIZING ACTIVITY COMPRISING
POLYPHOSPHATE AS AN EFFECTIVE INGREDIENT
Technical Field [1] The present invention relates to a pharmaceutical composition or health food
having an antioxidant activity containing polyphosphate as an effective ingredient, more precisely, a
pharmaceutical composition or health food having an antioxidant activity containing polyphosphate
represented by following as an effective ingredient.
[2] [3] [4]
[5] Wherein, n is as defined in the description.
[6]
Background Art [7] Oxides like free radical are produced in vivo by stimuli such as outside stress, ultraviolet rays, smoking, drugs, active oxygen, etc. They destroy important cell components such as
lipid, protein, glucose, DNA, etc, randomly and irreversibly, causing in variety of diseases, in
particular, aging, cancer, brain diseases such as cerebral apoplexy and Parkinson's disease, heart
diseases, ischemia, atherosclerosis, skin diseases, gastro-intestinal diseases, inflammation,
rheumatoid arthritis, auto- immune diseases, etc. Thus, preventing damage by oxides might lead to
prolongation of a life span with suppressing oxidation of cells and delaying aging.
[8] [9] Since the development of antioxidants was triggered by the discovery of SOD (superoxide
dismutase), an enzyme scavenging superoxide radical, in the late 1960,
studies on production of active oxygen, toxicity and a defense/scavenging mechanism have been
actively undergoing (Halliwell, B. , and J. M. C. Gutteridge. , The chemistry of oxygen radicals and
other oxygen-derived species. In: Free Radicals in Biology and
696/757
Medicine. , New York: Oxford University Press, 1985, pp 20-64). In recent, it was proved by the
studies on antioxidant agents included in food as food additives that active oxygen and superoxides
are directly involved in various diseases and aging.
Thus, studies are now aiming at developing an antioxidant agent for delaying aging and treating
various diseases.
[10] [11] Antioxidant agents now in use are divided into three classes; 1) artificially synthesized
antioxidant agents such as BHT (tert-butylhydroxytoluene) and BHA (tert-butylhydroxyanisol), 2)
natural antioxidant agents such as a-tocopherol, vitamin
C, carotenoid, flavonoid and tannin, and 3) antioxidant enzyme such as SOD.
However, those antioxidant agents have been limited in use because of their toxicity, low activity and
narrow range of application. Therefore, an active attempt to develop a safe and strong antioxidant
agent from natural substances or metabolites of mi- croorganism has been made. The subject of
studies has been expanded to preventive antioxidants, for example, lipid peroxidation inhibitor, free
radical scavenger and xanthine oxidase, and further includes macromolecules like SOD and low
molecular weight natural antioxidants that might be safer and practical.
[12] [13] Polyphosphate is a linear polymer of phosphate in which more than two phosphates are
linked together to make hundreds and thousands of chains, constructing an or- thophosphate (PI).
Each link of polyphosphate molecules is constructed by high- energy phosphoanhydride bond. The
end of a chain of polyphosphate is easily attacked by AMP, ADP, glucose or water, during which PAMP phosphotransferase, polyphosphate kinase, polyphosphate glucokinase or
exopolyphosphatase was used as a catalyst respectively, and inside attack was triggered by
endopolyphosphatase.
[14] A polyphosphate molecule has a high anionic value, so that it can be tightly combined with any
material having a high cationic value, for example, cobalt, copper, magnesium, calciun, iron, zinc,
etc. Such characteristics of a polyphosphate inhibit the growth of a microorganism because
materials obliged to be obtained from a normal metabolism of a microorganism become tightly
combined each other. Polyphosphate has been widely used as a coloring agent or an additive for
meats and cheese, as a curd remover for canned foods, as an additive for various mineral water, and
has been
697/757
included in tooth powders and gastrointestinal remedies. Polyphosphate was recognized to be safe
by FDA and Department of Agriculture, USA. Polyphosphate is often found in animal cells, but its
function has not been clearly explained except the anti-bacterial activity (Kornberg A. , Rao NN. ,
Ault-Riche D., Annu. Rev. Biochem.,
68.89-125, 1999; Eisenstadt, E. , B. C. Carlton, and B. J. Brown, "Gene mutation", pp
222-239, "Gene Transfer"pp 243-250, In P Gerhardt, R. G. E. Murray, W. A. Wood, and N. R. Krieg
(eds. ), Mannual of Methods for General and Molecular Bacteriology.
ASM, Washington. D. C. 1994).
[15]
Disclosure of Invention
Technical Problem [16] Thus, the present inventors have studied on polyphosphate and finally
confirmed that polyphosphate has an excellent anti-oxidant activity. So, the present inventors have
completed this invention by proving that polyphosphate can be effectively used for producing an
anti-oxidant pharmaceutical composition or health food.
[17]
Technical Solution [18] It is an object of this invention to provide an anti-oxidant pharmaceutical
composition or health food containing polyphosphate as an effective ingredient.
Brief Description of the Drawings [19] The application of the preferred embodiments of the present
invention is best understood with reference to the accompanying drawings, wherein: [20] [21] FIG. 1
is a schematic diagram showing the link of DNA and polyphosphate by ionic bond, for which Ca is
used as a bridge peer, [22] [23] FIG. 2 is a schematic diagram showing the three-dimensional
structure of the link of general biomolecules including DNA and polyphosphate, [24] [25] FIG. 3 is a
graph showing colony formations with or without UV-irradiation after
30 (le of 5% polyphosphate was added, [26] [27] FIG. 4 is a graph showing colony formations with or
without UV-irradiation after
40 (le of 5% polyphosphate was added,
698/757
[28] [29] FIG. 5 is a graph showing colony formations with or without UV-irradiation after
50 (le of 5% polyphosphate was added, [30] [31] FIG. 6 is a graph showing colony formations with or
without UV-irradiation after
60 (le of 5% polyphosphate was added.
[32]
Best Mode for Carrying Out the Invention [33] In order to achieve the above object, the present
invention provides an anti-oxidant pharmaceutical composition containing polyphosphate as an
effective ingredient.
[34] The present invention also provides an anti-oxidant health food containing polyphosphate as an
effective ingredient.
[35] The present invention further provides an anti-oxidant cosmetic composition containing
polyphosphate as an effective ingredient.
[36] [37] Hereinafter, the present invention is described in detail.
[38] The present invention provides a pharmaceutical composition containing polyphosphate
represented by as an effective ingredient.
[39] [40] [41]
[42] Wherein, n is 20-100.
[43] [44] DNA is a macrcmolecule having a negative ion charge. So is polyphosphate.
Macromolecules having negative ion charges cannot be combined each other, so that a molecule
having a positive ion charge, for example Ca2+, should lay a bridge between them (see FIG. 1). By
the bridge, a biomolecule like DNA can be linked with polyphosphate by ionic bonding. Once
polyphosphate is linked with DNA, an oxide
699/757
like free radical is not allowed to attack DNA, resulting in the prevention of oxidation of DNA and
aging. Figure 2 shows general models of biomolecules. The bond of polyphosphate and
biomolecules contributes to the prevention of aging caused by oxidation.
[45] [46] In the preferred embodiment of the present invention, strains that were highly sensitive to
UV and wild type strains were coated by polyphosphate to investigate how far polyphosphate could
protect them from the damage by UV. As a result, in the case of strains highly sensitive to UV, the
nunber of colony was increased gradually in a control group, in a group treated with polyphosphates
having 65 chains, and in a group treated with polyphosphates having 75 chains, in that order. This
result indicates that polyphosphate having 75 chains has better defensive effect against UV than
polyphosphate having 65 chains.
[47] There was no significant difference among groups of wild type strains. But, if comparison is
necessary, colonies were hardly found in a control, some colonies were observed in a group treated
with polyphosphate having 65 chains and more colonies were found in a group treated with
polyphosphate having 75 chains. As mentioned before, colonies were hardly found in a control,
suggesting that all the strains were killed by UV irradiation. When UV was not irradiated, colonies
were grown most in wild type and mutant strain groups among controls, and a group treated with
polyphosphate having 75 chains showed higher number of colony than a group treated with
polyphosphate having 65 chains (see Table 1 and FIG. 3-6). These results indicate that
polyphosphate having 75 chains has greater influence on the growth of stains than polyphosphate
having 65 chains, in some way.
[48] [49] In the preferred embodiment of the present invention, DNA was coated directly with Ca 2+
and polyphosphate, followed by UV irradiation, in order to investigate changes of base sequence
according to the formation of T-T dimer. Based on the in- vestigation, the effect of polyphosphate on
occurrence rate of a mutant was indirectly estimated. At last, data on the defensive action from DNA
damage of polyphosphate were gathered. The rate of DNA T-T dimer formation measured after direct
UV- irradiation on DNA was compared with that obtained when DNA was coated with polyphosphate
before UV-irradiation. As a result, when DNA was coated with polyphosphate before UV-irradiation,
T-T dimer formation was almost 100% inhibited (see Table 2). From the experiment, it was also
confirmed that polyphosphate having
700/757
75 chains had better protective effect on DNA than polyphosphate having 65 chains.
[50] [51] Considering all the results above, polyphosphate of the present invention can be effectively used for preventing or treating aging and various diseases caused by active oxygen.
[52] [53] The pharmaceutical composition for anti-oxidation, which contains polyphosphate of the
present invention as an effective ingredient, is very useful for the treatment or the prevention of
various diseases caused by oxidation of cell components by oxygen free radicals. The target
diseases are cancer, aging, coronary heart disease, hy- perlipemia, arteriosclerosis, multiple
sclerosis, autoimnune encephalomyelitis, cerebral apoplexy, Alzheimer's disease and enteritis, but
not always limited thereto.
[54] [55] The pharmaceutical composition containing polyphosphate as an effective ingredient can
additionally include diluents, disintegrating agents, sweetening agents, lubricators, flavorings, etc,
and can be produced in general forms of tablets, capsules, powders, granules, suspensions,
emulsions, syrups, and other liquid forms. Par- ticularly, the pharmaceutical composition containing
polyphosphate of the present invention as an effective ingredient can be produced in the forms of
tablets, troches, lozenges, water-soluble or oily suspensions, powders or granules, emulsions, hard
or soft capsules, syrups or elixirs, for oral administration. In order to make a form of tablets or
capsules, binding agents such as lactose, saccharose, sorbitol, manitol, starch, amylopectin,
cellulose or gelatin, diluents such as dicalcium phosphate, disin- tegrating agents such as
cornstarch or sweet potato starch, lubricants such as magnesium stearic acid, calciun stearic acid,
sodiun stearylfunaric acid or polyethylenglycol wax, can be included. In order to make a formulation
in the form of capsules, liquid carriers like fatty oil is included additionally to the above.
[56] The pharmaceutical composition containing polyphosphate of the present invention can be
administered parenterally. Intravenous injection, intramuscular injection or sub- cutaneous injection is
the way of parenteral administration. In order to make a composition suitable for parenteral
administration, polyphosphate of the present invention ought to be mixed with stabilizers or buffers in
water to make a form of solutions or suspensions, which are finally formulated in the form of
ampoules or vials.
[57]
701/757
[58] The effective dosage of the composition of the present invention is determined by considering
in vivo absorbance of an active ingredient, the rate of inactivation, excretory speed, age, sex and
other conditions of a patient, the seriousness of a disease, etc. In general, in the case of oral
administration, 80 mg of polyphosphate of the present invention per 1 kg of weight, once a day, is
recommended, and 40 mg, twice a day, is more preferred.
[59] [60] The present invention also provides a health food for anti-oxidation containing
polyphosphate represented by as an effective ingredient.
[61] The polyphosphate of the present invention has excellent anti-oxidant activities such as a
peroxidation inhibitory activity and a radical scavenging activity, so that it can be effectively used as
a health food for anti-oxidation.
[62] For the use thereof as a food, the polyphosphate can simply be added as it is or can be used
with other foods together following the general food producing process. The mixing rate or the
amount depends on the purpose of its use (prevention, health or therapeutic treatment). Generally,
when the polyphosphate is used for producing foods or drinks, it is recommended to add
polyphosphate with the concentration of 0. 1-15 weight% for total raw material and the concentration
of 0. 2-10 weight% is more preferred. The effective amount of the polyphosphate follows the effective
amount of the above pharmaceutical compounds, but it could be lower than the standard dosage
when long-term administration is required for controlling health. Over dosage, though, also can be
allowed since the polyphosphate has been proved not to have any side effects.
[63] Any kinds of food containing the polyphosphate can be made without limitation.
For example, meat, sausage, bread, chocolate, candies, snacks, cookies, pizza, ramyon and other
noodles, guns, dairy products including ice creams, soups, beverages, teas, drinks, alcoholic
beverages, vitamin complex, etc are the food to be made as a health food containing the
polyphosphate.
[64] [65] The present invention also provides a cosmetic composition for anti-oxidation containing
polyphosphate represented by as an effective ingredient.
702/757
[66] The conventional antioxidant agents such as vitamin C and vitamin E have been limited in use
because they are easily discolored by water or light, regardless of their formulations. Polyphosphate
dose not have such problems, so that it can also be ef- fectively used for the development of antioxidant cosmetics.
[67] [68] The polyphosphate of the present invention has excellent anti-oxidant activities such as a
peroxidation inhibitory activity and a radical scavenging activity, so that it can be effectively used as
a cosmetic composition having the effects of skin aging inhibition, promotion of skin elasticity or
wrinkle care owing to its capability of protecting skin and prolonging life span of a cell. The cosmetic
composition of the present invention can be used either as a raw material for a basic skin care
cosmetics such as softener, lotion, nutritive cream, essence, pack or bath powder, or as a basic skin
care.
[69] In order to produce a cosmetic composition containing polyphosphate, polyphosphate was
added by 0. 0001-10 weight% in addition to the ordinary composition, and was more preferably
added by 0. 001-I weight%.
[70] [71] Polyphosphates having 25-80 chains are preferable for producing a phar- maceutical
composition, health food or cosmetics according to the present invention, and polyphosphates
having 65-75 chains are more preferable.
[72]
Mode for the Invention [73] Practical and presently preferred embodiments of the present invention
are il- lustrative as shown in the following Examples.
[74] Fbwever, it will be appreciated that those skilled in the art, on consideration of this disclosure,
may make modifications and improvements within the spirit and scope of the present invention.
[75] [76] Example 1: UV-protective effect of polyphosphate according to strains and the number of
chains [77] The present inventors investigated how far the coating with polyphosphate could protect
703/757
DNA from damage by UV in both a UV-sensitive strain group and a wild type strain group.
Salmonella typhimurium LT2 was used as a wild type strain and
Salmonella typhimurium TA98 (KCTC 2053: hisD3052 rfa-uvrB) was used as a mutant strain, which
were both distributed from Korean Collection for Type Cultures (KCTC), Korea Institute of Bioscience
and Biotechnology (KRIBB). Salmonella ty- phimurium TA98 has been widely used for detecting a
mutagen and is characterized by not growing on histidine-deficient minimal median, indicating that it
needs nutrients like histidine and biotin for growth. Nevertheless, it can be growing on histidine-
deficient minimal medium only when reverse-mutation to Hs+ is induced by a mutagenic material.
Based on the fact, very small amount of histidine was added to a semi-solid medium where bacteriaculture solution was inoculated. Then, colonies with reverse-mutation, with mutation and without
mutation were separated to in- vestigate the UV-protective effect of polyphosphate.
[78] [79] TSB medium (Tryptone, Soyton), TSA medium (Tryptone, Soyton, agar), Ames minimal
meditm and soft-top agar meditm were used for the present invention. As a buffer, 0.65 M or 0.75 M
of CaCl2 buffer was used. TSB medium was prepared by dissolving 30 g of Tryptic Soy Broth (DB) in
11 of water. TSA medium was prepared by dissolving 30 g of Tryptic Soy Broth (DB) and 15 g of
Bacto Agar (DB) in 11 of water. Ames minimal medium was prepared by dissolving all of 200 m of
50X VB
Salts, 200 m of 10% glucose and 20 g of Bacto Agar in 1 1 of distilled water. At that time, 50X VB
Salts were prepared by dissolving 1 g of MgSO4#7H2O(Sigma), 1 g of citric acid#H O (Sigma), 50
g of K HPO (Sigma) and 17.5 g of Sodium ammonium
2 2 4 phosphate (Sigma) together in 670 m, 45 C distilled water. And soft top agar was prepared by
dissolving 1 g of NaCl and 1.2 g of Bacto Agar in 200 m of distilled water and then 20 m of histidinebiotin solution (a very small amount) was added thereto. The histidine-biotin solution was prepared
by dissolving 0. 0124 g of D-biotin (Sigma) and 0.0096 g of L-histidine (Sigma) in 100 m of distilled
water. 5% polyphosphate solution used for the experiment was composed of those having 65 or
75 chains.
[80] [81] 50 m of TSB medium was inoculated with Salmonella typhimurium LT2 or
Salmonella typhimurium TA98, followed by further culture for 24 hours. 24 hours later, strains (3#108
cells), Ca2+ buffer, polyphosphate solution and SDW were all mixed together. Precisely, 10 0 of
cells and 100 0 of Ca 2+ buffer were mixed, to which 5% polyphosphate having 65 or 75 chains was
704/757
added by 30,40, 50 or 60 0 each. Salmonella typhimurium LT2 or Salmonella typhimurium TA98 was
distributed on a plate, which was UV-irradiated at 20 cm distance, 254 nm, for 2 minutes. UV lamp
was preheated for 30 minutes before irradiation. After UV irradiation, 5mQ of soft-top agar was
inoculated with each 100 0 of strains, quickly followed by voltexing. Then, it was transferred to TSA
medium and Ames minimal medium. When soft top agar was all dried, the plate was reversed and
cultured in a 36 C incubator for
48-72 hours. Then, colonies were observed. When the amount of smeared strains was
great, small nunber of colonies was formed on the surface of minimal agar mediun because of the
limited amount of histidine. But, when the reverse-mutated strains were distributed, large nunber of
colonies was formed because such strains were not affected by histidine concentration. The results
suggests that large nunber of colonies should be growing in a control group without UV irradiation
and in a group being added with polyphosphate before UV irradiation, and the smallest nunber of
colonies must be growing in a control group with UV irradiation.
[82] [83] Table 1
UV ir- ## #X
radiatio
n
705/757
Experim 1 2 3 4 1 2 3 4
ent
D. W (TS 0 0 0 0 0 0 0 0
A)
D. W 0 0 0 0 0 0 0 0
706/757
-4C 810 1290 1276 1180 1112 1860 2608 2157
- 5C 660 550 487 358 470 918 682 690
- 465 3 34 286 184 0 434 166 16
Ca
-5 65 1 2 31 14 0 9 58 30
707/757
Ca
-4 75 0 18 118 20 #0 #262 #224 8
Ca
-5 75 0 2 7 3 0 4 13 8
Ca
-4 65 P 0 0 11 1 0 15 16 26
708/757
-5 565P 0 0 0 5 0 3 4 8
-4 75 P 0 0 6 0 0 4 8 6
-5 75 P 0 0 1 0 0 1 3 2
[84] [85] The above No. 1,2, 3 and 4 experiments were given each 30,40, 50 or 60 0 of 5%
polyphosphate, and-4 and-5 mean dilution times, more particularly, 10 and 10 fold dilution.
[86] [87] As a result, when Salmonella typhimurium TA98 was UV-irradiated, only 10 colonies were
observed in a control, but the number of colony was increased in a group treated with polyphosphate
having 65 chains and was more increased in a group treated with polyphosphate having 75 chains.
The result indicates that polyphosphate having 75 chains has better UV-protective effect than
polyphosphate having 65 chains.
709/757
In the case of wild type Salmonella typhimurium LT2 was used, there was no significant difference
among groups, but a group treated with polyphosphate having 75 chains showed the most colonies
among the three groups and a group treated with polyphosphate having 65 chains showed the
second most colonies and a control group hardly showed colony, suggesting that almost all the
strains were killed by UV ir- radiation. On the contrary, when Salmonella typhimurium TA98 or
Salmonella ty- phimurium LT2 were treated with polyphosphate without UV-irradiation, the most
colonies were observed in control groups for both cases, the second most colonies were seen in a
group treated with polyphosphate having 75 chains and the next was a group treated with
polyphosphate having 65 chains (Table 1 and FIG. 3-FIG. 6).
These results mean that polyphosphate having 75 chains can affect the growth of a strain in some
ways greater than that having 65 chains.
[88] [89] Example 2: Effect of UV irradiation on changes of base sequence [90] In order to
investigate of changes of base sequence according to UV-irradiation, the present inventors coated
DNA directly with Ca and polyphosphate. And the inventors confirmed that polyphosphate could
affect the occurrence of mutants. By this experiment, the present inventors could gather data on
defensive action of polyphosphate against DNA damage.
[91] [92] UV irradiation [93] First, DNA was extracted using a DNA extraction kit (Qiagen) from an E.
coli strain HB 101 (ATCC 33694) containing pUCl9 plasmid. The extracted DNA was quantified by
electrophoresis. Mixtures of DNA and polyphosphate were prepared, whose compositions were as
follows.
[94] [95] 1) DNA 20 0 + CaCl 10 + polyphosphate 10 l, CaCl buffer 10 l [96] 2) DNA 20 0 + distilled
water 10 + polyphosphate 10 uQ, CaCl buffer 10 uQ 2 [97] 3) DNA 20 0 + CaCl 10 + distilled water
10 l, CaCl buffer 10
2 2 [98] 4) DNA 20 + distilled water 20 (positive control) [99] 5) DNA 20 + distilled water 20 (negative
control) [100] [101] In this experiment, 5% polyphosphate was used. According to the nunber of
chains, 10 l of cach 0.65 M and 0.75 M CaCl2 buffer was added respectively. The compositions of
polyphosphate mixtures were as above, and every time a buffer was added, the mixtures were left
710/757
alone for 5 minutes to give DNA enough time to be coated. The mixtures were UV-irradiated at 20 an
distance, 254 nm, for 2 minutes, but a negative control group was excluded from UV-irradiation.
[102] [103] DNA isolation and sequence analysis [104] 40 0 of DNA mixture prepared in the above
example was mixed well with 460 0 of 0.5 M EDTA solution, and the mixture was centrifuged at
15,000 rpm for 15 minutes. Supernatant was recovered and then mixed with 1 m of cold isopropanol,
which was cultured at-70 C for 30 minutes. DNA pellet was obtained by cen- trifugation. The pellet
was washed with 1 m of cold 70% ethanol, followed by two times centrifugation at 12,000 rpm for 15
minutes. Then the DNA pellet was dried.
The DNA pellet was dissolved completely in 11-E buffer (Bioneer, DNA PreMateTM II,
Cat. No. K 3011) and DNA was quantified by measuring OD using electrophoresis or
UV spectrophotometer. Base sequence and T-T dimer formation of the DNA were analyzed. The
formative rate of T-T dimer was calculated by experimental value/ control x 100 (%).
[105] [106] Table 2
Ratio of solutions Number I II
of T-T dimer (ea)
Control 28 28
65 CaCl 19 17
711/757
2
75 CaCl2 17 12
65 polyphosphate 11 11
75 polyphosphate 8 9
65 CaCl2+polyphosphate 4 4
75 CaCl2+polyphosphate 1 0
[107] [108] In the above table, the experiment I was performed with a mixture of 20 0 of
DNA, 10 l of CaCl2 and 10 l of 5% polyphosphate, and the experiment II was performed with a
mixture of 20 l of DNA, 20 l of CaCl2 and 20 l of 5% polyphosphate.
[109] [110] The formation rates of T-T dimer in both cases of directly UV-irradiated DNA and
polyphosphate pre-treated DNA before UV irradiation were compared. First, when
DNA was directly UV-irradiated, the nunber of T-T dimer was 28. When 0.65 M
CaCl solution was treated, the nunber of T-T dimer was decreased to 9-11 and when 2
0.75 M CaCl2 solution was added, 11-16 dimers were decreased. Besides, when only
polyphosphate was treated, 17 dimers (in the case of polyphosphate having 65 chains) and 19-20
dimers (in the case of polyphosphate having 75 chains) disappeared. When
712/757
CaCl solution and polyphosphate were treated together, 24 (65 chains) and 27-28 (75 2 chains)
dimers disappeared each, indicating that T-T dimer was hardly formed (Table
2). From the results, it was confirmed that polyphosphate having 75 chains had greater protective
effect from DNA damage than polyphosphate having 65 chains.
[111] [112] Manufacturin. Example 1: Preparation of food containing polyphosphate [113] The
present inventors have prepared food containing polyphosphate as an effective ingredient as follows.
[114] [115] Preparation of beverage [116] Honey 522 mg [117] Thioctic acid amide 5 mg [118]
Nicotinic acid amide 10 mg [119] Hydrochloric acid riboflavin sodiun 3 mg [120] Hydrochloric acid
pyridoxine 2 mg [121] Inositol 30 mg [122] Ortho acid 50 mg [123] Polyphosphate 0. 48-1. 28 mg
[124] Water 200 m [125] [126] A beverage was prepared based on the above compositions and
contents by following a conventional method.
[127] [128] Preparation of chewing gu-n [129] Gun base 20 % [130] Sugar 76. 36-76. 76 % [131]
Polyphosphate 0. 24-0. 64% [132] Fruit flavor 1 % [133] Water 2 % [134] [135] A chewing gum was
prepared based on the above compositions and contents by following a conventional method.
[136] [137] Preparation of candy [138] Sugar 50-60 % [139] Starch syrup 39. 26-49. 66 % [140]
Polyphosphate 0. 24-0. 64% [141] Orange flavor 0. 1 % [142] [143] A candy was prepared based
on the above compositions and contents by following a conventional method.
[144] [145] Preparation of biscuit [146] Strong flour 1 class 88 kg [147] Cake flour 1 class 76.4 kg
[148] Refined sugar 16.5 kg [149] Salt 2. 5 kg [150] Glucose 2.7 kg [151] Palm shortening 40.5 kg
[152] Ammo 5.3 kg [153] Baking soda 0.6 kg [154] Sodium bisulfate 0.55 kg [155] Rice flour 5.0 kg
[156] Vitamin B1 10. 003 kg [157] Vitamin B2 0.003 kg [158] Milk flavor 0.16 kg [159] Water 71. 1 kg
[160] Whole milk powder 4 kg [161] Substitute milk powder 1 kg [162] Calcium phosphate,
monobasic 0.1 kg [163] Spraying salt 1 kg [164] Spraying milk 25 kg [165] Polyphosphate 0. 2-0. 5
713/757
kg [166] [167] A biscuit was prepared based on the above compositions and contents by following a
conventional method.
[168] [169] Preparation of ice cream [170] Milk fat 10. 0 % [171] Milk solids non fat 10.8 % [172]
167 sugar 12.0 % [173] Starch syrup 3. 0 % [174] Emulsifying stabilizer (span) 0.5 % [175] Perfume
(strawberry) 0.15 % [176] Water 63. 31-62. 91 % [177] Polyphosphate 0. 24-0. 64% [178] [179] An
ice cream was prepared based on the above compositions and contents by following a conventional
method.
[180] [181] Preparation of chocolate [182] Sugar 34. 36-34. 76% [183] Cocoa butter 34 % [184]
Cocoa mat 15 % [185] Cocoa powder 15 % [186] Lecithin 0. 5 % [187] Vanilla flavor 0. 5 % [188]
Polyphosphate 0. 24-0. 64%
[189] [190] A chocolate was prepared based on the above compositions and contents by following
a conventional method.
[191] [192] Manufacturin. Example 2: Preparation of an antioxidant pharmaceutical composition [193]
The present inventors have prepared an antioxidant pharmaceutical composition containing
polyphosphate as an effective ingredient as follows.
[194] [195] Preparation of syrups [196] Syrups containing polyphosphate by 2% (weight/volune) as
an effective ingredient were prepared as follows.
[197] Polyphosphate, saccharin and glucose were dissolved in 80 g of warm water. The mixture was
cooled down, to which a mixture of glycerin, saccharin, flavors, ethanol, sorbic acid and distilled
water was added. Water was added to the mixture, making a total volune of 100 m (Table 3).
[198] [199] Table 3
Ingredient Amount (g)
Polyphosphate 2
714/757
Saccharin 0.8
Sucrose 25.4
Glycerin 8.0
Feed flavor 0.04
Ethanol 4.0
Sorbic acid 0.4
Distilled water Proper amount
[200] [201] Preparation of tablets [202] Tablets containing 15 mg of polyphosphate as an effective
ingredient were prepared as follows.
[203] 250 g of polyphosphate, 175.9 g of lactose, 180 g of potato-starch and 32 g of
colloidal silicic acid were all mixed together. 10% gelatin solution was added to the mixture, which
was then pulverized and filtered with 14-mesh sieve. The pulverized mixture was dried, to which 160
g of potato-starch, 50 g of talc and 5 g of magnesium stearate were added to prepare tablets (Table
4).
[204] [205] Table 4
Ingredient Amount (g)
Polyphosphate 250
Lactose 175.9
715/757
Potato starch 180
Colloidal silicic acid 32
Gelatin solution 10%
Potato starch 160
Talc 50
Magnesiun stearate 5
[206] [207] As explained hereinbefore, polyphosphate of the present invention has an excellent
antioxidant activity, so that a pharmaceutical composition containing the same as an effective
ingredient can be used for the prevention and the treatment of peroxidation related diseases.
[208] [209] Manufacturin. Example 3: Preparation of softener containing polyphosphate [210] The
present inventors prepared softener based on the constitutions listed in the below Table 5 by
following a conventional method.
[211] [212] Table 5
Composition of softener containing polyphosphate or antioxidant
Manufacturin Manufacturin Manufacturin Comparative Comparative
g example < g example < g example < example 1 example 2
716/757
3-1 > 3-2 > 3-3 >
1. Purified 88.369 91.17 82.17 91.17 91.67
water
2. Glycerin 3 3 3 3 3
3.2 2 2 2 2
717/757
1,3-butylene
glycol
4.1 1 1 1 1
Hyaluronic
acid
5.0. 001 1 10
Polyphosphat
718/757
e
6. Vitamin C 1
7.5 1.2 1.2 1.2 1.2
Etanol (95%)
8. Antiseptic 0.1 0.1 0.1 0.1 0.1
9.0. 4 0.4 0.4 0.4 0.4
719/757
Solubilizer
10. Perfume 0.13 0.13 0.13 0.13 0.13
11. Vitamin 0. 5
E
[213] [214] In order to produce softener containing polyphosphate, law materials (1 6) represented
in Table 5 were mixed and completely dissolved. Next, other law materials (8-11) represented in
Table 5 were heated at 30 C to mix them, then they were added to material 7. The mixture was
poured slowly into the above mixture of material 1-6 to make it soluble, resulting in the production of
softener.
[215] [216] Manufacturin. Example 4: Preparation of milky lotion containing polyphosphate [217] The
present inventors prepared milky lotion based on the constitutions listed in the below Table 6 by
following a conventional method.
[218] [219] Table 6
720/757
No. Ingredient Manufacturing Manufacturing Manufacturing
Example Example Example
10 STEARIC 0.3 0.3 0.3
ACID
20 CETANOL-K 1 1 1
30 GMS ;105 0.5 0.5 0.5
40 WECOBEE SS 0.5 0.5 0.5
721/757
50 ARL ;165 0.8 0.8 0.8
60 ARL ;60 0.2 0.2 0.2
70 D-M 0.2 0.2 0.2
80 D-P 0.05 0.05 0.05
90 PHYTOSQUA 1 1 1
LANE
100 CEH 2 2 2
722/757
110 MDF 0.5 0.5 0.5
120 MANGO 0. 1 0.1 0.1
BUTTER
130 TWEEN ;60 1 1 1
140 DC 200 0.5 0.5 0.5
150 DI-WATER to 100 to 100 to 100
160 GLYCERINE 3 3 3
723/757
170 1,3-BG 1 1 1
180 25 chain 5 0 0
polyphosphate
190 65 chain 0 5 0
polyphosphate
200 75 chain 0 0 5
polyphosphate
200 EDTA-2NA 0.02 0. 02 0. 02
724/757
210 TEA 0.13 0.13 0.13
220 CARBOPOL 12 12 12
;941 (1%)
230 BIO-HE 1 1 1
240 GERMALL 0.2 0.2 0.2
115
250 PERFUME 0.15 0.15 0.15
[220] [221] Experimental Example 1: Stability test of softener [222] In order to investigate stability of
softener produced above, the present inventors examined discoloration, sense of using and
preservative stability of softener.
725/757
[223] [224] Discoloration [225] Softeners of Example 1-Example 3 and Comparative Example 1 and
Comparative
Example 2 were cultured in a 30 C incubator for one week. Then, discoloration of them was observed
and the results were shown in Table 7.
[226] [227] Table 7
Example 1 Example 2 Example 3 Comparative Comparative
Example 1 Example 2
Dis-coloratio X X X O O
n
[228] [229] As shown in Table 7, softeners containing polyphosphate of the present invention
showed no change of color, while other softeners containing vitamin C or vitamin E turned into yellow.
[230] [231] Sense of usine [232] 20 females (20-30 years old) were selected to put softeners of the
present invention on their face. Then, they were asked about sense of using, for example, how much
it was sticky, how well it covered the skin, or how much it moisturized the face and what was the
feeling when it was painted. The results were shown in Table 8, and evaluated as follows; 1: very bad,
2: bad, 3: mild, 4: good and 5: very good.
[233] [234] Table 8
Example 1 Example 2 Example 3 Comparative Comparative
726/757
Example 1 Example 2
Spread-abilit 4 4 3 4 4
y
Stickiness 4 4 3 4 4
Moisturizing 3 4 5 4 4
capacity
727/757
Feeling 4 4 3 4 4
[235] [236] As shown in Table 8, it was confirmed that a formulation containing polyphosphate of the
present invention could enhance moisturizing capacity, if properly applied, without dropping the
quality, sense of using.
[237] [238] Preservative stability [239] The present inventors investigated stability of softener
according to temperature changes. Particularly, each sample was put in-5,5, 30,37 and 45 C
incubators re- spectively, and changes of appearance, phase separation, or turbidity was observed
for
3 months. The results were shown in Table 9.
[240] [241] Table 9
Example example example
1 2 - month3 months 5 C 1 month3 months 30 C I month3 months
37 C Iweekl month3 months 45 C Iweekl month3 months 1 Example2 Example3 Comparati
Comparati[242] (H) ; Very good, A ; Discoloration, X; Separation [243] [244] As shown in Table 9,
softeners containing polyphosphate of the present invention were proved to have excellent stability in
forms of a water-soluble formulation and an oily formulation equally.
[245] [246] Ebwever, it will be appreciated that those skilled in the art, on consideration of this
disclosure, may make modifications and improvements within the spirit and scope of the present
invention.
[247] [248] Applicable Example 1 : Cancer [249] Cancer is developed by lots of reasons, but the
most primary reason is believed to be active oxygen. That is, active oxygen destroys cells and does
not allow for damaged cells to be recovered, resulting in malfunction of a cell, by which cancer is
728/757
developed (Ames, B. N., Science, 1983,221, 1256-1264). By the way, phenolic acid included in fruits
is good for liver cancer (Sun J et al., JAgric Food Chem, 2002,4 ; 50 (25),
7449-7454), lycopene contained in a tomato works for breast cancer (Hadley CW et al ., Exp Biol
Med, 2002, 227 (10), 869-80) and isoverbascoside has a positive effect on stomach cancer (Chen
RC et al., Acta Pharmacol Sin, 2002,23 (11), 997-1001), and such anti-oxidant agents are believed to
be effective for other cancers as well. Thus, an anti-oxidant agent can be effectively used for the
prevention and the treatment of various cancers, and the pharmaceutical composition of the present
invention having an excellent anti-oxidant activity can also be effectively used for the prevention and
the treatment of cancers.
[250] [251] Applicable Example 2: Aging [252] Active oxygen, generated during the normal
metabolism, destroys cell components such as lipid, protein and sugar or DNA randomly and
irreversibly, so that cells get
oxidative damage. The long-term accumulation of such damage causes aging and even death
(Harman, D, Free radical theory of aging, 1986,3-49). On the other hand, the prolongation of life span
by reducing the consumption of oxygen, meaning reducing basal metabolic rate, was investigated
by various methods having different conditions, for example, restricted diet, limitation in movement,
etc. (Medvedev, Z. A., Biol Rev.,
1990,65, 375-398; Loe, J. et al., J. Biol. Chem., 1971,32, 103-121 ; Sohal, R. S.,
Aging, 1982,5, 21-24). That is, the elimination of active oxygen is one way to delay aging, so thus
anti-oxidant agents eliminating active oxygen have been developed so far. Therefore, the
pharmaceutical composition of the present invention having an excellent anti-oxidant activity is
available for delaying aging.
[253] [254] Applicable Example 3: Coronary heart disease, hvpercholesterolemia and arteriosclerosis [255] When cholesterol synthase inhibitor was treated to patients with coronary heart
disease and with hypercholesterolemia, cholesterol content in low density lipid decreased, but low
density lipoprotein was still protected since ubiquinone Q10 synthesis was inhibited, suggesting the
agent was not so much effective for preventing peroxidation by active oxygen and thus for treating
the diseases above, either. On the contrary, when anti-oxidant agents such as cerivastatin or
probucol were administered to those patients, low-density lipoproteins in them were rapidly
decreased (Lankin VZ et al., Bull Exp Biol Med, 2002,134 (1), 39-42). In another clinical test, dehy-
729/757
dropyridine calcium antagonist lacidipine, also an anti-oxidant agent, was administered to a patient
with arterosclerosis. As a result, blood pressure was lowered, cholesterol in vessel wall was reduced
and the size of lesion of arterosclerosis was decreased (Haller
H et al., Drugs R D, 2002,3 (5), 311-23). So, an anti-oxidant substance was proved to be very
effective for preventing and treating cholesterol related vascular diseases such as coronary heart
disease, hypercholesterolemia and arteriosclerosis. Thus, the phar- maceutical composition of the
present invention having an excellent anti-oxidant activity can be effectively used for the prevention
and the treatment of vascular system diseases such as coronary heart disease,
hypercholesterolemia and arteriosclerosis.
[256] [257] Applicable Example 4: Multiple sclerosis and autoimmune encephalomyelitis [258] ALA
(alpha lipoic acid), a kind of an anti-oxidant agent, was administered to model mice with multiple
sclerosis and autoimnune encephalomyelitis, in which the diseases became less serious after the
administration. It suggested that oxidative stress was a
major reason for multiple sclerosis and autoimnune encephalomyelitis, so that an anti- oxidant agent
could be effectively used for the treatment of the said nervous related diseases (Marracci GH et al.,
JNeuroimmunol, 2002,131 (1-2), 104-14). Therefore, the pharmaceutical composition of the present
invention having an anti-oxidant activity is very useful for the prevention and the treatment of nervous
related diseases such as multiple sclerosis and autoimmune encephalomyelitis.
[259] [260] Applicable Example 5: Cerebral apoplexy and Alzheimer's disease [261] Oxidative stress
caused by active oxygen oxidizes cell components, resulting in malfunction of those cells. Such
abnormal function causes functional disorders in nerve cells, accompanying stroke, trauma, etc. If
such oxidative stress is accumulated for a long time without being properly treated, serious brain
diseases such as cerebral apoplexy, Alzheimer's disease, etc. , are developed. The brain diseases
such as cerebral apoplexy and Alzheimer's disease can be effectively treated by using an antioxidant agent which is able to eliminate active oxygen (Perry G et al., Comp Biochem Physiol
C Toxicol Phaarmacol, 2002,133 (4), 507-13; Cecchi C et al., Free Radic Biol Med,
2002,15 : 33 (10), 1372-9; Smith MA et al., Free Radic Biol Med, 2002,1 : 33 (9),
1194-9). Therefore, the pharmaceutical composition of the present invention having an excellent antioxidant activity is very useful for the prevention and the treatment of brain diseases such as cerebral
apoplexy, Alzheimer's disease, etc.
730/757
[262] [263] Applicable Example 6: Enteritis [264] Excessive peroxidative by-products are
accumulated in leucocytes of a patient with enteritis. Cell damage caused by the accumulated
peroxidative by-products in patients with enteritis works as primary and further secondary
pathological mechanism of infection of intestines. That is, oxidative stress induces inflammation in
intestines, developing inflammatory enteritis (Kruidenier L et al., Aliment Pharmacol Ther, 2002,
16 (12), 1997-2015). Therefore, the pharmaceutical composition of the present invention having an
excellent anti-oxidant activity can be effectively used for the prevention and the treatment of
inflammation related diseases such as inflammatory enteritis, etc.
[265]
Industrial Applicability [266] As explained hereinbefore, polyphosphate of the present invention,
unlike other synthetic antioxidant agents, is very safe in vivo and has an excellent antioxidant
activity, comparing to other natural antioxidant materials, so that it can be effectively used for
producing a pharmaceutical composition for preventing or treating diseases caused by active
oxygen including aging and as health food.Claims:
Claims [1] A pharmaceutical composition for anti-oxidation containing polyphosphate represented
by following as an effective ingredient.
Wherein, n is 20-100.
[2] The pharmaceutical composition as set forth in claim 1, wherein the phar- maceutical composition
is prepared in the form of a formulation selected from a group consisting of injections, tablets and
syrups.
[3] The pharmaceutical composition as set forth in claim 1, wherein the n is 25-80.
731/757
[4] The pharmaceutical composition as set forth in claim 3, wherein the n is 65-75.
[5] A health food for anti-oxidation containing polyphosphate represented by following as an
effective ingredient.
Wherein, n is 20-100.
[6] The health food as set forth in claim 5, wherein the health food is prepared in a form selected from
a group consisting of meat, sausage, bread, chocolate, candies, snacks, cookies, pizza, ramyon and
other noodles, gums, dairy products including ice creams, soups, beverages, teas, drinks, alcoholic
beverages and vitamin complex.
[7] The health food as set forth in claim 5, wherein the n is 25-80.
[8] The health food as set forth in claim 7, wherein the n is 65-75.
[9] A cosmetic composition for anti-oxidation containing polyphosphate represented by following as
an effective ingredient.
Wherein, n is 20-100.
[10] The cosmetic composition as set forth in claim 9, wherein the cosmetic composition is prepared
in a form selected from a group consisting of basic skin care cosmetics such as softener, lotion,
nutritive cream, essence, pack or bath powder.
[11] The cosmetic composition as set forth in claim 9, wherein the n is 25-80.
732/757
[12] The cosmetic composition as set forth in claim 11, wherein the n is 65-75.
733/757
392. WO2005034974 - 21.04.2005
HEALTH FOOD FOR PREVENTING OR IMPROVING THROMBOSIS AND MEDICINAL
COMPOSITION FOR PREVENTING OR TREATING THROMBOSIS
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=WO2005034974
Inventor(s):
KUMAGAI HITOMI (JP)
Applicant(s):
UNIV NIHON (JP); KUMAGAI HITOMI (JP)
IP Class 4 Digits: A23L; A61K; A61P; C07D
IP Class:
A61K35/78; A23L1/212; A61K31/385; A61P7/02; A23L1/30; C07D341/00
Application Number:
WO2004JP14872 (20041007)
Priority Number: JP20030350413 (20031009)
Family: WO2005034974
Cited Document(s):
JP8081385; JP62072620
Abstract:
IT IS INTENDED TO PROVIDE A HEALTH FOOD EFFICACIOUS IN PREVENTING OR IMPROVING
THROMBOSIS AND A MEDICINAL COMPOSITION FOR PREVENTING OR TREATING THROMBOSIS.
NAMELY, A HEALTH FOOD FOR PREVENTING OR IMPROVING THROMBOSIS WHICH CONTAINS,
AS THE ACTIVE INGREDIENT, AN EXTRACT OF SHIITAKE MUSHROOM WITH AN ORGANIC
SOLVENT OR A MIXTURE OF AN ORGANIC SOLVENT WITH WATER OR ACTIVE COMPONENTS OF
SHIITAKE MUSHROOM SUCH AS LENTHIONINE; AND A MEDICINAL COMPOSITION FOR
PREVENTING OR TREATING THROMBOSIS WHICH CONTAINS, AS THE ACTIVE INGREDIENT, AN
EXTRACT OF SHIITAKE MUSHROOM WITH AN ORGANIC SOLVENT OR A MIXTURE OF AN
ORGANIC SOLVENT WITH WATER OR ACTIVE COMPONENTS OF SHIITAKE MUSHROOM SUCH
AS LENTHIONINE.
734/757
393. WO2005036989 - 21.04.2005
HEALTH FOOD CONTAINING HYALURONIC ACID AND DERMATAN SULFATE
URL EPO = http://v3.espacenet.com/textdoc?F=3&CY=ep&LG=en&IDX=WO2005036989
Inventor(s):
ARAI YOSHIMI (JP)
Applicant(s):
MEDICARAISE (JP)
IP Class 4 Digits: A61K
IP Class:
A61K31/737; A61K31/728; A61K47/00
E Class: A61K31/728; A61K31/737
Application Number:
US20040960233 (20041006)
Priority Number: JP20030360048 (20031020)
Family: WO2005036989
Equivalent:
JP2005046133
Abstract:
IT IS AN OBJECT OF THE PRESENT INVENTION TO PROVIDE A HEALTH FOOD CONTAINING
HYALURONIC ACID AND DERMATAN SULFATE. A HEALTH FOOD ACCORDING TO THE PRESENT
INVENTION CONTAINS HYALURONIC ACID AND DERMATAN SULFATE AS ESSENTIAL
COMPONENTS. THE HEALTH FOOD CONTAINING HYALURONIC ACID AND DERMATAN SULFATE
ACCORDING TO THE PRESENT INVENTION MAKES IT POSSIBLE TO TAKE HYALURONIC ACID
AND DERMATAN SULFATE TOGETHER. FURTHER, HYALURONIC ACID CONTAINED IN THE
HEALTH FOOD ACCORDING TO THE PRESENT INVENTION FACILITATES THE ABSORPTION OF
DERMATAN SULFATE IN THE SMALL INTESTINE AND INCREASES THE EFFICIENCY OF
ABSORPTION OF DERMATAN SULFATE.Description:
735/757
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a
health food containing hyaluronic acid and dermatan sulfate. 1. Description of the Related Art
Dermatan sulfate, also called chondroitin sulfate B, is one of glycosaminoglycans and has a
molecular weight of 20,000 to 400,000. In general, dermatan sulfate is mainly made up of
disaccharide repeating units consisting of L-iduronic acid and N-acetylgalactosamine-4-sulfate
represented by the following chemical formula 1, but there is a case where some of the repeating
units contain sulfated L-iduronic acid or D-glucuronic acid as uronic acid, or contain non-sulfated Nacetylgalactosamine or 4,6-disulfated N-acetylgalactosamine instead of N-acetylgalactosamine-4sulfate. It is considered that dermatan sulfate is absorbed by the body when orally taken.
Hyaluronic acid is also one of glycosaminoglycans and has disaccharide repeating units consisting
of O-[beta]-D-glucuronosyl(1->3)-N-acetyl-[beta]-D-glucosaminyl(1->4) represented by the following
chemical formula 2. Hyaluronic acid is mainly present in the synovial fluid of joints, the vitreous humor
of the eye, the umbilical cord, the connective tissues such as upper dermis, and the like of animals. It
is considered that hyaluronic acid cannot be absorbed by the body even if it is orally taken because
hyaluronic acid has a molecular weight of hundreds of thousands to two millions or more.
In a living body, dermatan sulfate is linked to hyaluronic acid together with chondroitin sulfate A and
chondroitin sulfate C. Since dermatan sulfate, chondroitin sulfate A, chondroitin sulfate C and
hyaluronic acid, called glycosaminoglycans, are anionic molecules, when they are linked to each
other to form a polymer structure, the resulting polymeric compound can contain a lot of water
molecules. Therefore, it is considered that the polymeric compound helps the skin to maintain its
moisture. Further, it is pointed out that when orally taken, dermatan sulfate or chondroitin sulfate is
got into the body and is then linked to hyaluronic acid present in the body to enhance the effect of
maintaining skin's moisture. It is to be noted that some health foods containing hyaluronic acid have
been disclosed (see JP-A 2002-360292 and JP-A 09-98739 (1997)), but a health food containing
hyaluronic acid and dermatan sulfate together has not yet proposed. In a case where hyaluronic
acid is orally taken, only low-molecular-weight hyaluronic acid (having a molecular weight of 50,000
to 100,000) is absorbed by the body. However, it can be considered that hyaluronic acid orally taken
attracts various molecules and plays a role in facilitating the absorption of the molecules in the small
intestine. In particular, it can be considered that hyaluronic acid orally taken facilitates the absorption,
by the body, of dermatan sulfate, chondroitin sulfate A and chondroitin sulfate C, which are linked to
hyaluronic acid in the body.
736/757
SUMMARY OF THE INVENTION In view of the consideration, the present inventors have produced a
health food containing at least hyaluronic acid and dermatan sulfate to investigate the effect thereof
As a result, they have found that the health food has excellent effects of maintaining skin's moisture,
improving the softness and quality of the skin, and improving health, leading to the completion of the
present invention. It is therefore an object of the present invention to provide a health food
containing hyaluronic acid and dermatan sulfate. The health food containing hyaluronic acid and
dermatan sulfate according to the present invention makes it possible to take hyaluronic acid and
dermatan sulfate together. Further, hyaluronic acid contained in the health food according to the
present invention facilitates the absorption of dermatan sulfate in the small intestine and increases
the efficiency of absorption of dermatan sulfate. Furthermore, the health food according to the
present invention has the effects of rejuvenating skin, improving the softness of the skin, increasing
the moisture retention of the skin, increasing the metabolism of the skin, reducing damage to the skin
caused by ultraviolet rays, clearing a muddy complexion, reducing spots on the face, improving
appearance of makeup, reducing fine wrinkles, improving skin resilience around eye area, clearing
pimples, moisturizing the entire body, improving the color of the nails, curing dry skin, curing
chapped lips, improving a ruddy complexion, alleviating stiffness in the shoulders, reducing the risk
of a hangover or quickly recovering from a hangover, improving poor circulation, healing wounds
faster, strengthening the nails, alleviating backache, reducing memory loss, clearing up blurry vision,
alleviating joint pain, improving genital aging, alleviating menstrual pain, softening the skin of the heel,
recovering from fatigue, rejuvenating the skin, treating constipation, and reducing hair loss.
BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a micrograph of epidermal cells cultured in a
culture bottle to which a substance containing hyaluronic acid and dermatan sulfate was added in a
concentration of 1.4 mg/mL, which shows a result of Test Example 2; FIG. 2 is a micrograph of
epidermal cells cultured in a culture bottle to which a substance containing hyaluronic acid and
dermatan sulfate was added in a concentration of 0.8 mg/mL, which shows a result of Test Example
2; FIG. 3 is a micrograph of epidermal cells cultured in a culture bottle to which a substance
containing hyaluronic acid and dermatan sulfate was added in a concentration of 0.5 mg/mL, which
shows a result of Test Example 2; FIG. 4 is a micrograph of epidermal cells cultured in a culture
bottle to which a substance containing hyaluronic acid and dermatan sulfate was added in a
concentration of 0.25 mg/mL, which shows a result of Test Example 2; FIG. 5 is a micrograph of
epidermal cells cultured in a culture bottle to which a substance containing hyaluronic acid and
dermatan sulfate was added in a concentration of 0.125 mg/mL, which shows a result of Test
Example 2; FIG. 6 is a micrograph of epidermal cells cultured in a culture bottle to which a
substance containing hyaluronic acid and dermatan sulfate was added in a concentration of 0.0625
737/757
mg/mL, which shows a result of Test Example 2; FIG. 7 is a micrograph of epidermal cells cultured
in a culture bottle to which no substance containing hyaluronic acid and dermatan sulfate was added,
which shows a result of Test Example 2; FIG. 8 is a photograph which shows a cross section of skin
exposed to ultraviolet rays; FIG. 9 is a photograph which shows a cross section of skin exposed to
ultraviolet rays; and FIG. 10 is a photograph which shows a cross section of skin.
DESCRIPTION OF THE PREFERRED EMBODIMENTS A health food according to the present
invention contains hyaluronic acid and dermatan sulfate as essential components. Dermatan sulfate,
also called chondroitin sulfate B, is one of glycosaminoglycans and has a molecular weight of 20,000
to 400,000. In general, dermatan sulfate is mainly made up of disaccharide repeating units
consisting of L-iduronic acid and N-acetylgalactosamine-4-sulfate represented by the following
chemical formula 3, but there is a case where some of the repeating units contain sulfated L-iduronic
acid or D-glucuronic acid as uronic acid, or contain non-sulfated N-acetylgalactosamine or 4,6disulfated N-acetylgalactosamine instead of N-acetylgalactosamine-4-sulfate. It is considered that
dermatan sulfate is absorbed by the body when orally taken.
Hyaluronic acid is also one of glycosaminoglycans and has disaccharide repeating units consisting
of O-[beta]-D-glucuronosyl(1->3)-N-acetyl-[beta]-D-glucosaminyl(1->4) represented by the following
chemical formula 4. Hyaluronic acid is mainly present in the synovial fluid of joints, the vitreous humor
of the eye, the umbilical cord, the connective tissues such as upper dermis, and the like of animals. It
is considered that hyaluronic acid cannot be absorbed by the body even if it is orally taken because
hyaluronic acid has a molecular weight of hundreds of thousands to two millions or more.
Hyaluronic acid and dermatan sulfate to be used in the present invention may be either synthetic
products or semisynthetic products, or may be natural extracts derived from birds, fishes, mammals
and the like. In this regard, it is to be noted that a synthetic product refers to one produced by
chemical synthesis, and a semisynthetic product refers to one obtained by further carrying out
synthesis using a chemical synthetic product or a natural extract. In a case where hyaluronic acid
and dermatan sulfate extracted from natural sources are used, extraction sources are not particularly
limited, but are preferably mammals to which human beings belong. Among mammals, pigs (genus
Sus) are more preferably used as natural sources because it is said that tissue compatibility between
pigs and human beings is high. Examples of species of pigs may include Duroc, Berkshire,
Hampshire, Landrace, Large Yorkshire (Large White) and Middle Yorkshire (Middle White), and
hybrids between two species of them. The mixing ratio between hyaluronic acid and dermatan
sulfate is not limited to any specific value, but the weight ratio between hyaluronic acid and dermatan
738/757
sulfate to be mixed is preferably 1:0.001 to 200, more preferably 1:0.005 to 100. This is because it
can be considered that dermatan sulfate cannot be efficiently absorbed if there is a significant
difference between hyaluronic acid and dermatan sulfate in the mixing ratio. Further, there is a
possibility that some people have an allergic reaction so that pimples break out on their skin. The
health food containing hyaluronic acid and dermatan sulfate according to the present invention may
contain chondroitin sulfate A, chondroitin sulfate C and peptide in addition to the essential
components, hyaluronic acid and dermatan sulfate. The addition of chondroitin sulfate A and
chondroitin sulfate C makes it possible to synergistically enhance the effects obtained by the health
food containing hyaluronic acid and dermatan sulfate according to the present invention, such as the
effects of maintaining skin's moisture, improving the softness and quality of the skin, and improving
health. Further, addition of peptide makes it possible to synergistically enhance the effect of
rejuvenating skin tissue. Chondroitin sulfate A, also called chondroitin-4-sulfate, is one of
glycosaminoglycans, and often refers to chondroitin sulfate having sulfate groups at position 4.
Chondroitin sulfate A has a molecular weight of several thousands to several tens of thousands, and
the chain length and fine structure thereof vary depending on species of animals, age, and type or
region of tissue. Chondroitin sulfate C, also called chondroitin-6-sulfate, is one of
glycosaminoglycans, and often refers to chondroitin sulfate having sulfate groups at position 6. The
molecular weight of chondroitin sulfate C is the same as that of chondroitin sulfate B. Chondroitin
sulfate A and/or chondroitin sulfate C to be added to the health food containing hyaluronic acid and
dermatan sulfate according to the present invention is not particularly limited, but is preferably
extracted from mammals to which human beings belong. Among mammals, pigs (genus Sus) are
more preferably used as extraction sources because it is said that tissue compatibility between pigs
and human beings is high. The amount of chondroitin sulfate A and/or chondroitin sulfate C to be
added is not limited to any specific value, but the weight ratio between chondroitin sulfate A and/or
chondroitin sulfate C and hyaluronic acid to be mixed is preferably about 0.001 to 100:1, more
preferably about 0.01 to 50:1, even more preferably about 0.05 to 20:1. This is because it can be
considered that chondroitin sulfate A and/or chondroitin sulfate C cannot be efficiently absorbed if
there is a significant difference between chondroitin sulfate A and/or chondroitin sulfate C and
hyaluronic acid in the mixing ratio. Further, there is a possibility that some people have an allergic
reaction so that pimples break out on their skin. The kind of peptide to be added to the health food
containing hyaluronic acid and dermatan sulfate according to the present invention is not particularly
limited, but one consisting of 50,000 or less amino acids should be added. Specifically, one
consisting of about 5 to 5,000 amino acids is preferable, one consisting of about 5 to 500 amino
acids is more preferable, and one consisting of about 5 to 50 amino acids is even more preferable.
This is because if peptide consisting of too many amino acids is used, there is a fear that the peptide
739/757
cannot be absorbed by the body, that is, it can be considered that the smaller the number of linked
amino acids is, the easier the body can absorb the peptide. Such peptide may be extracted from
any source, but is preferably extracted from mammals to which human beings belong. Among
mammals, pigs are more preferably used as extraction sources because it is said that tissue
compatibility between pigs and human beings is high. Alternatively, peptide having a high affinity for
human tissue or peptide having a particular effect may be produced by chemical synthesis to add to
the health food of the present invention. The amount of peptide to be added is not limited to any
specific value, but the weight ratio between peptide and hyaluronic acid to be mixed is preferably
about 0.0001 to 200:1, more preferably about 0.001 to 100:1, even more preferably about 0.01 to
50:1. This is because it can be considered that peptide cannot be efficiently absorbed if there is a
significant difference between hyaluronic acid and peptide in the mixing ratio. Further, there is a
possibility that some people have an allergic reaction so that pimples break out on their skin.
Hyaluronic acid, dermatan sulfate, chondroitin sulfate A and chondroitin sulfate C to be added to the
health food containing hyaluronic acid and dermatan sulfate according to the present invention may
be derived from different living things, respectively, or may be synthesized, but they are preferably
derived from the same mammal. Among mammals, pigs (genus Sus) are more preferably used as
extraction sources because it is said that tissue compatibility between pigs and human beings is
high. This is because it can be considered that hyaluronic acid, dermatan sulfate, chondroitin sulfate
A and chondroitin sulfate C derived from the same living thing have a high affinity between molecules
so that dermatan sulfate, chondroitin sulfate A and chondroitin sulfate C are efficiently absorbed
through hyaluronic acid by the body. The health food containing hyaluronic acid and dermatan
sulfate according to the present invention may contain components that are generally used for health
foods, in addition to the essential components, hyaluronic acid and dermatan sulfate, and
supplemental components, chondroitin sulfate A, chondroitin sulfate C and peptide. Examples of
such components to be added may include various kinds of vitamins, collagen, propolis, royal jelly,
cellulose, sugar, citric acid, plant extracts, flavoring ingredients, preservatives and the like. The
health food containing hyaluronic acid and dermatan sulfate according to the present invention may
have any shape. For example, the health food of the present invention may be formed to be powders,
granules, capsules, tablets, liquids or the like. Further, the health food of the present invention may
be added to cookies, biscuits, gum, candies, noodles, drinks or the like to produce foods for
promoting health. The ratio of hyaluronic acid, dermatan sulfate and other additives with respect to
the entire health food containing hyaluronic acid and dermatan sulfate according to the present
invention is not limited to any specific value, but is preferably in the range of about 0.0001 to 90 wt %
with respect to the total weight of the health food, more preferably in the range of about 0.001 to 80
wt %, even more preferably in the range of about 0.01 to 70 wt %. In this regard, it is to be noted that
740/757
the ratio of hyaluronic acid, dermatan sulfate and other additives with respect to the total weight of
the health food actually varies depending on the form of the health food to be produced, but
preferably lies in the range described above. If the amount of hyaluronic acid, dermatan sulfate and
other additives contained in the health food is less than 0.0001 wt %, the effects of the present
invention cannot be obtained. On the other hand, even if the amount of hyaluronic acid, dermatan
sulfate and other additives contained in the health food exceeds 90 wt %, a higher degree of
effectiveness cannot be obtained. Hereinafter, the effects of the health food containing hyaluronic
acid and dermatan sulfate according to the present invention will be described with reference to test
examples. (Test for Evaluating Usefulness of Health Food containing Hyaluronic Acid and Dermatan
Sulfate) An administration test using a health food containing hyaluronic acid and dermatan sulfate
was carried out on 40 females in their 40s to 50s for 2 months from Aug. 1 to Oct. 1 in 2003 (that is,
from a humid season in summer to a dry season in autumn). In this regard, it is to be noted that the
examinees did not take any other health foods and had skin troubles such as "muddy complexion",
"presence of fine wrinkles", "loss of skin resilience", "presence of thick layer of dead skin on the heel",
and the like. The health food used in this administration test was in tablet form, and the examinees
took 3 tablets (300 mg per 1 tablet) at bedtime every day. It is to be noted that 300 mg of the tablet
contains 5 mg of a hyaluronic acid-containing substance and 5 mg of a dermatan sulfate-containing
substance.
Test Example 1 Evaluation of Moisture content of Skin and Softness of Skin For the examinees, the
moisture content of the skin in the cheek and the moisture content of the skin in an area around the
mouth were measured using a skin analyzer (which is manufactured and sold by Tanita Corporation
under the product name of Piera). The moisture content of the skin refers to the amount of water
contained in the stratum corneum, and is generally measured for checking the degree of moisture
retention of the skin. The softness of the skin refers to the degree of softness of the skin, and is
generally measured for checking the resilience of the skin. In this test, data about the examinees,
such as sexuality, age, and make-up or no make-up had been already input to a memory in the skin
analyzer. Based on the data and information obtained by a tactile sensor attached in the tip of the
analyzer, the skin analyzer displayed the graphs of the moisture content of the skin, the softness of
the skin and the amount of sebum, and skin age. In this regard, it is to be noted that the amount of
sebum was considered to be a factor having no bearing on the effect of the health food of the
present invention, and was left out of the results. Each of the moisture content of the skin and the
softness of the skin was read from the height of the graph on the display and skin age was directly
read from the display to record as measurement values. Measurement was carried out before the
examinees started to take the health food containing hyaluronic acid and dermatan sulfate and after
741/757
a month and 2 months from the beginning of the test. Evaluation was made by comparing the
measurement value before taking of the health food with the measurement value after a month or 2
months from beginning of the test. As for the evaluation results of skin age, the number of people
whose skin age became younger than their actual age is shown in Tables 1 and 2 as the "number of
people whose measurement values were improved", the number of people whose skin age became
older than their actual age is shown in Tables 1 and 2 as the "number of people whose measurement
values became worse", and the number of people whose skin age was the same as their actual age
is shown in Tables 1 and 2 as the "number of people whose measurement values were not changed".
It is to be noted that Table 1 shows the evaluation results as to the cheek, and Table 2 shows the
evaluation results as to an area around the mouth. As for the evaluation results of the moisture
content of the skin and the softness of the skin, the number of people whose measurement values
were increased is shown in Tables 1 and 2 as the "number of people whose measurement values
were improved", the number of people whose measurement values were decreased is shown in
Tables 1 and 2 as the "number of people whose measurement values became worse", and the
number of people whose measurement values were not changed is shown in Tables 1 and 2 as the
"number of people whose measurement values were not changed". As described above, Table 1
shows the evaluation results as to the cheek, and Table 2 shows the evaluation results as to an area
around the mouth. It is to be noted that in a case where the values of the moisture content of the skin
and/or the softness of the skin lie in an abnormal level, the skin analyzer used in this test cannot
display measurement values. Therefore, there was a case where the moisture content of the skin
and/or the softness of the skin could not be measured before taking of the health food so that the
measurement values thereof could not be obtained. In a case where the moisture content of the skin
and/or the softness of the skin could not be measured before taking of the health food but they could
be measured after a month or 2 months from the beginning of the test, it was considered that skin
condition was improved.
TABLE 1
1 month after2 months after
beginning of testbeginning of test
MoistureMoisture
Skin ageSoftnesscontentSkin ageSoftnesscontent
Number of people202832383639
whose measurement
values were improved
Number of people1258000
whose measurement
742/757
values became worse
Number of people870241
whose measurement
values were not
changed
TABLE 2
1 month after2 months after
beginning of testbeginning of test
MoistureMoisture
Skin ageSoftnesscontentSkin ageSoftnesscontent
Number of people263135373439
whose measurement
values were improved
Number of people432010
whose measurement
values became worse
Number of people1063351
whose measurement
values were not
changed As can be seen from the results shown in Tables 1 and 2, in all the measurement items for
the cheek, skin age, softness and moisture content after a month from the beginning of the test,
people whose measurement values were improved occupied the majority of the examinees. At the
time when 2 months had passed from the beginning of the test, the measurement values of 95% of
the examinees were improved in skin age, the measurement values of 90% of the examinees were
improved in softness, and the measurement values of 97.5% of the examinees were improved in
moisture content. Similarly, in all the measurement items for an area around the mouth, skin age,
softness and moisture content after a month from the beginning of the test, people whose
measurement values were improved occupied the majority of the examinees. At the time when 2
months had passed from the beginning of the test, the measurement values of 92.5% of the
examinees were improved in skin age, the measurement values of 85% of the examinees were
improved in softness, and the measurement values of 97.5% of the examinees were improved in
moisture content. As described above, the substance containing hyaluronic acid and dermatan
sulfate makes it possible to rejuvenate the skin and to improve the softness of the skin and the
moisture content of the skin. Further, it is apparent from the data mentioned above that the substance
743/757
containing hyaluronic acid and dermatan sulfate functions as an agent for rejuvenating the skin, an
agent for softening skin tissue, or an agent for maintaining skin's moisture.
Test Example 2 Epidermal Cell Culture Experiment using Mouse About 1 cm of epidermal tissue of
a Kunming species mouse (which was about one day old) was cut out, and cells were separated
using protease. A filtered tissue fluid was collected by a sterilized pipet, and the tissue fluid was
subjected to centrifugal separation at 1,000 rpm for 10 minutes. The resulting supernatant was
removed, and then MEM medium (containing 20% FES) for precipitate was added to the resulting
precipitate. The epidermal cells were observed using 1% placenta fluid. The following experiment
was carried out after the growth rate of the epidermal cells reached 98%. (Experiment) Culture
bottles were prepared, and then 0.2 mL of fluid containing the cells and 10 mL of MEM medium were
placed in each of the culture bottles to culture cells at 37[deg.] C. in 5% CO2. A substance
containing hyaluronic acid and dermatan sulfate was added to the culture bottles so that the
concentration thereof became 1.4 mg/mL, 0.8 mg/mL, 0.5 mg/mL, 0.25 mg/mL, 0.125 mg/mL, 0.0625
mg/mL and 0 mg/mL, respectively, and then cell growth was observed for 7 days. The results are
shown in Table 3. Further, the epidermal cells cultured for 7 days in each of the culture bottles were
micrographed. FIG. 1 shows a micrograph of the epidermal cells cultured in the culture bottle to
which the substance containing hyaluronic acid and dermatan sulfate was added in a concentration
of 1.4 mg/mL, FIG. 2 shows a micrograph of the epidermal cells cultured in the culture bottle to which
the substance was added in a concentration of 0.8 mg/mL, FIG. 3 shows a micrograph of the
epidermal cells cultured in the culture bottle to which the substance was added in a concentration of
0.5 mg/mL, FIG. 4 shows a micrograph of the epidermal cells cultured in the culture bottle to which
the substance was added in a concentration of 0.25 mg/mL, FIG. 5 shows a micrograph of the
epidermal cells cultured in the culture bottle to which the substance was added in a concentration of
0.125 mg/mL, FIG. 6 shows a micrograph of the epidermal cells cultured in the culture bottle to which
the substance was added in a concentration of 0.0625 mg/mL, and FIG. 7 shows a micrograph of the
epidermal cells cultured in the culture bottle to which the substance was added in a concentration of
0 mg/mL.
TABLE 3
Growth rate of epidermal cells (%)
Day 1Day 2Day 3Day 4Day 5Day 6Day 7
Concentration1.48.5817.1425.7134.2442.8551.459.79
(mg/mL)0.87.1714.2921.3828.5635.542.8449.98
0.55.7111.4117.1422.928.5534.2640.02
0.254.248.5612.8317.1321.425.7329.76
744/757
0.1253.286.549.8413.1516.4619.6822.96
0.06252.264.566.849.1711.4313.6915.86
0001.192.393.424.595.54 As can be seen from the results shown in Table 3 and FIGS. 1 to 7, the
substance containing hyaluronic acid and dermatan sulfate tends to increase the growth rate of the
cells. Further, the higher the concentration of the substance containing hyaluronic acid and dermatan
sulfate is, the higher the growth rate of the cells is. From the results, it is apparent that the substance
containing hyaluronic acid and dermatan sulfate increases skin's metabolism and that the substance
hyaluronic acid and dermatan sulfate functions as an agent for facilitating metabolism.
Test Example 3 Ultraviolet Rays Irradiation Experiment 4 Kunming species mice (including 2 male
mice and 2 female mice) were prepared, and the back of each of the mice was shaved to provide
skin to be exposed to ultraviolet rays. The skin was irradiated with 30 W of ultraviolet rays between 7
a.m. and 5 p.m. every day. The 4 mice were divided into 2 pairs each including 1 male mouse and 1
female mouse. To each of the male mouse and the female mouse in one of the pairs, a substance
containing hyaluronic acid and dermatan sulfate was administered in an amount of 1,920 mg per kg
body weight per day. After a seven-day irradiation with ultraviolet rays, the cross section of the skin
exposed to ultraviolet rays was photographed. The results are shown in FIGS. 8 to 10. FIG. 8 shows
a photograph of the cross sections of the skin exposed to ultraviolet rays of the pair of mice to which
the substance containing hyaluronic acid and dermatan sulfate was not administered. In this pair of
mice, thickening of the epidermis, shedding of the stratum corneum due to the lack of basic
substances, loss of power for growing new hair, and drying of the skin were confirmed. FIG. 9shows
a photograph of the cross sections of the skin exposed to ultraviolet rays of another pair of mice to
which the substance containing hyaluronic acid and dermatan sulfate was administered. In this pair
of mice to which the substance containing hyaluronic acid and dermatan sulfate was administered,
the dermis and subcutaneous tissue were increased, and basic substances were supplied to
emerging hair follicles. That is, the skin condition of the mice was close to the condition of the skin
that was not irradiated with ultraviolet rays (see FIG. 10). From the results, it can be considered that
the health food containing hyaluronic acid and dermatan sulfate according to the present invention
has the effect of reducing damage to the skin caused by ultraviolet rays. Further, it is apparent that
substance containing hyaluronic acid and dermatan sulfate functions as an agent for reducing
damage to the skin caused by ultraviolet rays. (Monitoring of Health Food containing Hyaluronic
Acid and Dermatan Sulfate) Monitoring of the health food containing hyaluronic acid and dermatan
sulfate according to the present invention was carried out by 20 males and 80 females. The results
are shown in Table 4.
TABLE 4
745/757
Period of use
Day 3Day 6Day 10Day 15Day 20Day 30TotalTotal
Sexuality
Male
Fe-Fe-Fe-Fe-Fe-Fe-Fe-and
EffectsMalemaleMalemaleMalemaleMalemaleMalemaleMalemaleMalemaleFemale
Muddy complexion was9101422234548
cleared
Spots on face were reduced131641332484755
Appearance of makeup was373912246767
improved
Fine wrinkles were reduced123122433942
Skin resilience around eye621921432929
area was improved
Pimples were gone11124369
Body was entirely153122632841124456
moisturized
Color of nails was3142111011
improved
Dry skin was cured12121612122
Chapped lips were cured411136582715124153
Ruddy complexion was312826232124
improved
Stiffness in shoulders was2431142429113041
alleviated
Risk of hangover was34519413
reduced
Poor circulation was4131641283240
improved
Wounds were healed faster122145
Nails were strengthened351711516
Backache was alleviated945221391726
Memory loss was reduced52412369
Blurry vision was cleared8362344211113124456
Joint pain was alleviated1213251015
746/757
Genital aging was improved1233
Menstrual pain was41277
alleviated
Skin of heel was softened3316242122693847
Fatigue was reduced1221516712218125567
Skin looked younger than921322426
actual age
Constipation was treated11273152154550
Hair loss was reduced1236108171330 As can be seen from Table 4, the health food containing
hyaluronic acid and dermatan sulfate according to the present invention has the effects of clearing a
muddy complexion, reducing spots on the face, improving appearance of makeup, reducing fine
wrinkles, improving skin resilience around eye area, clearing pimples, moisturizing the entire body,
improving the color of the nails, curing dry skin, curing chapped lips, improving a ruddy complexion,
alleviating stiffness in the shoulders, reducing the risk of a hangover or quickly recovering from a
hangover, improving poor circulation, healing wounds faster, strengthening the nails, alleviating
backache, reducing memory loss, clearing up blurry vision, alleviating joint pain, improving genital
aging, alleviating menstrual pain, softening the skin of the heel, recovering from fatigue, rejuvenating
the skin, treating constipation, and reducing hair loss. It is apparent from the results that the
substance containing hyaluronic acid and dermatan sulfate also functions as an agent for improving
constipation and an agent for reducing hair loss. The question, "Do you think the health food of the
present invention has the effect of improving your beauty or health?" was put to the 100 monitors, and
their answers are shown in Table 5. It is to be noted that the values in Table 5 represent the number
of people.
TABLE 5
Effect ofEffect of
improving beautyimproving health
Yes7638
No 010
No idea2452 As can be seen from Table 5, 76 monitors agreed that the health food of the present
invention had the effect of improving beauty. This indicates that they realized excellent effects of the
health food containing hyaluronic acid and dermatan sulfate according to the present
invention.Claims:
1 A health food comprising at least hyaluronic acid and dermatan sulfate.
747/757
2. An agent for producing beautiful skin and improving constipation, comprising at least hyaluronic
acid and dermatan sulfate.
3. The agent for producing beautiful skin and improving constipation according to claim 2, wherein
a mixing ratio between the hyaluronic acid and the dermatan sulfate is 1:0.001 to 200.
4. An agent for producing beautiful skin and reducing hair loss, comprising at least hyaluronic acid
and dermatan sulfate.
5. The agent for producing beautiful skin and reducing hair loss according to claim 4, wherein
a mixing ratio between the hyaluronic acid and the dermatan sulfate is 1:0.001 to 200.
6. A health food comprising the agent for producing beautiful skin and improving constipation
according to claim 2 or 3.
7. A health food comprising the agent for producing beautiful skin and reducing hair loss according
to claim 4 or 5.
8. The health food according to any one of claims 1, 6 and 7, further comprising chondroitin sulfate A
and/or chondroitin sulfate C.
9. The health food according to any one of claims 1, 6 and 7, further comprising peptide.
748/757
ผลการวิเคราะห์ ข้อมูลสิทธิบัตร
เกี่ยวกับ “Health
1. GENERAL
- Request Information
Name:
HealthFood
- Request Parameters
Search 0
Title: health food
Result:
1532
- Request Results
Inventors: 1889
Applicants: 1289
IP Class 4 digits:
IP Class Full: 584
E Class:
199
72
- Patent information repartition
Groups:
0
749/757
Food”
2. DETAILS
2.1. Inventors (Top 7)
2.2. Applicants (Top 6)
750/757
2.3. IP Class 4 Digits (Top 10)
A21D
TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION
OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
A23C
DAIRY PRODUCTS, e.g. MILK, BUTTER, CHEESE; MILK OR CHEESE
SUBSTITUTES; MAKING THEREOF (obtaining protein compositions for
foodstuffs A23J 1/00; preparation of peptides, e.g. of proteins, in general C07K
1/00)
A23D
EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
(animal feeding-stuffs A23K 1/00; foods or foodstuffs containing edible oils or
fats A21D, A23C, A23G, A23L; obtaining, refining, preserving C11B, C11C;
hydrogenation C11C 3/12)
A23G
COCOA; CHOCOLATE; CONFECTIONERY; ICE-CREAM
A23K
FODDER
751/757
A23L
FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED
BY SUBCLASSES A23B TO A23J; THEIR PREPARATION OR TREATMENT, e.g.
COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL
TREATMENT (shaping or working, not fully covered by this subclass, A23P);
PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
A61K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing
into special physical form A61J; chemical aspects of, or use of materials for
deodorisation of air, for disinfection or sterilisation, or for bandages, dressings,
absorbent pads or surgical articles A61L; compounds per se C01, C07, C08,
C12N; soap compositions C11D; micro-organisms per se C12N)
A61P
THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL
PREPARATIONS
C12G
WINE; OTHER ALCOHOLIC BEVERAGES; PREPARATION THEREOF (beer
C12C)
C12N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest
repellants or attractants, or plant growth regulators containing micro-organisms,
viruses, microbial fungi, enzymes, fermentates, or substances produced by, or
extracted from, micro- organisms or animal material A01N 63/00; food
compositions A21, A23; medicinal preparations A61K; chemical aspects of, or
use of materials for, bandages, dressings, absorbent pads or surgical articles
A61L; fertilisers C05); PROPAGATING, PRESERVING, OR MAINTAINING
MICRO-ORGANISMS (preservation of living parts of humans or animals A01N
1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
(microbiological testing media C12Q)
2.4. IP Class 7 digits (Top 9)
752/757
A23G
COCOA; CHOCOLATE; CONFECTIONERY; ICE-CREAM
A23L
FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED
BY SUBCLASSES A23B TO A23J; THEIR PREPARATION OR TREATMENT, e.g.
COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL
TREATMENT (shaping or working, not fully covered by this subclass, A23P);
PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
A61K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing
into special physical form A61J; chemical aspects of, or use of materials for
deodorisation of air, for disinfection or sterilisation, or for bandages, dressings,
absorbent pads or surgical articles A61L; compounds per se C01, C07, C08,
C12N; soap compositions C11D; micro-organisms per se C12N)
A61P
THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL
PREPARATIONS
2.5. IP Class Full (Top 10)
753/757
A23L
FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED
BY SUBCLASSES A23B TO A23J; THEIR PREPARATION OR TREATMENT, e.g.
COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL
TREATMENT (shaping or working, not fully covered by this subclass, A23P);
PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
A61K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing
into special physical form A61J; chemical aspects of, or use of materials for
deodorisation of air, for disinfection or sterilisation, or for bandages, dressings,
absorbent pads or surgical articles A61L; compounds per se C01, C07, C08,
C12N; soap compositions C11D; micro-organisms per se C12N)
2.6. E Class (Top 6)
754/757
A23K
FODDER
A23L
FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED
BY SUBCLASSES A23B TO A23J; THEIR PREPARATION OR TREATMENT, e.g.
COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL
TREATMENT (shaping or working, not fully covered by this subclass, A23P);
PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
A61K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing
into special physical form A61J; chemical aspects of, or use of materials for
deodorisation of air, for disinfection or sterilisation, or for bandages, dressings,
absorbent pads or surgical articles A61L; compounds per se C01, C07, C08,
C12N; soap compositions C11D; micro-organisms per se C12N)
755/757
3. STATISTICS
3.1. Inventors / Applicants (Top 6)
TAKAGAKI KINYA ( -- )
LIU ZUWEN ( CN )
MARUYAMA SHINJIRO ( -- )
YU NEIXUN ( CN )
SUH YOUNG HUN ( KR )
others: 01 ( -- )
SON YOUNG SUK ( KR )
TOYO SHINYAKU:KK ( -- )
LIU ZUWEN ( CN )
TOYO SHINYAKU:KK ( -- )
YU NEIXUN ( CN )
SUH YOUNG HUN ( KR )
others: 01 ( -- )
SON YOUNG SUK ( KR )
32
14
12
12
10
8
6
A23L
A23L
A23L
A61K
A61P
A61K
A23L
A61K
A23L
A61K
A23L
A23L
A23L
34
32
25
18
18
14
12
11
10
9
9
7
7
A23L
A23L
A61P
32
18
18
3.2. Inventors / IP Class 4 digits (Top 10)
others: 01 ( -- )
TAKAGAKI KINYA ( -- )
others: 02 ( -- )
TAKAGAKI KINYA ( -- )
TAKAGAKI KINYA ( -- )
LIU ZUWEN ( CN )
MARUYAMA SHINJIRO ( -- )
others: 01 ( -- )
SUH YOUNG HUN ( KR )
others: 02 ( -- )
others: 04 ( -- )
others: 03 ( -- )
YU NEIXUN ( CN )
3.3. Applicants / IP Class 4 digits (Top 6)
TOYO SHINYAKU:KK ( -- )
others: 01 ( -- )
TOYO SHINYAKU:KK ( -- )
756/757
TOYO SHINYAKU:KK ( -- )
LIU ZUWEN ( CN )
SUH YOUNG HUN ( KR )
YU NEIXUN ( CN )
YU NEIXUN ( CN )
others: 01 ( -- )
A61K
A61K
A23L
A23L
A23C
A61K
18
14
10
9
6
6
จัดทำโดย ปรำโมทย์ ธรรมรัตน์ และ พรวิ สำข์ บุญยงค์
หน่วย สสวพ. สำนักงำนกองทุนสนับสนุนกำรวิ จยั
สถำบันค้นคว้ำและพัฒนำผลิ ตภัณฑ์อำหำร มหำวิ ทยำลัยเกษตรศำสตร์
วิ เครำะห์และรวบรวมข้อมูลด้วยโปรแกรม Matheo Patent
757/757